{
    "601cb4541cb411341a000024_1": [
        {
            "start_logit": 14.1484375,
            "end_logit": 14.53125,
            "text": "Eosinophilic Gastritis",
            "probability": 1.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -1.9072265625,
            "text": "Eosinophilic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.134765625,
            "end_logit": 14.53125,
            "text": "Gastritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -7.29296875,
            "text": "Eosinophilic Gastritis and Duodenitis.",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -7.83203125,
            "text": "Eosinophilic Gastritis and Duodenitis",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": 14.53125,
            "text": "for Eosinophilic Gastritis",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.1875,
            "text": "Eosinophilic Gastritis and Duoden",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.375,
            "text": "Eosinophilic Gastritis and",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 14.53125,
            "text": "Anti-Siglec-8 Antibody for Eosinophilic Gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.53125,
            "text": "-Siglec-8 Antibody for Eosinophilic Gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 14.53125,
            "text": "Siglec-8 Antibody for Eosinophilic Gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": 14.53125,
            "text": "lec-8 Antibody for Eosinophilic Gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -3.134765625,
            "end_logit": -7.29296875,
            "text": "Gastritis and Duodenitis.",
            "probability": 0.0
        },
        {
            "start_logit": -3.134765625,
            "end_logit": -7.83203125,
            "text": "Gastritis and Duodenitis",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": -1.9072265625,
            "text": "for Eosinophilic",
            "probability": 0.0
        },
        {
            "start_logit": -3.134765625,
            "end_logit": -9.1875,
            "text": "Gastritis and Duoden",
            "probability": 0.0
        },
        {
            "start_logit": -3.134765625,
            "end_logit": -9.375,
            "text": "Gastritis and",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -1.9072265625,
            "text": "Anti-Siglec-8 Antibody for Eosinophilic",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": -1.9072265625,
            "text": "-Siglec-8 Antibody for Eosinophilic",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": -1.9072265625,
            "text": "Siglec-8 Antibody for Eosinophilic",
            "probability": 0.0
        }
    ],
    "601cb4541cb411341a000024_2": [
        {
            "start_logit": 12.671875,
            "end_logit": 13.2890625,
            "text": "eosinophilic gastritis",
            "probability": 1.0
        },
        {
            "start_logit": 12.671875,
            "end_logit": -3.56640625,
            "text": "eosinophilic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.4453125,
            "end_logit": 13.2890625,
            "text": "gastritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.671875,
            "end_logit": -5.296875,
            "text": "eosinophilic gastritis and duodenitis",
            "probability": 0.0
        },
        {
            "start_logit": 12.671875,
            "end_logit": -7.88671875,
            "text": "eosinophilic gastritis and duodenitis.",
            "probability": 0.0
        },
        {
            "start_logit": 12.671875,
            "end_logit": -9.328125,
            "text": "eosinophilic gastritis and duoden",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 13.2890625,
            "text": "eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 13.2890625,
            "text": "es eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": 12.671875,
            "end_logit": -9.484375,
            "text": "eosinophilic gastritis and",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 13.2890625,
            "text": "mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 13.2890625,
            "text": "for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 13.2890625,
            "text": "potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 13.2890625,
            "text": "shown potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 13.2890625,
            "text": "inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 13.2890625,
            "text": "treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 13.2890625,
            "text": "depletes eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 13.2890625,
            "text": "cells and that has shown potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -4.4453125,
            "end_logit": -5.296875,
            "text": "gastritis and duodenitis",
            "probability": 0.0
        },
        {
            "start_logit": -4.4453125,
            "end_logit": -7.88671875,
            "text": "gastritis and duodenitis.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": -3.56640625,
            "text": "eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic",
            "probability": 0.0
        }
    ],
    "601cb4541cb411341a000024_3": [
        {
            "start_logit": 13.0078125,
            "end_logit": 13.53125,
            "text": "eosinophilic gastritis",
            "probability": 1.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -3.333984375,
            "text": "eosinophilic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.2421875,
            "end_logit": 13.53125,
            "text": "gastritis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -6.6796875,
            "text": "eosinophilic gastritis and duodenitis",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -7.32421875,
            "text": "eosinophilic gastritis and duodenitis.",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.1171875,
            "text": "eosinophilic gastritis and duodenitis.M",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.203125,
            "text": "eosinophilic gastritis and duoden",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 13.53125,
            "text": "eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.515625,
            "text": "eosinophilic gastritis and",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 13.53125,
            "text": "for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 13.53125,
            "text": "es eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 13.53125,
            "text": "mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 13.53125,
            "text": "potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 13.53125,
            "text": "shown potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 13.53125,
            "text": "inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 13.53125,
            "text": "treatment for eosinophilic gastritis",
            "probability": 0.0
        },
        {
            "start_logit": -4.2421875,
            "end_logit": -6.6796875,
            "text": "gastritis and duodenitis",
            "probability": 0.0
        },
        {
            "start_logit": -4.2421875,
            "end_logit": -7.32421875,
            "text": "gastritis and duodenitis.",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": -3.333984375,
            "text": "eosinophils and inhibits mast cells and that has shown potential in animal models as a treatment for eosinophilic",
            "probability": 0.0
        },
        {
            "start_logit": -4.2421875,
            "end_logit": -9.1171875,
            "text": "gastritis and duodenitis.M",
            "probability": 0.0
        }
    ],
    "590c74d170f9fc6f0f00001e_1": [
        {
            "start_logit": 8.578125,
            "end_logit": 8.5390625,
            "text": "Ecm22",
            "probability": 1.0
        },
        {
            "start_logit": 8.578125,
            "end_logit": -2.791015625,
            "text": "Ecm22 and Upc2 in Saccharomyces cerevisiae filamentation.",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": 8.578125,
            "end_logit": -6.63671875,
            "text": "Ecm",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.578125,
            "end_logit": -7.4921875,
            "text": "Ecm22 and Upc2 in Saccharomyces cerevisiae filamentation",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.578125,
            "end_logit": -7.671875,
            "text": "Ecm22 and Upc2",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 8.5390625,
            "text": "22",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.5390625,
            "text": "transcription factors Ecm22",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.578125,
            "end_logit": -9.1015625,
            "text": "Ecm22 and",
            "probability": 0.0
        },
        {
            "start_logit": 8.578125,
            "end_logit": -9.1640625,
            "text": "Ecm22 and Upc2 in",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 8.5390625,
            "text": "factors Ecm22",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 8.5390625,
            "text": "examine the role of the related transcription factors Ecm22",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": -2.791015625,
            "text": "22 and Upc2 in Saccharomyces cerevisiae filamentation.",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": -2.791015625,
            "text": "transcription factors Ecm22 and Upc2 in Saccharomyces cerevisiae filamentation.",
            "probability": 0.0
        },
        {
            "start_logit": -9.1484375,
            "end_logit": -2.791015625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -9.3125,
            "end_logit": -2.791015625,
            "text": "Upc2 in Saccharomyces cerevisiae filamentation.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": -2.791015625,
            "text": "filamentation.",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": -2.791015625,
            "text": "factors Ecm22 and Upc2 in Saccharomyces cerevisiae filamentation.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -2.791015625,
            "text": "and Upc2 in Saccharomyces cerevisiae filamentation.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": -2.791015625,
            "text": "examine the role of the related transcription factors Ecm22 and Upc2 in Saccharomyces cerevisiae filamentation.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": -2.791015625,
            "text": "Saccharomyces cerevisiae filamentation.",
            "probability": 0.0
        }
    ],
    "590c74d170f9fc6f0f00001e_2": [
        {
            "start_logit": 9.59375,
            "end_logit": 9.140625,
            "text": "Ecm22",
            "probability": 1.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -4.0078125,
            "text": "Ecm22 promote filamentation in Saccharomyces cerevisiae by sterol biosynthesis-dependent and -independent pathways.",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": 9.59375,
            "end_logit": -6.0390625,
            "text": "Ecm",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.3359375,
            "end_logit": 9.140625,
            "text": "Upc2 and Ecm22",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.71875,
            "end_logit": 9.140625,
            "text": "22",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.125,
            "text": "Ecm22 promote filamentation in Saccharomyces cerevisiae by sterol biosynthesis",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.2265625,
            "text": "Ecm22 promote",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.265625,
            "text": "Ecm22 promote filamentation in",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.71875,
            "text": "Ecm22 promote filamentation",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.734375,
            "text": "Ecm22 promote filamentation in Saccharomyces cerevisiae by sterol biosynthesis-dependent and",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.7890625,
            "text": "Ecm22 promote filamentation in Saccharomyces cerevisiae by",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.8125,
            "text": "Ecm22 promote filamentation in Saccharomyces cerevisiae",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.9765625,
            "text": "Ecm22 promote filamentation in Saccharomyces cerevisiae by sterol biosynthesis-dependent and -independent pathways",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 9.140625,
            "text": "and Ecm22",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 9.140625,
            "text": "The zinc cluster proteins Upc2 and Ecm22",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 9.140625,
            "text": "zinc cluster proteins Upc2 and Ecm22",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 9.140625,
            "text": "proteins Upc2 and Ecm22",
            "probability": 0.0
        },
        {
            "start_logit": -6.3359375,
            "end_logit": -4.0078125,
            "text": "Upc2 and Ecm22 promote filamentation in Saccharomyces cerevisiae by sterol biosynthesis-dependent and -independent pathways.",
            "probability": 0.0
        },
        {
            "start_logit": -7.71875,
            "end_logit": -4.0078125,
            "text": "22 promote filamentation in Saccharomyces cerevisiae by sterol biosynthesis-dependent and -independent pathways.",
            "probability": 0.0
        },
        {
            "start_logit": -6.3359375,
            "end_logit": -6.0390625,
            "text": "Upc2 and Ecm",
            "probability": 0.0
        }
    ],
    "590c74d170f9fc6f0f00001e_3": [
        {
            "start_logit": -6.2578125,
            "end_logit": 4.57421875,
            "text": "Sut1 and Sut2 have initially been identified as regulators of sterol import in the budding yeast Saccharomyces cerevisiae.",
            "probability": 0.56787109375
        },
        {
            "start_logit": -6.96875,
            "end_logit": 4.57421875,
            "text": ".",
            "probability": 0.27880859375
        },
        {
            "start_logit": -8.15625,
            "end_logit": 4.57421875,
            "text": "Ecm22, Upc2, Sut1 and Sut2 have initially been identified as regulators of sterol import in the budding yeast Saccharomyces cerevisiae.",
            "probability": 0.08502197265625
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 4.57421875,
            "text": "Upc2, Sut1 and Sut2 have initially been identified as regulators of sterol import in the budding yeast Saccharomyces cerevisiae.",
            "probability": 0.014892578125
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 4.57421875,
            "text": ", Sut1 and Sut2 have initially been identified as regulators of sterol import in the budding yeast Saccharomyces cerevisiae.",
            "probability": 0.01334381103515625
        },
        {
            "start_logit": -10.296875,
            "end_logit": 4.57421875,
            "text": "sterol import in the budding yeast Saccharomyces cerevisiae.",
            "probability": 0.0099945068359375
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 4.57421875,
            "text": "proteins Ecm22, Upc2, Sut1 and Sut2 have initially been identified as regulators of sterol import in the budding yeast Saccharomyces cerevisiae.",
            "probability": 0.009613037109375
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 4.57421875,
            "text": "yeast Saccharomyces cerevisiae.",
            "probability": 0.00760650634765625
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 4.57421875,
            "text": "zinc cluster proteins Ecm22, Upc2, Sut1 and Sut2 have initially been identified as regulators of sterol import in the budding yeast Saccharomyces cerevisiae.",
            "probability": 0.0073699951171875
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 4.57421875,
            "text": "regulators of sterol import in the budding yeast Saccharomyces cerevisiae.",
            "probability": 0.005832672119140625
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -7.9453125,
            "text": "Sut1 and Sut2 have initially been identified as regulators of sterol import in the",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -8.65625,
            "text": "Sut1 and Sut2 have initially been identified as regulators of sterol import in",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -8.96875,
            "text": "Sut1 and Sut",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -8.15625,
            "end_logit": -7.49609375,
            "text": "Ecm22",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -9.5078125,
            "text": "Sut1 and Sut2 have",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -9.515625,
            "text": "Sut1 and Sut2 have initially been identified as regulators of sterol import in the budding yeast Saccharomyces cerevisiae",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -9.5234375,
            "text": "Sut1 and Sut2 have initially been identified as regulators of sterol import",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -9.6796875,
            "text": "Sut1 and Sut2",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -9.7265625,
            "text": "Sut1 and Sut2 have initially been identified as regulators of sterol import in the budding",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.2578125,
            "end_logit": -9.7578125,
            "text": "Sut1",
            "probability": 3.5762786865234375e-07
        }
    ],
    "590c74d170f9fc6f0f00001e_4": [
        {
            "start_logit": 0.6708984375,
            "end_logit": 2.23046875,
            "text": "Ecm22",
            "probability": 0.97705078125
        },
        {
            "start_logit": 0.6708984375,
            "end_logit": -1.525390625,
            "text": "Ecm22, which direct transcription of sterol biosynthetic genes.",
            "probability": 0.022796630859375
        },
        {
            "start_logit": -8.25,
            "end_logit": 2.23046875,
            "text": "and Ecm22",
            "probability": 0.0001302957534790039
        },
        {
            "start_logit": -8.859375,
            "end_logit": 2.23046875,
            "text": "Upc2 and Ecm22",
            "probability": 7.086992263793945e-05
        },
        {
            "start_logit": 0.6708984375,
            "end_logit": -8.0234375,
            "text": "Ecm22,",
            "probability": 3.451108932495117e-05
        },
        {
            "start_logit": -10.109375,
            "end_logit": 2.23046875,
            "text": "transcription factors, Upc2 and Ecm22",
            "probability": 2.0325183868408203e-05
        },
        {
            "start_logit": 0.6708984375,
            "end_logit": -8.7265625,
            "text": "Ecm",
            "probability": 1.710653305053711e-05
        },
        {
            "start_logit": -10.53125,
            "end_logit": 2.23046875,
            "text": "22",
            "probability": 1.33514404296875e-05
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 2.23046875,
            "text": "involved in sterol biosynthesis and two transcription factors, Upc2 and Ecm22",
            "probability": 1.2934207916259766e-05
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 2.23046875,
            "text": "sterol biosynthesis and two transcription factors, Upc2 and Ecm22",
            "probability": 1.2695789337158203e-05
        },
        {
            "start_logit": -10.640625,
            "end_logit": 2.23046875,
            "text": "sterol-response element (SRE) common to genes involved in sterol biosynthesis and two transcription factors, Upc2 and Ecm22",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": 0.6708984375,
            "end_logit": -9.28125,
            "text": "Ecm22, which",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 2.23046875,
            "text": "response element (SRE) common to genes involved in sterol biosynthesis and two transcription factors, Upc2 and Ecm22",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": 0.6708984375,
            "end_logit": -9.6796875,
            "text": "Ecm22, which direct transcription of sterol biosynthetic",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": 0.6708984375,
            "end_logit": -9.765625,
            "text": "Ecm22, which direct transcription of sterol biosynthetic genes",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -8.25,
            "end_logit": -1.525390625,
            "text": "and Ecm22, which direct transcription of sterol biosynthetic genes.",
            "probability": 3.0994415283203125e-06
        },
        {
            "start_logit": -8.859375,
            "end_logit": -1.525390625,
            "text": "Upc2 and Ecm22, which direct transcription of sterol biosynthetic genes.",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -10.109375,
            "end_logit": -1.525390625,
            "text": "transcription factors, Upc2 and Ecm22, which direct transcription of sterol biosynthetic genes.",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.53125,
            "end_logit": -1.525390625,
            "text": "22, which direct transcription of sterol biosynthetic genes.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.5546875,
            "end_logit": -1.525390625,
            "text": "involved in sterol biosynthesis and two transcription factors, Upc2 and Ecm22, which direct transcription of sterol biosynthetic genes.",
            "probability": 2.980232238769531e-07
        }
    ],
    "590c74d170f9fc6f0f00001e_5": [
        {
            "start_logit": 2.314453125,
            "end_logit": 6.08203125,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1, NPR1, PRR2 and sterol biosynthesis genes.",
            "probability": 0.990234375
        },
        {
            "start_logit": 2.314453125,
            "end_logit": 1.4326171875,
            "text": "Ecm22",
            "probability": 0.0094451904296875
        },
        {
            "start_logit": -5.24609375,
            "end_logit": 6.08203125,
            "text": ".",
            "probability": 0.0005145072937011719
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 6.08203125,
            "text": "Upc2 positively control the expression of FHN1, NPR1, PRR2 and sterol biosynthesis genes.",
            "probability": 2.7298927307128906e-05
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 6.08203125,
            "text": "sterol biosynthesis genes.",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 6.08203125,
            "text": "22 and Upc2 positively control the expression of FHN1, NPR1, PRR2 and sterol biosynthesis genes.",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -10.75,
            "end_logit": 6.08203125,
            "text": "FHN1, NPR1, PRR2 and sterol biosynthesis genes.",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -10.921875,
            "end_logit": 6.08203125,
            "text": "and Upc2 positively control the expression of FHN1, NPR1, PRR2 and sterol biosynthesis genes.",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -11.1328125,
            "end_logit": 6.08203125,
            "text": "control the expression of FHN1, NPR1, PRR2 and sterol biosynthesis genes.",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -11.140625,
            "end_logit": 6.08203125,
            "text": ", PRR2 and sterol biosynthesis genes.",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -11.1875,
            "end_logit": 6.08203125,
            "text": "positively control the expression of FHN1, NPR1, PRR2 and sterol biosynthesis genes.",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 2.314453125,
            "end_logit": -7.5,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1, NPR1, PRR2 and sterol biosynthesis",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 2.314453125,
            "end_logit": -8.1796875,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 2.314453125,
            "end_logit": -8.4765625,
            "text": "Ecm22 and Upc2 positively",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 2.314453125,
            "end_logit": -8.484375,
            "text": "Ecm22 and Upc2",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 2.314453125,
            "end_logit": -8.515625,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1, NPR1, PRR2",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 2.314453125,
            "end_logit": -8.5703125,
            "text": "Ecm22 and",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 2.314453125,
            "end_logit": -8.578125,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1, NPR",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 2.314453125,
            "end_logit": -8.7421875,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1, NPR1",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 2.314453125,
            "end_logit": -8.9140625,
            "text": "Ecm22 and Upc2 positively control the expression of FHN1, NPR1, PR",
            "probability": 2.980232238769531e-07
        }
    ],
    "590c74d170f9fc6f0f00001e_6": [
        {
            "start_logit": 5.7578125,
            "end_logit": 4.20703125,
            "text": "ECM22",
            "probability": 1.0
        },
        {
            "start_logit": 5.7578125,
            "end_logit": -7.3203125,
            "text": "ECM22 and UPC2 as well as mutation of the three Ste12-binding sites in the PRM1",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": 5.7578125,
            "end_logit": -7.91796875,
            "text": "ECM22 and UPC2 as",
            "probability": 5.424022674560547e-06
        },
        {
            "start_logit": 5.7578125,
            "end_logit": -8.0078125,
            "text": "ECM22 and UPC2",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": 5.7578125,
            "end_logit": -8.359375,
            "text": "ECM",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": 5.7578125,
            "end_logit": -8.5078125,
            "text": "ECM22 and",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": 5.7578125,
            "end_logit": -9.265625,
            "text": "ECM22 and UPC2 as well as mutation of the three Ste12-binding sites in the PR",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 5.7578125,
            "end_logit": -9.3828125,
            "text": "ECM22 and UPC2 as well as mutation of the three Ste12",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 5.7578125,
            "end_logit": -9.4765625,
            "text": "ECM22 and UPC2 as well as mutation of the three Ste12-binding sites in the PRM1 promoter",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 5.7578125,
            "end_logit": -9.5390625,
            "text": "ECM22 and UPC2 as well",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 5.7578125,
            "end_logit": -9.71875,
            "text": "ECM22 and UPC2 as well as mutation of the three Ste12-binding sites in the PRM1 promoter completely",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 5.7578125,
            "end_logit": -9.7578125,
            "text": "ECM22 and UPC2 as well as mutation of the",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -9.625,
            "end_logit": 4.20703125,
            "text": "22",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 4.20703125,
            "text": "of ECM22",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.671875,
            "end_logit": 4.20703125,
            "text": "deletion of ECM22",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.5,
            "end_logit": -6.7109375,
            "text": "Ecm22/Upc2 control PRM1 transcription through distinct pathways.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -7.3203125,
            "text": "PRM1",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": -7.3203125,
            "text": "UPC2 as well as mutation of the three Ste12-binding sites in the PRM1",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": -7.91796875,
            "text": "UPC2 as",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": -8.0078125,
            "text": "UPC2",
            "probability": 0.0
        }
    ],
    "590c74d170f9fc6f0f00001e_7": [
        {
            "start_logit": -0.5166015625,
            "end_logit": 7.93359375,
            "text": "Ecm22 and Upc2 positively regulate basal expression of PRM1 and PRM4.",
            "probability": 0.98388671875
        },
        {
            "start_logit": -4.984375,
            "end_logit": 7.93359375,
            "text": ".",
            "probability": 0.01126861572265625
        },
        {
            "start_logit": -6.03515625,
            "end_logit": 7.93359375,
            "text": "PRM1 and PRM4.",
            "probability": 0.00394439697265625
        },
        {
            "start_logit": -7.921875,
            "end_logit": 7.93359375,
            "text": "Upc2 positively regulate basal expression of PRM1 and PRM4.",
            "probability": 0.0005974769592285156
        },
        {
            "start_logit": -0.5166015625,
            "end_logit": -2.048828125,
            "text": "Ecm22 and Upc2 positively regulate basal expression of PRM1",
            "probability": 4.5359134674072266e-05
        },
        {
            "start_logit": -0.5166015625,
            "end_logit": -2.310546875,
            "text": "Ecm22",
            "probability": 3.4749507904052734e-05
        },
        {
            "start_logit": -0.5166015625,
            "end_logit": -6.99609375,
            "text": "Ecm22 and",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.03515625,
            "end_logit": -2.048828125,
            "text": "PRM1",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -0.5166015625,
            "end_logit": -8.125,
            "text": "Ecm22 and Upc2 positively regulate basal expression of PRM1 and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.5166015625,
            "end_logit": -8.1796875,
            "text": "Ecm22 and Upc2 positively",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.5166015625,
            "end_logit": -8.203125,
            "text": "Ecm22 and Upc2 positively regulate basal expression of PRM1 and PRM4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -0.5166015625,
            "end_logit": -8.4921875,
            "text": "Ecm22 and Upc2 positively regulate basal expression of PRM1 and PR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.5166015625,
            "end_logit": -8.671875,
            "text": "Ecm22 and Upc2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.5166015625,
            "end_logit": -8.953125,
            "text": "Ecm22 and Upc2 positively regulate basal expression of",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.5166015625,
            "end_logit": -9.1484375,
            "text": "Ecm22 and Upc2 positively regulate basal expression of PRM1 and PRM",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.921875,
            "end_logit": -2.048828125,
            "text": "Upc2 positively regulate basal expression of PRM1",
            "probability": 0.0
        },
        {
            "start_logit": -0.5166015625,
            "end_logit": -9.625,
            "text": "Ecm22 and Upc2 positively regulate basal expression of PR",
            "probability": 0.0
        },
        {
            "start_logit": -0.5166015625,
            "end_logit": -9.625,
            "text": "Ecm22 and Upc2 positively regulate",
            "probability": 0.0
        },
        {
            "start_logit": -0.5166015625,
            "end_logit": -9.734375,
            "text": "Ecm22 and Upc2 positively regulate basal expression",
            "probability": 0.0
        },
        {
            "start_logit": -6.03515625,
            "end_logit": -8.125,
            "text": "PRM1 and",
            "probability": 0.0
        }
    ],
    "590c74d170f9fc6f0f00001e_8": [
        {
            "start_logit": -3.69140625,
            "end_logit": 3.59375,
            "text": "AR1b elements are absolutely required for auto-induction of UPC2 gene expression and protein and require Upc2 and Ecm22 for function.",
            "probability": 0.65625
        },
        {
            "start_logit": -4.7109375,
            "end_logit": 3.59375,
            "text": "UPC2 gene expression and protein and require Upc2 and Ecm22 for function.",
            "probability": 0.23681640625
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 3.59375,
            "text": ".",
            "probability": 0.05120849609375
        },
        {
            "start_logit": -6.59375,
            "end_logit": 3.59375,
            "text": "Ecm22 for function.",
            "probability": 0.036041259765625
        },
        {
            "start_logit": -8.109375,
            "end_logit": 3.59375,
            "text": "The AR1b elements are absolutely required for auto-induction of UPC2 gene expression and protein and require Upc2 and Ecm22 for function.",
            "probability": 0.0079193115234375
        },
        {
            "start_logit": -8.265625,
            "end_logit": 3.59375,
            "text": "Upc2 and Ecm22 for function.",
            "probability": 0.006771087646484375
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 3.59375,
            "text": "and Ecm22 for function.",
            "probability": 0.0011138916015625
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 3.59375,
            "text": "require Upc2 and Ecm22 for function.",
            "probability": 0.0007658004760742188
        },
        {
            "start_logit": -10.5,
            "end_logit": 3.59375,
            "text": "1b elements are absolutely required for auto-induction of UPC2 gene expression and protein and require Upc2 and Ecm22 for function.",
            "probability": 0.00072479248046875
        },
        {
            "start_logit": -10.53125,
            "end_logit": 3.59375,
            "text": "required for auto-induction of UPC2 gene expression and protein and require Upc2 and Ecm22 for function.",
            "probability": 0.0007023811340332031
        },
        {
            "start_logit": -10.8125,
            "end_logit": 3.59375,
            "text": "elements are absolutely required for auto-induction of UPC2 gene expression and protein and require Upc2 and Ecm22 for function.",
            "probability": 0.000530242919921875
        },
        {
            "start_logit": -10.859375,
            "end_logit": 3.59375,
            "text": "protein and require Upc2 and Ecm22 for function.",
            "probability": 0.0005059242248535156
        },
        {
            "start_logit": -3.69140625,
            "end_logit": -3.86328125,
            "text": "AR1b",
            "probability": 0.0003790855407714844
        },
        {
            "start_logit": -3.69140625,
            "end_logit": -6.19140625,
            "text": "AR1b elements are absolutely required for auto-induction of UPC2 gene expression and protein and require Upc2 and Ecm22",
            "probability": 3.707408905029297e-05
        },
        {
            "start_logit": -3.69140625,
            "end_logit": -6.7890625,
            "text": "AR1b elements are absolutely required for auto-induction of UPC2",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -4.7109375,
            "end_logit": -6.19140625,
            "text": "UPC2 gene expression and protein and require Upc2 and Ecm22",
            "probability": 1.3232231140136719e-05
        },
        {
            "start_logit": -4.7109375,
            "end_logit": -6.7890625,
            "text": "UPC2",
            "probability": 7.331371307373047e-06
        },
        {
            "start_logit": -8.109375,
            "end_logit": -3.86328125,
            "text": "The AR1b",
            "probability": 4.589557647705078e-06
        },
        {
            "start_logit": -3.69140625,
            "end_logit": -8.453125,
            "text": "AR1b elements are absolutely required for auto-induction of UPC2 gene expression and protein and",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": -3.69140625,
            "end_logit": -8.625,
            "text": "AR1b elements are",
            "probability": 3.2186508178710938e-06
        }
    ],
    "5896271178275d0c4a000004_1": [
        {
            "start_logit": 13.859375,
            "end_logit": 14.7578125,
            "text": "respiratory distress syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": 14.7578125,
            "text": "syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.859375,
            "end_logit": -3.34375,
            "text": "respiratory",
            "probability": 0.0
        },
        {
            "start_logit": 13.859375,
            "end_logit": -5.3671875,
            "text": "respiratory distress",
            "probability": 0.0
        },
        {
            "start_logit": -8.65625,
            "end_logit": 14.7578125,
            "text": "distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 14.7578125,
            "text": "of respiratory distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": 14.7578125,
            "text": "prevention of respiratory distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.859375,
            "end_logit": -9.0078125,
            "text": "respiratory distress syndrome in premature infants.",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 14.7578125,
            "text": "the prevention of respiratory distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.859375,
            "end_logit": -9.8515625,
            "text": "respiratory distress syndrome in",
            "probability": 0.0
        },
        {
            "start_logit": 13.859375,
            "end_logit": -9.90625,
            "text": "respiratory distress syndrome in premature",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.7578125,
            "text": "Lucinactant for the prevention of respiratory distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 14.7578125,
            "text": "ctant for the prevention of respiratory distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 13.859375,
            "end_logit": -10.046875,
            "text": "respiratory distress syndrome in premature infants",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 14.7578125,
            "text": "inactant for the prevention of respiratory distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 14.7578125,
            "text": "for the prevention of respiratory distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -9.0078125,
            "text": "syndrome in premature infants.",
            "probability": 0.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -9.8515625,
            "text": "syndrome in",
            "probability": 0.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -9.90625,
            "text": "syndrome in premature",
            "probability": 0.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -10.046875,
            "text": "syndrome in premature infants",
            "probability": 0.0
        }
    ],
    "5896271178275d0c4a000004_2": [
        {
            "start_logit": 14.2109375,
            "end_logit": 15.0078125,
            "text": "respiratory distress syndrome",
            "probability": 1.0
        },
        {
            "start_logit": -2.0546875,
            "end_logit": 15.0078125,
            "text": "syndrome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -2.646484375,
            "text": "respiratory",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -5.046875,
            "text": "respiratory distress",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": 15.0078125,
            "text": "distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.6796875,
            "end_logit": 15.0078125,
            "text": "of respiratory distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 15.0078125,
            "text": "treatment of respiratory distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -9.359375,
            "text": "respiratory distress syndrome in neonates.",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -9.703125,
            "text": "respiratory distress syndrome in",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 15.0078125,
            "text": "the treatment of respiratory distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -9.84375,
            "text": "respiratory distress syndrome in neonates",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 15.0078125,
            "text": "Lucinactant for the treatment of respiratory distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 15.0078125,
            "text": "ctant for the treatment of respiratory distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 15.0078125,
            "text": "for the treatment of respiratory distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 15.0078125,
            "text": "inactant for the treatment of respiratory distress syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -2.0546875,
            "end_logit": -9.359375,
            "text": "syndrome in neonates.",
            "probability": 0.0
        },
        {
            "start_logit": -2.0546875,
            "end_logit": -9.703125,
            "text": "syndrome in",
            "probability": 0.0
        },
        {
            "start_logit": -2.0546875,
            "end_logit": -9.84375,
            "text": "syndrome in neonates",
            "probability": 0.0
        },
        {
            "start_logit": -9.6796875,
            "end_logit": -2.646484375,
            "text": "of respiratory",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": -2.646484375,
            "text": "treatment of respiratory",
            "probability": 0.0
        }
    ],
    "5c8974bcd558e5f232000008_1": [
        {
            "start_logit": 11.5,
            "end_logit": 13.5078125,
            "text": "Chiesi Pharma",
            "probability": 1.0
        },
        {
            "start_logit": -4.33984375,
            "end_logit": 13.5078125,
            "text": "a",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.484375,
            "end_logit": 13.5078125,
            "text": "Pharma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.859375,
            "end_logit": 13.5078125,
            "text": "from Chiesi Pharma",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -4.6796875,
            "text": "Chiesi Pharm",
            "probability": 0.0
        },
        {
            "start_logit": -6.74609375,
            "end_logit": 13.5078125,
            "text": "esi Pharma",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -5.26953125,
            "text": "Chi",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -8.2578125,
            "text": "Chiesi",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 13.5078125,
            "text": "market approvals of RM solutions in both Europe (Glybera and Holoclar\u00ae from Chiesi Pharma",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 13.5078125,
            "text": "increasing numbers of clinical trials and recent market approvals of RM solutions in both Europe (Glybera and Holoclar\u00ae from Chiesi Pharma",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.9765625,
            "text": "Chiesi Pharma and Strimvelis\u00ae from GSK",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.0546875,
            "text": "Chiesi Pharma and Strimvelis\u00ae from GSK) and Japan",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.1484375,
            "text": "Chiesi Pharma and Strimvelis\u00ae from GSK) and Japan (Remestemcel-L from Mesoblast\u00ae).",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.328125,
            "text": "Chiesi Pharma and Strimvelis\u00ae from GSK) and Japan (Remestemcel-L from Mesoblast",
            "probability": 0.0
        },
        {
            "start_logit": -4.484375,
            "end_logit": -4.6796875,
            "text": "Pharm",
            "probability": 0.0
        },
        {
            "start_logit": -5.859375,
            "end_logit": -4.6796875,
            "text": "from Chiesi Pharm",
            "probability": 0.0
        },
        {
            "start_logit": -5.859375,
            "end_logit": -5.26953125,
            "text": "from Chi",
            "probability": 0.0
        },
        {
            "start_logit": -6.74609375,
            "end_logit": -4.6796875,
            "text": "esi Pharm",
            "probability": 0.0
        },
        {
            "start_logit": -5.859375,
            "end_logit": -8.2578125,
            "text": "from Chiesi",
            "probability": 0.0
        },
        {
            "start_logit": -4.33984375,
            "end_logit": -9.9765625,
            "text": "a and Strimvelis\u00ae from GSK",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_1": [
        {
            "start_logit": 14.3046875,
            "end_logit": 15.1328125,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -0.313720703125,
            "text": "Xq",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.7998046875,
            "end_logit": 15.1328125,
            "text": "28",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -2.392578125,
            "text": "X",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -5.953125,
            "text": "Xq28) in human.",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 15.1328125,
            "text": "by TAZ gene (Cytogenetic Location: Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 15.1328125,
            "text": ": Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 15.1328125,
            "text": "TAZ gene (Cytogenetic Location: Xq28",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -8.96875,
            "text": "Xq28) in",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.4140625,
            "text": "Xq28)",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 15.1328125,
            "text": "q28",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 15.1328125,
            "text": "Phospholipid Transacylase involved in Cardiolipin remodeling on mitochondrial membrane and coded by TAZ gene (Cytogenetic Location: Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 15.1328125,
            "text": "mitochondrial membrane and coded by TAZ gene (Cytogenetic Location: Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 15.1328125,
            "text": "Location: Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": -0.313720703125,
            "text": "by TAZ gene (Cytogenetic Location: Xq",
            "probability": 0.0
        },
        {
            "start_logit": -1.7998046875,
            "end_logit": -5.953125,
            "text": "28) in human.",
            "probability": 0.0
        },
        {
            "start_logit": -8.8671875,
            "end_logit": -0.313720703125,
            "text": ": Xq",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": -2.392578125,
            "text": "by TAZ gene (Cytogenetic Location: X",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": -0.313720703125,
            "text": "TAZ gene (Cytogenetic Location: Xq",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": -0.313720703125,
            "text": "q",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_2": [
        {
            "start_logit": 14.2109375,
            "end_logit": 14.828125,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": 0.2296142578125,
            "text": "Xq",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -2.46875,
            "end_logit": 14.828125,
            "text": "28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -2.759765625,
            "text": "X",
            "probability": 0.0
        },
        {
            "start_logit": -6.05078125,
            "end_logit": 14.828125,
            "text": "in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 14.828125,
            "text": "located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 14.828125,
            "text": "G4.5 gene, located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 14.828125,
            "text": "q28",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -10.0,
            "text": "Xq28, have been described in four probands with Barth syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -10.015625,
            "text": "Xq28,",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 14.828125,
            "text": "the G4.5 gene, located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.828125,
            "text": "methylglutaconic aciduria. Recently, mutations in the G4.5 gene, located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.828125,
            "text": "mutations in the G4.5 gene, located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 14.828125,
            "text": "Recently, mutations in the G4.5 gene, located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 14.828125,
            "text": "3-methylglutaconic aciduria. Recently, mutations in the G4.5 gene, located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 14.828125,
            "text": "in the G4.5 gene, located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 14.828125,
            "text": "linked cardiomyopathy with neutropenia and 3-methylglutaconic aciduria. Recently, mutations in the G4.5 gene, located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 14.828125,
            "text": "glutaconic aciduria. Recently, mutations in the G4.5 gene, located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -6.05078125,
            "end_logit": 0.2296142578125,
            "text": "in Xq",
            "probability": 0.0
        },
        {
            "start_logit": -6.05078125,
            "end_logit": -2.759765625,
            "text": "in X",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_3": [
        {
            "start_logit": 13.9140625,
            "end_logit": 14.671875,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": 0.330322265625,
            "end_logit": 14.671875,
            "text": "tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -0.98681640625,
            "text": "Xq",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.720703125,
            "end_logit": 14.671875,
            "text": "28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -3.26953125,
            "text": "X",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -6.234375,
            "text": "Xq28.",
            "probability": 0.0
        },
        {
            "start_logit": -8.578125,
            "end_logit": 14.671875,
            "text": "gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 14.671875,
            "text": "on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 14.671875,
            "text": "zin (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 14.671875,
            "text": "azzin (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 14.671875,
            "text": "/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 14.671875,
            "text": "in (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 14.671875,
            "text": "q28",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 14.671875,
            "text": "located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 14.671875,
            "text": "the tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.671875,
            "text": "G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.671875,
            "text": "mutations in the tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": 0.330322265625,
            "end_logit": 0.96337890625,
            "text": "tafazzin (TAZ/G4.5) gene",
            "probability": 0.0
        },
        {
            "start_logit": 0.330322265625,
            "end_logit": -0.98681640625,
            "text": "tafazzin (TAZ/G4.5) gene located on Xq",
            "probability": 0.0
        },
        {
            "start_logit": 0.330322265625,
            "end_logit": -3.26953125,
            "text": "tafazzin (TAZ/G4.5) gene located on X",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_4": [
        {
            "start_logit": 13.90625,
            "end_logit": 14.6171875,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": 0.97314453125,
            "end_logit": 14.6171875,
            "text": "tafazzin (TAZ) gene, located at Xq28",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 13.90625,
            "end_logit": -1.4892578125,
            "text": "Xq",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.607421875,
            "end_logit": 14.6171875,
            "text": "28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.90625,
            "end_logit": -3.154296875,
            "text": "X",
            "probability": 0.0
        },
        {
            "start_logit": -6.515625,
            "end_logit": 14.6171875,
            "text": "at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": 14.6171875,
            "text": "gene, located at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 14.6171875,
            "text": "located at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.3125,
            "end_logit": 14.6171875,
            "text": "zin (TAZ) gene, located at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -8.875,
            "text": "Xq28,",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 14.6171875,
            "text": "in (TAZ) gene, located at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 14.6171875,
            "text": "azzin (TAZ) gene, located at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 14.6171875,
            "text": "q28",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -9.515625,
            "text": "Xq28, cause the disorder by reducing remodeling of cardiolipin, a principal phospholipid of the inner mitochondrial membrane",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 14.6171875,
            "text": "the tafazzin (TAZ) gene, located at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 14.6171875,
            "text": ", located at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -10.0078125,
            "text": "Xq28, cause the disorder by",
            "probability": 0.0
        },
        {
            "start_logit": 13.90625,
            "end_logit": -10.1015625,
            "text": "Xq28, cause the disorder",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 14.6171875,
            "text": ") gene, located at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 14.6171875,
            "text": "mutations or deletions of the tafazzin (TAZ) gene, located at Xq28",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_5": [
        {
            "start_logit": 14.25,
            "end_logit": 15.046875,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": -0.356201171875,
            "end_logit": 15.046875,
            "text": "tafazzin gene (TAZ) is located at Xq28",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -2.13671875,
            "end_logit": 15.046875,
            "text": "28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.25,
            "end_logit": -1.3720703125,
            "text": "Xq",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.25,
            "end_logit": -2.5078125,
            "text": "X",
            "probability": 0.0
        },
        {
            "start_logit": -4.625,
            "end_logit": 15.046875,
            "text": "The tafazzin gene (TAZ) is located at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -5.98828125,
            "text": "Xq28 and",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -7.58984375,
            "text": "Xq28 and encodes a protein involved in the transacylation of cardiolipin, an essential mitochondrial phospholipid",
            "probability": 0.0
        },
        {
            "start_logit": -8.515625,
            "end_logit": 15.046875,
            "text": "at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 15.046875,
            "text": "zin gene (TAZ) is located at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 15.046875,
            "text": "in gene (TAZ) is located at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 15.046875,
            "text": "gene (TAZ) is located at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 15.046875,
            "text": "azzin gene (TAZ) is located at Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 15.046875,
            "text": "q28",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.78125,
            "text": "Xq28 and encodes a protein involved in the transacylation of cardiolipin, an",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -9.8046875,
            "text": "Xq28 and encodes",
            "probability": 0.0
        },
        {
            "start_logit": -0.356201171875,
            "end_logit": -1.3720703125,
            "text": "tafazzin gene (TAZ) is located at Xq",
            "probability": 0.0
        },
        {
            "start_logit": -0.356201171875,
            "end_logit": -2.5078125,
            "text": "tafazzin gene (TAZ) is located at X",
            "probability": 0.0
        },
        {
            "start_logit": -4.625,
            "end_logit": -1.3720703125,
            "text": "The tafazzin gene (TAZ) is located at Xq",
            "probability": 0.0
        },
        {
            "start_logit": -0.356201171875,
            "end_logit": -5.78125,
            "text": "tafazzin gene",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_6": [
        {
            "start_logit": 12.8359375,
            "end_logit": 13.5,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": 2.537109375,
            "end_logit": 13.5,
            "text": "tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 3.319978713989258e-05
        },
        {
            "start_logit": 12.8359375,
            "end_logit": 0.29931640625,
            "text": "Xq",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -4.11328125,
            "end_logit": 13.5,
            "text": "28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8359375,
            "end_logit": -4.875,
            "text": "X",
            "probability": 0.0
        },
        {
            "start_logit": 2.537109375,
            "end_logit": 3.072265625,
            "text": "tafazzin (TAZ/G4.5) gene",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": 13.5,
            "text": "gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 13.5,
            "text": "on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 13.5,
            "text": "zin (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 13.5,
            "text": "/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 13.5,
            "text": "azzin (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 13.5,
            "text": "in (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": 2.537109375,
            "end_logit": 0.29931640625,
            "text": "tafazzin (TAZ/G4.5) gene located on Xq",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 13.5,
            "text": "located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 13.5,
            "text": "q28",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 13.5,
            "text": "G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 13.5,
            "text": "the tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 13.5,
            "text": "mutations in the tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": 2.537109375,
            "end_logit": -4.875,
            "text": "tafazzin (TAZ/G4.5) gene located on X",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": 3.072265625,
            "text": "gene",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_7": [
        {
            "start_logit": 13.9140625,
            "end_logit": 14.671875,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": 0.330322265625,
            "end_logit": 14.671875,
            "text": "tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -0.98681640625,
            "text": "Xq",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.720703125,
            "end_logit": 14.671875,
            "text": "28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -3.26953125,
            "text": "X",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -6.234375,
            "text": "Xq28.",
            "probability": 0.0
        },
        {
            "start_logit": -8.578125,
            "end_logit": 14.671875,
            "text": "gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 14.671875,
            "text": "on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 14.671875,
            "text": "zin (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 14.671875,
            "text": "azzin (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 14.671875,
            "text": "/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 14.671875,
            "text": "in (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 14.671875,
            "text": "q28",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 14.671875,
            "text": "located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 14.671875,
            "text": "the tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.671875,
            "text": "G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.671875,
            "text": "mutations in the tafazzin (TAZ/G4.5) gene located on Xq28",
            "probability": 0.0
        },
        {
            "start_logit": 0.330322265625,
            "end_logit": 0.96337890625,
            "text": "tafazzin (TAZ/G4.5) gene",
            "probability": 0.0
        },
        {
            "start_logit": 0.330322265625,
            "end_logit": -0.98681640625,
            "text": "tafazzin (TAZ/G4.5) gene located on Xq",
            "probability": 0.0
        },
        {
            "start_logit": 0.330322265625,
            "end_logit": -3.26953125,
            "text": "tafazzin (TAZ/G4.5) gene located on X",
            "probability": 0.0
        }
    ],
    "58d906b28acda3452900000d_8": [
        {
            "start_logit": 14.2890625,
            "end_logit": 15.046875,
            "text": "Xq28",
            "probability": 1.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -0.74365234375,
            "text": "Xq",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.078125,
            "end_logit": 15.046875,
            "text": "28",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -2.5234375,
            "text": "X",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 15.046875,
            "text": "in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 15.046875,
            "text": "located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 15.046875,
            "text": "q28",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -9.4296875,
            "text": "Xq28,",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 15.046875,
            "text": "G4.5 gene, located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 15.046875,
            "text": "Recently, mutations in the G4.5 gene, located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 15.046875,
            "text": "gene, located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -10.03125,
            "text": "Xq28, have been described in four probands with Barth syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 15.046875,
            "text": "mutations in the G4.5 gene, located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -10.0390625,
            "text": "Xq28, have been described",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -10.1328125,
            "text": "Xq28, have",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 15.046875,
            "text": "the G4.5 gene, located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -10.1640625,
            "text": "Xq28, have been described in four probands with Barth syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 15.046875,
            "text": ", located in Xq28",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -10.1875,
            "text": "Xq28, have been described in four",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 15.046875,
            "text": "in the G4.5 gene, located in Xq28",
            "probability": 0.0
        }
    ],
    "626aeba1e764a53204000040_1": [
        {
            "start_logit": 12.625,
            "end_logit": 15.25,
            "text": "Ionis Pharmaceuticals",
            "probability": 1.0
        },
        {
            "start_logit": -1.8017578125,
            "end_logit": 15.25,
            "text": "Pharmaceuticals",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 12.625,
            "end_logit": -4.52734375,
            "text": "Ionis",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -5.01953125,
            "text": "Ion",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 15.25,
            "text": "is Pharmaceuticals",
            "probability": 0.0
        },
        {
            "start_logit": -9.328125,
            "end_logit": 15.25,
            "text": "by Ionis Pharmaceuticals",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -7.00390625,
            "text": "Ionis Pharmaceuticals through its subsidiary company, Akcea Therapeutics",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 15.25,
            "text": "apolipoprotein CIII (apoCIII) mRNA, is being developed by Ionis Pharmaceuticals",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -9.0078125,
            "text": "Ionis Pharmaceuticals through its subsidiary company",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -9.8515625,
            "text": "Ionis Pharmaceuticals through its subsidiary",
            "probability": 0.0
        },
        {
            "start_logit": -1.8017578125,
            "end_logit": -7.00390625,
            "text": "Pharmaceuticals through its subsidiary company, Akcea Therapeutics",
            "probability": 0.0
        },
        {
            "start_logit": -1.8017578125,
            "end_logit": -9.0078125,
            "text": "Pharmaceuticals through its subsidiary company",
            "probability": 0.0
        },
        {
            "start_logit": -1.8017578125,
            "end_logit": -9.8515625,
            "text": "Pharmaceuticals through its subsidiary",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -4.52734375,
            "text": "is",
            "probability": 0.0
        },
        {
            "start_logit": -9.328125,
            "end_logit": -4.52734375,
            "text": "by Ionis",
            "probability": 0.0
        },
        {
            "start_logit": -9.328125,
            "end_logit": -5.01953125,
            "text": "by Ion",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -7.00390625,
            "text": "is Pharmaceuticals through its subsidiary company, Akcea Therapeutics",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -4.52734375,
            "text": "apolipoprotein CIII (apoCIII) mRNA, is being developed by Ionis",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": -5.01953125,
            "text": "anesorsen (Waylivra\u00ae), an antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA, is being developed by Ion",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": -5.01953125,
            "text": "apolipoprotein CIII (apoCIII) mRNA, is being developed by Ion",
            "probability": 0.0
        }
    ],
    "5a43a139966455904c000008_1": [
        {
            "start_logit": -0.032501220703125,
            "end_logit": 5.0234375,
            "text": "nucleosome positioning and DNA methylation within individual DNA molecules.",
            "probability": 0.853515625
        },
        {
            "start_logit": -2.083984375,
            "end_logit": 5.0234375,
            "text": "DNA methylation within individual DNA molecules.",
            "probability": 0.10955810546875
        },
        {
            "start_logit": -0.032501220703125,
            "end_logit": 1.7412109375,
            "text": "nucleosome positioning and DNA methylation",
            "probability": 0.032012939453125
        },
        {
            "start_logit": -2.083984375,
            "end_logit": 1.7412109375,
            "text": "DNA methylation",
            "probability": 0.004108428955078125
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 5.0234375,
            "text": "methylation within individual DNA molecules.",
            "probability": 0.00041484832763671875
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 5.0234375,
            "text": "positioning and DNA methylation within individual DNA molecules.",
            "probability": 0.00031566619873046875
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 5.0234375,
            "text": ".",
            "probability": 0.00019824504852294922
        },
        {
            "start_logit": -9.1484375,
            "end_logit": 5.0234375,
            "text": "within individual DNA molecules.",
            "probability": 9.369850158691406e-05
        },
        {
            "start_logit": -9.375,
            "end_logit": 5.0234375,
            "text": "Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules.",
            "probability": 7.468461990356445e-05
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 5.0234375,
            "text": "wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules.",
            "probability": 5.173683166503906e-05
        },
        {
            "start_logit": -9.796875,
            "end_logit": 5.0234375,
            "text": "and DNA methylation within individual DNA molecules.",
            "probability": 4.8995018005371094e-05
        },
        {
            "start_logit": -10.234375,
            "end_logit": 5.0234375,
            "text": "of nucleosome positioning and DNA methylation within individual DNA molecules.",
            "probability": 3.165006637573242e-05
        },
        {
            "start_logit": -10.3125,
            "end_logit": 5.0234375,
            "text": "DNA molecules.",
            "probability": 2.9265880584716797e-05
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 5.0234375,
            "text": "-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules.",
            "probability": 2.5570392608642578e-05
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 5.0234375,
            "text": "individual DNA molecules.",
            "probability": 2.4437904357910156e-05
        },
        {
            "start_logit": -10.875,
            "end_logit": 5.0234375,
            "text": "mapping of nucleosome positioning and DNA methylation within individual DNA molecules.",
            "probability": 1.6689300537109375e-05
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 1.7412109375,
            "text": "methylation",
            "probability": 1.5676021575927734e-05
        },
        {
            "start_logit": -0.032501220703125,
            "end_logit": -6.03125,
            "text": "nucleosome positioning and DNA methylation within individual DNA",
            "probability": 1.3470649719238281e-05
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 1.7412109375,
            "text": "positioning and DNA methylation",
            "probability": 1.1801719665527344e-05
        },
        {
            "start_logit": -0.032501220703125,
            "end_logit": -7.1953125,
            "text": "nucleosome positioning and DNA methylation within individual DNA molecules",
            "probability": 4.231929779052734e-06
        }
    ],
    "602a84ae1cb411341a000116_1": [
        {
            "start_logit": 13.4296875,
            "end_logit": 14.65625,
            "text": "Long noncoding RNAs",
            "probability": 1.0
        },
        {
            "start_logit": -1.1943359375,
            "end_logit": 14.65625,
            "text": "RNAs",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -2.53125,
            "text": "Long noncoding RNAs (",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -4.05859375,
            "text": "Long",
            "probability": 0.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -6.2890625,
            "text": "Long noncoding RNAs (lncRNAs)",
            "probability": 0.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -7.1171875,
            "text": "Long noncoding RNAs (lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": 13.4296875,
            "end_logit": -7.6484375,
            "text": "Long noncoding",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 14.65625,
            "text": "noncoding RNAs",
            "probability": 0.0
        },
        {
            "start_logit": -1.1943359375,
            "end_logit": -2.53125,
            "text": "RNAs (",
            "probability": 0.0
        },
        {
            "start_logit": -1.1943359375,
            "end_logit": -6.2890625,
            "text": "RNAs (lncRNAs)",
            "probability": 0.0
        },
        {
            "start_logit": -1.1943359375,
            "end_logit": -7.1171875,
            "text": "RNAs (lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": -2.53125,
            "text": "(",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -2.53125,
            "text": "noncoding RNAs (",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -5.6953125,
            "text": "ZNF213-AS1 and",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -5.6953125,
            "text": "over 1000 CAGE deep-sequencing libraries) for further exploration and highlight functional roles for ZNF213-AS1 and",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -6.2890625,
            "text": "lncRNAs)",
            "probability": 0.0
        },
        {
            "start_logit": -8.7578125,
            "end_logit": -7.9921875,
            "text": "lnc-KHDC3L",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": -6.2890625,
            "text": "(lncRNAs)",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -6.2890625,
            "text": "noncoding RNAs (lncRNAs)",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -7.1171875,
            "text": "lncRNAs",
            "probability": 0.0
        }
    ],
    "602a84ae1cb411341a000116_2": [
        {
            "start_logit": 11.4609375,
            "end_logit": 11.296875,
            "text": "lncRNAs",
            "probability": 1.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -9.3515625,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (CAGE",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -9.78125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (CAGE).",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -9.8125,
            "text": "lncRNAs in",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -9.8203125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -10.0078125,
            "text": "lncRNAs in human dermal fibroblasts and",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -10.0390625,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -10.0703125,
            "text": "lncRNAs in human dermal fibroblasts and quantified",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -10.2734375,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (CAGE)",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -10.296875,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and",
            "probability": 0.0
        },
        {
            "start_logit": 11.4609375,
            "end_logit": -10.3203125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 11.296875,
            "text": "285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 11.296875,
            "text": "the expression of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 11.296875,
            "text": "FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 11.296875,
            "text": "As part of the FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 11.296875,
            "text": "the FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.296875,
            "text": "of the FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -9.1171875,
            "text": "285",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -9.3515625,
            "text": "285 lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (CAGE",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -9.3515625,
            "text": "Capped Analysis of Gene Expression (CAGE",
            "probability": 0.0
        }
    ],
    "602a84ae1cb411341a000116_3": [
        {
            "start_logit": 11.40625,
            "end_logit": 11.6328125,
            "text": "lncRNAs",
            "probability": 1.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 11.6328125,
            "text": "285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.1328125,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling and cellular phenotyping.",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.2265625,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.28125,
            "text": "lncRNAs in human dermal fibroblasts",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 11.6328125,
            "text": "FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 11.6328125,
            "text": "until 2020, FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.3515625,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling and cellular phenotyping",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 11.6328125,
            "text": "2020, FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.375,
            "text": "lncRNAs in",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.453125,
            "text": "lncRNAs in human dermal fibroblasts; this is",
            "probability": 0.0
        },
        {
            "start_logit": 11.40625,
            "end_logit": -10.4765625,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling and",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 11.6328125,
            "text": "the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 11.6328125,
            "text": "creation until 2020, FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 11.6328125,
            "text": "contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.6328125,
            "text": "of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 11.6328125,
            "text": "-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 11.6328125,
            "text": "NTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 11.6328125,
            "text": "its creation until 2020, FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": -10.0859375,
            "text": "285",
            "probability": 0.0
        }
    ],
    "602a84ae1cb411341a000116_4": [
        {
            "start_logit": 11.1015625,
            "end_logit": 12.8203125,
            "text": "long non-coding RNAs",
            "probability": 0.9990234375
        },
        {
            "start_logit": 11.1015625,
            "end_logit": 5.7265625,
            "text": "long non-coding RNAs (lncRNAs)",
            "probability": 0.0008292198181152344
        },
        {
            "start_logit": 11.1015625,
            "end_logit": 1.287109375,
            "text": "long non-coding RNAs (lncRNAs",
            "probability": 9.834766387939453e-06
        },
        {
            "start_logit": -2.966796875,
            "end_logit": 12.8203125,
            "text": "RNAs",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 11.1015625,
            "end_logit": -1.994140625,
            "text": "long non-coding RNAs (",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -7.38671875,
            "end_logit": 12.8203125,
            "text": "coding RNAs",
            "probability": 0.0
        },
        {
            "start_logit": 11.1015625,
            "end_logit": -6.22265625,
            "text": "long",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 12.8203125,
            "text": "human long non-coding RNAs",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 12.8203125,
            "text": "non-coding RNAs",
            "probability": 0.0
        },
        {
            "start_logit": 11.1015625,
            "end_logit": -6.61328125,
            "text": "long non-coding RNAs (lncRNAs).",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 12.8203125,
            "text": "of human long non-coding RNAs",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 12.8203125,
            "text": "The sixth (latest) edition of the FANTOM project was launched to assess the function of human long non-coding RNAs",
            "probability": 0.0
        },
        {
            "start_logit": -2.966796875,
            "end_logit": 5.7265625,
            "text": "RNAs (lncRNAs)",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 12.8203125,
            "text": "the function of human long non-coding RNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 12.8203125,
            "text": "-coding RNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 12.8203125,
            "text": "launched to assess the function of human long non-coding RNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 12.8203125,
            "text": "the FANTOM project was launched to assess the function of human long non-coding RNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 12.8203125,
            "text": ") edition of the FANTOM project was launched to assess the function of human long non-coding RNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 12.8203125,
            "text": "(latest) edition of the FANTOM project was launched to assess the function of human long non-coding RNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 12.8203125,
            "text": "to assess the function of human long non-coding RNAs",
            "probability": 0.0
        }
    ],
    "602a84ae1cb411341a000116_5": [
        {
            "start_logit": 11.4375,
            "end_logit": 11.609375,
            "text": "lncRNAs",
            "probability": 1.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -9.0234375,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling and cellular phenotyping. Other updates",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 11.609375,
            "text": "285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 11.609375,
            "text": "until 2020, FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.1484375,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling and cellular phenotyping. Other",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.21875,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling and cellular phenotyping. Other updates to",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.2265625,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.2421875,
            "text": "lncRNAs in human dermal fibroblasts",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 11.609375,
            "text": "2020, FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.390625,
            "text": "lncRNAs in",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.3984375,
            "text": "lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling and cellular phenotyping",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 11.609375,
            "text": "FANTOM6 has contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -10.4375,
            "text": "lncRNAs in human dermal fibroblasts; this is",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 11.609375,
            "text": "the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 11.609375,
            "text": "of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 11.609375,
            "text": "-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.609375,
            "text": "from the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.609375,
            "text": "contributed to the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 11.609375,
            "text": "the research community a large dataset generated from the knock-down of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": -9.0234375,
            "text": "285 lncRNAs in human dermal fibroblasts; this is followed with extensive expression profiling and cellular phenotyping. Other updates",
            "probability": 0.0
        }
    ],
    "602a84ae1cb411341a000116_6": [
        {
            "start_logit": 11.3125,
            "end_logit": 11.5546875,
            "text": "lncRNAs",
            "probability": 1.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -9.515625,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (CAGE",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -9.8125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -9.8828125,
            "text": "lncRNAs in",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -9.8984375,
            "text": "lncRNAs in human dermal fibroblasts and",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 11.5546875,
            "text": "rt of the FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -9.9765625,
            "text": "lncRNAs in human dermal fibroblasts and quantified",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -10.0078125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (CAGE).",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -10.0390625,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -10.0546875,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (CAGE). Antise",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 11.5546875,
            "text": "285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 11.5546875,
            "text": "of the FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": 11.3125,
            "end_logit": -10.1953125,
            "text": "lncRNAs in human dermal fibroblasts and quantified cellular growth, morphological changes, and transcriptomic responses using Capped Analysis of Gene Expression (CAGE)",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 11.5546875,
            "text": "the expression of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 11.5546875,
            "text": "FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 11.5546875,
            "text": "the FANTOM6 project, we systematically knocked down the expression of 285 lncRNAs",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": -9.1953125,
            "text": "rt of the FANTOM6 project, we systematically knocked down the expression of 285",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": -9.1953125,
            "text": "285",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": -9.1953125,
            "text": "of the FANTOM6 project, we systematically knocked down the expression of 285",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": -10.0546875,
            "text": "Antise",
            "probability": 0.0
        }
    ],
    "56c1f009ef6e39474100003c_1": [
        {
            "start_logit": 12.8203125,
            "end_logit": 12.28125,
            "text": "Gaucher's disease",
            "probability": 1.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": 0.03924560546875,
            "text": "Gaucher's disease type 1",
            "probability": 4.887580871582031e-06
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -2.556640625,
            "text": "Gaucher",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -4.7421875,
            "text": "Ga",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.19140625,
            "end_logit": 12.28125,
            "text": "disease",
            "probability": 0.0
        },
        {
            "start_logit": -5.3359375,
            "end_logit": 12.28125,
            "text": "'s disease",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -7.61328125,
            "text": "Gaucher's disease type",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -8.375,
            "text": "Gaucher'",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -8.796875,
            "text": "Gaucher's",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": 12.28125,
            "text": "ucher's disease",
            "probability": 0.0
        },
        {
            "start_logit": -8.6484375,
            "end_logit": 12.28125,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -9.84375,
            "text": "Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -9.9453125,
            "text": "Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -10.078125,
            "text": "Gaucher's disease type 1 stabilised",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -10.125,
            "text": "Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial",
            "probability": 0.0
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -10.1875,
            "text": "Gaucher's disease type 1 stabilised on enzyme replacement therapy",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 12.28125,
            "text": "with Gaucher's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 12.28125,
            "text": "patients with Gaucher's disease",
            "probability": 0.0
        },
        {
            "start_logit": -11.09375,
            "end_logit": 12.28125,
            "text": "in patients with Gaucher's disease",
            "probability": 0.0
        },
        {
            "start_logit": -5.19140625,
            "end_logit": 0.03924560546875,
            "text": "disease type 1",
            "probability": 0.0
        }
    ],
    "56c1f009ef6e39474100003c_2": [
        {
            "start_logit": 12.234375,
            "end_logit": 13.0,
            "text": "Gaucher's disease",
            "probability": 1.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -2.06640625,
            "text": "Gaucher's disease type 1",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 12.234375,
            "end_logit": -2.1875,
            "text": "Gaucher",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -4.921875,
            "end_logit": 13.0,
            "text": "disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.6484375,
            "end_logit": 13.0,
            "text": "'s disease",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -5.015625,
            "text": "Ga",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -7.38671875,
            "text": "Gaucher's disease type",
            "probability": 0.0
        },
        {
            "start_logit": -8.875,
            "end_logit": 13.0,
            "text": "ucher's disease",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -8.1875,
            "text": "Gaucher'",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -8.3984375,
            "text": "Gaucher's",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 13.0,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -9.109375,
            "text": "Gaucher's disease type 1 already controlled by intravenous ERT and could be a useful therapeutic option.",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -9.21875,
            "text": "Gaucher's disease type 1 already controlled by intravenous ERT",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 13.0,
            "text": "with Gaucher's disease",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -9.671875,
            "text": "Gaucher's disease type 1 already controlled by intravenous ERT and could be a useful therapeutic option",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -9.765625,
            "text": "Gaucher's disease type 1 already controlled by intravenous ERT and could",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -9.8203125,
            "text": "Gaucher's disease type 1 already",
            "probability": 0.0
        },
        {
            "start_logit": 12.234375,
            "end_logit": -10.0078125,
            "text": "Gaucher's disease type 1 already controlled by intravenous ERT and",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 13.0,
            "text": "organ volume stability in adults with Gaucher's disease",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 13.0,
            "text": "Oral eliglustat maintained haematological and organ volume stability in adults with Gaucher's disease",
            "probability": 0.0
        }
    ],
    "53130a77e3eabad02100000f_1": [
        {
            "start_logit": 13.8671875,
            "end_logit": 14.6484375,
            "text": "growth hormone",
            "probability": 1.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -2.04296875,
            "text": "growth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.068359375,
            "end_logit": 14.6484375,
            "text": "hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -6.8828125,
            "text": "growth hormone deficiency and the presence of more than one papilloma",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.40625,
            "text": "growth hormone deficiency and the presence of more than one papilloma, which were less common in CFC",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.4296875,
            "text": "growth hormone deficiency",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.46875,
            "text": "growth hormone deficiency and the presence of more than one papilloma, which were less common in CFC compared to HRAS mutation positive",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.7734375,
            "text": "growth hormone deficiency and the presence of more than one papilloma, which were less common in CFC compared to HRAS mutation positive patients.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 14.6484375,
            "text": "polyhydramnios, growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 14.6484375,
            "text": "Statistical significance was achieved, despite the relatively small number of patients with BRAF and MEK1 mutations reported here, for polyhydramnios, growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.8359375,
            "text": "growth hormone deficiency and the presence of more than one papilloma, which",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.875,
            "text": "growth hormone deficiency and the presence of more than one papilloma, which were less common in CFC compared to HRAS",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.9375,
            "text": "growth hormone deficiency and the presence of more than one papilloma, which were less common in CFC compared to HR",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.9375,
            "text": "growth hormone deficiency and the presence of more than one papilloma, which were less common in CFC compared to HRAS mutation",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -9.96875,
            "text": "growth hormone deficiency and the presence of more than one papilloma, which were less common in CF",
            "probability": 0.0
        },
        {
            "start_logit": 13.8671875,
            "end_logit": -10.0234375,
            "text": "growth hormone deficiency and the presence of more than one papilloma, which were less common in CFC compared to HRAS mutation positive patients",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 14.6484375,
            "text": "patients with BRAF and MEK1 mutations reported here, for polyhydramnios, growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 14.6484375,
            "text": "amnios, growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 14.6484375,
            "text": "the relatively small number of patients with BRAF and MEK1 mutations reported here, for polyhydramnios, growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 14.6484375,
            "text": "relatively small number of patients with BRAF and MEK1 mutations reported here, for polyhydramnios, growth hormone",
            "probability": 0.0
        }
    ],
    "53130a77e3eabad02100000f_2": [
        {
            "start_logit": 12.015625,
            "end_logit": 13.984375,
            "text": "growth hormone",
            "probability": 1.0
        },
        {
            "start_logit": -3.669921875,
            "end_logit": 13.984375,
            "text": "hormone",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.015625,
            "end_logit": -4.52734375,
            "text": "growth",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 13.984375,
            "text": "Endocrine abnormalities including growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 13.984375,
            "text": "including growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -8.9765625,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid",
            "probability": 0.0
        },
        {
            "start_logit": -11.1640625,
            "end_logit": 13.984375,
            "text": "abnormalities including growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -9.3359375,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -9.6328125,
            "text": "growth hormone deficiency",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -9.828125,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described. Hypoglycemia has been documented due to growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -9.875,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -9.9609375,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described. Hypoglycemia has been documented",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -10.109375,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -10.1171875,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -10.140625,
            "text": "growth hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have",
            "probability": 0.0
        },
        {
            "start_logit": -3.669921875,
            "end_logit": -5.30078125,
            "text": "hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described. Hypoglycemia has been documented due to growth hormone and cortisol",
            "probability": 0.0
        },
        {
            "start_logit": -3.669921875,
            "end_logit": -8.9765625,
            "text": "hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid",
            "probability": 0.0
        },
        {
            "start_logit": -3.669921875,
            "end_logit": -9.3359375,
            "text": "hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described",
            "probability": 0.0
        },
        {
            "start_logit": -3.669921875,
            "end_logit": -9.6328125,
            "text": "hormone deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -3.669921875,
            "end_logit": -9.828125,
            "text": "hormone deficiency, adrenal insufficiency, glucose intolerance, parathyroid adenoma with hyperprolactinemia and hypoglycemia have been described. Hypoglycemia has been documented due to growth hormone",
            "probability": 0.0
        }
    ],
    "53130a77e3eabad02100000f_3": [
        {
            "start_logit": 14.2890625,
            "end_logit": 14.8515625,
            "text": "Growth hormone",
            "probability": 1.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -1.291015625,
            "text": "Growth",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.669921875,
            "end_logit": 14.8515625,
            "text": "hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -7.87109375,
            "text": "Growth hormone deficiency",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -9.3828125,
            "text": "Growth hormone deficiency in Costello syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -9.734375,
            "text": "Growth hormone deficiency in",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -10.0,
            "text": "Growth hormone deficiency in Costello syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -2.669921875,
            "end_logit": -7.87109375,
            "text": "hormone deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -2.669921875,
            "end_logit": -9.3828125,
            "text": "hormone deficiency in Costello syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -2.669921875,
            "end_logit": -9.734375,
            "text": "hormone deficiency in",
            "probability": 0.0
        },
        {
            "start_logit": -2.669921875,
            "end_logit": -10.0,
            "text": "hormone deficiency in Costello syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": -7.87109375,
            "text": "deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": -9.3828125,
            "text": "in Costello syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": -9.3828125,
            "text": "Costello syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": -9.3828125,
            "text": "deficiency in Costello syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": -9.3828125,
            "text": "ello syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": -9.3828125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": -9.734375,
            "text": "in",
            "probability": 0.0
        },
        {
            "start_logit": -11.2734375,
            "end_logit": -9.3828125,
            "text": "o syndrome.",
            "probability": 0.0
        },
        {
            "start_logit": -11.3515625,
            "end_logit": -9.3828125,
            "text": "syndrome.",
            "probability": 0.0
        }
    ],
    "53130a77e3eabad02100000f_4": [
        {
            "start_logit": 14.234375,
            "end_logit": 14.90625,
            "text": "growth hormone",
            "probability": 1.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -1.62890625,
            "text": "growth",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.57421875,
            "end_logit": 14.90625,
            "text": "hormone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.5234375,
            "text": "growth hormone deficiency",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.6796875,
            "text": "growth hormone deficiency and hypoglycemia: a new report and review of the endocrine associations.",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.890625,
            "text": "growth hormone deficiency and hypoglycemia: a new report and review of the endocrine associations",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.921875,
            "text": "growth hormone deficiency and hypoglycemia",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -10.1953125,
            "text": "growth hormone deficiency and",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -10.234375,
            "text": "growth hormone deficiency and hypoglycemia: a new report and review",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 14.90625,
            "text": "Costello syndrome with growth hormone",
            "probability": 0.0
        },
        {
            "start_logit": -2.57421875,
            "end_logit": -9.5234375,
            "text": "hormone deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -2.57421875,
            "end_logit": -9.6796875,
            "text": "hormone deficiency and hypoglycemia: a new report and review of the endocrine associations.",
            "probability": 0.0
        },
        {
            "start_logit": -2.57421875,
            "end_logit": -9.890625,
            "text": "hormone deficiency and hypoglycemia: a new report and review of the endocrine associations",
            "probability": 0.0
        },
        {
            "start_logit": -2.57421875,
            "end_logit": -9.921875,
            "text": "hormone deficiency and hypoglycemia",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": -1.62890625,
            "text": "Costello syndrome with growth",
            "probability": 0.0
        },
        {
            "start_logit": -2.57421875,
            "end_logit": -10.1953125,
            "text": "hormone deficiency and",
            "probability": 0.0
        },
        {
            "start_logit": -2.57421875,
            "end_logit": -10.234375,
            "text": "hormone deficiency and hypoglycemia: a new report and review",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": -9.6796875,
            "text": "the endocrine associations.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": -9.5234375,
            "text": "Costello syndrome with growth hormone deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": -9.6796875,
            "text": "hypoglycemia: a new report and review of the endocrine associations.",
            "probability": 0.0
        }
    ],
    "602343051cb411341a00008d_1": [
        {
            "start_logit": 14.3671875,
            "end_logit": 15.2109375,
            "text": "apoC-III",
            "probability": 1.0
        },
        {
            "start_logit": -1.6025390625,
            "end_logit": 15.2109375,
            "text": "III",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -2.181640625,
            "text": "apoC",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -4.62109375,
            "text": "apoC-",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 15.2109375,
            "text": "-III",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -8.9765625,
            "text": "apoC-III transcription/translation that",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 15.2109375,
            "text": "Volanesorsen is a second-generation antisense oligonucleotide inhibiting apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -9.640625,
            "text": "apoC-III transcription/translation that has been recently approved in Europe for Familial Chylomicronemia Syndrome (FCS) treatment.",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -9.7265625,
            "text": "apoC-III transcription/translation",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -9.875,
            "text": "apoC-III transcription/translation that has been recently approved in Europe for Familial Chylomicronemia Syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 15.2109375,
            "text": "generation antisense oligonucleotide inhibiting apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -9.953125,
            "text": "apoC-III transcription",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.2109375,
            "text": "anesorsen is a second-generation antisense oligonucleotide inhibiting apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -10.03125,
            "text": "apoC-III transcription/translation that has been recently approved in Europe for Familial Chylomicronemia Syndrome (FCS)",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 15.2109375,
            "text": "inhibiting apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -10.0859375,
            "text": "apoC-III transcription/translation that has been recently approved in Europe for Familial Chylomicronemia",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 15.2109375,
            "text": "orsen is a second-generation antisense oligonucleotide inhibiting apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": -1.6025390625,
            "end_logit": -8.9765625,
            "text": "III transcription/translation that",
            "probability": 0.0
        },
        {
            "start_logit": -1.6025390625,
            "end_logit": -9.640625,
            "text": "III transcription/translation that has been recently approved in Europe for Familial Chylomicronemia Syndrome (FCS) treatment.",
            "probability": 0.0
        },
        {
            "start_logit": -1.6025390625,
            "end_logit": -9.7265625,
            "text": "III transcription/translation",
            "probability": 0.0
        }
    ],
    "602343051cb411341a00008d_2": [
        {
            "start_logit": 14.4921875,
            "end_logit": 15.3046875,
            "text": "apoC-III",
            "probability": 1.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": 15.3046875,
            "text": "III",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -1.994140625,
            "text": "apoC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -3.484375,
            "text": "apoC-",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -5.73046875,
            "text": "apoC-III has shown reductions in plasma TG levels up to 90%.",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -8.2421875,
            "text": "apoC-III has shown reductions in plasma TG",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 15.3046875,
            "text": "-III",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.2109375,
            "text": "apoC-III has shown reductions in plasma TG levels up to 90",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 15.3046875,
            "text": "targeting apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.3515625,
            "text": "apoC-III has shown reductions in plasma TG levels up to 90%",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.765625,
            "text": "apoC-III has shown reductions",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.7734375,
            "text": "apoC-III has shown reductions in",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.9296875,
            "text": "apoC-III has shown reductions in plasma TG levels",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.9375,
            "text": "apoC-III has shown reductions in plasma TG levels up",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 15.3046875,
            "text": "Volanesorsen targeting apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": -11.171875,
            "end_logit": 15.3046875,
            "text": "anesorsen targeting apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -5.73046875,
            "text": "III has shown reductions in plasma TG levels up to 90%.",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -8.2421875,
            "text": "III has shown reductions in plasma TG",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -9.2109375,
            "text": "III has shown reductions in plasma TG levels up to 90",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -9.3515625,
            "text": "III has shown reductions in plasma TG levels up to 90%",
            "probability": 0.0
        }
    ],
    "602343051cb411341a00008d_3": [
        {
            "start_logit": 14.2890625,
            "end_logit": 15.1640625,
            "text": "apoC-III",
            "probability": 1.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": 15.1640625,
            "text": "III",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -2.369140625,
            "text": "apoC",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -4.23828125,
            "text": "apoC-",
            "probability": 0.0
        },
        {
            "start_logit": -8.8515625,
            "end_logit": 15.1640625,
            "text": "-III",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 15.1640625,
            "text": ", apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 15.1640625,
            "text": "As such, apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 15.1640625,
            "text": "such, apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -9.9140625,
            "text": "apoC-III has been recognised as a potential therapeutic target for patients with severe hypertriglyceridaemia with one of the most promising apoC",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -9.9765625,
            "text": "apoC-III has been recognised as a potential therapeutic target for patients with severe hypertriglyceridaemia",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -9.9921875,
            "text": "apoC-III has",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -10.0625,
            "text": "apoC-III has been recognised as a potential therapeutic target for patients with severe hypertriglyceridaemia with",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -10.15625,
            "text": "apoC-III has been recognised as a potential therapeutic target for patients with severe hypertriglyceridaemia with one of the most promising apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -10.1875,
            "text": "apoC-III has been recognised as a potential therapeutic target for patients with severe hypertriglycerid",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -10.21875,
            "text": "apoC-III has been recognised",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -10.25,
            "text": "apoC-III has been recognised as a potential therapeutic target",
            "probability": 0.0
        },
        {
            "start_logit": 14.2890625,
            "end_logit": -10.2890625,
            "text": "apoC-III has been recognised as a potential therapeutic target for patients with severe hypertriglyceridaemia with one of the most promising apoC-III-",
            "probability": 0.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": -9.9140625,
            "text": "III has been recognised as a potential therapeutic target for patients with severe hypertriglyceridaemia with one of the most promising apoC",
            "probability": 0.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": -9.9765625,
            "text": "III has been recognised as a potential therapeutic target for patients with severe hypertriglyceridaemia",
            "probability": 0.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": -9.9921875,
            "text": "III has",
            "probability": 0.0
        }
    ],
    "602343051cb411341a00008d_4": [
        {
            "start_logit": 14.296875,
            "end_logit": 15.1484375,
            "text": "apoC-III",
            "probability": 1.0
        },
        {
            "start_logit": -1.71484375,
            "end_logit": 15.1484375,
            "text": "III",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.296875,
            "end_logit": -2.375,
            "text": "apoC",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -4.98828125,
            "text": "apoC-",
            "probability": 0.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": 15.1484375,
            "text": "-III",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -9.015625,
            "text": "apoC-III synthesis",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 15.1484375,
            "text": "Volanesorsen, an investigational inhibitor of apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 15.1484375,
            "text": ": Volanesorsen, an investigational inhibitor of apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 15.1484375,
            "text": "BACKGROUND: Volanesorsen, an investigational inhibitor of apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -9.8984375,
            "text": "apoC-III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia syndrome (FCS),",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -10.078125,
            "text": "apoC-III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia syndrome",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -10.21875,
            "text": "apoC-III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -10.296875,
            "text": "apoC-III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia syndrome (FCS)",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -10.3203125,
            "text": "apoC-III synthesis, significantly reduced triglyceride levels in",
            "probability": 0.0
        },
        {
            "start_logit": -1.71484375,
            "end_logit": -9.015625,
            "text": "III synthesis",
            "probability": 0.0
        },
        {
            "start_logit": -1.71484375,
            "end_logit": -9.8984375,
            "text": "III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia syndrome (FCS),",
            "probability": 0.0
        },
        {
            "start_logit": -1.71484375,
            "end_logit": -10.078125,
            "text": "III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia syndrome",
            "probability": 0.0
        },
        {
            "start_logit": -1.71484375,
            "end_logit": -10.21875,
            "text": "III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia",
            "probability": 0.0
        },
        {
            "start_logit": -1.71484375,
            "end_logit": -10.296875,
            "text": "III synthesis, significantly reduced triglyceride levels in clinical trials in patients with familial chylomicronemia syndrome (FCS)",
            "probability": 0.0
        },
        {
            "start_logit": -1.71484375,
            "end_logit": -10.3203125,
            "text": "III synthesis, significantly reduced triglyceride levels in",
            "probability": 0.0
        }
    ],
    "602343051cb411341a00008d_5": [
        {
            "start_logit": 12.7578125,
            "end_logit": 12.7265625,
            "text": "APOC3",
            "probability": 0.998046875
        },
        {
            "start_logit": 12.7578125,
            "end_logit": 6.31640625,
            "text": "APOC3 mRNA",
            "probability": 0.00164794921875
        },
        {
            "start_logit": 12.7578125,
            "end_logit": 1.373046875,
            "text": "APOC3 mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoCIIIRx",
            "probability": 1.1742115020751953e-05
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -3.29296875,
            "text": "APOC",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -4.94921875,
            "end_logit": 12.7265625,
            "text": "3",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -7.62890625,
            "text": "APOC3 mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoC",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -8.828125,
            "text": "APOC3 mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoCIIIR",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -9.4375,
            "text": "APOC3 mRNA vol",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -9.53125,
            "text": "APOC3 mRNA volanesorsen (previously called ISIS 304801",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 12.7265625,
            "text": "he antisense oligonucleotide (ASO) against APOC3",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 12.7265625,
            "text": "against APOC3",
            "probability": 0.0
        },
        {
            "start_logit": -4.94921875,
            "end_logit": 6.31640625,
            "text": "3 mRNA",
            "probability": 0.0
        },
        {
            "start_logit": -5.0546875,
            "end_logit": 6.31640625,
            "text": "mRNA",
            "probability": 0.0
        },
        {
            "start_logit": -0.73388671875,
            "end_logit": 1.373046875,
            "text": "ApoCIIIRx",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 6.31640625,
            "text": "he antisense oligonucleotide (ASO) against APOC3 mRNA",
            "probability": 0.0
        },
        {
            "start_logit": -4.94921875,
            "end_logit": 1.373046875,
            "text": "3 mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoCIIIRx",
            "probability": 0.0
        },
        {
            "start_logit": -5.0546875,
            "end_logit": 1.373046875,
            "text": "mRNA volanesorsen (previously called ISIS 304801, ISIS-ApoCIIIRx",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 6.31640625,
            "text": "against APOC3 mRNA",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 1.373046875,
            "text": "x",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": 1.373046875,
            "text": "IIIRx",
            "probability": 0.0
        }
    ],
    "602343051cb411341a00008d_6": [
        {
            "start_logit": 14.2578125,
            "end_logit": 15.1796875,
            "text": "apoC-III",
            "probability": 1.0
        },
        {
            "start_logit": -1.5390625,
            "end_logit": 15.1796875,
            "text": "III",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -2.37890625,
            "text": "apoC",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -4.13671875,
            "text": "apoC-",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -8.375,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and whether apoC",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 15.1796875,
            "text": "et, it remains unclear whether apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 15.1796875,
            "text": "-III",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -8.828125,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and whether apoC-III antisense",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.28125,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and whether apoC-",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.484375,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and whether apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.4921875,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.515625,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.625,
            "text": "apoC-III glycosylation impacts TRL (triglyceride-rich lipoprotein)",
            "probability": 0.0
        },
        {
            "start_logit": 14.2578125,
            "end_logit": -9.7890625,
            "text": "apoC-III glycosylation impacts TRL (triglyceride",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 15.1796875,
            "text": "it remains unclear whether apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 15.1796875,
            "text": ", it remains unclear whether apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 15.1796875,
            "text": "remains unclear whether apoC-III",
            "probability": 0.0
        },
        {
            "start_logit": -1.5390625,
            "end_logit": -8.375,
            "text": "III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and whether apoC",
            "probability": 0.0
        },
        {
            "start_logit": -1.5390625,
            "end_logit": -8.828125,
            "text": "III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and whether apoC-III antisense",
            "probability": 0.0
        },
        {
            "start_logit": -1.5390625,
            "end_logit": -9.28125,
            "text": "III glycosylation impacts TRL (triglyceride-rich lipoprotein) clearance and whether apoC-",
            "probability": 0.0
        }
    ],
    "5e5286036d0a277941000040_1": [
        {
            "start_logit": 14.1640625,
            "end_logit": 15.03125,
            "text": "chromosome 15",
            "probability": 1.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -1.2783203125,
            "text": "chromosome",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.45703125,
            "end_logit": 15.03125,
            "text": "15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.65234375,
            "end_logit": 15.03125,
            "text": "in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": 15.03125,
            "text": "integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 15.03125,
            "text": "site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 15.03125,
            "text": "LiPS-A3 with an integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 15.03125,
            "text": "integration site. We selected one clone, LiPS-A3 with an integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.921875,
            "text": "chromosome 15 maintaining",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -10.109375,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -10.2578125,
            "text": "chromosome 15 maintaining robust expression without silencing and",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -10.265625,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase-mediated cassette",
            "probability": 0.0
        },
        {
            "start_logit": -6.65234375,
            "end_logit": -1.2783203125,
            "text": "in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": -1.2783203125,
            "text": "integration site in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": -1.2783203125,
            "text": "site in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -1.2783203125,
            "text": "LiPS-A3 with an integration site in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": -1.2783203125,
            "text": "integration site. We selected one clone, LiPS-A3 with an integration site in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -2.45703125,
            "end_logit": -9.921875,
            "text": "15 maintaining",
            "probability": 0.0
        },
        {
            "start_logit": -2.45703125,
            "end_logit": -10.109375,
            "text": "15 maintaining robust expression without silencing and demonstrate",
            "probability": 0.0
        },
        {
            "start_logit": -2.45703125,
            "end_logit": -10.2578125,
            "text": "15 maintaining robust expression without silencing and",
            "probability": 0.0
        }
    ],
    "5e5286036d0a277941000040_2": [
        {
            "start_logit": 14.6015625,
            "end_logit": 15.2265625,
            "text": "chromosome 15",
            "probability": 1.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -0.904296875,
            "text": "chromosome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.9033203125,
            "end_logit": 15.2265625,
            "text": "15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 15.2265625,
            "text": "in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": 15.2265625,
            "text": "integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 15.2265625,
            "text": "an integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 15.2265625,
            "text": "site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -9.9609375,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase-mediated cassette",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -10.0546875,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -10.09375,
            "text": "chromosome 15 maintaining robust expression without silencing and",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 15.2265625,
            "text": "We selected one clone, LiPS-A3 with an integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -10.171875,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -10.171875,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase-mediated cassette exchange",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -10.1953125,
            "text": "chromosome 15 maintaining",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.2265625,
            "text": ", LiPS-A3 with an integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -10.2109375,
            "text": "chromosome 15 maintaining robust expression without silencing",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 15.2265625,
            "text": "LiPS-A3 with an integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -7.2265625,
            "end_logit": -0.904296875,
            "text": "in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": -0.904296875,
            "text": "integration site in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -0.904296875,
            "text": "an integration site in chromosome",
            "probability": 0.0
        }
    ],
    "5e5286036d0a277941000040_3": [
        {
            "start_logit": 14.59375,
            "end_logit": 15.1953125,
            "text": "chromosome 15",
            "probability": 1.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -0.93994140625,
            "text": "chromosome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.017578125,
            "end_logit": 15.1953125,
            "text": "15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 15.1953125,
            "text": "in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": 15.1953125,
            "text": "integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 15.1953125,
            "text": "site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 15.1953125,
            "text": "an integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -9.90625,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase-mediated cassette",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -10.046875,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -10.078125,
            "text": "chromosome 15 maintaining",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -10.09375,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase-mediated cassette exchange",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -10.140625,
            "text": "chromosome 15 maintaining robust expression without silencing and",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -10.171875,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.1953125,
            "text": "We selected one clone , LiPS-A3 with an integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 15.1953125,
            "text": ", LiPS-A3 with an integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 15.1953125,
            "text": "LiPS-A3 with an integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -0.93994140625,
            "text": "in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": -0.93994140625,
            "text": "integration site in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": -0.93994140625,
            "text": "site in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -0.93994140625,
            "text": "an integration site in chromosome",
            "probability": 0.0
        }
    ],
    "5e5286036d0a277941000040_4": [
        {
            "start_logit": 14.6015625,
            "end_logit": 15.2265625,
            "text": "chromosome 15",
            "probability": 1.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -0.904296875,
            "text": "chromosome",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.9033203125,
            "end_logit": 15.2265625,
            "text": "15",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.2265625,
            "end_logit": 15.2265625,
            "text": "in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": 15.2265625,
            "text": "integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 15.2265625,
            "text": "an integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 15.2265625,
            "text": "site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -9.9609375,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase-mediated cassette",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -10.0546875,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -10.09375,
            "text": "chromosome 15 maintaining robust expression without silencing and",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 15.2265625,
            "text": "We selected one clone, LiPS-A3 with an integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -10.171875,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -10.171875,
            "text": "chromosome 15 maintaining robust expression without silencing and demonstrate that different transgenes can be inserted therein rapidly and efficiently through recombinase-mediated cassette exchange",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -10.1953125,
            "text": "chromosome 15 maintaining",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.2265625,
            "text": ", LiPS-A3 with an integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": 14.6015625,
            "end_logit": -10.2109375,
            "text": "chromosome 15 maintaining robust expression without silencing",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 15.2265625,
            "text": "LiPS-A3 with an integration site in chromosome 15",
            "probability": 0.0
        },
        {
            "start_logit": -7.2265625,
            "end_logit": -0.904296875,
            "text": "in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": -0.904296875,
            "text": "integration site in chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -0.904296875,
            "text": "an integration site in chromosome",
            "probability": 0.0
        }
    ],
    "56c1f020ef6e394741000047_1": [
        {
            "start_logit": 9.1875,
            "end_logit": 14.09375,
            "text": "focal cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -3.876953125,
            "end_logit": 14.09375,
            "text": "dysplasia",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -4.88671875,
            "end_logit": 14.09375,
            "text": "cortical dysplasia",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -10.46875,
            "end_logit": 14.09375,
            "text": "AE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.09375,
            "text": "ILAE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.453125,
            "text": "focal cortical",
            "probability": 0.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.87109375,
            "text": "focal",
            "probability": 0.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -8.234375,
            "text": "focal cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -9.0234375,
            "text": "focal cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia type IA",
            "probability": 0.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -9.375,
            "text": "focal cortical dysplasia type Ib",
            "probability": 0.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -9.5078125,
            "text": "focal cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -9.515625,
            "text": "focal cortical dysplasia type",
            "probability": 0.0
        },
        {
            "start_logit": -3.876953125,
            "end_logit": -8.234375,
            "text": "dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -4.88671875,
            "end_logit": -7.453125,
            "text": "cortical",
            "probability": 0.0
        },
        {
            "start_logit": -3.876953125,
            "end_logit": -9.0234375,
            "text": "dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia type IA",
            "probability": 0.0
        },
        {
            "start_logit": -4.88671875,
            "end_logit": -8.234375,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -3.876953125,
            "end_logit": -9.375,
            "text": "dysplasia type Ib",
            "probability": 0.0
        },
        {
            "start_logit": -3.876953125,
            "end_logit": -9.5078125,
            "text": "dysplasia type Ib, 41 with ILAE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -3.876953125,
            "end_logit": -9.515625,
            "text": "dysplasia type",
            "probability": 0.0
        },
        {
            "start_logit": -4.88671875,
            "end_logit": -9.0234375,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia type IA",
            "probability": 0.0
        }
    ],
    "56c1f020ef6e394741000047_2": [
        {
            "start_logit": 13.1328125,
            "end_logit": 14.9921875,
            "text": "focal cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -2.43359375,
            "end_logit": 14.9921875,
            "text": "dysplasia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 14.9921875,
            "text": "cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.1328125,
            "end_logit": -4.53125,
            "text": "focal",
            "probability": 0.0
        },
        {
            "start_logit": 13.1328125,
            "end_logit": -5.21875,
            "text": "focal cortical dysplasia type I or Palmini et al focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.1328125,
            "end_logit": -6.9609375,
            "text": "focal cortical",
            "probability": 0.0
        },
        {
            "start_logit": 13.1328125,
            "end_logit": -7.75390625,
            "text": "focal cortical dysplasia type I or",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 14.9921875,
            "text": "Crude analysis revealed no significant difference between patients with subtypes of ILAE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.1328125,
            "end_logit": -8.171875,
            "text": "focal cortical dysplasia type I",
            "probability": 0.0
        },
        {
            "start_logit": 13.1328125,
            "end_logit": -8.5625,
            "text": "focal cortical dysplasia type",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 14.9921875,
            "text": "of ILAE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.1328125,
            "end_logit": -9.6796875,
            "text": "focal cortical dysplasia type I or Palmini et al focal cortical dysplasia type I concerning",
            "probability": 0.0
        },
        {
            "start_logit": -2.43359375,
            "end_logit": -5.21875,
            "text": "dysplasia type I or Palmini et al focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -2.43359375,
            "end_logit": -7.75390625,
            "text": "dysplasia type I or",
            "probability": 0.0
        },
        {
            "start_logit": -2.43359375,
            "end_logit": -8.171875,
            "text": "dysplasia type I",
            "probability": 0.0
        },
        {
            "start_logit": -2.43359375,
            "end_logit": -8.5625,
            "text": "dysplasia type",
            "probability": 0.0
        },
        {
            "start_logit": -6.3515625,
            "end_logit": -5.21875,
            "text": "cortical dysplasia type I or Palmini et al focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -2.43359375,
            "end_logit": -9.6796875,
            "text": "dysplasia type I or Palmini et al focal cortical dysplasia type I concerning",
            "probability": 0.0
        },
        {
            "start_logit": -7.69140625,
            "end_logit": -5.21875,
            "text": "Palmini et al focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -6.3515625,
            "end_logit": -6.9609375,
            "text": "cortical",
            "probability": 0.0
        }
    ],
    "56c1f020ef6e394741000047_3": [
        {
            "start_logit": 13.6015625,
            "end_logit": 15.15625,
            "text": "focal cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -2.01953125,
            "end_logit": 15.15625,
            "text": "dysplasia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -3.701171875,
            "text": "focal",
            "probability": 0.0
        },
        {
            "start_logit": -6.625,
            "end_logit": 15.15625,
            "text": "cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -6.78125,
            "text": "focal cortical",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -7.88671875,
            "text": "focal cortical dysplasia of Palmini type 1a and b were compared with those in type 2a and b.",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -8.4140625,
            "text": "focal cortical dysplasia of",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 15.15625,
            "text": "confirmed focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 15.15625,
            "text": "pathologically confirmed focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -8.6171875,
            "text": "focal cortical dysplasia of Palmini type 1a",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 15.15625,
            "text": "Rates of high frequency oscillations in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.15625,
            "text": "in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.15625,
            "text": "with pathologically confirmed focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.15625,
            "text": "high frequency oscillations in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -9.265625,
            "text": "focal cortical dysplasia of Palmini type 1a and b were",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -9.28125,
            "text": "focal cortical dysplasia of Palmini type 1a and b were compared with those in",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -9.4296875,
            "text": "focal cortical dysplasia of Palmini type 1a and b were compared with",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -9.46875,
            "text": "focal cortical dysplasia of Palmini type 1a and b were compared with those in type 2a",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -9.515625,
            "text": "focal cortical dysplasia of Palmini type",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -9.578125,
            "text": "focal cortical dysplasia of Palmini type 1a and b were compared with those in type 2a and b",
            "probability": 0.0
        }
    ],
    "56c1f020ef6e394741000047_4": [
        {
            "start_logit": 11.4375,
            "end_logit": 13.046875,
            "text": "meningioangiomatosis",
            "probability": 0.99609375
        },
        {
            "start_logit": 11.4375,
            "end_logit": 7.53515625,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia",
            "probability": 0.004009246826171875
        },
        {
            "start_logit": -4.75,
            "end_logit": 13.046875,
            "text": "sis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.4375,
            "end_logit": -4.91015625,
            "text": "meningi",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -5.3515625,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with 6 of those (60%) classified as Palmini type IA",
            "probability": 0.0
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 13.046875,
            "text": "oangiomatosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 13.046875,
            "text": "matosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 13.046875,
            "text": "ngiomatosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 13.046875,
            "text": "iomatosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 13.046875,
            "text": "the meningioangiomatosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 13.046875,
            "text": "tosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 13.046875,
            "text": "tissue excised adjacent to the meningioangiomatosis",
            "probability": 0.0
        },
        {
            "start_logit": -4.75,
            "end_logit": 7.53515625,
            "text": "sis demonstrated evidence of focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -4.75390625,
            "end_logit": 7.53515625,
            "text": "cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 13.046875,
            "text": "patients (83%) who had adequate tissue excised adjacent to the meningioangiomatosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 13.046875,
            "text": "the 12 patients (83%) who had adequate tissue excised adjacent to the meningioangiomatosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -9.25,
            "text": "meningioangiomato",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -9.359375,
            "text": "meningioangio",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -9.5,
            "text": "meningioangiomatosis demonstrated",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -9.5703125,
            "text": "meningioa",
            "probability": 0.0
        }
    ],
    "56c1f020ef6e394741000047_5": [
        {
            "start_logit": 9.1875,
            "end_logit": 14.09375,
            "text": "focal cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -3.876953125,
            "end_logit": 14.09375,
            "text": "dysplasia",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -4.88671875,
            "end_logit": 14.09375,
            "text": "cortical dysplasia",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -10.46875,
            "end_logit": 14.09375,
            "text": "AE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.09375,
            "text": "ILAE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.453125,
            "text": "focal cortical",
            "probability": 0.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -7.87109375,
            "text": "focal",
            "probability": 0.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -8.234375,
            "text": "focal cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -9.0234375,
            "text": "focal cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia type IA",
            "probability": 0.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -9.375,
            "text": "focal cortical dysplasia type Ib",
            "probability": 0.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -9.5078125,
            "text": "focal cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 9.1875,
            "end_logit": -9.515625,
            "text": "focal cortical dysplasia type",
            "probability": 0.0
        },
        {
            "start_logit": -3.876953125,
            "end_logit": -8.234375,
            "text": "dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -4.88671875,
            "end_logit": -7.453125,
            "text": "cortical",
            "probability": 0.0
        },
        {
            "start_logit": -3.876953125,
            "end_logit": -9.0234375,
            "text": "dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia type IA",
            "probability": 0.0
        },
        {
            "start_logit": -4.88671875,
            "end_logit": -8.234375,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -3.876953125,
            "end_logit": -9.375,
            "text": "dysplasia type Ib",
            "probability": 0.0
        },
        {
            "start_logit": -3.876953125,
            "end_logit": -9.5078125,
            "text": "dysplasia type Ib, 41 with ILAE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -3.876953125,
            "end_logit": -9.515625,
            "text": "dysplasia type",
            "probability": 0.0
        },
        {
            "start_logit": -4.88671875,
            "end_logit": -9.0234375,
            "text": "cortical dysplasia type Ib, 41 with ILAE focal cortical dysplasia type Ic, 63 with Palmini et al focal cortical dysplasia type IA",
            "probability": 0.0
        }
    ],
    "56c1f020ef6e394741000047_6": [
        {
            "start_logit": 14.0859375,
            "end_logit": 15.2421875,
            "text": "focal cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -1.75390625,
            "end_logit": 15.2421875,
            "text": "dysplasia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -2.908203125,
            "text": "focal",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -5.76953125,
            "text": "focal cortical",
            "probability": 0.0
        },
        {
            "start_logit": -7.06640625,
            "end_logit": 15.2421875,
            "text": "cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.25,
            "text": "focal cortical dysplasia type",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.25,
            "text": "focal cortical dysplasia type I",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.84375,
            "text": "focal cortical dysplasia type I (Ib vs Ic) or Palmini et al focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 15.2421875,
            "text": "AE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 15.2421875,
            "text": "ILAE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.234375,
            "text": "focal cortical dysplasia type I (Ib vs Ic) or Palmini et al focal cortical dysplasia type I (IA vs IB).",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 15.2421875,
            "text": "histologic subtypes of ILAE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 15.2421875,
            "text": "of ILAE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.6953125,
            "text": "focal cortical dysplasia type I (Ib vs Ic) or Palmini et al focal cortical dysplasia type I (IA",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.734375,
            "text": "focal cortical dysplasia type I (Ib",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -10.015625,
            "text": "focal cortical dysplasia type I (Ib vs Ic) or Palmini et al focal cortical dysplasia type I (IA vs IB",
            "probability": 0.0
        },
        {
            "start_logit": -1.75390625,
            "end_logit": -8.25,
            "text": "dysplasia type",
            "probability": 0.0
        },
        {
            "start_logit": -1.75390625,
            "end_logit": -8.25,
            "text": "dysplasia type I",
            "probability": 0.0
        },
        {
            "start_logit": -1.75390625,
            "end_logit": -8.84375,
            "text": "dysplasia type I (Ib vs Ic) or Palmini et al focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -1.75390625,
            "end_logit": -9.234375,
            "text": "dysplasia type I (Ib vs Ic) or Palmini et al focal cortical dysplasia type I (IA vs IB).",
            "probability": 0.0
        }
    ],
    "56c1f020ef6e394741000047_7": [
        {
            "start_logit": 13.96875,
            "end_logit": 15.2109375,
            "text": "focal cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -1.900390625,
            "end_logit": 15.2109375,
            "text": "dysplasia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.96875,
            "end_logit": -3.10546875,
            "text": "focal",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -5.73046875,
            "text": "focal cortical",
            "probability": 0.0
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 15.2109375,
            "text": "cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -6.28515625,
            "text": "focal cortical dysplasia type I",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -8.3046875,
            "text": "focal cortical dysplasia type",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -8.34375,
            "text": "focal cortical dysplasia type I or Palmini et al focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -9.703125,
            "end_logit": 15.2109375,
            "text": "AE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 15.2109375,
            "text": "of ILAE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 15.2109375,
            "text": "ILAE focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.234375,
            "text": "focal cortical dysplasia type I or",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.765625,
            "text": "focal cortical dysplasia type I or Palmini et al focal cortical dysplasia type I",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.796875,
            "text": "focal cortical dysplasia type I or Palmini et al focal cortical dysplasia type I concerning",
            "probability": 0.0
        },
        {
            "start_logit": 13.96875,
            "end_logit": -9.8125,
            "text": "focal cortical dysplasia type I or Palmini et al focal cortical dysplasia type I concerning postoperative outcome according",
            "probability": 0.0
        },
        {
            "start_logit": -1.900390625,
            "end_logit": -6.28515625,
            "text": "dysplasia type I",
            "probability": 0.0
        },
        {
            "start_logit": -1.900390625,
            "end_logit": -8.3046875,
            "text": "dysplasia type",
            "probability": 0.0
        },
        {
            "start_logit": -1.900390625,
            "end_logit": -8.34375,
            "text": "dysplasia type I or Palmini et al focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -1.900390625,
            "end_logit": -9.15625,
            "text": "dysplasia type I or Palmini et al focal cortical dysplasia type I concerning postoperative outcome according to the Engel and ILAE scoring systems on seizure frequency.",
            "probability": 0.0
        },
        {
            "start_logit": -1.900390625,
            "end_logit": -9.234375,
            "text": "dysplasia type I or",
            "probability": 0.0
        }
    ],
    "56c1f020ef6e394741000047_8": [
        {
            "start_logit": 14.28125,
            "end_logit": 15.375,
            "text": "focal cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -1.330078125,
            "end_logit": 15.375,
            "text": "dysplasia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.28125,
            "end_logit": -2.501953125,
            "text": "focal",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -6.2734375,
            "text": "focal cortical dysplasia (FC",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -6.296875,
            "text": "focal cortical dysplasia (",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -6.87890625,
            "text": "focal cortical dysplasia (FCD",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 15.375,
            "text": "cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -7.1953125,
            "text": "focal cortical dysplasia (FCD) type",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -7.4453125,
            "text": "focal cortical",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -7.69140625,
            "text": "focal cortical dysplasia (FCD) type II",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -7.79296875,
            "text": "focal cortical dysplasia (FCD) type II.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 15.375,
            "text": "as focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -8.8125,
            "text": "focal cortical dysplasia (FCD)",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 15.375,
            "text": "lesions were categorized as focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 15.375,
            "text": "these lesions were categorized as focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 15.375,
            "text": "Palmini's classification system, these lesions were categorized as focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 15.375,
            "text": "categorized as focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 15.375,
            "text": ", these lesions were categorized as focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 15.375,
            "text": "to Palmini's classification system, these lesions were categorized as focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 15.375,
            "text": "were categorized as focal cortical dysplasia",
            "probability": 0.0
        }
    ],
    "56c1f020ef6e394741000047_9": [
        {
            "start_logit": 14.28125,
            "end_logit": 15.375,
            "text": "focal cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -1.330078125,
            "end_logit": 15.375,
            "text": "dysplasia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.28125,
            "end_logit": -2.501953125,
            "text": "focal",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -6.2734375,
            "text": "focal cortical dysplasia (FC",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -6.296875,
            "text": "focal cortical dysplasia (",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -6.87890625,
            "text": "focal cortical dysplasia (FCD",
            "probability": 0.0
        },
        {
            "start_logit": -8.2421875,
            "end_logit": 15.375,
            "text": "cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -7.1953125,
            "text": "focal cortical dysplasia (FCD) type",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -7.4453125,
            "text": "focal cortical",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -7.69140625,
            "text": "focal cortical dysplasia (FCD) type II",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -7.79296875,
            "text": "focal cortical dysplasia (FCD) type II.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 15.375,
            "text": "as focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -8.8125,
            "text": "focal cortical dysplasia (FCD)",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 15.375,
            "text": "lesions were categorized as focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 15.375,
            "text": "these lesions were categorized as focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 15.375,
            "text": "Palmini's classification system, these lesions were categorized as focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 15.375,
            "text": "categorized as focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 15.375,
            "text": ", these lesions were categorized as focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 15.375,
            "text": "to Palmini's classification system, these lesions were categorized as focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 15.375,
            "text": "were categorized as focal cortical dysplasia",
            "probability": 0.0
        }
    ],
    "56c1f020ef6e394741000047_10": [
        {
            "start_logit": 12.6953125,
            "end_logit": 15.0078125,
            "text": "focal cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -2.4375,
            "end_logit": 15.0078125,
            "text": "dysplasia",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.390625,
            "end_logit": 15.0078125,
            "text": "cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -5.23828125,
            "text": "focal",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -5.5546875,
            "text": "focal cortical dysplasia (FCD",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -7.609375,
            "text": "focal cortical dysplasia (FC",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -8.1484375,
            "text": "focal cortical dysplasia (",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 15.0078125,
            "text": "cortical development (mMCDs) were disclosed in three patients, focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 15.0078125,
            "text": "mMCDs) were disclosed in three patients, focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -8.5234375,
            "text": "focal cortical dysplasia (FCD)",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 15.0078125,
            "text": ", focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 15.0078125,
            "text": "In detail, according to Palmini's classification, mild malformations of cortical development (mMCDs) were disclosed in three patients, focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -8.6171875,
            "text": "focal cortical",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 15.0078125,
            "text": "of cortical development (mMCDs) were disclosed in three patients, focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 15.0078125,
            "text": "Palmini's classification, mild malformations of cortical development (mMCDs) were disclosed in three patients, focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -9.0703125,
            "text": "focal cortical dysplasia (FCD) type Ia in three patients, and FCD type Ib in five patients.",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -9.578125,
            "text": "focal cortical dysplasia (FCD) type Ia in three patients, and FCD type Ib",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -9.859375,
            "text": "focal cortical dysplasia (FCD) type Ia in three patients, and FCD",
            "probability": 0.0
        },
        {
            "start_logit": -2.4375,
            "end_logit": -5.5546875,
            "text": "dysplasia (FCD",
            "probability": 0.0
        },
        {
            "start_logit": -2.4375,
            "end_logit": -7.609375,
            "text": "dysplasia (FC",
            "probability": 0.0
        }
    ],
    "56c1f020ef6e394741000047_11": [
        {
            "start_logit": 13.6015625,
            "end_logit": 15.15625,
            "text": "focal cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -2.01953125,
            "end_logit": 15.15625,
            "text": "dysplasia",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -3.701171875,
            "text": "focal",
            "probability": 0.0
        },
        {
            "start_logit": -6.625,
            "end_logit": 15.15625,
            "text": "cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -6.78125,
            "text": "focal cortical",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -7.88671875,
            "text": "focal cortical dysplasia of Palmini type 1a and b were compared with those in type 2a and b.",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -8.4140625,
            "text": "focal cortical dysplasia of",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 15.15625,
            "text": "confirmed focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 15.15625,
            "text": "pathologically confirmed focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -8.6171875,
            "text": "focal cortical dysplasia of Palmini type 1a",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 15.15625,
            "text": "Rates of high frequency oscillations in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.15625,
            "text": "in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.15625,
            "text": "with pathologically confirmed focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.15625,
            "text": "high frequency oscillations in patients with pathologically confirmed focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -9.265625,
            "text": "focal cortical dysplasia of Palmini type 1a and b were",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -9.28125,
            "text": "focal cortical dysplasia of Palmini type 1a and b were compared with those in",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -9.4296875,
            "text": "focal cortical dysplasia of Palmini type 1a and b were compared with",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -9.46875,
            "text": "focal cortical dysplasia of Palmini type 1a and b were compared with those in type 2a",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -9.515625,
            "text": "focal cortical dysplasia of Palmini type",
            "probability": 0.0
        },
        {
            "start_logit": 13.6015625,
            "end_logit": -9.578125,
            "text": "focal cortical dysplasia of Palmini type 1a and b were compared with those in type 2a and b",
            "probability": 0.0
        }
    ],
    "56c1f020ef6e394741000047_12": [
        {
            "start_logit": 11.4375,
            "end_logit": 13.046875,
            "text": "meningioangiomatosis",
            "probability": 0.99609375
        },
        {
            "start_logit": 11.4375,
            "end_logit": 7.53515625,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia",
            "probability": 0.004009246826171875
        },
        {
            "start_logit": -4.75,
            "end_logit": 13.046875,
            "text": "sis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.4375,
            "end_logit": -4.91015625,
            "text": "meningi",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -5.3515625,
            "text": "meningioangiomatosis demonstrated evidence of focal cortical dysplasia, with 6 of those (60%) classified as Palmini type IA",
            "probability": 0.0
        },
        {
            "start_logit": -7.05859375,
            "end_logit": 13.046875,
            "text": "oangiomatosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.46484375,
            "end_logit": 13.046875,
            "text": "matosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 13.046875,
            "text": "ngiomatosis",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 13.046875,
            "text": "iomatosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 13.046875,
            "text": "the meningioangiomatosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 13.046875,
            "text": "tosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 13.046875,
            "text": "tissue excised adjacent to the meningioangiomatosis",
            "probability": 0.0
        },
        {
            "start_logit": -4.75,
            "end_logit": 7.53515625,
            "text": "sis demonstrated evidence of focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -4.75390625,
            "end_logit": 7.53515625,
            "text": "cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 13.046875,
            "text": "patients (83%) who had adequate tissue excised adjacent to the meningioangiomatosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 13.046875,
            "text": "the 12 patients (83%) who had adequate tissue excised adjacent to the meningioangiomatosis",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -9.25,
            "text": "meningioangiomato",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -9.359375,
            "text": "meningioangio",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -9.5,
            "text": "meningioangiomatosis demonstrated",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -9.5703125,
            "text": "meningioa",
            "probability": 0.0
        }
    ],
    "56c1f020ef6e394741000047_13": [
        {
            "start_logit": 14.0234375,
            "end_logit": 15.25,
            "text": "focal cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -1.7607421875,
            "end_logit": 15.25,
            "text": "dysplasia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -3.072265625,
            "text": "focal",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -6.015625,
            "text": "focal cortical",
            "probability": 0.0
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 15.25,
            "text": "cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": 15.25,
            "text": "of focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -8.9765625,
            "text": "focal cortical dysplasia have",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.1640625,
            "text": "focal cortical dysplasia have been proposed",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.46875,
            "text": "focal cortical dysplasia have been proposed - from Taylor et al. in 1971 to the last modification of Palmini classification",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.4921875,
            "text": "focal cortical dysplasia have been proposed - from Taylor et al. in 1971 to the last",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.5234375,
            "text": "focal cortical dysplasia have been proposed - from Taylor et al. in 1971",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 15.25,
            "text": "structural abnormalities of focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.7109375,
            "text": "focal cortical dysplasia have been proposed - from Taylor et al. in 1971 to the last modification of Palmini",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.7265625,
            "text": "focal cortical dysplasia have been proposed - from Taylor et al. in 1971 to the last modification of Palmini classification made by Blumcke",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.90625,
            "text": "focal cortical dysplasia have been proposed - from Taylor et al. in 1971 to the last modification of Palm",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.90625,
            "text": "focal cortical dysplasia have been proposed - from Taylor et al. in 1971 to the last modification",
            "probability": 0.0
        },
        {
            "start_logit": -1.7607421875,
            "end_logit": -8.1328125,
            "text": "dysplasia have been proposed - from Taylor et al. in 1971 to the last modification of Palmini classification made by Blumcke in 2011.",
            "probability": 0.0
        },
        {
            "start_logit": -1.7607421875,
            "end_logit": -8.6484375,
            "text": "dysplasia have been proposed - from Taylor et al. in 1971 to the last modification of Palmini classification made by Blumcke in 2011",
            "probability": 0.0
        },
        {
            "start_logit": -7.50390625,
            "end_logit": -3.072265625,
            "text": "of focal",
            "probability": 0.0
        },
        {
            "start_logit": -1.7607421875,
            "end_logit": -8.9765625,
            "text": "dysplasia have",
            "probability": 0.0
        }
    ],
    "56c1f020ef6e394741000047_14": [
        {
            "start_logit": 13.5546875,
            "end_logit": 14.5546875,
            "text": "cortical dysplasia",
            "probability": 1.0
        },
        {
            "start_logit": -3.251953125,
            "end_logit": 14.5546875,
            "text": "dysplasia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -2.69921875,
            "text": "cortical",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -7.09375,
            "text": "cortical dysplasia are recognized.Type I focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 14.5546875,
            "text": "Blumcke in 2011. In general, three types of cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 14.5546875,
            "text": "by Blumcke in 2011. In general, three types of cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 14.5546875,
            "text": "of cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.546875,
            "text": "cortical dysplasia are recognized",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 14.5546875,
            "text": "in 2011. In general, three types of cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.8125,
            "text": "cortical dysplasia are recognized.Type I",
            "probability": 0.0
        },
        {
            "start_logit": 13.5546875,
            "end_logit": -9.8828125,
            "text": "cortical dysplasia are",
            "probability": 0.0
        },
        {
            "start_logit": -3.251953125,
            "end_logit": -7.09375,
            "text": "dysplasia are recognized.Type I focal cortical dysplasia",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": -2.69921875,
            "text": "Blumcke in 2011. In general, three types of cortical",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": -2.69921875,
            "text": "by Blumcke in 2011. In general, three types of cortical",
            "probability": 0.0
        },
        {
            "start_logit": -3.251953125,
            "end_logit": -9.546875,
            "text": "dysplasia are recognized",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -2.69921875,
            "text": "of cortical",
            "probability": 0.0
        },
        {
            "start_logit": -3.251953125,
            "end_logit": -9.8125,
            "text": "dysplasia are recognized.Type I",
            "probability": 0.0
        },
        {
            "start_logit": -3.251953125,
            "end_logit": -9.8828125,
            "text": "dysplasia are",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -2.69921875,
            "text": "in 2011. In general, three types of cortical",
            "probability": 0.0
        },
        {
            "start_logit": -7.703125,
            "end_logit": -7.5,
            "text": "in the temporal lobe",
            "probability": 0.0
        }
    ],
    "58e74bff3e8b6dc87c000004_1": [
        {
            "start_logit": 10.0859375,
            "end_logit": 13.546875,
            "text": "ribosomal protein genes",
            "probability": 1.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": 1.3974609375,
            "text": "ribosomal protein",
            "probability": 5.364418029785156e-06
        },
        {
            "start_logit": -3.603515625,
            "end_logit": 13.546875,
            "text": "8 different ribosomal protein genes",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -3.865234375,
            "end_logit": 13.546875,
            "text": "genes",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -6.53515625,
            "end_logit": 13.546875,
            "text": "protein genes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.8203125,
            "end_logit": 13.546875,
            "text": "Diamond Blackfan anemia (DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.546875,
            "end_logit": 13.546875,
            "text": "different ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 13.546875,
            "text": "at least 8 different ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -6.8515625,
            "text": "ribosomal",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 13.546875,
            "text": "least 8 different ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 13.546875,
            "text": "in at least 8 different ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 13.546875,
            "text": "Blackfan anemia (DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 13.546875,
            "text": "mutations in at least 8 different ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 13.546875,
            "text": "fan anemia (DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 13.546875,
            "text": "inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 13.546875,
            "text": "(DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 13.546875,
            "text": "erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 13.546875,
            "text": "n anemia (DBA) is an inherited erythroblastopenia associated with mutations in at least 8 different ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -9.0,
            "text": "ribosomal protein genes.",
            "probability": 0.0
        },
        {
            "start_logit": -3.603515625,
            "end_logit": 1.7890625,
            "text": "8",
            "probability": 0.0
        }
    ],
    "58e74bff3e8b6dc87c000004_2": [
        {
            "start_logit": 9.9140625,
            "end_logit": 8.0546875,
            "text": "Ribosomal protein",
            "probability": 0.998046875
        },
        {
            "start_logit": 9.9140625,
            "end_logit": 1.96484375,
            "text": "Ribosomal protein genes",
            "probability": 0.0022525787353515625
        },
        {
            "start_logit": -4.59765625,
            "end_logit": 8.0546875,
            "text": "protein",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -6.48828125,
            "text": "Ribosomal",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -6.57421875,
            "text": "Ribosomal protein genes RPS10",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.60546875,
            "text": "Ribosomal protein genes RPS10 and RPS26",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.7890625,
            "text": "Ribosomal protein genes RPS10 and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3359375,
            "text": "Ribosomal protein genes RPS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -9.4453125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -9.703125,
            "text": "Ribosomal protein genes RPS10 and RPS",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -9.7578125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -9.9921875,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -10.0390625,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia",
            "probability": 0.0
        },
        {
            "start_logit": -4.59765625,
            "end_logit": 1.96484375,
            "text": "protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -5.29296875,
            "end_logit": 1.96484375,
            "text": "genes",
            "probability": 0.0
        },
        {
            "start_logit": -0.06402587890625,
            "end_logit": -6.57421875,
            "text": "RPS10",
            "probability": 0.0
        },
        {
            "start_logit": -0.06402587890625,
            "end_logit": -7.60546875,
            "text": "RPS10 and RPS26",
            "probability": 0.0
        },
        {
            "start_logit": -0.06402587890625,
            "end_logit": -7.7890625,
            "text": "RPS10 and",
            "probability": 0.0
        },
        {
            "start_logit": -0.06402587890625,
            "end_logit": -8.3359375,
            "text": "RPS",
            "probability": 0.0
        },
        {
            "start_logit": -0.06402587890625,
            "end_logit": -9.4453125,
            "text": "RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia.",
            "probability": 0.0
        }
    ],
    "58e74bff3e8b6dc87c000004_3": [
        {
            "start_logit": 11.96875,
            "end_logit": 14.2421875,
            "text": "ribosomal protein",
            "probability": 1.0
        },
        {
            "start_logit": -3.00390625,
            "end_logit": 14.2421875,
            "text": "protein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.96875,
            "end_logit": -4.96484375,
            "text": "ribosomal",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -5.26171875,
            "text": "ribosomal protein genes which",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -5.640625,
            "text": "ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 14.2421875,
            "text": "A new database for ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 14.2421875,
            "text": "new database for ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 14.2421875,
            "text": "for ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 14.2421875,
            "text": "database for ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -9.8671875,
            "text": "ribosomal protein genes which are",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -9.8828125,
            "text": "ribosomal protein genes which are mutated in Diamond-Blackfan Anemia.",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -10.03125,
            "text": "ribosomal protein genes which are mutated in Diamond-Blackfan Anemia",
            "probability": 0.0
        },
        {
            "start_logit": -3.00390625,
            "end_logit": -5.26171875,
            "text": "protein genes which",
            "probability": 0.0
        },
        {
            "start_logit": -3.00390625,
            "end_logit": -5.640625,
            "text": "protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -3.00390625,
            "end_logit": -9.8671875,
            "text": "protein genes which are",
            "probability": 0.0
        },
        {
            "start_logit": -3.00390625,
            "end_logit": -9.8828125,
            "text": "protein genes which are mutated in Diamond-Blackfan Anemia.",
            "probability": 0.0
        },
        {
            "start_logit": -3.00390625,
            "end_logit": -10.03125,
            "text": "protein genes which are mutated in Diamond-Blackfan Anemia",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": -4.96484375,
            "text": "A new database for ribosomal",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": -5.26171875,
            "text": "A new database for ribosomal protein genes which",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": -4.96484375,
            "text": "new database for ribosomal",
            "probability": 0.0
        }
    ],
    "58e74bff3e8b6dc87c000004_4": [
        {
            "start_logit": 8.0390625,
            "end_logit": 8.6640625,
            "text": "Ribosomal protein",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.0390625,
            "end_logit": 1.2060546875,
            "text": "Ribosomal protein genes",
            "probability": 0.0005745887756347656
        },
        {
            "start_logit": -4.62890625,
            "end_logit": 8.6640625,
            "text": "protein",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": 8.0390625,
            "end_logit": -7.33984375,
            "text": "Ribosomal",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.0390625,
            "end_logit": -9.0390625,
            "text": "Ribosomal protein genes RPS10 and RPS26",
            "probability": 0.0
        },
        {
            "start_logit": 8.0390625,
            "end_logit": -9.078125,
            "text": "Ribosomal protein genes RPS10 and",
            "probability": 0.0
        },
        {
            "start_logit": 8.0390625,
            "end_logit": -9.171875,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia",
            "probability": 0.0
        },
        {
            "start_logit": 8.0390625,
            "end_logit": -9.2109375,
            "text": "Ribosomal protein genes RPS",
            "probability": 0.0
        },
        {
            "start_logit": 8.0390625,
            "end_logit": -9.2421875,
            "text": "Ribosomal protein genes RPS10",
            "probability": 0.0
        },
        {
            "start_logit": 8.0390625,
            "end_logit": -9.90625,
            "text": "Ribosomal protein genes RPS10 and RPS26 are",
            "probability": 0.0
        },
        {
            "start_logit": 8.0390625,
            "end_logit": -10.1875,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly",
            "probability": 0.0
        },
        {
            "start_logit": 8.0390625,
            "end_logit": -10.1953125,
            "text": "Ribosomal protein genes RPS10 and RPS",
            "probability": 0.0
        },
        {
            "start_logit": 8.0390625,
            "end_logit": -10.34375,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan",
            "probability": 0.0
        },
        {
            "start_logit": -4.62890625,
            "end_logit": 1.2060546875,
            "text": "protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -6.62109375,
            "end_logit": 1.2060546875,
            "text": "genes",
            "probability": 0.0
        },
        {
            "start_logit": -4.62890625,
            "end_logit": -9.0390625,
            "text": "protein genes RPS10 and RPS26",
            "probability": 0.0
        },
        {
            "start_logit": -4.62890625,
            "end_logit": -9.078125,
            "text": "protein genes RPS10 and",
            "probability": 0.0
        },
        {
            "start_logit": -4.62890625,
            "end_logit": -9.171875,
            "text": "protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia",
            "probability": 0.0
        },
        {
            "start_logit": -4.62890625,
            "end_logit": -9.2109375,
            "text": "protein genes RPS",
            "probability": 0.0
        },
        {
            "start_logit": -4.62890625,
            "end_logit": -9.2421875,
            "text": "protein genes RPS10",
            "probability": 0.0
        }
    ],
    "58e74bff3e8b6dc87c000004_5": [
        {
            "start_logit": 5.03125,
            "end_logit": 11.7421875,
            "text": "ribosomal protein genes",
            "probability": 1.0
        },
        {
            "start_logit": -4.3515625,
            "end_logit": 11.7421875,
            "text": "protein genes",
            "probability": 8.350610733032227e-05
        },
        {
            "start_logit": -5.80859375,
            "end_logit": 11.7421875,
            "text": "genes",
            "probability": 1.9550323486328125e-05
        },
        {
            "start_logit": -10.109375,
            "end_logit": 11.7421875,
            "text": "several ribosomal protein genes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.03125,
            "end_logit": -3.478515625,
            "text": "ribosomal protein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.234375,
            "end_logit": 11.7421875,
            "text": "mutations in one of several ribosomal protein genes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.6875,
            "end_logit": 11.7421875,
            "text": "in one of several ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 11.7421875,
            "text": "pre-rRNA maturation patterns and the majority bear mutations in one of several ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.734375,
            "end_logit": 11.7421875,
            "text": "-rRNA maturation patterns and the majority bear mutations in one of several ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.765625,
            "end_logit": 11.7421875,
            "text": "patients exhibit abnormal pre-rRNA maturation patterns and the majority bear mutations in one of several ribosomal protein genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.03125,
            "end_logit": -5.203125,
            "text": "ribosomal protein genes that encode structural components of the ribosome essential for the correct assembly of the ribosomal subunits.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.03125,
            "end_logit": -9.0078125,
            "text": "ribosomal protein genes that",
            "probability": 0.0
        },
        {
            "start_logit": 5.03125,
            "end_logit": -9.4609375,
            "text": "ribosomal",
            "probability": 0.0
        },
        {
            "start_logit": -4.3515625,
            "end_logit": -3.478515625,
            "text": "protein",
            "probability": 0.0
        },
        {
            "start_logit": -4.3515625,
            "end_logit": -5.203125,
            "text": "protein genes that encode structural components of the ribosome essential for the correct assembly of the ribosomal subunits.",
            "probability": 0.0
        },
        {
            "start_logit": -5.80859375,
            "end_logit": -5.203125,
            "text": "genes that encode structural components of the ribosome essential for the correct assembly of the ribosomal subunits.",
            "probability": 0.0
        },
        {
            "start_logit": -4.3515625,
            "end_logit": -9.0078125,
            "text": "protein genes that",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -3.478515625,
            "text": "several ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": -3.478515625,
            "text": "mutations in one of several ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": -3.478515625,
            "text": "in one of several ribosomal protein",
            "probability": 0.0
        }
    ],
    "58e74bff3e8b6dc87c000004_6": [
        {
            "start_logit": 11.96875,
            "end_logit": 14.2421875,
            "text": "ribosomal protein",
            "probability": 1.0
        },
        {
            "start_logit": -3.00390625,
            "end_logit": 14.2421875,
            "text": "protein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 11.96875,
            "end_logit": -4.96484375,
            "text": "ribosomal",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -5.26171875,
            "text": "ribosomal protein genes which",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -5.640625,
            "text": "ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 14.2421875,
            "text": "A new database for ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 14.2421875,
            "text": "new database for ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 14.2421875,
            "text": "for ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 14.2421875,
            "text": "database for ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -9.8671875,
            "text": "ribosomal protein genes which are",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -9.8828125,
            "text": "ribosomal protein genes which are mutated in Diamond-Blackfan Anemia.",
            "probability": 0.0
        },
        {
            "start_logit": 11.96875,
            "end_logit": -10.03125,
            "text": "ribosomal protein genes which are mutated in Diamond-Blackfan Anemia",
            "probability": 0.0
        },
        {
            "start_logit": -3.00390625,
            "end_logit": -5.26171875,
            "text": "protein genes which",
            "probability": 0.0
        },
        {
            "start_logit": -3.00390625,
            "end_logit": -5.640625,
            "text": "protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -3.00390625,
            "end_logit": -9.8671875,
            "text": "protein genes which are",
            "probability": 0.0
        },
        {
            "start_logit": -3.00390625,
            "end_logit": -9.8828125,
            "text": "protein genes which are mutated in Diamond-Blackfan Anemia.",
            "probability": 0.0
        },
        {
            "start_logit": -3.00390625,
            "end_logit": -10.03125,
            "text": "protein genes which are mutated in Diamond-Blackfan Anemia",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": -4.96484375,
            "text": "A new database for ribosomal",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": -5.26171875,
            "text": "A new database for ribosomal protein genes which",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": -4.96484375,
            "text": "new database for ribosomal",
            "probability": 0.0
        }
    ],
    "58e74bff3e8b6dc87c000004_7": [
        {
            "start_logit": 11.1484375,
            "end_logit": 12.9453125,
            "text": "ribosomal protein genes",
            "probability": 0.9990234375
        },
        {
            "start_logit": 11.1484375,
            "end_logit": 5.5625,
            "text": "ribosomal protein",
            "probability": 0.0006260871887207031
        },
        {
            "start_logit": -4.359375,
            "end_logit": 12.9453125,
            "text": "genes",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.84375,
            "end_logit": 12.9453125,
            "text": "protein genes",
            "probability": 0.0
        },
        {
            "start_logit": 11.1484375,
            "end_logit": -6.12890625,
            "text": "ribosomal",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": 12.9453125,
            "text": "in ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 12.9453125,
            "text": "mutations in ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 12.9453125,
            "text": "In total, 12 (27%) of the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 12.9453125,
            "text": "12 (27%) of the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 12.9453125,
            "text": "the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 12.9453125,
            "text": "Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 12.9453125,
            "text": ", 12 (27%) of the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 12.9453125,
            "text": "of the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 12.9453125,
            "text": "27%) of the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 12.9453125,
            "text": "(27%) of the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 12.9453125,
            "text": "-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 12.9453125,
            "text": "Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 12.9453125,
            "text": "total, 12 (27%) of the Japanese Diamond-Blackfan anemia patients had mutations in ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": 11.1484375,
            "end_logit": -9.7265625,
            "text": "ribosomal protein genes.",
            "probability": 0.0
        },
        {
            "start_logit": -6.84375,
            "end_logit": 5.5625,
            "text": "protein",
            "probability": 0.0
        }
    ],
    "58e74bff3e8b6dc87c000004_8": [
        {
            "start_logit": 11.2890625,
            "end_logit": 12.921875,
            "text": "ribosomal protein genes",
            "probability": 0.994140625
        },
        {
            "start_logit": 11.2890625,
            "end_logit": 7.77734375,
            "text": "ribosomal protein",
            "probability": 0.00572967529296875
        },
        {
            "start_logit": -4.5703125,
            "end_logit": 12.921875,
            "text": "genes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 12.921875,
            "text": "protein genes",
            "probability": 0.0
        },
        {
            "start_logit": 11.2890625,
            "end_logit": -5.75,
            "text": "ribosomal",
            "probability": 0.0
        },
        {
            "start_logit": 11.2890625,
            "end_logit": -6.23046875,
            "text": "ribosomal protein genes in",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 12.921875,
            "text": "the ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 12.921875,
            "text": "Mutations in the ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": 11.2890625,
            "end_logit": -9.1171875,
            "text": "ribosomal protein genes in Japanese",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 12.921875,
            "text": "in the ribosomal protein genes",
            "probability": 0.0
        },
        {
            "start_logit": 11.2890625,
            "end_logit": -9.7109375,
            "text": "ribosomal protein genes in Japanese patients with Diamond-Blackfan anemia.",
            "probability": 0.0
        },
        {
            "start_logit": 11.2890625,
            "end_logit": -9.859375,
            "text": "ribosomal protein genes in Japanese patients with Diamond-Blackfan anemia",
            "probability": 0.0
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 7.77734375,
            "text": "protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 7.77734375,
            "text": "the ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 7.77734375,
            "text": "Mutations in the ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 7.77734375,
            "text": "in the ribosomal protein",
            "probability": 0.0
        },
        {
            "start_logit": -4.5703125,
            "end_logit": -6.23046875,
            "text": "genes in",
            "probability": 0.0
        },
        {
            "start_logit": -6.80078125,
            "end_logit": -6.23046875,
            "text": "protein genes in",
            "probability": 0.0
        },
        {
            "start_logit": -4.5703125,
            "end_logit": -9.1171875,
            "text": "genes in Japanese",
            "probability": 0.0
        },
        {
            "start_logit": -4.5703125,
            "end_logit": -9.7109375,
            "text": "genes in Japanese patients with Diamond-Blackfan anemia.",
            "probability": 0.0
        }
    ],
    "58e74bff3e8b6dc87c000004_9": [
        {
            "start_logit": 9.9140625,
            "end_logit": 8.0546875,
            "text": "Ribosomal protein",
            "probability": 0.998046875
        },
        {
            "start_logit": 9.9140625,
            "end_logit": 1.96484375,
            "text": "Ribosomal protein genes",
            "probability": 0.0022525787353515625
        },
        {
            "start_logit": -4.59765625,
            "end_logit": 8.0546875,
            "text": "protein",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -6.48828125,
            "text": "Ribosomal",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -6.57421875,
            "text": "Ribosomal protein genes RPS10",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.60546875,
            "text": "Ribosomal protein genes RPS10 and RPS26",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -7.7890625,
            "text": "Ribosomal protein genes RPS10 and",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -8.3359375,
            "text": "Ribosomal protein genes RPS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -9.4453125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -9.703125,
            "text": "Ribosomal protein genes RPS10 and RPS",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -9.7578125,
            "text": "Ribosomal protein genes RPS10 and RPS26 are",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -9.9921875,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly",
            "probability": 0.0
        },
        {
            "start_logit": 9.9140625,
            "end_logit": -10.0390625,
            "text": "Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia",
            "probability": 0.0
        },
        {
            "start_logit": -4.59765625,
            "end_logit": 1.96484375,
            "text": "protein genes",
            "probability": 0.0
        },
        {
            "start_logit": -5.29296875,
            "end_logit": 1.96484375,
            "text": "genes",
            "probability": 0.0
        },
        {
            "start_logit": -0.06402587890625,
            "end_logit": -6.57421875,
            "text": "RPS10",
            "probability": 0.0
        },
        {
            "start_logit": -0.06402587890625,
            "end_logit": -7.60546875,
            "text": "RPS10 and RPS26",
            "probability": 0.0
        },
        {
            "start_logit": -0.06402587890625,
            "end_logit": -7.7890625,
            "text": "RPS10 and",
            "probability": 0.0
        },
        {
            "start_logit": -0.06402587890625,
            "end_logit": -8.3359375,
            "text": "RPS",
            "probability": 0.0
        },
        {
            "start_logit": -0.06402587890625,
            "end_logit": -9.4453125,
            "text": "RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia.",
            "probability": 0.0
        }
    ],
    "56e857ae42442bac75000004_1": [
        {
            "start_logit": 11.6796875,
            "end_logit": 5.5390625,
            "text": "zinc",
            "probability": 1.0
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -5.015625,
            "text": "zinc ion at their active site, for proteolityc activity.",
            "probability": 2.6047229766845703e-05
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -7.0703125,
            "text": "zinc ion",
            "probability": 3.337860107421875e-06
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -9.6875,
            "text": "zinc ion at their active site, for proteolityc activity",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -10.15625,
            "text": "zinc ion at their active site",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.6796875,
            "end_logit": -10.171875,
            "text": "zinc ion at their active site,",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.46875,
            "end_logit": 5.5390625,
            "text": "recquire a zinc",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 5.5390625,
            "text": "metalloproteinases (MMPs) are a family of endopeptydases which recquire a zinc",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 5.5390625,
            "text": "matrix metalloproteinases (MMPs) are a family of endopeptydases which recquire a zinc",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": 5.5390625,
            "text": "a zinc",
            "probability": 0.0
        },
        {
            "start_logit": -8.4765625,
            "end_logit": 5.5390625,
            "text": "Extracellular matrix metalloproteinases (MMPs) are a family of endopeptydases which recquire a zinc",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": 5.5390625,
            "text": "MMPs) are a family of endopeptydases which recquire a zinc",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 5.5390625,
            "text": "ire a zinc",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 5.5390625,
            "text": "quire a zinc",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 5.5390625,
            "text": "endopeptydases which recquire a zinc",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 5.5390625,
            "text": "eptydases which recquire a zinc",
            "probability": 0.0
        },
        {
            "start_logit": -7.46875,
            "end_logit": -5.015625,
            "text": "recquire a zinc ion at their active site, for proteolityc activity.",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": -5.015625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -8.40625,
            "end_logit": -5.015625,
            "text": "a zinc ion at their active site, for proteolityc activity.",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": -5.015625,
            "text": "MMPs) are a family of endopeptydases which recquire a zinc ion at their active site, for proteolityc activity.",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_1": [
        {
            "start_logit": 14.0625,
            "end_logit": 14.84375,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -2.625,
            "end_logit": 14.84375,
            "text": "myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0625,
            "end_logit": -2.310546875,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.265625,
            "end_logit": 14.84375,
            "text": "in multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -9.8359375,
            "text": "multiple myeloma. Some of these agents such as belantamab mafodotin",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -10.0234375,
            "text": "multiple myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -10.140625,
            "text": "multiple myeloma. Some of these agents such as belantamab",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 14.84375,
            "text": "become a key target for antibody-drug conjugates, bispecific antibodies, chimeric antigen receptor T-cell therapies, and other immunotherapies in multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 14.84375,
            "text": "immunotherapies in multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -2.625,
            "end_logit": -9.8359375,
            "text": "myeloma. Some of these agents such as belantamab mafodotin",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -2.310546875,
            "text": "in multiple",
            "probability": 0.0
        },
        {
            "start_logit": -2.625,
            "end_logit": -10.0234375,
            "text": "myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -2.625,
            "end_logit": -10.140625,
            "text": "myeloma. Some of these agents such as belantamab",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": -2.310546875,
            "text": "become a key target for antibody-drug conjugates, bispecific antibodies, chimeric antigen receptor T-cell therapies, and other immunotherapies in multiple",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": -2.310546875,
            "text": "immunotherapies in multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": -9.2890625,
            "text": "B-cell maturation",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": -9.421875,
            "text": "B-cell maturation antigen (BCMA)",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": -9.734375,
            "text": "B-cell maturation antigen (BC",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": -9.7890625,
            "text": "B-cell maturation antigen (BCMA",
            "probability": 0.0
        },
        {
            "start_logit": -8.4140625,
            "end_logit": -9.8828125,
            "text": "B-cell maturation antigen (BCMA) has become a key target",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_2": [
        {
            "start_logit": 14.3515625,
            "end_logit": 15.1328125,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -2.044921875,
            "end_logit": 15.1328125,
            "text": "myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -1.8662109375,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 15.1328125,
            "text": "treatment of patients with relapsed or refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 15.1328125,
            "text": "refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 15.1328125,
            "text": "patients with relapsed or refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 15.1328125,
            "text": "KarMMa for the treatment of patients with relapsed or refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 15.1328125,
            "text": "with relapsed or refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -9.9375,
            "text": "multiple myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 15.1328125,
            "text": "versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 15.1328125,
            "text": "in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.1328125,
            "text": "or refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.1328125,
            "text": "the treatment of patients with relapsed or refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 15.1328125,
            "text": "of patients with relapsed or refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 15.1328125,
            "text": "for the treatment of patients with relapsed or refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -2.044921875,
            "end_logit": -9.9375,
            "text": "myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -1.8662109375,
            "text": "treatment of patients with relapsed or refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -1.8662109375,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": -1.8662109375,
            "text": "patients with relapsed or refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -1.8662109375,
            "text": "KarMMa for the treatment of patients with relapsed or refractory multiple",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_3": [
        {
            "start_logit": 14.5625,
            "end_logit": 15.2265625,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.8095703125,
            "end_logit": 15.2265625,
            "text": "myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5625,
            "end_logit": -1.359375,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.0703125,
            "end_logit": 15.2265625,
            "text": "KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.71875,
            "text": "multiple myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 15.2265625,
            "text": "in relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 15.2265625,
            "text": "real-world outcomes in relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 15.2265625,
            "text": "refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 15.2265625,
            "text": "MMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 15.2265625,
            "text": "-world outcomes in relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 15.2265625,
            "text": "idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 15.2265625,
            "text": "outcomes in relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 15.2265625,
            "text": ": comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 15.2265625,
            "text": "and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": -1.359375,
            "text": "KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -1.8095703125,
            "end_logit": -9.71875,
            "text": "myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": -1.359375,
            "text": "in relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -1.359375,
            "text": "real-world outcomes in relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -1.359375,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -1.359375,
            "text": "MMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_4": [
        {
            "start_logit": 14.5625,
            "end_logit": 15.21875,
            "text": "Multiple Myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.8525390625,
            "end_logit": 15.21875,
            "text": "Myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5625,
            "end_logit": -1.4296875,
            "text": "Multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.3671875,
            "end_logit": 15.21875,
            "text": "Refractory Multiple Myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 15.21875,
            "text": "Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.3984375,
            "text": "Multiple Myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 15.21875,
            "text": "in Relapsed and Refractory Multiple Myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 15.21875,
            "text": "and Refractory Multiple Myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 15.21875,
            "text": "Relapsed and Refractory Multiple Myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 15.21875,
            "text": "cabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 15.21875,
            "text": "Vicleucel in Relapsed and Refractory Multiple Myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 15.21875,
            "text": "agene Vicleucel in Relapsed and Refractory Multiple Myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.3671875,
            "end_logit": -1.4296875,
            "text": "Refractory Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": -1.4296875,
            "text": "Idecabtagene Vicleucel in Relapsed and Refractory Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -1.8525390625,
            "end_logit": -9.3984375,
            "text": "Myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": -1.4296875,
            "text": "in Relapsed and Refractory Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": -1.4296875,
            "text": "and Refractory Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -1.4296875,
            "text": "Relapsed and Refractory Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": -1.4296875,
            "text": "cabtagene Vicleucel in Relapsed and Refractory Multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -1.4296875,
            "text": "Vicleucel in Relapsed and Refractory Multiple",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_5": [
        {
            "start_logit": 14.5,
            "end_logit": 15.203125,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.8076171875,
            "end_logit": 15.203125,
            "text": "myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5,
            "end_logit": -1.458984375,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5,
            "end_logit": -9.640625,
            "text": "multiple myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 15.203125,
            "text": "idecabtagene vicleucel and its future role in the changing treatment landscape of relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 15.203125,
            "text": "refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 15.203125,
            "text": "of relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 15.203125,
            "text": "and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 15.203125,
            "text": "clinical development of idecabtagene vicleucel and its future role in the changing treatment landscape of relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 15.203125,
            "text": "vicleucel and its future role in the changing treatment landscape of relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 15.203125,
            "text": "relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 15.203125,
            "text": "its future role in the changing treatment landscape of relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 15.203125,
            "text": "future role in the changing treatment landscape of relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 15.203125,
            "text": "cabtagene vicleucel and its future role in the changing treatment landscape of relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -1.8076171875,
            "end_logit": -9.640625,
            "text": "myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -1.458984375,
            "text": "idecabtagene vicleucel and its future role in the changing treatment landscape of relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -1.458984375,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": -1.458984375,
            "text": "of relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": -1.458984375,
            "text": "and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": -1.458984375,
            "text": "clinical development of idecabtagene vicleucel and its future role in the changing treatment landscape of relapsed and refractory multiple",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_6": [
        {
            "start_logit": 13.75,
            "end_logit": 15.0234375,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -2.17578125,
            "end_logit": 15.0234375,
            "text": "myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.75,
            "end_logit": -2.544921875,
            "text": "multiple",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": 15.0234375,
            "text": "refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 15.0234375,
            "text": "treat refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 15.0234375,
            "text": "gain regulatory US Food and Drug Administration approval to treat refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 15.0234375,
            "text": "idecabtagene vicleucel is the first CAR-T to gain regulatory US Food and Drug Administration approval to treat refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -9.765625,
            "text": "multiple myeloma patients who have already been exposed to antibodies against CD38",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -10.0546875,
            "text": "multiple myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the last",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -10.15625,
            "text": "multiple myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the last therapy.",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -10.234375,
            "text": "multiple myeloma patients who have already been exposed to antibodies against CD38, proteasome",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -10.25,
            "text": "multiple myeloma patients",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": -2.544921875,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -2.17578125,
            "end_logit": -9.765625,
            "text": "myeloma patients who have already been exposed to antibodies against CD38",
            "probability": 0.0
        },
        {
            "start_logit": -2.17578125,
            "end_logit": -10.0546875,
            "text": "myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the last",
            "probability": 0.0
        },
        {
            "start_logit": -2.17578125,
            "end_logit": -10.15625,
            "text": "myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the last therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -2.17578125,
            "end_logit": -10.234375,
            "text": "myeloma patients who have already been exposed to antibodies against CD38, proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -2.17578125,
            "end_logit": -10.25,
            "text": "myeloma patients",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": -2.544921875,
            "text": "treat refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": -2.544921875,
            "text": "gain regulatory US Food and Drug Administration approval to treat refractory multiple",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_7": [
        {
            "start_logit": 13.84375,
            "end_logit": 14.9140625,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -2.3828125,
            "end_logit": 14.9140625,
            "text": "myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.84375,
            "end_logit": -2.578125,
            "text": "multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 14.9140625,
            "text": "] chimeric antigen receptor T-cell (CAR-T) therapies were single-arm studies conducted with relapse refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 14.9140625,
            "text": "refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 14.9140625,
            "text": "therapies were single-arm studies conducted with relapse refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 14.9140625,
            "text": "with relapse refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 14.9140625,
            "text": "chimeric antigen receptor T-cell (CAR-T) therapies were single-arm studies conducted with relapse refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 14.9140625,
            "text": "cell (CAR-T) therapies were single-arm studies conducted with relapse refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.9140625,
            "text": "[ide-cel] chimeric antigen receptor T-cell (CAR-T) therapies were single-arm studies conducted with relapse refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 13.84375,
            "end_logit": -9.6484375,
            "text": "multiple myeloma (MM",
            "probability": 0.0
        },
        {
            "start_logit": 13.84375,
            "end_logit": -10.0390625,
            "text": "multiple myeloma (MM) patients who were triple-class-exposed (TCE",
            "probability": 0.0
        },
        {
            "start_logit": 13.84375,
            "end_logit": -10.1953125,
            "text": "multiple myeloma (MM) patients who were triple-class-exposed (TCE) or triple-class-refractory (TCR",
            "probability": 0.0
        },
        {
            "start_logit": 13.84375,
            "end_logit": -10.2421875,
            "text": "multiple myeloma (MM)",
            "probability": 0.0
        },
        {
            "start_logit": 13.84375,
            "end_logit": -10.2578125,
            "text": "multiple myeloma (",
            "probability": 0.0
        },
        {
            "start_logit": -2.3828125,
            "end_logit": -9.6484375,
            "text": "myeloma (MM",
            "probability": 0.0
        },
        {
            "start_logit": -2.3828125,
            "end_logit": -10.0390625,
            "text": "myeloma (MM) patients who were triple-class-exposed (TCE",
            "probability": 0.0
        },
        {
            "start_logit": -2.3828125,
            "end_logit": -10.1953125,
            "text": "myeloma (MM) patients who were triple-class-exposed (TCE) or triple-class-refractory (TCR",
            "probability": 0.0
        },
        {
            "start_logit": -2.3828125,
            "end_logit": -10.2421875,
            "text": "myeloma (MM)",
            "probability": 0.0
        },
        {
            "start_logit": -2.3828125,
            "end_logit": -10.2578125,
            "text": "myeloma (",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_8": [
        {
            "start_logit": 14.171875,
            "end_logit": 15.0546875,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -2.10546875,
            "end_logit": 15.0546875,
            "text": "myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.171875,
            "end_logit": -1.9609375,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 15.0546875,
            "text": "refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 15.0546875,
            "text": "with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 15.0546875,
            "text": "patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 15.0546875,
            "text": "clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 15.0546875,
            "text": "and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -10.0234375,
            "text": "multiple myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -2.10546875,
            "end_logit": -10.0234375,
            "text": "myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": -1.9609375,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": -1.9609375,
            "text": "with relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": -1.9609375,
            "text": "patients with relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": -1.9609375,
            "text": "clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": -1.9609375,
            "text": "and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -9.71875,
            "text": "called bb2121",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -9.8046875,
            "text": "called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -9.9296875,
            "text": "called bb2121), a B-cell maturation",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -9.953125,
            "text": "called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": -10.0625,
            "text": "called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_9": [
        {
            "start_logit": 14.3203125,
            "end_logit": 15.203125,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.7705078125,
            "end_logit": 15.203125,
            "text": "myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -1.7802734375,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 15.203125,
            "text": ", bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 15.203125,
            "text": "-cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 15.203125,
            "text": "with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 15.203125,
            "text": "cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -9.6953125,
            "text": "multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 15.203125,
            "text": "patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 15.203125,
            "text": "refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 15.203125,
            "text": "and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -9.875,
            "text": "multiple myeloma (RRMM",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -10.0703125,
            "text": "multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -10.09375,
            "text": "multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome",
            "probability": 0.0
        },
        {
            "start_logit": 14.3203125,
            "end_logit": -10.171875,
            "text": "multiple myeloma (RR",
            "probability": 0.0
        },
        {
            "start_logit": -1.7705078125,
            "end_logit": -9.6953125,
            "text": "myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38",
            "probability": 0.0
        },
        {
            "start_logit": -1.7705078125,
            "end_logit": -9.875,
            "text": "myeloma (RRMM",
            "probability": 0.0
        },
        {
            "start_logit": -1.7705078125,
            "end_logit": -10.0703125,
            "text": "myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -1.7705078125,
            "end_logit": -10.09375,
            "text": "myeloma (RRMM) who have received an immunomodulatory drug, proteasome",
            "probability": 0.0
        },
        {
            "start_logit": -1.7705078125,
            "end_logit": -10.171875,
            "text": "myeloma (RR",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_10": [
        {
            "start_logit": 12.5546875,
            "end_logit": 13.9609375,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -4.3828125,
            "end_logit": 13.9609375,
            "text": "myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.5546875,
            "end_logit": -4.1484375,
            "text": "multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 13.9609375,
            "text": "refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 13.9609375,
            "text": "pretreated refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 13.9609375,
            "text": "with heavily pretreated refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 13.9609375,
            "text": "The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 13.9609375,
            "text": "heavily pretreated refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -11.1953125,
            "end_logit": 13.9609375,
            "text": "patients with heavily pretreated refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": -4.1484375,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": -4.1484375,
            "text": "pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": -4.1484375,
            "text": "with heavily pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": -4.1484375,
            "text": "The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": -4.1484375,
            "text": "heavily pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -11.1953125,
            "end_logit": -4.1484375,
            "text": "patients with heavily pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": -9.78125,
            "text": "refractory",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": -9.78125,
            "text": "pretreated refractory",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": -9.78125,
            "text": "with heavily pretreated refractory",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": -9.734375,
            "text": "The role of idecabtagene vicleucel in",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": -9.78125,
            "text": "The role of idecabtagene vicleucel in patients with heavily pretreated refractory",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_11": [
        {
            "start_logit": 14.546875,
            "end_logit": 15.2734375,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.7744140625,
            "end_logit": 15.2734375,
            "text": "myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.546875,
            "end_logit": -1.451171875,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.8984375,
            "end_logit": 15.2734375,
            "text": "refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 15.2734375,
            "text": "idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -9.46875,
            "text": "multiple myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 15.2734375,
            "text": "The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 15.2734375,
            "text": "pretreated refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 15.2734375,
            "text": "heavily pretreated refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 15.2734375,
            "text": "patients with heavily pretreated refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 15.2734375,
            "text": "with heavily pretreated refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 15.2734375,
            "text": "vicleucel in patients with heavily pretreated refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -8.8984375,
            "end_logit": -1.451171875,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -1.7744140625,
            "end_logit": -9.46875,
            "text": "myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": -1.451171875,
            "text": "idecabtagene vicleucel in patients with heavily pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -1.451171875,
            "text": "The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": -1.451171875,
            "text": "pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": -1.451171875,
            "text": "heavily pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": -1.451171875,
            "text": "patients with heavily pretreated refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": -1.451171875,
            "text": "with heavily pretreated refractory multiple",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_12": [
        {
            "start_logit": 14.3671875,
            "end_logit": 15.21875,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.740234375,
            "end_logit": 15.21875,
            "text": "myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -1.7109375,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.203125,
            "end_logit": 15.21875,
            "text": ", bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 15.21875,
            "text": "-cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 15.21875,
            "text": "cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 15.21875,
            "text": "with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -9.65625,
            "text": "multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 15.21875,
            "text": "patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 15.21875,
            "text": "bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.21875,
            "text": "chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -9.8515625,
            "text": "multiple myeloma (RRMM",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 15.21875,
            "text": "refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 15.21875,
            "text": "and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 15.21875,
            "text": "T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 15.21875,
            "text": "2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -9.9921875,
            "text": "multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -10.0390625,
            "text": "multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -10.1953125,
            "text": "multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -10.2265625,
            "text": "multiple myeloma (RR",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_13": [
        {
            "start_logit": 14.5078125,
            "end_logit": 15.3125,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.5576171875,
            "end_logit": 15.3125,
            "text": "myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -1.4912109375,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 15.3125,
            "text": "for relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 15.3125,
            "text": "gained approval by the US FDA for relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 15.3125,
            "text": "B-cell maturation antigen (BCMA), has recently gained approval by the US FDA for relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 15.3125,
            "text": "refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 15.3125,
            "text": "and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 15.3125,
            "text": "relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 15.3125,
            "text": "cell maturation antigen (BCMA), has recently gained approval by the US FDA for relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.9375,
            "text": "multiple myeloma (RRMM",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -10.3046875,
            "text": "multiple myeloma (RR",
            "probability": 0.0
        },
        {
            "start_logit": -1.5576171875,
            "end_logit": -9.9375,
            "text": "myeloma (RRMM",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -1.4912109375,
            "text": "for relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -1.5576171875,
            "end_logit": -10.3046875,
            "text": "myeloma (RR",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -1.4912109375,
            "text": "gained approval by the US FDA for relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -1.4912109375,
            "text": "B-cell maturation antigen (BCMA), has recently gained approval by the US FDA for relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -1.4912109375,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -1.4912109375,
            "text": "and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": -1.4912109375,
            "text": "relapsed and refractory multiple",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_14": [
        {
            "start_logit": 14.5390625,
            "end_logit": 15.265625,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.7490234375,
            "end_logit": 15.265625,
            "text": "myeloma",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -1.4580078125,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.140625,
            "end_logit": 15.265625,
            "text": "Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": 15.265625,
            "text": "refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 15.265625,
            "text": "cel) CAR T-cell therapy for relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 15.265625,
            "text": "ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 15.265625,
            "text": "T-cell therapy for relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -9.296875,
            "text": "multiple myeloma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 15.265625,
            "text": "relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 15.265625,
            "text": "CAR T-cell therapy for relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 15.265625,
            "text": "-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 15.265625,
            "text": "and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 15.265625,
            "text": "for relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 15.265625,
            "text": "cell therapy for relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 15.265625,
            "text": "cabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": -1.4580078125,
            "text": "Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": -1.4580078125,
            "text": "refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": -1.4580078125,
            "text": "cel) CAR T-cell therapy for relapsed and refractory multiple",
            "probability": 0.0
        },
        {
            "start_logit": -1.7490234375,
            "end_logit": -9.296875,
            "text": "myeloma.",
            "probability": 0.0
        }
    ],
    "61f7ce26882a024a1000002d_15": [
        {
            "start_logit": 14.2734375,
            "end_logit": 15.140625,
            "text": "multiple myeloma",
            "probability": 1.0
        },
        {
            "start_logit": -1.888671875,
            "end_logit": 15.140625,
            "text": "myeloma",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -1.849609375,
            "text": "multiple",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.296875,
            "text": "multiple myeloma.METHODS: In this phase 2 study, we sought to confirm the efficacy and safety of ide-cel in patients with relapsed",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 15.140625,
            "text": "refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 15.140625,
            "text": "with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 15.140625,
            "text": "and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.859375,
            "text": "multiple myeloma.METHODS: In this phase 2 study, we sought to confirm the efficacy and safety of ide-cel in patients with relapsed an",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 15.140625,
            "text": "patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.140625,
            "text": "clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -10.1328125,
            "text": "multiple myeloma.METHODS: In this phase 2 study, we sought to confirm",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -10.1953125,
            "text": "multiple myeloma.METHODS: In this phase 2 study, we sought to confirm the efficacy and safety of ide-cel in",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -10.25,
            "text": "multiple myeloma.METHODS: In this phase 2",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -10.25,
            "text": "multiple myeloma.METHODS: In this phase 2 study, we sought",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -10.265625,
            "text": "multiple myeloma.METHODS: In this phase 2 study,",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -10.265625,
            "text": "multiple myeloma.METHODS: In this phase 2 study, we sought to confirm the efficacy and safety of ide-cel",
            "probability": 0.0
        },
        {
            "start_logit": -1.888671875,
            "end_logit": -9.296875,
            "text": "myeloma.METHODS: In this phase 2 study, we sought to confirm the efficacy and safety of ide-cel in patients with relapsed",
            "probability": 0.0
        },
        {
            "start_logit": -1.888671875,
            "end_logit": -9.859375,
            "text": "myeloma.METHODS: In this phase 2 study, we sought to confirm the efficacy and safety of ide-cel in patients with relapsed an",
            "probability": 0.0
        },
        {
            "start_logit": -1.888671875,
            "end_logit": -10.1328125,
            "text": "myeloma.METHODS: In this phase 2 study, we sought to confirm",
            "probability": 0.0
        },
        {
            "start_logit": -1.888671875,
            "end_logit": -10.1953125,
            "text": "myeloma.METHODS: In this phase 2 study, we sought to confirm the efficacy and safety of ide-cel in",
            "probability": 0.0
        }
    ],
    "6200411cc9dfcb9c09000014_1": [
        {
            "start_logit": 13.9296875,
            "end_logit": 15.0234375,
            "text": "JUCHMME",
            "probability": 1.0
        },
        {
            "start_logit": -2.3046875,
            "end_logit": 15.0234375,
            "text": "E",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9296875,
            "end_logit": -2.91796875,
            "text": "JU",
            "probability": 0.0
        },
        {
            "start_logit": 13.9296875,
            "end_logit": -5.44921875,
            "text": "JUCHMME:",
            "probability": 0.0
        },
        {
            "start_logit": 13.9296875,
            "end_logit": -5.8359375,
            "text": "JUCH",
            "probability": 0.0
        },
        {
            "start_logit": -7.0703125,
            "end_logit": 15.0234375,
            "text": "MME",
            "probability": 0.0
        },
        {
            "start_logit": 13.9296875,
            "end_logit": -6.43359375,
            "text": "JUCHMM",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": 15.0234375,
            "text": "CHMME",
            "probability": 0.0
        },
        {
            "start_logit": 13.9296875,
            "end_logit": -9.3125,
            "text": "JUCHMME: a Java Utility for Class Hidden Markov Models and Extensions for biological sequence analysis.",
            "probability": 0.0
        },
        {
            "start_logit": 13.9296875,
            "end_logit": -9.8515625,
            "text": "JUCHMME: a Java Utility for Class Hidden Markov Models and Extensions for biological sequence analysis",
            "probability": 0.0
        },
        {
            "start_logit": 13.9296875,
            "end_logit": -9.984375,
            "text": "JUCHMME: a",
            "probability": 0.0
        },
        {
            "start_logit": 13.9296875,
            "end_logit": -10.0625,
            "text": "JUCHMME: a Java Utility for Class Hidden Markov Models and Extensions",
            "probability": 0.0
        },
        {
            "start_logit": 13.9296875,
            "end_logit": -10.0625,
            "text": "JUCHMME: a Java Utility for Class Hidden Markov Models and",
            "probability": 0.0
        },
        {
            "start_logit": 13.9296875,
            "end_logit": -10.078125,
            "text": "JUCHMME: a Java Utility for Class Hidden Markov Models and Extensions for biological sequence",
            "probability": 0.0
        },
        {
            "start_logit": 13.9296875,
            "end_logit": -10.0859375,
            "text": "JUCHMME: a Java Utility for Class Hidden Markov Models",
            "probability": 0.0
        },
        {
            "start_logit": 13.9296875,
            "end_logit": -10.2109375,
            "text": "JUCHMME: a Java Utility for Class Hidden Markov",
            "probability": 0.0
        },
        {
            "start_logit": -2.3046875,
            "end_logit": -5.44921875,
            "text": "E:",
            "probability": 0.0
        },
        {
            "start_logit": -2.3046875,
            "end_logit": -9.3125,
            "text": "E: a Java Utility for Class Hidden Markov Models and Extensions for biological sequence analysis.",
            "probability": 0.0
        },
        {
            "start_logit": -2.3046875,
            "end_logit": -9.8515625,
            "text": "E: a Java Utility for Class Hidden Markov Models and Extensions for biological sequence analysis",
            "probability": 0.0
        },
        {
            "start_logit": -2.3046875,
            "end_logit": -9.984375,
            "text": "E: a",
            "probability": 0.0
        }
    ],
    "6200411cc9dfcb9c09000014_2": [
        {
            "start_logit": 13.515625,
            "end_logit": 14.8359375,
            "text": "JUCHMME",
            "probability": 1.0
        },
        {
            "start_logit": -2.751953125,
            "end_logit": 14.8359375,
            "text": "E",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.515625,
            "end_logit": -3.35546875,
            "text": "JU",
            "probability": 0.0
        },
        {
            "start_logit": -6.73046875,
            "end_logit": 14.8359375,
            "text": "MME",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": 14.8359375,
            "text": "CHMME",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -6.46875,
            "text": "JUCH",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -6.8359375,
            "text": "JUCHMM",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -7.65234375,
            "text": "JUCHMME is",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -9.90625,
            "text": "JUCHMME is an open-source software package",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -10.0703125,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -10.15625,
            "text": "JUCHMME is an open",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -10.171875,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -10.234375,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs)",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -10.2421875,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs",
            "probability": 0.0
        },
        {
            "start_logit": 13.515625,
            "end_logit": -10.2578125,
            "text": "JUCHMME is an",
            "probability": 0.0
        },
        {
            "start_logit": -2.751953125,
            "end_logit": -7.65234375,
            "text": "E is",
            "probability": 0.0
        },
        {
            "start_logit": -2.751953125,
            "end_logit": -8.5859375,
            "text": "E is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs) with a discrete alphabet of symbols.",
            "probability": 0.0
        },
        {
            "start_logit": -2.751953125,
            "end_logit": -9.90625,
            "text": "E is an open-source software package",
            "probability": 0.0
        },
        {
            "start_logit": -2.751953125,
            "end_logit": -10.0703125,
            "text": "E is an open-source software package designed to fit arbitrary custom Hidden Markov Models",
            "probability": 0.0
        },
        {
            "start_logit": -2.751953125,
            "end_logit": -10.140625,
            "text": "E is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs) with a discrete alphabet of symbols",
            "probability": 0.0
        }
    ],
    "6200411cc9dfcb9c09000014_3": [
        {
            "start_logit": 13.40625,
            "end_logit": 14.7890625,
            "text": "JUCHMME",
            "probability": 1.0
        },
        {
            "start_logit": -2.826171875,
            "end_logit": 14.7890625,
            "text": "E",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.40625,
            "end_logit": -3.443359375,
            "text": "JU",
            "probability": 0.0
        },
        {
            "start_logit": -6.84375,
            "end_logit": 14.7890625,
            "text": "MME",
            "probability": 0.0
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 14.7890625,
            "text": "CHMME",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -6.453125,
            "text": "JUCH",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -6.74609375,
            "text": "JUCHMM",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 14.7890625,
            "text": ": JUCHMME",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 14.7890625,
            "text": "SUMMARY: JUCHMME",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -9.25,
            "text": "JUCHMME is",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -10.0859375,
            "text": "JUCHMME is an open-source software package",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -10.1953125,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -10.2890625,
            "text": "JUCHMME is an open",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -10.328125,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -10.34375,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -10.390625,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov",
            "probability": 0.0
        },
        {
            "start_logit": 13.40625,
            "end_logit": -10.421875,
            "text": "JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs) with a discrete alphabet",
            "probability": 0.0
        },
        {
            "start_logit": -2.826171875,
            "end_logit": -9.25,
            "text": "E is",
            "probability": 0.0
        },
        {
            "start_logit": -2.826171875,
            "end_logit": -9.9765625,
            "text": "E is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs) with a discrete alphabet of symbols.",
            "probability": 0.0
        },
        {
            "start_logit": -2.826171875,
            "end_logit": -10.0859375,
            "text": "E is an open-source software package",
            "probability": 0.0
        }
    ],
    "54f2210164850a5854000001_1": [
        {
            "start_logit": 11.8203125,
            "end_logit": 8.6796875,
            "text": "four",
            "probability": 1.0
        },
        {
            "start_logit": 11.8203125,
            "end_logit": -3.9140625,
            "text": "four disulfide bridges, which stabilize a hairpin-shaped structure with two beta sheets.",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": 11.8203125,
            "end_logit": -8.7421875,
            "text": "four disulfide bridges,",
            "probability": 0.0
        },
        {
            "start_logit": 11.8203125,
            "end_logit": -9.59375,
            "text": "four disulfide bridges",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": 8.6796875,
            "text": "Hepcidin contains eight cysteine residues that form four",
            "probability": 0.0
        },
        {
            "start_logit": 11.8203125,
            "end_logit": -10.2890625,
            "text": "four disulfide bridges, which stabilize a hairpin",
            "probability": 0.0
        },
        {
            "start_logit": 11.8203125,
            "end_logit": -10.3515625,
            "text": "four disulfide bridges, which stabilize a hairpin-",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 8.6796875,
            "text": "form four",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 8.6796875,
            "text": "cysteine residues that form four",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 8.6796875,
            "text": "residues that form four",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 8.6796875,
            "text": "contains eight cysteine residues that form four",
            "probability": 0.0
        },
        {
            "start_logit": -6.73046875,
            "end_logit": -3.9140625,
            "text": "disulfide bridges, which stabilize a hairpin-shaped structure with two beta sheets.",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": -3.9140625,
            "text": "Hepcidin contains eight cysteine residues that form four disulfide bridges, which stabilize a hairpin-shaped structure with two beta sheets.",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": -3.9140625,
            "text": "form four disulfide bridges, which stabilize a hairpin-shaped structure with two beta sheets.",
            "probability": 0.0
        },
        {
            "start_logit": -9.15625,
            "end_logit": -3.9140625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": -3.9140625,
            "text": "bridges, which stabilize a hairpin-shaped structure with two beta sheets.",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": -3.9140625,
            "text": "cysteine residues that form four disulfide bridges, which stabilize a hairpin-shaped structure with two beta sheets.",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": -3.9140625,
            "text": "two beta sheets.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -3.9140625,
            "text": "shaped structure with two beta sheets.",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": -3.9140625,
            "text": "stabilize a hairpin-shaped structure with two beta sheets.",
            "probability": 0.0
        }
    ],
    "5a7428090384be9551000001_1": [
        {
            "start_logit": 13.84375,
            "end_logit": 14.3125,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": 13.84375,
            "end_logit": -2.009765625,
            "text": "pulmonary",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.27734375,
            "end_logit": 14.3125,
            "text": "embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 14.3125,
            "text": "approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": 13.84375,
            "end_logit": -9.734375,
            "text": "pulmonary embolism (PE)",
            "probability": 0.0
        },
        {
            "start_logit": 13.84375,
            "end_logit": -9.8046875,
            "text": "pulmonary embolism (PE",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 14.3125,
            "text": "annual visits and included all patients who were suspected of having pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 14.3125,
            "text": "having pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": 13.84375,
            "end_logit": -9.875,
            "text": "pulmonary embolism (PE) and",
            "probability": 0.0
        },
        {
            "start_logit": 13.84375,
            "end_logit": -9.8984375,
            "text": "pulmonary embolism (PE) and who underwent CT pulmonary angiography between January 1, 2011",
            "probability": 0.0
        },
        {
            "start_logit": 13.84375,
            "end_logit": -10.0,
            "text": "pulmonary embolism (",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 14.3125,
            "text": "included all patients who were suspected of having pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 14.3125,
            "text": ", academic medical center ED with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 14.3125,
            "text": "medical center ED with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": 13.84375,
            "end_logit": -10.125,
            "text": "pulmonary embolism (PE) and who underwent CT pulmonary angiography",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": -2.009765625,
            "text": "approximately 60 000 annual visits and included all patients who were suspected of having pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": -2.009765625,
            "text": "annual visits and included all patients who were suspected of having pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": -2.009765625,
            "text": "having pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": -2.009765625,
            "text": "included all patients who were suspected of having pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": -2.009765625,
            "text": ", academic medical center ED with approximately 60 000 annual visits and included all patients who were suspected of having pulmonary",
            "probability": 0.0
        }
    ],
    "5a7428090384be9551000001_2": [
        {
            "start_logit": 13.46875,
            "end_logit": 13.8359375,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -2.767578125,
            "text": "pulmonary",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.8359375,
            "end_logit": 13.8359375,
            "text": "embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.2109375,
            "text": "pulmonary embolism by means of a Wells score Bayesian model: results from the ACDC collaboration.",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.28125,
            "text": "pulmonary embolism by means",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.515625,
            "text": "pulmonary embolism by means of a Wells score Bayesian model",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.5546875,
            "text": "pulmonary embolism by means of a",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.609375,
            "text": "pulmonary embolism by means of a Wells score Bayesian model: results from the ACDC collaboration",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.796875,
            "text": "pulmonary embolism by means of a Wells score",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.875,
            "text": "pulmonary embolism by means of a Wells score Bayesian",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.8828125,
            "text": "pulmonary embolism by means of a Wells",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.9375,
            "text": "pulmonary embolism by means of a Wells score Bayesian model: results from the ACDC",
            "probability": 0.0
        },
        {
            "start_logit": 13.46875,
            "end_logit": -9.9375,
            "text": "pulmonary embolism by means of",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 13.8359375,
            "text": "of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 13.8359375,
            "text": "/Q scan in the assessment of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 13.8359375,
            "text": "Incremental diagnostic quality gain of CTA over V/Q scan in the assessment of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 13.8359375,
            "text": "over V/Q scan in the assessment of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 13.8359375,
            "text": "V/Q scan in the assessment of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 13.8359375,
            "text": "diagnostic quality gain of CTA over V/Q scan in the assessment of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 13.8359375,
            "text": "Q scan in the assessment of pulmonary embolism",
            "probability": 0.0
        }
    ],
    "5a7428090384be9551000001_3": [
        {
            "start_logit": 12.3125,
            "end_logit": 13.3046875,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": -4.1484375,
            "end_logit": 13.3046875,
            "text": "embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.3125,
            "end_logit": -4.203125,
            "text": "pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -7.46875,
            "text": "pulmonary embolism (PE) by means of a Bayesian statistical model.METHODS: Wells criteria defined pretest probability",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -7.546875,
            "text": "pulmonary embolism (PE)",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -8.890625,
            "text": "pulmonary embolism (PE",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 13.3046875,
            "text": "of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 13.3046875,
            "text": "(V/Q) scan in the assessment of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 13.3046875,
            "text": "computed tomography angiography (CTA) and ventilation perfusion (V/Q) scan in the assessment of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 13.3046875,
            "text": "ventilation perfusion (V/Q) scan in the assessment of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 13.3046875,
            "text": "tomography angiography (CTA) and ventilation perfusion (V/Q) scan in the assessment of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 13.3046875,
            "text": "Our objective was to evaluate the diagnostic value of computed tomography angiography (CTA) and ventilation perfusion (V/Q) scan in the assessment of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 13.3046875,
            "text": "/Q) scan in the assessment of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -9.796875,
            "text": "pulmonary embolism (PE) by means of a",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -9.8125,
            "text": "pulmonary embolism (",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -9.96875,
            "text": "pulmonary embolism (PE) by means of a Bayesian statistical model",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -10.09375,
            "text": "pulmonary embolism (PE) by means of",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -10.1171875,
            "text": "pulmonary embolism (PE) by means",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -10.140625,
            "text": "pulmonary embolism (PE) by means of a Bayesian statistical model.METHODS: Wells criteria defined pretest probability.",
            "probability": 0.0
        },
        {
            "start_logit": -4.1484375,
            "end_logit": -7.46875,
            "text": "embolism (PE) by means of a Bayesian statistical model.METHODS: Wells criteria defined pretest probability",
            "probability": 0.0
        }
    ],
    "5a7428090384be9551000001_4": [
        {
            "start_logit": 11.5546875,
            "end_logit": 13.1171875,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": -4.296875,
            "end_logit": 13.1171875,
            "text": "embolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -4.60546875,
            "text": "pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": 13.1171875,
            "text": "in patients with pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 13.1171875,
            "text": "Quanadli index in patients with pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -8.0,
            "text": "pulmonary embolism.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 13.1171875,
            "text": "with pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 13.1171875,
            "text": "score and the Quanadli index in patients with pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 13.1171875,
            "text": "adli index in patients with pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 13.1171875,
            "text": "Wells score and the Quanadli index in patients with pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 13.1171875,
            "text": "the Wells score and the Quanadli index in patients with pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 13.1171875,
            "text": "index in patients with pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 13.1171875,
            "text": "patients with pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 13.1171875,
            "text": "the Quanadli index in patients with pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -4.296875,
            "end_logit": -8.0,
            "text": "embolism.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": -4.60546875,
            "text": "in patients with pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": -4.60546875,
            "text": "Quanadli index in patients with pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": -4.60546875,
            "text": "with pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": -4.60546875,
            "text": "score and the Quanadli index in patients with pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": -4.60546875,
            "text": "adli index in patients with pulmonary",
            "probability": 0.0
        }
    ],
    "5a7428090384be9551000001_5": [
        {
            "start_logit": 13.2421875,
            "end_logit": 13.7265625,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -3.212890625,
            "text": "pulmonary",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.921875,
            "end_logit": 13.7265625,
            "text": "embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -7.9609375,
            "text": "pulmonary embolism (PE)",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -9.515625,
            "text": "pulmonary embolism (",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 13.7265625,
            "text": "clinical probability of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -9.796875,
            "text": "pulmonary embolism (PE",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -9.796875,
            "text": "pulmonary embolism (PE) with Wells scoring system is the first step towards diagnosis of PE",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -9.8671875,
            "text": "pulmonary embolism (PE) with Wells scoring system",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -9.921875,
            "text": "pulmonary embolism (PE) with Wells scoring system is the first step towards diagnosis of PE.",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -10.0234375,
            "text": "pulmonary embolism (PE) with",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 13.7265625,
            "text": "Determining clinical probability of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -10.09375,
            "text": "pulmonary embolism (PE) with Wells",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 13.7265625,
            "text": ": Determining clinical probability of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -10.2421875,
            "text": "pulmonary embolism (PE) with Wells scoring system is",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 13.7265625,
            "text": "of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 13.7265625,
            "text": "AND AIMS: Determining clinical probability of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": 13.2421875,
            "end_logit": -10.3984375,
            "text": "pulmonary embolism (PE) with Wells scoring",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 13.7265625,
            "text": "AIMS: Determining clinical probability of pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 13.7265625,
            "text": "BACKGROUND AND AIMS: Determining clinical probability of pulmonary embolism",
            "probability": 0.0
        }
    ],
    "5a7428090384be9551000001_6": [
        {
            "start_logit": 12.890625,
            "end_logit": 13.5625,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": 12.890625,
            "end_logit": -3.392578125,
            "text": "pulmonary",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.09765625,
            "end_logit": 13.5625,
            "text": "embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.890625,
            "end_logit": -9.234375,
            "text": "pulmonary embolism prevalence was 2%, 15%, and 43%, respectively.",
            "probability": 0.0
        },
        {
            "start_logit": 12.890625,
            "end_logit": -9.296875,
            "text": "pulmonary embolism prevalence was 2%, 15%, and 43%, respectively",
            "probability": 0.0
        },
        {
            "start_logit": 12.890625,
            "end_logit": -9.3046875,
            "text": "pulmonary embolism prevalence",
            "probability": 0.0
        },
        {
            "start_logit": 12.890625,
            "end_logit": -9.4375,
            "text": "pulmonary embolism prevalence was 2%, 15%, and 43",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 13.5625,
            "text": "high pretest probability (n=14, 10%), the pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": 12.890625,
            "end_logit": -9.8984375,
            "text": "pulmonary embolism prevalence was 2%, 15%, and 43%",
            "probability": 0.0
        },
        {
            "start_logit": 12.890625,
            "end_logit": -9.9609375,
            "text": "pulmonary embolism prevalence was",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 13.5625,
            "text": "pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 13.5625,
            "text": "61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 13.5625,
            "text": "pretest probability (n=14, 10%), the pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 13.5625,
            "text": "moderate pretest probability (n=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": 12.890625,
            "end_logit": -10.0859375,
            "text": "pulmonary embolism prevalence was 2%",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 13.5625,
            "text": ", 46%), or high pretest probability (n=14, 10%), the pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 13.5625,
            "text": ", or high pretest probability (n=14, 10%), the pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 13.5625,
            "text": "=61, 46%), or high pretest probability (n=14, 10%), the pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 13.5625,
            "text": ", 10%), the pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 13.5625,
            "text": "the pulmonary embolism",
            "probability": 0.0
        }
    ],
    "5a7428090384be9551000001_7": [
        {
            "start_logit": 11.4140625,
            "end_logit": 13.21875,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": -4.5,
            "end_logit": 13.21875,
            "text": "embolism",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -4.640625,
            "text": "pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 13.21875,
            "text": ": Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 13.21875,
            "text": "/b>: Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 13.21875,
            "text": "suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 13.21875,
            "text": "Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 13.21875,
            "text": "risk stratify pretest probability in patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 13.21875,
            "text": "</b>: Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 13.21875,
            "text": "pretest probability in patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 13.21875,
            "text": "CONCLUSION</b>: Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 13.21875,
            "text": ">CONCLUSION</b>: Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": 11.4140625,
            "end_logit": -10.0078125,
            "text": "pulmonary embolism.<br",
            "probability": 0.0
        },
        {
            "start_logit": -4.5,
            "end_logit": -10.0078125,
            "text": "embolism.<br",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -4.640625,
            "text": ": Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -4.640625,
            "text": "/b>: Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": -4.640625,
            "text": "suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": -4.640625,
            "text": "<b>CONCLUSION</b>: Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": -4.640625,
            "text": "Wells Criteria have a moderate to substantial interrater agreement and reliably risk stratify pretest probability in patients with suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -4.640625,
            "text": "risk stratify pretest probability in patients with suspected pulmonary",
            "probability": 0.0
        }
    ],
    "5a7428090384be9551000001_8": [
        {
            "start_logit": 12.8203125,
            "end_logit": 13.6796875,
            "text": "pulmonary embolism",
            "probability": 1.0
        },
        {
            "start_logit": -4.17578125,
            "end_logit": 13.6796875,
            "text": "embolism",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -3.580078125,
            "text": "pulmonary",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.8203125,
            "end_logit": -9.5546875,
            "text": "pulmonary embolism.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 13.6796875,
            "text": "Wells Criteria in the evaluation of patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 13.6796875,
            "text": "suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 13.6796875,
            "text": "of Wells Criteria in the evaluation of patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 13.6796875,
            "text": "evaluation of patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 13.6796875,
            "text": "patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 13.6796875,
            "text": "with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 13.6796875,
            "text": "Prospective validation of Wells Criteria in the evaluation of patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 13.6796875,
            "text": "the evaluation of patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 13.6796875,
            "text": "of patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 13.6796875,
            "text": "validation of Wells Criteria in the evaluation of patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -11.1640625,
            "end_logit": 13.6796875,
            "text": "Criteria in the evaluation of patients with suspected pulmonary embolism",
            "probability": 0.0
        },
        {
            "start_logit": -4.17578125,
            "end_logit": -9.5546875,
            "text": "embolism.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -3.580078125,
            "text": "Wells Criteria in the evaluation of patients with suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -3.580078125,
            "text": "suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -3.580078125,
            "text": "of Wells Criteria in the evaluation of patients with suspected pulmonary",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": -3.580078125,
            "text": "evaluation of patients with suspected pulmonary",
            "probability": 0.0
        }
    ],
    "5e540c866d0a277941000052_1": [
        {
            "start_logit": 14.359375,
            "end_logit": 15.3359375,
            "text": "saracatinib",
            "probability": 1.0
        },
        {
            "start_logit": -1.3681640625,
            "end_logit": 15.3359375,
            "text": "tinib",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.359375,
            "end_logit": -2.259765625,
            "text": "sar",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -2.400390625,
            "text": "saraca",
            "probability": 0.0
        },
        {
            "start_logit": -8.9765625,
            "end_logit": 15.3359375,
            "text": "acatinib",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -8.765625,
            "text": "saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.078125,
            "text": "saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.1953125,
            "text": "saracatinib (AZD0530),",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.3671875,
            "text": "saracatinib (",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.40625,
            "text": "saracatinib (AZD0530), a c-Src/Abl kinase",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.40625,
            "text": "saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.46875,
            "text": "saracatinib (AZD0530)",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.5859375,
            "text": "saracatinib (AZD0530",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.65625,
            "text": "saracatinib (AZD0530), a c-Src/Abl kinase inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.6796875,
            "text": "saracatinib (AZ",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 15.3359375,
            "text": "Antitumor activity of saracatinib",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.71875,
            "text": "saracatinib (AZD",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.8203125,
            "text": "saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.8359375,
            "text": "saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination",
            "probability": 0.0
        },
        {
            "start_logit": -1.3681640625,
            "end_logit": -8.765625,
            "text": "tinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.",
            "probability": 0.0
        }
    ],
    "5e540c866d0a277941000052_2": [
        {
            "start_logit": 14.5078125,
            "end_logit": 15.390625,
            "text": "saracatinib",
            "probability": 1.0
        },
        {
            "start_logit": -1.2783203125,
            "end_logit": 15.390625,
            "text": "tinib",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -1.4755859375,
            "text": "saraca",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -1.8603515625,
            "text": "sar",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 15.390625,
            "text": "acatinib",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 15.390625,
            "text": ", saracatinib",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.0703125,
            "text": "saracatinib (AZ",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.0859375,
            "text": "saracatinib (",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.296875,
            "text": "saracatinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer cell lines and a NCI-N87 xenograft model.",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.5859375,
            "text": "saracatinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer cell lines and a NCI-N87",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.765625,
            "text": "saracatinib (AZD0530",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 15.390625,
            "text": "c-Src/Abl kinase inhibitor, saracatinib",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.84375,
            "text": "saracatinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.921875,
            "text": "saracatinib (AZD",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.921875,
            "text": "saracatinib (AZD0530), alone or combined with chemotherapeutic agents in",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 15.390625,
            "text": "-Src/Abl kinase inhibitor, saracatinib",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 15.390625,
            "text": "We evaluated the antitumor effect of a c-Src/Abl kinase inhibitor, saracatinib",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 15.390625,
            "text": "/Abl kinase inhibitor, saracatinib",
            "probability": 0.0
        },
        {
            "start_logit": -1.2783203125,
            "end_logit": -9.0703125,
            "text": "tinib (AZ",
            "probability": 0.0
        },
        {
            "start_logit": -1.2783203125,
            "end_logit": -9.0859375,
            "text": "tinib (",
            "probability": 0.0
        }
    ],
    "5c73ad367c78d69471000099_1": [
        {
            "start_logit": 11.6875,
            "end_logit": 11.8125,
            "text": "PDGFR\u03b1",
            "probability": 0.998046875
        },
        {
            "start_logit": 5.32421875,
            "end_logit": 11.8125,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1",
            "probability": 0.0017271041870117188
        },
        {
            "start_logit": 11.6875,
            "end_logit": 1.2783203125,
            "text": "PDGFR",
            "probability": 2.664327621459961e-05
        },
        {
            "start_logit": -4.484375,
            "end_logit": 11.8125,
            "text": "\u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 5.32421875,
            "end_logit": 1.2783203125,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.6875,
            "end_logit": -5.140625,
            "text": "PDGF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.6875,
            "end_logit": -5.4765625,
            "text": "PDGFR\u03b1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 11.8125,
            "text": "(PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 11.8125,
            "text": "to platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 11.8125,
            "text": "\u03b1 (PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -9.25,
            "end_logit": 11.8125,
            "text": "receptor-\u03b1 (PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 11.8125,
            "text": "derived growth factor receptor-\u03b1 (PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": 11.8125,
            "text": "growth factor receptor-\u03b1 (PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 11.8125,
            "text": "R\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 11.8125,
            "text": "-derived growth factor receptor-\u03b1 (PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -9.6640625,
            "text": "PDGFR\u03b1).",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 11.8125,
            "text": "factor receptor-\u03b1 (PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 11.8125,
            "text": "-\u03b1 (PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 11.8125,
            "text": "binds to platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 5.32421875,
            "end_logit": -3.814453125,
            "text": "platelet-derived growth factor receptor-\u03b1",
            "probability": 0.0
        }
    ],
    "5c73ad367c78d69471000099_2": [
        {
            "start_logit": 13.078125,
            "end_logit": 12.9296875,
            "text": "platelet-derived growth factor receptor-\u03b1",
            "probability": 1.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -1.0439453125,
            "text": "platelet-derived growth factor receptor",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -3.775390625,
            "end_logit": 12.9296875,
            "text": "\u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.078125,
            "end_logit": -4.35546875,
            "text": "platelet",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 12.9296875,
            "text": "receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 12.9296875,
            "text": "derived growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 12.9296875,
            "text": "growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -8.609375,
            "text": "platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -8.8984375,
            "text": "platelet-derived growth factor receptor-",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -8.9453125,
            "text": "platelet-derived growth factor",
            "probability": 0.0
        },
        {
            "start_logit": 13.078125,
            "end_logit": -9.140625,
            "text": "platelet-",
            "probability": 0.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": 12.9296875,
            "text": "-derived growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -9.1484375,
            "end_logit": 12.9296875,
            "text": "human platelet-derived growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 12.9296875,
            "text": "factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 12.9296875,
            "text": "-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 12.9296875,
            "text": "human IgG1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 12.9296875,
            "text": "binds the external domain of human platelet-derived growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 12.9296875,
            "text": "external domain of human platelet-derived growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 12.9296875,
            "text": "the external domain of human platelet-derived growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 12.9296875,
            "text": "-3G3) is a fully human IgG1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1",
            "probability": 0.0
        }
    ],
    "5c73ad367c78d69471000099_3": [
        {
            "start_logit": 12.046875,
            "end_logit": 5.3984375,
            "text": "platelet-derived growth factor receptor \u03b1",
            "probability": 0.9990234375
        },
        {
            "start_logit": 12.046875,
            "end_logit": -1.888671875,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGFR-\u03b1)",
            "probability": 0.0006880760192871094
        },
        {
            "start_logit": 12.046875,
            "end_logit": -5.26171875,
            "text": "platelet-derived growth factor receptor",
            "probability": 2.3543834686279297e-05
        },
        {
            "start_logit": 12.046875,
            "end_logit": -5.53515625,
            "text": "platelet",
            "probability": 1.806020736694336e-05
        },
        {
            "start_logit": 12.046875,
            "end_logit": -7.30859375,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGFR-\u03b1) preventing binding of its ligands and receptor activation.",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": 12.046875,
            "end_logit": -8.1328125,
            "text": "platelet-derived growth factor",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 12.046875,
            "end_logit": -8.4609375,
            "text": "platelet-derived growth factor receptor \u03b1 (",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 12.046875,
            "end_logit": -8.5859375,
            "text": "platelet-",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 12.046875,
            "end_logit": -8.71875,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGFR",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 12.046875,
            "end_logit": -9.3046875,
            "text": "platelet-derived growth",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 12.046875,
            "end_logit": -9.3515625,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGFR-\u03b1",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 12.046875,
            "end_logit": -9.7890625,
            "text": "platelet-derived growth factor receptor \u03b1 (PDGF",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.19140625,
            "end_logit": 5.3984375,
            "text": "\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 5.3984375,
            "text": "receptor \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -7.8046875,
            "end_logit": 5.3984375,
            "text": "to platelet-derived growth factor receptor \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -7.97265625,
            "end_logit": 5.3984375,
            "text": "derived growth factor receptor \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -8.2109375,
            "end_logit": 5.3984375,
            "text": "growth factor receptor \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 5.3984375,
            "text": "factor receptor \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 5.3984375,
            "text": "-derived growth factor receptor \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 5.3984375,
            "text": "human IgG1 monoclonal antibody that binds to platelet-derived growth factor receptor \u03b1",
            "probability": 0.0
        }
    ],
    "5c73ad367c78d69471000099_4": [
        {
            "start_logit": 10.234375,
            "end_logit": 4.671875,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1",
            "probability": 0.91162109375
        },
        {
            "start_logit": 10.234375,
            "end_logit": 2.328125,
            "text": "platelet-derived growth factor receptor-\u03b1",
            "probability": 0.08746337890625
        },
        {
            "start_logit": 2.61328125,
            "end_logit": 4.671875,
            "text": "PDGFR\u03b1",
            "probability": 0.0004470348358154297
        },
        {
            "start_logit": 10.234375,
            "end_logit": -3.0,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR",
            "probability": 0.0004246234893798828
        },
        {
            "start_logit": 10.234375,
            "end_logit": -6.0703125,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1)",
            "probability": 1.9729137420654297e-05
        },
        {
            "start_logit": 10.234375,
            "end_logit": -6.34765625,
            "text": "platelet",
            "probability": 1.5020370483398438e-05
        },
        {
            "start_logit": 10.234375,
            "end_logit": -6.69921875,
            "text": "platelet-derived growth factor receptor",
            "probability": 1.049041748046875e-05
        },
        {
            "start_logit": 10.234375,
            "end_logit": -8.5390625,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGF",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": 10.234375,
            "end_logit": -9.3359375,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1).",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 10.234375,
            "end_logit": -9.546875,
            "text": "platelet-derived growth factor receptor-\u03b1 (",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 10.234375,
            "end_logit": -9.953125,
            "text": "platelet-",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.234375,
            "end_logit": -10.2265625,
            "text": "platelet-derived growth factor",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 2.61328125,
            "end_logit": -3.0,
            "text": "PDGFR",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.99609375,
            "end_logit": 4.671875,
            "text": "to platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.203125,
            "end_logit": 4.671875,
            "text": "\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -7.84765625,
            "end_logit": 4.671875,
            "text": "\u03b1 (PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -8.0234375,
            "end_logit": 4.671875,
            "text": "(PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 2.61328125,
            "end_logit": -6.0703125,
            "text": "PDGFR\u03b1)",
            "probability": 0.0
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 4.671875,
            "text": "derived growth factor receptor-\u03b1 (PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 4.671875,
            "text": "receptor-\u03b1 (PDGFR\u03b1",
            "probability": 0.0
        }
    ],
    "5c73ad367c78d69471000099_5": [
        {
            "start_logit": 12.9375,
            "end_logit": 12.7578125,
            "text": "platelet-derived growth factor receptor \u03b1",
            "probability": 1.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": 3.041015625,
            "text": "platelet-derived growth factor receptor",
            "probability": 6.0617923736572266e-05
        },
        {
            "start_logit": 12.9375,
            "end_logit": -4.7265625,
            "text": "platelet",
            "probability": 0.0
        },
        {
            "start_logit": -4.5859375,
            "end_logit": 12.7578125,
            "text": "\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -6.265625,
            "end_logit": 12.7578125,
            "text": "human platelet-derived growth factor receptor \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 12.7578125,
            "text": "receptor \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -7.6796875,
            "text": "platelet-derived growth factor",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": 12.7578125,
            "text": "derived growth factor receptor \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 12.7578125,
            "text": "growth factor receptor \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 12.7578125,
            "text": "factor receptor \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -8.6328125,
            "end_logit": 12.7578125,
            "text": "-derived growth factor receptor \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -9.03125,
            "text": "platelet-derived growth",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -9.2890625,
            "text": "platelet-",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -9.65625,
            "text": "platelet-derived",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -9.9140625,
            "text": "platelet-derived growth factor receptor \u03b1, plus doxorubicin",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -10.0078125,
            "text": "platelet-derived growth factor receptor \u03b1, plus doxorubicin significantly improved overall survival in patients with advanced soft-tissue sarcoma",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -10.0859375,
            "text": "platelet-derived growth factor receptor \u03b1, plus doxorubicin significantly improved overall survival in patients with advanced soft-tissue sarcoma (STS) in a prior phase 1b",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -10.2421875,
            "text": "platelet-derived growth factor receptor \u03b1, plus doxorubicin significantly improved overall survival in patients with advanced soft-tissue sarcoma (STS",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 12.7578125,
            "text": "targeting human platelet-derived growth factor receptor \u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -6.265625,
            "end_logit": 3.041015625,
            "text": "human platelet-derived growth factor receptor",
            "probability": 0.0
        }
    ],
    "5c73ad367c78d69471000099_6": [
        {
            "start_logit": 13.7265625,
            "end_logit": 14.0546875,
            "text": "platelet-derived growth factor receptor-\u03b1",
            "probability": 1.0
        },
        {
            "start_logit": -3.25,
            "end_logit": 14.0546875,
            "text": "\u03b1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -3.45703125,
            "text": "platelet",
            "probability": 0.0
        },
        {
            "start_logit": -5.17578125,
            "end_logit": 14.0546875,
            "text": "derived growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -5.1953125,
            "text": "platelet-derived growth factor receptor",
            "probability": 0.0
        },
        {
            "start_logit": -6.19140625,
            "end_logit": 14.0546875,
            "text": "receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 14.0546875,
            "text": "growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": 14.0546875,
            "text": "factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -8.0078125,
            "end_logit": 14.0546875,
            "text": "-derived growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -8.34375,
            "text": "platelet-derived growth factor receptor-",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -8.7578125,
            "text": "platelet-derived growth factor",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.109375,
            "text": "platelet-",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 14.0546875,
            "text": "-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.5,
            "text": "platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": 14.0546875,
            "text": "human platelet-derived growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -9.703125,
            "text": "platelet-derived growth",
            "probability": 0.0
        },
        {
            "start_logit": 13.7265625,
            "end_logit": -10.1484375,
            "text": "platelet-derived",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.0546875,
            "text": "human IgG1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 14.0546875,
            "text": "external domain of human platelet-derived growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -5.17578125,
            "end_logit": -5.1953125,
            "text": "derived growth factor receptor",
            "probability": 0.0
        }
    ],
    "5c73ad367c78d69471000099_7": [
        {
            "start_logit": 11.734375,
            "end_logit": 12.546875,
            "text": "PDGFR\u03b1",
            "probability": 1.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -1.982421875,
            "text": "PDGFR",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -4.16796875,
            "end_logit": 12.546875,
            "text": "\u03b1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.734375,
            "end_logit": -4.97265625,
            "text": "PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 5.2890625,
            "end_logit": 1.0615234375,
            "text": "platelet-derived growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 12.546875,
            "text": "R\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 12.546875,
            "text": "Anti-PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 12.546875,
            "text": "-PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 11.734375,
            "end_logit": -10.1015625,
            "text": "PDGFR\u03b1 Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer",
            "probability": 0.0
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -4.51953125,
            "text": "platelet-derived growth factor receptor",
            "probability": 0.0
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -8.4140625,
            "text": "platelet",
            "probability": 0.0
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -8.5,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1).",
            "probability": 0.0
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -8.5,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR",
            "probability": 0.0
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -8.6796875,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -9.4140625,
            "text": "platelet-derived growth factor",
            "probability": 0.0
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -10.0859375,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGF",
            "probability": 0.0
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -10.0859375,
            "text": "platelet-derived growth factor receptor-",
            "probability": 0.0
        },
        {
            "start_logit": 5.2890625,
            "end_logit": -10.109375,
            "text": "platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1)",
            "probability": 0.0
        },
        {
            "start_logit": -6.3671875,
            "end_logit": 1.0615234375,
            "text": "to platelet-derived growth factor receptor-\u03b1",
            "probability": 0.0
        },
        {
            "start_logit": -7.51953125,
            "end_logit": 1.0615234375,
            "text": "\u03b1",
            "probability": 0.0
        }
    ],
    "5c8fe1f10101eac87000000a_1": [
        {
            "start_logit": -4.80859375,
            "end_logit": 0.4521484375,
            "text": "astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 0.67138671875
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 0.4521484375,
            "text": "NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 0.10833740234375
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 0.4521484375,
            "text": "ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 0.09014892578125
        },
        {
            "start_logit": -4.80859375,
            "end_logit": -2.822265625,
            "text": "astrocyte differentiation from neural precursor cells while RUNX2",
            "probability": 0.02532958984375
        },
        {
            "start_logit": -8.171875,
            "end_logit": 0.4521484375,
            "text": ".",
            "probability": 0.0232391357421875
        },
        {
            "start_logit": -8.40625,
            "end_logit": 0.4521484375,
            "text": "drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 0.0183868408203125
        },
        {
            "start_logit": -8.5234375,
            "end_logit": 0.4521484375,
            "text": "astrocyte maturation.",
            "probability": 0.016357421875
        },
        {
            "start_logit": -8.703125,
            "end_logit": 0.4521484375,
            "text": "neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 0.01366424560546875
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 0.4521484375,
            "text": "transcription factors that function at these elements, we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 0.00592041015625
        },
        {
            "start_logit": -6.6328125,
            "end_logit": -2.822265625,
            "text": "NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2",
            "probability": 0.0041046142578125
        },
        {
            "start_logit": -6.81640625,
            "end_logit": -2.822265625,
            "text": "ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2",
            "probability": 0.0034008026123046875
        },
        {
            "start_logit": -10.09375,
            "end_logit": 0.4521484375,
            "text": "of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 0.0034008026123046875
        },
        {
            "start_logit": -10.15625,
            "end_logit": 0.4521484375,
            "text": "at these elements, we identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 0.00319671630859375
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 0.4521484375,
            "text": "promotes astrocyte maturation.",
            "probability": 0.0025482177734375
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 0.4521484375,
            "text": "from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 0.002048492431640625
        },
        {
            "start_logit": -10.625,
            "end_logit": 0.4521484375,
            "text": "identified NFIA and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 0.0019989013671875
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 0.4521484375,
            "text": "and ATF3 as drivers of astrocyte differentiation from neural precursor cells while RUNX2 promotes astrocyte maturation.",
            "probability": 0.001644134521484375
        },
        {
            "start_logit": -10.84375,
            "end_logit": 0.4521484375,
            "text": "RUNX2 promotes astrocyte maturation.",
            "probability": 0.0016069412231445312
        },
        {
            "start_logit": -4.80859375,
            "end_logit": -5.6484375,
            "text": "astrocyte differentiation",
            "probability": 0.0015096664428710938
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 0.4521484375,
            "text": "while RUNX2 promotes astrocyte maturation.",
            "probability": 0.0014524459838867188
        }
    ],
    "5e5438c3b761aafe09000003_1": [
        {
            "start_logit": 13.828125,
            "end_logit": 15.0078125,
            "text": "senktide",
            "probability": 1.0
        },
        {
            "start_logit": -2.357421875,
            "end_logit": 15.0078125,
            "text": "ide",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.828125,
            "end_logit": -3.587890625,
            "text": "sen",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -4.46875,
            "text": "senkt",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": 15.0078125,
            "text": "ktide",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 15.0078125,
            "text": "Administration of senktide",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -8.90625,
            "text": "senktide,",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 15.0078125,
            "text": "of senktide",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.390625,
            "text": "senktide, highly potent and selective NK",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.3984375,
            "text": "senktide, highly potent and selective NK3R agonist, resulted in increase of serum LH",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.5703125,
            "text": "senktide, highly potent and selective NK3R agonist, resulted in increase of serum LH concentration, induction of VMS",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.640625,
            "text": "senktide, highly potent and selective NK3R agonist, resulted",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.6484375,
            "text": "senktide, highly potent and selective NK3R agonist,",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.671875,
            "text": "senktide, highly potent",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.6796875,
            "text": "senktide, highly potent and selective NK3R agonist",
            "probability": 0.0
        },
        {
            "start_logit": -2.357421875,
            "end_logit": -8.90625,
            "text": "ide,",
            "probability": 0.0
        },
        {
            "start_logit": -2.357421875,
            "end_logit": -9.390625,
            "text": "ide, highly potent and selective NK",
            "probability": 0.0
        },
        {
            "start_logit": -2.357421875,
            "end_logit": -9.3984375,
            "text": "ide, highly potent and selective NK3R agonist, resulted in increase of serum LH",
            "probability": 0.0
        },
        {
            "start_logit": -2.357421875,
            "end_logit": -9.5703125,
            "text": "ide, highly potent and selective NK3R agonist, resulted in increase of serum LH concentration, induction of VMS",
            "probability": 0.0
        },
        {
            "start_logit": -2.357421875,
            "end_logit": -9.640625,
            "text": "ide, highly potent and selective NK3R agonist, resulted",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_1": [
        {
            "start_logit": 14.4453125,
            "end_logit": 15.4453125,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.6005859375,
            "end_logit": 15.4453125,
            "text": "synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -2.064453125,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -5.93359375,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": 15.4453125,
            "text": "Parkinson's disease and dementia with Lewy bodies are very frequent neurological disorders of the elderly. Mutations in the alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 15.4453125,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 15.4453125,
            "text": "the alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -8.9375,
            "text": "alpha-synuclein (",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 15.4453125,
            "text": "Lewy bodies are very frequent neurological disorders of the elderly. Mutations in the alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -9.0390625,
            "text": "alpha-synuclein (alphaSYN)",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -9.046875,
            "text": "alpha-synuclein (alpha",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -9.0625,
            "text": "alpha-synuclein (alphaSYN) gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 15.4453125,
            "text": "Mutations in the alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -9.3359375,
            "text": "alpha-synuclein (alphaSYN",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -9.8125,
            "text": "alpha-synuclein (alphaSYN) gene cause Parkinson's disease, often associated with dementia",
            "probability": 0.0
        },
        {
            "start_logit": 14.4453125,
            "end_logit": -10.015625,
            "text": "alpha-synuclein (alphaSYN) gene cause Parkinson's disease, often associated with dementia.",
            "probability": 0.0
        },
        {
            "start_logit": -0.6005859375,
            "end_logit": -8.9375,
            "text": "synuclein (",
            "probability": 0.0
        },
        {
            "start_logit": -0.6005859375,
            "end_logit": -9.0390625,
            "text": "synuclein (alphaSYN)",
            "probability": 0.0
        },
        {
            "start_logit": -0.6005859375,
            "end_logit": -9.046875,
            "text": "synuclein (alpha",
            "probability": 0.0
        },
        {
            "start_logit": -0.6005859375,
            "end_logit": -9.0625,
            "text": "synuclein (alphaSYN) gene",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_2": [
        {
            "start_logit": 14.5625,
            "end_logit": 15.5625,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.45361328125,
            "end_logit": 15.5625,
            "text": "synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 14.5625,
            "end_logit": -1.6923828125,
            "text": "alpha",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5625,
            "end_logit": -5.69921875,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -8.546875,
            "end_logit": 15.5625,
            "text": "Immunohistochemistry for alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 15.5625,
            "text": "for alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 15.5625,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -8.7890625,
            "text": "alpha-synuclein revealed LBs in 31 of 290 PSP",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.0234375,
            "text": "alpha-synuclein revealed LBs in 31 of 290 PSP cases (11%).",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.1640625,
            "text": "alpha-synuclein revealed",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.4609375,
            "text": "alpha-synuclein revealed LBs in",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.5234375,
            "text": "alpha-synuclein revealed LBs in 31 of 290",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.59375,
            "text": "alpha-synuclein revealed LBs in 31",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.625,
            "text": "alpha-synuclein revealed LBs in 31 of 290 PSP cases (11%)",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.8046875,
            "text": "alpha-synuclein revealed LBs in 31 of 290 PSP cases (11%",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -10.0078125,
            "text": "alpha-synuclein revealed LBs in 31 of 290 PSP cases",
            "probability": 0.0
        },
        {
            "start_logit": -0.45361328125,
            "end_logit": -8.7890625,
            "text": "synuclein revealed LBs in 31 of 290 PSP",
            "probability": 0.0
        },
        {
            "start_logit": -0.45361328125,
            "end_logit": -9.0234375,
            "text": "synuclein revealed LBs in 31 of 290 PSP cases (11%).",
            "probability": 0.0
        },
        {
            "start_logit": -0.45361328125,
            "end_logit": -9.1640625,
            "text": "synuclein revealed",
            "probability": 0.0
        },
        {
            "start_logit": -0.45361328125,
            "end_logit": -9.4609375,
            "text": "synuclein revealed LBs in",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_3": [
        {
            "start_logit": 14.5625,
            "end_logit": 15.53125,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.53857421875,
            "end_logit": 15.53125,
            "text": "synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 14.5625,
            "end_logit": -1.7333984375,
            "text": "alpha",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5625,
            "end_logit": -4.8515625,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 15.53125,
            "text": "substantia nigra possessed alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -7.96484375,
            "text": "alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen exhibited diffuse or granular alpha-synuclein-immunostaining.",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 15.53125,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -8.8359375,
            "text": "alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 15.53125,
            "text": "The substantia nigra possessed alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.4140625,
            "text": "alpha-synuclein-",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.421875,
            "text": "alpha-synuclein-positive LB",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.5625,
            "text": "alpha-synuclein-positive",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.6171875,
            "text": "alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed,",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.65625,
            "text": "alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen exhibited diffuse or granular",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.6796875,
            "text": "alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen exhibited diffuse",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.71875,
            "text": "alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen exhibited diffuse or granular alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.75,
            "text": "alpha-synuclein-positive LB-bearing neurons that were almost evenly distributed, while",
            "probability": 0.0
        },
        {
            "start_logit": 14.5625,
            "end_logit": -9.7734375,
            "text": "alpha-synuclein-positive LB-bearing neurons",
            "probability": 0.0
        },
        {
            "start_logit": -0.53857421875,
            "end_logit": -7.96484375,
            "text": "synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen exhibited diffuse or granular alpha-synuclein-immunostaining.",
            "probability": 0.0
        },
        {
            "start_logit": -0.53857421875,
            "end_logit": -8.8359375,
            "text": "synuclein-positive LB-bearing neurons that were almost evenly distributed, while the putamen",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_4": [
        {
            "start_logit": 14.515625,
            "end_logit": 15.421875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.998046875,
            "end_logit": 15.421875,
            "text": "synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.515625,
            "end_logit": -1.8486328125,
            "text": "alpha",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.515625,
            "end_logit": -4.65625,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 15.421875,
            "text": "be alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -8.6640625,
            "end_logit": 15.421875,
            "text": "considered to be alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -8.359375,
            "text": "alpha-synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 15.421875,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 15.421875,
            "text": "Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 15.421875,
            "text": "to be alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 15.421875,
            "text": "Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 15.421875,
            "text": "protein constituent of Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 15.421875,
            "text": "Lewy bodies, is considered to be alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 15.421875,
            "text": "pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.421875,
            "text": "the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.421875,
            "text": "of Parkinson disease and dementia with Lewy bodies, is considered to be alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -0.998046875,
            "end_logit": -8.359375,
            "text": "synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -1.8486328125,
            "text": "be alpha",
            "probability": 0.0
        },
        {
            "start_logit": -8.6640625,
            "end_logit": -1.8486328125,
            "text": "considered to be alpha",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": -1.8486328125,
            "text": "Lewy bodies (LBs), the pathological hallmark of Parkinson disease and dementia with Lewy bodies, is considered to be alpha",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_5": [
        {
            "start_logit": 14.4609375,
            "end_logit": 15.578125,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.09490966796875,
            "end_logit": 15.578125,
            "text": "synuclein",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -2.08984375,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -5.140625,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 15.578125,
            "text": "Recently, alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -8.15625,
            "end_logit": 15.578125,
            "text": ", alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -7.1640625,
            "text": "alpha-synuclein (alpha",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -7.34765625,
            "text": "alpha-synuclein (alphaS)",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -7.390625,
            "text": "alpha-synuclein (",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 15.578125,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -8.5234375,
            "text": "alpha-synuclein (alphaS) has been found to be a central constituent of LB",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -8.5703125,
            "text": "alpha-synuclein (alphaS",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -8.6875,
            "text": "alpha-synuclein (alphaS) has been found to be a central constituent of LB.",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.21875,
            "text": "alpha-synuclein (alphaS) has",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.375,
            "text": "alpha-synuclein (alphaS) has been found",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.7109375,
            "text": "alpha-synuclein (alphaS) has been found to be",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -9.9921875,
            "text": "alpha-synuclein (alphaS) has been found to be a central constituent of",
            "probability": 0.0
        },
        {
            "start_logit": 14.4609375,
            "end_logit": -10.0,
            "text": "alpha-synuclein (alphaS) has been found to",
            "probability": 0.0
        },
        {
            "start_logit": -0.09490966796875,
            "end_logit": -7.1640625,
            "text": "synuclein (alpha",
            "probability": 0.0
        },
        {
            "start_logit": -0.09490966796875,
            "end_logit": -7.34765625,
            "text": "synuclein (alphaS)",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_6": [
        {
            "start_logit": 14.515625,
            "end_logit": 15.4609375,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.70556640625,
            "end_logit": 15.4609375,
            "text": "synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 14.515625,
            "end_logit": -1.794921875,
            "text": "alpha",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.515625,
            "end_logit": -4.69921875,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -6.53125,
            "end_logit": 15.4609375,
            "text": "to alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": 15.4609375,
            "text": "antibody AFshp raised specifically to alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -8.0859375,
            "text": "alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -8.515625,
            "text": "alpha-synuclein to",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 15.4609375,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -8.6015625,
            "text": "alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 15.4609375,
            "text": "the antibody AFshp raised specifically to alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 15.4609375,
            "text": "AFshp raised specifically to alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.484375,
            "text": "alpha-synuclein to label Parkinson",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.796875,
            "text": "alpha-synuclein to label Parkinson disease",
            "probability": 0.0
        },
        {
            "start_logit": -6.53125,
            "end_logit": -1.794921875,
            "text": "to alpha",
            "probability": 0.0
        },
        {
            "start_logit": -0.70556640625,
            "end_logit": -8.0859375,
            "text": "synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered",
            "probability": 0.0
        },
        {
            "start_logit": -0.70556640625,
            "end_logit": -8.515625,
            "text": "synuclein to",
            "probability": 0.0
        },
        {
            "start_logit": -0.70556640625,
            "end_logit": -8.6015625,
            "text": "synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.66015625,
            "end_logit": -1.794921875,
            "text": "antibody AFshp raised specifically to alpha",
            "probability": 0.0
        },
        {
            "start_logit": -0.70556640625,
            "end_logit": -9.484375,
            "text": "synuclein to label Parkinson",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_7": [
        {
            "start_logit": 14.203125,
            "end_logit": 15.390625,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.91162109375,
            "end_logit": 15.390625,
            "text": "synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 14.203125,
            "end_logit": -2.388671875,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -5.70703125,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": 14.203125,
            "end_logit": -7.52734375,
            "text": "alpha-synuclein.",
            "probability": 0.0
        },
        {
            "start_logit": -8.8984375,
            "end_logit": 15.390625,
            "text": "against alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 15.390625,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 15.390625,
            "text": "LBs with antibody against alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 15.390625,
            "text": "antibody against alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 15.390625,
            "text": "NFTs and neuropil threads with various antibodies against phosphorylated tau, and in LBs with antibody against alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 15.390625,
            "text": "phosphorylated tau, and in LBs with antibody against alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 15.390625,
            "text": "neuropil threads with various antibodies against phosphorylated tau, and in LBs with antibody against alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 15.390625,
            "text": "in LBs with antibody against alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 15.390625,
            "text": "tau, and in LBs with antibody against alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 15.390625,
            "text": ", and in LBs with antibody against alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.390625,
            "text": "with antibody against alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -0.91162109375,
            "end_logit": -7.52734375,
            "text": "synuclein.",
            "probability": 0.0
        },
        {
            "start_logit": -8.8984375,
            "end_logit": -2.388671875,
            "text": "against alpha",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": -2.388671875,
            "text": "LBs with antibody against alpha",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": -2.388671875,
            "text": "antibody against alpha",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_8": [
        {
            "start_logit": 14.5703125,
            "end_logit": 15.5,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.52294921875,
            "end_logit": 15.5,
            "text": "synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -1.7255859375,
            "text": "alpha",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -4.359375,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": 15.5,
            "text": "the alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -8.5078125,
            "text": "alpha-synuclein gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": 15.5,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 15.5,
            "text": "The identification of the alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.7421875,
            "text": "alpha-synuclein gene on chromosome 4q as a locus for familial Lewy-body parkinsonism and of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -10.03125,
            "text": "alpha-synuclein gene on chromosome 4q",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -10.1328125,
            "text": "alpha-synuclein gene on chromosome 4",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -10.1640625,
            "text": "alpha-synuclein gene on",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -10.2109375,
            "text": "alpha-synuclein gene on chromosome 4q as a locus for familial Lewy-body parkinsonism",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -10.2109375,
            "text": "alpha-synuclein gene on chromosome 4q as a locus for familial Lewy-body parkinsonism and",
            "probability": 0.0
        },
        {
            "start_logit": -0.52294921875,
            "end_logit": -8.5078125,
            "text": "synuclein gene",
            "probability": 0.0
        },
        {
            "start_logit": -0.52294921875,
            "end_logit": -9.7421875,
            "text": "synuclein gene on chromosome 4q as a locus for familial Lewy-body parkinsonism and of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -0.52294921875,
            "end_logit": -10.03125,
            "text": "synuclein gene on chromosome 4q",
            "probability": 0.0
        },
        {
            "start_logit": -0.52294921875,
            "end_logit": -10.1328125,
            "text": "synuclein gene on chromosome 4",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": -1.7255859375,
            "text": "the alpha",
            "probability": 0.0
        },
        {
            "start_logit": -0.52294921875,
            "end_logit": -10.1640625,
            "text": "synuclein gene on",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_9": [
        {
            "start_logit": 14.1640625,
            "end_logit": 15.1640625,
            "text": "Alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": 15.1640625,
            "text": "synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -2.55078125,
            "text": "Alpha",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -6.19140625,
            "text": "Alpha-synuclein cortical",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -6.49609375,
            "text": "Alpha-",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -8.0,
            "text": "Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": 15.1640625,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.1484375,
            "text": "Alpha-synuclein cortical Lewy bodies correlate",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.1953125,
            "text": "Alpha-synuclein cortical Lewy bodies correlate with dementia",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.4765625,
            "text": "Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.9765625,
            "text": "Alpha-synuclein cortical Lewy bodies correlate with dementia in",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -10.1796875,
            "text": "Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -10.2109375,
            "text": "Alpha-synuclein cortical Lewy bodies correlate with",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -6.19140625,
            "text": "synuclein cortical",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -8.0,
            "text": "synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -9.1484375,
            "text": "synuclein cortical Lewy bodies correlate",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -9.1953125,
            "text": "synuclein cortical Lewy bodies correlate with dementia",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -9.4765625,
            "text": "synuclein cortical Lewy bodies correlate with dementia in Parkinson",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -9.9765625,
            "text": "synuclein cortical Lewy bodies correlate with dementia in",
            "probability": 0.0
        },
        {
            "start_logit": -1.4267578125,
            "end_logit": -10.1796875,
            "text": "synuclein cortical Lewy bodies correlate with dementia in Parkinson's",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_10": [
        {
            "start_logit": 14.5859375,
            "end_logit": 15.5546875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.439697265625,
            "end_logit": 15.5546875,
            "text": "synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 14.5859375,
            "end_logit": -1.6474609375,
            "text": "alpha",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5859375,
            "end_logit": -4.91015625,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": 15.5546875,
            "text": "recent advances in immunostaining of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": 15.5546875,
            "text": "of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5859375,
            "end_logit": -8.5859375,
            "text": "alpha-synuclein have",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": 15.5546875,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 15.5546875,
            "text": "advances in immunostaining of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5859375,
            "end_logit": -9.4765625,
            "text": "alpha-synuclein have suggested the possible importance of cortical Lewy bodies (CLBs) in the brains of demented patients with PD",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 15.5546875,
            "text": "in immunostaining of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 15.5546875,
            "text": "immunostaining of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5859375,
            "end_logit": -9.65625,
            "text": "alpha-synuclein have suggested the possible importance of cortical Lewy bodies (CLBs) in the brains of demented patients with PD.",
            "probability": 0.0
        },
        {
            "start_logit": 14.5859375,
            "end_logit": -10.0703125,
            "text": "alpha-synuclein have suggested",
            "probability": 0.0
        },
        {
            "start_logit": 14.5859375,
            "end_logit": -10.09375,
            "text": "alpha-synuclein have suggested the possible importance of cortical Lewy bodies (CLBs) in the brains of demented",
            "probability": 0.0
        },
        {
            "start_logit": 14.5859375,
            "end_logit": -10.09375,
            "text": "alpha-synuclein have suggested the possible importance of cortical Lewy bodies (CLBs)",
            "probability": 0.0
        },
        {
            "start_logit": -7.34375,
            "end_logit": -1.6474609375,
            "text": "recent advances in immunostaining of alpha",
            "probability": 0.0
        },
        {
            "start_logit": -0.439697265625,
            "end_logit": -8.5859375,
            "text": "synuclein have",
            "probability": 0.0
        },
        {
            "start_logit": -0.439697265625,
            "end_logit": -9.4765625,
            "text": "synuclein have suggested the possible importance of cortical Lewy bodies (CLBs) in the brains of demented patients with PD",
            "probability": 0.0
        },
        {
            "start_logit": -0.439697265625,
            "end_logit": -9.65625,
            "text": "synuclein have suggested the possible importance of cortical Lewy bodies (CLBs) in the brains of demented patients with PD.",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_11": [
        {
            "start_logit": 14.5390625,
            "end_logit": 15.4765625,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.70703125,
            "end_logit": 15.4765625,
            "text": "synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -1.76953125,
            "text": "alpha",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -4.921875,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -6.078125,
            "text": "alpha-synuclein are highly sensitive (91%) and specific (90%) neuropathologic markers of dementia in PD",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -8.578125,
            "text": "alpha-synuclein are",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 15.4765625,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 15.4765625,
            "text": "positive for alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -9.0546875,
            "text": "alpha-synuclein are highly sensitive (91%) and specific (90%) neuropathologic markers of dementia",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 15.4765625,
            "text": "CLBs positive for alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 15.4765625,
            "text": "for alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -9.703125,
            "text": "alpha-synuclein are highly sensitive (91%)",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -9.8046875,
            "text": "alpha-synuclein are highly sensitive (91%) and specific (90%",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -9.8046875,
            "text": "alpha-synuclein are highly sensitive (91",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -9.8203125,
            "text": "alpha-synuclein are highly sensitive (91%",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 15.4765625,
            "text": "Bs positive for alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -0.70703125,
            "end_logit": -6.078125,
            "text": "synuclein are highly sensitive (91%) and specific (90%) neuropathologic markers of dementia in PD",
            "probability": 0.0
        },
        {
            "start_logit": -0.70703125,
            "end_logit": -8.578125,
            "text": "synuclein are",
            "probability": 0.0
        },
        {
            "start_logit": -0.70703125,
            "end_logit": -9.0546875,
            "text": "synuclein are highly sensitive (91%) and specific (90%) neuropathologic markers of dementia",
            "probability": 0.0
        },
        {
            "start_logit": -0.70703125,
            "end_logit": -9.703125,
            "text": "synuclein are highly sensitive (91%)",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_12": [
        {
            "start_logit": 14.15625,
            "end_logit": 15.21875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -1.294921875,
            "end_logit": 15.21875,
            "text": "synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.15625,
            "end_logit": -2.501953125,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -4.46875,
            "text": "alpha-synuclein antibodies in patients with PD are a more sensitive and specific correlate of dementia",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -5.51953125,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -7.91015625,
            "text": "alpha-synuclein antibodies",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -8.4375,
            "text": "alpha-synuclein antibodies in patients with PD",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 15.21875,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -8.9140625,
            "text": "alpha-synuclein antibodies in",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 15.21875,
            "text": "by alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 15.21875,
            "text": "CLBs detected by alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.8203125,
            "text": "alpha-synuclein antibodies in patients with PD are",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -10.0390625,
            "text": "alpha-synuclein antibodies in patients with PD are a more sensitive and specific correlate",
            "probability": 0.0
        },
        {
            "start_logit": -1.294921875,
            "end_logit": -4.46875,
            "text": "synuclein antibodies in patients with PD are a more sensitive and specific correlate of dementia",
            "probability": 0.0
        },
        {
            "start_logit": -1.294921875,
            "end_logit": -7.91015625,
            "text": "synuclein antibodies",
            "probability": 0.0
        },
        {
            "start_logit": -1.294921875,
            "end_logit": -8.4375,
            "text": "synuclein antibodies in patients with PD",
            "probability": 0.0
        },
        {
            "start_logit": -1.294921875,
            "end_logit": -8.9140625,
            "text": "synuclein antibodies in",
            "probability": 0.0
        },
        {
            "start_logit": -1.294921875,
            "end_logit": -9.8203125,
            "text": "synuclein antibodies in patients with PD are",
            "probability": 0.0
        },
        {
            "start_logit": -1.294921875,
            "end_logit": -10.0390625,
            "text": "synuclein antibodies in patients with PD are a more sensitive and specific correlate",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": -2.501953125,
            "text": "by alpha",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_13": [
        {
            "start_logit": 14.296875,
            "end_logit": 15.2421875,
            "text": "alpha-Synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -1.2490234375,
            "end_logit": 15.2421875,
            "text": "Synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.296875,
            "end_logit": -2.314453125,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -5.94921875,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -7.83984375,
            "text": "alpha-Synuclein immunoreactivity in dementia",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -8.5,
            "text": "alpha-Synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -9.0078125,
            "text": "alpha-Synuclein immunoreactivity in",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 15.2421875,
            "text": "-Synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -9.1796875,
            "text": "alpha-Synuclein immunoreactivity in dementia with Lewy bodies",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -10.03125,
            "text": "alpha-Synuclein immunoreactivity in dementia with",
            "probability": 0.0
        },
        {
            "start_logit": -1.2490234375,
            "end_logit": -7.83984375,
            "text": "Synuclein immunoreactivity in dementia",
            "probability": 0.0
        },
        {
            "start_logit": -1.2490234375,
            "end_logit": -8.5,
            "text": "Synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": -1.2490234375,
            "end_logit": -9.0078125,
            "text": "Synuclein immunoreactivity in",
            "probability": 0.0
        },
        {
            "start_logit": -1.2490234375,
            "end_logit": -9.1796875,
            "text": "Synuclein immunoreactivity in dementia with Lewy bodies",
            "probability": 0.0
        },
        {
            "start_logit": -1.2490234375,
            "end_logit": -10.03125,
            "text": "Synuclein immunoreactivity in dementia with",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -5.94921875,
            "text": "-",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -7.83984375,
            "text": "-Synuclein immunoreactivity in dementia",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -7.83984375,
            "text": "in dementia",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -8.5,
            "text": "-Synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -7.83984375,
            "text": "dementia",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_14": [
        {
            "start_logit": 14.34375,
            "end_logit": 15.4765625,
            "text": "alpha-Synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.6650390625,
            "end_logit": 15.4765625,
            "text": "Synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 14.34375,
            "end_logit": -2.271484375,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -4.76171875,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -6.06640625,
            "text": "alpha-Synuclein is",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": 15.4765625,
            "text": "-Synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -8.9921875,
            "text": "alpha-Synuclein is a presynaptic protein recently identified as a specific component of Lewy bodies (LB) and Lewy neurites.",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.203125,
            "text": "alpha-Synuclein is a presynaptic",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.2890625,
            "text": "alpha-Synuclein is a presynaptic protein",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.53125,
            "text": "alpha-Synuclein is a",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.5625,
            "text": "alpha-Synuclein is a presynaptic protein recently",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -9.796875,
            "text": "alpha-Synuclein is a presynaptic protein recently identified",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -10.1171875,
            "text": "alpha-Synuclein is a presynaptic protein recently identified as a specific component of Lewy bodies (LB",
            "probability": 0.0
        },
        {
            "start_logit": 14.34375,
            "end_logit": -10.1640625,
            "text": "alpha-Synuclein is a presynaptic protein recently identified as a specific component of Lewy bodies (LB) and Lewy neurites",
            "probability": 0.0
        },
        {
            "start_logit": -0.6650390625,
            "end_logit": -6.06640625,
            "text": "Synuclein is",
            "probability": 0.0
        },
        {
            "start_logit": -0.6650390625,
            "end_logit": -8.9921875,
            "text": "Synuclein is a presynaptic protein recently identified as a specific component of Lewy bodies (LB) and Lewy neurites.",
            "probability": 0.0
        },
        {
            "start_logit": -0.6650390625,
            "end_logit": -9.203125,
            "text": "Synuclein is a presynaptic",
            "probability": 0.0
        },
        {
            "start_logit": -0.6650390625,
            "end_logit": -9.2890625,
            "text": "Synuclein is a presynaptic protein",
            "probability": 0.0
        },
        {
            "start_logit": -0.6650390625,
            "end_logit": -9.53125,
            "text": "Synuclein is a",
            "probability": 0.0
        },
        {
            "start_logit": -0.6650390625,
            "end_logit": -9.5625,
            "text": "Synuclein is a presynaptic protein recently",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_15": [
        {
            "start_logit": 14.46875,
            "end_logit": 15.5078125,
            "text": "alpha-Synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.67822265625,
            "end_logit": 15.5078125,
            "text": "Synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 14.46875,
            "end_logit": -1.978515625,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -3.927734375,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -5.64453125,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -7.83984375,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB from globose tangles.",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 15.5078125,
            "text": "-Synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -8.7421875,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB from globose tang",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -8.8125,
            "text": "alpha-Synuclein immunostaining was",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -8.9140625,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB from globose tangles",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -9.171875,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -9.203125,
            "text": "alpha-Synuclein immunostaining",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -9.3203125,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -9.5625,
            "text": "alpha-Synuclein immunostaining was more specific than",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -9.6015625,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB from globose",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -9.625,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB from glob",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -9.671875,
            "text": "alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining",
            "probability": 0.0
        },
        {
            "start_logit": -0.67822265625,
            "end_logit": -3.927734375,
            "text": "Synuclein immunostaining was more specific than ubiquitin",
            "probability": 0.0
        },
        {
            "start_logit": -3.248046875,
            "end_logit": -3.927734375,
            "text": "ubiquitin",
            "probability": 0.0
        },
        {
            "start_logit": -0.67822265625,
            "end_logit": -7.83984375,
            "text": "Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB from globose tangles.",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_16": [
        {
            "start_logit": 14.5546875,
            "end_logit": 15.4609375,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.3798828125,
            "end_logit": 15.4609375,
            "text": "synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -1.650390625,
            "text": "alpha",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.619140625,
            "end_logit": 15.4609375,
            "text": "as alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -4.98828125,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -6.7109375,
            "end_logit": 15.4609375,
            "text": "The precursor of the non-Abeta component of Alzheimer's disease amyloid (NACP) (also known as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 15.4609375,
            "text": "NACP) (also known as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -8.1640625,
            "text": "alpha-synuclein)",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": 15.4609375,
            "text": "amyloid (NACP) (also known as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.125,
            "end_logit": 15.4609375,
            "text": "known as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -8.703125,
            "text": "alpha-synuclein) is",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 15.4609375,
            "text": "Alzheimer's disease amyloid (NACP) (also known as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 15.4609375,
            "text": "also known as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 15.4609375,
            "text": "P) (also known as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 15.4609375,
            "text": ") (also known as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 15.4609375,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 15.4609375,
            "text": "disease amyloid (NACP) (also known as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 15.4609375,
            "text": "non-Abeta component of Alzheimer's disease amyloid (NACP) (also known as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 15.4609375,
            "text": "Abeta component of Alzheimer's disease amyloid (NACP) (also known as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5546875,
            "end_logit": -9.9453125,
            "text": "alpha-synuclein) is a presynaptic terminal molecule that",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_17": [
        {
            "start_logit": 14.421875,
            "end_logit": 15.421875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.6826171875,
            "end_logit": 15.421875,
            "text": "synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 14.421875,
            "end_logit": -2.134765625,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": -4.66015625,
            "end_logit": 15.421875,
            "text": "NACP/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -3.83203125,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -9.171875,
            "end_logit": 15.421875,
            "text": "/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 15.421875,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 15.421875,
            "text": "P/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.359375,
            "text": "alpha-synuclein and",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.5390625,
            "text": "alpha-synuclein and its fragments in the LB-bearing neurons and neurites, as well as to clarify",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.640625,
            "text": "alpha-synuclein and its fragments in the LB-bearing neurons and neurites,",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.671875,
            "text": "alpha-synuclein and its fragments in the LB-bearing neurons and neurites, as well as to clarify the patterns of NACP/alpha-synuclein compartmental",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.421875,
            "text": "better understand the distribution of NACP/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.421875,
            "end_logit": -9.7109375,
            "text": "alpha-synuclein and its fragments in the LB-bearing neurons and neurites, as well",
            "probability": 0.0
        },
        {
            "start_logit": -4.66015625,
            "end_logit": -2.134765625,
            "text": "NACP/alpha",
            "probability": 0.0
        },
        {
            "start_logit": -4.66015625,
            "end_logit": -3.83203125,
            "text": "NACP/alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -0.6826171875,
            "end_logit": -9.359375,
            "text": "synuclein and",
            "probability": 0.0
        },
        {
            "start_logit": -0.6826171875,
            "end_logit": -9.5390625,
            "text": "synuclein and its fragments in the LB-bearing neurons and neurites, as well as to clarify",
            "probability": 0.0
        },
        {
            "start_logit": -0.6826171875,
            "end_logit": -9.546875,
            "text": "synuclein and its fragments in the LB-bearing neurons and neurites, as well as to clarify the patterns of NACP/alpha-synuclein compartmentalization",
            "probability": 0.0
        },
        {
            "start_logit": -0.6826171875,
            "end_logit": -9.640625,
            "text": "synuclein and its fragments in the LB-bearing neurons and neurites,",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_18": [
        {
            "start_logit": 14.6328125,
            "end_logit": 15.53125,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.422119140625,
            "end_logit": 15.53125,
            "text": "synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 14.6328125,
            "end_logit": -1.50390625,
            "text": "alpha",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.6328125,
            "end_logit": -3.6640625,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -5.40234375,
            "end_logit": 15.53125,
            "text": "NACP/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 15.53125,
            "text": "/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 15.53125,
            "text": "P/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 15.53125,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 15.53125,
            "text": "Ultrastructural analysis revealed that NACP/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.6328125,
            "end_logit": -9.5546875,
            "text": "alpha-synuclein immunoreactivity was",
            "probability": 0.0
        },
        {
            "start_logit": 14.6328125,
            "end_logit": -9.5703125,
            "text": "alpha-synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": 14.6328125,
            "end_logit": -9.6640625,
            "text": "alpha-synuclein immunoreactivity was diffusely distributed within the amorphous electrodense material in the LB",
            "probability": 0.0
        },
        {
            "start_logit": 14.6328125,
            "end_logit": -9.6953125,
            "text": "alpha-synuclein immunoreactivity was diffusely",
            "probability": 0.0
        },
        {
            "start_logit": 14.6328125,
            "end_logit": -9.796875,
            "text": "alpha-synuclein immunoreactivity was diffusely distributed within the amorphous electrodense material",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 15.53125,
            "text": "that NACP/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -5.40234375,
            "end_logit": -1.50390625,
            "text": "NACP/alpha",
            "probability": 0.0
        },
        {
            "start_logit": -5.40234375,
            "end_logit": -3.6640625,
            "text": "NACP/alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -0.422119140625,
            "end_logit": -8.84375,
            "text": "synuclein immunoreactivity was diffusely distributed within the amorphous electrodense material in the LBs and as small clusters in the filaments of LBs and neurites.",
            "probability": 0.0
        },
        {
            "start_logit": -0.422119140625,
            "end_logit": -9.5546875,
            "text": "synuclein immunoreactivity was",
            "probability": 0.0
        },
        {
            "start_logit": -0.422119140625,
            "end_logit": -9.5703125,
            "text": "synuclein immunoreactivity",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_19": [
        {
            "start_logit": 14.6171875,
            "end_logit": 15.5546875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.1976318359375,
            "end_logit": 15.5546875,
            "text": "synuclein",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -1.52734375,
            "text": "alpha",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -4.03125,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -4.2265625,
            "text": "alpha-synuclein might",
            "probability": 0.0
        },
        {
            "start_logit": -7.03515625,
            "end_logit": 15.5546875,
            "text": "NACP/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -8.78125,
            "end_logit": 15.5546875,
            "text": "aggregated NACP/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 15.5546875,
            "text": "/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": 15.5546875,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 15.5546875,
            "text": "P/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 15.5546875,
            "text": "view that aggregated NACP/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 15.5546875,
            "text": "the view that aggregated NACP/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.6328125,
            "text": "alpha-synuclein might play an important role in the pathogenesis of disorders associated with LBs.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.5546875,
            "text": "These results support the view that aggregated NACP/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.7734375,
            "text": "alpha-synuclein might play an important",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 15.5546875,
            "text": "support the view that aggregated NACP/alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.9921875,
            "text": "alpha-synuclein might play an important role in the pathogenesis of disorders associated with LBs",
            "probability": 0.0
        },
        {
            "start_logit": -0.1976318359375,
            "end_logit": -4.2265625,
            "text": "synuclein might",
            "probability": 0.0
        },
        {
            "start_logit": -7.03515625,
            "end_logit": -1.52734375,
            "text": "NACP/alpha",
            "probability": 0.0
        },
        {
            "start_logit": -0.1976318359375,
            "end_logit": -9.6328125,
            "text": "synuclein might play an important role in the pathogenesis of disorders associated with LBs.",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_20": [
        {
            "start_logit": 14.25,
            "end_logit": 15.28125,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -1.328125,
            "end_logit": 15.28125,
            "text": "synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.25,
            "end_logit": -2.33203125,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": 15.28125,
            "text": "Parkinson's disease and cortical Lewy body disease contain alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -7.15625,
            "text": "alpha-synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": 14.25,
            "end_logit": -7.64453125,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 15.28125,
            "text": "in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 15.28125,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 15.28125,
            "text": "contain alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 15.28125,
            "text": "Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 15.28125,
            "text": "Lewy body disease contain alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 15.28125,
            "text": "Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 15.28125,
            "text": "dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 15.28125,
            "text": "nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 15.28125,
            "text": "cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 15.28125,
            "text": "disease contain alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -1.328125,
            "end_logit": -7.15625,
            "text": "synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": -7.84375,
            "end_logit": -2.33203125,
            "text": "Parkinson's disease and cortical Lewy body disease contain alpha",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -2.33203125,
            "text": "in Parkinson's disease and cortical Lewy body disease contain alpha",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -2.33203125,
            "text": "contain alpha",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_21": [
        {
            "start_logit": 14.5703125,
            "end_logit": 15.46875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.78564453125,
            "end_logit": 15.46875,
            "text": "synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -1.6875,
            "text": "alpha",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.60546875,
            "end_logit": 15.46875,
            "text": "PD brain demonstrated alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -4.953125,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 15.46875,
            "text": "brain demonstrated alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -8.3828125,
            "text": "alpha-synuclein immunoreactivity in nigral Lewy bodies, pale bodies and abnormal neurites.",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -8.6640625,
            "text": "alpha-synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 15.46875,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 15.46875,
            "text": "demonstrated alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.6640625,
            "text": "alpha-synuclein immunoreactivity in",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.78125,
            "text": "alpha-synuclein immunoreactivity in nigra",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -10.0390625,
            "text": "alpha-synuclein immunoreactivity in nigral Lewy bodies, pale bodies and abnormal neurites",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -10.15625,
            "text": "alpha-synuclein immunoreactivity in nigral Lewy bodies",
            "probability": 0.0
        },
        {
            "start_logit": -5.60546875,
            "end_logit": -1.6875,
            "text": "PD brain demonstrated alpha",
            "probability": 0.0
        },
        {
            "start_logit": -0.78564453125,
            "end_logit": -8.3828125,
            "text": "synuclein immunoreactivity in nigral Lewy bodies, pale bodies and abnormal neurites.",
            "probability": 0.0
        },
        {
            "start_logit": -0.78564453125,
            "end_logit": -8.6640625,
            "text": "synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": -0.78564453125,
            "end_logit": -9.6640625,
            "text": "synuclein immunoreactivity in",
            "probability": 0.0
        },
        {
            "start_logit": -5.60546875,
            "end_logit": -4.953125,
            "text": "PD brain demonstrated alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -0.78564453125,
            "end_logit": -9.78125,
            "text": "synuclein immunoreactivity in nigra",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_22": [
        {
            "start_logit": 14.6171875,
            "end_logit": 15.53125,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.5673828125,
            "end_logit": 15.53125,
            "text": "synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -1.5576171875,
            "text": "alpha",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -4.671875,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 15.53125,
            "text": "DLB cases demonstrated these findings as well as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -8.5234375,
            "text": "alpha-synuclein immunoreactivity in cortical Lewy bodies and CA2-3 neurites.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 15.53125,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 15.53125,
            "text": "cases demonstrated these findings as well as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.4375,
            "text": "alpha-synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.5,
            "text": "alpha-synuclein immunoreactivity in",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.625,
            "text": "alpha-synuclein immunoreactivity in cortical Lewy bodies and CA2-3 neurites",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.6953125,
            "text": "alpha-synuclein immunoreactivity in cortical Lewy bodies and CA2",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.703125,
            "text": "alpha-synuclein immunoreactivity in cortical Lewy",
            "probability": 0.0
        },
        {
            "start_logit": 14.6171875,
            "end_logit": -9.796875,
            "text": "alpha-synuclein immunoreactivity in cortical",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.53125,
            "text": "these findings as well as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.53125,
            "text": "as alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -0.5673828125,
            "end_logit": -8.5234375,
            "text": "synuclein immunoreactivity in cortical Lewy bodies and CA2-3 neurites.",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": -1.5576171875,
            "text": "DLB cases demonstrated these findings as well as alpha",
            "probability": 0.0
        },
        {
            "start_logit": -0.5673828125,
            "end_logit": -9.4375,
            "text": "synuclein immunoreactivity",
            "probability": 0.0
        },
        {
            "start_logit": -0.5673828125,
            "end_logit": -9.5,
            "text": "synuclein immunoreactivity in",
            "probability": 0.0
        }
    ],
    "53189656b166e2b80600001c_23": [
        {
            "start_logit": 14.3125,
            "end_logit": 15.4140625,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.55908203125,
            "end_logit": 15.4140625,
            "text": "synuclein",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 14.3125,
            "end_logit": -2.33203125,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -5.09765625,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 15.4140625,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 15.4140625,
            "text": ", even in sporadic cases, there is an early and direct role for alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.453125,
            "text": "alpha-synuclein in the pathogenesis of PD",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 15.4140625,
            "text": "for alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 15.4140625,
            "text": "an early and direct role for alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 15.4140625,
            "text": "in sporadic cases, there is an early and direct role for alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 15.4140625,
            "text": "and direct role for alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 15.4140625,
            "text": "cases, there is an early and direct role for alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 15.4140625,
            "text": "there is an early and direct role for alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.8671875,
            "text": "alpha-synuclein in the pathogenesis of PD and the neuropathologically related disorder DLB",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -9.984375,
            "text": "alpha-synuclein in the pathogenesis of PD and the neuropathologically related disorder DLB.",
            "probability": 0.0
        },
        {
            "start_logit": 14.3125,
            "end_logit": -10.109375,
            "text": "alpha-synuclein in the pathogenesis",
            "probability": 0.0
        },
        {
            "start_logit": -0.55908203125,
            "end_logit": -9.453125,
            "text": "synuclein in the pathogenesis of PD",
            "probability": 0.0
        },
        {
            "start_logit": -0.55908203125,
            "end_logit": -9.8671875,
            "text": "synuclein in the pathogenesis of PD and the neuropathologically related disorder DLB",
            "probability": 0.0
        },
        {
            "start_logit": -0.55908203125,
            "end_logit": -9.984375,
            "text": "synuclein in the pathogenesis of PD and the neuropathologically related disorder DLB.",
            "probability": 0.0
        },
        {
            "start_logit": -0.55908203125,
            "end_logit": -10.109375,
            "text": "synuclein in the pathogenesis",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_1": [
        {
            "start_logit": 13.921875,
            "end_logit": 14.7734375,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -1.6513671875,
            "end_logit": 14.7734375,
            "text": "C-terminal SET domain",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -2.943359375,
            "end_logit": 14.7734375,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.921875,
            "end_logit": -2.462890625,
            "text": "SET domain that catalyzes methylation of histone H3",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.921875,
            "end_logit": -2.5390625,
            "text": "SET",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.921875,
            "end_logit": -5.37890625,
            "text": "SET domain that",
            "probability": 0.0
        },
        {
            "start_logit": -6.859375,
            "end_logit": 14.7734375,
            "text": "terminal SET domain",
            "probability": 0.0
        },
        {
            "start_logit": 13.921875,
            "end_logit": -10.140625,
            "text": "SET domain that catalyzes methylation of",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": 14.7734375,
            "text": "-terminal SET domain",
            "probability": 0.0
        },
        {
            "start_logit": 13.921875,
            "end_logit": -10.2734375,
            "text": "SET domain that catalyzes methylation",
            "probability": 0.0
        },
        {
            "start_logit": -1.6513671875,
            "end_logit": -2.462890625,
            "text": "C-terminal SET domain that catalyzes methylation of histone H3",
            "probability": 0.0
        },
        {
            "start_logit": -1.6513671875,
            "end_logit": -2.5390625,
            "text": "C-terminal SET",
            "probability": 0.0
        },
        {
            "start_logit": -2.943359375,
            "end_logit": -2.462890625,
            "text": "domain that catalyzes methylation of histone H3",
            "probability": 0.0
        },
        {
            "start_logit": -1.6513671875,
            "end_logit": -5.37890625,
            "text": "C-terminal SET domain that",
            "probability": 0.0
        },
        {
            "start_logit": -2.943359375,
            "end_logit": -5.37890625,
            "text": "domain that",
            "probability": 0.0
        },
        {
            "start_logit": -1.6513671875,
            "end_logit": -7.16015625,
            "text": "C",
            "probability": 0.0
        },
        {
            "start_logit": -6.859375,
            "end_logit": -2.462890625,
            "text": "terminal SET domain that catalyzes methylation of histone H3",
            "probability": 0.0
        },
        {
            "start_logit": -6.859375,
            "end_logit": -2.5390625,
            "text": "terminal SET",
            "probability": 0.0
        },
        {
            "start_logit": -1.6513671875,
            "end_logit": -9.4140625,
            "text": "C-",
            "probability": 0.0
        },
        {
            "start_logit": -1.6513671875,
            "end_logit": -10.140625,
            "text": "C-terminal SET domain that catalyzes methylation of",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_2": [
        {
            "start_logit": 13.1015625,
            "end_logit": 14.3203125,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -3.69140625,
            "end_logit": 14.3203125,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.1015625,
            "end_logit": -3.953125,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": 13.1015625,
            "end_logit": -7.5,
            "text": "SET domain histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 14.3203125,
            "text": "a SET domain",
            "probability": 0.0
        },
        {
            "start_logit": 13.1015625,
            "end_logit": -10.03125,
            "text": "SET domain histone",
            "probability": 0.0
        },
        {
            "start_logit": -3.69140625,
            "end_logit": -7.5,
            "text": "domain histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -3.69140625,
            "end_logit": -10.03125,
            "text": "domain histone",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -3.953125,
            "text": "a SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -7.5,
            "text": "a SET domain histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": -7.5,
            "text": "histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -9.5390625,
            "text": "a",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -10.03125,
            "text": "a SET domain histone",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": -10.03125,
            "text": "histone",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_3": [
        {
            "start_logit": 11.921875,
            "end_logit": 13.9453125,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -4.21875,
            "end_logit": 13.9453125,
            "text": "domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.921875,
            "end_logit": -5.171875,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": -8.9375,
            "end_logit": 13.9453125,
            "text": "a SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 13.9453125,
            "text": "containing a SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 13.9453125,
            "text": "the presence of three core components (RbBP5, Ash2L and WDR5) and a catalytic subunit containing a SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 13.9453125,
            "text": "1 complexes is the presence of three core components (RbBP5, Ash2L and WDR5) and a catalytic subunit containing a SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": -5.171875,
            "text": "SET1 complexes is the presence of three core components (RbBP5, Ash2L and WDR5) and a catalytic subunit containing a SET",
            "probability": 0.0
        },
        {
            "start_logit": -8.9375,
            "end_logit": -5.171875,
            "text": "a SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -5.171875,
            "text": "containing a SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": -5.171875,
            "text": "the presence of three core components (RbBP5, Ash2L and WDR5) and a catalytic subunit containing a SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": -5.171875,
            "text": "1 complexes is the presence of three core components (RbBP5, Ash2L and WDR5) and a catalytic subunit containing a SET",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": -9.5234375,
            "text": "SET1",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": -9.8671875,
            "text": "SET1 complexes is the presence of three core",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": -9.9375,
            "text": "SET1 complexes is the presence of three core components (RbBP5, Ash2L and WD",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": -9.9453125,
            "text": "SET1 complexes is the presence of three core components (RbBP5",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": -9.953125,
            "text": "SET1 complexes",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": -9.96875,
            "text": "SET1 complexes is the presence",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": -10.015625,
            "text": "SET1 complexes is the presence of three",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": -10.125,
            "text": "SET1 complexes is the presence of three core components (RbBP5, Ash2L and WDR5) and",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_4": [
        {
            "start_logit": 12.703125,
            "end_logit": 13.6796875,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -4.49609375,
            "end_logit": 13.6796875,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.703125,
            "end_logit": -4.33984375,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -7.9921875,
            "text": "SET domain methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -8.9609375,
            "text": "SET domain methyltransferases deposit methyl marks on specific histone tail lysine residues",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -9.28125,
            "text": "SET domain methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -9.4375,
            "text": "SET domain methyltransferases deposit",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -10.046875,
            "text": "SET domain methyltransferases deposit methyl marks on specific histone tail",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -10.109375,
            "text": "SET domain methyltransferases deposit methyl marks",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -10.125,
            "text": "SET domain methyltransferases deposit methyl marks on",
            "probability": 0.0
        },
        {
            "start_logit": 12.703125,
            "end_logit": -10.1796875,
            "text": "SET domain methyltransferases deposit methyl marks on specific",
            "probability": 0.0
        },
        {
            "start_logit": -4.49609375,
            "end_logit": -7.9921875,
            "text": "domain methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -4.49609375,
            "end_logit": -8.9609375,
            "text": "domain methyltransferases deposit methyl marks on specific histone tail lysine residues",
            "probability": 0.0
        },
        {
            "start_logit": -4.49609375,
            "end_logit": -9.28125,
            "text": "domain methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": -4.49609375,
            "end_logit": -9.4375,
            "text": "domain methyltransferases deposit",
            "probability": 0.0
        },
        {
            "start_logit": -4.49609375,
            "end_logit": -10.046875,
            "text": "domain methyltransferases deposit methyl marks on specific histone tail",
            "probability": 0.0
        },
        {
            "start_logit": -4.49609375,
            "end_logit": -10.109375,
            "text": "domain methyltransferases deposit methyl marks",
            "probability": 0.0
        },
        {
            "start_logit": -4.49609375,
            "end_logit": -10.125,
            "text": "domain methyltransferases deposit methyl marks on",
            "probability": 0.0
        },
        {
            "start_logit": -4.49609375,
            "end_logit": -10.1796875,
            "text": "domain methyltransferases deposit methyl marks on specific",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": -7.9921875,
            "text": "methyltransferase",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_5": [
        {
            "start_logit": 13.71875,
            "end_logit": 14.34375,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -2.234375,
            "end_logit": 14.34375,
            "text": "the carboxyl-terminal SET domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.71875,
            "end_logit": -2.69140625,
            "text": "SET",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.759765625,
            "end_logit": 14.34375,
            "text": "domain",
            "probability": 0.0
        },
        {
            "start_logit": 13.71875,
            "end_logit": -3.638671875,
            "text": "SET domain.",
            "probability": 0.0
        },
        {
            "start_logit": -4.609375,
            "end_logit": 14.34375,
            "text": "MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -5.921875,
            "end_logit": 14.34375,
            "text": "carboxyl-terminal SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -5.94140625,
            "end_logit": 14.34375,
            "text": "terminal SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 14.34375,
            "text": "The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 14.34375,
            "text": "of the carboxyl-terminal SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 14.34375,
            "text": "-terminal SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 14.34375,
            "text": "of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 14.34375,
            "text": "L1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 14.34375,
            "text": "biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 14.34375,
            "text": "by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 14.34375,
            "text": "methyltransferase activity of the carboxyl-terminal SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -2.234375,
            "end_logit": -2.69140625,
            "text": "the carboxyl-terminal SET",
            "probability": 0.0
        },
        {
            "start_logit": -2.234375,
            "end_logit": -3.638671875,
            "text": "the carboxyl-terminal SET domain.",
            "probability": 0.0
        },
        {
            "start_logit": -4.609375,
            "end_logit": -2.69140625,
            "text": "MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET",
            "probability": 0.0
        },
        {
            "start_logit": -3.759765625,
            "end_logit": -3.638671875,
            "text": "domain.",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_6": [
        {
            "start_logit": 12.625,
            "end_logit": 13.4765625,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -4.73046875,
            "end_logit": 13.4765625,
            "text": "domain",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -4.2578125,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 13.4765625,
            "text": "(E(Z)), and the paucity of E(z) mutant alleles that alter its SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 13.4765625,
            "text": "its SET domain",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -9.171875,
            "text": "SET domain.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 13.4765625,
            "text": "alter its SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 13.4765625,
            "text": "Enhancer of zeste (E(Z)), and the paucity of E(z) mutant alleles that alter its SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 13.4765625,
            "text": "E(Z)), and the paucity of E(z) mutant alleles that alter its SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 13.4765625,
            "text": ", Enhancer of zeste (E(Z)), and the paucity of E(z) mutant alleles that alter its SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 13.4765625,
            "text": "of zeste (E(Z)), and the paucity of E(z) mutant alleles that alter its SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 13.4765625,
            "text": "zeste (E(Z)), and the paucity of E(z) mutant alleles that alter its SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -4.2578125,
            "text": "(E(Z)), and the paucity of E(z) mutant alleles that alter its SET",
            "probability": 0.0
        },
        {
            "start_logit": -4.73046875,
            "end_logit": -9.171875,
            "text": "domain.",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": -4.2578125,
            "text": "its SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -4.2578125,
            "text": "alter its SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": -4.2578125,
            "text": "Enhancer of zeste (E(Z)), and the paucity of E(z) mutant alleles that alter its SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -4.2578125,
            "text": "E(Z)), and the paucity of E(z) mutant alleles that alter its SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": -4.2578125,
            "text": ", Enhancer of zeste (E(Z)), and the paucity of E(z) mutant alleles that alter its SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -4.2578125,
            "text": "of zeste (E(Z)), and the paucity of E(z) mutant alleles that alter its SET",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_7": [
        {
            "start_logit": 13.2578125,
            "end_logit": 14.1875,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -4.03515625,
            "end_logit": 14.1875,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.2578125,
            "end_logit": -3.40234375,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": 14.1875,
            "text": "PKMTs contain a conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 14.1875,
            "text": "protein lysine methyltransferases (PKMTs). PKMTs contain a conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 14.1875,
            "text": "conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 14.1875,
            "text": ". PKMTs contain a conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 14.1875,
            "text": "s contain a conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 14.1875,
            "text": "MTs contain a conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 14.1875,
            "text": "contain a conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 14.1875,
            "text": "by protein lysine methyltransferases (PKMTs). PKMTs contain a conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 14.1875,
            "text": "a conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 14.1875,
            "text": "histone modification is catalyzed by protein lysine methyltransferases (PKMTs). PKMTs contain a conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 14.1875,
            "text": "lysine methyltransferases (PKMTs). PKMTs contain a conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 14.1875,
            "text": "modification is catalyzed by protein lysine methyltransferases (PKMTs). PKMTs contain a conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -8.3046875,
            "end_logit": -3.40234375,
            "text": "PKMTs contain a conserved SET",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": -3.40234375,
            "text": "protein lysine methyltransferases (PKMTs). PKMTs contain a conserved SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": -3.40234375,
            "text": "conserved SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -3.40234375,
            "text": ". PKMTs contain a conserved SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": -3.40234375,
            "text": "s contain a conserved SET",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_8": [
        {
            "start_logit": 13.3359375,
            "end_logit": 14.4375,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -3.638671875,
            "end_logit": 14.4375,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -3.42578125,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 14.4375,
            "text": "Set1A protein shares 39% identity with an uncharacterized SET domain",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -8.9453125,
            "text": "SET domain protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 14.4375,
            "text": "protein shares 39% identity with an uncharacterized SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.2109375,
            "end_logit": 14.4375,
            "text": "1A protein shares 39% identity with an uncharacterized SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -3.42578125,
            "text": "Set1A protein shares 39% identity with an uncharacterized SET",
            "probability": 0.0
        },
        {
            "start_logit": -3.638671875,
            "end_logit": -8.9453125,
            "text": "domain protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": -3.42578125,
            "text": "protein shares 39% identity with an uncharacterized SET",
            "probability": 0.0
        },
        {
            "start_logit": -11.2109375,
            "end_logit": -3.42578125,
            "text": "1A protein shares 39% identity with an uncharacterized SET",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.8984375,
            "text": "Set1A",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -8.9453125,
            "text": "Set1A protein shares 39% identity with an uncharacterized SET domain protein",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -9.3671875,
            "text": "Set1A protein shares 39",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -9.4140625,
            "text": "Set",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -9.484375,
            "text": "Set1A protein shares 39% identity with an uncharacterized",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -9.59375,
            "text": "Set1A protein shares 39% identity",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -9.65625,
            "text": "Set1A protein shares 39%",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -9.6796875,
            "text": "Set1A protein shares 39% identity with",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -9.703125,
            "text": "Set1A protein shares",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_9": [
        {
            "start_logit": 12.6328125,
            "end_logit": 13.5703125,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -4.640625,
            "end_logit": 13.5703125,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.6328125,
            "end_logit": -4.48828125,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": 12.6328125,
            "end_logit": -6.7890625,
            "text": "SET domain protein methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": 12.6328125,
            "end_logit": -8.0703125,
            "text": "SET domain protein methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": 12.6328125,
            "end_logit": -8.8515625,
            "text": "SET domain protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 13.5703125,
            "text": "by SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": 13.5703125,
            "text": "multiple methylations catalyzed by SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.3359375,
            "end_logit": 13.5703125,
            "text": "methylations catalyzed by SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -4.640625,
            "end_logit": -6.7890625,
            "text": "domain protein methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": -4.640625,
            "end_logit": -8.0703125,
            "text": "domain protein methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -4.640625,
            "end_logit": -8.8515625,
            "text": "domain protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -4.48828125,
            "text": "by SET",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": -4.48828125,
            "text": "multiple methylations catalyzed by SET",
            "probability": 0.0
        },
        {
            "start_logit": -11.3359375,
            "end_logit": -4.48828125,
            "text": "methylations catalyzed by SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": -6.7890625,
            "text": "protein methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -6.7890625,
            "text": "by SET domain protein methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": -6.7890625,
            "text": "multiple methylations catalyzed by SET domain protein methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": -11.3359375,
            "end_logit": -6.7890625,
            "text": "methylations catalyzed by SET domain protein methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": -8.0703125,
            "text": "protein methyltransferase",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_10": [
        {
            "start_logit": 12.71875,
            "end_logit": 13.3671875,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": 12.71875,
            "end_logit": -1.9580078125,
            "text": "SET domain protein lysine methyltransferases.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -4.79296875,
            "end_logit": 13.3671875,
            "text": "domain",
            "probability": 0.0
        },
        {
            "start_logit": 12.71875,
            "end_logit": -4.390625,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": 12.71875,
            "end_logit": -6.953125,
            "text": "SET domain protein lysine methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": 12.71875,
            "end_logit": -7.421875,
            "text": "SET domain protein lysine methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": 13.3671875,
            "text": "methyl group transfers by SET domain",
            "probability": 0.0
        },
        {
            "start_logit": 12.71875,
            "end_logit": -8.8828125,
            "text": "SET domain protein lysine",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 13.3671875,
            "text": "by SET domain",
            "probability": 0.0
        },
        {
            "start_logit": 12.71875,
            "end_logit": -9.8046875,
            "text": "SET domain protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 13.3671875,
            "text": "transfers by SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 13.3671875,
            "text": "group transfers by SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -4.79296875,
            "end_logit": -1.9580078125,
            "text": "domain protein lysine methyltransferases.",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": -1.9580078125,
            "text": "methyl group transfers by SET domain protein lysine methyltransferases.",
            "probability": 0.0
        },
        {
            "start_logit": -4.79296875,
            "end_logit": -6.953125,
            "text": "domain protein lysine methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": -1.9580078125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -1.9580078125,
            "text": "by SET domain protein lysine methyltransferases.",
            "probability": 0.0
        },
        {
            "start_logit": -4.79296875,
            "end_logit": -7.421875,
            "text": "domain protein lysine methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -1.9580078125,
            "text": "protein lysine methyltransferases.",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -1.9580078125,
            "text": "transfers by SET domain protein lysine methyltransferases.",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_11": [
        {
            "start_logit": 11.8203125,
            "end_logit": 13.2890625,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -4.8359375,
            "end_logit": 13.2890625,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.8203125,
            "end_logit": -4.72265625,
            "text": "SET domain protein",
            "probability": 0.0
        },
        {
            "start_logit": 11.8203125,
            "end_logit": -5.70703125,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": 11.8203125,
            "end_logit": -8.3125,
            "text": "SET domain protein functions as a histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": 11.8203125,
            "end_logit": -8.6796875,
            "text": "SET domain protein functions",
            "probability": 0.0
        },
        {
            "start_logit": 11.8203125,
            "end_logit": -9.453125,
            "text": "SET domain protein functions as a",
            "probability": 0.0
        },
        {
            "start_logit": 11.8203125,
            "end_logit": -9.78125,
            "text": "SET domain protein functions as",
            "probability": 0.0
        },
        {
            "start_logit": 11.8203125,
            "end_logit": -10.3359375,
            "text": "SET domain protein functions as a histone",
            "probability": 0.0
        },
        {
            "start_logit": -4.8359375,
            "end_logit": -4.72265625,
            "text": "domain protein",
            "probability": 0.0
        },
        {
            "start_logit": -4.8359375,
            "end_logit": -8.3125,
            "text": "domain protein functions as a histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -4.8359375,
            "end_logit": -8.6796875,
            "text": "domain protein functions",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": -4.72265625,
            "text": "protein",
            "probability": 0.0
        },
        {
            "start_logit": -4.8359375,
            "end_logit": -9.453125,
            "text": "domain protein functions as a",
            "probability": 0.0
        },
        {
            "start_logit": -4.8359375,
            "end_logit": -9.78125,
            "text": "domain protein functions as",
            "probability": 0.0
        },
        {
            "start_logit": -4.8359375,
            "end_logit": -10.3359375,
            "text": "domain protein functions as a histone",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": -8.3125,
            "text": "protein functions as a histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": -8.6796875,
            "text": "protein functions",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": -9.453125,
            "text": "protein functions as a",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": -9.78125,
            "text": "protein functions as",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_12": [
        {
            "start_logit": 10.4609375,
            "end_logit": 12.671875,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -5.828125,
            "end_logit": 12.671875,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.4609375,
            "end_logit": -5.71875,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 12.671875,
            "text": "catalytic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 12.671875,
            "text": "SUV39H1 impaired enzyme activity despite the presence of an intact catalytic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 12.671875,
            "text": "39H1 impaired enzyme activity despite the presence of an intact catalytic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 12.671875,
            "text": "enzyme activity despite the presence of an intact catalytic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": -5.71875,
            "text": "catalytic SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -5.71875,
            "text": "SUV39H1 impaired enzyme activity despite the presence of an intact catalytic SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -5.71875,
            "text": "39H1 impaired enzyme activity despite the presence of an intact catalytic SET",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": -5.71875,
            "text": "enzyme activity despite the presence of an intact catalytic SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -8.3671875,
            "text": "SUV39H1",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -8.3671875,
            "text": "39H1",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -9.359375,
            "text": "SUV39H1 impaired",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -9.7109375,
            "text": "SUV39H1 impaired enzyme activity despite",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -9.359375,
            "text": "39H1 impaired",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -9.8828125,
            "text": "SUV39H1 impaired enzyme activity",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -10.0234375,
            "text": "SUV39H1 impaired enzyme activity despite the presence",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -10.0703125,
            "text": "SUV39H1 impaired enzyme activity despite the presence of",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": -9.7109375,
            "text": "39H1 impaired enzyme activity despite",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_13": [
        {
            "start_logit": -3.533203125,
            "end_logit": 10.515625,
            "text": "SET domain",
            "probability": 0.63427734375
        },
        {
            "start_logit": -4.33203125,
            "end_logit": 10.515625,
            "text": "Meisetz (meiosis-induced factor containing a PR/SET domain",
            "probability": 0.28466796875
        },
        {
            "start_logit": -6.37109375,
            "end_logit": 10.515625,
            "text": "domain",
            "probability": 0.03704833984375
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 10.515625,
            "text": "PR/SET domain",
            "probability": 0.01922607421875
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 10.515625,
            "text": "a PR/SET domain",
            "probability": 0.01207733154296875
        },
        {
            "start_logit": -8.078125,
            "end_logit": 10.515625,
            "text": "/SET domain",
            "probability": 0.006717681884765625
        },
        {
            "start_logit": -3.533203125,
            "end_logit": 4.6953125,
            "text": "SET domain and zinc-finger motif)",
            "probability": 0.001880645751953125
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 10.515625,
            "text": "containing a PR/SET domain",
            "probability": 0.0011234283447265625
        },
        {
            "start_logit": -4.33203125,
            "end_logit": 4.6953125,
            "text": "Meisetz (meiosis-induced factor containing a PR/SET domain and zinc-finger motif)",
            "probability": 0.0008449554443359375
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 10.515625,
            "text": "isetz (meiosis-induced factor containing a PR/SET domain",
            "probability": 0.0006203651428222656
        },
        {
            "start_logit": -10.5,
            "end_logit": 10.515625,
            "text": "induced factor containing a PR/SET domain",
            "probability": 0.0005965232849121094
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 10.515625,
            "text": "-induced factor containing a PR/SET domain",
            "probability": 0.0004467964172363281
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 10.515625,
            "text": "factor containing a PR/SET domain",
            "probability": 0.0004467964172363281
        },
        {
            "start_logit": -6.37109375,
            "end_logit": 4.6953125,
            "text": "domain and zinc-finger motif)",
            "probability": 0.00011032819747924805
        },
        {
            "start_logit": -7.02734375,
            "end_logit": 4.6953125,
            "text": "PR/SET domain and zinc-finger motif)",
            "probability": 5.728006362915039e-05
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 4.6953125,
            "text": "a PR/SET domain and zinc-finger motif)",
            "probability": 3.5822391510009766e-05
        },
        {
            "start_logit": -8.078125,
            "end_logit": 4.6953125,
            "text": "/SET domain and zinc-finger motif)",
            "probability": 1.996755599975586e-05
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 4.6953125,
            "text": ")",
            "probability": 1.424551010131836e-05
        },
        {
            "start_logit": -9.328125,
            "end_logit": 4.6953125,
            "text": "zinc-finger motif)",
            "probability": 5.7220458984375e-06
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 4.6953125,
            "text": "and zinc-finger motif)",
            "probability": 4.291534423828125e-06
        }
    ],
    "532dcfc9d6d3ac6a34000021_14": [
        {
            "start_logit": 12.984375,
            "end_logit": 14.0625,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -4.18359375,
            "end_logit": 14.0625,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.984375,
            "end_logit": -4.09375,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": 12.984375,
            "end_logit": -7.171875,
            "text": "SET domain subuni",
            "probability": 0.0
        },
        {
            "start_logit": 12.984375,
            "end_logit": -8.5390625,
            "text": "SET domain subun",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 14.0625,
            "text": "The fly complex contains a catalytic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 14.0625,
            "text": "fly complex contains a catalytic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 14.0625,
            "text": "catalytic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 14.0625,
            "text": "a catalytic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.125,
            "end_logit": 14.0625,
            "text": "complex contains a catalytic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -4.18359375,
            "end_logit": -7.171875,
            "text": "domain subuni",
            "probability": 0.0
        },
        {
            "start_logit": -4.18359375,
            "end_logit": -8.5390625,
            "text": "domain subun",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": -4.09375,
            "text": "The fly complex contains a catalytic SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": -4.09375,
            "text": "fly complex contains a catalytic SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": -4.09375,
            "text": "catalytic SET",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": -4.09375,
            "text": "a catalytic SET",
            "probability": 0.0
        },
        {
            "start_logit": -11.125,
            "end_logit": -4.09375,
            "text": "complex contains a catalytic SET",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": -7.171875,
            "text": "subuni",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": -7.171875,
            "text": "i",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": -7.171875,
            "text": "The fly complex contains a catalytic SET domain subuni",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_15": [
        {
            "start_logit": 13.3203125,
            "end_logit": 14.2109375,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -3.92578125,
            "end_logit": 14.2109375,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.3203125,
            "end_logit": -3.6171875,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": 14.2109375,
            "text": "G9a is a 1263 amino acid H3-K9 methyltransferase that possesses characteristic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 14.2109375,
            "text": "9a is a 1263 amino acid H3-K9 methyltransferase that possesses characteristic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": 14.2109375,
            "text": "characteristic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": 13.3203125,
            "end_logit": -8.6640625,
            "text": "SET domain and ANK repeats",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 14.2109375,
            "text": "possesses characteristic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 14.2109375,
            "text": "Murine G9a is a 1263 amino acid H3-K9 methyltransferase that possesses characteristic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 14.2109375,
            "text": "amino acid H3-K9 methyltransferase that possesses characteristic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": 13.3203125,
            "end_logit": -9.5234375,
            "text": "SET domain and",
            "probability": 0.0
        },
        {
            "start_logit": 13.3203125,
            "end_logit": -9.5625,
            "text": "SET domain and ANK",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 14.2109375,
            "text": "K9 methyltransferase that possesses characteristic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 14.2109375,
            "text": "-K9 methyltransferase that possesses characteristic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.2109375,
            "text": "acid H3-K9 methyltransferase that possesses characteristic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 14.2109375,
            "text": "H3-K9 methyltransferase that possesses characteristic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 14.2109375,
            "text": "a 1263 amino acid H3-K9 methyltransferase that possesses characteristic SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": -3.6171875,
            "text": "G9a is a 1263 amino acid H3-K9 methyltransferase that possesses characteristic SET",
            "probability": 0.0
        },
        {
            "start_logit": -3.92578125,
            "end_logit": -8.6640625,
            "text": "domain and ANK repeats",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": -3.6171875,
            "text": "9a is a 1263 amino acid H3-K9 methyltransferase that possesses characteristic SET",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_16": [
        {
            "start_logit": 14.1015625,
            "end_logit": 15.2109375,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -1.8330078125,
            "end_logit": 15.2109375,
            "text": "domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -1.833984375,
            "text": "SET",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.3671875,
            "text": "SET domain,",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.8828125,
            "text": "SET domain, first identified within and named after proteins encoded by three",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.953125,
            "text": "SET domain, first identified within and named after proteins encoded by three Drosophila genes [Su(var)3-9, E(z)",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -10.03125,
            "text": "SET domain, first identified within and named after proteins encoded by three Drosophila genes [Su(var)3",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -10.03125,
            "text": "SET domain, first identified within and named after proteins encoded by three Drosophila genes [Su(var)",
            "probability": 0.0
        },
        {
            "start_logit": -1.8330078125,
            "end_logit": -9.3671875,
            "text": "domain,",
            "probability": 0.0
        },
        {
            "start_logit": -1.8330078125,
            "end_logit": -9.8828125,
            "text": "domain, first identified within and named after proteins encoded by three",
            "probability": 0.0
        },
        {
            "start_logit": -1.8330078125,
            "end_logit": -9.953125,
            "text": "domain, first identified within and named after proteins encoded by three Drosophila genes [Su(var)3-9, E(z)",
            "probability": 0.0
        },
        {
            "start_logit": -1.8330078125,
            "end_logit": -10.03125,
            "text": "domain, first identified within and named after proteins encoded by three Drosophila genes [Su(var)3",
            "probability": 0.0
        },
        {
            "start_logit": -1.8330078125,
            "end_logit": -10.03125,
            "text": "domain, first identified within and named after proteins encoded by three Drosophila genes [Su(var)",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -9.4765625,
            "text": "recognized as a signature",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -9.4609375,
            "text": "after proteins encoded by three Drosophila genes [Su(var)3-9, E(z), and Trithorax",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -9.78125,
            "text": "recognized as a signature motif for histone methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -9.8046875,
            "text": "recognized as a signature motif",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -9.9375,
            "text": "recognized",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -9.8828125,
            "text": "after proteins encoded by three",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -9.96875,
            "text": "recognized as a signature motif for",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_17": [
        {
            "start_logit": 11.3359375,
            "end_logit": 13.8125,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -4.4296875,
            "end_logit": 13.8125,
            "text": "domain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.05859375,
            "end_logit": 13.8125,
            "text": "the SET domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.3359375,
            "end_logit": -5.54296875,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 13.8125,
            "text": "(HMT)(1) class enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 13.8125,
            "text": "lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 13.8125,
            "text": "termed the SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 13.8125,
            "text": "methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 13.8125,
            "text": "residues of histones or proteins contain a conserved catalytic core termed the SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.09375,
            "end_logit": 13.8125,
            "text": "ate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": 13.8125,
            "text": "histones or proteins contain a conserved catalytic core termed the SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": 13.8125,
            "text": "catalytic core termed the SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": 13.8125,
            "text": "1) class enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.1640625,
            "end_logit": 13.8125,
            "text": "proteins contain a conserved catalytic core termed the SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.1640625,
            "end_logit": 13.8125,
            "text": "enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -5.05859375,
            "end_logit": -5.54296875,
            "text": "the SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": -5.54296875,
            "text": "(HMT)(1) class enzymes that methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": -5.54296875,
            "text": "lysine residues of histones or proteins contain a conserved catalytic core termed the SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": -5.54296875,
            "text": "termed the SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": -5.54296875,
            "text": "methylate lysine residues of histones or proteins contain a conserved catalytic core termed the SET",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_18": [
        {
            "start_logit": 2.552734375,
            "end_logit": 13.6796875,
            "text": "SET domain",
            "probability": 0.998046875
        },
        {
            "start_logit": -4.13671875,
            "end_logit": 13.6796875,
            "text": "ERG-associated protein with a SET domain",
            "probability": 0.00124359130859375
        },
        {
            "start_logit": -4.51171875,
            "end_logit": 13.6796875,
            "text": "domain",
            "probability": 0.0008544921875
        },
        {
            "start_logit": -8.6015625,
            "end_logit": 13.6796875,
            "text": "a SET domain",
            "probability": 1.430511474609375e-05
        },
        {
            "start_logit": -9.28125,
            "end_logit": 13.6796875,
            "text": "protein with a SET domain",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 13.6796875,
            "text": "associated protein with a SET domain",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 13.6796875,
            "text": "with a SET domain",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 13.6796875,
            "text": "-associated protein with a SET domain",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": 2.552734375,
            "end_logit": -1.375,
            "text": "SET domain, also called SETDB1)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 1.1328125,
            "end_logit": -1.375,
            "text": "SETDB1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.552734375,
            "end_logit": -5.34375,
            "text": "SET domain, also called SETDB1",
            "probability": 0.0
        },
        {
            "start_logit": 1.1328125,
            "end_logit": -5.34375,
            "text": "SETDB1",
            "probability": 0.0
        },
        {
            "start_logit": 2.552734375,
            "end_logit": -6.9609375,
            "text": "SET domain,",
            "probability": 0.0
        },
        {
            "start_logit": -4.13671875,
            "end_logit": -1.375,
            "text": "ERG-associated protein with a SET domain, also called SETDB1)",
            "probability": 0.0
        },
        {
            "start_logit": 2.552734375,
            "end_logit": -8.1796875,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": -4.51171875,
            "end_logit": -1.375,
            "text": "domain, also called SETDB1)",
            "probability": 0.0
        },
        {
            "start_logit": 2.552734375,
            "end_logit": -8.828125,
            "text": "SET domain, also called SETDB1) is",
            "probability": 0.0
        },
        {
            "start_logit": 2.552734375,
            "end_logit": -8.8828125,
            "text": "SET domain, also called SETDB1) is a novel histone methyltransferase that catalyzes methylation of histone H3-lysine 9 (H3-K9)",
            "probability": 0.0
        },
        {
            "start_logit": 2.552734375,
            "end_logit": -9.234375,
            "text": "SET domain, also called SETDB",
            "probability": 0.0
        },
        {
            "start_logit": 2.552734375,
            "end_logit": -9.609375,
            "text": "SET domain, also called SETDB1) is a novel",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_19": [
        {
            "start_logit": 12.9375,
            "end_logit": 13.9921875,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -4.125,
            "end_logit": 13.9921875,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.9375,
            "end_logit": -4.26953125,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -6.76953125,
            "text": "SET domain histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": 12.9375,
            "end_logit": -9.7109375,
            "text": "SET domain histone",
            "probability": 0.0
        },
        {
            "start_logit": -4.125,
            "end_logit": -6.76953125,
            "text": "domain histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -4.125,
            "end_logit": -9.7109375,
            "text": "domain histone",
            "probability": 0.0
        },
        {
            "start_logit": -8.84375,
            "end_logit": -6.76953125,
            "text": "histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -11.171875,
            "end_logit": -6.76953125,
            "text": "methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -8.84375,
            "end_logit": -9.7109375,
            "text": "histone",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_20": [
        {
            "start_logit": 13.09375,
            "end_logit": 14.2265625,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -3.66015625,
            "end_logit": 14.2265625,
            "text": "Dot1 does not contain a SET domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.86328125,
            "end_logit": 14.2265625,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.09375,
            "end_logit": -3.48828125,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 14.2265625,
            "text": "a SET domain",
            "probability": 0.0
        },
        {
            "start_logit": 13.09375,
            "end_logit": -6.62890625,
            "text": "SET domain,",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": 14.2265625,
            "text": "contain a SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 14.2265625,
            "text": "1 does not contain a SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 14.2265625,
            "text": "not contain a SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.2265625,
            "text": "histone methyltransferases, Dot1 does not contain a SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 14.2265625,
            "text": ", Dot1 does not contain a SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.2265625,
            "text": "does not contain a SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 14.2265625,
            "text": "other histone methyltransferases, Dot1 does not contain a SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -11.171875,
            "end_logit": 14.2265625,
            "text": "methyltransferases, Dot1 does not contain a SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -3.66015625,
            "end_logit": -3.48828125,
            "text": "Dot1 does not contain a SET",
            "probability": 0.0
        },
        {
            "start_logit": -3.66015625,
            "end_logit": -6.62890625,
            "text": "Dot1 does not contain a SET domain,",
            "probability": 0.0
        },
        {
            "start_logit": -3.86328125,
            "end_logit": -6.62890625,
            "text": "domain,",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": -3.48828125,
            "text": "a SET",
            "probability": 0.0
        },
        {
            "start_logit": -3.66015625,
            "end_logit": -7.5859375,
            "text": "Dot1",
            "probability": 0.0
        },
        {
            "start_logit": -3.66015625,
            "end_logit": -7.72265625,
            "text": "Dot",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_21": [
        {
            "start_logit": 13.3671875,
            "end_logit": 14.7265625,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -3.03515625,
            "end_logit": 14.7265625,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -3.3515625,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.0625,
            "text": "SET domain contains the catalytic center of",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.625,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that target the N-terminal tails of histones and",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.671875,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.71875,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that target the N-terminal tails of histones and regulate chromatin function",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.7421875,
            "text": "SET domain contains the catalytic center",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.7578125,
            "text": "SET domain contains the catalytic center of lysine methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.828125,
            "text": "SET domain contains the catalytic center of lysine methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -9.828125,
            "text": "SET domain contains the catalytic center of lysine",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -10.140625,
            "text": "SET domain contains",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -10.1796875,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that target the N-terminal tails",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -10.2265625,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that target the N",
            "probability": 0.0
        },
        {
            "start_logit": 13.3671875,
            "end_logit": -10.2421875,
            "text": "SET domain contains the catalytic center of lysine methyltransferases that target the N-terminal tails of histones and regulate chromatin",
            "probability": 0.0
        },
        {
            "start_logit": -3.03515625,
            "end_logit": -9.0625,
            "text": "domain contains the catalytic center of",
            "probability": 0.0
        },
        {
            "start_logit": -3.03515625,
            "end_logit": -9.625,
            "text": "domain contains the catalytic center of lysine methyltransferases that target the N-terminal tails of histones and",
            "probability": 0.0
        },
        {
            "start_logit": -3.03515625,
            "end_logit": -9.671875,
            "text": "domain contains the catalytic center of lysine methyltransferases that",
            "probability": 0.0
        },
        {
            "start_logit": -3.03515625,
            "end_logit": -9.71875,
            "text": "domain contains the catalytic center of lysine methyltransferases that target the N-terminal tails of histones and regulate chromatin function",
            "probability": 0.0
        },
        {
            "start_logit": -3.03515625,
            "end_logit": -9.7421875,
            "text": "domain contains the catalytic center",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_22": [
        {
            "start_logit": 13.2734375,
            "end_logit": 14.578125,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -3.40234375,
            "end_logit": 14.578125,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.2734375,
            "end_logit": -3.2421875,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 14.578125,
            "text": "The evolutionarily conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 14.578125,
            "text": "conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.578125,
            "text": "evolutionarily conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": 13.2734375,
            "end_logit": -9.53125,
            "text": "SET domain occurs in most",
            "probability": 0.0
        },
        {
            "start_logit": 13.2734375,
            "end_logit": -9.6640625,
            "text": "SET domain occurs in",
            "probability": 0.0
        },
        {
            "start_logit": 13.2734375,
            "end_logit": -9.8359375,
            "text": "SET domain occurs",
            "probability": 0.0
        },
        {
            "start_logit": 13.2734375,
            "end_logit": -9.890625,
            "text": "SET domain occurs in most proteins known to possess histone lysine methyltransferase activity",
            "probability": 0.0
        },
        {
            "start_logit": 13.2734375,
            "end_logit": -10.0390625,
            "text": "SET domain occurs in most proteins known to possess histone lysine methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": 13.2734375,
            "end_logit": -10.0859375,
            "text": "SET domain occurs in most proteins known to",
            "probability": 0.0
        },
        {
            "start_logit": 13.2734375,
            "end_logit": -10.109375,
            "text": "SET domain occurs in most proteins known",
            "probability": 0.0
        },
        {
            "start_logit": 13.2734375,
            "end_logit": -10.140625,
            "text": "SET domain occurs in most proteins",
            "probability": 0.0
        },
        {
            "start_logit": 13.2734375,
            "end_logit": -10.1875,
            "text": "SET domain occurs in most proteins known to possess",
            "probability": 0.0
        },
        {
            "start_logit": 13.2734375,
            "end_logit": -10.3984375,
            "text": "SET domain occurs in most proteins known to possess histone lysine",
            "probability": 0.0
        },
        {
            "start_logit": -8.0546875,
            "end_logit": -3.2421875,
            "text": "The evolutionarily conserved SET",
            "probability": 0.0
        },
        {
            "start_logit": -3.40234375,
            "end_logit": -9.53125,
            "text": "domain occurs in most",
            "probability": 0.0
        },
        {
            "start_logit": -3.40234375,
            "end_logit": -9.6640625,
            "text": "domain occurs in",
            "probability": 0.0
        },
        {
            "start_logit": -3.40234375,
            "end_logit": -9.8359375,
            "text": "domain occurs",
            "probability": 0.0
        }
    ],
    "532dcfc9d6d3ac6a34000021_23": [
        {
            "start_logit": 13.765625,
            "end_logit": 14.734375,
            "text": "SET domain",
            "probability": 1.0
        },
        {
            "start_logit": -3.05859375,
            "end_logit": 14.734375,
            "text": "domain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.765625,
            "end_logit": -2.689453125,
            "text": "SET",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -6.328125,
            "text": "SET domain,",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.0,
            "text": "SET domain, which",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.390625,
            "text": "SET domain, which requires adjacent cysteine-rich regions to confer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 14.734375,
            "text": "the evolutionarily conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.484375,
            "text": "SET domain, which requires adjacent cysteine-rich regions to confer histone methyltransferase activity",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.6640625,
            "text": "SET domain, which requires adjacent cysteine-rich",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.6953125,
            "text": "SET domain, which requires",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.7265625,
            "text": "SET domain, which requires adjacent cysteine-rich regions to",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.8125,
            "text": "SET domain, which requires adjacent cysteine-rich regions",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.734375,
            "text": "conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -10.09375,
            "text": "SET domain, which requires adjacent cysteine-rich regions to confer histone methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -10.109375,
            "text": "SET domain, which requires adjacent cysteine-",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": 14.734375,
            "text": "evolutionarily conserved SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -3.05859375,
            "end_logit": -6.328125,
            "text": "domain,",
            "probability": 0.0
        },
        {
            "start_logit": -3.05859375,
            "end_logit": -9.0,
            "text": "domain, which",
            "probability": 0.0
        },
        {
            "start_logit": -3.05859375,
            "end_logit": -9.390625,
            "text": "domain, which requires adjacent cysteine-rich regions to confer",
            "probability": 0.0
        },
        {
            "start_logit": -3.05859375,
            "end_logit": -9.484375,
            "text": "domain, which requires adjacent cysteine-rich regions to confer histone methyltransferase activity",
            "probability": 0.0
        }
    ],
    "52bf1f1303868f1b06000014_1": [
        {
            "start_logit": 8.6953125,
            "end_logit": 8.4140625,
            "text": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone-like protein critical for cell function.",
            "probability": 0.97900390625
        },
        {
            "start_logit": 4.83203125,
            "end_logit": 8.4140625,
            "text": "antioxidant and chaperone-like protein critical for cell function.",
            "probability": 0.0206451416015625
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -2.939453125,
            "text": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone-like protein",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": -4.3359375,
            "end_logit": 8.4140625,
            "text": ".",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -5.5703125,
            "end_logit": 8.4140625,
            "text": "(PRDX-2) is an antioxidant and chaperone-like protein critical for cell function.",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -5.90234375,
            "text": "Peroxiredoxin-2 (PRDX-2)",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -6.09765625,
            "end_logit": 8.4140625,
            "text": "iredoxin-2 (PRDX-2) is an antioxidant and chaperone-like protein critical for cell function.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.40625,
            "end_logit": 8.4140625,
            "text": "protein critical for cell function.",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 4.83203125,
            "end_logit": -2.939453125,
            "text": "antioxidant and chaperone-like protein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -7.75390625,
            "text": "Peroxiredoxin-2 (PRDX-2) is",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -8.0390625,
            "text": "Perox",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 8.4140625,
            "text": "and chaperone-like protein critical for cell function.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -8.78125,
            "text": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -8.8125,
            "text": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -8.984375,
            "text": "Peroxiredoxin-",
            "probability": 0.0
        },
        {
            "start_logit": -8.875,
            "end_logit": 8.4140625,
            "text": "chaperone-like protein critical for cell function.",
            "probability": 0.0
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -9.1640625,
            "text": "Peroxiredoxin-2 (PRDX-2) is an antioxidant",
            "probability": 0.0
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -9.28125,
            "text": "Peroxiredoxin-2 (",
            "probability": 0.0
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -9.75,
            "text": "Peroxiredoxin",
            "probability": 0.0
        },
        {
            "start_logit": 8.6953125,
            "end_logit": -9.8359375,
            "text": "Peroxiredoxin-2 (PRDX",
            "probability": 0.0
        }
    ],
    "52bf1f1303868f1b06000014_2": [
        {
            "start_logit": 12.9453125,
            "end_logit": 13.71875,
            "text": "antioxidant enzyme",
            "probability": 1.0
        },
        {
            "start_logit": -1.28125,
            "end_logit": 13.71875,
            "text": "enzyme",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 12.9453125,
            "end_logit": -1.0224609375,
            "text": "antioxidant",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -8.3671875,
            "end_logit": 13.71875,
            "text": "the antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 12.9453125,
            "end_logit": -8.3046875,
            "text": "antioxidant enzyme peroxiredoxin-2 (Prx2",
            "probability": 0.0
        },
        {
            "start_logit": 12.9453125,
            "end_logit": -8.53125,
            "text": "antioxidant enzyme peroxiredoxin-2 (Prx2) inversely",
            "probability": 0.0
        },
        {
            "start_logit": 12.9453125,
            "end_logit": -8.65625,
            "text": "antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells.",
            "probability": 0.0
        },
        {
            "start_logit": 12.9453125,
            "end_logit": -8.9140625,
            "text": "antioxidant enzyme peroxiredoxin-2 (Prx2)",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 13.71875,
            "text": "We found that the antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 12.9453125,
            "end_logit": -9.5234375,
            "text": "antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 13.71875,
            "text": "that the antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 12.9453125,
            "end_logit": -9.7421875,
            "text": "antioxidant enzyme peroxiredoxin-",
            "probability": 0.0
        },
        {
            "start_logit": 12.9453125,
            "end_logit": -9.8515625,
            "text": "antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma",
            "probability": 0.0
        },
        {
            "start_logit": 12.9453125,
            "end_logit": -9.8515625,
            "text": "antioxidant enzyme peroxiredoxin-2 (Pr",
            "probability": 0.0
        },
        {
            "start_logit": 12.9453125,
            "end_logit": -10.0390625,
            "text": "antioxidant enzyme peroxiredoxin-2",
            "probability": 0.0
        },
        {
            "start_logit": 12.9453125,
            "end_logit": -10.0546875,
            "text": "antioxidant enzyme peroxiredoxin",
            "probability": 0.0
        },
        {
            "start_logit": 12.9453125,
            "end_logit": -10.0625,
            "text": "antioxidant enzyme perox",
            "probability": 0.0
        },
        {
            "start_logit": 12.9453125,
            "end_logit": -10.1171875,
            "text": "antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells",
            "probability": 0.0
        },
        {
            "start_logit": 12.9453125,
            "end_logit": -10.234375,
            "text": "antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with",
            "probability": 0.0
        },
        {
            "start_logit": -0.12164306640625,
            "end_logit": -8.3046875,
            "text": "peroxiredoxin-2 (Prx2",
            "probability": 0.0
        }
    ],
    "52bf1f1303868f1b06000014_3": [
        {
            "start_logit": 9.65625,
            "end_logit": 2.36328125,
            "text": "antioxidant enzyme",
            "probability": 0.98193359375
        },
        {
            "start_logit": 9.65625,
            "end_logit": -1.6064453125,
            "text": "antioxidant",
            "probability": 0.0185394287109375
        },
        {
            "start_logit": 9.65625,
            "end_logit": -9.09375,
            "text": "antioxidant enzyme sulfiredoxin (Srx) and",
            "probability": 1.043081283569336e-05
        },
        {
            "start_logit": 9.65625,
            "end_logit": -9.1796875,
            "text": "antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions and modification during the ovulatory process in rats.",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": 9.65625,
            "end_logit": -9.1875,
            "text": "antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2",
            "probability": 9.47713851928711e-06
        },
        {
            "start_logit": 9.65625,
            "end_logit": -9.40625,
            "text": "antioxidant enzyme sulfiredoxin (Srx)",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": 9.65625,
            "end_logit": -9.53125,
            "text": "antioxidant enzyme sulfiredoxin (Srx",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": 9.65625,
            "end_logit": -9.5390625,
            "text": "antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions and modification",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": 9.65625,
            "end_logit": -9.5859375,
            "text": "antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PR",
            "probability": 6.377696990966797e-06
        },
        {
            "start_logit": 9.65625,
            "end_logit": -9.609375,
            "text": "antioxidant enzyme sulfiredoxin",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": 9.65625,
            "end_logit": -9.78125,
            "text": "antioxidant enzyme sulfiredoxin (",
            "probability": 5.245208740234375e-06
        },
        {
            "start_logit": 9.65625,
            "end_logit": -9.8671875,
            "text": "antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": 9.65625,
            "end_logit": -9.9453125,
            "text": "antioxidant enzyme sulfiredoxin (Sr",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": -2.80859375,
            "end_logit": 2.36328125,
            "text": "enzyme",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 9.65625,
            "end_logit": -10.109375,
            "text": "antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRD",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 9.65625,
            "end_logit": -10.140625,
            "text": "antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2)",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": -10.640625,
            "end_logit": 2.36328125,
            "text": "The aim of this study was to examine gonadotropin regulation of antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 2.36328125,
            "text": "of this study was to examine gonadotropin regulation of antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -2.80859375,
            "end_logit": -9.09375,
            "text": "enzyme sulfiredoxin (Srx) and",
            "probability": 0.0
        },
        {
            "start_logit": -2.80859375,
            "end_logit": -9.1796875,
            "text": "enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions and modification during the ovulatory process in rats.",
            "probability": 0.0
        }
    ],
    "52bf1f1303868f1b06000014_4": [
        {
            "start_logit": 8.890625,
            "end_logit": 4.2890625,
            "text": "antioxidant enzyme whose main function is H(2)O(2) reduction in cells.",
            "probability": 0.88818359375
        },
        {
            "start_logit": 8.890625,
            "end_logit": 2.216796875,
            "text": "antioxidant enzyme",
            "probability": 0.11199951171875
        },
        {
            "start_logit": 2.09765625,
            "end_logit": 2.216796875,
            "text": "Peroxiredoxin 2 (PRDX2) has been known to act as an antioxidant enzyme",
            "probability": 0.0001251697540283203
        },
        {
            "start_logit": 8.890625,
            "end_logit": -5.74609375,
            "text": "antioxidant",
            "probability": 3.904104232788086e-05
        },
        {
            "start_logit": 8.890625,
            "end_logit": -8.21875,
            "text": "antioxidant enzyme whose main function is H(2)O(2) reduction in cells",
            "probability": 3.2782554626464844e-06
        },
        {
            "start_logit": 8.890625,
            "end_logit": -8.9375,
            "text": "antioxidant enzyme whose main function is H(2)O(2) reduction in",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 8.890625,
            "end_logit": -9.0859375,
            "text": "antioxidant enzyme whose main function is H(2)O",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 8.890625,
            "end_logit": -9.1484375,
            "text": "antioxidant enzyme whose main function is H(2)O(2) reduction",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": 8.890625,
            "end_logit": -10.265625,
            "text": "antioxidant enzyme whose main function is H(2)O(2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -10.34375,
            "text": "antioxidant enzyme whose main",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -10.4140625,
            "text": "antioxidant enzyme whose main function is H(2)O(",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 8.890625,
            "end_logit": -10.453125,
            "text": "antioxidant enzyme whose main function is H(2)O(2)",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.08984375,
            "end_logit": 4.2890625,
            "text": ".",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.53125,
            "end_logit": 4.2890625,
            "text": "H(2)O(2) reduction in cells.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 4.2890625,
            "text": "enzyme whose main function is H(2)O(2) reduction in cells.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 2.09765625,
            "end_logit": -5.74609375,
            "text": "Peroxiredoxin 2 (PRDX2) has been known to act as an antioxidant",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.0,
            "end_logit": 4.2890625,
            "text": "reduction in cells.",
            "probability": 0.0
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 2.216796875,
            "text": "enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 4.2890625,
            "text": ")O(2) reduction in cells.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 4.2890625,
            "text": "is H(2)O(2) reduction in cells.",
            "probability": 0.0
        }
    ],
    "52bf1f1303868f1b06000014_5": [
        {
            "start_logit": 13.5625,
            "end_logit": 14.328125,
            "text": "antioxidant enzyme",
            "probability": 1.0
        },
        {
            "start_logit": -0.76611328125,
            "end_logit": 14.328125,
            "text": "enzyme",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 13.5625,
            "end_logit": -0.1064453125,
            "text": "antioxidant",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 13.5625,
            "end_logit": -5.5234375,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2)",
            "probability": 0.0
        },
        {
            "start_logit": -7.265625,
            "end_logit": 14.328125,
            "text": "the antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 13.5625,
            "end_logit": -6.8046875,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2) as a critical cytoplasmic target of cdk5.",
            "probability": 0.0
        },
        {
            "start_logit": 13.5625,
            "end_logit": -9.265625,
            "text": "antioxidant enzyme Prx2",
            "probability": 0.0
        },
        {
            "start_logit": 13.5625,
            "end_logit": -9.390625,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2) as a critical cytoplasmic target of cdk5",
            "probability": 0.0
        },
        {
            "start_logit": 13.5625,
            "end_logit": -9.578125,
            "text": "antioxidant enzyme Pr",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 14.328125,
            "text": "demonstrate the antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 14.328125,
            "text": "we also demonstrate the antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 13.5625,
            "end_logit": -9.625,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2) as",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 14.328125,
            "text": ", we also demonstrate the antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 14.328125,
            "text": "Importantly, we also demonstrate the antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 13.5625,
            "end_logit": -10.1640625,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2) as a",
            "probability": 0.0
        },
        {
            "start_logit": 13.5625,
            "end_logit": -10.2578125,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin",
            "probability": 0.0
        },
        {
            "start_logit": 13.5625,
            "end_logit": -10.265625,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2) as a critical cytoplasmic target of",
            "probability": 0.0
        },
        {
            "start_logit": 13.5625,
            "end_logit": -10.3984375,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2) as a critical cytoplasmic target of cdk",
            "probability": 0.0
        },
        {
            "start_logit": 13.5625,
            "end_logit": -10.484375,
            "text": "antioxidant enzyme Prx2 (peroxiredoxin 2) as a critical cytoplasmic target",
            "probability": 0.0
        },
        {
            "start_logit": -0.76611328125,
            "end_logit": -5.5234375,
            "text": "enzyme Prx2 (peroxiredoxin 2)",
            "probability": 0.0
        }
    ],
    "52bf1f1303868f1b06000014_6": [
        {
            "start_logit": 12.15625,
            "end_logit": 7.31640625,
            "text": "antioxidant enzyme",
            "probability": 0.9990234375
        },
        {
            "start_logit": 4.328125,
            "end_logit": 7.31640625,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme",
            "probability": 0.0003979206085205078
        },
        {
            "start_logit": 12.15625,
            "end_logit": -1.2890625,
            "text": "antioxidant enzyme that uses cysteine residues to decompose peroxides.",
            "probability": 0.00018358230590820312
        },
        {
            "start_logit": 12.15625,
            "end_logit": -3.759765625,
            "text": "antioxidant",
            "probability": 1.5556812286376953e-05
        },
        {
            "start_logit": 4.328125,
            "end_logit": -1.2890625,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decompose peroxides.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.15625,
            "end_logit": -10.265625,
            "text": "antioxidant enzyme that uses cysteine residues to decompose peroxides",
            "probability": 0.0
        },
        {
            "start_logit": 12.15625,
            "end_logit": -10.3046875,
            "text": "antioxidant enzyme that uses cysteine residues to decompose peroxide",
            "probability": 0.0
        },
        {
            "start_logit": -5.484375,
            "end_logit": 7.31640625,
            "text": "enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 4.328125,
            "end_logit": -3.759765625,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 7.31640625,
            "text": "iredoxin 2 (Prx2) is an antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 7.31640625,
            "text": "Prx2) is an antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 7.31640625,
            "text": "oxin 2 (Prx2) is an antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 7.31640625,
            "text": "(Prx2) is an antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 7.31640625,
            "text": "an antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 4.328125,
            "end_logit": -8.78125,
            "text": "Perox",
            "probability": 0.0
        },
        {
            "start_logit": 4.328125,
            "end_logit": -9.25,
            "text": "Peroxiredoxin 2 (Prx2",
            "probability": 0.0
        },
        {
            "start_logit": 4.328125,
            "end_logit": -9.8203125,
            "text": "Peroxiredoxin 2 (Prx2) is",
            "probability": 0.0
        },
        {
            "start_logit": 4.328125,
            "end_logit": -9.890625,
            "text": "Peroxiredoxin 2 (Prx2)",
            "probability": 0.0
        },
        {
            "start_logit": 4.328125,
            "end_logit": -10.265625,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decompose peroxides",
            "probability": 0.0
        },
        {
            "start_logit": 4.328125,
            "end_logit": -10.3046875,
            "text": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decompose peroxide",
            "probability": 0.0
        }
    ],
    "52bf1f1303868f1b06000014_7": [
        {
            "start_logit": 13.7890625,
            "end_logit": 13.453125,
            "text": "antioxidant enzyme",
            "probability": 1.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -0.9306640625,
            "text": "antioxidant",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -2.99609375,
            "end_logit": 13.453125,
            "text": "enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.6875,
            "end_logit": 13.453125,
            "text": "an antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -8.6875,
            "end_logit": 13.453125,
            "text": "Peroxiredoxin 2 (PRDX2), an antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -9.6484375,
            "text": "antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -9.859375,
            "text": "antioxidant enzyme, was",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -9.9375,
            "text": "antioxidant enzyme,",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -9.96875,
            "text": "antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3)",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -9.9765625,
            "text": "antioxidant enzyme, was the most upregulated",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -10.0,
            "text": "antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3), a pro-apoptotic protein, was the most downregulated, implying",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -10.1953125,
            "text": "antioxidant enzyme, was the",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -10.2109375,
            "text": "antioxidant enzyme, was the most upregulated while",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -10.2109375,
            "text": "antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3), a pro-apoptotic protein, was",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -10.2109375,
            "text": "antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3), a pro-apoptotic protein, was the most downregulated",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -10.2265625,
            "text": "antioxidant enzyme, was the most",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 13.453125,
            "text": "iredoxin 2 (PRDX2), an antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 13.453125,
            "text": "(PRDX2), an antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 13.453125,
            "text": ", an antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -8.6875,
            "end_logit": -0.9306640625,
            "text": "an antioxidant",
            "probability": 0.0
        }
    ],
    "52bf1f1303868f1b06000014_8": [
        {
            "start_logit": 12.625,
            "end_logit": 12.4140625,
            "text": "antioxidant enzyme",
            "probability": 0.8935546875
        },
        {
            "start_logit": 12.625,
            "end_logit": 10.28125,
            "text": "antioxidant enzyme, and latexin, an inhibitor of carboxypeptidase",
            "probability": 0.10675048828125
        },
        {
            "start_logit": 12.625,
            "end_logit": -1.3076171875,
            "text": "antioxidant",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -3.81640625,
            "end_logit": 12.4140625,
            "text": "enzyme",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.81640625,
            "end_logit": 10.28125,
            "text": "enzyme, and latexin, an inhibitor of carboxypeptidase",
            "probability": 0.0
        },
        {
            "start_logit": -3.904296875,
            "end_logit": 10.28125,
            "text": "carboxypeptidase",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -7.390625,
            "text": "antioxidant enzyme, and latexin, an inhibitor of carboxypeptidase, increased",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -8.0078125,
            "text": "antioxidant enzyme, and latexin, an inhibitor of carboxypeptidase, increased.",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -8.9921875,
            "text": "antioxidant enzyme, and latexin, an inhibitor of carboxyp",
            "probability": 0.0
        },
        {
            "start_logit": -6.859375,
            "end_logit": 10.28125,
            "text": "eptidase",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -9.4453125,
            "text": "antioxidant enzyme, and latexin, an inhibitor of carboxypeptidase,",
            "probability": 0.0
        },
        {
            "start_logit": -9.328125,
            "end_logit": 12.4140625,
            "text": "peroxiredoxin 2, an antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -9.8671875,
            "text": "antioxidant enzyme, and",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -9.984375,
            "text": "antioxidant enzyme, and latexin,",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -10.015625,
            "text": "antioxidant enzyme,",
            "probability": 0.0
        },
        {
            "start_logit": 12.625,
            "end_logit": -10.0625,
            "text": "antioxidant enzyme, and latexin",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 12.4140625,
            "text": "an antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 12.4140625,
            "text": "iredoxin 2, an antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 12.4140625,
            "text": "irradiation, the relative abundance of peroxiredoxin 2, an antioxidant enzyme",
            "probability": 0.0
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 10.28125,
            "text": "of carboxypeptidase",
            "probability": 0.0
        }
    ],
    "52bf1f1303868f1b06000014_9": [
        {
            "start_logit": 11.640625,
            "end_logit": 11.421875,
            "text": "antioxidant enzymes",
            "probability": 1.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -3.708984375,
            "text": "antioxidant",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.5234375,
            "end_logit": 11.421875,
            "text": "enzymes",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.75,
            "end_logit": 11.421875,
            "text": "peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes",
            "probability": 0.0
        },
        {
            "start_logit": -7.39453125,
            "end_logit": 11.421875,
            "text": "Peroxiredoxins are antioxidant enzymes",
            "probability": 0.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -9.6953125,
            "text": "antioxidant enzymes involved in protein and lipid protection against oxidative injury",
            "probability": 0.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -9.8359375,
            "text": "antioxidant enzymes involved in protein and lipid protection against oxidative injury and in cellular signalling pathways regulating apoptosis.",
            "probability": 0.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -9.9765625,
            "text": "antioxidant enzymes involved in protein and lipid protection against oxidative injury and in cellular signalling pathways regulating apoptosis",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 11.421875,
            "text": "at 13q12. Peroxiredoxins are antioxidant enzymes",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 11.421875,
            "text": "versus control fetal brains revealed differential expression of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 11.421875,
            "text": "differential expression of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 11.421875,
            "text": "fetal brains revealed differential expression of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 11.421875,
            "text": "brains revealed differential expression of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 11.421875,
            "text": "are antioxidant enzymes",
            "probability": 0.0
        },
        {
            "start_logit": -5.75,
            "end_logit": -3.708984375,
            "text": "peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant",
            "probability": 0.0
        },
        {
            "start_logit": -7.39453125,
            "end_logit": -3.708984375,
            "text": "Peroxiredoxins are antioxidant",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": -3.708984375,
            "text": "at 13q12. Peroxiredoxins are antioxidant",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": -3.708984375,
            "text": "versus control fetal brains revealed differential expression of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": -3.708984375,
            "text": "differential expression of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": -3.708984375,
            "text": "fetal brains revealed differential expression of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant",
            "probability": 0.0
        }
    ],
    "603251f81cb411341a00013a_1": [
        {
            "start_logit": 10.109375,
            "end_logit": 14.484375,
            "text": "c-Myc",
            "probability": 1.0
        },
        {
            "start_logit": -0.78564453125,
            "end_logit": 14.484375,
            "text": "Myc",
            "probability": 1.8477439880371094e-05
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 14.484375,
            "text": "and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": 10.109375,
            "end_logit": -5.29296875,
            "text": "c",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 14.484375,
            "text": "-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 14.484375,
            "text": "MLL1, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 14.484375,
            "text": "WDR5 functions to sustain proper execution of DNA replication in PDAC cells, as previously suggested by replication stress studies involving MLL1, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 14.484375,
            "text": ", and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 14.484375,
            "text": "involving MLL1, and c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": 10.109375,
            "end_logit": -8.9453125,
            "text": "c-",
            "probability": 0.0
        },
        {
            "start_logit": 10.109375,
            "end_logit": -9.703125,
            "text": "c-Myc, also found to interact with WDR5. We indeed demonstrate",
            "probability": 0.0
        },
        {
            "start_logit": 10.109375,
            "end_logit": -9.8984375,
            "text": "c-Myc, also found to interact with WDR5. We indeed demonstrate that interaction with c-Myc is critical for this function.",
            "probability": 0.0
        },
        {
            "start_logit": 10.109375,
            "end_logit": -10.0078125,
            "text": "c-Myc,",
            "probability": 0.0
        },
        {
            "start_logit": 10.109375,
            "end_logit": -10.1171875,
            "text": "c-Myc, also found to interact with WDR5. We indeed demonstrate that interaction with c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -0.78564453125,
            "end_logit": -9.625,
            "text": "Myc, also found to interact with WDR5. We indeed demonstrate that interaction with c-Myc is critical for this function. By showing that ATR",
            "probability": 0.0
        },
        {
            "start_logit": -0.78564453125,
            "end_logit": -9.703125,
            "text": "Myc, also found to interact with WDR5. We indeed demonstrate",
            "probability": 0.0
        },
        {
            "start_logit": -0.78564453125,
            "end_logit": -9.8984375,
            "text": "Myc, also found to interact with WDR5. We indeed demonstrate that interaction with c-Myc is critical for this function.",
            "probability": 0.0
        },
        {
            "start_logit": -0.78564453125,
            "end_logit": -10.0078125,
            "text": "Myc,",
            "probability": 0.0
        },
        {
            "start_logit": -0.78564453125,
            "end_logit": -10.1171875,
            "text": "Myc, also found to interact with WDR5. We indeed demonstrate that interaction with c-Myc",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": -5.29296875,
            "text": "and c",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_1": [
        {
            "start_logit": 13.8359375,
            "end_logit": 15.09375,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.66015625,
            "end_logit": 15.09375,
            "text": "cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -3.08984375,
            "text": "metastatic",
            "probability": 0.0
        },
        {
            "start_logit": -6.19140625,
            "end_logit": 15.09375,
            "text": "resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.3203125,
            "end_logit": 15.09375,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -5.74609375,
            "text": "metastatic castration-resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": -7.390625,
            "end_logit": 15.09375,
            "text": "castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 15.09375,
            "text": "-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 15.09375,
            "text": "Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.0625,
            "text": "metastatic castration",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 15.09375,
            "text": "with chemotherapy-naive metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 15.09375,
            "text": "naive metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.984375,
            "text": "metastatic castration-resistant",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -10.3125,
            "text": "metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -10.421875,
            "text": "metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -10.4453125,
            "text": "metastatic castration-resistant prostate cancer (ELM-PC 4",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -10.4609375,
            "text": "metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind",
            "probability": 0.0
        },
        {
            "start_logit": -6.19140625,
            "end_logit": -5.74609375,
            "text": "resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": -1.66015625,
            "end_logit": -10.3125,
            "text": "cancer (ELM-PC 4): a double-blind, multicentre",
            "probability": 0.0
        },
        {
            "start_logit": -6.3203125,
            "end_logit": -5.74609375,
            "text": "prostate",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_2": [
        {
            "start_logit": 12.0546875,
            "end_logit": 14.171875,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.904296875,
            "end_logit": 14.171875,
            "text": "cancer",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -1.99609375,
            "text": "metastatic castration-resistant prostate",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -4.73828125,
            "text": "metastatic",
            "probability": 0.0
        },
        {
            "start_logit": -7.40625,
            "end_logit": 14.171875,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.6953125,
            "end_logit": 14.171875,
            "text": "castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 14.171875,
            "text": "resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": 14.171875,
            "text": "in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": 14.171875,
            "text": "-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.5625,
            "end_logit": 14.171875,
            "text": "the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 14.171875,
            "text": "for metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 14.171875,
            "text": "CYP 17,20-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 14.171875,
            "text": "validated therapeutic target for metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 14.171875,
            "text": "-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 14.171875,
            "text": "of CYP 17,20-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 14.171875,
            "text": ",20-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 14.171875,
            "text": ", partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -9.25,
            "text": "metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -9.6796875,
            "text": "metastatic castration",
            "probability": 0.0
        },
        {
            "start_logit": 12.0546875,
            "end_logit": -9.9296875,
            "text": "metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_3": [
        {
            "start_logit": 13.8203125,
            "end_logit": 15.0546875,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.85546875,
            "end_logit": 15.0546875,
            "text": "cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -3.103515625,
            "text": "metastatic",
            "probability": 0.0
        },
        {
            "start_logit": -5.5078125,
            "end_logit": 15.0546875,
            "text": "resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -4.60546875,
            "text": "metastatic castration-resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": -6.06640625,
            "end_logit": 15.0546875,
            "text": "castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.5546875,
            "end_logit": 15.0546875,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -8.0078125,
            "text": "metastatic castration",
            "probability": 0.0
        },
        {
            "start_logit": -9.4609375,
            "end_logit": 15.0546875,
            "text": "-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.703125,
            "end_logit": 15.0546875,
            "text": "NTERPRETATION: In chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 15.0546875,
            "text": "with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 15.0546875,
            "text": "ERPRETATION: In chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -9.9453125,
            "text": "metastatic castration-resistant",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -10.03125,
            "text": "metastatic castration-resistant prostate cancer, radiographic progression-free survival was prolonged with orterone",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -10.171875,
            "text": "metastatic castration-resistant prostate cancer, radiographic progression-free survival was prolonged with orteronel",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -10.25,
            "text": "metastatic castration-resistant prostate cancer, radiographic progression-free survival was prolonged with orteronel plus prednisone",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -10.25,
            "text": "metastatic castration-resistant prostate cancer, radiographic progression-free survival was prolonged with orteronel plus prednisone versus placebo",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -10.328125,
            "text": "metastatic castration-resistant prostate cancer, radiographic progression-free survival was prolonged with orteronel plus prednisone versus placebo plus prednisone.",
            "probability": 0.0
        },
        {
            "start_logit": 13.8203125,
            "end_logit": -10.3671875,
            "text": "metastatic castration-resistant prostate cancer, radiographic progression-free survival was prolonged with",
            "probability": 0.0
        },
        {
            "start_logit": -5.5078125,
            "end_logit": -4.60546875,
            "text": "resistant prostate",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_4": [
        {
            "start_logit": 13.0078125,
            "end_logit": 14.9609375,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -2.0234375,
            "end_logit": 14.9609375,
            "text": "cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -3.84765625,
            "text": "metastatic",
            "probability": 0.0
        },
        {
            "start_logit": -5.8828125,
            "end_logit": 14.9609375,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.1171875,
            "end_logit": 14.9609375,
            "text": "resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -4.46875,
            "text": "metastatic castration-resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": -7.01953125,
            "end_logit": 14.9609375,
            "text": "castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 14.9609375,
            "text": "orteronel is not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 14.9609375,
            "text": "-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 14.9609375,
            "text": "in metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 14.9609375,
            "text": "undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -8.578125,
            "text": "metastatic castration",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 14.9609375,
            "text": "not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.9609375,
            "text": ", orteronel is not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 14.9609375,
            "text": "further development in metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.9609375,
            "text": "the basis of these and other data, orteronel is not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.3671875,
            "text": "metastatic castration-resistant prostate cancer.",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.8515625,
            "text": "metastatic castration-resistant",
            "probability": 0.0
        },
        {
            "start_logit": -5.8828125,
            "end_logit": -4.46875,
            "text": "prostate",
            "probability": 0.0
        },
        {
            "start_logit": -6.1171875,
            "end_logit": -4.46875,
            "text": "resistant prostate",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_5": [
        {
            "start_logit": 12.421875,
            "end_logit": 14.703125,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -2.458984375,
            "end_logit": 14.703125,
            "text": "cancer",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -6.76171875,
            "end_logit": 14.703125,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.890625,
            "end_logit": 14.703125,
            "text": "resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -4.7265625,
            "text": "metastatic",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -5.0546875,
            "text": "metastatic castration-resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 14.703125,
            "text": "castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 14.703125,
            "text": "with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 14.703125,
            "text": "-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 14.703125,
            "text": "double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 14.703125,
            "text": ", multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 14.703125,
            "text": "-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -9.0234375,
            "text": "metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -9.5234375,
            "text": "metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -9.9921875,
            "text": "metastatic castration",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -10.1484375,
            "text": "metastatic castration-resistant",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -10.3046875,
            "text": "metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -10.3671875,
            "text": "metastatic castration-resistant prostate cancer that",
            "probability": 0.0
        },
        {
            "start_logit": 12.421875,
            "end_logit": -10.4453125,
            "text": "metastatic castration-resistant prostate cancer that has progressed",
            "probability": 0.0
        },
        {
            "start_logit": -2.458984375,
            "end_logit": -9.0234375,
            "text": "cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_6": [
        {
            "start_logit": 13.0078125,
            "end_logit": 14.890625,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.9599609375,
            "end_logit": 14.890625,
            "text": "cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -5.76171875,
            "end_logit": 14.890625,
            "text": "castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -5.77734375,
            "end_logit": 14.890625,
            "text": "resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -3.955078125,
            "text": "metastatic",
            "probability": 0.0
        },
        {
            "start_logit": -6.4296875,
            "end_logit": 14.890625,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -5.046875,
            "text": "metastatic castration-resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 14.890625,
            "text": "-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -7.95703125,
            "text": "metastatic castration",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 14.890625,
            "text": "with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 14.890625,
            "text": "orteronel in patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.890625,
            "text": "patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 14.890625,
            "text": "This study examined orteronel in patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.7109375,
            "text": "metastatic castration-resistant prostate cancer that",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -10.0703125,
            "text": "metastatic castration-resistant prostate cancer that progressed",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -10.2265625,
            "text": "metastatic castration-resistant prostate cancer that progressed after docetaxel therapy.",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -10.234375,
            "text": "metastatic castration-resistant",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -10.3515625,
            "text": "metastatic castration-resistant prostate cancer that progressed after docetaxel",
            "probability": 0.0
        },
        {
            "start_logit": -5.76171875,
            "end_logit": -5.046875,
            "text": "castration-resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": -5.77734375,
            "end_logit": -5.046875,
            "text": "resistant prostate",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_7": [
        {
            "start_logit": 12.640625,
            "end_logit": 14.5,
            "text": "castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -2.080078125,
            "end_logit": 14.5,
            "text": "resistant prostate cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -2.41015625,
            "end_logit": 14.5,
            "text": "cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 12.640625,
            "end_logit": -3.630859375,
            "text": "castration-resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -4.01953125,
            "text": "castration",
            "probability": 0.0
        },
        {
            "start_logit": -6.1640625,
            "end_logit": 14.5,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 14.5,
            "text": "with castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": 14.5,
            "text": "-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 14.5,
            "text": "orteronel in Japanese patients with castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.5,
            "text": "dose study of orteronel in Japanese patients with castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 14.5,
            "text": "patients with castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 14.5,
            "text": "phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.5,
            "text": "of orteronel in Japanese patients with castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 14.5,
            "text": "-dose study of orteronel in Japanese patients with castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.5,
            "text": "teronel in Japanese patients with castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -9.390625,
            "text": "castration-",
            "probability": 0.0
        },
        {
            "start_logit": 12.640625,
            "end_logit": -9.96875,
            "text": "castration-resistant prostate cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -2.080078125,
            "end_logit": -3.630859375,
            "text": "resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": -6.1640625,
            "end_logit": -3.630859375,
            "text": "prostate",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": -3.630859375,
            "text": "with castration-resistant prostate",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_8": [
        {
            "start_logit": 3.98828125,
            "end_logit": 13.140625,
            "text": "castration-resistant prostate cancer",
            "probability": 0.9970703125
        },
        {
            "start_logit": -2.017578125,
            "end_logit": 13.140625,
            "text": "cancer",
            "probability": 0.002471923828125
        },
        {
            "start_logit": -5.62109375,
            "end_logit": 13.140625,
            "text": "resistant prostate cancer",
            "probability": 6.693601608276367e-05
        },
        {
            "start_logit": -5.6484375,
            "end_logit": 13.140625,
            "text": "prostate cancer",
            "probability": 6.538629531860352e-05
        },
        {
            "start_logit": -7.99609375,
            "end_logit": 13.140625,
            "text": "with castration-resistant prostate cancer",
            "probability": 6.258487701416016e-06
        },
        {
            "start_logit": -9.1015625,
            "end_logit": 13.140625,
            "text": "-resistant prostate cancer",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -10.15625,
            "end_logit": 13.140625,
            "text": "orteronel with or without prednisolone in Japanese patients with castration-resistant prostate cancer",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -10.671875,
            "end_logit": 13.140625,
            "text": "patients with castration-resistant prostate cancer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 13.140625,
            "text": "the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effect of orteronel with or without prednisolone in Japanese patients with castration-resistant prostate cancer",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 13.140625,
            "text": "without prednisolone in Japanese patients with castration-resistant prostate cancer",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 13.140625,
            "text": "safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effect of orteronel with or without prednisolone in Japanese patients with castration-resistant prostate cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.984375,
            "end_logit": 13.140625,
            "text": ", pharmacodynamics, and antitumor effect of orteronel with or without prednisolone in Japanese patients with castration-resistant prostate cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 3.98828125,
            "end_logit": -4.76953125,
            "text": "castration-resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": 3.98828125,
            "end_logit": -7.3359375,
            "text": "castration-resistant prostate cancer (CRPC",
            "probability": 0.0
        },
        {
            "start_logit": 3.98828125,
            "end_logit": -8.5,
            "text": "castration",
            "probability": 0.0
        },
        {
            "start_logit": 3.98828125,
            "end_logit": -9.859375,
            "text": "castration-resistant prostate cancer (CRPC).",
            "probability": 0.0
        },
        {
            "start_logit": 3.98828125,
            "end_logit": -10.0,
            "text": "castration-resistant prostate cancer (CRPC)",
            "probability": 0.0
        },
        {
            "start_logit": 3.98828125,
            "end_logit": -10.15625,
            "text": "castration-resistant prostate cancer (CRP",
            "probability": 0.0
        },
        {
            "start_logit": -2.017578125,
            "end_logit": -7.3359375,
            "text": "cancer (CRPC",
            "probability": 0.0
        },
        {
            "start_logit": -5.62109375,
            "end_logit": -4.76953125,
            "text": "resistant prostate",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_9": [
        {
            "start_logit": 12.015625,
            "end_logit": 14.078125,
            "text": "castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -3.021484375,
            "end_logit": 14.078125,
            "text": "cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.453125,
            "end_logit": 14.078125,
            "text": "resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.015625,
            "end_logit": -3.150390625,
            "text": "castration-resistant prostate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.76171875,
            "end_logit": 14.078125,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.203125,
            "end_logit": 14.078125,
            "text": "for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -4.2421875,
            "text": "castration",
            "probability": 0.0
        },
        {
            "start_logit": -8.7265625,
            "end_logit": 14.078125,
            "text": "-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 14.078125,
            "text": "in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 14.078125,
            "text": "of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 14.078125,
            "text": "treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 14.078125,
            "text": "recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 14.078125,
            "text": "clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.078125,
            "text": ", selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.078125,
            "text": "inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.078125,
            "text": "20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -9.171875,
            "text": "castration-resistant prostate cancer.",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -9.734375,
            "text": "castration-",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -9.921875,
            "text": "castration-resistant",
            "probability": 0.0
        },
        {
            "start_logit": -4.453125,
            "end_logit": -3.150390625,
            "text": "resistant prostate",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_10": [
        {
            "start_logit": 12.890625,
            "end_logit": 14.46875,
            "text": "castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.232421875,
            "end_logit": 14.46875,
            "text": "resistant prostate cancer",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -2.33984375,
            "end_logit": 14.46875,
            "text": "cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 12.890625,
            "end_logit": -2.501953125,
            "text": "castration-resistant prostate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.890625,
            "end_logit": -3.61328125,
            "text": "castration",
            "probability": 0.0
        },
        {
            "start_logit": -5.9375,
            "end_logit": 14.46875,
            "text": "of castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.1953125,
            "end_logit": 14.46875,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 14.46875,
            "text": "-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 14.46875,
            "text": "treatment of castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 12.890625,
            "end_logit": -9.0546875,
            "text": "castration-",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.46875,
            "text": "-700]) was selected as a candidate for clinical evaluation and is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 14.46875,
            "text": "]) was selected as a candidate for clinical evaluation and is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 12.890625,
            "end_logit": -9.9453125,
            "text": "castration-resistant prostate cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -1.232421875,
            "end_logit": -2.501953125,
            "text": "resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": -5.9375,
            "end_logit": -2.501953125,
            "text": "of castration-resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": -6.1953125,
            "end_logit": -2.501953125,
            "text": "prostate",
            "probability": 0.0
        },
        {
            "start_logit": -5.9375,
            "end_logit": -3.61328125,
            "text": "of castration",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": -2.501953125,
            "text": "-resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": -1.232421875,
            "end_logit": -9.9453125,
            "text": "resistant prostate cancer.",
            "probability": 0.0
        },
        {
            "start_logit": -2.33984375,
            "end_logit": -9.9453125,
            "text": "cancer.",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_11": [
        {
            "start_logit": 13.828125,
            "end_logit": 15.15625,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.564453125,
            "end_logit": 15.15625,
            "text": "cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.828125,
            "end_logit": -3.015625,
            "text": "metastatic",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -4.3125,
            "text": "metastatic castration-resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": -6.07421875,
            "end_logit": 15.15625,
            "text": "resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.33203125,
            "end_logit": 15.15625,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.91015625,
            "end_logit": 15.15625,
            "text": "castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -8.40625,
            "text": "metastatic castration",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 15.15625,
            "text": "-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 15.15625,
            "text": "with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 15.15625,
            "text": "orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 15.15625,
            "text": "patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 15.15625,
            "text": "chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 15.15625,
            "text": "-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 15.15625,
            "text": "We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.8984375,
            "text": "metastatic castration-resistant prostate cancer.",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.9921875,
            "text": "metastatic castration-resistant",
            "probability": 0.0
        },
        {
            "start_logit": -6.07421875,
            "end_logit": -4.3125,
            "text": "resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": -6.33203125,
            "end_logit": -4.3125,
            "text": "prostate",
            "probability": 0.0
        },
        {
            "start_logit": -6.91015625,
            "end_logit": -4.3125,
            "text": "castration-resistant prostate",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_12": [
        {
            "start_logit": 12.015625,
            "end_logit": 14.078125,
            "text": "castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -3.021484375,
            "end_logit": 14.078125,
            "text": "cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -4.453125,
            "end_logit": 14.078125,
            "text": "resistant prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.015625,
            "end_logit": -3.150390625,
            "text": "castration-resistant prostate",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.76171875,
            "end_logit": 14.078125,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.203125,
            "end_logit": 14.078125,
            "text": "for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -4.2421875,
            "text": "castration",
            "probability": 0.0
        },
        {
            "start_logit": -8.7265625,
            "end_logit": 14.078125,
            "text": "-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 14.078125,
            "text": "in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 14.078125,
            "text": "of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 14.078125,
            "text": "treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 14.078125,
            "text": "recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 14.078125,
            "text": "clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.078125,
            "text": ", selective inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.078125,
            "text": "inhibitor of 17,20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.078125,
            "text": "20-lyase that was recently in phase 3 clinical development as a treatment for castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -9.171875,
            "text": "castration-resistant prostate cancer.",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -9.734375,
            "text": "castration-",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -9.921875,
            "text": "castration-resistant",
            "probability": 0.0
        },
        {
            "start_logit": -4.453125,
            "end_logit": -3.150390625,
            "text": "resistant prostate",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_13": [
        {
            "start_logit": 13.3359375,
            "end_logit": 14.953125,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -2.044921875,
            "end_logit": 14.953125,
            "text": "cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -3.69921875,
            "text": "metastatic",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -4.09375,
            "text": "metastatic castration-resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": -6.6484375,
            "end_logit": 14.953125,
            "text": "resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 14.953125,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.296875,
            "end_logit": 14.953125,
            "text": "castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 14.953125,
            "text": "with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 14.953125,
            "text": "-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 14.953125,
            "text": "-an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 14.953125,
            "text": "orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 14.953125,
            "text": "investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.953125,
            "text": "an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -9.0234375,
            "text": "metastatic castration",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 14.953125,
            "text": "-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.953125,
            "text": "TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.953125,
            "text": ",20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 14.953125,
            "text": "(TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 14.953125,
            "text": "-in patients with metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -9.6640625,
            "text": "metastatic castration-resistant prostate cancer.",
            "probability": 0.0
        }
    ],
    "56c1f01def6e394741000045_14": [
        {
            "start_logit": 13.2109375,
            "end_logit": 15.0078125,
            "text": "metastatic castration-resistant prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": -1.865234375,
            "end_logit": 15.0078125,
            "text": "cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -3.033203125,
            "text": "metastatic castration-resistant prostate",
            "probability": 0.0
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -3.79296875,
            "text": "metastatic",
            "probability": 0.0
        },
        {
            "start_logit": -6.09375,
            "end_logit": 15.0078125,
            "text": "resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.12109375,
            "end_logit": 15.0078125,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -6.2109375,
            "end_logit": 15.0078125,
            "text": "castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 15.0078125,
            "text": "-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -8.015625,
            "text": "metastatic castration",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 15.0078125,
            "text": "in metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 15.0078125,
            "text": "orteronel is not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 15.0078125,
            "text": "undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 15.0078125,
            "text": "not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 15.0078125,
            "text": ", orteronel is not undergoing further development in metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 15.0078125,
            "text": "further development in metastatic castration-resistant prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -9.7890625,
            "text": "metastatic castration-resistant prostate cancer.FUNDING: Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company",
            "probability": 0.0
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -9.8125,
            "text": "metastatic castration-resistant",
            "probability": 0.0
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -9.9765625,
            "text": "metastatic castration-resistant prostate cancer.FUNDING: Millennium Pharmaceuticals",
            "probability": 0.0
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -10.0078125,
            "text": "metastatic castration-resistant prostate cancer.FUNDING: Millennium Pharmaceuticals, Inc",
            "probability": 0.0
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -10.046875,
            "text": "metastatic castration-resistant prostate cancer.FUNDING",
            "probability": 0.0
        }
    ],
    "61f919cc882a024a10000048_1": [
        {
            "start_logit": -5.98046875,
            "end_logit": -1.4365234375,
            "text": "involving 4660 participants from 218",
            "probability": 0.68603515625
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -1.4365234375,
            "text": "4660 participants from 218",
            "probability": 0.1536865234375
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -1.4365234375,
            "text": "218",
            "probability": 0.07257080078125
        },
        {
            "start_logit": -9.3515625,
            "end_logit": -1.4365234375,
            "text": "participants from 218",
            "probability": 0.0235748291015625
        },
        {
            "start_logit": -9.359375,
            "end_logit": -1.4365234375,
            "text": "from 218",
            "probability": 0.02337646484375
        },
        {
            "start_logit": -9.71875,
            "end_logit": -1.4365234375,
            "text": "60 participants from 218",
            "probability": 0.0163116455078125
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -1.4365234375,
            "text": ": We conducted a pilot study involving 4660 participants from 218",
            "probability": 0.0107879638671875
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -1.4365234375,
            "text": "METHODS: We conducted a pilot study involving 4660 participants from 218",
            "probability": 0.00839996337890625
        },
        {
            "start_logit": -5.98046875,
            "end_logit": -7.55078125,
            "text": "involving 46",
            "probability": 0.0015172958374023438
        },
        {
            "start_logit": -5.98046875,
            "end_logit": -7.77734375,
            "text": "involving 4660 participants from 2183 families, among whom 161",
            "probability": 0.0012102127075195312
        },
        {
            "start_logit": -6.48828125,
            "end_logit": -7.77734375,
            "text": "3 families, among whom 161",
            "probability": 0.000728607177734375
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -7.55078125,
            "text": "46",
            "probability": 0.0003387928009033203
        },
        {
            "start_logit": -5.98046875,
            "end_logit": -9.1171875,
            "text": "involving 4660",
            "probability": 0.00031828880310058594
        },
        {
            "start_logit": -5.98046875,
            "end_logit": -9.2109375,
            "text": "involving 4660 participants from 2183",
            "probability": 0.00028967857360839844
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -7.77734375,
            "text": "4660 participants from 2183 families, among whom 161",
            "probability": 0.00026988983154296875
        },
        {
            "start_logit": -5.98046875,
            "end_logit": -9.4765625,
            "text": "involving 4660 participants from 2183 families, among whom 161 disorders",
            "probability": 0.00022304058074951172
        },
        {
            "start_logit": -5.98046875,
            "end_logit": -9.6171875,
            "text": "involving 4660 participants from 2183 families",
            "probability": 0.0001938343048095703
        },
        {
            "start_logit": -6.48828125,
            "end_logit": -9.2109375,
            "text": "3",
            "probability": 0.00017368793487548828
        },
        {
            "start_logit": -5.98046875,
            "end_logit": -9.8828125,
            "text": "involving 4660 participants from 2183 families, among whom 161 disorders covering a broad spectrum of rare diseases were present.",
            "probability": 0.00014853477478027344
        },
        {
            "start_logit": -5.98046875,
            "end_logit": -9.9140625,
            "text": "involving 4660 participants from 2183 families, among whom 161 disorders covering a broad",
            "probability": 0.00014400482177734375
        }
    ],
    "606ae4fd94d57fd879000056_1": [
        {
            "start_logit": 11.5,
            "end_logit": 11.9140625,
            "text": "CYP2D6",
            "probability": 1.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.078125,
            "text": "CYP2D6 ultrarapid metabolizer phenotype",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.125,
            "text": "CYP2D6 ultrarapid metabolizer phenotype may",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 11.9140625,
            "text": "Mothers with a CYP2D6",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 11.9140625,
            "text": "a CYP2D6",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -9.59375,
            "text": "CYP2D6 ultra",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 11.9140625,
            "text": "with a CYP2D6",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.2109375,
            "text": "CYP2D6 ultrarapid metabolizer phenotype may expose their infants to risk of adverse events when taking codeine while breastfeeding",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.2421875,
            "text": "CYP2D6 ultrarapid",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.3046875,
            "text": "CYP2D6 ultrarapid metabolizer",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.34375,
            "text": "CYP2D6 ultrarapid metabolizer phenotype may expose",
            "probability": 0.0
        },
        {
            "start_logit": 11.5,
            "end_logit": -10.3515625,
            "text": "CYP2D6 ultrarapid metabolizer phenotype may expose their infants to risk of adverse events when taking codeine",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": -9.078125,
            "text": "ultrarapid metabolizer phenotype",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": -9.125,
            "text": "ultrarapid metabolizer phenotype may",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": -9.59375,
            "text": "ultra",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": -9.078125,
            "text": "Mothers with a CYP2D6 ultrarapid metabolizer phenotype",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": -9.125,
            "text": "Mothers with a CYP2D6 ultrarapid metabolizer phenotype may",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": -9.078125,
            "text": "a CYP2D6 ultrarapid metabolizer phenotype",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": -9.125,
            "text": "a CYP2D6 ultrarapid metabolizer phenotype may",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": -10.2109375,
            "text": "ultrarapid metabolizer phenotype may expose their infants to risk of adverse events when taking codeine while breastfeeding",
            "probability": 0.0
        }
    ],
    "5e808ef4835f4e477700002a_1": [
        {
            "start_logit": 6.0078125,
            "end_logit": 2.017578125,
            "text": "angiotensin II",
            "probability": 0.77294921875
        },
        {
            "start_logit": 6.0078125,
            "end_logit": 0.78955078125,
            "text": "angiotensin II receptor antagonist for administrating cardiovascular diseases.",
            "probability": 0.2265625
        },
        {
            "start_logit": 6.0078125,
            "end_logit": -6.015625,
            "text": "angiotensin II receptor antagonist",
            "probability": 0.0002512931823730469
        },
        {
            "start_logit": 6.0078125,
            "end_logit": -6.96484375,
            "text": "angiotensin",
            "probability": 9.691715240478516e-05
        },
        {
            "start_logit": 6.0078125,
            "end_logit": -8.015625,
            "text": "angiotensin II receptor",
            "probability": 3.3974647521972656e-05
        },
        {
            "start_logit": 6.0078125,
            "end_logit": -9.1171875,
            "text": "angiotensin II receptor antagonist for administrating cardiovascular diseases",
            "probability": 1.1265277862548828e-05
        },
        {
            "start_logit": -7.296875,
            "end_logit": 2.017578125,
            "text": "of Olmesartan medoxomil (OM), an FDA-approved angiotensin II",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -7.296875,
            "end_logit": 0.78955078125,
            "text": "of Olmesartan medoxomil (OM), an FDA-approved angiotensin II receptor antagonist for administrating cardiovascular diseases.",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -8.828125,
            "end_logit": 2.017578125,
            "text": "approved angiotensin II",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.68359375,
            "end_logit": 0.78955078125,
            "text": ".",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.34375,
            "end_logit": 2.017578125,
            "text": "FDA-approved angiotensin II",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 2.017578125,
            "text": "II",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.828125,
            "end_logit": 0.78955078125,
            "text": "approved angiotensin II receptor antagonist for administrating cardiovascular diseases.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.09375,
            "end_logit": 2.017578125,
            "text": "Olmesartan medoxomil (OM), an FDA-approved angiotensin II",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.125,
            "end_logit": 2.017578125,
            "text": "an FDA-approved angiotensin II",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 2.017578125,
            "text": "-approved angiotensin II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.34375,
            "end_logit": 0.78955078125,
            "text": "FDA-approved angiotensin II receptor antagonist for administrating cardiovascular diseases.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.59375,
            "end_logit": 2.017578125,
            "text": "mesartan medoxomil (OM), an FDA-approved angiotensin II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.609375,
            "end_logit": 2.017578125,
            "text": "(OM), an FDA-approved angiotensin II",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 0.78955078125,
            "text": "II receptor antagonist for administrating cardiovascular diseases.",
            "probability": 5.960464477539063e-08
        }
    ],
    "533be71dfd9a95ea0d000009_1": [
        {
            "start_logit": 13.6953125,
            "end_logit": 14.5078125,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -2.486328125,
            "text": "H3K",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.341796875,
            "end_logit": 14.5078125,
            "text": "4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4765625,
            "end_logit": 14.5078125,
            "text": "ates H3K4",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -8.84375,
            "text": "H3K4 residues",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 14.5078125,
            "text": "MLL1 (Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 14.5078125,
            "text": "methylates H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.5078125,
            "text": "histone methyltransferase that methylates H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 14.5078125,
            "text": "Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 14.5078125,
            "text": "Lineage Leukemia 1), a histone methyltransferase that methylates H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 14.5078125,
            "text": "(Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -11.15625,
            "end_logit": 14.5078125,
            "text": "L1 (Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": 14.5078125,
            "text": "methyltransferase that methylates H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -11.28125,
            "end_logit": 14.5078125,
            "text": "a histone methyltransferase that methylates H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -8.4765625,
            "end_logit": -2.486328125,
            "text": "ates H3K",
            "probability": 0.0
        },
        {
            "start_logit": -3.341796875,
            "end_logit": -8.84375,
            "text": "4 residues",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": -2.486328125,
            "text": "MLL1 (Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -2.486328125,
            "text": "methylates H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -2.486328125,
            "text": "histone methyltransferase that methylates H3K",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": -2.486328125,
            "text": "Mixed Lineage Leukemia 1), a histone methyltransferase that methylates H3K",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_2": [
        {
            "start_logit": 14.03125,
            "end_logit": 14.7109375,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": 5.5390625,
            "text": "H3K4)",
            "probability": 0.00010228157043457031
        },
        {
            "start_logit": -2.71484375,
            "end_logit": 14.7109375,
            "text": "4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.03125,
            "end_logit": -2.515625,
            "text": "H3K",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.03125,
            "end_logit": -6.6953125,
            "text": "H3K4) in",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -8.71875,
            "text": "H3K4) in Saccharomyces cerevisiae is implemented by Set1/COMPASS,",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.1640625,
            "text": "H3K4) in Saccharomyces cerevisiae is implemented by Set1",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.2265625,
            "text": "H3K4) in Saccharomyces cerevisiae is implemented by Set1/COMPASS",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.4921875,
            "text": "H3K4) in Saccharomyces cerevisiae is implemented by Set1/",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.7734375,
            "text": "H3K4) in Saccharomyces cerevisiae is implemented by Set1/COMPASS, which was originally purified based on the similarity",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.7890625,
            "text": "H3K4) in Saccharomyces cerevisiae is implemented by Set1/COMPASS, which",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.8125,
            "text": "H3K4) in Saccharomyces cerevisiae is implemented by Set1/COMPASS, which was originally purified based on the similarity of yeast Set1",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -10.0,
            "text": "H3K4) in Saccharomyces cerevisiae",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -10.0234375,
            "text": "H3K4) in Saccharomyces cerevisiae is implemented",
            "probability": 0.0
        },
        {
            "start_logit": -2.71484375,
            "end_logit": 5.5390625,
            "text": "4)",
            "probability": 0.0
        },
        {
            "start_logit": -4.578125,
            "end_logit": 5.5390625,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": -2.71484375,
            "end_logit": -6.6953125,
            "text": "4) in",
            "probability": 0.0
        },
        {
            "start_logit": -4.578125,
            "end_logit": -6.6953125,
            "text": ") in",
            "probability": 0.0
        },
        {
            "start_logit": -2.71484375,
            "end_logit": -8.71875,
            "text": "4) in Saccharomyces cerevisiae is implemented by Set1/COMPASS,",
            "probability": 0.0
        },
        {
            "start_logit": -2.71484375,
            "end_logit": -9.1640625,
            "text": "4) in Saccharomyces cerevisiae is implemented by Set1",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_3": [
        {
            "start_logit": 13.359375,
            "end_logit": 14.3046875,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": -3.607421875,
            "end_logit": 14.3046875,
            "text": "4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.359375,
            "end_logit": -3.0234375,
            "text": "H3K",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.296875,
            "end_logit": 14.3046875,
            "text": "for H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 14.3046875,
            "text": "the mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 14.3046875,
            "text": "protein, a histone methyltransferase specific for H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.3046875,
            "text": "histone methyltransferase specific for H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 14.3046875,
            "text": "mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 14.3046875,
            "text": "lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": 14.3046875,
            "text": "We show that the mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -11.2734375,
            "end_logit": 14.3046875,
            "text": "1 (MLL1) protein, a histone methyltransferase specific for H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -11.28125,
            "end_logit": 14.3046875,
            "text": "MLL1) protein, a histone methyltransferase specific for H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -11.3203125,
            "end_logit": 14.3046875,
            "text": "that the mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -11.34375,
            "end_logit": 14.3046875,
            "text": "methyltransferase specific for H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -9.296875,
            "end_logit": -3.0234375,
            "text": "for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": -3.0234375,
            "text": "the mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": -3.0234375,
            "text": "protein, a histone methyltransferase specific for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -3.0234375,
            "text": "histone methyltransferase specific for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": -3.0234375,
            "text": "mixed lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": -3.0234375,
            "text": "lineage leukemia 1 (MLL1) protein, a histone methyltransferase specific for H3K",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_4": [
        {
            "start_logit": 9.8984375,
            "end_logit": 9.328125,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -0.376953125,
            "text": "H3K4 methyltransferase",
            "probability": 6.157159805297852e-05
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.375,
            "text": "H3K",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.6484375,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha promoter, and the H3K4 trimethyltransferase activity r",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -7.8125,
            "text": "H3K4 methyltransferase complexes are tethered by p52",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 9.328125,
            "text": "4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.5078125,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha promoter,",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.640625,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.671875,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha promoter, and the H3K4 trimethyltransferase activity",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -8.9921875,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -9.1796875,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha promoter",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -9.6640625,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaB",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -9.6796875,
            "text": "H3K4 methyltransferase complexes are",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -9.703125,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha promoter, and",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -9.8515625,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -9.875,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha promoter, and the H3K",
            "probability": 0.0
        },
        {
            "start_logit": 9.8984375,
            "end_logit": -9.8828125,
            "text": "H3K4 methyltransferase complexes are tethered by p52 on the MMP9 but not on the IkappaBalpha promoter, and the H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 9.328125,
            "text": "MLL1 and MLL2 H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 9.328125,
            "text": "MLL2 H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -7.4296875,
            "end_logit": -0.376953125,
            "text": "4 methyltransferase",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_5": [
        {
            "start_logit": 14.3515625,
            "end_logit": 14.96875,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -1.6650390625,
            "text": "H3K",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.375,
            "end_logit": 14.96875,
            "text": "4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -5.74609375,
            "text": "H3K4 methyltransferase activity of the carboxyl-terminal SET domain.",
            "probability": 0.0
        },
        {
            "start_logit": -8.5234375,
            "end_logit": 14.96875,
            "text": "The biological function of MLL1 is mediated by the histone H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -8.546875,
            "end_logit": 14.96875,
            "text": "histone H3K4",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -9.125,
            "text": "H3K4 methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 14.96875,
            "text": "MLL1 is mediated by the histone H3K4",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -9.71875,
            "text": "H3K4 methyltransferase activity",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -9.8515625,
            "text": "H3K4 methyltransferase activity of the carboxyl-terminal SET domain",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 14.96875,
            "text": "biological function of MLL1 is mediated by the histone H3K4",
            "probability": 0.0
        },
        {
            "start_logit": 14.3515625,
            "end_logit": -10.078125,
            "text": "H3K4 methyltransferase activity of the carboxyl-terminal SET",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 14.96875,
            "text": "function of MLL1 is mediated by the histone H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 14.96875,
            "text": "mediated by the histone H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -2.375,
            "end_logit": -5.74609375,
            "text": "4 methyltransferase activity of the carboxyl-terminal SET domain.",
            "probability": 0.0
        },
        {
            "start_logit": -8.5234375,
            "end_logit": -1.6650390625,
            "text": "The biological function of MLL1 is mediated by the histone H3K",
            "probability": 0.0
        },
        {
            "start_logit": -8.546875,
            "end_logit": -1.6650390625,
            "text": "histone H3K",
            "probability": 0.0
        },
        {
            "start_logit": -2.375,
            "end_logit": -9.125,
            "text": "4 methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": -1.6650390625,
            "text": "MLL1 is mediated by the histone H3K",
            "probability": 0.0
        },
        {
            "start_logit": -2.375,
            "end_logit": -9.71875,
            "text": "4 methyltransferase activity",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_6": [
        {
            "start_logit": 14.1953125,
            "end_logit": 14.734375,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -2.013671875,
            "text": "H3K",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.6484375,
            "end_logit": 14.734375,
            "text": "4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -8.2734375,
            "text": "H3K4,",
            "probability": 0.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -8.4296875,
            "text": "H3K4, a posttranslational modification associated with actively transcribed genes.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": 14.734375,
            "text": "Set1/COMPASS is capable of methylating H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 14.734375,
            "text": "ating H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 14.734375,
            "text": "methylating H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 14.734375,
            "text": "/COMPASS is capable of methylating H3K4",
            "probability": 0.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -9.96875,
            "text": "H3K4, a posttranslational modification associated with actively transcribed genes. There is only one Set1 in yeast; yet in mammalian cells there are multiple H3K4",
            "probability": 0.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -10.1171875,
            "text": "H3K4, a posttranslational modification associated with actively transcribed genes. There is only one Set1 in yeast; yet in mammalian cells there are multiple",
            "probability": 0.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -10.15625,
            "text": "H3K4, a posttranslational modification associated with actively transcribed genes. There is only one Set1 in yeast; yet",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 14.734375,
            "text": "is capable of methylating H3K4",
            "probability": 0.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -10.2265625,
            "text": "H3K4, a posttranslational modification associated with actively transcribed genes. There is only one Set1",
            "probability": 0.0
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -8.2734375,
            "text": "4,",
            "probability": 0.0
        },
        {
            "start_logit": -2.6484375,
            "end_logit": -8.4296875,
            "text": "4, a posttranslational modification associated with actively transcribed genes.",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": -2.013671875,
            "text": "Set1/COMPASS is capable of methylating H3K",
            "probability": 0.0
        },
        {
            "start_logit": -9.5546875,
            "end_logit": -2.013671875,
            "text": "ating H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": -2.013671875,
            "text": "methylating H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -2.013671875,
            "text": "/COMPASS is capable of methylating H3K",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_7": [
        {
            "start_logit": 13.3203125,
            "end_logit": 14.359375,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": -3.408203125,
            "end_logit": 14.359375,
            "text": "4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.3203125,
            "end_logit": -3.017578125,
            "text": "H3K",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": 14.359375,
            "text": "trimethylated H3K4",
            "probability": 0.0
        },
        {
            "start_logit": 13.3203125,
            "end_logit": -7.76953125,
            "text": "H3K4 histones",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 14.359375,
            "text": "ated H3K4",
            "probability": 0.0
        },
        {
            "start_logit": 13.3203125,
            "end_logit": -8.4453125,
            "text": "H3K4 histones and",
            "probability": 0.0
        },
        {
            "start_logit": 13.3203125,
            "end_logit": -9.625,
            "text": "H3K4 histones and histone methyltransferase MLL1",
            "probability": 0.0
        },
        {
            "start_logit": 13.3203125,
            "end_logit": -10.1640625,
            "text": "H3K4 histones and histone methyltransferase ML",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -3.017578125,
            "text": "trimethylated H3K",
            "probability": 0.0
        },
        {
            "start_logit": -3.408203125,
            "end_logit": -7.76953125,
            "text": "4 histones",
            "probability": 0.0
        },
        {
            "start_logit": -3.408203125,
            "end_logit": -8.4453125,
            "text": "4 histones and",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": -3.017578125,
            "text": "ated H3K",
            "probability": 0.0
        },
        {
            "start_logit": -3.408203125,
            "end_logit": -9.625,
            "text": "4 histones and histone methyltransferase MLL1",
            "probability": 0.0
        },
        {
            "start_logit": -3.408203125,
            "end_logit": -10.1640625,
            "text": "4 histones and histone methyltransferase ML",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -7.76953125,
            "text": "trimethylated H3K4 histones",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -8.4453125,
            "text": "trimethylated H3K4 histones and",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -9.625,
            "text": "trimethylated H3K4 histones and histone methyltransferase MLL1",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -9.7734375,
            "text": "trimethyl",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -10.078125,
            "text": "trimethylated",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_8": [
        {
            "start_logit": 14.40625,
            "end_logit": 15.015625,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -1.2548828125,
            "text": "H3K",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.24609375,
            "end_logit": 15.015625,
            "text": "4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.7734375,
            "end_logit": 15.015625,
            "text": "mixed-lineage leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -8.265625,
            "text": "H3K4 methylation",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 15.015625,
            "text": "decreased H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 15.015625,
            "text": "histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 15.015625,
            "text": "1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 15.015625,
            "text": "lineage leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 15.015625,
            "text": "methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 15.015625,
            "text": "-lineage leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 15.015625,
            "text": "expressed in GABAergic and other cortical neurons, resulted in decreased H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.015625,
            "text": "Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 15.015625,
            "text": "neurons, resulted in decreased H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 15.015625,
            "text": "cortical neurons, resulted in decreased H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -8.7734375,
            "end_logit": -1.2548828125,
            "text": "mixed-lineage leukemia 1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K",
            "probability": 0.0
        },
        {
            "start_logit": -2.24609375,
            "end_logit": -8.265625,
            "text": "4 methylation",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": -1.2548828125,
            "text": "decreased H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -1.2548828125,
            "text": "histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -1.2548828125,
            "text": "1 (Mll1), a histone methyltransferase expressed in GABAergic and other cortical neurons, resulted in decreased H3K",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_9": [
        {
            "start_logit": 13.7890625,
            "end_logit": 14.6875,
            "text": "H3K4",
            "probability": 1.0
        },
        {
            "start_logit": -2.8125,
            "end_logit": 14.6875,
            "text": "4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -2.595703125,
            "text": "H3K",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -9.109375,
            "text": "H3K4 methylation is",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -9.1171875,
            "text": "H3K4 methylation",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -9.265625,
            "text": "H3K4 methylation is mixed-lineage leukemia 1 (MLL1)",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -9.359375,
            "text": "H3K4 methylation is mixed-lineage leukemia",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -9.5546875,
            "text": "H3K4 methylation is mixed-lineage leukemia 1",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 14.6875,
            "text": "effectors of H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.6875,
            "text": "of H3K4",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -9.765625,
            "text": "H3K4 methylation is mixed-lineage leukemia 1 (MLL1",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -9.9453125,
            "text": "H3K4 methylation is mixed-lineage leukemia 1 (",
            "probability": 0.0
        },
        {
            "start_logit": 13.7890625,
            "end_logit": -10.21875,
            "text": "H3K4 methylation is mixed-lineage leukemia 1 (ML",
            "probability": 0.0
        },
        {
            "start_logit": -2.8125,
            "end_logit": -9.109375,
            "text": "4 methylation is",
            "probability": 0.0
        },
        {
            "start_logit": -2.8125,
            "end_logit": -9.1171875,
            "text": "4 methylation",
            "probability": 0.0
        },
        {
            "start_logit": -2.8125,
            "end_logit": -9.265625,
            "text": "4 methylation is mixed-lineage leukemia 1 (MLL1)",
            "probability": 0.0
        },
        {
            "start_logit": -2.8125,
            "end_logit": -9.359375,
            "text": "4 methylation is mixed-lineage leukemia",
            "probability": 0.0
        },
        {
            "start_logit": -2.8125,
            "end_logit": -9.5546875,
            "text": "4 methylation is mixed-lineage leukemia 1",
            "probability": 0.0
        },
        {
            "start_logit": -2.8125,
            "end_logit": -9.765625,
            "text": "4 methylation is mixed-lineage leukemia 1 (MLL1",
            "probability": 0.0
        },
        {
            "start_logit": -2.8125,
            "end_logit": -9.9453125,
            "text": "4 methylation is mixed-lineage leukemia 1 (",
            "probability": 0.0
        }
    ],
    "533be71dfd9a95ea0d000009_10": [
        {
            "start_logit": 14.1015625,
            "end_logit": 14.234375,
            "text": "Lys4",
            "probability": 1.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -1.8603515625,
            "text": "Lys",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -3.486328125,
            "text": "Lys4 of histone H3 (H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -3.708984375,
            "end_logit": 14.234375,
            "text": "4",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -7.14453125,
            "text": "Lys4 of histone H3 (H3K",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -7.5546875,
            "text": "Lys4 of histone H3",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -7.99609375,
            "text": "Lys4 of histone H3 (H3K4)",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.2265625,
            "text": "Lys4 of",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 14.234375,
            "text": "for Lys4",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -10.0390625,
            "text": "Lys4 of histone H3 (",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 14.234375,
            "text": "histone methyltransferase complexes specific for Lys4",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 14.234375,
            "text": "MLL1/MLL2 histone methyltransferase complexes specific for Lys4",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 14.234375,
            "text": "MLL2 histone methyltransferase complexes specific for Lys4",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 14.234375,
            "text": "/MLL2 histone methyltransferase complexes specific for Lys4",
            "probability": 0.0
        },
        {
            "start_logit": -0.5849609375,
            "end_logit": -3.486328125,
            "text": "H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -3.708984375,
            "end_logit": -3.486328125,
            "text": "4 of histone H3 (H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -0.5849609375,
            "end_logit": -7.14453125,
            "text": "H3K",
            "probability": 0.0
        },
        {
            "start_logit": -0.5849609375,
            "end_logit": -7.99609375,
            "text": "H3K4)",
            "probability": 0.0
        },
        {
            "start_logit": -5.2890625,
            "end_logit": -3.486328125,
            "text": "histone H3 (H3K4",
            "probability": 0.0
        },
        {
            "start_logit": -3.708984375,
            "end_logit": -7.14453125,
            "text": "4 of histone H3 (H3K",
            "probability": 0.0
        }
    ],
    "5fe3131ca43ad31278000048_1": [
        {
            "start_logit": 0.8095703125,
            "end_logit": 13.4375,
            "text": "poly(dA:dT) tracts",
            "probability": 0.6123046875
        },
        {
            "start_logit": 0.310546875,
            "end_logit": 13.4375,
            "text": "G+C content, 10.5 bp periodicity, and poly(dA:dT) tracts",
            "probability": 0.37109375
        },
        {
            "start_logit": -3.13671875,
            "end_logit": 13.4375,
            "text": "and poly(dA:dT) tracts",
            "probability": 0.011749267578125
        },
        {
            "start_logit": -4.21484375,
            "end_logit": 13.4375,
            "text": "tracts",
            "probability": 0.003997802734375
        },
        {
            "start_logit": -6.04296875,
            "end_logit": 13.4375,
            "text": "(dA:dT) tracts",
            "probability": 0.0006451606750488281
        },
        {
            "start_logit": -7.18359375,
            "end_logit": 13.4375,
            "text": "dA:dT) tracts",
            "probability": 0.00020623207092285156
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 13.4375,
            "text": "5 bp periodicity, and poly(dA:dT) tracts",
            "probability": 6.210803985595703e-05
        },
        {
            "start_logit": -8.6328125,
            "end_logit": 13.4375,
            "text": "+C content, 10.5 bp periodicity, and poly(dA:dT) tracts",
            "probability": 4.839897155761719e-05
        },
        {
            "start_logit": -8.6796875,
            "end_logit": 13.4375,
            "text": "dT) tracts",
            "probability": 4.6193599700927734e-05
        },
        {
            "start_logit": -9.53125,
            "end_logit": 13.4375,
            "text": ":dT) tracts",
            "probability": 1.9729137420654297e-05
        },
        {
            "start_logit": -9.59375,
            "end_logit": 13.4375,
            "text": "including G+C content, 10.5 bp periodicity, and poly(dA:dT) tracts",
            "probability": 1.8477439880371094e-05
        },
        {
            "start_logit": -9.78125,
            "end_logit": 13.4375,
            "text": ") tracts",
            "probability": 1.537799835205078e-05
        },
        {
            "start_logit": -9.953125,
            "end_logit": 13.4375,
            "text": "bp periodicity, and poly(dA:dT) tracts",
            "probability": 1.2934207916259766e-05
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 13.4375,
            "text": "C content, 10.5 bp periodicity, and poly(dA:dT) tracts",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": -10.046875,
            "end_logit": 13.4375,
            "text": "10.5 bp periodicity, and poly(dA:dT) tracts",
            "probability": 1.1801719665527344e-05
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 13.4375,
            "text": "sequence features-including G+C content, 10.5 bp periodicity, and poly(dA:dT) tracts",
            "probability": 1.1324882507324219e-05
        },
        {
            "start_logit": 0.310546875,
            "end_logit": -4.6484375,
            "text": "G+C content",
            "probability": 0.0
        },
        {
            "start_logit": 0.8095703125,
            "end_logit": -5.83203125,
            "text": "poly(dA:dT",
            "probability": 0.0
        },
        {
            "start_logit": 0.310546875,
            "end_logit": -5.83203125,
            "text": "G+C content, 10.5 bp periodicity, and poly(dA:dT",
            "probability": 0.0
        },
        {
            "start_logit": 0.8095703125,
            "end_logit": -7.77734375,
            "text": "poly(dA:dT)",
            "probability": 0.0
        }
    ],
    "5fe3131ca43ad31278000048_2": [
        {
            "start_logit": 12.4765625,
            "end_logit": 14.5390625,
            "text": "G+C content",
            "probability": 1.0
        },
        {
            "start_logit": -3.224609375,
            "end_logit": 14.5390625,
            "text": "content",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.4765625,
            "end_logit": -5.0546875,
            "text": "G",
            "probability": 0.0
        },
        {
            "start_logit": -7.7109375,
            "end_logit": 14.5390625,
            "text": "C content",
            "probability": 0.0
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 14.5390625,
            "text": "+C content",
            "probability": 0.0
        },
        {
            "start_logit": 12.4765625,
            "end_logit": -6.6328125,
            "text": "G+C",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 14.5390625,
            "text": "although G+C content",
            "probability": 0.0
        },
        {
            "start_logit": 12.4765625,
            "end_logit": -8.765625,
            "text": "G+",
            "probability": 0.0
        },
        {
            "start_logit": 12.4765625,
            "end_logit": -9.515625,
            "text": "G+C content is the primary determinant of MNase",
            "probability": 0.0
        },
        {
            "start_logit": 12.4765625,
            "end_logit": -9.75,
            "text": "G+C content is the primary determinant of MNase-derived nucleosome occupancy, MNase digestion biases may substantially influence this GC",
            "probability": 0.0
        },
        {
            "start_logit": 12.4765625,
            "end_logit": -9.7578125,
            "text": "G+C content is the primary determinant",
            "probability": 0.0
        },
        {
            "start_logit": 12.4765625,
            "end_logit": -9.8671875,
            "text": "G+C content is the primary determinant of MNase-derived nucleosome occupancy, MNase digestion biases may substantially influence this GC dependence. By contrast",
            "probability": 0.0
        },
        {
            "start_logit": 12.4765625,
            "end_logit": -9.890625,
            "text": "G+C content is the primary determinant of MNase-derived nucleosome occupancy, MNase digestion biases may",
            "probability": 0.0
        },
        {
            "start_logit": 12.4765625,
            "end_logit": -9.9140625,
            "text": "G+C content is the primary",
            "probability": 0.0
        },
        {
            "start_logit": 12.4765625,
            "end_logit": -9.9296875,
            "text": "G+C content is the primary determinant of MNase-derived nucleosome occupancy, MNase digestion",
            "probability": 0.0
        },
        {
            "start_logit": -3.224609375,
            "end_logit": -9.515625,
            "text": "content is the primary determinant of MNase",
            "probability": 0.0
        },
        {
            "start_logit": -3.224609375,
            "end_logit": -9.75,
            "text": "content is the primary determinant of MNase-derived nucleosome occupancy, MNase digestion biases may substantially influence this GC",
            "probability": 0.0
        },
        {
            "start_logit": -3.224609375,
            "end_logit": -9.7578125,
            "text": "content is the primary determinant",
            "probability": 0.0
        },
        {
            "start_logit": -3.224609375,
            "end_logit": -9.8671875,
            "text": "content is the primary determinant of MNase-derived nucleosome occupancy, MNase digestion biases may substantially influence this GC dependence. By contrast",
            "probability": 0.0
        },
        {
            "start_logit": -3.224609375,
            "end_logit": -9.890625,
            "text": "content is the primary determinant of MNase-derived nucleosome occupancy, MNase digestion biases may",
            "probability": 0.0
        }
    ],
    "5d387c20a1e1595105000010_1": [
        {
            "start_logit": 1.08984375,
            "end_logit": 1.3115234375,
            "text": "783",
            "probability": 0.9404296875
        },
        {
            "start_logit": 1.08984375,
            "end_logit": -1.62109375,
            "text": "78",
            "probability": 0.050018310546875
        },
        {
            "start_logit": -3.609375,
            "end_logit": 1.3115234375,
            "text": "3",
            "probability": 0.0085601806640625
        },
        {
            "start_logit": 1.08984375,
            "end_logit": -5.640625,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome genes",
            "probability": 0.0008983612060546875
        },
        {
            "start_logit": 1.08984375,
            "end_logit": -7.3046875,
            "text": "783 non-pseudoautosomal region (PAR",
            "probability": 0.00017011165618896484
        },
        {
            "start_logit": 1.08984375,
            "end_logit": -8.484375,
            "text": "783 non-pseudoautosomal region (PAR) X",
            "probability": 5.227327346801758e-05
        },
        {
            "start_logit": 1.08984375,
            "end_logit": -9.21875,
            "text": "783 non-pseudoautosomal region (PAR)",
            "probability": 2.5093555450439453e-05
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 1.3115234375,
            "text": "of 783",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": 1.08984375,
            "end_logit": -9.6484375,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome genes (ATRX",
            "probability": 1.621246337890625e-05
        },
        {
            "start_logit": 1.08984375,
            "end_logit": -9.8984375,
            "text": "783 non-pseudoautosomal region",
            "probability": 1.2636184692382812e-05
        },
        {
            "start_logit": 1.08984375,
            "end_logit": -10.046875,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome genes (ATRX, CNKSR2",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": 1.08984375,
            "end_logit": -10.1875,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome genes (",
            "probability": 9.5367431640625e-06
        },
        {
            "start_logit": 1.08984375,
            "end_logit": -10.1953125,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome genes (ATRX, CNKSR2, DDX3X",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -3.609375,
            "end_logit": -5.640625,
            "text": "3 non-pseudoautosomal region (PAR) X-chromosome genes",
            "probability": 8.106231689453125e-06
        },
        {
            "start_logit": -3.609375,
            "end_logit": -7.3046875,
            "text": "3 non-pseudoautosomal region (PAR",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -9.8046875,
            "end_logit": -1.62109375,
            "text": "of 78",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -3.609375,
            "end_logit": -8.484375,
            "text": "3 non-pseudoautosomal region (PAR) X",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -3.609375,
            "end_logit": -9.21875,
            "text": "3 non-pseudoautosomal region (PAR)",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -3.609375,
            "end_logit": -9.6484375,
            "text": "3 non-pseudoautosomal region (PAR) X-chromosome genes (ATRX",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.609375,
            "end_logit": -9.8984375,
            "text": "3 non-pseudoautosomal region",
            "probability": 1.1920928955078125e-07
        }
    ],
    "5d387c20a1e1595105000010_2": [
        {
            "start_logit": -2.7890625,
            "end_logit": -2.85546875,
            "text": "78",
            "probability": 0.433837890625
        },
        {
            "start_logit": -2.7890625,
            "end_logit": -3.30078125,
            "text": "783",
            "probability": 0.278076171875
        },
        {
            "start_logit": -2.900390625,
            "end_logit": -3.30078125,
            "text": "3",
            "probability": 0.248046875
        },
        {
            "start_logit": -2.7890625,
            "end_logit": -6.45703125,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome genes",
            "probability": 0.0117950439453125
        },
        {
            "start_logit": -2.900390625,
            "end_logit": -6.45703125,
            "text": "3 non-pseudoautosomal region (PAR) X-chromosome genes",
            "probability": 0.01056671142578125
        },
        {
            "start_logit": -2.7890625,
            "end_logit": -7.19140625,
            "text": "783 non-pseudoautosomal region (PAR",
            "probability": 0.005657196044921875
        },
        {
            "start_logit": -2.900390625,
            "end_logit": -7.19140625,
            "text": "3 non-pseudoautosomal region (PAR",
            "probability": 0.005069732666015625
        },
        {
            "start_logit": -2.7890625,
            "end_logit": -8.3515625,
            "text": "783 non-pseudoautosomal region (PAR) X",
            "probability": 0.0017805099487304688
        },
        {
            "start_logit": -2.900390625,
            "end_logit": -8.3515625,
            "text": "3 non-pseudoautosomal region (PAR) X",
            "probability": 0.0015954971313476562
        },
        {
            "start_logit": -2.7890625,
            "end_logit": -9.65625,
            "text": "783 non-pseudoautosomal region (PAR)",
            "probability": 0.00048279762268066406
        },
        {
            "start_logit": -9.625,
            "end_logit": -2.85546875,
            "text": "of 78",
            "probability": 0.0004642009735107422
        },
        {
            "start_logit": -2.900390625,
            "end_logit": -9.65625,
            "text": "3 non-pseudoautosomal region (PAR)",
            "probability": 0.00043272972106933594
        },
        {
            "start_logit": -2.7890625,
            "end_logit": -9.890625,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome genes (ATRX",
            "probability": 0.0003819465637207031
        },
        {
            "start_logit": -2.7890625,
            "end_logit": -9.9609375,
            "text": "783 non-pseudoautosomal region",
            "probability": 0.0003559589385986328
        },
        {
            "start_logit": -2.900390625,
            "end_logit": -9.890625,
            "text": "3 non-pseudoautosomal region (PAR) X-chromosome genes (ATRX",
            "probability": 0.00034236907958984375
        },
        {
            "start_logit": -2.900390625,
            "end_logit": -9.9609375,
            "text": "3 non-pseudoautosomal region",
            "probability": 0.0003192424774169922
        },
        {
            "start_logit": -2.7890625,
            "end_logit": -10.1171875,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome genes (",
            "probability": 0.0003044605255126953
        },
        {
            "start_logit": -9.625,
            "end_logit": -3.30078125,
            "text": "of 783",
            "probability": 0.00029969215393066406
        },
        {
            "start_logit": -2.7890625,
            "end_logit": -10.203125,
            "text": "783 non-pseudoautosomal region (PAR) X-chromosome genes (ATRX, CNKSR2",
            "probability": 0.00027942657470703125
        },
        {
            "start_logit": -2.900390625,
            "end_logit": -10.1171875,
            "text": "3 non-pseudoautosomal region (PAR) X-chromosome genes (",
            "probability": 0.00027298927307128906
        }
    ],
    "5c9791d2ecadf2e73f000026_1": [
        {
            "start_logit": 7.17578125,
            "end_logit": 12.0,
            "text": "fleas",
            "probability": 0.970703125
        },
        {
            "start_logit": 11.0859375,
            "end_logit": 4.33203125,
            "text": "Ctenocephalides felis",
            "probability": 0.0228271484375
        },
        {
            "start_logit": 2.08984375,
            "end_logit": 12.0,
            "text": "Cat fleas",
            "probability": 0.00605010986328125
        },
        {
            "start_logit": 7.17578125,
            "end_logit": 4.33203125,
            "text": "fleas (Ctenocephalides felis",
            "probability": 0.00045561790466308594
        },
        {
            "start_logit": 11.0859375,
            "end_logit": 0.337890625,
            "text": "Ctenocephalides",
            "probability": 0.0004181861877441406
        },
        {
            "start_logit": 7.17578125,
            "end_logit": 0.337890625,
            "text": "fleas (Ctenocephalides",
            "probability": 8.404254913330078e-06
        },
        {
            "start_logit": -5.140625,
            "end_logit": 12.0,
            "text": "as",
            "probability": 4.351139068603516e-06
        },
        {
            "start_logit": 2.08984375,
            "end_logit": 4.33203125,
            "text": "Cat fleas (Ctenocephalides felis",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -5.21484375,
            "text": "Ct",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -8.609375,
            "text": "Ctenocephalides felis)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 2.08984375,
            "end_logit": 0.337890625,
            "text": "Cat fleas (Ctenocephalides",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -8.9765625,
            "text": "Ctenocephalides felis) carrying Rickettsia felis and Bartonella species in Hong Kong.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.17578125,
            "end_logit": -5.21484375,
            "text": "fleas (Ct",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.4296875,
            "text": "Ctenocephalides felis) carrying",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.46875,
            "text": "Ctenocephalides felis) carrying Rickettsia felis and Bartonella species in",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.5,
            "text": "Ctenocephalides felis) carrying Rickettsia felis and Bartonella species in Hong Kong",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -9.8515625,
            "text": "Ctenocephalides fel",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -10.0234375,
            "text": "Ctenocephalides felis) carrying Rickettsia felis",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -10.078125,
            "text": "Ctenocephalides felis) carrying Rickettsia felis and",
            "probability": 0.0
        },
        {
            "start_logit": 11.0859375,
            "end_logit": -10.1015625,
            "text": "Ctenocephalides felis) carrying Rickettsia felis and Bartonella species",
            "probability": 0.0
        }
    ],
    "5c9791d2ecadf2e73f000026_2": [
        {
            "start_logit": 13.6953125,
            "end_logit": 11.8359375,
            "text": "Ctenocephalides felis",
            "probability": 0.998046875
        },
        {
            "start_logit": 13.6953125,
            "end_logit": 5.63671875,
            "text": "Ctenocephalides",
            "probability": 0.0020198822021484375
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -3.1484375,
            "text": "Ct",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -3.556640625,
            "end_logit": 11.8359375,
            "text": "enocephalides felis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.94140625,
            "end_logit": 11.8359375,
            "text": "cephalides felis",
            "probability": 0.0
        },
        {
            "start_logit": -5.3671875,
            "end_logit": 11.8359375,
            "text": "is",
            "probability": 0.0
        },
        {
            "start_logit": -5.65234375,
            "end_logit": 11.8359375,
            "text": "fleas from dogs and cats living in Hong Kong revealed only cat fleas (Ctenocephalides felis",
            "probability": 0.0
        },
        {
            "start_logit": -7.0625,
            "end_logit": 11.8359375,
            "text": "ides felis",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -9.4296875,
            "text": "Cteno",
            "probability": 0.0
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 11.8359375,
            "text": "cat fleas (Ctenocephalides felis",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -9.8828125,
            "text": "Ctenocephalides fel",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 11.8359375,
            "text": "as from dogs and cats living in Hong Kong revealed only cat fleas (Ctenocephalides felis",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -9.90625,
            "text": "Ctenocephalides felis)",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -9.90625,
            "text": "Ctenocephalides felis).",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 11.8359375,
            "text": "fleas (Ctenocephalides felis",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": 11.8359375,
            "text": "felis",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 11.8359375,
            "text": "(Ctenocephalides felis",
            "probability": 0.0
        },
        {
            "start_logit": -3.556640625,
            "end_logit": 5.63671875,
            "text": "enocephalides",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 11.8359375,
            "text": "as (Ctenocephalides felis",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 11.8359375,
            "text": "from dogs and cats living in Hong Kong revealed only cat fleas (Ctenocephalides felis",
            "probability": 0.0
        }
    ],
    "571f609c0fd6f91b6800000c_1": [
        {
            "start_logit": -4.828125,
            "end_logit": 11.0390625,
            "text": "\u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 0.8291015625
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 11.0390625,
            "text": "osaminidase",
            "probability": 0.06243896484375
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 11.0390625,
            "text": "and \u03b2-hexosaminidase",
            "probability": 0.061737060546875
        },
        {
            "start_logit": -9.1875,
            "end_logit": 11.0390625,
            "text": "\u03b2-hexosaminidase",
            "probability": 0.0106048583984375
        },
        {
            "start_logit": -9.46875,
            "end_logit": 11.0390625,
            "text": "-galactosidase and \u03b2-hexosaminidase",
            "probability": 0.00800323486328125
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 11.0390625,
            "text": "hexosaminidase",
            "probability": 0.006282806396484375
        },
        {
            "start_logit": -9.75,
            "end_logit": 11.0390625,
            "text": "-hexosaminidase",
            "probability": 0.00604248046875
        },
        {
            "start_logit": -10.4375,
            "end_logit": 11.0390625,
            "text": "of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 0.0030384063720703125
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.0390625,
            "text": "galactosidase and \u03b2-hexosaminidase",
            "probability": 0.0029201507568359375
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 11.0390625,
            "text": "GM1 and GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 0.00197601318359375
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 11.0390625,
            "text": "deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 0.0017709732055664062
        },
        {
            "start_logit": -11.0625,
            "end_logit": 11.0390625,
            "text": "GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 0.0016260147094726562
        },
        {
            "start_logit": -11.171875,
            "end_logit": 11.0390625,
            "text": "gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 0.00145721435546875
        },
        {
            "start_logit": -11.1875,
            "end_logit": 11.0390625,
            "text": "and GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 0.0014352798461914062
        },
        {
            "start_logit": -11.1953125,
            "end_logit": 11.0390625,
            "text": "associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 0.001422882080078125
        },
        {
            "start_logit": -4.828125,
            "end_logit": 2.5,
            "text": "\u03b2-galactosidase and \u03b2-hexosaminidase respectively",
            "probability": 0.00016224384307861328
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 2.5,
            "text": "osaminidase respectively",
            "probability": 1.2218952178955078e-05
        },
        {
            "start_logit": -7.42578125,
            "end_logit": 2.5,
            "text": "and \u03b2-hexosaminidase respectively",
            "probability": 1.1980533599853516e-05
        },
        {
            "start_logit": -9.1875,
            "end_logit": 2.5,
            "text": "\u03b2-hexosaminidase respectively",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -9.46875,
            "end_logit": 2.5,
            "text": "-galactosidase and \u03b2-hexosaminidase respectively",
            "probability": 1.6093254089355469e-06
        }
    ],
    "571f609c0fd6f91b6800000c_2": [
        {
            "start_logit": 3.060546875,
            "end_logit": 11.15625,
            "text": "\u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 0.94970703125
        },
        {
            "start_logit": 3.060546875,
            "end_logit": 8.203125,
            "text": "\u03b2-galactosidase",
            "probability": 0.049560546875
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 11.15625,
            "text": "and \u03b2-hexosaminidase",
            "probability": 6.377696990966797e-05
        },
        {
            "start_logit": -6.72265625,
            "end_logit": 11.15625,
            "text": "\u03b2-hexosaminidase",
            "probability": 5.370378494262695e-05
        },
        {
            "start_logit": -7.140625,
            "end_logit": 11.15625,
            "text": "osaminidase",
            "probability": 3.522634506225586e-05
        },
        {
            "start_logit": -8.125,
            "end_logit": 11.15625,
            "text": "galactosidase and \u03b2-hexosaminidase",
            "probability": 1.3113021850585938e-05
        },
        {
            "start_logit": 3.060546875,
            "end_logit": -0.422119140625,
            "text": "\u03b2-galactosidase and \u03b2-hexosaminidase respectively",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": -8.7265625,
            "end_logit": 11.15625,
            "text": "-galactosidase and \u03b2-hexosaminidase",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -9.046875,
            "end_logit": 11.15625,
            "text": "hexosaminidase",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": -9.0859375,
            "end_logit": 11.15625,
            "text": "-hexosaminidase",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": -9.953125,
            "end_logit": 11.15625,
            "text": "deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -9.96875,
            "end_logit": 11.15625,
            "text": "of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 11.15625,
            "text": "GM1 and GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -11.015625,
            "end_logit": 11.15625,
            "text": "GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -8.125,
            "end_logit": 8.203125,
            "text": "galactosidase",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -11.1171875,
            "end_logit": 11.15625,
            "text": "gangliosidosis are associated with deficiency of \u03b2-galactosidase and \u03b2-hexosaminidase",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -8.7265625,
            "end_logit": 8.203125,
            "text": "-galactosidase",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -9.953125,
            "end_logit": 8.203125,
            "text": "deficiency of \u03b2-galactosidase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.96875,
            "end_logit": 8.203125,
            "text": "of \u03b2-galactosidase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 8.203125,
            "text": "GM1 and GM2 gangliosidosis are associated with deficiency of \u03b2-galactosidase",
            "probability": 5.960464477539063e-08
        }
    ],
    "601ebde11cb411341a00005d_1": [
        {
            "start_logit": 14.0859375,
            "end_logit": 14.9140625,
            "text": "signatureSearch",
            "probability": 1.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -1.58984375,
            "text": "signatureS",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.744140625,
            "end_logit": 14.9140625,
            "text": "earch",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.4453125,
            "text": "signatureSearch: environment for gene expression signature searching and functional interpretation.",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.5546875,
            "text": "signatureSearch:",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.625,
            "text": "signatureSearch: environment",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.8203125,
            "text": "signatureSearch: environment for gene expression signature searching and functional interpretation",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.875,
            "text": "signatureSearch: environment for gene expression signature",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.8828125,
            "text": "signatureSearch: environment for gene expression",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -10.1328125,
            "text": "signatureSearch: environment for gene expression signature searching",
            "probability": 0.0
        },
        {
            "start_logit": -2.744140625,
            "end_logit": -8.4453125,
            "text": "earch: environment for gene expression signature searching and functional interpretation.",
            "probability": 0.0
        },
        {
            "start_logit": -2.744140625,
            "end_logit": -8.5546875,
            "text": "earch:",
            "probability": 0.0
        },
        {
            "start_logit": -2.744140625,
            "end_logit": -8.625,
            "text": "earch: environment",
            "probability": 0.0
        },
        {
            "start_logit": -2.744140625,
            "end_logit": -9.8203125,
            "text": "earch: environment for gene expression signature searching and functional interpretation",
            "probability": 0.0
        },
        {
            "start_logit": -2.744140625,
            "end_logit": -9.875,
            "text": "earch: environment for gene expression signature",
            "probability": 0.0
        },
        {
            "start_logit": -2.744140625,
            "end_logit": -9.8828125,
            "text": "earch: environment for gene expression",
            "probability": 0.0
        },
        {
            "start_logit": -2.744140625,
            "end_logit": -10.1328125,
            "text": "earch: environment for gene expression signature searching",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": -8.4453125,
            "text": "environment for gene expression signature searching and functional interpretation.",
            "probability": 0.0
        },
        {
            "start_logit": -9.140625,
            "end_logit": -8.625,
            "text": "environment",
            "probability": 0.0
        },
        {
            "start_logit": -9.703125,
            "end_logit": -8.4453125,
            "text": ": environment for gene expression signature searching and functional interpretation.",
            "probability": 0.0
        }
    ],
    "601ebde11cb411341a00005d_2": [
        {
            "start_logit": 13.75,
            "end_logit": 14.3671875,
            "text": "signatureSearch",
            "probability": 1.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -1.2626953125,
            "text": "signatureS",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.654296875,
            "end_logit": 14.3671875,
            "text": "earch",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -7.875,
            "text": "signatureSearch is",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -9.640625,
            "text": "signatureSearch is an R",
            "probability": 0.0
        },
        {
            "start_logit": 13.75,
            "end_logit": -9.8515625,
            "text": "signatureSearch is an R/Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": -3.654296875,
            "end_logit": -7.875,
            "text": "earch is",
            "probability": 0.0
        },
        {
            "start_logit": -3.654296875,
            "end_logit": -9.640625,
            "text": "earch is an R",
            "probability": 0.0
        },
        {
            "start_logit": -3.654296875,
            "end_logit": -9.8515625,
            "text": "earch is an R/Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": -3.654296875,
            "end_logit": -9.8671875,
            "text": "earch is an R/Bioconductor package that integrates a suite of existing and novel algorithms into an analysis environment for gene expression signature (GES)",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": -9.5390625,
            "text": "which processes are predominantly modulated in the GESS results, we developed specialized FEA methods combined with drug-target network visualization tools.",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": -9.734375,
            "text": "which processes are predominantly modulated in the GESS results, we developed specialized FEA methods combined with drug-target network visualization tools. The provided",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": -9.8359375,
            "text": "which processes are predominantly modulated in the GESS results, we developed specialized FEA methods combined with drug-target network visualization tools. The provided analysis",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": -9.8515625,
            "text": "which processes are predominantly",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": -9.8671875,
            "text": "which processes are predominantly modulated in the GESS results,",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -9.265625,
            "text": "biological systems,",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": -9.703125,
            "text": "cellular responses frequently governed by connected mechanisms, such as drugs mimicking the expression responses of a disease.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -9.4921875,
            "text": "biological systems, as well as searching single cell GES databases to identify novel network connections or cell types.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -9.5,
            "text": "biological systems",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -9.4921875,
            "text": "cell types.",
            "probability": 0.0
        }
    ],
    "5e2a080caa19d7443100000a_1": [
        {
            "start_logit": 7.38671875,
            "end_logit": 9.96875,
            "text": "AMPK/Sirt1 pathway",
            "probability": 0.94970703125
        },
        {
            "start_logit": 7.38671875,
            "end_logit": 7.0390625,
            "text": "AMPK/Sirt1",
            "probability": 0.05035400390625
        },
        {
            "start_logit": -3.15234375,
            "end_logit": 9.96875,
            "text": "the AMPK/Sirt1 pathway",
            "probability": 2.4974346160888672e-05
        },
        {
            "start_logit": -3.32421875,
            "end_logit": 9.96875,
            "text": "Sirt1 pathway",
            "probability": 2.09808349609375e-05
        },
        {
            "start_logit": -5.7265625,
            "end_logit": 9.96875,
            "text": "pathway",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": -3.15234375,
            "end_logit": 7.0390625,
            "text": "the AMPK/Sirt1",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -3.32421875,
            "end_logit": 7.0390625,
            "text": "Sirt1",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 7.38671875,
            "end_logit": -5.12109375,
            "text": "AMPK",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -7.890625,
            "end_logit": 9.96875,
            "text": "/Sirt1 pathway",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 7.38671875,
            "end_logit": -5.40625,
            "text": "AMPK/Sirt1 pathway.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.78125,
            "end_logit": 9.96875,
            "text": "fatty acid oxidation via the AMPK/Sirt1 pathway",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 9.96875,
            "text": "PP2A inhibition by LB100 significantly ameliorates hepatic steatosis by regulating hepatic lipogenesis and fatty acid oxidation via the AMPK/Sirt1 pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 9.96875,
            "text": "hepatic steatosis by regulating hepatic lipogenesis and fatty acid oxidation via the AMPK/Sirt1 pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 9.96875,
            "text": "via the AMPK/Sirt1 pathway",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 9.96875,
            "text": "hepatic lipogenesis and fatty acid oxidation via the AMPK/Sirt1 pathway",
            "probability": 0.0
        },
        {
            "start_logit": 7.38671875,
            "end_logit": -8.0625,
            "text": "AMPK/",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 9.96875,
            "text": "LB100 significantly ameliorates hepatic steatosis by regulating hepatic lipogenesis and fatty acid oxidation via the AMPK/Sirt1 pathway",
            "probability": 0.0
        },
        {
            "start_logit": -7.890625,
            "end_logit": 7.0390625,
            "text": "/Sirt1",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 7.0390625,
            "text": "fatty acid oxidation via the AMPK/Sirt1",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 7.0390625,
            "text": "PP2A inhibition by LB100 significantly ameliorates hepatic steatosis by regulating hepatic lipogenesis and fatty acid oxidation via the AMPK/Sirt1",
            "probability": 0.0
        }
    ],
    "621ec0313a8413c65300005e_1": [
        {
            "start_logit": 9.8828125,
            "end_logit": 11.5234375,
            "text": "bleomycin",
            "probability": 0.998046875
        },
        {
            "start_logit": 3.65234375,
            "end_logit": 11.5234375,
            "text": "cytotoxic drugs which are most often implicated in causing this are bleomycin",
            "probability": 0.001956939697265625
        },
        {
            "start_logit": 3.65234375,
            "end_logit": 2.08984375,
            "text": "cytotoxic drugs",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -6.078125,
            "end_logit": 11.5234375,
            "text": "drugs which are most often implicated in causing this are bleomycin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 11.5234375,
            "text": "causing this are bleomycin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 11.5234375,
            "text": "The cytotoxic drugs which are most often implicated in causing this are bleomycin",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 11.5234375,
            "text": "implicated in causing this are bleomycin",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 11.5234375,
            "text": "often implicated in causing this are bleomycin",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 11.5234375,
            "text": "most often implicated in causing this are bleomycin",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -9.5,
            "text": "bleomycin, methotrexate",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -9.6015625,
            "text": "bleomycin, methotrexate, cyclophosphamide and busulfan.",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -9.890625,
            "text": "bleomycin, methotrexate, cyclophosphamide and busulfan",
            "probability": 0.0
        },
        {
            "start_logit": 9.8828125,
            "end_logit": -9.890625,
            "text": "bleomycin, methotrexate, cyclophosphamide",
            "probability": 0.0
        },
        {
            "start_logit": 3.65234375,
            "end_logit": -4.8125,
            "text": "cytotoxic",
            "probability": 0.0
        },
        {
            "start_logit": -6.078125,
            "end_logit": 2.08984375,
            "text": "drugs",
            "probability": 0.0
        },
        {
            "start_logit": 3.65234375,
            "end_logit": -8.3203125,
            "text": "cytotoxic drugs which",
            "probability": 0.0
        },
        {
            "start_logit": 3.65234375,
            "end_logit": -9.5,
            "text": "cytotoxic drugs which are most often implicated in causing this are bleomycin, methotrexate",
            "probability": 0.0
        },
        {
            "start_logit": 3.65234375,
            "end_logit": -9.6015625,
            "text": "cytotoxic drugs which are most often implicated in causing this are bleomycin, methotrexate, cyclophosphamide and busulfan.",
            "probability": 0.0
        },
        {
            "start_logit": 3.65234375,
            "end_logit": -9.890625,
            "text": "cytotoxic drugs which are most often implicated in causing this are",
            "probability": 0.0
        },
        {
            "start_logit": 3.65234375,
            "end_logit": -9.890625,
            "text": "cytotoxic drugs which are most often implicated in causing this are bleomycin, methotrexate, cyclophosphamide and busulfan",
            "probability": 0.0
        }
    ],
    "621ec0313a8413c65300005e_2": [
        {
            "start_logit": 13.6328125,
            "end_logit": 14.9453125,
            "text": "Cytotoxic drugs",
            "probability": 1.0
        },
        {
            "start_logit": -0.88037109375,
            "end_logit": 14.9453125,
            "text": "drugs",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -1.900390625,
            "text": "Cytotoxic",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -8.859375,
            "text": "Cytotoxic drugs are the most common cause of toxic lung disease.",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -9.2421875,
            "text": "Cytotoxic drugs are",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -9.78125,
            "text": "Cytotoxic drugs are the most common",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -9.9609375,
            "text": "Cytotoxic drugs are the most",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -10.03125,
            "text": "Cytotoxic drugs are the most common cause of toxic lung disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -10.0390625,
            "text": "Cytotoxic drugs are the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": 13.6328125,
            "end_logit": -10.1640625,
            "text": "Cytotoxic drugs are the",
            "probability": 0.0
        },
        {
            "start_logit": -0.88037109375,
            "end_logit": -8.859375,
            "text": "drugs are the most common cause of toxic lung disease.",
            "probability": 0.0
        },
        {
            "start_logit": -0.88037109375,
            "end_logit": -9.2421875,
            "text": "drugs are",
            "probability": 0.0
        },
        {
            "start_logit": -0.88037109375,
            "end_logit": -9.78125,
            "text": "drugs are the most common",
            "probability": 0.0
        },
        {
            "start_logit": -0.88037109375,
            "end_logit": -9.9609375,
            "text": "drugs are the most",
            "probability": 0.0
        },
        {
            "start_logit": -0.88037109375,
            "end_logit": -10.03125,
            "text": "drugs are the most common cause of toxic lung disease",
            "probability": 0.0
        },
        {
            "start_logit": -0.88037109375,
            "end_logit": -10.0390625,
            "text": "drugs are the most common cause",
            "probability": 0.0
        },
        {
            "start_logit": -0.88037109375,
            "end_logit": -10.1640625,
            "text": "drugs are the",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": -8.859375,
            "text": "toxic lung disease.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": -8.859375,
            "text": "most common cause of toxic lung disease.",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": -8.859375,
            "text": "the most common cause of toxic lung disease.",
            "probability": 0.0
        }
    ],
    "56cae3eb5795f9a73e000021_1": [
        {
            "start_logit": 14.0078125,
            "end_logit": 14.75,
            "text": "20 and 50 years",
            "probability": 1.0
        },
        {
            "start_logit": 3.431640625,
            "end_logit": 14.75,
            "text": "50 years",
            "probability": 2.586841583251953e-05
        },
        {
            "start_logit": -2.38671875,
            "end_logit": 14.75,
            "text": "years",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -1.703125,
            "text": "20",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.50390625,
            "end_logit": 14.75,
            "text": "and 50 years",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -6.13671875,
            "text": "20 and 50",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": 14.75,
            "text": "Crohn's disease has a bimodal age distribution of disease onset diagnosis. The peaks (20 and 50 years",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -8.71875,
            "text": "20 and 50 years) may represent different phenotypes or different genetic and/or environmental influences between younger- and older-onset individuals.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 14.75,
            "text": "disease onset diagnosis. The peaks (20 and 50 years",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -9.3203125,
            "text": "20 and 50 years) may",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 14.75,
            "text": "age distribution of disease onset diagnosis. The peaks (20 and 50 years",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 14.75,
            "text": "(20 and 50 years",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -9.8125,
            "text": "20 and 50 years) may represent different phenotypes or different genetic and/or environmental influences between younger",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -9.8671875,
            "text": "20 and 50 years) may represent different phenotypes or different genetic and/or environmental influences between younger- and older",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.75,
            "text": "peaks (20 and 50 years",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -10.0546875,
            "text": "20 and 50 years) may represent different phenotypes or different genetic and/or environmental influences between",
            "probability": 0.0
        },
        {
            "start_logit": 14.0078125,
            "end_logit": -10.078125,
            "text": "20 and 50 years) may represent different phenotypes or different genetic and/or environmental influences",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 14.75,
            "text": "'s disease has a bimodal age distribution of disease onset diagnosis. The peaks (20 and 50 years",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 14.75,
            "text": "The peaks (20 and 50 years",
            "probability": 0.0
        },
        {
            "start_logit": 3.431640625,
            "end_logit": -6.13671875,
            "text": "50",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_1": [
        {
            "start_logit": 1.0888671875,
            "end_logit": 7.234375,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": 1.0888671875,
            "end_logit": -9.6796875,
            "text": "migraine and more are coming. Three calcitonin gene-related peptide",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.0888671875,
            "end_logit": -9.7265625,
            "text": "migraine and more are coming.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.0888671875,
            "end_logit": -9.828125,
            "text": "migraine and more are coming. Three calcitonin gene-related peptide (CGRP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.0888671875,
            "end_logit": -9.90625,
            "text": "migraine and more are coming. Three calcitonin gene-related peptide (CGRP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.0888671875,
            "end_logit": -9.953125,
            "text": "migraine and more are coming. Three calcitonin gene-related peptide (CGRP) antagonist monoclonal antibodies have been approved and a 4th",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -4.6796875,
            "text": "patch",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -4.6796875,
            "text": "needle patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -4.6796875,
            "text": "acute treatments coming soon include the 5HT1F agonist lasmiditan, a zolmitriptan intradermal micro-needle patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -4.6796875,
            "text": "-needle patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": -4.6796875,
            "text": "New acute treatments coming soon include the 5HT1F agonist lasmiditan, a zolmitriptan intradermal micro-needle patch",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -4.6796875,
            "text": "intradermal micro-needle patch",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -9.4453125,
            "text": "patch, and a nasal mist sumatriptan with a permeability enhancer.",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -9.5625,
            "text": "patch,",
            "probability": 0.0
        },
        {
            "start_logit": -7.64453125,
            "end_logit": -9.921875,
            "text": "patch, and a nasal mist sumatriptan",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -9.4453125,
            "text": "needle patch, and a nasal mist sumatriptan with a permeability enhancer.",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -9.5625,
            "text": "needle patch,",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": -9.078125,
            "text": "acute care and prevention",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": -9.078125,
            "text": "due in early 2020. Small molecule CGRP receptor-blocking oral compounds, both for acute care and prevention",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -9.921875,
            "text": "needle patch, and a nasal mist sumatriptan",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_2": [
        {
            "start_logit": 8.0703125,
            "end_logit": 12.671875,
            "text": "Migraine has recently become a major interest to the neuroscientists. Zolmitriptan is an effective medicine used in the treatment of migraine",
            "probability": 0.9970703125
        },
        {
            "start_logit": 8.0703125,
            "end_logit": 6.86328125,
            "text": "Migraine",
            "probability": 0.0029811859130859375
        },
        {
            "start_logit": -2.978515625,
            "end_logit": 12.671875,
            "text": "migraine",
            "probability": 1.5735626220703125e-05
        },
        {
            "start_logit": -4.44140625,
            "end_logit": 12.671875,
            "text": "treatment of migraine",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 12.671875,
            "text": "of migraine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 12.671875,
            "text": "Zolmitriptan is an effective medicine used in the treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -5.71875,
            "text": "Migraine has recently become a major interest to the neuroscientists. Zolmitriptan is an effective medicine used in the treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 12.671875,
            "text": "in the treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 12.671875,
            "text": "the treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 12.671875,
            "text": "become a major interest to the neuroscientists. Zolmitriptan is an effective medicine used in the treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 12.671875,
            "text": "recently become a major interest to the neuroscientists. Zolmitriptan is an effective medicine used in the treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 12.671875,
            "text": "mitriptan is an effective medicine used in the treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 12.671875,
            "text": "riptan is an effective medicine used in the treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 12.671875,
            "text": "ptan is an effective medicine used in the treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 12.671875,
            "text": "an effective medicine used in the treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 12.671875,
            "text": "a major interest to the neuroscientists. Zolmitriptan is an effective medicine used in the treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -8.1953125,
            "text": "Migraine has recently become a major interest to the neuroscientists.",
            "probability": 0.0
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -9.7109375,
            "text": "Migraine has recently become a major interest to the neuroscientists. Zolmitriptan is an effective medicine used in the treatment of",
            "probability": 0.0
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -9.8046875,
            "text": "Migraine has recently become a major interest to the neuroscientists. Zolmitriptan is an effective",
            "probability": 0.0
        },
        {
            "start_logit": 8.0703125,
            "end_logit": -9.875,
            "text": "Migraine has recently become a major interest to the neuroscientists",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_3": [
        {
            "start_logit": 13.78125,
            "end_logit": 14.828125,
            "text": "acute treatment of migraine",
            "probability": 1.0
        },
        {
            "start_logit": -2.609375,
            "end_logit": 14.828125,
            "text": "migraine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.78125,
            "end_logit": -3.2421875,
            "text": "acute",
            "probability": 0.0
        },
        {
            "start_logit": -7.17578125,
            "end_logit": 14.828125,
            "text": "treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.1796875,
            "end_logit": 14.828125,
            "text": "the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.8125,
            "end_logit": 14.828125,
            "text": "of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -9.6796875,
            "end_logit": 14.828125,
            "text": "Qtrypta\u2122) for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 13.78125,
            "end_logit": -8.65625,
            "text": "acute treatment",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 14.828125,
            "text": "microneedle system (Qtrypta\u2122) for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 13.78125,
            "end_logit": -8.9375,
            "text": "acute treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 14.828125,
            "text": "eedle system (Qtrypta\u2122) for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 14.828125,
            "text": "system (Qtrypta\u2122) for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 14.828125,
            "text": "intracutaneous microneedle system (Qtrypta\u2122) for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 14.828125,
            "text": "\u2122) for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 14.828125,
            "text": "pta\u2122) for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 14.828125,
            "text": "rypta\u2122) for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 14.828125,
            "text": "for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 14.828125,
            "text": "utaneous microneedle system (Qtrypta\u2122) for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.828125,
            "text": "an intracutaneous microneedle system (Qtrypta\u2122) for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.828125,
            "text": "zolmitriptan intracutaneous microneedle system (Qtrypta\u2122) for the acute treatment of migraine",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_4": [
        {
            "start_logit": 13.53125,
            "end_logit": 15.296875,
            "text": "acute oral treatment for migraine",
            "probability": 1.0
        },
        {
            "start_logit": -1.1044921875,
            "end_logit": 15.296875,
            "text": "migraine",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 13.53125,
            "end_logit": -3.767578125,
            "text": "acute",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -4.0546875,
            "text": "acute oral treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -6.13671875,
            "end_logit": 15.296875,
            "text": "Zolmitriptan is a novel and highly selective 5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 15.296875,
            "text": "for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 15.296875,
            "text": "treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 15.296875,
            "text": "an acute oral treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 15.296875,
            "text": "oral treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 15.296875,
            "text": "HT(1B/1D) receptor agonist used as an acute oral treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 15.296875,
            "text": "selective 5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -8.765625,
            "text": "acute oral treatment for",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 15.296875,
            "text": "ptan is a novel and highly selective 5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 15.296875,
            "text": "5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 15.296875,
            "text": "mitriptan is a novel and highly selective 5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.296875,
            "text": "novel and highly selective 5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 15.296875,
            "text": "as an acute oral treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 15.296875,
            "text": "used as an acute oral treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 15.296875,
            "text": "an is a novel and highly selective 5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -9.1875,
            "text": "acute oral treatment",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_5": [
        {
            "start_logit": 13.7734375,
            "end_logit": 15.3828125,
            "text": "acute migraine therapy",
            "probability": 1.0
        },
        {
            "start_logit": -0.63623046875,
            "end_logit": 15.3828125,
            "text": "therapy",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 13.7734375,
            "end_logit": 0.310546875,
            "text": "acute migraine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 13.7734375,
            "end_logit": -1.25,
            "text": "acute migraine therapy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.7734375,
            "end_logit": -3.552734375,
            "text": "acute",
            "probability": 0.0
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 15.3828125,
            "text": "Zolmitriptan is a potent selective 5HT1B/1D receptor agonist for acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -8.8359375,
            "end_logit": 15.3828125,
            "text": "migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": 15.3828125,
            "text": "for acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 15.3828125,
            "text": "selective 5HT1B/1D receptor agonist for acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 15.3828125,
            "text": "potent selective 5HT1B/1D receptor agonist for acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 15.3828125,
            "text": "mitriptan is a potent selective 5HT1B/1D receptor agonist for acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 15.3828125,
            "text": "ptan is a potent selective 5HT1B/1D receptor agonist for acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 15.3828125,
            "text": "receptor agonist for acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 15.3828125,
            "text": "an is a potent selective 5HT1B/1D receptor agonist for acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 15.3828125,
            "text": "riptan is a potent selective 5HT1B/1D receptor agonist for acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 15.3828125,
            "text": "1D receptor agonist for acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -11.09375,
            "end_logit": 15.3828125,
            "text": "a potent selective 5HT1B/1D receptor agonist for acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": 15.3828125,
            "text": "5HT1B/1D receptor agonist for acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -0.63623046875,
            "end_logit": -1.25,
            "text": "therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.4140625,
            "end_logit": 0.310546875,
            "text": "Zolmitriptan is a potent selective 5HT1B/1D receptor agonist for acute migraine",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_6": [
        {
            "start_logit": 13.2109375,
            "end_logit": 14.3125,
            "text": "cluster headache",
            "probability": 1.0
        },
        {
            "start_logit": -3.634765625,
            "end_logit": 14.3125,
            "text": "headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -3.19140625,
            "text": "cluster",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": 14.3125,
            "text": "SIONS: The 5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": 14.3125,
            "text": "of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 14.3125,
            "text": "symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 14.3125,
            "text": "The 5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 14.3125,
            "text": ": The 5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -8.84375,
            "text": "cluster headache.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 14.3125,
            "text": "treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 14.3125,
            "text": "nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 14.3125,
            "text": "potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 14.3125,
            "text": "NS: The 5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 14.3125,
            "text": "the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 14.3125,
            "text": "zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 14.3125,
            "text": "new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -9.3515625,
            "text": "cluster headache. This",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 14.3125,
            "text": "mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -8.4921875,
            "end_logit": -3.19140625,
            "text": "SIONS: The 5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": -3.19140625,
            "text": "of cluster",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_7": [
        {
            "start_logit": 13.9609375,
            "end_logit": 15.2578125,
            "text": "acute treatment for migraine",
            "probability": 1.0
        },
        {
            "start_logit": -1.34765625,
            "end_logit": 15.2578125,
            "text": "migraine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -3.001953125,
            "text": "acute",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -7.03515625,
            "text": "acute treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 15.2578125,
            "text": "for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -8.4296875,
            "end_logit": 15.2578125,
            "text": "Zolmitriptan (Zomig, formerly 311C90) is a novel, oral, acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -8.484375,
            "end_logit": 15.2578125,
            "text": "treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -9.1953125,
            "end_logit": 15.2578125,
            "text": "novel, oral, acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -8.546875,
            "text": "acute treatment for",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -8.6015625,
            "text": "acute treatment",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 15.2578125,
            "text": ", acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 15.2578125,
            "text": "311C90) is a novel, oral, acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 15.2578125,
            "text": "Zomig, formerly 311C90) is a novel, oral, acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 15.2578125,
            "text": ", oral, acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 15.2578125,
            "text": "(Zomig, formerly 311C90) is a novel, oral, acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 15.2578125,
            "text": "ptan (Zomig, formerly 311C90) is a novel, oral, acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.2578125,
            "text": "formerly 311C90) is a novel, oral, acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 15.2578125,
            "text": "mig, formerly 311C90) is a novel, oral, acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 15.2578125,
            "text": "mitriptan (Zomig, formerly 311C90) is a novel, oral, acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 15.2578125,
            "text": "oral, acute treatment for migraine",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_8": [
        {
            "start_logit": 14.3671875,
            "end_logit": 15.2265625,
            "text": "acute treatment of migraine",
            "probability": 1.0
        },
        {
            "start_logit": -1.5341796875,
            "end_logit": 15.2265625,
            "text": "migraine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -2.103515625,
            "text": "acute",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -4.9765625,
            "text": "acute treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.265625,
            "end_logit": 15.2265625,
            "text": "the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.296875,
            "end_logit": 15.2265625,
            "text": "treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 15.2265625,
            "text": "of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -7.83203125,
            "text": "acute treatment",
            "probability": 0.0
        },
        {
            "start_logit": 14.3671875,
            "end_logit": -8.5234375,
            "text": "acute treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 15.2265625,
            "text": "selective 5-hydroxytryptamine (5-HT)1B/1D-receptor agonist with central and peripheral activity for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 15.2265625,
            "text": "5-hydroxytryptamine (5-HT)1B/1D-receptor agonist with central and peripheral activity for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 15.2265625,
            "text": "hydroxytryptamine (5-HT)1B/1D-receptor agonist with central and peripheral activity for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 15.2265625,
            "text": "receptor agonist with central and peripheral activity for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -1.5341796875,
            "end_logit": -4.9765625,
            "text": "migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.265625,
            "end_logit": -2.103515625,
            "text": "the acute",
            "probability": 0.0
        },
        {
            "start_logit": -7.265625,
            "end_logit": -4.9765625,
            "text": "the acute treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.296875,
            "end_logit": -4.9765625,
            "text": "treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -2.103515625,
            "text": "selective 5-hydroxytryptamine (5-HT)1B/1D-receptor agonist with central and peripheral activity for the acute",
            "probability": 0.0
        },
        {
            "start_logit": -7.75390625,
            "end_logit": -4.9765625,
            "text": "of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": -2.103515625,
            "text": "5-hydroxytryptamine (5-HT)1B/1D-receptor agonist with central and peripheral activity for the acute",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_9": [
        {
            "start_logit": -0.61376953125,
            "end_logit": 14.515625,
            "text": "migraine",
            "probability": 0.92919921875
        },
        {
            "start_logit": -3.671875,
            "end_logit": 14.515625,
            "text": "treatment of migraine",
            "probability": 0.0438232421875
        },
        {
            "start_logit": -4.1953125,
            "end_logit": 14.515625,
            "text": "Zolmitriptan is an effective medicine used in the treatment of migraine",
            "probability": 0.02593994140625
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 14.515625,
            "text": "of migraine",
            "probability": 0.00040650367736816406
        },
        {
            "start_logit": -9.515625,
            "end_logit": 14.515625,
            "text": "mitriptan is an effective medicine used in the treatment of migraine",
            "probability": 0.00012695789337158203
        },
        {
            "start_logit": -9.78125,
            "end_logit": 14.515625,
            "text": "the treatment of migraine",
            "probability": 9.733438491821289e-05
        },
        {
            "start_logit": -9.875,
            "end_logit": 14.515625,
            "text": "in the treatment of migraine",
            "probability": 8.863210678100586e-05
        },
        {
            "start_logit": -10.0,
            "end_logit": 14.515625,
            "text": "ptan is an effective medicine used in the treatment of migraine",
            "probability": 7.82012939453125e-05
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 14.515625,
            "text": "an is an effective medicine used in the treatment of migraine",
            "probability": 6.633996963500977e-05
        },
        {
            "start_logit": -10.328125,
            "end_logit": 14.515625,
            "text": "riptan is an effective medicine used in the treatment of migraine",
            "probability": 5.632638931274414e-05
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 14.515625,
            "text": "medicine used in the treatment of migraine",
            "probability": 4.220008850097656e-05
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 14.515625,
            "text": "used in the treatment of migraine",
            "probability": 3.719329833984375e-05
        },
        {
            "start_logit": -10.765625,
            "end_logit": 14.515625,
            "text": "an effective medicine used in the treatment of migraine",
            "probability": 3.635883331298828e-05
        },
        {
            "start_logit": -10.984375,
            "end_logit": 14.515625,
            "text": "effective medicine used in the treatment of migraine",
            "probability": 2.9265880584716797e-05
        },
        {
            "start_logit": -0.61376953125,
            "end_logit": -3.951171875,
            "text": "migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -3.671875,
            "end_logit": -3.951171875,
            "text": "treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -4.1953125,
            "end_logit": -3.951171875,
            "text": "Zolmitriptan is an effective medicine used in the treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -3.951171875,
            "text": "of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -3.671875,
            "end_logit": -8.9375,
            "text": "treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -4.1953125,
            "end_logit": -8.9375,
            "text": "Zolmitriptan is an effective medicine used in the treatment of",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_10": [
        {
            "start_logit": 12.1015625,
            "end_logit": 15.140625,
            "text": "acute oral treatment of migraine",
            "probability": 1.0
        },
        {
            "start_logit": -1.689453125,
            "end_logit": 15.140625,
            "text": "migraine",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -6.6953125,
            "end_logit": 15.140625,
            "text": "treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -5.109375,
            "text": "acute",
            "probability": 0.0
        },
        {
            "start_logit": -8.7734375,
            "end_logit": 15.140625,
            "text": "of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 15.140625,
            "text": "for acute oral treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 15.140625,
            "text": "selective serotonin (5HT)1B/1D receptor agonist with both central and peripheral activity, now in late-stage clinical development for acute oral treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 15.140625,
            "text": "serotonin (5HT)1B/1D receptor agonist with both central and peripheral activity, now in late-stage clinical development for acute oral treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 15.140625,
            "text": "oral treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 15.140625,
            "text": "in late-stage clinical development for acute oral treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 15.140625,
            "text": "stage clinical development for acute oral treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 15.140625,
            "text": "clinical development for acute oral treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -8.09375,
            "text": "acute oral treatment of",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -8.390625,
            "text": "acute oral treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -8.7734375,
            "text": "acute oral treatment of migraine. Sever",
            "probability": 0.0
        },
        {
            "start_logit": 12.1015625,
            "end_logit": -8.96875,
            "text": "acute oral treatment",
            "probability": 0.0
        },
        {
            "start_logit": -1.689453125,
            "end_logit": -8.390625,
            "text": "migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -1.689453125,
            "end_logit": -8.7734375,
            "text": "migraine. Sever",
            "probability": 0.0
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -8.09375,
            "text": "treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -6.6953125,
            "end_logit": -8.390625,
            "text": "treatment of migraine.",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_11": [
        {
            "start_logit": 4.90625,
            "end_logit": 6.79296875,
            "text": "headache",
            "probability": 1.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 6.79296875,
            "text": "moderate and severe headache",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -9.34375,
            "end_logit": 6.79296875,
            "text": "severe headache",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 6.79296875,
            "text": "for moderate and severe headache",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -9.578125,
            "end_logit": 6.79296875,
            "text": "and severe headache",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 6.79296875,
            "text": "appropriate for moderate and severe headache",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.578125,
            "end_logit": 6.79296875,
            "text": "would be appropriate for moderate and severe headache",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 6.79296875,
            "text": "rizatriptan or zolmitriptan would be appropriate for moderate and severe headache",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.640625,
            "end_logit": 6.79296875,
            "text": "either rizatriptan or zolmitriptan would be appropriate for moderate and severe headache",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.90625,
            "end_logit": -8.921875,
            "text": "headache. Rizatriptan has a more rapid on",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 6.79296875,
            "text": "atriptan or zolmitriptan would be appropriate for moderate and severe headache",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 4.90625,
            "end_logit": -9.625,
            "text": "headache.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.90625,
            "end_logit": -10.1953125,
            "text": "headache. Rizatriptan has a more rapid",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 4.90625,
            "end_logit": -10.34375,
            "text": "headache. Rizatriptan",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -8.921875,
            "text": "moderate and severe headache. Rizatriptan has a more rapid on",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": -8.921875,
            "text": "on",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -9.625,
            "text": "moderate and severe headache.",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": -8.921875,
            "text": "severe headache. Rizatriptan has a more rapid on",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -8.921875,
            "text": "for moderate and severe headache. Rizatriptan has a more rapid on",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": -8.921875,
            "text": "and severe headache. Rizatriptan has a more rapid on",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_12": [
        {
            "start_logit": 13.875,
            "end_logit": 14.9453125,
            "text": "acute attacks of migraine",
            "probability": 1.0
        },
        {
            "start_logit": -1.7509765625,
            "end_logit": 14.9453125,
            "text": "migraine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.875,
            "end_logit": -2.986328125,
            "text": "acute",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -6.9921875,
            "text": "acute attacks",
            "probability": 0.0
        },
        {
            "start_logit": -8.140625,
            "end_logit": 14.9453125,
            "text": "of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -8.46875,
            "end_logit": 14.9453125,
            "text": "treatment of acute attacks of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": 14.9453125,
            "text": "of acute attacks of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": 14.9453125,
            "text": "attacks of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": 14.9453125,
            "text": "agonist zolmitriptan (311C90) has been shown to be effective in the treatment of acute attacks of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -8.9453125,
            "text": "acute attacks of migraine and",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.1328125,
            "text": "acute attacks of migraine and experimental data suggest that it may have both peripheral and central sites of action. This s",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 14.9453125,
            "text": "the treatment of acute attacks of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.46875,
            "text": "acute attacks of migraine and experimental data suggest that it may have both peripheral and central sites of action.",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.4921875,
            "text": "acute attacks of migraine and experimental data suggest that it may",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.5234375,
            "text": "acute attacks of migraine and experimental data suggest that it may have both peripheral and central sites of action. This",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 14.9453125,
            "text": "in the treatment of acute attacks of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.59375,
            "text": "acute attacks of migraine and experimental data suggest",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 14.9453125,
            "text": "been shown to be effective in the treatment of acute attacks of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 13.875,
            "end_logit": -9.7734375,
            "text": "acute attacks of",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 14.9453125,
            "text": "(311C90) has been shown to be effective in the treatment of acute attacks of migraine",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_13": [
        {
            "start_logit": -1.5126953125,
            "end_logit": 1.296875,
            "text": "headache",
            "probability": 0.998046875
        },
        {
            "start_logit": -1.5126953125,
            "end_logit": -5.48046875,
            "text": "headache rate than sumatriptan, rizatriptan or zolmitriptan.",
            "probability": 0.0011377334594726562
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 1.296875,
            "text": "recurrent headache",
            "probability": 0.0001474618911743164
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 1.296875,
            "text": "atriptan would appear to have a lower recurrent headache",
            "probability": 8.940696716308594e-05
        },
        {
            "start_logit": -10.875,
            "end_logit": 1.296875,
            "text": "lower recurrent headache",
            "probability": 8.594989776611328e-05
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 1.296875,
            "text": "appear to have a lower recurrent headache",
            "probability": 7.766485214233398e-05
        },
        {
            "start_logit": -11.03125,
            "end_logit": 1.296875,
            "text": "would appear to have a lower recurrent headache",
            "probability": 7.355213165283203e-05
        },
        {
            "start_logit": -1.5126953125,
            "end_logit": -9.59375,
            "text": "headache rate than",
            "probability": 1.8596649169921875e-05
        },
        {
            "start_logit": -1.5126953125,
            "end_logit": -9.6875,
            "text": "headache rate",
            "probability": 1.6927719116210938e-05
        },
        {
            "start_logit": -1.5126953125,
            "end_logit": -10.0078125,
            "text": "headache rate than sumatriptan, rizatriptan or zolmitript",
            "probability": 1.233816146850586e-05
        },
        {
            "start_logit": -1.5126953125,
            "end_logit": -10.078125,
            "text": "headache rate than sumatriptan",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": -1.5126953125,
            "end_logit": -10.140625,
            "text": "headache rate than sumatriptan, rizatriptan",
            "probability": 1.0788440704345703e-05
        },
        {
            "start_logit": -1.5126953125,
            "end_logit": -10.1484375,
            "text": "headache rate than sumatript",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": -1.5126953125,
            "end_logit": -10.1640625,
            "text": "headache rate than sumatriptan, rizatript",
            "probability": 1.055002212524414e-05
        },
        {
            "start_logit": -10.3359375,
            "end_logit": -5.48046875,
            "text": "recurrent headache rate than sumatriptan, rizatriptan or zolmitriptan.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -5.48046875,
            "text": "atriptan would appear to have a lower recurrent headache rate than sumatriptan, rizatriptan or zolmitriptan.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.875,
            "end_logit": -5.48046875,
            "text": "lower recurrent headache rate than sumatriptan, rizatriptan or zolmitriptan.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.96875,
            "end_logit": -5.48046875,
            "text": ".",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.9765625,
            "end_logit": -5.48046875,
            "text": "appear to have a lower recurrent headache rate than sumatriptan, rizatriptan or zolmitriptan.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.03125,
            "end_logit": -5.48046875,
            "text": "would appear to have a lower recurrent headache rate than sumatriptan, rizatriptan or zolmitriptan.",
            "probability": 5.960464477539063e-08
        }
    ],
    "601dbe2b1cb411341a00004d_14": [
        {
            "start_logit": 7.1328125,
            "end_logit": 7.39453125,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": 7.1328125,
            "end_logit": -9.0625,
            "text": "migraine management",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 7.1328125,
            "end_logit": -9.8828125,
            "text": "migraine management:",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 7.39453125,
            "text": "more rational migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 7.39453125,
            "text": "TELs (naratriptan, rizatriptan and zolmitriptan) which may lead to more rational migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 7.39453125,
            "text": "atriptan and zolmitriptan) which may lead to more rational migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 7.39453125,
            "text": "and zolmitriptan) which may lead to more rational migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 7.39453125,
            "text": "new TELs (naratriptan, rizatriptan and zolmitriptan) which may lead to more rational migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 7.39453125,
            "text": "rational migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": -8.5,
            "text": "0 mg) have demonstrated superior efficacy to sumatriptan 100 mg",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": -8.5703125,
            "text": "0 mg) have demonstrated superior efficacy to sumatriptan",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -8.609375,
            "text": "Critical differences for the new TELs (naratriptan, rizatriptan and zolmitriptan) which",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -8.5,
            "text": "and 5.0 mg) have demonstrated superior efficacy to sumatriptan 100 mg",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": -8.5703125,
            "text": "and 5.0 mg) have demonstrated superior efficacy to sumatriptan",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": -9.0625,
            "text": "more rational migraine management",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -9.265625,
            "text": ", and 25 and 50 mg",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -8.5,
            "text": "5 mg and 5.0 mg) have demonstrated superior efficacy to sumatriptan 100 mg",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": -9.265625,
            "text": "0 mg) have demonstrated superior efficacy to sumatriptan 100 mg, and 25 and 50 mg",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -9.3359375,
            "text": ", and 25 and 50 mg respectively.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -8.5703125,
            "text": "5 mg and 5.0 mg) have demonstrated superior efficacy to sumatriptan",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_15": [
        {
            "start_logit": 1.5146484375,
            "end_logit": 10.078125,
            "text": "migraine associated with menses and migraine with aura",
            "probability": 0.99609375
        },
        {
            "start_logit": -4.2421875,
            "end_logit": 10.078125,
            "text": "migraine with aura",
            "probability": 0.003147125244140625
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 10.078125,
            "text": "associated with menses and migraine with aura",
            "probability": 7.998943328857422e-05
        },
        {
            "start_logit": -8.0,
            "end_logit": 10.078125,
            "text": "aura",
            "probability": 7.337331771850586e-05
        },
        {
            "start_logit": -8.9140625,
            "end_logit": 10.078125,
            "text": "with aura",
            "probability": 2.944469451904297e-05
        },
        {
            "start_logit": -9.2421875,
            "end_logit": 10.078125,
            "text": "and migraine with aura",
            "probability": 2.1219253540039062e-05
        },
        {
            "start_logit": -9.453125,
            "end_logit": 10.078125,
            "text": "Zolmitriptan is effective in the treatment of migraine associated with menses and migraine with aura",
            "probability": 1.71661376953125e-05
        },
        {
            "start_logit": 1.5146484375,
            "end_logit": -1.1484375,
            "text": "migraine",
            "probability": 1.3232231140136719e-05
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 10.078125,
            "text": "menses and migraine with aura",
            "probability": 1.2040138244628906e-05
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 10.078125,
            "text": "with menses and migraine with aura",
            "probability": 1.0311603546142578e-05
        },
        {
            "start_logit": -10.125,
            "end_logit": 10.078125,
            "text": "treatment of migraine associated with menses and migraine with aura",
            "probability": 8.761882781982422e-06
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 10.078125,
            "text": "of migraine associated with menses and migraine with aura",
            "probability": 6.496906280517578e-06
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 10.078125,
            "text": "mitriptan is effective in the treatment of migraine associated with menses and migraine with aura",
            "probability": 4.827976226806641e-06
        },
        {
            "start_logit": -10.859375,
            "end_logit": 10.078125,
            "text": "riptan is effective in the treatment of migraine associated with menses and migraine with aura",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -10.875,
            "end_logit": 10.078125,
            "text": "ses and migraine with aura",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 10.078125,
            "text": "in the treatment of migraine associated with menses and migraine with aura",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 10.078125,
            "text": "ptan is effective in the treatment of migraine associated with menses and migraine with aura",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 1.5146484375,
            "end_logit": -5.49609375,
            "text": "migraine associated with menses and",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 1.5146484375,
            "end_logit": -8.25,
            "text": "migraine associated with menses",
            "probability": 0.0
        },
        {
            "start_logit": 1.5146484375,
            "end_logit": -9.5703125,
            "text": "migraine associated with mense",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_16": [
        {
            "start_logit": 7.859375,
            "end_logit": 9.6640625,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 9.6640625,
            "text": "in migraine",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 9.6640625,
            "text": "Zolmitriptan: a review of its use in migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 9.6640625,
            "text": "use in migraine",
            "probability": 0.0
        },
        {
            "start_logit": 7.859375,
            "end_logit": -8.5234375,
            "text": "migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 9.6640625,
            "text": "review of its use in migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 9.6640625,
            "text": "its use in migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 9.6640625,
            "text": "of its use in migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 9.6640625,
            "text": "mitriptan: a review of its use in migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 9.6640625,
            "text": ": a review of its use in migraine",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 9.6640625,
            "text": "ptan: a review of its use in migraine",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 9.6640625,
            "text": "riptan: a review of its use in migraine",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -8.5234375,
            "text": "in migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": -8.5234375,
            "text": "Zolmitriptan: a review of its use in migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": -8.5234375,
            "text": "use in migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -8.5234375,
            "text": "review of its use in migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -8.5234375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": -8.5234375,
            "text": "its use in migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": -8.5234375,
            "text": "of its use in migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -8.5234375,
            "text": "mitriptan: a review of its use in migraine.",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_17": [
        {
            "start_logit": 2.890625,
            "end_logit": -0.434814453125,
            "text": "migraine",
            "probability": 0.994140625
        },
        {
            "start_logit": 2.890625,
            "end_logit": -5.59375,
            "text": "migraine headache",
            "probability": 0.00572967529296875
        },
        {
            "start_logit": 2.890625,
            "end_logit": -9.0390625,
            "text": "migraine headache,",
            "probability": 0.00018274784088134766
        },
        {
            "start_logit": 2.890625,
            "end_logit": -9.8828125,
            "text": "migraine headache, zolmitriptan 5mg",
            "probability": 7.855892181396484e-05
        },
        {
            "start_logit": 2.890625,
            "end_logit": -9.9296875,
            "text": "migraine headache, zolmitriptan 5mg had similar efficacy to sumatriptan 100mg",
            "probability": 7.50422477722168e-05
        },
        {
            "start_logit": 2.890625,
            "end_logit": -10.0,
            "text": "migraine headache, zolmitriptan 5mg had similar efficacy to sumatriptan 100mg for a single attack",
            "probability": 6.99162483215332e-05
        },
        {
            "start_logit": 2.890625,
            "end_logit": -10.1171875,
            "text": "migraine headache, zolmitriptan 5mg had similar efficacy to sumatriptan 100mg for a single attack, but generally",
            "probability": 6.216764450073242e-05
        },
        {
            "start_logit": 2.890625,
            "end_logit": -10.140625,
            "text": "migraine headache, zolmitriptan 5mg had similar efficacy to sumatriptan 100mg for a single attack, but",
            "probability": 6.073713302612305e-05
        },
        {
            "start_logit": -10.421875,
            "end_logit": -0.434814453125,
            "text": "of migraine",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -0.434814453125,
            "text": "relief of migraine",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -10.796875,
            "end_logit": -0.434814453125,
            "text": "For relief of migraine",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -10.5078125,
            "end_logit": -4.52734375,
            "text": "in single trials",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -4.52734375,
            "text": "more effective than sumatriptan 25 and 50mg for multiple attacks, in single trials",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -4.52734375,
            "text": ", in single trials",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": -4.52734375,
            "text": "was more effective than sumatriptan 25 and 50mg for multiple attacks, in single trials",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": -4.52734375,
            "text": "a single attack, but generally was more effective than sumatriptan 25 and 50mg for multiple attacks, in single trials",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": -4.52734375,
            "text": "single attack, but generally was more effective than sumatriptan 25 and 50mg for multiple attacks, in single trials",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": -4.52734375,
            "text": "effective than sumatriptan 25 and 50mg for multiple attacks, in single trials",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": -5.59375,
            "text": "of migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -5.59375,
            "text": "relief of migraine headache",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_18": [
        {
            "start_logit": 3.767578125,
            "end_logit": 6.61328125,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": 3.767578125,
            "end_logit": -7.28515625,
            "text": "migraine subtypes, maintains efficacy when used in the long term and is generally well tolerated.",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 6.61328125,
            "text": "a wide range of migraine",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.65625,
            "end_logit": 6.61328125,
            "text": ": Zolmitriptan is effective across a wide range of migraine",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 6.61328125,
            "text": "across a wide range of migraine",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 6.61328125,
            "text": "NCLUSION: Zolmitriptan is effective across a wide range of migraine",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 6.61328125,
            "text": "wide range of migraine",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 6.61328125,
            "text": "effective across a wide range of migraine",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -10.890625,
            "end_logit": 6.61328125,
            "text": "range of migraine",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 3.767578125,
            "end_logit": -8.5703125,
            "text": "migraine subtypes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 3.767578125,
            "end_logit": -9.9765625,
            "text": "migraine subtypes,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.767578125,
            "end_logit": -10.1953125,
            "text": "migraine subtypes, maintains efficacy when used in the long term and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.2265625,
            "end_logit": -7.28515625,
            "text": "tolerated.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": -7.28515625,
            "text": "well tolerated.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": -7.28515625,
            "text": "generally well tolerated.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -7.28515625,
            "text": "a wide range of migraine subtypes, maintains efficacy when used in the long term and is generally well tolerated.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -7.28515625,
            "text": "used in the long term and is generally well tolerated.",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -7.28515625,
            "text": ": Zolmitriptan is effective across a wide range of migraine subtypes, maintains efficacy when used in the long term and is generally well tolerated.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -7.28515625,
            "text": "across a wide range of migraine subtypes, maintains efficacy when used in the long term and is generally well tolerated.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -7.28515625,
            "text": "long term and is generally well tolerated.",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_19": [
        {
            "start_logit": 5.390625,
            "end_logit": 8.8046875,
            "text": "migraine headache",
            "probability": 1.0
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 8.8046875,
            "text": "headache",
            "probability": 1.9073486328125e-06
        },
        {
            "start_logit": 5.390625,
            "end_logit": -5.76171875,
            "text": "migraine",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 8.8046875,
            "text": "Zolmitriptan has also demonstrated efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -9.859375,
            "end_logit": 8.8046875,
            "text": "treatment of persistent and/or recurrent migraine headache",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.171875,
            "end_logit": 8.8046875,
            "text": "recurrent migraine headache",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 8.8046875,
            "text": "persistent and/or recurrent migraine headache",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 8.8046875,
            "text": "of persistent and/or recurrent migraine headache",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.71875,
            "end_logit": 8.8046875,
            "text": "mitriptan has also demonstrated efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 8.8046875,
            "text": "demonstrated efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 8.8046875,
            "text": "/or recurrent migraine headache",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.875,
            "end_logit": 8.8046875,
            "text": "riptan has also demonstrated efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 8.8046875,
            "text": "efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 8.8046875,
            "text": "or recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.984375,
            "end_logit": 8.8046875,
            "text": "and/or recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.984375,
            "end_logit": 8.8046875,
            "text": "ptan has also demonstrated efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.984375,
            "end_logit": 8.8046875,
            "text": "in the treatment of persistent and/or recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.2109375,
            "end_logit": -5.76171875,
            "text": "Zolmitriptan has also demonstrated efficacy in the treatment of persistent and/or recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": -5.76171875,
            "text": "treatment of persistent and/or recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": -5.76171875,
            "text": "recurrent migraine",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_20": [
        {
            "start_logit": -1.95703125,
            "end_logit": 9.3125,
            "text": "migraine",
            "probability": 0.9853515625
        },
        {
            "start_logit": -6.4140625,
            "end_logit": 9.3125,
            "text": "patients with migraine",
            "probability": 0.0114288330078125
        },
        {
            "start_logit": -8.8828125,
            "end_logit": 9.3125,
            "text": "with migraine",
            "probability": 0.0009679794311523438
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 9.3125,
            "text": "use of zolmitriptan in patients with migraine",
            "probability": 0.0004296302795410156
        },
        {
            "start_logit": -9.84375,
            "end_logit": 9.3125,
            "text": "in patients with migraine",
            "probability": 0.00037026405334472656
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 9.3125,
            "text": "the use of zolmitriptan in patients with migraine",
            "probability": 0.0003452301025390625
        },
        {
            "start_logit": -10.265625,
            "end_logit": 9.3125,
            "text": "support the use of zolmitriptan in patients with migraine",
            "probability": 0.00024175643920898438
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 9.3125,
            "text": "zolmitriptan in patients with migraine",
            "probability": 0.00018262863159179688
        },
        {
            "start_logit": -10.796875,
            "end_logit": 9.3125,
            "text": "of zolmitriptan in patients with migraine",
            "probability": 0.00014221668243408203
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 9.3125,
            "text": "some evidence to support the use of zolmitriptan in patients with migraine",
            "probability": 0.00013566017150878906
        },
        {
            "start_logit": -1.95703125,
            "end_logit": -8.9296875,
            "text": "migraine who have had a poor response to previous therapy",
            "probability": 0.0
        },
        {
            "start_logit": -1.95703125,
            "end_logit": -9.875,
            "text": "migraine who",
            "probability": 0.0
        },
        {
            "start_logit": -6.4140625,
            "end_logit": -8.9296875,
            "text": "patients with migraine who have had a poor response to previous therapy",
            "probability": 0.0
        },
        {
            "start_logit": -6.4140625,
            "end_logit": -9.75,
            "text": "patients with",
            "probability": 0.0
        },
        {
            "start_logit": -6.4140625,
            "end_logit": -9.875,
            "text": "patients with migraine who",
            "probability": 0.0
        },
        {
            "start_logit": -8.8828125,
            "end_logit": -8.9296875,
            "text": "with migraine who have had a poor response to previous therapy",
            "probability": 0.0
        },
        {
            "start_logit": -8.8828125,
            "end_logit": -9.75,
            "text": "with",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": -8.9296875,
            "text": "use of zolmitriptan in patients with migraine who have had a poor response to previous therapy",
            "probability": 0.0
        },
        {
            "start_logit": -8.8828125,
            "end_logit": -9.875,
            "text": "with migraine who",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": -8.9296875,
            "text": "in patients with migraine who have had a poor response to previous therapy",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_21": [
        {
            "start_logit": 1.1015625,
            "end_logit": 6.05078125,
            "text": "migraine",
            "probability": 1.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 6.05078125,
            "text": "attacks of migraine",
            "probability": 1.6450881958007812e-05
        },
        {
            "start_logit": -10.109375,
            "end_logit": 6.05078125,
            "text": "zolmitriptan appears to be maintained, with no tachyphylaxis, following repeated administration for multiple attacks of migraine",
            "probability": 1.3530254364013672e-05
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 6.05078125,
            "text": "of migraine",
            "probability": 1.239776611328125e-05
        },
        {
            "start_logit": -10.53125,
            "end_logit": 6.05078125,
            "text": "multiple attacks of migraine",
            "probability": 8.881092071533203e-06
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 6.05078125,
            "text": "no tachyphylaxis, following repeated administration for multiple attacks of migraine",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 6.05078125,
            "text": "repeated administration for multiple attacks of migraine",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 6.05078125,
            "text": "for multiple attacks of migraine",
            "probability": 6.556510925292969e-06
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 6.05078125,
            "text": "mitriptan appears to be maintained, with no tachyphylaxis, following repeated administration for multiple attacks of migraine",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 6.05078125,
            "text": "The efficacy of zolmitriptan appears to be maintained, with no tachyphylaxis, following repeated administration for multiple attacks of migraine",
            "probability": 6.4373016357421875e-06
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 6.05078125,
            "text": "tachyphylaxis, following repeated administration for multiple attacks of migraine",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 6.05078125,
            "text": "riptan appears to be maintained, with no tachyphylaxis, following repeated administration for multiple attacks of migraine",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 6.05078125,
            "text": "administration for multiple attacks of migraine",
            "probability": 5.9604644775390625e-06
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 6.05078125,
            "text": "of zolmitriptan appears to be maintained, with no tachyphylaxis, following repeated administration for multiple attacks of migraine",
            "probability": 5.781650543212891e-06
        },
        {
            "start_logit": 1.1015625,
            "end_logit": -8.3046875,
            "text": "migraine over a prolonged period of time, with high headache response rates reported over all attacks",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 1.1015625,
            "end_logit": -10.265625,
            "text": "migraine over a prolonged period of time,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.1015625,
            "end_logit": -10.3046875,
            "text": "migraine over a prolonged period of time, with high headache response rates reported over all",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.1015625,
            "end_logit": -10.3203125,
            "text": "migraine over a prolonged",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.1015625,
            "end_logit": -10.328125,
            "text": "migraine over a",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.1015625,
            "end_logit": -10.375,
            "text": "migraine over a prolonged period of time, with high headache response rates",
            "probability": 5.960464477539063e-08
        }
    ],
    "601dbe2b1cb411341a00004d_22": [
        {
            "start_logit": 6.1328125,
            "end_logit": 9.5234375,
            "text": "migraine headache",
            "probability": 1.0
        },
        {
            "start_logit": -5.78125,
            "end_logit": 9.5234375,
            "text": "headache",
            "probability": 6.67572021484375e-06
        },
        {
            "start_logit": 6.1328125,
            "end_logit": -5.86328125,
            "text": "migraine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 9.5234375,
            "text": "persistent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.0625,
            "end_logit": 9.5234375,
            "text": "of persistent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.1328125,
            "end_logit": 9.5234375,
            "text": "In comparison with placebo, the incidence of persistent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.1328125,
            "end_logit": -8.7734375,
            "text": "migraine headache is reduced by zolmitriptan and recurrent migraine headache occurs less frequently with the active treatment",
            "probability": 0.0
        },
        {
            "start_logit": 6.1328125,
            "end_logit": -9.421875,
            "text": "migraine headache is",
            "probability": 0.0
        },
        {
            "start_logit": 6.1328125,
            "end_logit": -9.8359375,
            "text": "migraine headache is reduced by zolmitriptan",
            "probability": 0.0
        },
        {
            "start_logit": 6.1328125,
            "end_logit": -9.9609375,
            "text": "migraine headache is reduced by zolmitriptan and recurrent migraine headache occurs less frequently with",
            "probability": 0.0
        },
        {
            "start_logit": 6.1328125,
            "end_logit": -10.03125,
            "text": "migraine headache is reduced by zolmitriptan and",
            "probability": 0.0
        },
        {
            "start_logit": 6.1328125,
            "end_logit": -10.0625,
            "text": "migraine headache is reduced by zolmitript",
            "probability": 0.0
        },
        {
            "start_logit": 6.1328125,
            "end_logit": -10.09375,
            "text": "migraine headache is reduced by zolmitriptan and recurrent migraine headache occurs less frequently with the active",
            "probability": 0.0
        },
        {
            "start_logit": 6.1328125,
            "end_logit": -10.125,
            "text": "migraine headache is reduced by zolmitriptan and recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -5.78125,
            "end_logit": -8.7734375,
            "text": "headache is reduced by zolmitriptan and recurrent migraine headache occurs less frequently with the active treatment",
            "probability": 0.0
        },
        {
            "start_logit": -5.78125,
            "end_logit": -9.421875,
            "text": "headache is",
            "probability": 0.0
        },
        {
            "start_logit": -5.78125,
            "end_logit": -9.8359375,
            "text": "headache is reduced by zolmitriptan",
            "probability": 0.0
        },
        {
            "start_logit": -5.78125,
            "end_logit": -9.9609375,
            "text": "headache is reduced by zolmitriptan and recurrent migraine headache occurs less frequently with",
            "probability": 0.0
        },
        {
            "start_logit": -5.78125,
            "end_logit": -10.03125,
            "text": "headache is reduced by zolmitriptan and",
            "probability": 0.0
        },
        {
            "start_logit": -5.78125,
            "end_logit": -10.0625,
            "text": "headache is reduced by zolmitript",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_23": [
        {
            "start_logit": 12.84375,
            "end_logit": 14.25,
            "text": "cluster headache",
            "probability": 1.0
        },
        {
            "start_logit": -3.6875,
            "end_logit": 14.25,
            "text": "headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.84375,
            "end_logit": -3.44140625,
            "text": "cluster",
            "probability": 0.0
        },
        {
            "start_logit": 12.84375,
            "end_logit": -6.68359375,
            "text": "cluster headache. Th",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": 14.25,
            "text": "of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": 12.84375,
            "end_logit": -8.59375,
            "text": "cluster headache.",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 14.25,
            "text": "potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 14.25,
            "text": "nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 14.25,
            "text": "symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 14.25,
            "text": "treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 14.25,
            "text": "zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 14.25,
            "text": "new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 14.25,
            "text": "the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 14.25,
            "text": "5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 14.25,
            "text": "mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 14.25,
            "text": "ptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 14.25,
            "text": "formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 14.25,
            "text": "of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.25,
            "text": "an is a potential new option for the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -3.51171875,
            "end_logit": -6.68359375,
            "text": "Th",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_24": [
        {
            "start_logit": 13.0703125,
            "end_logit": 14.296875,
            "text": "cluster headache",
            "probability": 1.0
        },
        {
            "start_logit": -3.603515625,
            "end_logit": 14.296875,
            "text": "headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -3.28125,
            "text": "cluster",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 14.296875,
            "text": "of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 14.296875,
            "text": "symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 14.296875,
            "text": "treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -8.921875,
            "text": "cluster headache in daily clinical practice.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 14.296875,
            "text": "the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 14.296875,
            "text": "The objective is to analyse our experience with the new intranasal formulation of zolmitriptan 5 mg in the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 14.296875,
            "text": "new intranasal formulation of zolmitriptan 5 mg in the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 14.296875,
            "text": "zolmitriptan 5 mg in the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 14.296875,
            "text": "an 5 mg in the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 14.296875,
            "text": "our experience with the new intranasal formulation of zolmitriptan 5 mg in the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -9.7421875,
            "text": "cluster headache in daily clinical practice",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 14.296875,
            "text": "to analyse our experience with the new intranasal formulation of zolmitriptan 5 mg in the symptomatic treatment of cluster headache",
            "probability": 0.0
        },
        {
            "start_logit": 13.0703125,
            "end_logit": -9.953125,
            "text": "cluster headache in daily clinical practice.P",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -3.28125,
            "text": "of cluster",
            "probability": 0.0
        },
        {
            "start_logit": -3.603515625,
            "end_logit": -8.921875,
            "text": "headache in daily clinical practice.",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": -3.28125,
            "text": "symptomatic treatment of cluster",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": -3.28125,
            "text": "treatment of cluster",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_25": [
        {
            "start_logit": 3.9453125,
            "end_logit": 13.0703125,
            "text": "acute migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks",
            "probability": 0.97705078125
        },
        {
            "start_logit": 3.9453125,
            "end_logit": 9.2890625,
            "text": "acute migraine attacks",
            "probability": 0.02227783203125
        },
        {
            "start_logit": -4.6796875,
            "end_logit": 13.0703125,
            "text": "cluster attacks",
            "probability": 0.00017547607421875
        },
        {
            "start_logit": -5.14453125,
            "end_logit": 13.0703125,
            "text": "attacks",
            "probability": 0.00010979175567626953
        },
        {
            "start_logit": -5.79296875,
            "end_logit": 13.0703125,
            "text": "Zolmitriptan is FDA approved for the treatment of acute migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks",
            "probability": 5.7816505432128906e-05
        },
        {
            "start_logit": -6.1796875,
            "end_logit": 13.0703125,
            "text": "attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks",
            "probability": 3.916025161743164e-05
        },
        {
            "start_logit": -6.47265625,
            "end_logit": 13.0703125,
            "text": "migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks",
            "probability": 2.9146671295166016e-05
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 13.0703125,
            "text": "of cluster attacks",
            "probability": 7.212162017822266e-06
        },
        {
            "start_logit": -7.98828125,
            "end_logit": 13.0703125,
            "text": "acute treatment of cluster attacks",
            "probability": 6.377696990966797e-06
        },
        {
            "start_logit": -8.484375,
            "end_logit": 13.0703125,
            "text": "treatment of acute migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks",
            "probability": 3.874301910400391e-06
        },
        {
            "start_logit": -8.796875,
            "end_logit": 13.0703125,
            "text": "FDA approved for the treatment of acute migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -9.34375,
            "end_logit": 13.0703125,
            "text": "of acute migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks",
            "probability": 1.6093254089355469e-06
        },
        {
            "start_logit": -9.421875,
            "end_logit": 13.0703125,
            "text": "recent literature demonstrating its efficacy in the acute treatment of cluster attacks",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -9.546875,
            "end_logit": 13.0703125,
            "text": "approved for the treatment of acute migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 13.0703125,
            "text": "treatment of cluster attacks",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 13.0703125,
            "text": "the treatment of acute migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -5.79296875,
            "end_logit": 9.2890625,
            "text": "Zolmitriptan is FDA approved for the treatment of acute migraine attacks",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -6.1796875,
            "end_logit": 9.2890625,
            "text": "attacks",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 13.0703125,
            "text": "for the treatment of acute migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 13.0703125,
            "text": "the acute treatment of cluster attacks",
            "probability": 7.748603820800781e-07
        }
    ],
    "601dbe2b1cb411341a00004d_26": [
        {
            "start_logit": 14.109375,
            "end_logit": 15.296875,
            "text": "acute treatment of migraine",
            "probability": 1.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": 15.296875,
            "text": "migraine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 14.109375,
            "end_logit": -2.734375,
            "text": "acute",
            "probability": 0.0
        },
        {
            "start_logit": -7.46875,
            "end_logit": 15.296875,
            "text": "of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.5,
            "end_logit": 15.296875,
            "text": "treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": 15.296875,
            "text": "the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -8.203125,
            "text": "acute treatment of migraine with or without preceding aura.",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -8.4609375,
            "text": "acute treatment of migraine with or without preceding aura",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -8.59375,
            "text": "acute treatment",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 15.296875,
            "text": "novel 5-hydroxytryptamine (5HT)1B/1D receptor agonist with proven efficacy in the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 15.296875,
            "text": "5-hydroxytryptamine (5HT)1B/1D receptor agonist with proven efficacy in the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 15.296875,
            "text": "; formerly 311C90) is a novel 5-hydroxytryptamine (5HT)1B/1D receptor agonist with proven efficacy in the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 15.296875,
            "text": "hydroxytryptamine (5HT)1B/1D receptor agonist with proven efficacy in the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 15.296875,
            "text": "proven efficacy in the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 14.109375,
            "end_logit": -9.3359375,
            "text": "acute treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 15.296875,
            "text": "311C90) is a novel 5-hydroxytryptamine (5HT)1B/1D receptor agonist with proven efficacy in the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 15.296875,
            "text": "formerly 311C90) is a novel 5-hydroxytryptamine (5HT)1B/1D receptor agonist with proven efficacy in the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": -8.203125,
            "text": "migraine with or without preceding aura.",
            "probability": 0.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": -8.4609375,
            "text": "migraine with or without preceding aura",
            "probability": 0.0
        },
        {
            "start_logit": -8.0,
            "end_logit": -2.734375,
            "text": "the acute",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_27": [
        {
            "start_logit": 14.296875,
            "end_logit": 15.34375,
            "text": "acute treatment for migraine",
            "probability": 1.0
        },
        {
            "start_logit": -1.1767578125,
            "end_logit": 15.34375,
            "text": "migraine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.296875,
            "end_logit": -2.255859375,
            "text": "acute",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -5.90234375,
            "text": "acute treatment for migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -7.05078125,
            "end_logit": 15.34375,
            "text": "treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 15.34375,
            "text": "Zolmitriptan is a suitable first-line drug for acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": 15.34375,
            "text": "for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -8.5078125,
            "end_logit": 15.34375,
            "text": "for acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -8.03125,
            "text": "acute treatment for",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -8.359375,
            "text": "acute treatment",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 15.34375,
            "text": "ptan is a suitable first-line drug for acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 15.34375,
            "text": "first-line drug for acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 15.34375,
            "text": "line drug for acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 15.34375,
            "text": "mitriptan is a suitable first-line drug for acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 15.34375,
            "text": "drug for acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 15.34375,
            "text": "a suitable first-line drug for acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.34375,
            "text": "an is a suitable first-line drug for acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.34375,
            "text": "suitable first-line drug for acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 15.34375,
            "text": "riptan is a suitable first-line drug for acute treatment for migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 15.34375,
            "text": "-line drug for acute treatment for migraine",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_28": [
        {
            "start_logit": 14.5,
            "end_logit": 15.3125,
            "text": "acute treatment of migraine",
            "probability": 1.0
        },
        {
            "start_logit": -1.283203125,
            "end_logit": 15.3125,
            "text": "migraine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.5,
            "end_logit": -1.8154296875,
            "text": "acute",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5,
            "end_logit": -3.80078125,
            "text": "acute treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -6.62890625,
            "end_logit": 15.3125,
            "text": "the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.09375,
            "end_logit": 15.3125,
            "text": "treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 15.3125,
            "text": "of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 15.3125,
            "text": "Zolmitriptan, a selective 5-HT(1B/D) agonist was developed for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 14.5,
            "end_logit": -7.859375,
            "text": "acute treatment",
            "probability": 0.0
        },
        {
            "start_logit": 14.5,
            "end_logit": -8.3828125,
            "text": "acute treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 15.3125,
            "text": "selective 5-HT(1B/D) agonist was developed for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -9.578125,
            "end_logit": 15.3125,
            "text": "HT(1B/D) agonist was developed for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 15.3125,
            "text": "D) agonist was developed for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 15.3125,
            "text": "5-HT(1B/D) agonist was developed for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 15.3125,
            "text": "developed for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 15.3125,
            "text": "for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 15.3125,
            "text": "agonist was developed for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 15.3125,
            "text": "was developed for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 15.3125,
            "text": "a selective 5-HT(1B/D) agonist was developed for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 15.3125,
            "text": "ptan, a selective 5-HT(1B/D) agonist was developed for the acute treatment of migraine",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_29": [
        {
            "start_logit": 7.3828125,
            "end_logit": 5.08203125,
            "text": "migraine associated with menses and migrain",
            "probability": 0.998046875
        },
        {
            "start_logit": 7.3828125,
            "end_logit": -1.298828125,
            "text": "migraine",
            "probability": 0.0016870498657226562
        },
        {
            "start_logit": 7.3828125,
            "end_logit": -4.83984375,
            "text": "migraine associated with menses",
            "probability": 4.8995018005371094e-05
        },
        {
            "start_logit": 7.3828125,
            "end_logit": -8.3125,
            "text": "migraine associated with menses and migr",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -6.10546875,
            "end_logit": 5.08203125,
            "text": "associated with menses and migrain",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 7.3828125,
            "end_logit": -8.8984375,
            "text": "migraine associated with menses and",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.3828125,
            "end_logit": -9.640625,
            "text": "migraine associated with mense",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 5.08203125,
            "text": "and migrain",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.7734375,
            "end_logit": 5.08203125,
            "text": "with menses and migrain",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.90625,
            "end_logit": 5.08203125,
            "text": "menses and migrain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 5.08203125,
            "text": "migrain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.84375,
            "end_logit": 5.08203125,
            "text": "ain",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 5.08203125,
            "text": "treatment of migraine associated with menses and migrain",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 5.08203125,
            "text": "of migraine associated with menses and migrain",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 5.08203125,
            "text": "ses and migrain",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 5.08203125,
            "text": "lmitriptan. Zolmitriptan is effective in the treatment of migraine associated with menses and migrain",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 5.08203125,
            "text": "Zolmitriptan is effective in the treatment of migraine associated with menses and migrain",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 5.08203125,
            "text": "in the treatment of migraine associated with menses and migrain",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 5.08203125,
            "text": "the treatment of migraine associated with menses and migrain",
            "probability": 0.0
        },
        {
            "start_logit": -6.10546875,
            "end_logit": -4.83984375,
            "text": "associated with menses",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_30": [
        {
            "start_logit": 9.0078125,
            "end_logit": 9.984375,
            "text": "migraine associated with menses and migraine with aura",
            "probability": 1.0
        },
        {
            "start_logit": -1.0166015625,
            "end_logit": 9.984375,
            "text": "migraine with aura",
            "probability": 4.398822784423828e-05
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -1.66796875,
            "text": "migraine associated with menses and migraine with aura.",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -2.080078125,
            "text": "migraine",
            "probability": 5.7220458984375e-06
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -3.568359375,
            "text": "migraine associated with menses and",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -5.97265625,
            "end_logit": 9.984375,
            "text": "associated with menses and migraine with aura",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.0625,
            "end_logit": 9.984375,
            "text": "aura",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -6.7265625,
            "end_logit": 9.984375,
            "text": "Zolmitriptan is effective in the treatment of migraine associated with menses and migraine with aura",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -6.3984375,
            "text": "migraine associated with menses",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.5,
            "end_logit": 9.984375,
            "text": "with aura",
            "probability": 0.0
        },
        {
            "start_logit": -8.5546875,
            "end_logit": 9.984375,
            "text": "with menses and migraine with aura",
            "probability": 0.0
        },
        {
            "start_logit": -8.828125,
            "end_logit": 9.984375,
            "text": "and migraine with aura",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 9.984375,
            "text": "menses and migraine with aura",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 9.984375,
            "text": "treatment of migraine associated with menses and migraine with aura",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 9.984375,
            "text": "of migraine associated with menses and migraine with aura",
            "probability": 0.0
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -8.9609375,
            "text": "migraine associated with menses and migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 9.984375,
            "text": "mitriptan is effective in the treatment of migraine associated with menses and migraine with aura",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 9.984375,
            "text": "ses and migraine with aura",
            "probability": 0.0
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -9.4765625,
            "text": "migraine associated with mense",
            "probability": 0.0
        },
        {
            "start_logit": 9.0078125,
            "end_logit": -9.4765625,
            "text": "migraine associated with menses and migraine with",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_31": [
        {
            "start_logit": 13.328125,
            "end_logit": 15.171875,
            "text": "acute migraine therapy",
            "probability": 1.0
        },
        {
            "start_logit": -1.111328125,
            "end_logit": 15.171875,
            "text": "therapy",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 13.328125,
            "end_logit": -1.31640625,
            "text": "acute migraine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.328125,
            "end_logit": -2.345703125,
            "text": "acute migraine therapy.",
            "probability": 0.0
        },
        {
            "start_logit": 13.328125,
            "end_logit": -4.12890625,
            "text": "acute",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 15.171875,
            "text": "migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -9.25,
            "end_logit": 15.171875,
            "text": "in acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 15.171875,
            "text": "used in acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 15.171875,
            "text": "5-hydroxytryptophan(1B/1D) receptor agonist, is once such drug that is used in acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 15.171875,
            "text": "once such drug that is used in acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 15.171875,
            "text": "hydroxytryptophan(1B/1D) receptor agonist, is once such drug that is used in acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 15.171875,
            "text": "receptor agonist, is once such drug that is used in acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 15.171875,
            "text": "tryptophan(1B/1D) receptor agonist, is once such drug that is used in acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 15.171875,
            "text": "ophan(1B/1D) receptor agonist, is once such drug that is used in acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 15.171875,
            "text": "/1D) receptor agonist, is once such drug that is used in acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 15.171875,
            "text": "such drug that is used in acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 15.171875,
            "text": "drug that is used in acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 15.171875,
            "text": "(1B/1D) receptor agonist, is once such drug that is used in acute migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": -1.111328125,
            "end_logit": -2.345703125,
            "text": "therapy.",
            "probability": 0.0
        },
        {
            "start_logit": -7.9140625,
            "end_logit": -1.31640625,
            "text": "Zolmitriptan, a 5-hydroxytryptophan(1B/1D) receptor agonist, is once such drug that is used in acute migraine",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_32": [
        {
            "start_logit": 10.6640625,
            "end_logit": 12.8125,
            "text": "migraine headache",
            "probability": 1.0
        },
        {
            "start_logit": -4.2890625,
            "end_logit": 12.8125,
            "text": "headache",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.6640625,
            "end_logit": -4.1171875,
            "text": "migraine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.9921875,
            "end_logit": 12.8125,
            "text": "Zolmitriptan has also shown efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": 10.6640625,
            "end_logit": -6.0625,
            "text": "migraine headache.",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": 12.8125,
            "text": "treatment of persistent and/or recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 12.8125,
            "text": "of persistent and/or recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 12.8125,
            "text": "recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 12.8125,
            "text": "persistent and/or recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 12.8125,
            "text": "mitriptan has also shown efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 12.8125,
            "text": "shown efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 12.8125,
            "text": "riptan has also shown efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 12.8125,
            "text": "efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 12.8125,
            "text": "ptan has also shown efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 12.8125,
            "text": "and/or recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 12.8125,
            "text": "/or recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 12.8125,
            "text": "an has also shown efficacy in the treatment of persistent and/or recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 12.8125,
            "text": "or recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 12.8125,
            "text": "in the treatment of persistent and/or recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -4.2890625,
            "end_logit": -6.0625,
            "text": "headache.",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_33": [
        {
            "start_logit": 11.140625,
            "end_logit": 13.1328125,
            "text": "migraine headache",
            "probability": 1.0
        },
        {
            "start_logit": -4.109375,
            "end_logit": 13.1328125,
            "text": "headache",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.93359375,
            "end_logit": 13.1328125,
            "text": "Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.140625,
            "end_logit": -4.0234375,
            "text": "migraine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4140625,
            "end_logit": 13.1328125,
            "text": "treatment of persistent and recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": 11.140625,
            "end_logit": -6.6484375,
            "text": "migraine headache.",
            "probability": 0.0
        },
        {
            "start_logit": -8.6484375,
            "end_logit": 13.1328125,
            "text": "of persistent and recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 13.1328125,
            "text": "recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -9.1875,
            "end_logit": 13.1328125,
            "text": "persistent and recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 13.1328125,
            "text": "mitriptan is effective for the treatment of persistent and recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 13.1328125,
            "text": "for the treatment of persistent and recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 13.1328125,
            "text": "and recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 13.1328125,
            "text": "an is effective for the treatment of persistent and recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 13.1328125,
            "text": "ptan is effective for the treatment of persistent and recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 13.1328125,
            "text": "the treatment of persistent and recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 13.1328125,
            "text": "riptan is effective for the treatment of persistent and recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 13.1328125,
            "text": "effective for the treatment of persistent and recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 13.1328125,
            "text": "is effective for the treatment of persistent and recurrent migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -5.93359375,
            "end_logit": -4.0234375,
            "text": "Zolmitriptan is effective for the treatment of persistent and recurrent migraine",
            "probability": 0.0
        },
        {
            "start_logit": -4.109375,
            "end_logit": -6.6484375,
            "text": "headache.",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_34": [
        {
            "start_logit": 11.4375,
            "end_logit": 14.4453125,
            "text": "acute oral migraine",
            "probability": 1.0
        },
        {
            "start_logit": -2.455078125,
            "end_logit": 14.4453125,
            "text": "migraine",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -5.81640625,
            "end_logit": 14.4453125,
            "text": "Zolmitriptan is a selective 5-HT1B/1D receptor agonist for acute oral migraine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.4375,
            "end_logit": -3.19140625,
            "text": "acute oral migraine therapy",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -4.08984375,
            "text": "acute oral migraine therapy.",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -4.98828125,
            "text": "acute",
            "probability": 0.0
        },
        {
            "start_logit": -9.34375,
            "end_logit": 14.4453125,
            "text": "oral migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 14.4453125,
            "text": "for acute oral migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 14.4453125,
            "text": "mitriptan is a selective 5-HT1B/1D receptor agonist for acute oral migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 14.4453125,
            "text": "selective 5-HT1B/1D receptor agonist for acute oral migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 14.4453125,
            "text": "ptan is a selective 5-HT1B/1D receptor agonist for acute oral migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.4453125,
            "text": "HT1B/1D receptor agonist for acute oral migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.4453125,
            "text": "5-HT1B/1D receptor agonist for acute oral migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 14.4453125,
            "text": "an is a selective 5-HT1B/1D receptor agonist for acute oral migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.4453125,
            "text": "riptan is a selective 5-HT1B/1D receptor agonist for acute oral migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 14.4453125,
            "text": "a selective 5-HT1B/1D receptor agonist for acute oral migraine",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 14.4453125,
            "text": "receptor agonist for acute oral migraine",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 14.4453125,
            "text": "is a selective 5-HT1B/1D receptor agonist for acute oral migraine",
            "probability": 0.0
        },
        {
            "start_logit": 11.4375,
            "end_logit": -9.84375,
            "text": "acute oral",
            "probability": 0.0
        },
        {
            "start_logit": -2.455078125,
            "end_logit": -3.19140625,
            "text": "migraine therapy",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_35": [
        {
            "start_logit": 14.5390625,
            "end_logit": 15.3203125,
            "text": "acute treatment of migraine",
            "probability": 1.0
        },
        {
            "start_logit": -1.224609375,
            "end_logit": 15.3203125,
            "text": "migraine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -1.5576171875,
            "text": "acute",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -3.359375,
            "text": "acute treatment of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": -5.08984375,
            "end_logit": 15.3203125,
            "text": "Zolmitriptan is a 5-HT1B/1D receptor agonist for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -6.83203125,
            "end_logit": 15.3203125,
            "text": "the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.0390625,
            "end_logit": 15.3203125,
            "text": "treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -7.75,
            "end_logit": 15.3203125,
            "text": "of migraine",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -8.6640625,
            "text": "acute treatment",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -8.8515625,
            "text": "acute treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": 15.3203125,
            "text": "5-HT1B/1D receptor agonist for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 15.3203125,
            "text": "mitriptan is a 5-HT1B/1D receptor agonist for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 15.3203125,
            "text": "ptan is a 5-HT1B/1D receptor agonist for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 15.3203125,
            "text": "HT1B/1D receptor agonist for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 15.3203125,
            "text": "an is a 5-HT1B/1D receptor agonist for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 15.3203125,
            "text": "receptor agonist for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 15.3203125,
            "text": "riptan is a 5-HT1B/1D receptor agonist for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 15.3203125,
            "text": "for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 15.3203125,
            "text": "a 5-HT1B/1D receptor agonist for the acute treatment of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 15.3203125,
            "text": "1D receptor agonist for the acute treatment of migraine",
            "probability": 0.0
        }
    ],
    "601dbe2b1cb411341a00004d_36": [
        {
            "start_logit": 12.1875,
            "end_logit": 11.3359375,
            "text": "acute treatment of migraine headache",
            "probability": 0.9873046875
        },
        {
            "start_logit": 12.1875,
            "end_logit": 6.97265625,
            "text": "acute treatment of migraine",
            "probability": 0.01242828369140625
        },
        {
            "start_logit": -4.3984375,
            "end_logit": 11.3359375,
            "text": "headache",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.1875,
            "end_logit": -5.45703125,
            "text": "acute",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.34375,
            "end_logit": 11.3359375,
            "text": "of migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -6.5,
            "end_logit": 11.3359375,
            "text": "migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": 12.1875,
            "end_logit": -7.6640625,
            "text": "acute treatment of migraine headache and its associated symptoms.",
            "probability": 0.0
        },
        {
            "start_logit": 12.1875,
            "end_logit": -8.0859375,
            "text": "acute treatment",
            "probability": 0.0
        },
        {
            "start_logit": -8.4453125,
            "end_logit": 11.3359375,
            "text": "treatment of migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -8.6953125,
            "end_logit": 11.3359375,
            "text": "the acute treatment of migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 11.3359375,
            "text": "tolerated in the acute treatment of migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": 12.1875,
            "end_logit": -9.8125,
            "text": "acute treatment of migraine headache and its associated symptoms",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 11.3359375,
            "text": "well tolerated in the acute treatment of migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 11.3359375,
            "text": "consistently effective and well tolerated in the acute treatment of migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -6.34375,
            "end_logit": 6.97265625,
            "text": "of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 11.3359375,
            "text": "novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 11.3359375,
            "text": "formerly 311C90) is a novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.3359375,
            "text": "311C90) is a novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache",
            "probability": 0.0
        },
        {
            "start_logit": -6.5,
            "end_logit": 6.97265625,
            "text": "migraine",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 11.3359375,
            "text": ", oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache",
            "probability": 0.0
        }
    ],
    "5fe3131fa43ad3127800004a_1": [
        {
            "start_logit": 10.4921875,
            "end_logit": 12.1796875,
            "text": "TGF\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -3.107421875,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3, which associate with a variety of nuclear factors to regulate gene transcription.",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -8.921875,
            "text": "TGF\u03b2 signaling",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -9.2578125,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3,",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -9.2890625,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -9.8515625,
            "text": "TGF\u03b2 signaling activates receptor SMAD",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -9.859375,
            "text": "TGF\u03b2 signaling activates receptor SMADs",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -10.078125,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3, which associate with a variety",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -10.171875,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -10.203125,
            "text": "TGF\u03b2 signaling activates receptor",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -10.2109375,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3, which associate",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -10.21875,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3, which",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -10.234375,
            "text": "TGF\u03b2 signaling activates",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -10.25,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3, which associate with a",
            "probability": 0.0
        },
        {
            "start_logit": 10.4921875,
            "end_logit": -10.265625,
            "text": "TGF\u03b2 signaling activates receptor SMADs, SMAD2 and SMAD3, which associate with a variety of nuclear factors to regulate gene transcription",
            "probability": 0.0
        },
        {
            "start_logit": -8.7734375,
            "end_logit": -3.107421875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": -3.107421875,
            "text": "receptor SMADs, SMAD2 and SMAD3, which associate with a variety of nuclear factors to regulate gene transcription.",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -3.107421875,
            "text": "signaling activates receptor SMADs, SMAD2 and SMAD3, which associate with a variety of nuclear factors to regulate gene transcription.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -3.107421875,
            "text": "gene transcription.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -3.107421875,
            "text": "and SMAD3, which associate with a variety of nuclear factors to regulate gene transcription.",
            "probability": 0.0
        }
    ],
    "5fe3131fa43ad3127800004a_2": [
        {
            "start_logit": 10.3984375,
            "end_logit": 11.8046875,
            "text": "TGF\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": -4.64453125,
            "end_logit": 11.8046875,
            "text": "IL-6, TGF\u03b2",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -4.91796875,
            "text": "TGF\u03b2 promotes Th17 cell differentiation.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.7421875,
            "end_logit": 11.8046875,
            "text": ", TGF\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -9.71875,
            "end_logit": 11.8046875,
            "text": "cytokine IL-6, TGF\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 11.8046875,
            "text": "6, TGF\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 11.8046875,
            "text": "the inflammatory cytokine IL-6, TGF\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -9.2109375,
            "text": "TGF\u03b2 promotes Th17 cell differentiation",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 11.8046875,
            "text": "inflammatory cytokine IL-6, TGF\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 11.8046875,
            "text": "-6, TGF\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -9.6171875,
            "text": "TGF\u03b2 promotes",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -9.9140625,
            "text": "TGF\u03b2 promotes Th17",
            "probability": 0.0
        },
        {
            "start_logit": 10.3984375,
            "end_logit": -10.203125,
            "text": "TGF\u03b2 promotes Th17 cell",
            "probability": 0.0
        },
        {
            "start_logit": -4.64453125,
            "end_logit": -4.703125,
            "text": "IL-6",
            "probability": 0.0
        },
        {
            "start_logit": -4.64453125,
            "end_logit": -4.91796875,
            "text": "IL-6, TGF\u03b2 promotes Th17 cell differentiation.",
            "probability": 0.0
        },
        {
            "start_logit": -8.7421875,
            "end_logit": -4.91796875,
            "text": ", TGF\u03b2 promotes Th17 cell differentiation.",
            "probability": 0.0
        },
        {
            "start_logit": -8.9140625,
            "end_logit": -4.91796875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -4.64453125,
            "end_logit": -9.2109375,
            "text": "IL-6, TGF\u03b2 promotes Th17 cell differentiation",
            "probability": 0.0
        },
        {
            "start_logit": -4.64453125,
            "end_logit": -9.40625,
            "text": "IL-6,",
            "probability": 0.0
        },
        {
            "start_logit": -4.64453125,
            "end_logit": -9.6171875,
            "text": "IL-6, TGF\u03b2 promotes",
            "probability": 0.0
        }
    ],
    "5fe3131fa43ad3127800004a_3": [
        {
            "start_logit": 11.3671875,
            "end_logit": 11.8828125,
            "text": "TGF\u03b2",
            "probability": 1.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -5.93359375,
            "text": "TGF\u03b2 is the quintessential cytokine of T cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -9.1875,
            "text": "TGF\u03b2 is",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -10.2578125,
            "text": "TGF\u03b2 is the quintessential cytokine",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -10.2734375,
            "text": "TGF\u03b2 is the quintessential cytokine of T",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -10.3203125,
            "text": "TGF\u03b2 is the quintessential cytokine of T cell homeostasis",
            "probability": 0.0
        },
        {
            "start_logit": -8.7265625,
            "end_logit": -5.93359375,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -9.4765625,
            "end_logit": -5.93359375,
            "text": "T cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": -5.93359375,
            "text": "quintessential cytokine of T cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -5.93359375,
            "text": "cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -5.93359375,
            "text": "cytokine of T cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -5.93359375,
            "text": "is the quintessential cytokine of T cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -5.93359375,
            "text": "the quintessential cytokine of T cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": -5.93359375,
            "text": "ntial cytokine of T cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -5.93359375,
            "text": "sential cytokine of T cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": -5.93359375,
            "text": "of T cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": -5.93359375,
            "text": "ial cytokine of T cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -5.93359375,
            "text": "tessential cytokine of T cell homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": -5.93359375,
            "text": "homeostasis.",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": -9.1875,
            "text": "is",
            "probability": 0.0
        }
    ],
    "5fe3131fa43ad3127800004a_4": [
        {
            "start_logit": 11.1796875,
            "end_logit": 11.9765625,
            "text": "TGFbeta",
            "probability": 1.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -4.14453125,
            "text": "TGFbeta binding to serine/threonine kinase receptors on the plasma membrane activates Smad molecules and additional signaling proteins that together regulate gene expression.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.7578125,
            "text": "TGFbeta binding to serine/threonine kinase receptors",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -9.9296875,
            "text": "TGFbeta binding to serine/threonine kinase receptors on the plasma membrane activates Smad molecules and additional signaling proteins that",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -10.0234375,
            "text": "TGFbeta binding to serine/threonine kinase receptors on the plasma membrane",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -10.0234375,
            "text": "TGFbeta binding to serine/threonine kinase receptors on the",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -10.0546875,
            "text": "TGFbeta binding to serine/threonine kinase receptors on the plasma membrane activates Smad molecules and additional signaling proteins that together regulate gene expression",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -10.125,
            "text": "TGFbeta binding to serine/threonine kinase receptors on the plasma membrane activates Smad molecules and",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -10.15625,
            "text": "TGFbeta binding to serine/threonine kinase receptors on the plasma membrane activates Smad",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -10.296875,
            "text": "TGFbeta binding to serine/threonine kinase",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -10.3046875,
            "text": "TGFbeta binding to serine/threonine kinase receptors on the plasma membrane activates Smad molecules and additional signaling",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -10.3203125,
            "text": "TGFbeta binding to serine/threonine kinase receptors on the plasma membrane activates Smad molecules and additional signaling proteins that together",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -10.359375,
            "text": "TGFbeta binding to",
            "probability": 0.0
        },
        {
            "start_logit": 11.1796875,
            "end_logit": -10.40625,
            "text": "TGFbeta binding to serine/",
            "probability": 0.0
        },
        {
            "start_logit": -9.5234375,
            "end_logit": -4.14453125,
            "text": "binding to serine/threonine kinase receptors on the plasma membrane activates Smad molecules and additional signaling proteins that together regulate gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -4.14453125,
            "text": "on the plasma membrane activates Smad molecules and additional signaling proteins that together regulate gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -4.14453125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": -4.14453125,
            "text": "to serine/threonine kinase receptors on the plasma membrane activates Smad molecules and additional signaling proteins that together regulate gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -4.14453125,
            "text": "membrane activates Smad molecules and additional signaling proteins that together regulate gene expression.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": -4.14453125,
            "text": "receptors on the plasma membrane activates Smad molecules and additional signaling proteins that together regulate gene expression.",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_1": [
        {
            "start_logit": 9.3515625,
            "end_logit": 11.1328125,
            "text": "activin type II receptors",
            "probability": 0.9970703125
        },
        {
            "start_logit": 9.3515625,
            "end_logit": 5.25,
            "text": "activin type II receptors (ActRII",
            "probability": 0.0027790069580078125
        },
        {
            "start_logit": 2.294921875,
            "end_logit": 5.25,
            "text": "ActRII",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -3.767578125,
            "text": "activin type II",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.8359375,
            "end_logit": 11.1328125,
            "text": "type II receptors",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.12890625,
            "end_logit": 11.1328125,
            "text": "receptors",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -5.3984375,
            "text": "activin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -6.88671875,
            "text": "activin type II receptors (ActRI",
            "probability": 0.0
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.41796875,
            "text": "activin type",
            "probability": 0.0
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -7.796875,
            "text": "activin type II receptors (ActRII)",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 11.1328125,
            "text": "Bimagrumab is a human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 11.1328125,
            "text": "II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 11.1328125,
            "text": "of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 11.1328125,
            "text": ": Bimagrumab is a human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.1328125,
            "text": "human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 11.1328125,
            "text": "BACKGROUND: Bimagrumab is a human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -9.3203125,
            "text": "activin type II receptors (ActRII),",
            "probability": 0.0
        },
        {
            "start_logit": -5.8359375,
            "end_logit": 5.25,
            "text": "type II receptors (ActRII",
            "probability": 0.0
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -10.09375,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin",
            "probability": 0.0
        },
        {
            "start_logit": 9.3515625,
            "end_logit": -10.109375,
            "text": "activin type II receptors (Act",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_2": [
        {
            "start_logit": 13.8984375,
            "end_logit": 14.7578125,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": -2.583984375,
            "end_logit": 14.7578125,
            "text": "receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -2.166015625,
            "text": "activin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -2.87109375,
            "text": "activin type II",
            "probability": 0.0
        },
        {
            "start_logit": -6.8203125,
            "end_logit": 14.7578125,
            "text": "type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -6.91015625,
            "text": "activin type",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 14.7578125,
            "text": "the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -8.890625,
            "text": "activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 14.7578125,
            "text": "II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 14.7578125,
            "text": "Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 14.7578125,
            "text": "human monoclonal antibody that blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -9.7578125,
            "text": "activin type II receptors,",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 14.7578125,
            "text": "blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 14.7578125,
            "text": ": Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -10.1640625,
            "text": "activin type II receptors, preventing the activity of myostatin",
            "probability": 0.0
        },
        {
            "start_logit": 13.8984375,
            "end_logit": -10.3203125,
            "text": "activin type II receptors, preventing the activity of myostatin and",
            "probability": 0.0
        },
        {
            "start_logit": -6.8203125,
            "end_logit": -2.87109375,
            "text": "type II",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": -2.166015625,
            "text": "the activin",
            "probability": 0.0
        },
        {
            "start_logit": -2.583984375,
            "end_logit": -8.890625,
            "text": "receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
            "probability": 0.0
        },
        {
            "start_logit": -8.9296875,
            "end_logit": -2.87109375,
            "text": "the activin type II",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_3": [
        {
            "start_logit": 13.8359375,
            "end_logit": 14.546875,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -1.4306640625,
            "text": "activin type II",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.775390625,
            "end_logit": 14.546875,
            "text": "receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -2.345703125,
            "text": "activin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -6.44921875,
            "text": "activin type",
            "probability": 0.0
        },
        {
            "start_logit": -7.28515625,
            "end_logit": 14.546875,
            "text": "type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": 14.546875,
            "text": "the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.4609375,
            "end_logit": 14.546875,
            "text": "II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 14.546875,
            "text": "through the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.0625,
            "text": "activin type II receptors with",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.34375,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.6171875,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD and low muscle mass.",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 14.546875,
            "text": "Blocking the action of negative muscle regulators through the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -10.0234375,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 14.546875,
            "text": ": Blocking the action of negative muscle regulators through the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -10.1328125,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -10.25,
            "text": "activin type II receptors with bimagr",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -10.3125,
            "text": "activin type II receptors with bimagrumab",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -10.4140625,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did",
            "probability": 0.0
        },
        {
            "start_logit": -7.28515625,
            "end_logit": -1.4306640625,
            "text": "type II",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_4": [
        {
            "start_logit": 10.5234375,
            "end_logit": 7.53125,
            "text": "activin type II receptors",
            "probability": 0.92333984375
        },
        {
            "start_logit": 10.5234375,
            "end_logit": 5.046875,
            "text": "activin type II receptors (ActRII",
            "probability": 0.07635498046875
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -3.708984375,
            "text": "activin type II",
            "probability": 1.1980533599853516e-05
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -4.65234375,
            "text": "activin type II receptors (ActRII).",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 0.64501953125,
            "end_logit": 5.046875,
            "text": "ActRII",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -5.37109375,
            "text": "activin",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -7.5,
            "text": "activin type II receptors (ActRI",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -7.578125,
            "text": "activin type",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -9.765625,
            "text": "activin type II receptors (ActRII)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 7.53125,
            "text": "type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 7.53125,
            "text": "receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 7.53125,
            "text": "blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 7.53125,
            "text": "II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 5.046875,
            "text": "I",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 5.046875,
            "text": "type II receptors (ActRII",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 7.53125,
            "text": "human monoclonal antibody that exerts strong promyogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 7.53125,
            "text": "promyogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 7.53125,
            "text": "strong promyogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 7.53125,
            "text": "skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 7.53125,
            "text": "(BYM338) is a novel fully human monoclonal antibody that exerts strong promyogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_5": [
        {
            "start_logit": 10.640625,
            "end_logit": 12.5,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": 2.404296875,
            "text": "activin type II receptors (ActRII",
            "probability": 4.1365623474121094e-05
        },
        {
            "start_logit": 10.640625,
            "end_logit": -2.818359375,
            "text": "activin type II",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.140625,
            "end_logit": 12.5,
            "text": "receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.94921875,
            "end_logit": 12.5,
            "text": "type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.640625,
            "end_logit": -4.90234375,
            "text": "activin",
            "probability": 0.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": -7.34375,
            "text": "activin type",
            "probability": 0.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": -7.9140625,
            "text": "activin type II receptors (ActRI",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 12.5,
            "text": "BACKGROUND  Bimagrumab is a human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": 12.5,
            "text": "II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 12.5,
            "text": "Bimagrumab is a human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -0.3037109375,
            "end_logit": 2.404296875,
            "text": "ActRII",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 12.5,
            "text": "of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 12.5,
            "text": "human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": -8.7109375,
            "text": "activin type II receptors (ActRII)",
            "probability": 0.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": -9.28125,
            "text": "activin type II receptors (ActRII),",
            "probability": 0.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": -10.09375,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin",
            "probability": 0.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": -10.2578125,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and",
            "probability": 0.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": -10.3203125,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other",
            "probability": 0.0
        },
        {
            "start_logit": -5.140625,
            "end_logit": 2.404296875,
            "text": "receptors (ActRII",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_6": [
        {
            "start_logit": 13.9609375,
            "end_logit": 14.7890625,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": -2.5625,
            "end_logit": 14.7890625,
            "text": "receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -2.130859375,
            "text": "activin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -3.34375,
            "text": "activin type II",
            "probability": 0.0
        },
        {
            "start_logit": -6.921875,
            "end_logit": 14.7890625,
            "text": "type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 14.7890625,
            "text": "RATIONALE  Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -6.765625,
            "text": "activin type",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -8.2265625,
            "text": "activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
            "probability": 0.0
        },
        {
            "start_logit": -9.1328125,
            "end_logit": 14.7890625,
            "text": "the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 14.7890625,
            "text": "II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 14.7890625,
            "text": "Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 14.7890625,
            "text": "human monoclonal antibody that blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 14.7890625,
            "text": "blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.859375,
            "text": "activin type II receptors,",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -10.1171875,
            "text": "activin type II receptors, preventing the activity of myostatin",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -10.28125,
            "text": "activin type II receptors, preventing the activity of myostatin and",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -2.130859375,
            "text": "RATIONALE  Bimagrumab is a fully human monoclonal antibody that blocks the activin",
            "probability": 0.0
        },
        {
            "start_logit": -6.921875,
            "end_logit": -3.34375,
            "text": "type II",
            "probability": 0.0
        },
        {
            "start_logit": -2.5625,
            "end_logit": -8.2265625,
            "text": "receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -3.34375,
            "text": "RATIONALE  Bimagrumab is a fully human monoclonal antibody that blocks the activin type II",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_7": [
        {
            "start_logit": 9.7890625,
            "end_logit": 12.7109375,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -1.6650390625,
            "text": "activin type II receptors ( ActRII",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -4.9921875,
            "end_logit": 12.7109375,
            "text": "receptors",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -2.853515625,
            "text": "activin type II",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.8828125,
            "end_logit": 12.7109375,
            "text": "type II receptors",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -5.0,
            "text": "activin",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 12.7109375,
            "text": "Bimagrumab is a human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 12.7109375,
            "text": "II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 12.7109375,
            "text": "of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 12.7109375,
            "text": "human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -7.8203125,
            "text": "activin type",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -7.89453125,
            "text": "activin type II receptors ( ActRII)",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 12.7109375,
            "text": "agrumab is a human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.4375,
            "text": "activin type II receptors ( ActRII) ,",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -8.890625,
            "text": "activin type II receptors ( ActRI",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -10.0625,
            "text": "activin type II receptors ( ActRII) , with anabolic action on skeletal muscle mass by blocking binding of myostatin",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -10.171875,
            "text": "activin type II receptors ( ActRII) , with anabolic action on skeletal muscle mass by blocking binding of myostatin and",
            "probability": 0.0
        },
        {
            "start_logit": 9.7890625,
            "end_logit": -10.265625,
            "text": "activin type II receptors ( ActRII) , with anabolic action on skeletal muscle mass by blocking binding of myostatin and other",
            "probability": 0.0
        },
        {
            "start_logit": -3.923828125,
            "end_logit": -1.6650390625,
            "text": "ActRII",
            "probability": 0.0
        },
        {
            "start_logit": -4.9921875,
            "end_logit": -1.6650390625,
            "text": "receptors ( ActRII",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_8": [
        {
            "start_logit": 10.0546875,
            "end_logit": 8.2265625,
            "text": "activin type II receptors",
            "probability": 0.984375
        },
        {
            "start_logit": 10.0546875,
            "end_logit": 4.03515625,
            "text": "activin type II receptors ( ActRII",
            "probability": 0.01494598388671875
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -4.59765625,
            "text": "activin type II",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -5.7578125,
            "text": "activin",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -6.953125,
            "text": "activin type II receptors ( ActRI",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -7.765625,
            "text": "activin type",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.486328125,
            "end_logit": 4.03515625,
            "text": "ActRII",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 8.2265625,
            "text": "type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 8.2265625,
            "text": "receptors",
            "probability": 0.0
        },
        {
            "start_logit": 10.0546875,
            "end_logit": -10.140625,
            "text": "activin type II receptors (",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 8.2265625,
            "text": "blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 8.2265625,
            "text": "II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 8.2265625,
            "text": "human monoclonal antibody that exerts strong promyogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 8.2265625,
            "text": "promyogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 8.2265625,
            "text": "strong promyogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 8.2265625,
            "text": "( BYM338 ) is a novel fully human monoclonal antibody that exerts strong promyogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 8.2265625,
            "text": "skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -7.87109375,
            "end_logit": 4.03515625,
            "text": "type II receptors ( ActRII",
            "probability": 0.0
        },
        {
            "start_logit": -7.9296875,
            "end_logit": 4.03515625,
            "text": "receptors ( ActRII",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": 4.03515625,
            "text": "( ActRII",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_9": [
        {
            "start_logit": 10.5234375,
            "end_logit": 7.53125,
            "text": "activin type II receptors",
            "probability": 0.92333984375
        },
        {
            "start_logit": 10.5234375,
            "end_logit": 5.046875,
            "text": "activin type II receptors (ActRII",
            "probability": 0.07635498046875
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -3.708984375,
            "text": "activin type II",
            "probability": 1.1980533599853516e-05
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -4.65234375,
            "text": "activin type II receptors (ActRII).",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 0.64501953125,
            "end_logit": 5.046875,
            "text": "ActRII",
            "probability": 3.933906555175781e-06
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -5.37109375,
            "text": "activin",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -7.5,
            "text": "activin type II receptors (ActRI",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -7.578125,
            "text": "activin type",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.5234375,
            "end_logit": -9.765625,
            "text": "activin type II receptors (ActRII)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 7.53125,
            "text": "type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 7.53125,
            "text": "receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.2734375,
            "end_logit": 7.53125,
            "text": "blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 7.53125,
            "text": "II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -7.69921875,
            "end_logit": 5.046875,
            "text": "I",
            "probability": 0.0
        },
        {
            "start_logit": -7.8203125,
            "end_logit": 5.046875,
            "text": "type II receptors (ActRII",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 7.53125,
            "text": "human monoclonal antibody that exerts strong promyogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 7.53125,
            "text": "promyogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 7.53125,
            "text": "strong promyogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 7.53125,
            "text": "skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 7.53125,
            "text": "(BYM338) is a novel fully human monoclonal antibody that exerts strong promyogenic effects on skeletal muscle by blocking activin type II receptors",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_10": [
        {
            "start_logit": 10.640625,
            "end_logit": 12.5,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": 2.404296875,
            "text": "activin type II receptors (ActRII",
            "probability": 4.1365623474121094e-05
        },
        {
            "start_logit": 10.640625,
            "end_logit": -2.818359375,
            "text": "activin type II",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.140625,
            "end_logit": 12.5,
            "text": "receptors",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.94921875,
            "end_logit": 12.5,
            "text": "type II receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.640625,
            "end_logit": -4.90234375,
            "text": "activin",
            "probability": 0.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": -7.34375,
            "text": "activin type",
            "probability": 0.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": -7.9140625,
            "text": "activin type II receptors (ActRI",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 12.5,
            "text": "BACKGROUND Bimagrumab is a human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.828125,
            "end_logit": 12.5,
            "text": "II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 12.5,
            "text": "Bimagrumab is a human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -0.3037109375,
            "end_logit": 2.404296875,
            "text": "ActRII",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 12.5,
            "text": "of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 12.5,
            "text": "human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": -8.7109375,
            "text": "activin type II receptors (ActRII)",
            "probability": 0.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": -9.28125,
            "text": "activin type II receptors (ActRII),",
            "probability": 0.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": -10.09375,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin",
            "probability": 0.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": -10.2578125,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and",
            "probability": 0.0
        },
        {
            "start_logit": 10.640625,
            "end_logit": -10.3203125,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and other",
            "probability": 0.0
        },
        {
            "start_logit": -5.140625,
            "end_logit": 2.404296875,
            "text": "receptors (ActRII",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_11": [
        {
            "start_logit": 13.9609375,
            "end_logit": 14.7890625,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": -2.5625,
            "end_logit": 14.7890625,
            "text": "receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -2.130859375,
            "text": "activin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -3.34375,
            "text": "activin type II",
            "probability": 0.0
        },
        {
            "start_logit": -6.921875,
            "end_logit": 14.7890625,
            "text": "type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": 14.7890625,
            "text": "RATIONALE Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -6.765625,
            "text": "activin type",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -8.2265625,
            "text": "activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
            "probability": 0.0
        },
        {
            "start_logit": -9.1328125,
            "end_logit": 14.7890625,
            "text": "the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 14.7890625,
            "text": "II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 14.7890625,
            "text": "Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 14.7890625,
            "text": "human monoclonal antibody that blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 14.7890625,
            "text": "blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -9.859375,
            "text": "activin type II receptors,",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -10.1171875,
            "text": "activin type II receptors, preventing the activity of myostatin",
            "probability": 0.0
        },
        {
            "start_logit": 13.9609375,
            "end_logit": -10.28125,
            "text": "activin type II receptors, preventing the activity of myostatin and",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -2.130859375,
            "text": "RATIONALE Bimagrumab is a fully human monoclonal antibody that blocks the activin",
            "probability": 0.0
        },
        {
            "start_logit": -6.921875,
            "end_logit": -3.34375,
            "text": "type II",
            "probability": 0.0
        },
        {
            "start_logit": -2.5625,
            "end_logit": -8.2265625,
            "text": "receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
            "probability": 0.0
        },
        {
            "start_logit": -7.48046875,
            "end_logit": -3.34375,
            "text": "RATIONALE Bimagrumab is a fully human monoclonal antibody that blocks the activin type II",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_12": [
        {
            "start_logit": 12.25,
            "end_logit": 13.5078125,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": 12.25,
            "end_logit": -1.0517578125,
            "text": "activin type II receptors (ActRII",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 12.25,
            "end_logit": -2.109375,
            "text": "activin type II",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.28515625,
            "end_logit": 13.5078125,
            "text": "receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.25,
            "end_logit": -3.83984375,
            "text": "activin",
            "probability": 0.0
        },
        {
            "start_logit": -6.07421875,
            "end_logit": 13.5078125,
            "text": "type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 12.25,
            "end_logit": -7.2734375,
            "text": "activin type",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": 13.5078125,
            "text": "Bimagrumab is a human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 12.25,
            "end_logit": -8.203125,
            "text": "activin type II receptors (ActRII)",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": 13.5078125,
            "text": "II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 12.25,
            "end_logit": -8.7265625,
            "text": "activin type II receptors (ActRI",
            "probability": 0.0
        },
        {
            "start_logit": 12.25,
            "end_logit": -9.0,
            "text": "activin type II receptors (ActRII),",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 13.5078125,
            "text": "of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 13.5078125,
            "text": "human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 13.5078125,
            "text": "agrumab is a human monoclonal antibody inhibitor of activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 12.25,
            "end_logit": -9.9765625,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin",
            "probability": 0.0
        },
        {
            "start_logit": 12.25,
            "end_logit": -10.21875,
            "text": "activin type II receptors (ActRII), with anabolic action on skeletal muscle mass by blocking binding of myostatin and",
            "probability": 0.0
        },
        {
            "start_logit": -3.6171875,
            "end_logit": -1.0517578125,
            "text": "ActRII",
            "probability": 0.0
        },
        {
            "start_logit": -4.28515625,
            "end_logit": -1.0517578125,
            "text": "receptors (ActRII",
            "probability": 0.0
        },
        {
            "start_logit": -6.07421875,
            "end_logit": -1.0517578125,
            "text": "type II receptors (ActRII",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_13": [
        {
            "start_logit": 13.7734375,
            "end_logit": 14.7265625,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": -2.6640625,
            "end_logit": 14.7265625,
            "text": "receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.7734375,
            "end_logit": -2.0546875,
            "text": "activin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.7734375,
            "end_logit": -3.75390625,
            "text": "activin type II",
            "probability": 0.0
        },
        {
            "start_logit": -5.8828125,
            "end_logit": 14.7265625,
            "text": "type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.7734375,
            "end_logit": -6.88671875,
            "text": "activin type",
            "probability": 0.0
        },
        {
            "start_logit": 13.7734375,
            "end_logit": -7.42578125,
            "text": "activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
            "probability": 0.0
        },
        {
            "start_logit": -8.671875,
            "end_logit": 14.7265625,
            "text": "Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 14.7265625,
            "text": "the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 14.7265625,
            "text": "II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 14.7265625,
            "text": "human monoclonal antibody that blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.7734375,
            "end_logit": -9.6171875,
            "text": "activin type II receptors,",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 14.7265625,
            "text": "blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 14.7265625,
            "text": "agrumab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 14.7265625,
            "text": "umab is a fully human monoclonal antibody that blocks the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.7734375,
            "end_logit": -10.0859375,
            "text": "activin type II receptors, preventing the activity of myostatin",
            "probability": 0.0
        },
        {
            "start_logit": 13.7734375,
            "end_logit": -10.234375,
            "text": "activin type II receptors, preventing the activity of myostatin and",
            "probability": 0.0
        },
        {
            "start_logit": -5.8828125,
            "end_logit": -3.75390625,
            "text": "type II",
            "probability": 0.0
        },
        {
            "start_logit": -2.6640625,
            "end_logit": -7.42578125,
            "text": "receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.",
            "probability": 0.0
        },
        {
            "start_logit": -8.671875,
            "end_logit": -2.0546875,
            "text": "Bimagrumab is a fully human monoclonal antibody that blocks the activin",
            "probability": 0.0
        }
    ],
    "5e44b04c48dab47f26000016_14": [
        {
            "start_logit": 13.9453125,
            "end_logit": 14.7421875,
            "text": "activin type II receptors",
            "probability": 1.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -1.1884765625,
            "text": "activin type II",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.4296875,
            "end_logit": 14.7421875,
            "text": "receptors",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -2.267578125,
            "text": "activin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -6.5234375,
            "text": "activin type",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": 14.7421875,
            "text": "type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.2578125,
            "end_logit": 14.7421875,
            "text": "the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": 14.7421875,
            "text": "II receptors",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": 14.7421875,
            "text": "through the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -8.8359375,
            "text": "activin type II receptors with",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.2890625,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD and low muscle mass.",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.296875,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 14.7421875,
            "text": "Blocking the action of negative muscle regulators through the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.8515625,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -9.9921875,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 14.7421875,
            "text": "muscle regulators through the activin type II receptors",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -10.2109375,
            "text": "activin type II receptors with bimagr",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -10.2734375,
            "text": "activin type II receptors with bimagrumab",
            "probability": 0.0
        },
        {
            "start_logit": 13.9453125,
            "end_logit": -10.359375,
            "text": "activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did",
            "probability": 0.0
        },
        {
            "start_logit": -7.5546875,
            "end_logit": -1.1884765625,
            "text": "type II",
            "probability": 0.0
        }
    ],
    "5e776443835f4e4777000008_1": [
        {
            "start_logit": 10.0078125,
            "end_logit": 10.078125,
            "text": "Astellas Pharma GmbH",
            "probability": 0.9912109375
        },
        {
            "start_logit": 10.0078125,
            "end_logit": 5.36328125,
            "text": "Astellas Pharma",
            "probability": 0.00885009765625
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -3.505859375,
            "text": "Astellas Pharm",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -3.63671875,
            "end_logit": 10.078125,
            "text": "s Pharma GmbH",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -4.1796875,
            "end_logit": 10.078125,
            "text": "GmbH",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -4.87890625,
            "end_logit": 10.078125,
            "text": "H",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -4.90625,
            "end_logit": 10.078125,
            "text": ", Astellas Pharma GmbH",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -5.43359375,
            "text": "Astellas Pharma Gm",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -5.73046875,
            "text": "Astella",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.2578125,
            "end_logit": 10.078125,
            "text": "Pharma GmbH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -6.48828125,
            "text": "Ast",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.859375,
            "end_logit": 10.078125,
            "text": "ellas Pharma GmbH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 10.078125,
            "text": "a GmbH",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.63671875,
            "end_logit": 5.36328125,
            "text": "s Pharma",
            "probability": 0.0
        },
        {
            "start_logit": -8.8125,
            "end_logit": 10.078125,
            "text": "bH",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -8.7890625,
            "text": "Astellas Pharma Gmb",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -9.3125,
            "text": "Astellas",
            "probability": 0.0
        },
        {
            "start_logit": -4.90625,
            "end_logit": 5.36328125,
            "text": ", Astellas Pharma",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -9.5859375,
            "text": "Astellas Pharma GmbH) in patients with advanced prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -9.7109375,
            "text": "Astellas Pharma GmbH) in patients with advanced prostate cancer treated in routine clinical practice in Germany.",
            "probability": 0.0
        }
    ],
    "5e7641a0c6a8763d23000011_1": [
        {
            "start_logit": 13.796875,
            "end_logit": 14.2578125,
            "text": "Vaxchora",
            "probability": 1.0
        },
        {
            "start_logit": -3.115234375,
            "end_logit": 14.2578125,
            "text": "ora",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.796875,
            "end_logit": -3.275390625,
            "text": "Va",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 14.2578125,
            "text": "xchora",
            "probability": 0.0
        },
        {
            "start_logit": -6.62890625,
            "end_logit": 14.2578125,
            "text": "chora",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -7.3828125,
            "text": "Vax",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -7.58203125,
            "text": "Vaxch",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -7.9375,
            "text": "Vaxchora:",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -9.2421875,
            "text": "Vaxchora: The First FDA-Approved Cholera Vaccination in the United States.",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -10.203125,
            "text": "Vaxchora: The First FDA-Approved Cholera",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -10.2265625,
            "text": "Vaxchora: The First FDA-Approved Cholera Vaccination",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -10.2578125,
            "text": "Vaxchora: The First FDA",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -10.3359375,
            "text": "Vaxchora: The First FDA-Approved Cholera Vaccination in the United States",
            "probability": 0.0
        },
        {
            "start_logit": 13.796875,
            "end_logit": -10.375,
            "text": "Vaxchora: The First",
            "probability": 0.0
        },
        {
            "start_logit": -3.115234375,
            "end_logit": -7.9375,
            "text": "ora:",
            "probability": 0.0
        },
        {
            "start_logit": -3.115234375,
            "end_logit": -9.2421875,
            "text": "ora: The First FDA-Approved Cholera Vaccination in the United States.",
            "probability": 0.0
        },
        {
            "start_logit": -3.115234375,
            "end_logit": -10.203125,
            "text": "ora: The First FDA-Approved Cholera",
            "probability": 0.0
        },
        {
            "start_logit": -3.115234375,
            "end_logit": -10.2265625,
            "text": "ora: The First FDA-Approved Cholera Vaccination",
            "probability": 0.0
        },
        {
            "start_logit": -3.115234375,
            "end_logit": -10.2578125,
            "text": "ora: The First FDA",
            "probability": 0.0
        },
        {
            "start_logit": -3.115234375,
            "end_logit": -10.3359375,
            "text": "ora: The First FDA-Approved Cholera Vaccination in the United States",
            "probability": 0.0
        }
    ],
    "5e7641a0c6a8763d23000011_2": [
        {
            "start_logit": 13.9140625,
            "end_logit": 14.2734375,
            "text": "Vaxchora",
            "probability": 1.0
        },
        {
            "start_logit": -3.15234375,
            "end_logit": 14.2734375,
            "text": "ora",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -3.115234375,
            "text": "Va",
            "probability": 0.0
        },
        {
            "start_logit": -6.234375,
            "end_logit": 14.2734375,
            "text": "xchora",
            "probability": 0.0
        },
        {
            "start_logit": -6.625,
            "end_logit": 14.2734375,
            "text": "chora",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -7.44921875,
            "text": "Vax",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -7.578125,
            "text": "Vaxch",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -8.3515625,
            "text": "Vaxchora is",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -8.828125,
            "text": "Vaxchora is the first vaccine approved by the Food and Drug Administration for the prophylaxis of cholera infection.",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -9.734375,
            "text": "Vaxchora is the first",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -9.890625,
            "text": "Vaxchora is the first vaccine approved by the Food and Drug Administration for the prophylaxis of cholera infection",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -9.9140625,
            "text": "Vaxchora is the first vaccine approved by the Food and Drug Administration",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -9.9375,
            "text": "Vaxchora is the first vaccine approved by the Food and Drug Administration for the prophylaxis",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -10.0546875,
            "text": "Vaxchora is the first vaccine approved by the Food and Drug Administration for the prophylaxis of cholera",
            "probability": 0.0
        },
        {
            "start_logit": 13.9140625,
            "end_logit": -10.09375,
            "text": "Vaxchora is the first vaccine",
            "probability": 0.0
        },
        {
            "start_logit": -3.15234375,
            "end_logit": -8.3515625,
            "text": "ora is",
            "probability": 0.0
        },
        {
            "start_logit": -3.15234375,
            "end_logit": -8.828125,
            "text": "ora is the first vaccine approved by the Food and Drug Administration for the prophylaxis of cholera infection.",
            "probability": 0.0
        },
        {
            "start_logit": -3.15234375,
            "end_logit": -9.734375,
            "text": "ora is the first",
            "probability": 0.0
        },
        {
            "start_logit": -3.15234375,
            "end_logit": -9.890625,
            "text": "ora is the first vaccine approved by the Food and Drug Administration for the prophylaxis of cholera infection",
            "probability": 0.0
        },
        {
            "start_logit": -3.15234375,
            "end_logit": -9.9140625,
            "text": "ora is the first vaccine approved by the Food and Drug Administration",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_1": [
        {
            "start_logit": 14.375,
            "end_logit": 15.1953125,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.900390625,
            "end_logit": 15.1953125,
            "text": "xin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.375,
            "end_logit": -2.376953125,
            "text": "frataxin expression, a",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -2.384765625,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -4.01953125,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -7.140625,
            "text": "frataxin expression,",
            "probability": 0.0
        },
        {
            "start_logit": -8.421875,
            "end_logit": 15.1953125,
            "text": "FRDA) is caused by a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -8.6796875,
            "text": "frataxin expression",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 15.1953125,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 15.1953125,
            "text": "(FRDA) is caused by a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 15.1953125,
            "text": "accepted that Friedreich's ataxia (FRDA) is caused by a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 15.1953125,
            "text": "Friedreich's ataxia (FRDA) is caused by a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 15.1953125,
            "text": "It is generally accepted that Friedreich's ataxia (FRDA) is caused by a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -9.59375,
            "text": "frataxin expression, a mitochondrial protein involved in iron homeostasis, which mainly",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 15.1953125,
            "text": "generally accepted that Friedreich's ataxia (FRDA) is caused by a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -9.6953125,
            "text": "frataxin expression, a mitochondrial protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 15.1953125,
            "text": "DA) is caused by a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -9.734375,
            "text": "frataxin expression, a mitochondrial protein involved in iron homeostasis, which",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 15.1953125,
            "text": "in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -9.7890625,
            "text": "frataxin expression, a mitochondrial protein involved in iron homeostasis,",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_2": [
        {
            "start_logit": 14.0390625,
            "end_logit": 14.9921875,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -2.265625,
            "end_logit": 14.9921875,
            "text": "xin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -2.62890625,
            "text": "frataxin, a",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -3.10546875,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -3.56640625,
            "text": "frataxin,",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -5.27734375,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 14.9921875,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -8.7109375,
            "text": "frataxin, a mitochondrial protein that stimulates iron-sulfur (Fe-S) cluster biogenesis",
            "probability": 0.0
        },
        {
            "start_logit": -9.75,
            "end_logit": 14.9921875,
            "text": "Friedreich's ataxia is a severe neurodegenerative disease caused by the decreased expression of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -9.4921875,
            "text": "frataxin, a mitochondrial protein that stimulates iron-sulfur (Fe-S) cluster",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 14.9921875,
            "text": "of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.9921875,
            "text": "neurodegenerative disease caused by the decreased expression of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 14.9921875,
            "text": "decreased expression of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 14.9921875,
            "text": "ich's ataxia is a severe neurodegenerative disease caused by the decreased expression of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 14.9921875,
            "text": "reich's ataxia is a severe neurodegenerative disease caused by the decreased expression of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -9.9453125,
            "text": "frataxin, a mitochondrial",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 14.9921875,
            "text": "severe neurodegenerative disease caused by the decreased expression of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 14.9921875,
            "text": "'s ataxia is a severe neurodegenerative disease caused by the decreased expression of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -10.0390625,
            "text": "frataxin, a mitochondrial protein",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 14.9921875,
            "text": "s ataxia is a severe neurodegenerative disease caused by the decreased expression of frataxin",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_3": [
        {
            "start_logit": 13.828125,
            "end_logit": 14.859375,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": 14.859375,
            "text": "xin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.828125,
            "end_logit": -3.359375,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -5.0625,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -7.6171875,
            "text": "frataxin deficiency (FXN",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -7.9296875,
            "text": "frataxin deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -9.3671875,
            "end_logit": 14.859375,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.203125,
            "text": "frataxin deficiency (FX",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 14.859375,
            "text": "eukaryotes, frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.578125,
            "text": "frataxin deficiency (FXN) causes severe phenotypes including loss of iron-sulfur (Fe-S) cluster",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 14.859375,
            "text": ", frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 14.859375,
            "text": "In eukaryotes, frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.921875,
            "text": "frataxin deficiency (FXN)",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -9.9765625,
            "text": "frataxin deficiency (FXN) causes",
            "probability": 0.0
        },
        {
            "start_logit": 13.828125,
            "end_logit": -10.109375,
            "text": "frataxin deficiency (FXN) causes severe",
            "probability": 0.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -7.6171875,
            "text": "xin deficiency (FXN",
            "probability": 0.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -7.9296875,
            "text": "xin deficiency",
            "probability": 0.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -9.203125,
            "text": "xin deficiency (FX",
            "probability": 0.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -9.578125,
            "text": "xin deficiency (FXN) causes severe phenotypes including loss of iron-sulfur (Fe-S) cluster",
            "probability": 0.0
        },
        {
            "start_logit": -2.404296875,
            "end_logit": -9.859375,
            "text": "xin deficiency (FXN) causes severe phenotypes including loss of iron-sulfur (Fe-S) cluster protein activity, accumulation of mitochondrial iron and",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_4": [
        {
            "start_logit": 14.4765625,
            "end_logit": 15.3046875,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.5810546875,
            "end_logit": 15.3046875,
            "text": "xin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -2.060546875,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -3.95703125,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -5.12890625,
            "text": "frataxin,",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -7.28515625,
            "text": "frataxin, the",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 15.3046875,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.0,
            "text": "frataxin, the mitochondrial protein",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.296875,
            "text": "frataxin, the mitochondrial protein defective in patients with Friedreich's ataxia,",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.3359375,
            "text": "frataxin, the mitochondrial",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 15.3046875,
            "text": "Complete absence of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 15.3046875,
            "text": "of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 15.3046875,
            "text": "absence of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.8203125,
            "text": "frataxin, the mitochondrial protein defective in patients with Friedreich's ataxia",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.8515625,
            "text": "frataxin, the mitochondrial protein defective in patients with Friedreich's ataxia, is lethal in C. elegans, while",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -10.0625,
            "text": "frataxin, the mitochondrial protein defective in patients with Friedreich's ataxia, is",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -10.1015625,
            "text": "frataxin, the mitochondrial protein defective in patients with Friedreich's ataxia, is lethal in",
            "probability": 0.0
        },
        {
            "start_logit": -1.5810546875,
            "end_logit": -5.12890625,
            "text": "xin,",
            "probability": 0.0
        },
        {
            "start_logit": -1.5810546875,
            "end_logit": -7.28515625,
            "text": "xin, the",
            "probability": 0.0
        },
        {
            "start_logit": -1.5810546875,
            "end_logit": -9.0,
            "text": "xin, the mitochondrial protein",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_5": [
        {
            "start_logit": 14.390625,
            "end_logit": 15.1953125,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.91796875,
            "end_logit": 15.1953125,
            "text": "xin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.390625,
            "end_logit": -2.298828125,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -4.2421875,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": -7.62109375,
            "end_logit": 15.1953125,
            "text": "Friedreich ataxia (FRDA) is a neurodegenerative disease characterized by a decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 15.1953125,
            "text": "FRDA) is a neurodegenerative disease characterized by a decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -7.71875,
            "end_logit": 15.1953125,
            "text": "protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.390625,
            "end_logit": -7.33984375,
            "text": "frataxin.",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 15.1953125,
            "text": "(FRDA) is a neurodegenerative disease characterized by a decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 15.1953125,
            "text": "DA) is a neurodegenerative disease characterized by a decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 15.1953125,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 15.1953125,
            "text": "mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.1875,
            "end_logit": 15.1953125,
            "text": ") is a neurodegenerative disease characterized by a decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 15.1953125,
            "text": "ich ataxia (FRDA) is a neurodegenerative disease characterized by a decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 15.1953125,
            "text": "the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 15.1953125,
            "text": "reich ataxia (FRDA) is a neurodegenerative disease characterized by a decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 15.1953125,
            "text": "decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 15.1953125,
            "text": "ataxia (FRDA) is a neurodegenerative disease characterized by a decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 15.1953125,
            "text": "expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -1.91796875,
            "end_logit": -7.33984375,
            "text": "xin.",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_6": [
        {
            "start_logit": 14.4140625,
            "end_logit": 15.21875,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.884765625,
            "end_logit": 15.21875,
            "text": "xin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -2.251953125,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -3.87890625,
            "text": "frataxin,",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -4.34375,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": -7.32421875,
            "end_logit": 15.21875,
            "text": "protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -7.76171875,
            "text": "frataxin, which",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -8.1875,
            "text": "frataxin, which carries single point mutations in some patients.",
            "probability": 0.0
        },
        {
            "start_logit": -9.015625,
            "end_logit": 15.21875,
            "text": "Friedreich's ataxia results from a deficiency in the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 15.21875,
            "text": "mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 15.21875,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -9.421875,
            "text": "frataxin, which carries",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -9.5234375,
            "text": "frataxin, which carries single point mutations in some",
            "probability": 0.0
        },
        {
            "start_logit": -10.546875,
            "end_logit": 15.21875,
            "text": "the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 15.21875,
            "text": "reich's ataxia results from a deficiency in the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 15.21875,
            "text": "ich's ataxia results from a deficiency in the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -1.884765625,
            "end_logit": -3.87890625,
            "text": "xin,",
            "probability": 0.0
        },
        {
            "start_logit": -7.32421875,
            "end_logit": -2.251953125,
            "text": "protein fra",
            "probability": 0.0
        },
        {
            "start_logit": -1.884765625,
            "end_logit": -7.76171875,
            "text": "xin, which",
            "probability": 0.0
        },
        {
            "start_logit": -1.884765625,
            "end_logit": -8.1875,
            "text": "xin, which carries single point mutations in some patients.",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_7": [
        {
            "start_logit": 14.265625,
            "end_logit": 15.1640625,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -2.05078125,
            "end_logit": 15.1640625,
            "text": "xin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.265625,
            "end_logit": -2.662109375,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -4.515625,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -4.91796875,
            "text": "frataxin,",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -5.34375,
            "text": "frataxin, a",
            "probability": 0.0
        },
        {
            "start_logit": -8.828125,
            "end_logit": 15.1640625,
            "text": "Friedreich's ataxia (FRDA), an autosomal recessive cardio- and neurodegenerative disease, is caused by low expression of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -8.2734375,
            "text": "frataxin, a small mitochondrial protein, encoded in the nucleus.",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 15.1640625,
            "text": "FRDA), an autosomal recessive cardio- and neurodegenerative disease, is caused by low expression of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -8.890625,
            "text": "frataxin, a small",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.015625,
            "text": "frataxin, a small mitochondrial protein",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 15.1640625,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 15.1640625,
            "text": "low expression of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.328125,
            "text": "frataxin, a small mitochondrial protein, encoded in the nucleus",
            "probability": 0.0
        },
        {
            "start_logit": 14.265625,
            "end_logit": -9.4375,
            "text": "frataxin, a small mitochondrial protein, encoded",
            "probability": 0.0
        },
        {
            "start_logit": -10.359375,
            "end_logit": 15.1640625,
            "text": "of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 15.1640625,
            "text": "DA), an autosomal recessive cardio- and neurodegenerative disease, is caused by low expression of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.1640625,
            "text": "cardio- and neurodegenerative disease, is caused by low expression of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.1640625,
            "text": "(FRDA), an autosomal recessive cardio- and neurodegenerative disease, is caused by low expression of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 15.1640625,
            "text": "expression of frataxin",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_8": [
        {
            "start_logit": 14.375,
            "end_logit": 15.1796875,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.8916015625,
            "end_logit": 15.1796875,
            "text": "xin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.375,
            "end_logit": -2.353515625,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -4.1875,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": 15.1796875,
            "text": "protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -7.03125,
            "text": "frataxin, encoded by the X",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -7.30859375,
            "text": "frataxin,",
            "probability": 0.0
        },
        {
            "start_logit": -9.1875,
            "end_logit": 15.1796875,
            "text": "The severe reduction in mRNA and protein levels of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -8.65625,
            "text": "frataxin, encoded by the X25 gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": 15.1796875,
            "text": "mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 15.1796875,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 15.1796875,
            "text": "the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -9.2578125,
            "text": "frataxin, encoded by the X25",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -9.6171875,
            "text": "frataxin, encoded by the X25 gene, causes Friedreich ataxia (FRDA), the most common form of recessive hereditary ataxia.",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -9.6640625,
            "text": "frataxin, encoded by the X25 gene, causes Friedreich ataxia (FRDA",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -9.6953125,
            "text": "frataxin, encoded by the X25 gene,",
            "probability": 0.0
        },
        {
            "start_logit": 14.375,
            "end_logit": -9.796875,
            "text": "frataxin, encoded by the X25 gene, causes Friedreich ataxia",
            "probability": 0.0
        },
        {
            "start_logit": -1.8916015625,
            "end_logit": -7.03125,
            "text": "xin, encoded by the X",
            "probability": 0.0
        },
        {
            "start_logit": -1.8916015625,
            "end_logit": -7.30859375,
            "text": "xin,",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -2.353515625,
            "text": "protein fra",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_9": [
        {
            "start_logit": 14.4140625,
            "end_logit": 15.2734375,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.6865234375,
            "end_logit": 15.2734375,
            "text": "xin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -2.216796875,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -3.98046875,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": -6.15625,
            "end_logit": 15.2734375,
            "text": "human frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -6.65625,
            "text": "frataxin,",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -7.57421875,
            "text": "frataxin, the protein deficient in Friedreich ataxia.",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -9.03125,
            "text": "frataxin, the protein deficient in Friedreich ataxia",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 15.2734375,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -9.15625,
            "text": "frataxin, the protein deficient",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -9.4375,
            "text": "frataxin, the protein",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -9.5390625,
            "text": "frataxin, the protein deficient in Fried",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -9.578125,
            "text": "frataxin, the protein deficient in Friedreich",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -9.703125,
            "text": "frataxin, the protein deficient in Friedre",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 15.2734375,
            "text": "of human frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 15.2734375,
            "text": "-binding properties of human frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -1.6865234375,
            "end_logit": -6.65625,
            "text": "xin,",
            "probability": 0.0
        },
        {
            "start_logit": -6.15625,
            "end_logit": -2.216796875,
            "text": "human fra",
            "probability": 0.0
        },
        {
            "start_logit": -1.6865234375,
            "end_logit": -7.57421875,
            "text": "xin, the protein deficient in Friedreich ataxia.",
            "probability": 0.0
        },
        {
            "start_logit": -6.15625,
            "end_logit": -3.98046875,
            "text": "human frata",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_10": [
        {
            "start_logit": 14.453125,
            "end_logit": 15.234375,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.8623046875,
            "end_logit": 15.234375,
            "text": "xin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.453125,
            "end_logit": -2.11328125,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -3.751953125,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": -7.1328125,
            "end_logit": 15.234375,
            "text": "Friedreich ataxia is a human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 15.234375,
            "text": "protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -7.57421875,
            "text": "frataxin.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 15.234375,
            "text": "mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 15.234375,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": 15.234375,
            "text": "human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 15.234375,
            "text": "decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 15.234375,
            "text": "ich ataxia is a human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 15.234375,
            "text": "reich ataxia is a human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 15.234375,
            "text": "the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 15.234375,
            "text": "expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 15.234375,
            "text": "myocardial disease caused by decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 15.234375,
            "text": "ataxia is a human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -7.1328125,
            "end_logit": -2.11328125,
            "text": "Friedreich ataxia is a human neurodegenerative and myocardial disease caused by decreased expression of the mitochondrial protein fra",
            "probability": 0.0
        },
        {
            "start_logit": -1.8623046875,
            "end_logit": -7.57421875,
            "text": "xin.",
            "probability": 0.0
        },
        {
            "start_logit": -7.3359375,
            "end_logit": -2.11328125,
            "text": "protein fra",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_11": [
        {
            "start_logit": 14.4140625,
            "end_logit": 15.1875,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.96484375,
            "end_logit": 15.1875,
            "text": "xin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -2.251953125,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -4.0390625,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -4.8125,
            "text": "frataxin,",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -7.73046875,
            "text": "frataxin, an",
            "probability": 0.0
        },
        {
            "start_logit": -9.1015625,
            "end_logit": 15.1875,
            "text": "Friedreich ataxia, an autosomal recessive neurodegenerative and cardiac disease, is caused by abnormally low levels of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -8.3671875,
            "text": "frataxin, an essential mitochondrial protein.",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -8.796875,
            "text": "frataxin, an essential mitochondrial protein",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 15.1875,
            "text": "of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 15.1875,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 15.1875,
            "text": "abnormally low levels of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 15.1875,
            "text": "low levels of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.4140625,
            "end_logit": -9.65625,
            "text": "frataxin, an essential",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 15.1875,
            "text": "levels of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 15.1875,
            "text": "cardiac disease, is caused by abnormally low levels of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 15.1875,
            "text": "autosomal recessive neurodegenerative and cardiac disease, is caused by abnormally low levels of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 15.1875,
            "text": "caused by abnormally low levels of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 15.1875,
            "text": "an autosomal recessive neurodegenerative and cardiac disease, is caused by abnormally low levels of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -1.96484375,
            "end_logit": -4.8125,
            "text": "xin,",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_12": [
        {
            "start_logit": 14.359375,
            "end_logit": 15.1796875,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.9775390625,
            "end_logit": 15.1796875,
            "text": "xin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.359375,
            "end_logit": -2.40625,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -4.39453125,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -5.9375,
            "text": "frataxin,",
            "probability": 0.0
        },
        {
            "start_logit": -8.125,
            "end_logit": 15.1796875,
            "text": "FRDA) is an autosomal recessive degenerative disease caused by a deficiency of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -8.8984375,
            "end_logit": 15.1796875,
            "text": "Friedreich ataxia (FRDA) is an autosomal recessive degenerative disease caused by a deficiency of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -8.453125,
            "text": "frataxin, a conserved mitochondrial protein of unknown function.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 15.1796875,
            "text": "of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -8.8203125,
            "text": "frataxin, a",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 15.1796875,
            "text": "DA) is an autosomal recessive degenerative disease caused by a deficiency of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 15.1796875,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.2578125,
            "text": "frataxin, a conserved",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 15.1796875,
            "text": "(FRDA) is an autosomal recessive degenerative disease caused by a deficiency of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.625,
            "text": "frataxin, a conserved mitochondrial protein",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.8828125,
            "text": "frataxin, a conserved mitochondrial protein of unknown function",
            "probability": 0.0
        },
        {
            "start_logit": 14.359375,
            "end_logit": -9.8828125,
            "text": "frataxin, a conserved mitochondrial protein of unknown",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 15.1796875,
            "text": "ich ataxia (FRDA) is an autosomal recessive degenerative disease caused by a deficiency of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 15.1796875,
            "text": ") is an autosomal recessive degenerative disease caused by a deficiency of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 15.1796875,
            "text": "autosomal recessive degenerative disease caused by a deficiency of frataxin",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_13": [
        {
            "start_logit": 14.2265625,
            "end_logit": 15.1484375,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.958984375,
            "end_logit": 15.1484375,
            "text": "xin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -2.642578125,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -3.763671875,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 15.1484375,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.078125,
            "text": "frataxin message",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 15.1484375,
            "text": "increase the level of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.2265625,
            "text": "frataxin message and protein.",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 15.1484375,
            "text": "Friedreich ataxia that target the GAA expanded gene and seek to increase the level of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 15.1484375,
            "text": "of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 15.1484375,
            "text": "GAA expanded gene and seek to increase the level of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 15.1484375,
            "text": "the GAA expanded gene and seek to increase the level of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 15.1484375,
            "text": "level of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 15.1484375,
            "text": "treatment strategies for Friedreich ataxia that target the GAA expanded gene and seek to increase the level of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 15.1484375,
            "text": "potential treatment strategies for Friedreich ataxia that target the GAA expanded gene and seek to increase the level of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 15.1484375,
            "text": "the level of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 15.1484375,
            "text": "the progress of potential treatment strategies for Friedreich ataxia that target the GAA expanded gene and seek to increase the level of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 15.1484375,
            "text": "to increase the level of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 15.1484375,
            "text": "gene and seek to increase the level of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -10.03125,
            "text": "frataxin message and protein",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_14": [
        {
            "start_logit": 14.28125,
            "end_logit": 15.171875,
            "text": "Frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.9169921875,
            "end_logit": 15.171875,
            "text": "xin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.28125,
            "end_logit": -2.60546875,
            "text": "Fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -3.236328125,
            "text": "Frataxin is",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -4.1328125,
            "text": "Frataxin is a",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -4.51953125,
            "text": "Frata",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -8.265625,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA) and which",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -8.546875,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA) and which is associated with abnormal intramitochondrial iron handling",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -8.5546875,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -8.8203125,
            "text": "Frataxin is a mitochondrial protein deficient",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -8.9453125,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FR",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 15.171875,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.0078125,
            "text": "Frataxin is a mitochondrial protein",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.09375,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA) and",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.1875,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.3046875,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA) and which is associated with abnormal intramitochondrial iron",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.34375,
            "text": "Frataxin is a mitochondrial",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.4609375,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA) and which is associated with",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.5,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA)",
            "probability": 0.0
        },
        {
            "start_logit": 14.28125,
            "end_logit": -9.59375,
            "text": "Frataxin is a mitochondrial protein deficient in Friedreich ataxia (FRDA) and which is associated",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_15": [
        {
            "start_logit": 14.015625,
            "end_logit": 14.9453125,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -2.3671875,
            "end_logit": 14.9453125,
            "text": "xin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.015625,
            "end_logit": -3.171875,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -4.046875,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 14.9453125,
            "text": "&apos;s ataxia) results from a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 14.9453125,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.140625,
            "end_logit": 14.9453125,
            "text": ";s ataxia) results from a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -9.3125,
            "text": "frataxin,",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -9.3671875,
            "text": "frataxin, a putative iron chaperone, and",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 14.9453125,
            "text": "apos;s ataxia) results from a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 14.9453125,
            "text": "Friedreich&apos;s ataxia) results from a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -9.7265625,
            "text": "frataxin, a putative iron chaperone,",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 14.9453125,
            "text": "in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.9453125,
            "text": "disorder FRDA (Friedreich&apos;s ataxia) results from a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -9.9296875,
            "text": "frataxin, a putative",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 14.9453125,
            "text": "The neurodegenerative disorder FRDA (Friedreich&apos;s ataxia) results from a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 14.9453125,
            "text": "FRDA (Friedreich&apos;s ataxia) results from a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 14.9453125,
            "text": "neurodegenerative disorder FRDA (Friedreich&apos;s ataxia) results from a deficiency in frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.0703125,
            "text": "frataxin, a",
            "probability": 0.0
        },
        {
            "start_logit": 14.015625,
            "end_logit": -10.1484375,
            "text": "frataxin, a putative iron chaperone, and is",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_16": [
        {
            "start_logit": 14.3828125,
            "end_logit": 15.2265625,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.765625,
            "end_logit": 15.2265625,
            "text": "xin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -2.306640625,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -4.0625,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": -8.5234375,
            "end_logit": 15.2265625,
            "text": "The Friedreich's ataxia protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -8.015625,
            "text": "frataxin modulates DNA base excision repair in prokaryotes and mammals.",
            "probability": 0.0
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 15.2265625,
            "text": "protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -8.9140625,
            "end_logit": 15.2265625,
            "text": "Friedreich's ataxia protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -8.671875,
            "text": "frataxin modulates",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 15.2265625,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -9.3515625,
            "text": "frataxin modulates DNA base excision repair in",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 15.2265625,
            "text": "ataxia protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -9.40625,
            "text": "frataxin modulates DNA base excision repair",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -9.46875,
            "text": "frataxin modulates DNA base excision",
            "probability": 0.0
        },
        {
            "start_logit": 14.3828125,
            "end_logit": -9.84375,
            "text": "frataxin modulates DNA base excision repair in prokaryotes and",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 15.2265625,
            "text": "ich's ataxia protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 15.2265625,
            "text": "'s ataxia protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 15.2265625,
            "text": "s ataxia protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 15.2265625,
            "text": "reich's ataxia protein frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -1.765625,
            "end_logit": -8.015625,
            "text": "xin modulates DNA base excision repair in prokaryotes and mammals.",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_17": [
        {
            "start_logit": 14.234375,
            "end_logit": 15.1640625,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.90625,
            "end_logit": 15.1640625,
            "text": "xin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.234375,
            "end_logit": -2.76171875,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -4.0859375,
            "text": "frataxin,",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -4.33203125,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -8.5703125,
            "text": "frataxin, a",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 15.1640625,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 15.1640625,
            "text": "of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.5859375,
            "text": "frataxin, a highly conserved nuclear-encoded protein localized in mitochondria. The DNA abnormality found in 98% of Friedreich's ataxia",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.6328125,
            "text": "frataxin, a highly conserved nuclear-encoded protein localized in mitochondria.",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 15.1640625,
            "text": "deficiency of frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.734375,
            "text": "frataxin, a highly conserved nuclear-encoded protein localized in",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.7578125,
            "text": "frataxin, a highly conserved nuclear-encoded protein",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.953125,
            "text": "frataxin, a highly conserved nuclear-encoded protein localized in mitochondria. The DNA abnormality found in 98",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.96875,
            "text": "frataxin, a highly conserved nuclear-",
            "probability": 0.0
        },
        {
            "start_logit": -1.90625,
            "end_logit": -4.0859375,
            "text": "xin,",
            "probability": 0.0
        },
        {
            "start_logit": -1.90625,
            "end_logit": -8.5703125,
            "text": "xin, a",
            "probability": 0.0
        },
        {
            "start_logit": -1.90625,
            "end_logit": -9.5859375,
            "text": "xin, a highly conserved nuclear-encoded protein localized in mitochondria. The DNA abnormality found in 98% of Friedreich's ataxia",
            "probability": 0.0
        },
        {
            "start_logit": -1.90625,
            "end_logit": -9.6328125,
            "text": "xin, a highly conserved nuclear-encoded protein localized in mitochondria.",
            "probability": 0.0
        },
        {
            "start_logit": -1.90625,
            "end_logit": -9.734375,
            "text": "xin, a highly conserved nuclear-encoded protein localized in",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_18": [
        {
            "start_logit": 14.3984375,
            "end_logit": 15.2890625,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.541015625,
            "end_logit": 15.2890625,
            "text": "xin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -2.275390625,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -3.84375,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -8.015625,
            "text": "frataxin gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 15.2890625,
            "text": "the frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 15.2890625,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 15.2890625,
            "text": "Friedreich's ataxia chromosomes is the unstable hyperexpansion of a GAA triplet repeat in the first intron of the frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.4453125,
            "text": "frataxin gene.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 15.2890625,
            "text": "of Friedreich's ataxia chromosomes is the unstable hyperexpansion of a GAA triplet repeat in the first intron of the frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 15.2890625,
            "text": "chromosomes is the unstable hyperexpansion of a GAA triplet repeat in the first intron of the frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 15.2890625,
            "text": "the unstable hyperexpansion of a GAA triplet repeat in the first intron of the frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 15.2890625,
            "text": "a GAA triplet repeat in the first intron of the frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -1.541015625,
            "end_logit": -8.015625,
            "text": "xin gene",
            "probability": 0.0
        },
        {
            "start_logit": -1.541015625,
            "end_logit": -9.4453125,
            "text": "xin gene.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -2.275390625,
            "text": "the fra",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -2.275390625,
            "text": "Friedreich's ataxia chromosomes is the unstable hyperexpansion of a GAA triplet repeat in the first intron of the fra",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -2.275390625,
            "text": "of Friedreich's ataxia chromosomes is the unstable hyperexpansion of a GAA triplet repeat in the first intron of the fra",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": -2.275390625,
            "text": "chromosomes is the unstable hyperexpansion of a GAA triplet repeat in the first intron of the fra",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": -2.275390625,
            "text": "the unstable hyperexpansion of a GAA triplet repeat in the first intron of the fra",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_19": [
        {
            "start_logit": 14.453125,
            "end_logit": 15.296875,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.552734375,
            "end_logit": 15.296875,
            "text": "xin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.453125,
            "end_logit": -2.16015625,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": -3.76953125,
            "end_logit": 15.296875,
            "text": "Drosophila frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -4.66796875,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -5.87109375,
            "text": "frataxin (dfh)",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -7.1171875,
            "text": "frataxin (",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -8.46875,
            "text": "frataxin (dfh),",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": 15.296875,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 15.296875,
            "text": ", Drosophila frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -9.453125,
            "text": "frataxin (dfh), which causes Friedreich's ataxia if mutated in humans, displayed",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -9.6953125,
            "text": "frataxin (dfh",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -9.734375,
            "text": "frataxin (dfh), which",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -10.0078125,
            "text": "frataxin (dfh), which causes Friedreich's ataxia",
            "probability": 0.0
        },
        {
            "start_logit": 14.453125,
            "end_logit": -10.0234375,
            "text": "frataxin (dfh), which causes Friedreich's ataxia if mutated in humans, displayed an interacting effect",
            "probability": 0.0
        },
        {
            "start_logit": -3.76953125,
            "end_logit": -2.16015625,
            "text": "Drosophila fra",
            "probability": 0.0
        },
        {
            "start_logit": -1.552734375,
            "end_logit": -5.87109375,
            "text": "xin (dfh)",
            "probability": 0.0
        },
        {
            "start_logit": -3.76953125,
            "end_logit": -4.66796875,
            "text": "Drosophila frata",
            "probability": 0.0
        },
        {
            "start_logit": -1.552734375,
            "end_logit": -7.1171875,
            "text": "xin (",
            "probability": 0.0
        },
        {
            "start_logit": -3.76953125,
            "end_logit": -5.87109375,
            "text": "Drosophila frataxin (dfh)",
            "probability": 0.0
        }
    ],
    "571f5c150fd6f91b68000009_20": [
        {
            "start_logit": 14.46875,
            "end_logit": 15.25,
            "text": "frataxin",
            "probability": 1.0
        },
        {
            "start_logit": -1.7548828125,
            "end_logit": 15.25,
            "text": "xin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.46875,
            "end_logit": -2.091796875,
            "text": "fra",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -3.892578125,
            "text": "frata",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 15.25,
            "text": ", frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 15.25,
            "text": "taxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 15.25,
            "text": "decreased expression of a mitochondrially targeted protein, frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -9.390625,
            "text": "frataxin, mitochondrial myopathy has not been described as a feature of the disease.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 15.25,
            "text": "the Friedreich's ataxia phenotype results from decreased expression of a mitochondrially targeted protein, frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 15.25,
            "text": "Friedreich's ataxia phenotype results from decreased expression of a mitochondrially targeted protein, frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 15.25,
            "text": "mitochondrially targeted protein, frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 15.25,
            "text": "targeted protein, frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 15.25,
            "text": "protein, frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.25,
            "text": "expression of a mitochondrially targeted protein, frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 15.25,
            "text": "Although the Friedreich's ataxia phenotype results from decreased expression of a mitochondrially targeted protein, frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -10.0859375,
            "text": "frataxin,",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 15.25,
            "text": "a mitochondrially targeted protein, frataxin",
            "probability": 0.0
        },
        {
            "start_logit": 14.46875,
            "end_logit": -10.1484375,
            "text": "frataxin, mitochondrial myopathy has not been described as a",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 15.25,
            "text": "phenotype results from decreased expression of a mitochondrially targeted protein, frataxin",
            "probability": 0.0
        },
        {
            "start_logit": -1.7548828125,
            "end_logit": -9.390625,
            "text": "xin, mitochondrial myopathy has not been described as a feature of the disease.",
            "probability": 0.0
        }
    ],
    "57136a7e1174fb1755000006_1": [
        {
            "start_logit": 9.9375,
            "end_logit": 13.84375,
            "text": "first trimester",
            "probability": 1.0
        },
        {
            "start_logit": -2.826171875,
            "end_logit": 13.84375,
            "text": "the first trimester",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -4.13671875,
            "end_logit": 13.84375,
            "text": "trimester",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 9.9375,
            "end_logit": -4.375,
            "text": "first",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 13.84375,
            "text": "during the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": 13.84375,
            "text": "fetal sex determination during the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 13.84375,
            "text": "sex determination during the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 13.84375,
            "text": "The use of cffDNA in fetal sex determination during the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -7.65234375,
            "text": "first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -9.5625,
            "text": "first trimester of pregnancy of female DMD carriers.",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -9.8203125,
            "text": "first trimester of pregnancy of female DMD",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -10.1328125,
            "text": "first trimester of pregnancy of female DMD carriers",
            "probability": 0.0
        },
        {
            "start_logit": 9.9375,
            "end_logit": -10.265625,
            "text": "first trimester of pregnancy of",
            "probability": 0.0
        },
        {
            "start_logit": -2.826171875,
            "end_logit": -4.375,
            "text": "the first",
            "probability": 0.0
        },
        {
            "start_logit": -2.826171875,
            "end_logit": -7.65234375,
            "text": "the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -4.13671875,
            "end_logit": -7.65234375,
            "text": "trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -2.826171875,
            "end_logit": -9.5625,
            "text": "the first trimester of pregnancy of female DMD carriers.",
            "probability": 0.0
        },
        {
            "start_logit": -2.826171875,
            "end_logit": -9.8203125,
            "text": "the first trimester of pregnancy of female DMD",
            "probability": 0.0
        },
        {
            "start_logit": -2.826171875,
            "end_logit": -10.1328125,
            "text": "the first trimester of pregnancy of female DMD carriers",
            "probability": 0.0
        },
        {
            "start_logit": -2.826171875,
            "end_logit": -10.265625,
            "text": "the first trimester of pregnancy of",
            "probability": 0.0
        }
    ],
    "57136a7e1174fb1755000006_2": [
        {
            "start_logit": 8.2890625,
            "end_logit": 12.8515625,
            "text": "first trimester",
            "probability": 0.99609375
        },
        {
            "start_logit": 8.2890625,
            "end_logit": 7.23046875,
            "text": "first trimester of pregnancy",
            "probability": 0.00359344482421875
        },
        {
            "start_logit": -5.0703125,
            "end_logit": 12.8515625,
            "text": "trimester",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -5.453125,
            "end_logit": 12.8515625,
            "text": "the first trimester",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -8.796875,
            "end_logit": 12.8515625,
            "text": "fetal gender determination which is significant in the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.953125,
            "end_logit": 12.8515625,
            "text": "Considerable 97.3% sensitivity and 97.3% specificity were obtained in fetal gender determination which is significant in the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.09375,
            "end_logit": 12.8515625,
            "text": "significant in the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 12.8515625,
            "text": "in the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -4.8359375,
            "text": "first",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 12.8515625,
            "text": "gender determination which is significant in the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -5.0703125,
            "end_logit": 7.23046875,
            "text": "trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 12.8515625,
            "text": "in fetal gender determination which is significant in the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -5.453125,
            "end_logit": 7.23046875,
            "text": "the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -7.18359375,
            "text": "first trimester of pregnancy.",
            "probability": 0.0
        },
        {
            "start_logit": -6.54296875,
            "end_logit": 7.23046875,
            "text": "pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": 8.2890625,
            "end_logit": -9.8046875,
            "text": "first trimester of",
            "probability": 0.0
        },
        {
            "start_logit": -8.796875,
            "end_logit": 7.23046875,
            "text": "fetal gender determination which is significant in the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": 7.23046875,
            "text": "Considerable 97.3% sensitivity and 97.3% specificity were obtained in fetal gender determination which is significant in the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": 7.23046875,
            "text": "significant in the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 7.23046875,
            "text": "in the first trimester of pregnancy",
            "probability": 0.0
        }
    ],
    "57136a7e1174fb1755000006_3": [
        {
            "start_logit": 7.23828125,
            "end_logit": 11.734375,
            "text": "first trimester",
            "probability": 0.998046875
        },
        {
            "start_logit": 7.23828125,
            "end_logit": 5.33984375,
            "text": "first trimester of pregnancy",
            "probability": 0.001674652099609375
        },
        {
            "start_logit": -4.0546875,
            "end_logit": 11.734375,
            "text": "the first trimester",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": -6.015625,
            "end_logit": 11.734375,
            "text": "trimester",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 7.23828125,
            "end_logit": -5.08984375,
            "text": "first",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 11.734375,
            "text": "fetal gender using maternal plasma cell-free fetal DNA (cffDNA) for fetal sex assessment in the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.921875,
            "end_logit": 11.734375,
            "text": "fetal sex assessment in the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.328125,
            "end_logit": 11.734375,
            "text": "in the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 11.734375,
            "text": "fetal DNA (cffDNA) for fetal sex assessment in the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 11.734375,
            "text": "prenatal diagnosis of fetal gender using maternal plasma cell-free fetal DNA (cffDNA) for fetal sex assessment in the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -4.0546875,
            "end_logit": 5.33984375,
            "text": "the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 11.734375,
            "text": "maternal plasma cell-free fetal DNA (cffDNA) for fetal sex assessment in the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 11.734375,
            "text": "cell-free fetal DNA (cffDNA) for fetal sex assessment in the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 11.734375,
            "text": "plasma cell-free fetal DNA (cffDNA) for fetal sex assessment in the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.734375,
            "text": "sex assessment in the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 11.734375,
            "text": "free fetal DNA (cffDNA) for fetal sex assessment in the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 11.734375,
            "text": "gender using maternal plasma cell-free fetal DNA (cffDNA) for fetal sex assessment in the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -6.015625,
            "end_logit": 5.33984375,
            "text": "trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -7.359375,
            "end_logit": 5.33984375,
            "text": "pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": 7.23828125,
            "end_logit": -9.609375,
            "text": "first trimester of pregnancy and",
            "probability": 0.0
        }
    ],
    "57136a7e1174fb1755000006_4": [
        {
            "start_logit": 7.09765625,
            "end_logit": 12.0390625,
            "text": "first trimester",
            "probability": 1.0
        },
        {
            "start_logit": 7.09765625,
            "end_logit": 1.3154296875,
            "text": "first trimester of pregnancy",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": -3.708984375,
            "end_logit": 12.0390625,
            "text": "the first trimester",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 12.0390625,
            "text": "trimester",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -9.78125,
            "end_logit": 12.0390625,
            "text": "fetal sex during the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 12.0390625,
            "text": "during the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 12.0390625,
            "text": "prenatal determination of fetal sex during the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.296875,
            "end_logit": 12.0390625,
            "text": "the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": 7.09765625,
            "end_logit": -5.578125,
            "text": "first",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 12.0390625,
            "text": "performed a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 12.0390625,
            "text": "published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 12.0390625,
            "text": "the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 12.0390625,
            "text": "review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 12.0390625,
            "text": "of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 0.0
        },
        {
            "start_logit": 7.09765625,
            "end_logit": -8.3671875,
            "text": "first trimester of pregnancy.",
            "probability": 0.0
        },
        {
            "start_logit": -3.708984375,
            "end_logit": 1.3154296875,
            "text": "the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": 7.09765625,
            "end_logit": -10.2421875,
            "text": "first trimester of",
            "probability": 0.0
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 1.3154296875,
            "text": "trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -7.203125,
            "end_logit": 1.3154296875,
            "text": "pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -9.1640625,
            "end_logit": 1.3154296875,
            "text": "of pregnancy",
            "probability": 0.0
        }
    ],
    "57136a7e1174fb1755000006_5": [
        {
            "start_logit": 1.9365234375,
            "end_logit": 10.8046875,
            "text": "first trimester",
            "probability": 0.97900390625
        },
        {
            "start_logit": -1.9130859375,
            "end_logit": 10.8046875,
            "text": "the first trimester",
            "probability": 0.0207977294921875
        },
        {
            "start_logit": -6.64453125,
            "end_logit": 10.8046875,
            "text": "trimester",
            "probability": 0.0001842975616455078
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 10.8046875,
            "text": "fetal sex determination during the first trimester",
            "probability": 5.7220458984375e-06
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 10.8046875,
            "text": "during the first trimester",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 10.8046875,
            "text": "sex determination during the first trimester",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 1.9365234375,
            "end_logit": -4.52734375,
            "text": "first",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 1.9365234375,
            "end_logit": -8.375,
            "text": "first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -1.9130859375,
            "end_logit": -4.52734375,
            "text": "the first",
            "probability": 0.0
        },
        {
            "start_logit": 1.9365234375,
            "end_logit": -8.4609375,
            "text": "first trimester of pregnancy of female DMD carriers",
            "probability": 0.0
        },
        {
            "start_logit": 1.9365234375,
            "end_logit": -8.8671875,
            "text": "first trimester of pregnancy of female DMD",
            "probability": 0.0
        },
        {
            "start_logit": 1.9365234375,
            "end_logit": -10.2890625,
            "text": "first trimester of pregnancy of",
            "probability": 0.0
        },
        {
            "start_logit": -1.9130859375,
            "end_logit": -8.375,
            "text": "the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -1.9130859375,
            "end_logit": -8.4609375,
            "text": "the first trimester of pregnancy of female DMD carriers",
            "probability": 0.0
        },
        {
            "start_logit": -1.9130859375,
            "end_logit": -8.8671875,
            "text": "the first trimester of pregnancy of female DMD",
            "probability": 0.0
        },
        {
            "start_logit": -1.9130859375,
            "end_logit": -10.2890625,
            "text": "the first trimester of pregnancy of",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": -4.52734375,
            "text": "fetal sex determination during the first",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -4.52734375,
            "text": "during the first",
            "probability": 0.0
        },
        {
            "start_logit": -6.64453125,
            "end_logit": -8.375,
            "text": "trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": -4.52734375,
            "text": "sex determination during the first",
            "probability": 0.0
        }
    ],
    "57136a7e1174fb1755000006_6": [
        {
            "start_logit": 5.546875,
            "end_logit": 11.6484375,
            "text": "first trimester",
            "probability": 0.9951171875
        },
        {
            "start_logit": 5.546875,
            "end_logit": 6.20703125,
            "text": "first trimester of pregnancy",
            "probability": 0.00432586669921875
        },
        {
            "start_logit": -4.65625,
            "end_logit": 11.6484375,
            "text": "the first trimester",
            "probability": 3.719329833984375e-05
        },
        {
            "start_logit": -6.1484375,
            "end_logit": 11.6484375,
            "text": "trimester",
            "probability": 8.344650268554688e-06
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 11.6484375,
            "text": "during the first trimester",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 11.6484375,
            "text": "fetal sex during the first trimester",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -4.65625,
            "end_logit": 6.20703125,
            "text": "the first trimester of pregnancy",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 11.6484375,
            "text": "prenatal determination of fetal sex during the first trimester",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.421875,
            "end_logit": 11.6484375,
            "text": "the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.6484375,
            "text": "performed a review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 11.6484375,
            "text": "published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.765625,
            "end_logit": 11.6484375,
            "text": "the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 11.6484375,
            "text": "of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 11.6484375,
            "text": "review of the published literature evaluating the use of cffDNA and ultrasound for prenatal determination of fetal sex during the first trimester",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.1484375,
            "end_logit": 6.20703125,
            "text": "trimester of pregnancy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 5.546875,
            "end_logit": -5.9375,
            "text": "first",
            "probability": 0.0
        },
        {
            "start_logit": -7.31640625,
            "end_logit": 6.20703125,
            "text": "pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 6.20703125,
            "text": "of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 6.20703125,
            "text": "during the first trimester of pregnancy",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 6.20703125,
            "text": "fetal sex during the first trimester of pregnancy",
            "probability": 0.0
        }
    ],
    "587f795d92a5b8ad44000007_1": [
        {
            "start_logit": -0.5263671875,
            "end_logit": 4.1171875,
            "text": "Left-Right Asymmetry in the Pond Snail and the Frog",
            "probability": 0.98095703125
        },
        {
            "start_logit": -4.72265625,
            "end_logit": 4.1171875,
            "text": "Formin Is Associated with Left-Right Asymmetry in the Pond Snail and the Frog",
            "probability": 0.01477813720703125
        },
        {
            "start_logit": -6.45703125,
            "end_logit": 4.1171875,
            "text": "Right Asymmetry in the Pond Snail and the Frog",
            "probability": 0.0026073455810546875
        },
        {
            "start_logit": -7.9453125,
            "end_logit": 4.1171875,
            "text": "Asymmetry in the Pond Snail and the Frog",
            "probability": 0.0005888938903808594
        },
        {
            "start_logit": -8.9296875,
            "end_logit": 4.1171875,
            "text": "-Right Asymmetry in the Pond Snail and the Frog",
            "probability": 0.00021922588348388672
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 4.1171875,
            "text": "Frog",
            "probability": 0.0001933574676513672
        },
        {
            "start_logit": -9.15625,
            "end_logit": 4.1171875,
            "text": "the Frog",
            "probability": 0.0001760721206665039
        },
        {
            "start_logit": -0.5263671875,
            "end_logit": -4.76171875,
            "text": "Left-Right Asymmetry",
            "probability": 0.00013720989227294922
        },
        {
            "start_logit": -10.03125,
            "end_logit": 4.1171875,
            "text": "in Is Associated with Left-Right Asymmetry in the Pond Snail and the Frog",
            "probability": 7.343292236328125e-05
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 4.1171875,
            "text": "with Left-Right Asymmetry in the Pond Snail and the Frog",
            "probability": 7.224082946777344e-05
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 4.1171875,
            "text": "and the Frog",
            "probability": 5.2034854888916016e-05
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 4.1171875,
            "text": "Associated with Left-Right Asymmetry in the Pond Snail and the Frog",
            "probability": 5.125999450683594e-05
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 4.1171875,
            "text": "in the Pond Snail and the Frog",
            "probability": 3.4689903259277344e-05
        },
        {
            "start_logit": -10.859375,
            "end_logit": 4.1171875,
            "text": "the Pond Snail and the Frog",
            "probability": 3.2067298889160156e-05
        },
        {
            "start_logit": -11.1875,
            "end_logit": 4.1171875,
            "text": "Snail and the Frog",
            "probability": 2.3066997528076172e-05
        },
        {
            "start_logit": -0.5263671875,
            "end_logit": -6.578125,
            "text": "Left-Right Asymmetry in",
            "probability": 2.2232532501220703e-05
        },
        {
            "start_logit": -0.5263671875,
            "end_logit": -8.9140625,
            "text": "Left-Right Asymmetry in the Pond Snail",
            "probability": 2.1457672119140625e-06
        },
        {
            "start_logit": -4.72265625,
            "end_logit": -4.76171875,
            "text": "Formin Is Associated with Left-Right Asymmetry",
            "probability": 2.0265579223632812e-06
        },
        {
            "start_logit": -0.5263671875,
            "end_logit": -8.9921875,
            "text": "Left-Right Asymmetry in the",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -0.5263671875,
            "end_logit": -9.0,
            "text": "Left-Right Asymmetry in the Pond",
            "probability": 1.9669532775878906e-06
        }
    ],
    "5a72302b2dc08e987e000005_1": [
        {
            "start_logit": 14.0390625,
            "end_logit": 14.5390625,
            "text": "Patent foramen ovale",
            "probability": 1.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": 2.953125,
            "text": "Patent foramen ovale closure",
            "probability": 9.357929229736328e-06
        },
        {
            "start_logit": -2.720703125,
            "end_logit": 14.5390625,
            "text": "e",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -2.9921875,
            "text": "Patent",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": 14.5390625,
            "text": "foramen ovale",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 14.5390625,
            "text": "ovale",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -7.703125,
            "text": "Patent foramen oval",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -8.078125,
            "text": "Patent foramen",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -8.4921875,
            "text": "Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -9.015625,
            "text": "Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -9.6484375,
            "text": "Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -9.84375,
            "text": "Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -9.859375,
            "text": "Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -10.0546875,
            "text": "Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -10.1328125,
            "text": "Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet",
            "probability": 0.0
        },
        {
            "start_logit": -2.720703125,
            "end_logit": 2.953125,
            "text": "e closure",
            "probability": 0.0
        },
        {
            "start_logit": -6.71484375,
            "end_logit": 2.953125,
            "text": "foramen ovale closure",
            "probability": 0.0
        },
        {
            "start_logit": -6.80078125,
            "end_logit": 2.953125,
            "text": "closure",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 2.953125,
            "text": "ovale closure",
            "probability": 0.0
        },
        {
            "start_logit": -2.720703125,
            "end_logit": -8.4921875,
            "text": "e closure with GORE HELEX or CARDIOFORM Septal Occluder vs",
            "probability": 0.0
        }
    ],
    "5a72302b2dc08e987e000005_2": [
        {
            "start_logit": 13.0078125,
            "end_logit": 12.6484375,
            "text": "patent foramen ovale",
            "probability": 1.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -0.44287109375,
            "text": "patent foramen ovale closure",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -4.78125,
            "text": "patent",
            "probability": 0.0
        },
        {
            "start_logit": -4.87890625,
            "end_logit": 12.6484375,
            "text": "e",
            "probability": 0.0
        },
        {
            "start_logit": -6.59375,
            "end_logit": 12.6484375,
            "text": "ovale",
            "probability": 0.0
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 12.6484375,
            "text": "foramen ovale",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -7.74609375,
            "text": "patent foramen oval",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -8.375,
            "text": "patent foramen",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -8.390625,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.5625,
            "text": "patent foramen ovale closure in conjunction",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.8515625,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.8671875,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.953125,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.9765625,
            "text": "patent foramen ovale closure in conjunction with",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -10.0390625,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -10.15625,
            "text": "patent foramen ovale closure in conjunction with antiplatelet",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 12.6484375,
            "text": "Aims The Gore REDUCE Clinical Study (REDUCE) aims to establish superiority of patent foramen ovale",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 12.6484375,
            "text": "of patent foramen ovale",
            "probability": 0.0
        },
        {
            "start_logit": -4.87890625,
            "end_logit": -0.44287109375,
            "text": "e closure",
            "probability": 0.0
        },
        {
            "start_logit": -6.59375,
            "end_logit": -0.44287109375,
            "text": "ovale closure",
            "probability": 0.0
        }
    ],
    "5a72302b2dc08e987e000005_3": [
        {
            "start_logit": 13.0078125,
            "end_logit": 12.6484375,
            "text": "patent foramen ovale",
            "probability": 1.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -0.44287109375,
            "text": "patent foramen ovale closure",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -4.78125,
            "text": "patent",
            "probability": 0.0
        },
        {
            "start_logit": -4.87890625,
            "end_logit": 12.6484375,
            "text": "e",
            "probability": 0.0
        },
        {
            "start_logit": -6.59375,
            "end_logit": 12.6484375,
            "text": "ovale",
            "probability": 0.0
        },
        {
            "start_logit": -6.77734375,
            "end_logit": 12.6484375,
            "text": "foramen ovale",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -7.74609375,
            "text": "patent foramen oval",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -8.375,
            "text": "patent foramen",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -8.390625,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.5625,
            "text": "patent foramen ovale closure in conjunction",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.8515625,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in reducing the risk of recurrent clinical ischemic stroke or new silent brain infarct in",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.8671875,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone in",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.953125,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -9.9765625,
            "text": "patent foramen ovale closure in conjunction with",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -10.0390625,
            "text": "patent foramen ovale closure in conjunction with antiplatelet therapy over antiplatelet therapy alone",
            "probability": 0.0
        },
        {
            "start_logit": 13.0078125,
            "end_logit": -10.15625,
            "text": "patent foramen ovale closure in conjunction with antiplatelet",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 12.6484375,
            "text": "Aims The Gore REDUCE Clinical Study (REDUCE) aims to establish superiority of patent foramen ovale",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 12.6484375,
            "text": "of patent foramen ovale",
            "probability": 0.0
        },
        {
            "start_logit": -4.87890625,
            "end_logit": -0.44287109375,
            "text": "e closure",
            "probability": 0.0
        },
        {
            "start_logit": -6.59375,
            "end_logit": -0.44287109375,
            "text": "ovale closure",
            "probability": 0.0
        }
    ],
    "6026ef311cb411341a0000d4_1": [
        {
            "start_logit": 13.53125,
            "end_logit": 14.09375,
            "text": "Lundbeck",
            "probability": 1.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -2.671875,
            "text": "Lundbeck Seattle BioPharmaceuticals",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.236328125,
            "end_logit": 14.09375,
            "text": "eck",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.53125,
            "end_logit": -3.78515625,
            "text": "Lun",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -4.88671875,
            "text": "Lundb",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -6.96875,
            "text": "Lundbeck Seat",
            "probability": 0.0
        },
        {
            "start_logit": -8.0390625,
            "end_logit": 14.09375,
            "text": "by Lundbeck",
            "probability": 0.0
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 14.09375,
            "text": "dbeck",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -8.3203125,
            "text": "Lundbeck Seattle",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -9.046875,
            "text": "Lundbeck Seattle BioPharmaceuticals for the prevention of migraine.",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -9.1796875,
            "text": "Lundbeck Seattle BioPharmaceuticals for the prevention of migraine",
            "probability": 0.0
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 14.09375,
            "text": "Eptinezumab, delivered by intravenous (IV) administration, is being developed by Lundbeck",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -9.4765625,
            "text": "Lundbeck Seattle BioPharmaceuticals for",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -9.7421875,
            "text": "Lundbeck Seattle BioPhar",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.09375,
            "text": "administration, is being developed by Lundbeck",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.09375,
            "text": "intravenous (IV) administration, is being developed by Lundbeck",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 14.09375,
            "text": "developed by Lundbeck",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 14.09375,
            "text": "being developed by Lundbeck",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": 14.09375,
            "text": "by intravenous (IV) administration, is being developed by Lundbeck",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": 14.09375,
            "text": "(IV) administration, is being developed by Lundbeck",
            "probability": 0.0
        }
    ],
    "624c838ee764a53204000001_1": [
        {
            "start_logit": 14.2109375,
            "end_logit": 14.875,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": -2.244140625,
            "end_logit": 14.875,
            "text": "disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -2.140625,
            "text": "Alzheimer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.36328125,
            "end_logit": 14.875,
            "text": "'s disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.00390625,
            "end_logit": 14.875,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -6.87109375,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": -8.8125,
            "end_logit": 14.875,
            "text": "presenilin genes (PSEN1 and PSEN2) are mainly responsible for causing early-onset familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 14.875,
            "text": "The presenilin genes (PSEN1 and PSEN2) are mainly responsible for causing early-onset familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 14.875,
            "text": "PSEN1 and PSEN2) are mainly responsible for causing early-onset familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -8.9765625,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 14.875,
            "text": "familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 14.875,
            "text": "causing early-onset familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -9.6328125,
            "text": "Alzheimer's disease, harboring ~300 causative mutations, and representing ~90% of all mutations associated with a very aggressive disease form.",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -9.7734375,
            "text": "Alzheimer's disease, harboring ~300 causative mutations, and representing ~90%",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 14.875,
            "text": "and PSEN2) are mainly responsible for causing early-onset familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 14.875,
            "text": "enilin genes (PSEN1 and PSEN2) are mainly responsible for causing early-onset familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -9.9765625,
            "text": "Alzheimer's disease,",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.875,
            "text": "ilin genes (PSEN1 and PSEN2) are mainly responsible for causing early-onset familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -10.046875,
            "text": "Alzheimer's disease, harboring ~300 causative mutations, and representing ~90",
            "probability": 0.0
        },
        {
            "start_logit": 14.2109375,
            "end_logit": -10.1015625,
            "text": "Alzheimer's disease, harboring ~300 causative mutations, and",
            "probability": 0.0
        }
    ],
    "624c838ee764a53204000001_2": [
        {
            "start_logit": 14.0390625,
            "end_logit": 14.3515625,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -2.40625,
            "text": "Alzheimer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.947265625,
            "end_logit": 14.3515625,
            "text": "disease",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.77734375,
            "end_logit": 14.3515625,
            "text": "PSEN1/2 genes are the leading cause of familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -6.45703125,
            "end_logit": 14.3515625,
            "text": "'s disease",
            "probability": 0.0
        },
        {
            "start_logit": -6.9140625,
            "end_logit": 14.3515625,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -6.98828125,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -8.71875,
            "text": "Alzheimer's disease (fAD).",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -8.921875,
            "text": "Alzheimer's disease (fAD",
            "probability": 0.0
        },
        {
            "start_logit": -9.3359375,
            "end_logit": 14.3515625,
            "text": "familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -9.390625,
            "text": "Alzheimer's disease (",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -9.796875,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 14.3515625,
            "text": "Loss-of-function mutations in PSEN1/2 genes are the leading cause of familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -10.0625,
            "text": "Alzheimer's disease (fAD)",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 14.3515625,
            "text": "mutations in PSEN1/2 genes are the leading cause of familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 14.3515625,
            "text": "in PSEN1/2 genes are the leading cause of familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 14.3515625,
            "text": "genes are the leading cause of familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 14.3515625,
            "text": "of familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 14.3515625,
            "text": "the leading cause of familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 14.3515625,
            "text": "/2 genes are the leading cause of familial Alzheimer's disease",
            "probability": 0.0
        }
    ],
    "624c838ee764a53204000001_3": [
        {
            "start_logit": 13.21875,
            "end_logit": 10.7109375,
            "text": "Alzheimer's disease",
            "probability": 1.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -3.181640625,
            "text": "Alzheimer's disease (AD",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 13.21875,
            "end_logit": -4.0390625,
            "text": "Alzheimer",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 13.21875,
            "end_logit": -6.1953125,
            "text": "Alzheimer's disease (AD).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.21875,
            "end_logit": -8.015625,
            "text": "Alzheimer'",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": 10.7109375,
            "text": "disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -8.5625,
            "text": "Alzheimer's disease (AD)",
            "probability": 0.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -8.84375,
            "text": "Alzheimer's disease (",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": 10.7109375,
            "text": "'s disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -9.984375,
            "text": "Alzheimer's",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 10.7109375,
            "text": "s disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 10.7109375,
            "text": "PS/PSEN) genes encoding the catalytic components of \u03b3-secretase accelerate amyloid-\u03b2 (A\u03b2) and tau pathologies in familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 10.7109375,
            "text": "familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 10.7109375,
            "text": "/PSEN) genes encoding the catalytic components of \u03b3-secretase accelerate amyloid-\u03b2 (A\u03b2) and tau pathologies in familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 10.7109375,
            "text": "amyloid-\u03b2 (A\u03b2) and tau pathologies in familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 10.7109375,
            "text": "PSEN) genes encoding the catalytic components of \u03b3-secretase accelerate amyloid-\u03b2 (A\u03b2) and tau pathologies in familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 10.7109375,
            "text": "of \u03b3-secretase accelerate amyloid-\u03b2 (A\u03b2) and tau pathologies in familial Alzheimer's disease",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -3.181640625,
            "text": "disease (AD",
            "probability": 0.0
        },
        {
            "start_logit": -6.43359375,
            "end_logit": -3.181640625,
            "text": "'s disease (AD",
            "probability": 0.0
        },
        {
            "start_logit": -7.12109375,
            "end_logit": -3.181640625,
            "text": "AD",
            "probability": 0.0
        }
    ],
    "587e07023ec846c24f000001_1": [
        {
            "start_logit": 14.1171875,
            "end_logit": 14.78125,
            "text": "PHYLUCE",
            "probability": 1.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -1.9775390625,
            "text": "PHYL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.880859375,
            "end_logit": 14.78125,
            "text": "UCE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -7.28125,
            "text": "PHYLUCE is",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.7109375,
            "text": "PHYLUCE is a",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.75,
            "text": "PHYLUCE is a software package",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.8046875,
            "text": "PHYLUCE is a software package for the analysis of conserved genomic loci",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -9.9921875,
            "text": "PHYLUCE is a software",
            "probability": 0.0
        },
        {
            "start_logit": 14.1171875,
            "end_logit": -10.21875,
            "text": "PHYLUCE is a software package for the analysis",
            "probability": 0.0
        },
        {
            "start_logit": -2.880859375,
            "end_logit": -7.28125,
            "text": "UCE is",
            "probability": 0.0
        },
        {
            "start_logit": -2.880859375,
            "end_logit": -9.7109375,
            "text": "UCE is a",
            "probability": 0.0
        },
        {
            "start_logit": -2.880859375,
            "end_logit": -9.75,
            "text": "UCE is a software package",
            "probability": 0.0
        },
        {
            "start_logit": -2.880859375,
            "end_logit": -9.8046875,
            "text": "UCE is a software package for the analysis of conserved genomic loci",
            "probability": 0.0
        },
        {
            "start_logit": -2.880859375,
            "end_logit": -9.9921875,
            "text": "UCE is a software",
            "probability": 0.0
        },
        {
            "start_logit": -2.880859375,
            "end_logit": -10.21875,
            "text": "UCE is a software package for the analysis",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": -7.28125,
            "text": "is",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": -9.7109375,
            "text": "is a",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": -9.75,
            "text": "is a software package",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": -9.8046875,
            "text": "is a software package for the analysis of conserved genomic loci",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": -9.9921875,
            "text": "is a software",
            "probability": 0.0
        }
    ],
    "587e07023ec846c24f000001_2": [
        {
            "start_logit": 13.375,
            "end_logit": 14.5078125,
            "text": "PHYLUCE",
            "probability": 1.0
        },
        {
            "start_logit": -3.376953125,
            "end_logit": 14.5078125,
            "text": "UCE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.375,
            "end_logit": -3.3203125,
            "text": "PHYL",
            "probability": 0.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 14.5078125,
            "text": ". PHYLUCE",
            "probability": 0.0
        },
        {
            "start_logit": 13.375,
            "end_logit": -8.7421875,
            "text": "PHYLUCE is",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 14.5078125,
            "text": "; align enriched contigs representing conserved loci to one another; and prepare and manipulate these alignments for subsequent phylogenomic inference. PHYLUCE",
            "probability": 0.0
        },
        {
            "start_logit": -10.2265625,
            "end_logit": 14.5078125,
            "text": "representing conserved loci to one another; and prepare and manipulate these alignments for subsequent phylogenomic inference. PHYLUCE",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 14.5078125,
            "text": "; and prepare and manipulate these alignments for subsequent phylogenomic inference. PHYLUCE",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": 14.5078125,
            "text": "subsequent phylogenomic inference. PHYLUCE",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 14.5078125,
            "text": "phylogenomic inference. PHYLUCE",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.5078125,
            "text": "target background data; align enriched contigs representing conserved loci to one another; and prepare and manipulate these alignments for subsequent phylogenomic inference. PHYLUCE",
            "probability": 0.0
        },
        {
            "start_logit": 13.375,
            "end_logit": -9.9140625,
            "text": "PHYLUCE is an efficient and easy-to-install software package that accomplishes these tasks across hundreds of taxa and thousands of enriched loci.",
            "probability": 0.0
        },
        {
            "start_logit": 13.375,
            "end_logit": -10.1015625,
            "text": "PHYLUCE is an efficient and easy-to-install software package",
            "probability": 0.0
        },
        {
            "start_logit": 13.375,
            "end_logit": -10.1015625,
            "text": "PHYLUCE is an efficient",
            "probability": 0.0
        },
        {
            "start_logit": 13.375,
            "end_logit": -10.203125,
            "text": "PHYLUCE is an efficient and easy-to-install",
            "probability": 0.0
        },
        {
            "start_logit": 13.375,
            "end_logit": -10.265625,
            "text": "PHYLUCE is an efficient and easy-to-install software package that accomplishes these tasks across hundreds of taxa and thousands of enriched",
            "probability": 0.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": -3.3203125,
            "text": ". PHYL",
            "probability": 0.0
        },
        {
            "start_logit": -3.376953125,
            "end_logit": -8.7421875,
            "text": "UCE is",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": -3.3203125,
            "text": "; align enriched contigs representing conserved loci to one another; and prepare and manipulate these alignments for subsequent phylogenomic inference. PHYL",
            "probability": 0.0
        },
        {
            "start_logit": -3.376953125,
            "end_logit": -9.9140625,
            "text": "UCE is an efficient and easy-to-install software package that accomplishes these tasks across hundreds of taxa and thousands of enriched loci.",
            "probability": 0.0
        }
    ],
    "587e07023ec846c24f000001_3": [
        {
            "start_logit": 14.546875,
            "end_logit": 15.09375,
            "text": "PHYLUCE",
            "probability": 1.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -1.240234375,
            "text": "PHYL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.19921875,
            "end_logit": 15.09375,
            "text": "UCE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.546875,
            "end_logit": -7.33984375,
            "text": "PHYLUCE is",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -9.0078125,
            "text": "PHYLUCE is a software package for the analysis of conserved genomic loci.",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -9.59375,
            "text": "PHYLUCE is a",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -9.625,
            "text": "PHYLUCE is a software package",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -10.0,
            "text": "PHYLUCE is a software",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -10.1171875,
            "text": "PHYLUCE is a software package for the analysis of conserved genomic loci",
            "probability": 0.0
        },
        {
            "start_logit": -2.19921875,
            "end_logit": -7.33984375,
            "text": "UCE is",
            "probability": 0.0
        },
        {
            "start_logit": -2.19921875,
            "end_logit": -9.0078125,
            "text": "UCE is a software package for the analysis of conserved genomic loci.",
            "probability": 0.0
        },
        {
            "start_logit": -2.19921875,
            "end_logit": -9.59375,
            "text": "UCE is a",
            "probability": 0.0
        },
        {
            "start_logit": -2.19921875,
            "end_logit": -9.625,
            "text": "UCE is a software package",
            "probability": 0.0
        },
        {
            "start_logit": -2.19921875,
            "end_logit": -10.0,
            "text": "UCE is a software",
            "probability": 0.0
        },
        {
            "start_logit": -2.19921875,
            "end_logit": -10.1171875,
            "text": "UCE is a software package for the analysis of conserved genomic loci",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": -7.33984375,
            "text": "is",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": -9.0078125,
            "text": "is a software package for the analysis of conserved genomic loci.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -9.0078125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": -9.59375,
            "text": "is a",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": -9.625,
            "text": "is a software package",
            "probability": 0.0
        }
    ],
    "554356d0ed966d112c000005_1": [
        {
            "start_logit": 13.3359375,
            "end_logit": 14.9921875,
            "text": "delta-distance",
            "probability": 1.0
        },
        {
            "start_logit": -1.9970703125,
            "end_logit": 14.9921875,
            "text": "distance",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -3.859375,
            "text": "delta",
            "probability": 0.0
        },
        {
            "start_logit": -6.6796875,
            "end_logit": 14.9921875,
            "text": "termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -5.71484375,
            "text": "delta-distance,",
            "probability": 0.0
        },
        {
            "start_logit": -7.62890625,
            "end_logit": 14.9921875,
            "text": "The average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -6.8515625,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature',",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -7.18359375,
            "text": "delta-",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -7.671875,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition,",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": 14.9921875,
            "text": "-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 14.9921875,
            "text": "difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 14.9921875,
            "text": "absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -8.78125,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 14.9921875,
            "text": "dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.9921875,
            "text": "relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 14.9921875,
            "text": "average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -9.515625,
            "text": "delta-distance, has",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -9.625,
            "text": "delta-distance, has been commonly used to",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -9.9296875,
            "text": "delta-distance, has been commonly",
            "probability": 0.0
        },
        {
            "start_logit": 13.3359375,
            "end_logit": -10.03125,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature",
            "probability": 0.0
        }
    ],
    "554356d0ed966d112c000005_2": [
        {
            "start_logit": 13.4375,
            "end_logit": 15.0703125,
            "text": "delta-distance",
            "probability": 1.0
        },
        {
            "start_logit": -1.8330078125,
            "end_logit": 15.0703125,
            "text": "distance",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 13.4375,
            "end_logit": -3.67578125,
            "text": "delta",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -4.33984375,
            "text": "delta-distance,",
            "probability": 0.0
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 15.0703125,
            "text": "termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 15.0703125,
            "text": "The average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -6.0859375,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and plasmids.",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -6.82421875,
            "text": "delta-",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -8.0625,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and plasmids",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 15.0703125,
            "text": "-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 15.0703125,
            "text": "absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 15.0703125,
            "text": "difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 15.0703125,
            "text": "dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.0,
            "text": "delta-distance, has been commonly used to",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 15.0703125,
            "text": "average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.203125,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 15.0703125,
            "text": "relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.2578125,
            "text": "delta-distance, has",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.2578125,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.3046875,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between",
            "probability": 0.0
        }
    ],
    "554356d0ed966d112c000005_3": [
        {
            "start_logit": 13.421875,
            "end_logit": 15.03125,
            "text": "delta-distance",
            "probability": 1.0
        },
        {
            "start_logit": -1.8984375,
            "end_logit": 15.03125,
            "text": "distance",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 13.421875,
            "end_logit": -3.712890625,
            "text": "delta",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -4.41796875,
            "text": "delta-distance,",
            "probability": 0.0
        },
        {
            "start_logit": -6.4921875,
            "end_logit": 15.03125,
            "text": "termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -6.81640625,
            "end_logit": 15.03125,
            "text": "The average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -5.43359375,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or genomic signature, between bacterial chromosomes and plasmids.",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -6.859375,
            "text": "delta-",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -8.0703125,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or genomic signature, between bacterial chromosomes and plasmids",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 15.03125,
            "text": "-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 15.03125,
            "text": "absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 15.03125,
            "text": "difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 15.03125,
            "text": "dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -9.09375,
            "text": "delta-distance, has been commonly used to",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 15.03125,
            "text": "average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -9.140625,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition,",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -9.1484375,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or genomic signature, between bacterial chromosomes and",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -9.3515625,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -9.390625,
            "text": "delta-distance, has",
            "probability": 0.0
        },
        {
            "start_logit": 13.421875,
            "end_logit": -9.5390625,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or genomic signature, between",
            "probability": 0.0
        }
    ],
    "554356d0ed966d112c000005_4": [
        {
            "start_logit": 12.3046875,
            "end_logit": 14.1796875,
            "text": "Mahalanobis distance",
            "probability": 1.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": 2.20703125,
            "text": "Mahalanobis",
            "probability": 6.318092346191406e-06
        },
        {
            "start_logit": -2.267578125,
            "end_logit": 14.1796875,
            "text": "the Mahalanobis distance",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -3.177734375,
            "end_logit": 14.1796875,
            "text": "distance",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.15234375,
            "end_logit": 14.1796875,
            "text": "nobis distance",
            "probability": 0.0
        },
        {
            "start_logit": -6.69921875,
            "end_logit": 14.1796875,
            "text": "bis distance",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -5.21484375,
            "text": "Mah",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -5.82421875,
            "text": "Mahalanobis distance is better than the delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -8.1015625,
            "end_logit": 14.1796875,
            "text": "alanobis distance",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -6.6484375,
            "text": "Mahala",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -6.69140625,
            "text": "Mahalanobis distance is better than the delta-distance at measuring genomic signature differences between plasmids and chromosomes of potential hosts.",
            "probability": 0.0
        },
        {
            "start_logit": -8.6484375,
            "end_logit": 14.1796875,
            "text": "s distance",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -7.74609375,
            "text": "Mahalanobis distance is better than the delta",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -8.0,
            "text": "Mahalanobi",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 14.1796875,
            "text": "that the Mahalanobis distance",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -8.96875,
            "text": "Mahalanobis distance is",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.4296875,
            "text": "Mahalanobis distance is better than the delta-",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.5703125,
            "text": "Mahalanobis distance is better than the delta-distance at measuring genomic signature differences",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.6640625,
            "text": "Mahalanobis distance is better than the delta-distance at measuring genomic signature differences between",
            "probability": 0.0
        },
        {
            "start_logit": 12.3046875,
            "end_logit": -9.7421875,
            "text": "Mahalanobis distance is better than the delta-distance at measuring genomic signature differences between plasmids and chromosomes of",
            "probability": 0.0
        }
    ],
    "554356d0ed966d112c000005_5": [
        {
            "start_logit": 13.4375,
            "end_logit": 15.0703125,
            "text": "delta-distance",
            "probability": 1.0
        },
        {
            "start_logit": -1.8330078125,
            "end_logit": 15.0703125,
            "text": "distance",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 13.4375,
            "end_logit": -3.67578125,
            "text": "delta",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -4.33984375,
            "text": "delta-distance,",
            "probability": 0.0
        },
        {
            "start_logit": -6.60546875,
            "end_logit": 15.0703125,
            "text": "termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -6.86328125,
            "end_logit": 15.0703125,
            "text": "The average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -6.0859375,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and plasmids.",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -6.82421875,
            "text": "delta-",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -8.0625,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and plasmids",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 15.0703125,
            "text": "-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 15.0703125,
            "text": "absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": 15.0703125,
            "text": "difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 15.0703125,
            "text": "dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.0,
            "text": "delta-distance, has been commonly used to",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 15.0703125,
            "text": "average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.203125,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 15.0703125,
            "text": "relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.2578125,
            "text": "delta-distance, has",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.2578125,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and",
            "probability": 0.0
        },
        {
            "start_logit": 13.4375,
            "end_logit": -9.3046875,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between",
            "probability": 0.0
        }
    ],
    "554356d0ed966d112c000005_6": [
        {
            "start_logit": 13.390625,
            "end_logit": 15.015625,
            "text": "delta-distance",
            "probability": 1.0
        },
        {
            "start_logit": -1.9990234375,
            "end_logit": 15.015625,
            "text": "distance",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.390625,
            "end_logit": -3.73046875,
            "text": "delta",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -4.4296875,
            "text": "delta-distance,",
            "probability": 0.0
        },
        {
            "start_logit": -6.9453125,
            "end_logit": 15.015625,
            "text": "termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -6.359375,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and plasmids",
            "probability": 0.0
        },
        {
            "start_logit": -8.1796875,
            "end_logit": 15.015625,
            "text": "The average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -6.9140625,
            "text": "delta-",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 15.015625,
            "text": "-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 15.015625,
            "text": "absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 15.015625,
            "text": "difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -9.03125,
            "text": "delta-distance, has been commonly used to",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 15.015625,
            "text": "dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 15.015625,
            "text": "average absolute dinucleotide relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -9.2421875,
            "text": "delta-distance, has",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 15.015625,
            "text": "relative abundance difference, termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -9.3359375,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -9.3515625,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition,",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 15.015625,
            "text": ", termed delta-distance",
            "probability": 0.0
        },
        {
            "start_logit": 13.390625,
            "end_logit": -9.6015625,
            "text": "delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between",
            "probability": 0.0
        }
    ],
    "5a7d5ce0faa1ab7d2e00001b_1": [
        {
            "start_logit": 0.798828125,
            "end_logit": 3.466796875,
            "text": "weight loss",
            "probability": 1.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": 3.466796875,
            "text": "elevated GDF15 correlates with weight loss",
            "probability": 0.0001302957534790039
        },
        {
            "start_logit": -9.34375,
            "end_logit": 3.466796875,
            "text": "loss",
            "probability": 3.9458274841308594e-05
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 3.466796875,
            "text": "GDF15 correlates with weight loss",
            "probability": 2.86102294921875e-05
        },
        {
            "start_logit": 0.798828125,
            "end_logit": -8.6953125,
            "text": "weight loss,",
            "probability": 5.185604095458984e-06
        },
        {
            "start_logit": 0.798828125,
            "end_logit": -9.0546875,
            "text": "weight loss, and the administration of GDF15 to mice with obesity",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": 0.798828125,
            "end_logit": -9.7890625,
            "text": "weight loss, and the administration of GDF15 to mice with obesity reduces body weight, at least in part, by decreasing food intake",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": 0.798828125,
            "end_logit": -10.0078125,
            "text": "weight loss, and the administration of GDF15 to mice with obesity reduces body weight, at least in part",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 0.798828125,
            "end_logit": -10.0546875,
            "text": "weight loss, and the administration of GDF15 to mice with obesity reduces body weight, at least in part, by decreasing food intake.",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -7.17578125,
            "end_logit": -9.2265625,
            "text": "weight loss in mice fed a high-fat diet and in nonhuman primates with spontaneous obesity.",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -8.6953125,
            "text": "elevated GDF15 correlates with weight loss,",
            "probability": 0.0
        },
        {
            "start_logit": -7.17578125,
            "end_logit": -9.6875,
            "text": "weight loss in",
            "probability": 0.0
        },
        {
            "start_logit": -7.17578125,
            "end_logit": -9.7109375,
            "text": "weight loss",
            "probability": 0.0
        },
        {
            "start_logit": -7.17578125,
            "end_logit": -9.7734375,
            "text": "weight loss in mice fed a high-fat diet and in nonhuman primates with spontaneous obesity",
            "probability": 0.0
        },
        {
            "start_logit": -8.1484375,
            "end_logit": -9.0546875,
            "text": "elevated GDF15 correlates with weight loss, and the administration of GDF15 to mice with obesity",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -9.6015625,
            "text": "food intake. The mechanisms through which GDF15 reduces body weight remain poorly understood, because the cognate receptor for GDF15 is unknown.",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -9.7890625,
            "text": "food intake. The mechanisms through which GDF15 reduces body weight remain poorly understood, because the cognate receptor for GDF15",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -9.7890625,
            "text": "food intake",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -9.796875,
            "text": "food intake. The mechanisms through which GDF15 reduces body weight remain poorly understood, because the cognate receptor for GDF",
            "probability": 0.0
        },
        {
            "start_logit": -7.625,
            "end_logit": -10.0546875,
            "text": "food intake.",
            "probability": 0.0
        }
    ],
    "61f7d683882a024a10000036_1": [
        {
            "start_logit": 9.8359375,
            "end_logit": 8.9296875,
            "text": "stearoyl-CoA desaturase 1",
            "probability": 0.81005859375
        },
        {
            "start_logit": 9.8359375,
            "end_logit": 7.47265625,
            "text": "stearoyl-CoA desaturase",
            "probability": 0.189453125
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -6.25390625,
            "text": "stearoyl-CoA desaturase 1 (SCD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -6.52734375,
            "text": "stear",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.1640625,
            "end_logit": 8.9296875,
            "text": "1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.2109375,
            "text": "stearoyl-CoA desaturase 1 (SCD1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.796875,
            "end_logit": 8.9296875,
            "text": "desaturase 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.8046875,
            "text": "stearoyl-CoA desaturase 1 (SCD1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.34375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.796875,
            "end_logit": 7.47265625,
            "text": "desaturase",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -9.2109375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -9.5,
            "text": "stearoyl",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -9.84375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -9.84375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -9.890625,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.0078125,
            "end_logit": 8.9296875,
            "text": "Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 8.9296875,
            "text": "CoA desaturase 1",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 8.9296875,
            "text": "yl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 8.9296875,
            "text": "-CoA desaturase 1",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 8.9296875,
            "text": "oyl-CoA desaturase 1",
            "probability": 0.0
        }
    ],
    "61f7d683882a024a10000036_2": [
        {
            "start_logit": 9.8359375,
            "end_logit": 8.9296875,
            "text": "stearoyl-CoA desaturase 1",
            "probability": 0.81005859375
        },
        {
            "start_logit": 9.8359375,
            "end_logit": 7.47265625,
            "text": "stearoyl-CoA desaturase",
            "probability": 0.189453125
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -6.25390625,
            "text": "stearoyl-CoA desaturase 1 (SCD",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -6.52734375,
            "text": "stear",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.1640625,
            "end_logit": 8.9296875,
            "text": "1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.2109375,
            "text": "stearoyl-CoA desaturase 1 (SCD1",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.796875,
            "end_logit": 8.9296875,
            "text": "desaturase 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -7.8046875,
            "text": "stearoyl-CoA desaturase 1 (SCD1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -8.34375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.796875,
            "end_logit": 7.47265625,
            "text": "desaturase",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -9.2109375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatohepatitis",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -9.5,
            "text": "stearoyl",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -9.84375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -9.84375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that",
            "probability": 0.0
        },
        {
            "start_logit": 9.8359375,
            "end_logit": -9.890625,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": -9.0078125,
            "end_logit": 8.9296875,
            "text": "Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 8.9296875,
            "text": "CoA desaturase 1",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 8.9296875,
            "text": "yl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 8.9296875,
            "text": "-CoA desaturase 1",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 8.9296875,
            "text": "oyl-CoA desaturase 1",
            "probability": 0.0
        }
    ],
    "61f7d683882a024a10000036_3": [
        {
            "start_logit": 9.7734375,
            "end_logit": 8.5234375,
            "text": "stearoyl-CoA desaturase",
            "probability": 0.7578125
        },
        {
            "start_logit": 9.7734375,
            "end_logit": 7.375,
            "text": "stearoyl-CoA desaturase 1",
            "probability": 0.2421875
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -1.783203125,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steatoh",
            "probability": 2.5391578674316406e-05
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -6.39453125,
            "text": "stearoyl-CoA desaturase 1 (SCD",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -6.41796875,
            "text": "stearoyl-CoA desaturase 1 (SCD1",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -6.53125,
            "text": "stear",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.37890625,
            "end_logit": 8.5234375,
            "text": "desaturase",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -7.75390625,
            "text": "stearoyl-CoA desaturase 1 (SCD1)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -8.3515625,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of steat",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.37890625,
            "end_logit": 7.375,
            "text": "desaturase 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.76953125,
            "end_logit": 7.375,
            "text": "1",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -9.453125,
            "text": "stearoyl",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -9.5078125,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -9.53125,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -9.6953125,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -9.75,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -9.78125,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression",
            "probability": 0.0
        },
        {
            "start_logit": -9.3515625,
            "end_logit": 8.5234375,
            "text": "Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 8.5234375,
            "text": "oyl-CoA desaturase",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 8.5234375,
            "text": "-CoA desaturase",
            "probability": 0.0
        }
    ],
    "61f7d683882a024a10000036_4": [
        {
            "start_logit": 9.6328125,
            "end_logit": 7.91015625,
            "text": "stearoyl-CoA desaturase",
            "probability": 0.5849609375
        },
        {
            "start_logit": 9.6328125,
            "end_logit": 7.5703125,
            "text": "stearoyl-CoA desaturase 1",
            "probability": 0.414794921875
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -5.26171875,
            "text": "stearoyl-CoA desaturase 1 (SCD1",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -6.13671875,
            "text": "stearoyl-CoA desaturase 1 (SCD",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -6.6328125,
            "text": "stear",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -7.1484375,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of stea",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -7.46875,
            "text": "stearoyl-CoA desaturase 1 (SCD1)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.6171875,
            "end_logit": 7.91015625,
            "text": "desaturase",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -8.5,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of ste",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.6171875,
            "end_logit": 7.5703125,
            "text": "desaturase 1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.88671875,
            "end_logit": 7.5703125,
            "text": "1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -9.1953125,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -9.2890625,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -9.515625,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides and fibrosis in animal models of",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -9.671875,
            "text": "stearoyl",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -9.6875,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that",
            "probability": 0.0
        },
        {
            "start_logit": 9.6328125,
            "end_logit": -9.7265625,
            "text": "stearoyl-CoA desaturase 1 (SCD1) protein expression that reduces liver triglycerides",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.91015625,
            "text": "Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase",
            "probability": 0.0
        },
        {
            "start_logit": -8.203125,
            "end_logit": 7.5703125,
            "text": "Arachidyl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase 1",
            "probability": 0.0
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 7.91015625,
            "text": "yl amido cholanoic acid (Aramchol) is a potent downregulator of hepatic stearoyl-CoA desaturase",
            "probability": 0.0
        }
    ],
    "60527e8c94d57fd879000012_1": [
        {
            "start_logit": 13.578125,
            "end_logit": 14.0390625,
            "text": "phase IV",
            "probability": 1.0
        },
        {
            "start_logit": -3.775390625,
            "end_logit": 14.0390625,
            "text": "IV",
            "probability": 0.0
        },
        {
            "start_logit": 13.578125,
            "end_logit": -3.4765625,
            "text": "phase",
            "probability": 0.0
        },
        {
            "start_logit": 13.578125,
            "end_logit": -9.765625,
            "text": "phase IV, single-blind study, 40 MS patients treated with fingolimod and 39 untreated age, gender, and disability",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 14.0390625,
            "text": ", phase IV",
            "probability": 0.0
        },
        {
            "start_logit": 13.578125,
            "end_logit": -10.15625,
            "text": "phase IV, single-blind study, 40 MS patients treated with fingolimod and 39 untreated age, gender, and disability-matched MS",
            "probability": 0.0
        },
        {
            "start_logit": 13.578125,
            "end_logit": -10.203125,
            "text": "phase IV, single-blind study, 40 MS",
            "probability": 0.0
        },
        {
            "start_logit": 13.578125,
            "end_logit": -10.21875,
            "text": "phase IV, single-blind study,",
            "probability": 0.0
        },
        {
            "start_logit": 13.578125,
            "end_logit": -10.21875,
            "text": "phase IV, single-blind study, 40 MS patients treated with fingolimod",
            "probability": 0.0
        },
        {
            "start_logit": 13.578125,
            "end_logit": -10.2265625,
            "text": "phase IV, single-blind study, 40 MS patients treated with fingolimod and",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.0390625,
            "text": "In this longitudinal, 2-year prospective, phase IV",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 14.0390625,
            "text": ", 2-year prospective, phase IV",
            "probability": 0.0
        },
        {
            "start_logit": -3.775390625,
            "end_logit": -9.765625,
            "text": "IV, single-blind study, 40 MS patients treated with fingolimod and 39 untreated age, gender, and disability",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": -3.4765625,
            "text": ", phase",
            "probability": 0.0
        },
        {
            "start_logit": -3.775390625,
            "end_logit": -10.15625,
            "text": "IV, single-blind study, 40 MS patients treated with fingolimod and 39 untreated age, gender, and disability-matched MS",
            "probability": 0.0
        },
        {
            "start_logit": -3.775390625,
            "end_logit": -10.203125,
            "text": "IV, single-blind study, 40 MS",
            "probability": 0.0
        },
        {
            "start_logit": -3.775390625,
            "end_logit": -10.21875,
            "text": "IV, single-blind study,",
            "probability": 0.0
        },
        {
            "start_logit": -3.775390625,
            "end_logit": -10.21875,
            "text": "IV, single-blind study, 40 MS patients treated with fingolimod",
            "probability": 0.0
        },
        {
            "start_logit": -3.775390625,
            "end_logit": -10.2265625,
            "text": "IV, single-blind study, 40 MS patients treated with fingolimod and",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": -3.4765625,
            "text": "In this longitudinal, 2-year prospective, phase",
            "probability": 0.0
        }
    ],
    "56ffdc1ccf1c32585100000b_1": [
        {
            "start_logit": 5.30078125,
            "end_logit": 10.140625,
            "text": "A-to-I editing",
            "probability": 1.0
        },
        {
            "start_logit": 5.30078125,
            "end_logit": 1.37890625,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 0.00015723705291748047
        },
        {
            "start_logit": 5.30078125,
            "end_logit": 1.2568359375,
            "text": "A-to-I",
            "probability": 0.0001398324966430664
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -0.11376953125,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.",
            "probability": 3.534555435180664e-05
        },
        {
            "start_logit": -5.56640625,
            "end_logit": 10.140625,
            "text": "editing",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -1.6689453125,
            "text": "A-to-I editing,",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 10.140625,
            "text": "to-I editing",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 10.140625,
            "text": "-to-I editing",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 10.140625,
            "text": "One of the most common forms of pre-mRNA editing is A-to-I editing",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -8.7578125,
            "end_logit": 10.140625,
            "text": "-I editing",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -9.46875,
            "end_logit": 10.140625,
            "text": "I editing",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -3.962890625,
            "end_logit": 1.37890625,
            "text": "deaminated to inosine",
            "probability": 0.0
        },
        {
            "start_logit": -4.83984375,
            "end_logit": 1.37890625,
            "text": "inosine",
            "probability": 0.0
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -8.9375,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": -3.962890625,
            "end_logit": -0.11376953125,
            "text": "deaminated to inosine, which is read as guanosine during translation.",
            "probability": 0.0
        },
        {
            "start_logit": -5.56640625,
            "end_logit": 1.37890625,
            "text": "editing, in which adenosine is deaminated to inosine",
            "probability": 0.0
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -9.578125,
            "text": "A-to-I editing, in",
            "probability": 0.0
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -9.609375,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine,",
            "probability": 0.0
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -9.9140625,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine",
            "probability": 0.0
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -9.9375,
            "text": "A-to-",
            "probability": 0.0
        }
    ],
    "56ffdc1ccf1c32585100000b_2": [
        {
            "start_logit": 9.140625,
            "end_logit": 10.6015625,
            "text": "A-to-I",
            "probability": 0.97509765625
        },
        {
            "start_logit": 9.140625,
            "end_logit": 6.79296875,
            "text": "A-to-I editing",
            "probability": 0.02154541015625
        },
        {
            "start_logit": 9.140625,
            "end_logit": 4.81640625,
            "text": "A-to-I editing events in normal and cancerous human keratinocytes",
            "probability": 0.0029621124267578125
        },
        {
            "start_logit": -6.58203125,
            "end_logit": 10.6015625,
            "text": "I",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -6.671875,
            "end_logit": 10.6015625,
            "text": "to-I",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 9.140625,
            "end_logit": -6.78125,
            "text": "A-to-I editing events in",
            "probability": 0.0
        },
        {
            "start_logit": 9.140625,
            "end_logit": -7.6484375,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": -9.59375,
            "end_logit": 10.6015625,
            "text": "-I",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 10.6015625,
            "text": "-to-I",
            "probability": 0.0
        },
        {
            "start_logit": 9.140625,
            "end_logit": -8.9296875,
            "text": "A-to-I editing events",
            "probability": 0.0
        },
        {
            "start_logit": -6.58203125,
            "end_logit": 6.79296875,
            "text": "I editing",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": 6.79296875,
            "text": "to-I editing",
            "probability": 0.0
        },
        {
            "start_logit": 9.140625,
            "end_logit": -9.34375,
            "text": "A-to-",
            "probability": 0.0
        },
        {
            "start_logit": 9.140625,
            "end_logit": -9.3515625,
            "text": "A-to-I editing events in normal and cancerous",
            "probability": 0.0
        },
        {
            "start_logit": 9.140625,
            "end_logit": -9.7109375,
            "text": "A-to-I editing events in normal and",
            "probability": 0.0
        },
        {
            "start_logit": 9.140625,
            "end_logit": -9.890625,
            "text": "A-to-I editing events in normal",
            "probability": 0.0
        },
        {
            "start_logit": -7.61328125,
            "end_logit": 6.79296875,
            "text": "editing",
            "probability": 0.0
        },
        {
            "start_logit": 9.140625,
            "end_logit": -10.2421875,
            "text": "A-",
            "probability": 0.0
        },
        {
            "start_logit": 9.140625,
            "end_logit": -10.2890625,
            "text": "A-to",
            "probability": 0.0
        },
        {
            "start_logit": -6.58203125,
            "end_logit": 4.81640625,
            "text": "I editing events in normal and cancerous human keratinocytes",
            "probability": 0.0
        }
    ],
    "56ffdc1ccf1c32585100000b_3": [
        {
            "start_logit": 6.4140625,
            "end_logit": 2.869140625,
            "text": "A-to-I RNA editing",
            "probability": 0.63916015625
        },
        {
            "start_logit": 6.4140625,
            "end_logit": 2.244140625,
            "text": "A-to-I",
            "probability": 0.342041015625
        },
        {
            "start_logit": 6.4140625,
            "end_logit": -0.66455078125,
            "text": "A-to-I RNA editing can alter codons, substitute amino acids and affect protein sequence, structure, and function.",
            "probability": 0.018707275390625
        },
        {
            "start_logit": -3.126953125,
            "end_logit": 2.869140625,
            "text": "RNA editing",
            "probability": 4.601478576660156e-05
        },
        {
            "start_logit": 6.4140625,
            "end_logit": -6.71875,
            "text": "A-to-I RNA",
            "probability": 4.38690185546875e-05
        },
        {
            "start_logit": 6.4140625,
            "end_logit": -7.98046875,
            "text": "A-to-I RNA editing can",
            "probability": 1.2516975402832031e-05
        },
        {
            "start_logit": 6.4140625,
            "end_logit": -8.875,
            "text": "A",
            "probability": 5.066394805908203e-06
        },
        {
            "start_logit": 6.4140625,
            "end_logit": -9.2421875,
            "text": "A-to-",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 6.4140625,
            "end_logit": -9.25,
            "text": "A-to-I RNA editing can alter codons, substitute amino acids and",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": 6.4140625,
            "end_logit": -10.078125,
            "text": "A-to-I RNA editing can alter codons, substitute amino acids and affect protein sequence, structure, and",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 6.4140625,
            "end_logit": -10.09375,
            "text": "A-to",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 6.4140625,
            "end_logit": -10.1328125,
            "text": "A-",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 6.4140625,
            "end_logit": -10.171875,
            "text": "A-to-I RNA editing can alter codons",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 6.4140625,
            "end_logit": -10.1796875,
            "text": "A-to-I RNA editing can alter codons, substitute amino acids and affect protein sequence, structure, and function",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -3.126953125,
            "end_logit": -0.66455078125,
            "text": "RNA editing can alter codons, substitute amino acids and affect protein sequence, structure, and function.",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 6.4140625,
            "end_logit": -10.2578125,
            "text": "A-to-I RNA editing can alter codons, substitute amino acids and affect protein sequence",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -8.109375,
            "end_logit": 2.869140625,
            "text": "to-I RNA editing",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.109375,
            "end_logit": 2.244140625,
            "text": "to-I",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -9.140625,
            "end_logit": 2.869140625,
            "text": "-to-I RNA editing",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.3359375,
            "end_logit": 2.869140625,
            "text": "I RNA editing",
            "probability": 5.960464477539063e-08
        }
    ],
    "56ffdc1ccf1c32585100000b_4": [
        {
            "start_logit": 12.5390625,
            "end_logit": 11.5390625,
            "text": "A-to-I",
            "probability": 0.94970703125
        },
        {
            "start_logit": 12.5390625,
            "end_logit": 8.6015625,
            "text": "A-to-I editing",
            "probability": 0.05035400390625
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -4.92578125,
            "text": "A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.52734375,
            "end_logit": 11.5390625,
            "text": "I",
            "probability": 0.0
        },
        {
            "start_logit": -5.73046875,
            "end_logit": 11.5390625,
            "text": "to-I",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -7.796875,
            "text": "A-to-I editing in the coding sequence of a tumor suppressor gene in humans, and suggests that IGFBP7",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -8.546875,
            "text": "A-to-",
            "probability": 0.0
        },
        {
            "start_logit": -4.73046875,
            "end_logit": 8.6015625,
            "text": "editing",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -8.6953125,
            "text": "A-to-I editing in the coding sequence of a tumor suppressor gene in humans,",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -9.3828125,
            "text": "A-to-I editing in the coding sequence of a",
            "probability": 0.0
        },
        {
            "start_logit": -5.52734375,
            "end_logit": 8.6015625,
            "text": "I editing",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -9.546875,
            "text": "A-to-I editing in the coding sequence of a tumor suppressor gene",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -9.59375,
            "text": "A-",
            "probability": 0.0
        },
        {
            "start_logit": -5.73046875,
            "end_logit": 8.6015625,
            "text": "to-I editing",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -9.6953125,
            "text": "A-to-I editing in the coding sequence of",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": 11.5390625,
            "text": "-I",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -9.7578125,
            "text": "A-to-I editing in the coding sequence of a tumor suppressor gene in humans, and suggests",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -9.828125,
            "text": "A-to-I editing in the coding sequence of a tumor suppressor gene in",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -9.8359375,
            "text": "A-to-I editing in the coding sequence of a tumor suppressor gene in humans, and suggests that IGFBP",
            "probability": 0.0
        },
        {
            "start_logit": 12.5390625,
            "end_logit": -9.8515625,
            "text": "A-to-I editing in the coding sequence of a tumor suppressor gene in humans, and",
            "probability": 0.0
        }
    ],
    "56ffdc1ccf1c32585100000b_5": [
        {
            "start_logit": 12.6953125,
            "end_logit": 14.015625,
            "text": "ADARs",
            "probability": 0.9990234375
        },
        {
            "start_logit": 12.6953125,
            "end_logit": 7.140625,
            "text": "ADARs) catalyze the adenosine-to-inosine (A-to-I) conversion",
            "probability": 0.0010318756103515625
        },
        {
            "start_logit": 12.6953125,
            "end_logit": 2.89453125,
            "text": "ADARs) catalyze the adenosine-to-inosine",
            "probability": 1.4722347259521484e-05
        },
        {
            "start_logit": -3.7109375,
            "end_logit": 14.015625,
            "text": "Rs",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -4.40234375,
            "text": "ADARs) catalyze the adenosine-to-inosine (A-to-I) conversion,",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -4.41015625,
            "text": "ADA",
            "probability": 0.0
        },
        {
            "start_logit": -6.15234375,
            "end_logit": 14.015625,
            "text": "(ADARs",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -5.015625,
            "text": "ADARs) catalyze the adenosine-to-inosine (A-to-I",
            "probability": 0.0
        },
        {
            "start_logit": -1.3447265625,
            "end_logit": 7.140625,
            "text": "adenosine-to-inosine (A-to-I) conversion",
            "probability": 0.0
        },
        {
            "start_logit": -1.4404296875,
            "end_logit": 7.140625,
            "text": "(A-to-I) conversion",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": 14.015625,
            "text": "Adenosine deaminases that act on RNA (ADARs",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -8.7734375,
            "text": "ADARs) catalyze the adenosine-to-inosine (A-to-I)",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 14.015625,
            "text": "on RNA (ADARs",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -9.1484375,
            "text": "ADARs)",
            "probability": 0.0
        },
        {
            "start_logit": -3.7109375,
            "end_logit": 7.140625,
            "text": "Rs) catalyze the adenosine-to-inosine (A-to-I) conversion",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -9.5546875,
            "text": "ADARs) catalyze the adenosine-to-inosine (",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -9.9296875,
            "text": "ADARs) catalyze the adenosine-to-inosine (A-to-I) conversion, the",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -9.953125,
            "text": "ADARs) catalyze the adenosine-to-inosine (A-to",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -9.96875,
            "text": "ADARs) catalyze the adenosine-to-inosine (A-to-I) conversion, the most common type of RNA editing in",
            "probability": 0.0
        },
        {
            "start_logit": 12.6953125,
            "end_logit": -10.109375,
            "text": "ADARs) catalyze the adenosine-to-inosine (A-to-I) conversion, the most common type",
            "probability": 0.0
        }
    ],
    "56ffdc1ccf1c32585100000b_6": [
        {
            "start_logit": 4.9765625,
            "end_logit": 11.609375,
            "text": "inosine",
            "probability": 0.9990234375
        },
        {
            "start_logit": 5.5546875,
            "end_logit": 3.236328125,
            "text": "(A to I",
            "probability": 0.0004074573516845703
        },
        {
            "start_logit": 4.9765625,
            "end_logit": 3.236328125,
            "text": "inosine (A to I",
            "probability": 0.00022852420806884766
        },
        {
            "start_logit": -6.3984375,
            "end_logit": 11.609375,
            "text": "the adenosine residue is base-modified to inosine",
            "probability": 1.138448715209961e-05
        },
        {
            "start_logit": -6.67578125,
            "end_logit": 11.609375,
            "text": "ine",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": -6.890625,
            "end_logit": 11.609375,
            "text": "to inosine",
            "probability": 6.973743438720703e-06
        },
        {
            "start_logit": -7.59765625,
            "end_logit": 11.609375,
            "text": "adenosine residue is base-modified to inosine",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -9.3828125,
            "end_logit": 11.609375,
            "text": "base-modified to inosine",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -9.765625,
            "end_logit": 11.609375,
            "text": "is base-modified to inosine",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -9.8125,
            "end_logit": 11.609375,
            "text": "residue is base-modified to inosine",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -9.96875,
            "end_logit": 11.609375,
            "text": "base modification, where the adenosine residue is base-modified to inosine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 11.609375,
            "text": "modified to inosine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 11.609375,
            "text": "-modified to inosine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 11.609375,
            "text": "The most common RNA editing in the mammalian central nervous system is a base modification, where the adenosine residue is base-modified to inosine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.234375,
            "end_logit": 11.609375,
            "text": "a base modification, where the adenosine residue is base-modified to inosine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 5.5546875,
            "end_logit": -7.13671875,
            "text": "(A to I).",
            "probability": 0.0
        },
        {
            "start_logit": 4.9765625,
            "end_logit": -7.13671875,
            "text": "inosine (A to I).",
            "probability": 0.0
        },
        {
            "start_logit": 5.5546875,
            "end_logit": -7.81640625,
            "text": "(",
            "probability": 0.0
        },
        {
            "start_logit": 5.5546875,
            "end_logit": -8.328125,
            "text": "(A",
            "probability": 0.0
        },
        {
            "start_logit": 5.5546875,
            "end_logit": -8.328125,
            "text": "(A to",
            "probability": 0.0
        }
    ],
    "56ffdc1ccf1c32585100000b_7": [
        {
            "start_logit": 0.258544921875,
            "end_logit": 11.6640625,
            "text": "A-to-I editing",
            "probability": 0.9560546875
        },
        {
            "start_logit": 0.258544921875,
            "end_logit": 8.2265625,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 0.030731201171875
        },
        {
            "start_logit": -4.69921875,
            "end_logit": 11.6640625,
            "text": "editing",
            "probability": 0.006725311279296875
        },
        {
            "start_logit": -1.50390625,
            "end_logit": 8.2265625,
            "text": "inosine",
            "probability": 0.005275726318359375
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 11.6640625,
            "text": "to-I editing",
            "probability": 0.00043845176696777344
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 11.6640625,
            "text": "-to-I editing",
            "probability": 0.00035643577575683594
        },
        {
            "start_logit": -4.69921875,
            "end_logit": 8.2265625,
            "text": "editing, in which adenosine is deaminated to inosine",
            "probability": 0.00021696090698242188
        },
        {
            "start_logit": -8.5859375,
            "end_logit": 11.6640625,
            "text": "-I editing",
            "probability": 0.0001379251480102539
        },
        {
            "start_logit": -5.3046875,
            "end_logit": 8.2265625,
            "text": "deaminated to inosine",
            "probability": 0.00011795759201049805
        },
        {
            "start_logit": -9.25,
            "end_logit": 11.6640625,
            "text": "One of the most common forms of pre-mRNA editing is A-to-I editing",
            "probability": 7.098913192749023e-05
        },
        {
            "start_logit": -9.78125,
            "end_logit": 11.6640625,
            "text": "I editing",
            "probability": 4.178285598754883e-05
        },
        {
            "start_logit": -7.4296875,
            "end_logit": 8.2265625,
            "text": "to-I editing, in which adenosine is deaminated to inosine",
            "probability": 1.4066696166992188e-05
        },
        {
            "start_logit": -7.6171875,
            "end_logit": 8.2265625,
            "text": "to inosine",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": -7.63671875,
            "end_logit": 8.2265625,
            "text": "-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 1.150369644165039e-05
        },
        {
            "start_logit": -8.1875,
            "end_logit": 8.2265625,
            "text": "adenosine is deaminated to inosine",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -8.5859375,
            "end_logit": 8.2265625,
            "text": "-I editing, in which adenosine is deaminated to inosine",
            "probability": 4.470348358154297e-06
        },
        {
            "start_logit": -8.8203125,
            "end_logit": 8.2265625,
            "text": "ine",
            "probability": 3.516674041748047e-06
        },
        {
            "start_logit": -9.25,
            "end_logit": 8.2265625,
            "text": "One of the most common forms of pre-mRNA editing is A-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -9.46875,
            "end_logit": 8.2265625,
            "text": "ated to inosine",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": -9.703125,
            "end_logit": 8.2265625,
            "text": "which adenosine is deaminated to inosine",
            "probability": 1.430511474609375e-06
        }
    ],
    "56ffdc1ccf1c32585100000b_8": [
        {
            "start_logit": 6.6640625,
            "end_logit": 4.8671875,
            "text": "(A to I",
            "probability": 0.82177734375
        },
        {
            "start_logit": -0.82958984375,
            "end_logit": 10.7109375,
            "text": "inosine",
            "probability": 0.1580810546875
        },
        {
            "start_logit": -3.353515625,
            "end_logit": 10.7109375,
            "text": "the adenosine residue is base-modified to inosine",
            "probability": 0.0126800537109375
        },
        {
            "start_logit": 6.6640625,
            "end_logit": -0.35595703125,
            "text": "(A to I).",
            "probability": 0.00443267822265625
        },
        {
            "start_logit": -5.73828125,
            "end_logit": 10.7109375,
            "text": "adenosine residue is base-modified to inosine",
            "probability": 0.0011653900146484375
        },
        {
            "start_logit": -0.82958984375,
            "end_logit": 4.8671875,
            "text": "inosine (A to I",
            "probability": 0.00045800209045410156
        },
        {
            "start_logit": -7.20703125,
            "end_logit": 10.7109375,
            "text": "ine",
            "probability": 0.00026726722717285156
        },
        {
            "start_logit": -7.41796875,
            "end_logit": 10.7109375,
            "text": "to inosine",
            "probability": 0.0002180337905883789
        },
        {
            "start_logit": -8.0546875,
            "end_logit": 10.7109375,
            "text": "base-modified to inosine",
            "probability": 0.00011491775512695312
        },
        {
            "start_logit": -8.09375,
            "end_logit": 10.7109375,
            "text": "The most common RNA editing in the mammalian central nervous system is a base modification, where the adenosine residue is base-modified to inosine",
            "probability": 0.00011050701141357422
        },
        {
            "start_logit": 6.6640625,
            "end_logit": -4.4609375,
            "text": "(A to I)",
            "probability": 7.301568984985352e-05
        },
        {
            "start_logit": -8.953125,
            "end_logit": 10.7109375,
            "text": "is base-modified to inosine",
            "probability": 4.678964614868164e-05
        },
        {
            "start_logit": -9.046875,
            "end_logit": 10.7109375,
            "text": "residue is base-modified to inosine",
            "probability": 4.26173210144043e-05
        },
        {
            "start_logit": -3.353515625,
            "end_logit": 4.8671875,
            "text": "the adenosine residue is base-modified to inosine (A to I",
            "probability": 3.6716461181640625e-05
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 10.7109375,
            "text": "modified to inosine",
            "probability": 3.24249267578125e-05
        },
        {
            "start_logit": -3.4921875,
            "end_logit": 4.8671875,
            "text": "A to I",
            "probability": 3.1948089599609375e-05
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 10.7109375,
            "text": "base modification, where the adenosine residue is base-modified to inosine",
            "probability": 2.485513687133789e-05
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 10.7109375,
            "text": "RNA editing in the mammalian central nervous system is a base modification, where the adenosine residue is base-modified to inosine",
            "probability": 2.3365020751953125e-05
        },
        {
            "start_logit": -9.703125,
            "end_logit": 10.7109375,
            "text": "-modified to inosine",
            "probability": 2.2113323211669922e-05
        },
        {
            "start_logit": 6.6640625,
            "end_logit": -6.76953125,
            "text": "(",
            "probability": 7.271766662597656e-06
        }
    ],
    "56ffdc1ccf1c32585100000b_9": [
        {
            "start_logit": 5.30078125,
            "end_logit": 10.140625,
            "text": "A-to-I editing",
            "probability": 1.0
        },
        {
            "start_logit": 5.30078125,
            "end_logit": 1.37890625,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine",
            "probability": 0.00015723705291748047
        },
        {
            "start_logit": 5.30078125,
            "end_logit": 1.2568359375,
            "text": "A-to-I",
            "probability": 0.0001398324966430664
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -0.11376953125,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine during translation.",
            "probability": 3.534555435180664e-05
        },
        {
            "start_logit": -5.56640625,
            "end_logit": 10.140625,
            "text": "editing",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -1.6689453125,
            "text": "A-to-I editing,",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": -6.6328125,
            "end_logit": 10.140625,
            "text": "to-I editing",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -7.58203125,
            "end_logit": 10.140625,
            "text": "-to-I editing",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 10.140625,
            "text": "One of the most common forms of pre-mRNA editing is A-to-I editing",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -8.7578125,
            "end_logit": 10.140625,
            "text": "-I editing",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -9.46875,
            "end_logit": 10.140625,
            "text": "I editing",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -3.962890625,
            "end_logit": 1.37890625,
            "text": "deaminated to inosine",
            "probability": 0.0
        },
        {
            "start_logit": -4.83984375,
            "end_logit": 1.37890625,
            "text": "inosine",
            "probability": 0.0
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -8.9375,
            "text": "A",
            "probability": 0.0
        },
        {
            "start_logit": -3.962890625,
            "end_logit": -0.11376953125,
            "text": "deaminated to inosine, which is read as guanosine during translation.",
            "probability": 0.0
        },
        {
            "start_logit": -5.56640625,
            "end_logit": 1.37890625,
            "text": "editing, in which adenosine is deaminated to inosine",
            "probability": 0.0
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -9.578125,
            "text": "A-to-I editing, in",
            "probability": 0.0
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -9.609375,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine,",
            "probability": 0.0
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -9.9140625,
            "text": "A-to-I editing, in which adenosine is deaminated to inosine, which is read as guanosine",
            "probability": 0.0
        },
        {
            "start_logit": 5.30078125,
            "end_logit": -9.9375,
            "text": "A-to-",
            "probability": 0.0
        }
    ],
    "56ffdc1ccf1c32585100000b_10": [
        {
            "start_logit": 10.78125,
            "end_logit": 14.1328125,
            "text": "adenosine deamination",
            "probability": 1.0
        },
        {
            "start_logit": -3.603515625,
            "end_logit": 14.1328125,
            "text": "amination",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 10.78125,
            "end_logit": -0.638671875,
            "text": "adenosine deamination (A-to-I",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -5.640625,
            "end_logit": 14.1328125,
            "text": "deamination",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.78125,
            "end_logit": -5.11328125,
            "text": "adenosine de",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 14.1328125,
            "text": "RNA editing by adenosine deamination",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 14.1328125,
            "text": "editing by adenosine deamination",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -6.796875,
            "text": "adenosine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 14.1328125,
            "text": "by adenosine deamination",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -7.3203125,
            "text": "adenosine deamination (A-to-I)",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -8.046875,
            "text": "adenosine deamination (",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -8.4296875,
            "text": "adenosine deamination (A-to-I) is",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -8.921875,
            "text": "adenosine deamination (A",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -9.3671875,
            "text": "adenosine deamination (A-to-I) is widespread in humans and",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -9.7109375,
            "text": "adenosine deamination (A-to-I) is widespread in humans and can lead to a variety of biological effects depending",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -9.78125,
            "text": "adenosine deamination (A-to-I) is widespread in",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -9.796875,
            "text": "adenosine deamination (A-to-",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -9.8125,
            "text": "adenosine deamination (A-to-I) is widespread in humans and can lead to a variety",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -9.84375,
            "text": "adenosine deamination (A-to-I) is widespread in humans and can lead to a variety of biological effects depending on",
            "probability": 0.0
        },
        {
            "start_logit": 10.78125,
            "end_logit": -9.875,
            "text": "adenosine deamination (A-to-I) is widespread in humans and can lead to a variety of biological effects depending on the RNA",
            "probability": 0.0
        }
    ],
    "5a7d6287faa1ab7d2e00001c_1": [
        {
            "start_logit": 11.296875,
            "end_logit": 14.2734375,
            "text": "GDNF family receptor \u03b1-like (GFRAL)",
            "probability": 1.0
        },
        {
            "start_logit": -1.2509765625,
            "end_logit": 14.2734375,
            "text": "GFRAL)",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": 11.296875,
            "end_logit": 0.861328125,
            "text": "GDNF family receptor \u03b1-like (GFRAL",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -3.314453125,
            "end_logit": 14.2734375,
            "text": ")",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -4.65234375,
            "end_logit": 14.2734375,
            "text": "(GFRAL)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.296875,
            "end_logit": -2.44140625,
            "text": "GDNF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.65234375,
            "end_logit": 14.2734375,
            "text": "receptor \u03b1-like (GFRAL)",
            "probability": 0.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 14.2734375,
            "text": "to GDNF family receptor \u03b1-like (GFRAL)",
            "probability": 0.0
        },
        {
            "start_logit": -8.3125,
            "end_logit": 14.2734375,
            "text": "family receptor \u03b1-like (GFRAL)",
            "probability": 0.0
        },
        {
            "start_logit": -8.625,
            "end_logit": 14.2734375,
            "text": "AL)",
            "probability": 0.0
        },
        {
            "start_logit": -9.1484375,
            "end_logit": 14.2734375,
            "text": "GDF15 binds specifically to GDNF family receptor \u03b1-like (GFRAL)",
            "probability": 0.0
        },
        {
            "start_logit": -9.1875,
            "end_logit": 14.2734375,
            "text": "\u03b1-like (GFRAL)",
            "probability": 0.0
        },
        {
            "start_logit": 11.296875,
            "end_logit": -6.52734375,
            "text": "GDNF family receptor \u03b1-like (",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 14.2734375,
            "text": "-like (GFRAL)",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 14.2734375,
            "text": "like (GFRAL)",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 14.2734375,
            "text": "specifically to GDNF family receptor \u03b1-like (GFRAL)",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 14.2734375,
            "text": "binds specifically to GDNF family receptor \u03b1-like (GFRAL)",
            "probability": 0.0
        },
        {
            "start_logit": 11.296875,
            "end_logit": -7.7265625,
            "text": "GDNF family",
            "probability": 0.0
        },
        {
            "start_logit": 11.296875,
            "end_logit": -8.5859375,
            "text": "GDNF family receptor \u03b1-like (GFR",
            "probability": 0.0
        },
        {
            "start_logit": 11.296875,
            "end_logit": -8.6328125,
            "text": "GDNF family receptor",
            "probability": 0.0
        }
    ],
    "5abcf0b0fcf4565872000024_1": [
        {
            "start_logit": 12.4375,
            "end_logit": 7.62109375,
            "text": "Leishmania species",
            "probability": 1.0
        },
        {
            "start_logit": 12.4375,
            "end_logit": -3.9296875,
            "text": "Leishmania",
            "probability": 9.59634780883789e-06
        },
        {
            "start_logit": 12.4375,
            "end_logit": -9.1328125,
            "text": "Leishmania species cause leishmaniasis,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.4375,
            "end_logit": -9.625,
            "text": "Leishmania species cause leishmaniasis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.4375,
            "end_logit": -9.6484375,
            "text": "Leishmania species cause",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.4375,
            "end_logit": -10.0625,
            "text": "Leishmania species cause leishmaniasis, a disease that ranges from self-healing but scarring cutaneous lesions to fatal visceral leishmaniasis in which parasites disseminate",
            "probability": 0.0
        },
        {
            "start_logit": 12.4375,
            "end_logit": -10.0859375,
            "text": "Leishmania species cause leishmaniasis, a disease that ranges from self-healing but scarring cutaneous lesions to fatal visceral leishmaniasis",
            "probability": 0.0
        },
        {
            "start_logit": 12.4375,
            "end_logit": -10.109375,
            "text": "Leishmania species cause leishmaniasis, a",
            "probability": 0.0
        },
        {
            "start_logit": 12.4375,
            "end_logit": -10.109375,
            "text": "Leishmania species cause leishmaniasis, a disease that ranges from self-healing but scarring cutaneous lesions to fatal visceral leishmaniasis in which parasites dissem",
            "probability": 0.0
        },
        {
            "start_logit": 12.4375,
            "end_logit": -10.15625,
            "text": "Leishmania species cause leishmaniasis, a disease that ranges from self-healing but scarring cutaneous lesions to fatal visceral leishmaniasis in",
            "probability": 0.0
        },
        {
            "start_logit": 12.4375,
            "end_logit": -10.3046875,
            "text": "Leishmania species cause leishmaniasis, a disease that",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": 7.62109375,
            "text": "species",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": 7.62109375,
            "text": ", Leishmania species",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 7.62109375,
            "text": "Finally, Leishmania species",
            "probability": 0.0
        },
        {
            "start_logit": -8.3515625,
            "end_logit": -3.9296875,
            "text": ", Leishmania",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": -3.9296875,
            "text": "Finally, Leishmania",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -9.1328125,
            "text": "species cause leishmaniasis,",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -9.625,
            "text": "species cause leishmaniasis",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -9.6484375,
            "text": "species cause",
            "probability": 0.0
        },
        {
            "start_logit": -7.37109375,
            "end_logit": -10.0625,
            "text": "species cause leishmaniasis, a disease that ranges from self-healing but scarring cutaneous lesions to fatal visceral leishmaniasis in which parasites disseminate",
            "probability": 0.0
        }
    ],
    "5abcf0b0fcf4565872000024_2": [
        {
            "start_logit": 10.015625,
            "end_logit": -2.529296875,
            "text": "Leishmania",
            "probability": 0.984375
        },
        {
            "start_logit": 10.015625,
            "end_logit": -7.67578125,
            "text": "Leishmania species",
            "probability": 0.005741119384765625
        },
        {
            "start_logit": 10.015625,
            "end_logit": -7.90234375,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species responsible for visceral leishmaniasis (VL",
            "probability": 0.00457763671875
        },
        {
            "start_logit": 10.015625,
            "end_logit": -9.5234375,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species responsible for visceral leishmaniasis (VL).",
            "probability": 0.0009045600891113281
        },
        {
            "start_logit": 10.015625,
            "end_logit": -10.0078125,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL",
            "probability": 0.0005574226379394531
        },
        {
            "start_logit": 10.015625,
            "end_logit": -10.0234375,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III)",
            "probability": 0.0005488395690917969
        },
        {
            "start_logit": 10.015625,
            "end_logit": -10.203125,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species responsible for visceral leishmaniasis",
            "probability": 0.0004584789276123047
        },
        {
            "start_logit": 10.015625,
            "end_logit": -10.234375,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III",
            "probability": 0.0004444122314453125
        },
        {
            "start_logit": 10.015625,
            "end_logit": -10.25,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the",
            "probability": 0.0004374980926513672
        },
        {
            "start_logit": 10.015625,
            "end_logit": -10.2578125,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb",
            "probability": 0.0004343986511230469
        },
        {
            "start_logit": 10.015625,
            "end_logit": -10.2578125,
            "text": "Leishmania species causing cutaneous leishmaniasis",
            "probability": 0.0004343986511230469
        },
        {
            "start_logit": 10.015625,
            "end_logit": -10.28125,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are",
            "probability": 0.0004241466522216797
        },
        {
            "start_logit": 10.015625,
            "end_logit": -10.3671875,
            "text": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species",
            "probability": 0.00038909912109375
        },
        {
            "start_logit": -10.0,
            "end_logit": -2.529296875,
            "text": ", Leishmania",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": -2.529296875,
            "text": "In general, Leishmania",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": -7.90234375,
            "text": "cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species responsible for visceral leishmaniasis (VL",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": -7.67578125,
            "text": ", Leishmania species",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": -7.90234375,
            "text": "more sensitive to Sb(III) than the species responsible for visceral leishmaniasis (VL",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": -7.90234375,
            "text": ", Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species responsible for visceral leishmaniasis (VL",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -7.90234375,
            "text": "causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species responsible for visceral leishmaniasis (VL",
            "probability": 0.0
        }
    ],
    "5abcf0b0fcf4565872000024_3": [
        {
            "start_logit": 13.8359375,
            "end_logit": 12.734375,
            "text": "Leishmania viannia braziliensis",
            "probability": 1.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -2.857421875,
            "text": "Leishmania",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -5.03125,
            "text": "Leishmania viannia",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -5.26953125,
            "text": "Leishmania viannia braziliensis complex",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -6.0859375,
            "text": "Leishmania viann",
            "probability": 0.0
        },
        {
            "start_logit": -5.28125,
            "end_logit": 12.734375,
            "text": "iensis",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -6.68359375,
            "text": "Leishmania viannia brazil",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -7.08984375,
            "text": "Leishmania viannia braziliensis complex parasites. L. braziliensis and Leishmania viannia peruviana are the 2 predominant Leishmania species in Peru",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -7.328125,
            "text": "Leishmania via",
            "probability": 0.0
        },
        {
            "start_logit": -7.25,
            "end_logit": 12.734375,
            "text": "ia braziliensis",
            "probability": 0.0
        },
        {
            "start_logit": -7.29296875,
            "end_logit": 12.734375,
            "text": "braziliensis",
            "probability": 0.0
        },
        {
            "start_logit": -7.5390625,
            "end_logit": 12.734375,
            "text": "nnia braziliensis",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -8.8359375,
            "text": "Leishmania viannia braziliensis complex parasites. L. braziliensis and Leishmania viannia peruviana are the 2 predominant",
            "probability": 0.0
        },
        {
            "start_logit": -8.078125,
            "end_logit": 12.734375,
            "text": "viannia braziliensis",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.5,
            "text": "Leishmania viannia braziliensis complex parasites. L. braziliensis and Leishmania viannia peruviana",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.515625,
            "text": "Leishmania viannia braziliensis complex parasites. L. braziliensis and Leishmania viannia peruvian",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.6015625,
            "text": "Leishmania viannia braziliensis complex parasites. L. braziliensis and Leishmania viannia peruviana are the 2 predominant Leishmania species in Peru.",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.9609375,
            "text": "Leishmania viannia braziliensis complex parasites. L. braziliensis and Leishmania viannia peruviana are",
            "probability": 0.0
        },
        {
            "start_logit": 13.8359375,
            "end_logit": -9.9765625,
            "text": "Leishmania viannia braziliensis complex parasites. L. braziliensis and Leishmania viannia peru",
            "probability": 0.0
        },
        {
            "start_logit": -8.96875,
            "end_logit": 12.734375,
            "text": "Tegumentary leishmaniasis in Latin America is caused mainly by Leishmania viannia braziliensis",
            "probability": 0.0
        }
    ],
    "5abcf0b0fcf4565872000024_4": [
        {
            "start_logit": 7.296875,
            "end_logit": 4.1640625,
            "text": "Leishmania species",
            "probability": 1.0
        },
        {
            "start_logit": 7.296875,
            "end_logit": -5.359375,
            "text": "Leishmania",
            "probability": 7.31348991394043e-05
        },
        {
            "start_logit": 7.296875,
            "end_logit": -9.0859375,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 7.296875,
            "end_logit": -9.2421875,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 7.296875,
            "end_logit": -9.484375,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD-PCR",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 7.296875,
            "end_logit": -9.5859375,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD-PCR) in Kharve, Iran",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 7.296875,
            "end_logit": -9.78125,
            "text": "Leishmania species causing",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": 7.296875,
            "end_logit": -9.8046875,
            "text": "Leishmania species causing cutaneous leishmaniasis",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.296875,
            "end_logit": -9.828125,
            "text": "Leishmania species causing cutaneous leishmaniasis using",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 7.296875,
            "end_logit": -9.921875,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 7.296875,
            "end_logit": -9.9609375,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD-PCR) in Kharve, Iran.",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 7.296875,
            "end_logit": -10.1171875,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD-PCR)",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.296875,
            "end_logit": -10.1171875,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD-PCR) in Khar",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 7.296875,
            "end_logit": -10.1328125,
            "text": "Leishmania species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA (RAPD-PCR) in Kharve",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -9.03125,
            "end_logit": 4.1640625,
            "text": "species",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -11.046875,
            "end_logit": 4.1640625,
            "text": "of Leishmania species",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": 4.1640625,
            "text": "Identification of Leishmania species",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": -5.359375,
            "text": "of Leishmania",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": -5.359375,
            "text": "Identification of Leishmania",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": -9.0859375,
            "text": "species causing cutaneous leishmaniasis using Random Amplified Polymorphic DNA",
            "probability": 0.0
        }
    ],
    "550c4011a103b78016000009_1": [
        {
            "start_logit": 14.1640625,
            "end_logit": 14.8359375,
            "text": "serine 129",
            "probability": 1.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -1.7744140625,
            "text": "serine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.630859375,
            "end_logit": 14.8359375,
            "text": "129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -6.43359375,
            "text": "serine 129 (S129",
            "probability": 0.0
        },
        {
            "start_logit": -8.578125,
            "end_logit": 14.8359375,
            "text": "Alpha-synuclein phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -8.0625,
            "text": "serine 129 (S1",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -8.3515625,
            "text": "serine 129 (",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 14.8359375,
            "text": "at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.21875,
            "text": "serine 129 (S129)",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.4375,
            "text": "serine 129 (S129) is",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.7265625,
            "text": "serine 129 (S129) is highly elevated in Parkinson's disease patients where it mainly",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 14.8359375,
            "text": "synuclein phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -9.8046875,
            "text": "serine 129 (S129) is highly elevated in Parkinson's disease patients where it mainly accumulates in the Lewy bodies",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -10.0078125,
            "text": "serine 129 (S129) is highly elevated in Parkinson's disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.8359375,
            "text": "phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -10.078125,
            "text": "serine 129 (S129) is highly elevated in",
            "probability": 0.0
        },
        {
            "start_logit": 14.1640625,
            "end_logit": -10.1171875,
            "text": "serine 129 (S129) is highly",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 14.8359375,
            "text": "-synuclein phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -2.630859375,
            "end_logit": -6.43359375,
            "text": "129 (S129",
            "probability": 0.0
        },
        {
            "start_logit": -8.578125,
            "end_logit": -1.7744140625,
            "text": "Alpha-synuclein phosphorylated at serine",
            "probability": 0.0
        }
    ],
    "550c4011a103b78016000009_2": [
        {
            "start_logit": 13.203125,
            "end_logit": 13.3671875,
            "text": "serine 129",
            "probability": 0.9990234375
        },
        {
            "start_logit": 13.203125,
            "end_logit": 6.7265625,
            "text": "serine 129 (Ser129",
            "probability": 0.0013256072998046875
        },
        {
            "start_logit": 13.203125,
            "end_logit": -3.42578125,
            "text": "serine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.53515625,
            "end_logit": 13.3671875,
            "text": "129",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -5.98046875,
            "text": "serine 129 (Ser12",
            "probability": 0.0
        },
        {
            "start_logit": -0.11407470703125,
            "end_logit": 6.7265625,
            "text": "Ser129",
            "probability": 0.0
        },
        {
            "start_logit": -7.9375,
            "end_logit": 13.3671875,
            "text": "at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -8.265625,
            "end_logit": 13.3671875,
            "text": "Approximately 90% of \u03b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.140625,
            "text": "serine 129 (Ser129)",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.3359375,
            "text": "serine 129 (",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": 13.3671875,
            "text": "\u03b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -10.0390625,
            "end_logit": 13.3671875,
            "text": "Lewy bodies is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 13.3671875,
            "text": "90% of \u03b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -10.078125,
            "text": "serine 129 (Ser",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -10.1015625,
            "text": "serine 129 (Ser129). In contrast",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -10.25,
            "text": "serine 129 (Ser129).",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 13.3671875,
            "text": "in Lewy bodies is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -10.421875,
            "text": "serine 129 (Ser129). In contrast, only 4% or less of total \u03b1-syn is phosphorylated at this residue in the normal brain",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 13.3671875,
            "text": "of \u03b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 13.3671875,
            "text": "phosphorylated at serine 129",
            "probability": 0.0
        }
    ],
    "550c4011a103b78016000009_3": [
        {
            "start_logit": 14.15625,
            "end_logit": 14.6171875,
            "text": "serine 129",
            "probability": 1.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -1.859375,
            "text": "serine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.80078125,
            "end_logit": 14.6171875,
            "text": "129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.15625,
            "end_logit": -3.7109375,
            "text": "serine 129 (Ser129",
            "probability": 0.0
        },
        {
            "start_logit": -7.2578125,
            "end_logit": 14.6171875,
            "text": "Alpha-synuclein is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -7.96875,
            "text": "serine 129 (Ser12",
            "probability": 0.0
        },
        {
            "start_logit": -8.6171875,
            "end_logit": 14.6171875,
            "text": "at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -8.4765625,
            "text": "serine 129 (Ser129)",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -8.8515625,
            "text": "serine 129 (",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.265625,
            "text": "serine 129 (Ser129) in",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.296875,
            "text": "serine 129 (Ser",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.84375,
            "text": "serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -9.921875,
            "text": "serine 129 (Ser129) in intracellular protein aggregates",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -10.0,
            "text": "serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies.",
            "probability": 0.0
        },
        {
            "start_logit": 14.15625,
            "end_logit": -10.046875,
            "text": "serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies. These inclusion bodies are the characteristic pathologic lesions of Parkinson disease",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 14.6171875,
            "text": "synuclein is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 14.6171875,
            "text": "phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -2.80078125,
            "end_logit": -3.7109375,
            "text": "129 (Ser129",
            "probability": 0.0
        },
        {
            "start_logit": -7.2578125,
            "end_logit": -1.859375,
            "text": "Alpha-synuclein is phosphorylated at serine",
            "probability": 0.0
        },
        {
            "start_logit": -5.4765625,
            "end_logit": -3.7109375,
            "text": "Ser129",
            "probability": 0.0
        }
    ],
    "550c4011a103b78016000009_4": [
        {
            "start_logit": 14.0859375,
            "end_logit": 14.609375,
            "text": "serine 129",
            "probability": 1.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -1.998046875,
            "text": "serine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.751953125,
            "end_logit": 14.609375,
            "text": "129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -2.87890625,
            "text": "serine 129 (Ser129",
            "probability": 0.0
        },
        {
            "start_logit": -6.7578125,
            "end_logit": 14.609375,
            "text": "Alpha-synuclein is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -7.5625,
            "text": "serine 129 (Ser12",
            "probability": 0.0
        },
        {
            "start_logit": -8.46875,
            "end_logit": 14.609375,
            "text": "at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.7734375,
            "text": "serine 129 (Ser129)",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -8.9140625,
            "text": "serine 129 (",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.015625,
            "text": "serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies.",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.609375,
            "text": "serine 129 (Ser129) in",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.6171875,
            "text": "serine 129 (Ser",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.7421875,
            "text": "serine 129 (Ser129) in intracellular protein aggregates",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 14.609375,
            "text": "synuclein is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 14.0859375,
            "end_logit": -9.9375,
            "text": "serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 14.609375,
            "text": "phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 14.609375,
            "text": "-synuclein is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -2.751953125,
            "end_logit": -2.87890625,
            "text": "129 (Ser129",
            "probability": 0.0
        },
        {
            "start_logit": -5.02734375,
            "end_logit": -2.87890625,
            "text": "Ser129",
            "probability": 0.0
        },
        {
            "start_logit": -6.7578125,
            "end_logit": -1.998046875,
            "text": "Alpha-synuclein is phosphorylated at serine",
            "probability": 0.0
        }
    ],
    "550c4011a103b78016000009_5": [
        {
            "start_logit": 14.078125,
            "end_logit": 14.65625,
            "text": "serine 129",
            "probability": 1.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -1.9580078125,
            "text": "serine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.8125,
            "end_logit": 14.65625,
            "text": "129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.078125,
            "end_logit": -3.67578125,
            "text": "serine 129 (Ser129",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": 14.65625,
            "text": "\u00ce\u00b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": 14.65625,
            "text": "at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -7.81640625,
            "text": "serine 129 (Ser12",
            "probability": 0.0
        },
        {
            "start_logit": -8.7421875,
            "end_logit": 14.65625,
            "text": "\u00b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -8.8515625,
            "end_logit": 14.65625,
            "text": "Approximately 90% of \u00ce\u00b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -8.4765625,
            "text": "serine 129 (Ser129).",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": 14.65625,
            "text": "90% of \u00ce\u00b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": 14.65625,
            "text": "syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -8.859375,
            "text": "serine 129 (Ser129)",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": 14.65625,
            "text": "Lewy bodies is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 14.65625,
            "text": "of \u00ce\u00b1-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -9.390625,
            "text": "serine 129 (",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 14.65625,
            "text": "-syn deposited in Lewy bodies is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 14.078125,
            "end_logit": -9.6640625,
            "text": "serine 129 (Ser",
            "probability": 0.0
        },
        {
            "start_logit": -2.8125,
            "end_logit": -3.67578125,
            "text": "129 (Ser129",
            "probability": 0.0
        },
        {
            "start_logit": -5.9453125,
            "end_logit": -1.9580078125,
            "text": "\u00ce\u00b1-syn deposited in Lewy bodies is phosphorylated at serine",
            "probability": 0.0
        }
    ],
    "550c4011a103b78016000009_6": [
        {
            "start_logit": 13.53125,
            "end_logit": 14.2734375,
            "text": "serine 129",
            "probability": 1.0
        },
        {
            "start_logit": -3.359375,
            "end_logit": 14.2734375,
            "text": "129",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.53125,
            "end_logit": -2.744140625,
            "text": "serine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.53125,
            "end_logit": -5.23828125,
            "text": "serine 129 (Ser129",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": 14.2734375,
            "text": "at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -8.3203125,
            "text": "serine 129 (Ser12",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": 14.2734375,
            "text": "Alpha-synuclein is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -8.890625,
            "text": "serine 129 (Ser129)",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -8.984375,
            "text": "serine 129 (",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -9.6796875,
            "text": "serine 129 (Ser",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -9.7734375,
            "text": "serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -9.796875,
            "text": "serine 129 (Ser129) in",
            "probability": 0.0
        },
        {
            "start_logit": 13.53125,
            "end_logit": -9.8125,
            "text": "serine 129 (Ser129) in intracellular protein aggregates",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 14.2734375,
            "text": "synuclein is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 14.2734375,
            "text": "phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 14.2734375,
            "text": "-synuclein is phosphorylated at serine 129",
            "probability": 0.0
        },
        {
            "start_logit": -3.359375,
            "end_logit": -5.23828125,
            "text": "129 (Ser129",
            "probability": 0.0
        },
        {
            "start_logit": -3.359375,
            "end_logit": -8.3203125,
            "text": "129 (Ser12",
            "probability": 0.0
        },
        {
            "start_logit": -8.9453125,
            "end_logit": -2.744140625,
            "text": "at serine",
            "probability": 0.0
        },
        {
            "start_logit": -9.109375,
            "end_logit": -2.744140625,
            "text": "Alpha-synuclein is phosphorylated at serine",
            "probability": 0.0
        }
    ],
    "56d19a363975bb303a000017_1": [
        {
            "start_logit": 12.3125,
            "end_logit": 15.1875,
            "text": "MDM two binding protein (MTBP)",
            "probability": 1.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": 6.859375,
            "text": "MDM two binding protein",
            "probability": 0.0002416372299194336
        },
        {
            "start_logit": -0.430419921875,
            "end_logit": 15.1875,
            "text": "(MTBP)",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": -1.2919921875,
            "end_logit": 15.1875,
            "text": "protein (MTBP)",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -2.0546875,
            "end_logit": 15.1875,
            "text": ")",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.21875,
            "end_logit": 15.1875,
            "text": "MTBP)",
            "probability": 0.0
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 15.1875,
            "text": "binding protein (MTBP)",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -4.91015625,
            "text": "MD",
            "probability": 0.0
        },
        {
            "start_logit": -8.8515625,
            "end_logit": 15.1875,
            "text": "identified MDM two binding protein (MTBP)",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 15.1875,
            "text": "M two binding protein (MTBP)",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -6.5234375,
            "text": "MDM two binding protein (MTBP",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 15.1875,
            "text": "two binding protein (MTBP)",
            "probability": 0.0
        },
        {
            "start_logit": -1.2919921875,
            "end_logit": 6.859375,
            "text": "protein",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 15.1875,
            "text": "P)",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -8.34375,
            "text": "MDM two binding protein (MTBP) as",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -8.390625,
            "text": "MDM two binding protein (",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -9.359375,
            "text": "MDM two binding protein (MTBP) as a",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -9.7421875,
            "text": "MDM",
            "probability": 0.0
        },
        {
            "start_logit": 12.3125,
            "end_logit": -9.90625,
            "text": "MDM two binding protein (MTBP) as a factor that interacts with Treslin/TICRR throughout the cell cycle. We show",
            "probability": 0.0
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 6.859375,
            "text": "binding protein",
            "probability": 0.0
        }
    ],
    "56d19a363975bb303a000017_2": [
        {
            "start_logit": 8.6171875,
            "end_logit": 14.28125,
            "text": "MDM two binding protein (MTBP)",
            "probability": 1.0
        },
        {
            "start_logit": -2.3515625,
            "end_logit": 14.28125,
            "text": "protein (MTBP)",
            "probability": 1.710653305053711e-05
        },
        {
            "start_logit": -3.65625,
            "end_logit": 14.28125,
            "text": ")",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": 8.6171875,
            "end_logit": 0.66748046875,
            "text": "MDM two binding protein",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -5.9375,
            "end_logit": 14.28125,
            "text": "(MTBP)",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.96875,
            "end_logit": 14.28125,
            "text": "binding protein (MTBP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.8828125,
            "end_logit": 14.28125,
            "text": "identified MDM two binding protein (MTBP)",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": 14.28125,
            "text": "MTBP)",
            "probability": 0.0
        },
        {
            "start_logit": -9.3125,
            "end_logit": 14.28125,
            "text": "P)",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 14.28125,
            "text": "two binding protein (MTBP)",
            "probability": 0.0
        },
        {
            "start_logit": -9.390625,
            "end_logit": 14.28125,
            "text": "M two binding protein (MTBP)",
            "probability": 0.0
        },
        {
            "start_logit": 8.6171875,
            "end_logit": -6.96875,
            "text": "MD",
            "probability": 0.0
        },
        {
            "start_logit": 8.6171875,
            "end_logit": -8.53125,
            "text": "MDM two binding protein (MTBP) as",
            "probability": 0.0
        },
        {
            "start_logit": 8.6171875,
            "end_logit": -8.859375,
            "text": "MDM two binding protein (MTBP",
            "probability": 0.0
        },
        {
            "start_logit": 8.6171875,
            "end_logit": -9.34375,
            "text": "MDM two binding protein (",
            "probability": 0.0
        },
        {
            "start_logit": 8.6171875,
            "end_logit": -9.4609375,
            "text": "MDM two binding protein (MTBP) as a factor that interacts with Treslin/TICRR throughout the cell cycle",
            "probability": 0.0
        },
        {
            "start_logit": 8.6171875,
            "end_logit": -9.765625,
            "text": "MDM two binding protein (MTBP) as a",
            "probability": 0.0
        },
        {
            "start_logit": 8.6171875,
            "end_logit": -9.859375,
            "text": "MDM",
            "probability": 0.0
        },
        {
            "start_logit": 8.6171875,
            "end_logit": -9.9765625,
            "text": "MDM two binding protein (MTB",
            "probability": 0.0
        },
        {
            "start_logit": 8.6171875,
            "end_logit": -10.09375,
            "text": "MDM two binding protein (MTBP) as a factor that interacts with Treslin/TICRR",
            "probability": 0.0
        }
    ],
    "56d19a363975bb303a000017_3": [
        {
            "start_logit": 7.234375,
            "end_logit": 11.9765625,
            "text": "MDM two binding protein (MTBP)",
            "probability": 0.994140625
        },
        {
            "start_logit": 7.234375,
            "end_logit": 6.765625,
            "text": "MDM two binding protein",
            "probability": 0.005382537841796875
        },
        {
            "start_logit": -4.76171875,
            "end_logit": 11.9765625,
            "text": "protein (MTBP)",
            "probability": 6.079673767089844e-06
        },
        {
            "start_logit": -5.28515625,
            "end_logit": 11.9765625,
            "text": "identified MDM two binding protein (MTBP)",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -5.83203125,
            "end_logit": 11.9765625,
            "text": ")",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 11.9765625,
            "text": "binding protein (MTBP)",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -8.7734375,
            "end_logit": 11.9765625,
            "text": "(MTBP)",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.5078125,
            "end_logit": 11.9765625,
            "text": "two binding protein (MTBP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.78125,
            "end_logit": 11.9765625,
            "text": "M two binding protein (MTBP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.76171875,
            "end_logit": 6.765625,
            "text": "protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.0,
            "end_logit": 11.9765625,
            "text": "DNA replication factor that is regulated by cyclin-dependent kinases and the DNA damage checkpoint. We identified MDM two binding protein (MTBP)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 11.9765625,
            "text": "MTBP)",
            "probability": 0.0
        },
        {
            "start_logit": -5.28515625,
            "end_logit": 6.765625,
            "text": "identified MDM two binding protein",
            "probability": 0.0
        },
        {
            "start_logit": 7.234375,
            "end_logit": -7.21484375,
            "text": "MD",
            "probability": 0.0
        },
        {
            "start_logit": -7.71484375,
            "end_logit": 6.765625,
            "text": "binding protein",
            "probability": 0.0
        },
        {
            "start_logit": 7.234375,
            "end_logit": -8.328125,
            "text": "MDM two binding protein (MTBP",
            "probability": 0.0
        },
        {
            "start_logit": 7.234375,
            "end_logit": -9.15625,
            "text": "MDM two binding protein (MTBP) as",
            "probability": 0.0
        },
        {
            "start_logit": 7.234375,
            "end_logit": -9.5390625,
            "text": "MDM two binding protein (MTBP) as a factor that interacts with Treslin/TICRR throughout the cell cycle.",
            "probability": 0.0
        },
        {
            "start_logit": 7.234375,
            "end_logit": -9.6640625,
            "text": "MDM two binding protein (MTBP) as a",
            "probability": 0.0
        },
        {
            "start_logit": 7.234375,
            "end_logit": -9.90625,
            "text": "MDM two binding protein (MTBP) as a factor that interacts with Treslin/TICRR throughout the cell cycle",
            "probability": 0.0
        }
    ],
    "620c28d03a8413c653000007_1": [
        {
            "start_logit": 10.3359375,
            "end_logit": 13.796875,
            "text": "myeloid leukaemia",
            "probability": 1.0
        },
        {
            "start_logit": -4.35546875,
            "end_logit": 13.796875,
            "text": "leukaemia",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.8125,
            "end_logit": 13.796875,
            "text": "against myeloid leukaemia",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.3359375,
            "end_logit": -5.46875,
            "text": "myeloid",
            "probability": 0.0
        },
        {
            "start_logit": 10.3359375,
            "end_logit": -6.8828125,
            "text": "myeloid leukaemia.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 13.796875,
            "text": "Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 13.796875,
            "text": "METTL3 as a strategy against myeloid leukaemia",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 13.796875,
            "text": "molecule inhibition of METTL3 as a strategy against myeloid leukaemia",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 13.796875,
            "text": "-molecule inhibition of METTL3 as a strategy against myeloid leukaemia",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 13.796875,
            "text": "inhibition of METTL3 as a strategy against myeloid leukaemia",
            "probability": 0.0
        },
        {
            "start_logit": -4.35546875,
            "end_logit": -6.8828125,
            "text": "leukaemia.",
            "probability": 0.0
        },
        {
            "start_logit": -6.8125,
            "end_logit": -5.46875,
            "text": "against myeloid",
            "probability": 0.0
        },
        {
            "start_logit": -6.8125,
            "end_logit": -6.8828125,
            "text": "against myeloid leukaemia.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": -5.46875,
            "text": "Small-molecule inhibition of METTL3 as a strategy against myeloid",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": -5.46875,
            "text": "METTL3 as a strategy against myeloid",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": -5.46875,
            "text": "molecule inhibition of METTL3 as a strategy against myeloid",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": -5.46875,
            "text": "-molecule inhibition of METTL3 as a strategy against myeloid",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": -5.46875,
            "text": "inhibition of METTL3 as a strategy against myeloid",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": -6.8828125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": -6.8828125,
            "text": "Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia.",
            "probability": 0.0
        }
    ],
    "5ad6e431133db5eb7800000e_1": [
        {
            "start_logit": 8.15625,
            "end_logit": 9.4609375,
            "text": "Ishihara test",
            "probability": 0.9951171875
        },
        {
            "start_logit": 8.15625,
            "end_logit": 4.171875,
            "text": "Ishihara",
            "probability": 0.004985809326171875
        },
        {
            "start_logit": -5.84765625,
            "end_logit": 9.4609375,
            "text": "test",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -6.16015625,
            "end_logit": 9.4609375,
            "text": "ara test",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 9.4609375,
            "text": "ihara test",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 9.4609375,
            "text": "color blindness based on the Ishihara test",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.21875,
            "end_logit": 9.4609375,
            "text": "the Ishihara test",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.2109375,
            "text": "Ishih",
            "probability": 0.0
        },
        {
            "start_logit": 8.15625,
            "end_logit": -8.2734375,
            "text": "Ish",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 9.4609375,
            "text": "on the Ishihara test",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 9.4609375,
            "text": "patients had color blindness based on the Ishihara test",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 9.4609375,
            "text": "12 patients had color blindness based on the Ishihara test",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 9.4609375,
            "text": "had color blindness based on the Ishihara test",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 9.4609375,
            "text": "based on the Ishihara test",
            "probability": 0.0
        },
        {
            "start_logit": -6.16015625,
            "end_logit": 4.171875,
            "text": "ara",
            "probability": 0.0
        },
        {
            "start_logit": -7.66796875,
            "end_logit": 4.171875,
            "text": "ihara",
            "probability": 0.0
        },
        {
            "start_logit": -7.85546875,
            "end_logit": 4.171875,
            "text": "color blindness based on the Ishihara",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 4.171875,
            "text": "the Ishihara",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 4.171875,
            "text": "on the Ishihara",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 4.171875,
            "text": "patients had color blindness based on the Ishihara",
            "probability": 0.0
        }
    ],
    "5ad6e431133db5eb7800000e_2": [
        {
            "start_logit": 10.84375,
            "end_logit": 13.375,
            "text": "Ishihara",
            "probability": 1.0
        },
        {
            "start_logit": -3.359375,
            "end_logit": 13.375,
            "text": "ara",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 10.84375,
            "end_logit": -4.96484375,
            "text": "Ishihara test cards (1987",
            "probability": 0.0
        },
        {
            "start_logit": 10.84375,
            "end_logit": -5.56640625,
            "text": "Ishihara test cards",
            "probability": 0.0
        },
        {
            "start_logit": -8.4765625,
            "end_logit": 13.375,
            "text": "the Ishihara",
            "probability": 0.0
        },
        {
            "start_logit": 10.84375,
            "end_logit": -6.29296875,
            "text": "Ishih",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": 13.375,
            "text": "ihara",
            "probability": 0.0
        },
        {
            "start_logit": 10.84375,
            "end_logit": -6.8515625,
            "text": "Ish",
            "probability": 0.0
        },
        {
            "start_logit": 10.84375,
            "end_logit": -7.34765625,
            "text": "Ishihara test",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 13.375,
            "text": "using the Ishihara",
            "probability": 0.0
        },
        {
            "start_logit": 10.84375,
            "end_logit": -7.8515625,
            "text": "Ishihara test cards (1987).",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 13.375,
            "text": "Basque students (174 males and 218 females), using the Ishihara",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 13.375,
            "text": "and 218 females), using the Ishihara",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 13.375,
            "text": "males and 218 females), using the Ishihara",
            "probability": 0.0
        },
        {
            "start_logit": 10.84375,
            "end_logit": -9.953125,
            "text": "Ishihara test cards (1987)",
            "probability": 0.0
        },
        {
            "start_logit": -3.359375,
            "end_logit": -4.96484375,
            "text": "ara test cards (1987",
            "probability": 0.0
        },
        {
            "start_logit": -3.359375,
            "end_logit": -5.56640625,
            "text": "ara test cards",
            "probability": 0.0
        },
        {
            "start_logit": -3.359375,
            "end_logit": -7.34765625,
            "text": "ara test",
            "probability": 0.0
        },
        {
            "start_logit": -3.359375,
            "end_logit": -7.8515625,
            "text": "ara test cards (1987).",
            "probability": 0.0
        },
        {
            "start_logit": -7.484375,
            "end_logit": -4.96484375,
            "text": "test cards (1987",
            "probability": 0.0
        }
    ],
    "5ad6e431133db5eb7800000e_3": [
        {
            "start_logit": 10.296875,
            "end_logit": 13.34375,
            "text": "Ishihara Test",
            "probability": 1.0
        },
        {
            "start_logit": 10.296875,
            "end_logit": 4.328125,
            "text": "Ishihara",
            "probability": 0.0001214742660522461
        },
        {
            "start_logit": -3.7734375,
            "end_logit": 13.34375,
            "text": "Test",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -6.375,
            "end_logit": 13.34375,
            "text": "ara Test",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 13.34375,
            "text": "ihara Test",
            "probability": 0.0
        },
        {
            "start_logit": -8.625,
            "end_logit": 13.34375,
            "text": "color-blindness problems by Ishihara Test",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 13.34375,
            "text": "by Ishihara Test",
            "probability": 0.0
        },
        {
            "start_logit": 10.296875,
            "end_logit": -7.078125,
            "text": "Ish",
            "probability": 0.0
        },
        {
            "start_logit": 10.296875,
            "end_logit": -7.09765625,
            "text": "Ishihara Test.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 13.34375,
            "text": "3 TUMS Clinical Laboratory Sciences' Students and Hospitals' Clinical Laboratories' Employees to detect color-blindness problems by Ishihara Test",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 13.34375,
            "text": "TUMS Clinical Laboratory Sciences' Students and Hospitals' Clinical Laboratories' Employees to detect color-blindness problems by Ishihara Test",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 13.34375,
            "text": "633 TUMS Clinical Laboratory Sciences' Students and Hospitals' Clinical Laboratories' Employees to detect color-blindness problems by Ishihara Test",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 13.34375,
            "text": "Clinical Laboratories' Employees to detect color-blindness problems by Ishihara Test",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 13.34375,
            "text": "among 633 TUMS Clinical Laboratory Sciences' Students and Hospitals' Clinical Laboratories' Employees to detect color-blindness problems by Ishihara Test",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 13.34375,
            "text": "' Employees to detect color-blindness problems by Ishihara Test",
            "probability": 0.0
        },
        {
            "start_logit": 10.296875,
            "end_logit": -8.15625,
            "text": "Ishih",
            "probability": 0.0
        },
        {
            "start_logit": -6.375,
            "end_logit": 4.328125,
            "text": "ara",
            "probability": 0.0
        },
        {
            "start_logit": -7.13671875,
            "end_logit": 4.328125,
            "text": "ihara",
            "probability": 0.0
        },
        {
            "start_logit": -8.625,
            "end_logit": 4.328125,
            "text": "color-blindness problems by Ishihara",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 4.328125,
            "text": "by Ishihara",
            "probability": 0.0
        }
    ],
    "5321bc309b2d7acc7e00000d_1": [
        {
            "start_logit": 14.5390625,
            "end_logit": 15.2421875,
            "text": "PI3K-\u03b4",
            "probability": 1.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": 15.2421875,
            "text": "\u03b4",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -1.7041015625,
            "text": "PI3K",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -4.52734375,
            "text": "PI3K-",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": 15.2421875,
            "text": "-\u03b4",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -9.2578125,
            "text": "PI3K-\u03b4 inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -9.5859375,
            "text": "PI3K-\u03b4 inhibitor idelalisib",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -9.8671875,
            "text": "PI3K-\u03b4 inhibitor ide",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -10.1171875,
            "text": "PI3K-\u03b4 inhibitor idela",
            "probability": 0.0
        },
        {
            "start_logit": 14.5390625,
            "end_logit": -10.21875,
            "text": "PI3K-\u03b4 inhibitor idelalisi",
            "probability": 0.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": -9.2578125,
            "text": "\u03b4 inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": -9.5859375,
            "text": "\u03b4 inhibitor idelalisib",
            "probability": 0.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": -9.8671875,
            "text": "\u03b4 inhibitor ide",
            "probability": 0.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": -10.1171875,
            "text": "\u03b4 inhibitor idela",
            "probability": 0.0
        },
        {
            "start_logit": -1.615234375,
            "end_logit": -10.21875,
            "text": "\u03b4 inhibitor idelalisi",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -4.52734375,
            "text": "-",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -9.2578125,
            "text": "-\u03b4 inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -9.5859375,
            "text": "-\u03b4 inhibitor idelalisib",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -9.8671875,
            "text": "-\u03b4 inhibitor ide",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -10.1171875,
            "text": "-\u03b4 inhibitor idela",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_1": [
        {
            "start_logit": 11.4296875,
            "end_logit": 11.546875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.4296875,
            "end_logit": -9.671875,
            "text": "BRAF inhibitors (BRAFi) vemurafenib (PLX4032",
            "probability": 0.0
        },
        {
            "start_logit": 11.4296875,
            "end_logit": -9.9296875,
            "text": "BRAF inhibitors (BRAFi) vemurafenib",
            "probability": 0.0
        },
        {
            "start_logit": 11.4296875,
            "end_logit": -9.9375,
            "text": "BRAF inhibitors (BRAFi) vemurafenib (PLX4032), dabrafenib, or encorafenib with",
            "probability": 0.0
        },
        {
            "start_logit": 11.4296875,
            "end_logit": -10.0,
            "text": "BRAF inhibitors (BRAFi",
            "probability": 0.0
        },
        {
            "start_logit": 11.4296875,
            "end_logit": -10.03125,
            "text": "BRAF inhibitors (BRAFi) ve",
            "probability": 0.0
        },
        {
            "start_logit": 11.4296875,
            "end_logit": -10.1015625,
            "text": "BRAF inhibitors (BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.4296875,
            "end_logit": -10.125,
            "text": "BRAF inhibitors",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -8.6796875,
            "text": "the metabolic activity and proliferative potential of CRC",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": -8.6796875,
            "text": "the EGFR and HER2 (such as lapatinib, canertinib, and afatinib) significantly reduced the metabolic activity and proliferative potential of CRC",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": -8.6796875,
            "text": "reduced the metabolic activity and proliferative potential of CRC",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": -8.6796875,
            "text": "metabolic activity and proliferative potential of CRC",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": -8.6796875,
            "text": "and proliferative potential of CRC",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": -8.6796875,
            "text": "of CRC",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": -8.6796875,
            "text": "potential of CRC",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": -8.6796875,
            "text": "targeting the EGFR and HER2 (such as lapatinib, canertinib, and afatinib) significantly reduced the metabolic activity and proliferative potential of CRC",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": -8.6796875,
            "text": ", and afatinib) significantly reduced the metabolic activity and proliferative potential of CRC",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -9.671875,
            "text": "BRAFi) vemurafenib (PLX4032",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -9.6796875,
            "text": "the metabolic activity and proliferative potential of CRC cells.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -9.875,
            "text": ", or encorafenib with inhibitors dually targeting the EGFR and HER2",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_2": [
        {
            "start_logit": 11.2109375,
            "end_logit": 11.5078125,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": -5.453125,
            "end_logit": 11.5078125,
            "text": "V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.359375,
            "end_logit": 11.5078125,
            "text": "Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 11.5078125,
            "text": "(BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 11.5078125,
            "text": "Murine Sarcoma Viral Oncogene Homolog B (BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 11.5078125,
            "text": "Viral Oncogene Homolog B (BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 11.5078125,
            "text": "-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.2109375,
            "end_logit": -9.8359375,
            "text": "BRAF)",
            "probability": 0.0
        },
        {
            "start_logit": 11.2109375,
            "end_logit": -10.03125,
            "text": "BRAF)-inhibitor encorafenib",
            "probability": 0.0
        },
        {
            "start_logit": 11.2109375,
            "end_logit": -10.125,
            "text": "BRAF)-inhibitor enc",
            "probability": 0.0
        },
        {
            "start_logit": 11.2109375,
            "end_logit": -10.203125,
            "text": "BRAF)-inhibitor encorafenib (LGX818) and",
            "probability": 0.0
        },
        {
            "start_logit": 11.2109375,
            "end_logit": -10.3125,
            "text": "BRAF)-inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 11.2109375,
            "end_logit": -10.3359375,
            "text": "BRAF)-inhibitor encorafenib (LGX818",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 11.5078125,
            "text": "Oncogene Homolog B (BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 11.5078125,
            "text": "clinical data of the novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 11.5078125,
            "text": "novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 11.5078125,
            "text": "OF REVIEW: To describe the pharmacological properties, preclinical and clinical data of the novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 11.5078125,
            "text": "PURPOSE OF REVIEW: To describe the pharmacological properties, preclinical and clinical data of the novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -5.453125,
            "end_logit": -7.7109375,
            "text": "V-Raf Murine Sarcoma Viral Oncogene Homolog B",
            "probability": 0.0
        },
        {
            "start_logit": -5.453125,
            "end_logit": -9.25,
            "text": "V-Raf Murine Sarcoma Viral Oncogene Homolog B (",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_3": [
        {
            "start_logit": 11.4765625,
            "end_logit": 11.640625,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -9.546875,
            "text": "BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -9.734375,
            "text": "BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -10.1875,
            "text": "BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -10.2890625,
            "text": "BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binime",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -10.3046875,
            "text": "BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor bin",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -10.3359375,
            "text": "BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafen",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -10.3671875,
            "text": "BRAF inhibitor with unique target-binding properties, alone or in combination",
            "probability": 0.0
        },
        {
            "start_logit": 11.4765625,
            "end_logit": -10.4140625,
            "text": "BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 11.640625,
            "text": "a BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 11.640625,
            "text": "encorafenib, a BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -9.8125,
            "text": "BRAFV600-mutant melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": -10.125,
            "text": "BRAFV600-mutant melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": -9.8125,
            "text": "versus vemurafenib in patients with advanced BRAFV600-mutant melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -9.546875,
            "text": "target-binding properties, alone or in combination with the MEK",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -9.546875,
            "text": "a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -9.546875,
            "text": "binding properties, alone or in combination with the MEK",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -9.734375,
            "text": "target-binding properties, alone or in combination with the MEK inhibitor binimetinib",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -9.734375,
            "text": "a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": -9.546875,
            "text": "unique target-binding properties, alone or in combination with the MEK",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_4": [
        {
            "start_logit": 11.3671875,
            "end_logit": 11.375,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": 11.375,
            "text": "p-loop) mutations and compared these with WT or V600E/K BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -9.7265625,
            "end_logit": 11.375,
            "text": "class IIa (activation segment) or IIb (p-loop) mutations and compared these with WT or V600E/K BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -10.1796875,
            "text": "BRAF mutant cells. Cell lines and PDXs were treated with BRAFi (vemurafenib",
            "probability": 0.0
        },
        {
            "start_logit": 11.3671875,
            "end_logit": -10.2265625,
            "text": "BRAF mutant cells. Cell lines and PDXs were treated with BRAFi (vemurafenib, dabrafenib",
            "probability": 0.0
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 11.375,
            "text": "-loop) mutations and compared these with WT or V600E/K BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 11.375,
            "text": "K BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 11.375,
            "text": "(p-loop) mutations and compared these with WT or V600E/K BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 11.375,
            "text": "V600E/K BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 11.375,
            "text": "or V600E/K BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 11.375,
            "text": "/K BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.375,
            "text": "or IIb (p-loop) mutations and compared these with WT or V600E/K BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 11.375,
            "text": "600E/K BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -9.359375,
            "text": "BRAF L597S",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -9.59375,
            "text": "BRAF L597S metastatic melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -9.734375,
            "text": "BRAF L597S metastatic melanoma who were treated with dMAPKi",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -9.8125,
            "text": "BRAF L597S metastatic",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -9.84375,
            "text": "BRAF L597",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -9.9375,
            "text": "BRAF L5",
            "probability": 0.0
        },
        {
            "start_logit": -6.9609375,
            "end_logit": -10.125,
            "text": "BRAF L597S metastatic melanoma who were treated with dMAPKi.",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_5": [
        {
            "start_logit": 8.65625,
            "end_logit": 0.5576171875,
            "text": "BRAF/MEK",
            "probability": 0.533203125
        },
        {
            "start_logit": 8.65625,
            "end_logit": 0.41796875,
            "text": "BRAF",
            "probability": 0.466796875
        },
        {
            "start_logit": 8.65625,
            "end_logit": -8.734375,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic or inoperable melanoma with a BRAF",
            "probability": 4.929304122924805e-05
        },
        {
            "start_logit": 8.65625,
            "end_logit": -9.7109375,
            "text": "BRAF/",
            "probability": 1.8537044525146484e-05
        },
        {
            "start_logit": 8.65625,
            "end_logit": -9.8515625,
            "text": "BRAF/MEK inhibitor combination",
            "probability": 1.609325408935547e-05
        },
        {
            "start_logit": 8.65625,
            "end_logit": -9.9609375,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": 8.65625,
            "end_logit": -10.1015625,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic or inoperable melanoma with a BRAF V600E",
            "probability": 1.2576580047607422e-05
        },
        {
            "start_logit": 8.65625,
            "end_logit": -10.1015625,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic or inoperable melanoma with a BRAF V600E or V600K",
            "probability": 1.2576580047607422e-05
        },
        {
            "start_logit": 8.65625,
            "end_logit": -10.1953125,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic or inoperable melanoma",
            "probability": 1.1444091796875e-05
        },
        {
            "start_logit": 8.65625,
            "end_logit": -10.2421875,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic or inoperable",
            "probability": 1.0907649993896484e-05
        },
        {
            "start_logit": 8.65625,
            "end_logit": -10.3046875,
            "text": "BRAF/MEK inhibitor",
            "probability": 1.0251998901367188e-05
        },
        {
            "start_logit": 8.65625,
            "end_logit": -10.40625,
            "text": "BRAF/MEK inhibitor combination encorafenib/binime",
            "probability": 9.238719940185547e-06
        },
        {
            "start_logit": 8.65625,
            "end_logit": -10.4765625,
            "text": "BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": -5.39453125,
            "end_logit": 0.5576171875,
            "text": "MEK",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 0.5576171875,
            "text": "The FDA approved the BRAF/MEK",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.54296875,
            "end_logit": 0.41796875,
            "text": "The FDA approved the BRAF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.796875,
            "end_logit": 0.5576171875,
            "text": "/MEK",
            "probability": 0.0
        },
        {
            "start_logit": -8.9375,
            "end_logit": 0.5576171875,
            "text": "FDA approved the BRAF/MEK",
            "probability": 0.0
        },
        {
            "start_logit": -8.9375,
            "end_logit": 0.41796875,
            "text": "FDA approved the BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 0.5576171875,
            "text": "approved the BRAF/MEK",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_6": [
        {
            "start_logit": 11.09375,
            "end_logit": 11.5,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": 11.5,
            "text": "Braftovi\u2122), a BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -7.34765625,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -8.8671875,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally bioavailable drugs developed by Array BioPharma.",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -9.25,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally bioavailable drugs developed by Array BioPharma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 11.5,
            "text": "a BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.1484375,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.171875,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally bioavailable drugs developed by Array BioPhar",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.21875,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.21875,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.3125,
            "text": "BRAF inhibitor, and binimetinib (Mek",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.34375,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally bioavailable",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.34375,
            "text": "BRAF inhibitor, and binimetinib (Mektovi",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.3671875,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally bioavailable drugs developed",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.375,
            "text": "BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally bioavailable drugs",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 11.5,
            "text": "(Braftovi\u2122), a BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -7.34765625,
            "text": "Braftovi\u2122), a BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -9.1640625,
            "text": "Braf",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -10.1484375,
            "text": "Braftovi\u2122), a BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally",
            "probability": 0.0
        },
        {
            "start_logit": -6.68359375,
            "end_logit": -10.21875,
            "text": "Braftovi\u2122), a BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_7": [
        {
            "start_logit": 11.8125,
            "end_logit": 11.3359375,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.8125,
            "end_logit": -9.5625,
            "text": "BRAF mutations.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 11.3359375,
            "text": "with BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 11.3359375,
            "text": "Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 11.3359375,
            "text": "for unresectable or metastatic melanoma with BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 11.3359375,
            "text": "fenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 11.3359375,
            "text": "or metastatic melanoma with BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 11.3359375,
            "text": "unresectable or metastatic melanoma with BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 11.3359375,
            "text": "melanoma with BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 11.3359375,
            "text": "metastatic melanoma with BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 11.3359375,
            "text": "orafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 11.3359375,
            "text": "with binimetinib for unresectable or metastatic melanoma with BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": -9.5625,
            "text": "with BRAF mutations.",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -9.4296875,
            "text": "Encorafenib in combination with binimetinib",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": -9.5625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -9.5625,
            "text": "Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": -9.4296875,
            "text": "fenib in combination with binimetinib",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": -9.5625,
            "text": "for unresectable or metastatic melanoma with BRAF mutations.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": -9.5625,
            "text": "fenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": -9.5625,
            "text": "or metastatic melanoma with BRAF mutations.",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_8": [
        {
            "start_logit": 3.447265625,
            "end_logit": 6.6875,
            "text": "BRAF/MEK",
            "probability": 0.998046875
        },
        {
            "start_logit": -2.98828125,
            "end_logit": 6.6875,
            "text": "MEK",
            "probability": 0.0016040802001953125
        },
        {
            "start_logit": 3.447265625,
            "end_logit": -3.59765625,
            "text": "BRAF",
            "probability": 3.421306610107422e-05
        },
        {
            "start_logit": 3.447265625,
            "end_logit": -4.35546875,
            "text": "BRAF/MEK inhibitor combinations.",
            "probability": 1.5974044799804688e-05
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 6.6875,
            "text": "likely to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -10.015625,
            "end_logit": 6.6875,
            "text": "/MEK",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -10.46875,
            "end_logit": 6.6875,
            "text": "established BRAF/MEK",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -10.671875,
            "end_logit": 6.6875,
            "text": "Encorafenib plus binimetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 6.6875,
            "text": "fenib plus binimetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 6.6875,
            "text": "to established BRAF/MEK",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 6.6875,
            "text": "plus binimetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 6.6875,
            "text": "seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.953125,
            "end_logit": 6.6875,
            "text": "to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -11.015625,
            "end_logit": 6.6875,
            "text": "binimetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 6.6875,
            "text": "therapeutic alternative to established BRAF/MEK",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 3.447265625,
            "end_logit": -9.4140625,
            "text": "BRAF/MEK inhibitor combinations",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 3.447265625,
            "end_logit": -9.6484375,
            "text": "BRAF/MEK inhibitor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.98828125,
            "end_logit": -4.35546875,
            "text": "MEK inhibitor combinations.",
            "probability": 0.0
        },
        {
            "start_logit": -2.98828125,
            "end_logit": -9.4140625,
            "text": "MEK inhibitor combinations",
            "probability": 0.0
        },
        {
            "start_logit": -2.98828125,
            "end_logit": -9.6484375,
            "text": "MEK inhibitor",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_9": [
        {
            "start_logit": 11.625,
            "end_logit": 11.328125,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.34375,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same class.",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.4765625,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same class",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 11.328125,
            "text": "greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.953125,
            "text": "BRAF inhibition and increased potency",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -10.21875,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 11.328125,
            "text": "target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.328125,
            "text": "encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 11.328125,
            "text": "the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 11.328125,
            "text": "binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.328125,
            "text": "providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 11.328125,
            "text": "prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 11.328125,
            "text": "to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 11.328125,
            "text": "the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 11.328125,
            "text": "fenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -9.34375,
            "text": "greater BRAF inhibition and increased potency compared with other drugs in the same class.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -9.4765625,
            "text": "greater BRAF inhibition and increased potency compared with other drugs in the same class",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -9.34375,
            "text": "target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -9.953125,
            "text": "greater BRAF inhibition and increased potency",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -9.4765625,
            "text": "target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_10": [
        {
            "start_logit": 2.78125,
            "end_logit": 0.36376953125,
            "text": "BRAF/MEK",
            "probability": 0.8935546875
        },
        {
            "start_logit": 2.78125,
            "end_logit": -1.76953125,
            "text": "BRAF",
            "probability": 0.10589599609375
        },
        {
            "start_logit": 2.78125,
            "end_logit": -8.1640625,
            "text": "BRAF/MEK inhibitor combinations.",
            "probability": 0.0001761913299560547
        },
        {
            "start_logit": 2.78125,
            "end_logit": -9.84375,
            "text": "BRAF/MEK inhibitor",
            "probability": 3.314018249511719e-05
        },
        {
            "start_logit": 2.78125,
            "end_logit": -9.9921875,
            "text": "BRAF/MEK inhibitor combinations",
            "probability": 2.8312206268310547e-05
        },
        {
            "start_logit": -7.90625,
            "end_logit": 0.36376953125,
            "text": "MEK",
            "probability": 2.0384788513183594e-05
        },
        {
            "start_logit": -8.6171875,
            "end_logit": 0.36376953125,
            "text": "Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 0.36376953125,
            "text": "/MEK",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -10.390625,
            "end_logit": 0.36376953125,
            "text": "existing BRAF/MEK",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -10.421875,
            "end_logit": 0.36376953125,
            "text": "bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -10.484375,
            "end_logit": 0.36376953125,
            "text": "Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -10.515625,
            "end_logit": 0.36376953125,
            "text": ": Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 0.36376953125,
            "text": "over existing BRAF/MEK",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -10.734375,
            "end_logit": 0.36376953125,
            "text": "fenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 0.36376953125,
            "text": "approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -8.6171875,
            "end_logit": -1.76953125,
            "text": "Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -10.859375,
            "end_logit": 0.36376953125,
            "text": "with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 0.36376953125,
            "text": "etinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 0.36376953125,
            "text": "a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -10.390625,
            "end_logit": -1.76953125,
            "text": "existing BRAF",
            "probability": 2.384185791015625e-07
        }
    ],
    "5e319789fbd6abf43b00004a_11": [
        {
            "start_logit": 11.5546875,
            "end_logit": 11.5625,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -9.5078125,
            "text": "BRAF inhibitor that",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 11.5625,
            "text": "generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -9.7265625,
            "text": "BRAF inhibitor that is under evaluation in clinical trials.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 11.5625,
            "text": "Encorafenib (LGX818) is a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -10.2421875,
            "text": "BRAF inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 11.5625,
            "text": "new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -10.3515625,
            "text": "BRAF inhibitor that is under evaluation in clinical trials",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -10.390625,
            "text": "BRAF inhibitor that is under evaluation",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.5625,
            "text": "fenib (LGX818) is a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 11.5625,
            "text": "(LGX818) is a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 11.5625,
            "text": "-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 11.5625,
            "text": "orafenib (LGX818) is a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 11.5625,
            "text": "a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 11.5625,
            "text": "818) is a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 11.5625,
            "text": "LGX818) is a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 11.5625,
            "text": "X818) is a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": -9.5078125,
            "text": "generation BRAF inhibitor that",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": -9.7265625,
            "text": "generation BRAF inhibitor that is under evaluation in clinical trials.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -9.5078125,
            "text": "Encorafenib (LGX818) is a new-generation BRAF inhibitor that",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_12": [
        {
            "start_logit": 1.87890625,
            "end_logit": 0.51416015625,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 1.87890625,
            "end_logit": -9.171875,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF",
            "probability": 6.204843521118164e-05
        },
        {
            "start_logit": 1.87890625,
            "end_logit": -9.2734375,
            "text": "BRAF/MEK",
            "probability": 5.608797073364258e-05
        },
        {
            "start_logit": -8.34375,
            "end_logit": 0.51416015625,
            "text": "Expert Opinion: While other BRAF",
            "probability": 3.647804260253906e-05
        },
        {
            "start_logit": 1.87890625,
            "end_logit": -10.03125,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive melanoma",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": 1.87890625,
            "end_logit": -10.109375,
            "text": "BRAF/MEK inhibitor combinations",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": 1.87890625,
            "end_logit": -10.171875,
            "text": "BRAF/MEK inhibitor combinations have",
            "probability": 2.282857894897461e-05
        },
        {
            "start_logit": 1.87890625,
            "end_logit": -10.21875,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": 1.87890625,
            "end_logit": -10.3515625,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS)",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": -5.87109375,
            "end_logit": -9.171875,
            "text": "BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -5.87109375,
            "end_logit": -10.0,
            "text": "BRAF mutation-positive melanoma treated with encorafenib plus binimetinib achieved a median OS of 33",
            "probability": 0.0
        },
        {
            "start_logit": -5.87109375,
            "end_logit": -10.03125,
            "text": "BRAF mutation-positive melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -5.87109375,
            "end_logit": -10.03125,
            "text": "BRAF mutation-positive melanoma treated with encorafenib plus binimetinib",
            "probability": 0.0
        },
        {
            "start_logit": -5.87109375,
            "end_logit": -10.3671875,
            "text": "BRAF mutation-positive melanoma treated with encorafenib plus binimetinib achieved a median OS",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -9.171875,
            "text": "Expert Opinion: While other BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -9.2734375,
            "text": "Expert Opinion: While other BRAF/MEK",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -9.5390625,
            "text": "Expert Opinion",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -10.109375,
            "text": "Expert Opinion: While other BRAF/MEK inhibitor combinations",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -10.171875,
            "text": "Expert Opinion: While other BRAF/MEK inhibitor combinations have",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -10.21875,
            "text": "Expert Opinion: While other BRAF/MEK inhibitor combinations have achieved a median overall survival (OS",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_13": [
        {
            "start_logit": 11.875,
            "end_logit": 11.328125,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -9.171875,
            "text": "BRAF __sup__ V600E",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 11.328125,
            "text": "promising BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -10.09375,
            "text": "BRAF __sup__ V600E __end_sup__  inhibitor that",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -10.1328125,
            "text": "BRAF __sup__ V600E __end_sup__  inhibitor that has efficacy against metastatic melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -10.1953125,
            "text": "BRAF __sup__ V600E __end_sup__",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -10.2421875,
            "text": "BRAF _",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -10.34375,
            "text": "BRAF __sup__ V600E __end_sup_",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -10.375,
            "text": "BRAF __sup__ V600E __end_sup__  inhibitor that has efficacy against metastatic melanoma",
            "probability": 0.0
        },
        {
            "start_logit": 11.875,
            "end_logit": -10.515625,
            "text": "BRAF __sup__ V600E __end_sup__  inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 11.328125,
            "text": "Encorafenib (LGX818) is a promising BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 11.328125,
            "text": "a promising BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -9.234375,
            "end_logit": -9.171875,
            "text": "V600E",
            "probability": 0.0
        },
        {
            "start_logit": -9.2578125,
            "end_logit": -9.171875,
            "text": "_ V600E",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": -9.171875,
            "text": "promising BRAF __sup__ V600E",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": -9.171875,
            "text": "_sup__ V600E",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": -10.09375,
            "text": "end_sup__  inhibitor that",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": -10.1328125,
            "text": "end_sup__  inhibitor that has efficacy against metastatic melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -8.9609375,
            "end_logit": -10.1953125,
            "text": "end_sup__",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": -9.171875,
            "text": "600E",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_14": [
        {
            "start_logit": 11.546875,
            "end_logit": 11.453125,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -9.46875,
            "text": "BRAF inhibitor (BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -9.8828125,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis.",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.0078125,
            "text": "BRAF inhibitor (BRAFi",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.171875,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.2265625,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.2421875,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.2421875,
            "text": "BRAF inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.3515625,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.4375,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.4453125,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 11.453125,
            "text": ":  Encorafenib, a selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 11.453125,
            "text": "selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 11.453125,
            "text": "Encorafenib, a selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 11.453125,
            "text": "a selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 11.453125,
            "text": "fenib, a selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 11.453125,
            "text": "Purpose:  Encorafenib, a selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -9.46875,
            "text": "BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -9.8828125,
            "text": "BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis.",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -10.0078125,
            "text": "BRAFi",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_15": [
        {
            "start_logit": 11.84375,
            "end_logit": 11.21875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -8.328125,
            "text": "BRAF V600E/K-mutated melanoma",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -8.46875,
            "text": "BRAF V600E/K-mutated melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -10.15625,
            "text": "BRAF V600E/K",
            "probability": 0.0
        },
        {
            "start_logit": 11.84375,
            "end_logit": -10.3828125,
            "text": "BRAF V600E",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 11.21875,
            "text": "treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 11.21875,
            "text": "of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 11.21875,
            "text": "for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 11.21875,
            "text": "the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -8.328125,
            "text": "V600E/K-mutated melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": -8.328125,
            "text": "600E/K-mutated melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -8.46875,
            "text": "V600E/K-mutated melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5,
            "end_logit": -8.46875,
            "text": "600E/K-mutated melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": -8.328125,
            "text": "K-mutated melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": -8.46875,
            "text": "K-mutated melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -8.328125,
            "text": "mutated melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -8.328125,
            "text": "/K-mutated melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": -8.46875,
            "text": "mutated melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -8.46875,
            "text": "/K-mutated melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": -8.328125,
            "text": "treatment of BRAF V600E/K-mutated melanoma",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_16": [
        {
            "start_logit": 1.9580078125,
            "end_logit": 1.3037109375,
            "text": "BRAF",
            "probability": 0.61376953125
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": 0.62939453125,
            "text": "BRAF and MEK",
            "probability": 0.312744140625
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": 1.3037109375,
            "text": "Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 0.04766845703125
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": 0.62939453125,
            "text": "Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0243072509765625
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": -5.22265625,
            "text": "BRAF and MEK, respectively",
            "probability": 0.0008974075317382812
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": -6.03125,
            "text": "BRAF and MEK, respectively.",
            "probability": 0.0003998279571533203
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": -5.22265625,
            "text": "Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK, respectively",
            "probability": 7.003545761108398e-05
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": -5.57421875,
            "text": "Braf",
            "probability": 4.887580871582031e-05
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": -6.03125,
            "text": "Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK, respectively.",
            "probability": 3.1113624572753906e-05
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": -10.0546875,
            "text": "BRAF and",
            "probability": 7.152557373046875e-06
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 1.3037109375,
            "text": "MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": -10.125,
            "text": "BRAF and MEK,",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 1.3037109375,
            "text": ", Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 0.62939453125,
            "text": "MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 1.3037109375,
            "text": ", Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": -8.578125,
            "text": "Braftovi",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 0.62939453125,
            "text": ", Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -10.640625,
            "end_logit": 1.3037109375,
            "text": "tovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 1.3037109375,
            "text": "(MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -10.71875,
            "end_logit": 1.3037109375,
            "text": "and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 1.9669532775878906e-06
        }
    ],
    "5e319789fbd6abf43b00004a_17": [
        {
            "start_logit": 1.9580078125,
            "end_logit": 1.3037109375,
            "text": "BRAF",
            "probability": 0.61376953125
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": 0.62939453125,
            "text": "BRAF and MEK",
            "probability": 0.312744140625
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": 1.3037109375,
            "text": "Braftovi ) and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF",
            "probability": 0.04766845703125
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": 0.62939453125,
            "text": "Braftovi ) and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0243072509765625
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": -5.22265625,
            "text": "BRAF and MEK , respectively",
            "probability": 0.0008974075317382812
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": -6.03125,
            "text": "BRAF and MEK , respectively .",
            "probability": 0.0003998279571533203
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": -5.22265625,
            "text": "Braftovi ) and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF and MEK , respectively",
            "probability": 7.003545761108398e-05
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": -5.57421875,
            "text": "Braf",
            "probability": 4.887580871582031e-05
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": -6.03125,
            "text": "Braftovi ) and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF and MEK , respectively .",
            "probability": 3.1113624572753906e-05
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": -10.0546875,
            "text": "BRAF and",
            "probability": 7.152557373046875e-06
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 1.3037109375,
            "text": "MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": -10.125,
            "text": "BRAF and MEK ,",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 1.3037109375,
            "text": ", Braftovi ) and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 0.62939453125,
            "text": "MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF and MEK",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 1.3037109375,
            "text": ", Mektovi ) are small-molecule inhibitors of BRAF",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": -8.578125,
            "text": "Braftovi",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 0.62939453125,
            "text": ", Braftovi ) and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF and MEK",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -10.640625,
            "end_logit": 1.3037109375,
            "text": "tovi ) and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 1.3037109375,
            "text": "( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -10.71875,
            "end_logit": 1.3037109375,
            "text": "and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF",
            "probability": 1.9669532775878906e-06
        }
    ],
    "5e319789fbd6abf43b00004a_18": [
        {
            "start_logit": 11.625,
            "end_logit": 11.328125,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.34375,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same class .",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.4765625,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same class",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 11.328125,
            "text": "greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.953125,
            "text": "BRAF inhibition and increased potency",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -10.21875,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 11.328125,
            "text": "target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.328125,
            "text": "encorafenib , with prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 11.328125,
            "text": "the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 11.328125,
            "text": "binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.328125,
            "text": "providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 11.328125,
            "text": "prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 11.328125,
            "text": "to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 11.328125,
            "text": "the distinct pharmacokinetics of encorafenib , with prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 11.328125,
            "text": "fenib , with prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -9.34375,
            "text": "greater BRAF inhibition and increased potency compared with other drugs in the same class .",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -9.4765625,
            "text": "greater BRAF inhibition and increased potency compared with other drugs in the same class",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -9.34375,
            "text": "target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class .",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -9.953125,
            "text": "greater BRAF inhibition and increased potency",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -9.4765625,
            "text": "target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_19": [
        {
            "start_logit": 13.203125,
            "end_logit": 0.5380859375,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -8.625,
            "text": "BRAF V600E/K-mutated melanoma",
            "probability": 0.00010472536087036133
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.2578125,
            "text": "BRAF V600E",
            "probability": 5.561113357543945e-05
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.546875,
            "text": "BRAF V600E/K-mutated melanoma in June 2018 .",
            "probability": 4.166364669799805e-05
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.578125,
            "text": "BRAF V600",
            "probability": 4.035234451293945e-05
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.9296875,
            "text": "BRAF V600E/K",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": 13.203125,
            "end_logit": -10.2734375,
            "text": "BRAF V600E/K-mutated melanoma in June 2018",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -10.25,
            "end_logit": 0.5380859375,
            "text": "received approval by the Food and Drug Administration ( FDA ) for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 0.5380859375,
            "text": "of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 0.5380859375,
            "text": "treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 0.5380859375,
            "text": "Food and Drug Administration ( FDA ) for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 0.5380859375,
            "text": "which received approval by the Food and Drug Administration ( FDA ) for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 0.5380859375,
            "text": "approval by the Food and Drug Administration ( FDA ) for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 0.5380859375,
            "text": "Drug Administration ( FDA ) for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 0.5380859375,
            "text": "the Food and Drug Administration ( FDA ) for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 0.5380859375,
            "text": "by the Food and Drug Administration ( FDA ) for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -8.625,
            "text": "V600E/K-mutated melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": -8.625,
            "text": "600E/K-mutated melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -9.2578125,
            "text": "V600E",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -9.546875,
            "text": "V600E/K-mutated melanoma in June 2018 .",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_20": [
        {
            "start_logit": 11.7109375,
            "end_logit": 11.4921875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -9.578125,
            "text": "BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination with binimetinib.",
            "probability": 0.0
        },
        {
            "start_logit": -9.3671875,
            "end_logit": 11.4921875,
            "text": "generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -9.6171875,
            "text": "BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination with binimetinib",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 11.4921875,
            "text": "new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -10.0,
            "text": "BRAF inhibitor, has been approved by FDA for the treatment of melanoma",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -10.078125,
            "text": "BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination with binime",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -10.234375,
            "text": "BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination with bin",
            "probability": 0.0
        },
        {
            "start_logit": -10.015625,
            "end_logit": 11.4921875,
            "text": "Encorafenib, a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -10.3125,
            "text": "BRAF inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -10.390625,
            "text": "BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination",
            "probability": 0.0
        },
        {
            "start_logit": 11.7109375,
            "end_logit": -10.4375,
            "text": "BRAF inhibitor, has been approved by FDA",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 11.4921875,
            "text": "a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 11.4921875,
            "text": "fenib, a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 11.4921875,
            "text": "-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -9.3671875,
            "end_logit": -9.578125,
            "text": "generation BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination with binimetinib.",
            "probability": 0.0
        },
        {
            "start_logit": -9.3671875,
            "end_logit": -9.6171875,
            "text": "generation BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination with binimetinib",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": -9.578125,
            "text": "new-generation BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination with binimetinib.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": -9.6171875,
            "text": "new-generation BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination with binimetinib",
            "probability": 0.0
        },
        {
            "start_logit": -9.3671875,
            "end_logit": -10.0,
            "text": "generation BRAF inhibitor, has been approved by FDA for the treatment of melanoma",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_21": [
        {
            "start_logit": 1.9580078125,
            "end_logit": 1.3037109375,
            "text": "BRAF",
            "probability": 0.61376953125
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": 0.62939453125,
            "text": "BRAF and MEK",
            "probability": 0.312744140625
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": 1.3037109375,
            "text": "Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 0.04766845703125
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": 0.62939453125,
            "text": "Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK",
            "probability": 0.0243072509765625
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": -5.22265625,
            "text": "BRAF and MEK, respectively",
            "probability": 0.0008974075317382812
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": -6.03125,
            "text": "BRAF and MEK, respectively.",
            "probability": 0.0003998279571533203
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": -5.22265625,
            "text": "Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK, respectively",
            "probability": 7.003545761108398e-05
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": -5.57421875,
            "text": "Braf",
            "probability": 4.887580871582031e-05
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": -6.03125,
            "text": "Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK, respectively.",
            "probability": 3.1113624572753906e-05
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": -10.0546875,
            "text": "BRAF and",
            "probability": 7.152557373046875e-06
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 1.3037109375,
            "text": "MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 6.854534149169922e-06
        },
        {
            "start_logit": 1.9580078125,
            "end_logit": -10.125,
            "text": "BRAF and MEK,",
            "probability": 6.735324859619141e-06
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 1.3037109375,
            "text": ", Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 4.708766937255859e-06
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 0.62939453125,
            "text": "MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -10.3671875,
            "end_logit": 1.3037109375,
            "text": ", Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 2.682209014892578e-06
        },
        {
            "start_logit": -0.59619140625,
            "end_logit": -8.578125,
            "text": "Braftovi",
            "probability": 2.4437904357910156e-06
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 0.62939453125,
            "text": ", Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK",
            "probability": 2.384185791015625e-06
        },
        {
            "start_logit": -10.640625,
            "end_logit": 1.3037109375,
            "text": "tovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 2.086162567138672e-06
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 1.3037109375,
            "text": "(MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -10.71875,
            "end_logit": 1.3037109375,
            "text": "and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF",
            "probability": 1.9669532775878906e-06
        }
    ],
    "5e319789fbd6abf43b00004a_22": [
        {
            "start_logit": 13.203125,
            "end_logit": 0.5380859375,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 13.203125,
            "end_logit": -8.625,
            "text": "BRAF V600E/K-mutated melanoma",
            "probability": 0.00010472536087036133
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.2578125,
            "text": "BRAF V600E",
            "probability": 5.561113357543945e-05
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.546875,
            "text": "BRAF V600E/K-mutated melanoma in June 2018.",
            "probability": 4.166364669799805e-05
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.578125,
            "text": "BRAF V600",
            "probability": 4.035234451293945e-05
        },
        {
            "start_logit": 13.203125,
            "end_logit": -9.9296875,
            "text": "BRAF V600E/K",
            "probability": 2.8431415557861328e-05
        },
        {
            "start_logit": 13.203125,
            "end_logit": -10.2734375,
            "text": "BRAF V600E/K-mutated melanoma in June 2018",
            "probability": 2.014636993408203e-05
        },
        {
            "start_logit": -10.25,
            "end_logit": 0.5380859375,
            "text": "received approval by the Food and Drug Administration (FDA) for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 0.5380859375,
            "text": "of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 0.5380859375,
            "text": "treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 0.5380859375,
            "text": "Food and Drug Administration (FDA) for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 0.5380859375,
            "text": "which received approval by the Food and Drug Administration (FDA) for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 0.5380859375,
            "text": "approval by the Food and Drug Administration (FDA) for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 0.5380859375,
            "text": "Drug Administration (FDA) for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 0.5380859375,
            "text": "the Food and Drug Administration (FDA) for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 0.5380859375,
            "text": "by the Food and Drug Administration (FDA) for the treatment of BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -8.625,
            "text": "V600E/K-mutated melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -8.59375,
            "end_logit": -8.625,
            "text": "600E/K-mutated melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -9.2578125,
            "text": "V600E",
            "probability": 0.0
        },
        {
            "start_logit": -8.2265625,
            "end_logit": -9.546875,
            "text": "V600E/K-mutated melanoma in June 2018.",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_23": [
        {
            "start_logit": 11.34375,
            "end_logit": 10.7265625,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.3125,
            "text": "BRAF V600-mutated melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.7265625,
            "text": "BRAF V600",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -8.796875,
            "text": "BRAF V600-mutated melanoma",
            "probability": 0.0
        },
        {
            "start_logit": 11.34375,
            "end_logit": -9.9296875,
            "text": "BRAF V600-",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 10.7265625,
            "text": "in BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 10.7265625,
            "text": "clinical utility of encorafenib and binimetinib in BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 10.7265625,
            "text": "the preclinical pharmacology, pharmacokinetics and clinical utility of encorafenib and binimetinib in BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 10.7265625,
            "text": "utility of encorafenib and binimetinib in BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 10.7265625,
            "text": "will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of encorafenib and binimetinib in BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 10.7265625,
            "text": "This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of encorafenib and binimetinib in BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": 10.7265625,
            "text": "fenib and binimetinib in BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": 10.7265625,
            "text": "encorafenib and binimetinib in BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.140625,
            "end_logit": 10.7265625,
            "text": "and clinical utility of encorafenib and binimetinib in BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -8.3125,
            "text": "V600-mutated melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -8.7265625,
            "text": "V600",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -8.796875,
            "text": "V600-mutated melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -8.3125,
            "text": "in BRAF V600-mutated melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": -8.3125,
            "text": "clinical utility of encorafenib and binimetinib in BRAF V600-mutated melanoma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": -8.3125,
            "text": "600-mutated melanoma.",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_24": [
        {
            "start_logit": 11.671875,
            "end_logit": 11.4453125,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": -7.93359375,
            "end_logit": 11.4453125,
            "text": "potent BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -9.359375,
            "text": "BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells.",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -9.703125,
            "text": "BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -9.765625,
            "text": "BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -10.0390625,
            "text": "BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -10.0546875,
            "text": "BRAF inhibitor, induces senescence",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -10.203125,
            "text": "BRAF inhibitor, induces senescence accompanied by autophagy in",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -10.2421875,
            "text": "BRAF inhibitor, induces senescence accompanied",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -10.2578125,
            "text": "BRAF inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -10.2734375,
            "text": "BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV6",
            "probability": 0.0
        },
        {
            "start_logit": 11.671875,
            "end_logit": -10.3203125,
            "text": "BRAF inhibitor, induces senescence accompanied by autophagy",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 11.4453125,
            "text": "Encorafenib (LGX818), a potent BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 11.4453125,
            "text": "fenib (LGX818), a potent BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.4453125,
            "text": "(LGX818), a potent BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 11.4453125,
            "text": "818), a potent BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 11.4453125,
            "text": "orafenib (LGX818), a potent BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 11.4453125,
            "text": "LGX818), a potent BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 11.4453125,
            "text": "X818), a potent BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 11.4453125,
            "text": "a potent BRAF",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_25": [
        {
            "start_logit": 11.5546875,
            "end_logit": 11.5625,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -9.5078125,
            "text": "BRAF inhibitor that",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 11.5625,
            "text": "generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -9.7265625,
            "text": "BRAF inhibitor that is under evaluation in clinical trials.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 11.5625,
            "text": "Encorafenib (LGX818) is a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -10.2421875,
            "text": "BRAF inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 11.5625,
            "text": "new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -10.3515625,
            "text": "BRAF inhibitor that is under evaluation in clinical trials",
            "probability": 0.0
        },
        {
            "start_logit": 11.5546875,
            "end_logit": -10.390625,
            "text": "BRAF inhibitor that is under evaluation",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.5625,
            "text": "fenib (LGX818) is a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 11.5625,
            "text": "(LGX818) is a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 11.5625,
            "text": "-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 11.5625,
            "text": "orafenib (LGX818) is a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 11.5625,
            "text": "a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 11.5625,
            "text": "818) is a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 11.5625,
            "text": "LGX818) is a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 11.5625,
            "text": "X818) is a new-generation BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": -9.5078125,
            "text": "generation BRAF inhibitor that",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": -9.7265625,
            "text": "generation BRAF inhibitor that is under evaluation in clinical trials.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -9.5078125,
            "text": "Encorafenib (LGX818) is a new-generation BRAF inhibitor that",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_26": [
        {
            "start_logit": 11.625,
            "end_logit": 11.328125,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.34375,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same class.",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.4765625,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same class",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 11.328125,
            "text": "greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.953125,
            "text": "BRAF inhibition and increased potency",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -10.21875,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 11.328125,
            "text": "target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.328125,
            "text": "encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 11.328125,
            "text": "the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 11.328125,
            "text": "binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.328125,
            "text": "providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 11.328125,
            "text": "prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 11.328125,
            "text": "to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 11.328125,
            "text": "the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 11.328125,
            "text": "fenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -9.34375,
            "text": "greater BRAF inhibition and increased potency compared with other drugs in the same class.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -9.4765625,
            "text": "greater BRAF inhibition and increased potency compared with other drugs in the same class",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -9.34375,
            "text": "target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -9.953125,
            "text": "greater BRAF inhibition and increased potency",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -9.4765625,
            "text": "target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_27": [
        {
            "start_logit": 1.87890625,
            "end_logit": 0.51416015625,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 1.87890625,
            "end_logit": -9.171875,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF",
            "probability": 6.204843521118164e-05
        },
        {
            "start_logit": 1.87890625,
            "end_logit": -9.2734375,
            "text": "BRAF/MEK",
            "probability": 5.608797073364258e-05
        },
        {
            "start_logit": -8.34375,
            "end_logit": 0.51416015625,
            "text": "Expert opinion: While other BRAF",
            "probability": 3.647804260253906e-05
        },
        {
            "start_logit": 1.87890625,
            "end_logit": -10.03125,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive melanoma",
            "probability": 2.6285648345947266e-05
        },
        {
            "start_logit": 1.87890625,
            "end_logit": -10.109375,
            "text": "BRAF/MEK inhibitor combinations",
            "probability": 2.4318695068359375e-05
        },
        {
            "start_logit": 1.87890625,
            "end_logit": -10.171875,
            "text": "BRAF/MEK inhibitor combinations have",
            "probability": 2.282857894897461e-05
        },
        {
            "start_logit": 1.87890625,
            "end_logit": -10.21875,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS",
            "probability": 2.1755695343017578e-05
        },
        {
            "start_logit": 1.87890625,
            "end_logit": -10.3515625,
            "text": "BRAF/MEK inhibitor combinations have achieved a median overall survival (OS)",
            "probability": 1.9252300262451172e-05
        },
        {
            "start_logit": -5.87109375,
            "end_logit": -9.171875,
            "text": "BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -5.87109375,
            "end_logit": -10.0,
            "text": "BRAF mutation-positive melanoma treated with encorafenib plus binimetinib achieved a median OS of 33",
            "probability": 0.0
        },
        {
            "start_logit": -5.87109375,
            "end_logit": -10.03125,
            "text": "BRAF mutation-positive melanoma",
            "probability": 0.0
        },
        {
            "start_logit": -5.87109375,
            "end_logit": -10.03125,
            "text": "BRAF mutation-positive melanoma treated with encorafenib plus binimetinib",
            "probability": 0.0
        },
        {
            "start_logit": -5.87109375,
            "end_logit": -10.3671875,
            "text": "BRAF mutation-positive melanoma treated with encorafenib plus binimetinib achieved a median OS",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -9.171875,
            "text": "Expert opinion: While other BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -9.2734375,
            "text": "Expert opinion: While other BRAF/MEK",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -9.5390625,
            "text": "Expert opinion",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -10.109375,
            "text": "Expert opinion: While other BRAF/MEK inhibitor combinations",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -10.171875,
            "text": "Expert opinion: While other BRAF/MEK inhibitor combinations have",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": -10.21875,
            "text": "Expert opinion: While other BRAF/MEK inhibitor combinations have achieved a median overall survival (OS",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_28": [
        {
            "start_logit": 2.78125,
            "end_logit": 0.36376953125,
            "text": "BRAF/MEK",
            "probability": 0.8935546875
        },
        {
            "start_logit": 2.78125,
            "end_logit": -1.76953125,
            "text": "BRAF",
            "probability": 0.10589599609375
        },
        {
            "start_logit": 2.78125,
            "end_logit": -8.1640625,
            "text": "BRAF/MEK inhibitor combinations.",
            "probability": 0.0001761913299560547
        },
        {
            "start_logit": 2.78125,
            "end_logit": -9.84375,
            "text": "BRAF/MEK inhibitor",
            "probability": 3.314018249511719e-05
        },
        {
            "start_logit": 2.78125,
            "end_logit": -9.9921875,
            "text": "BRAF/MEK inhibitor combinations",
            "probability": 2.8312206268310547e-05
        },
        {
            "start_logit": -7.90625,
            "end_logit": 0.36376953125,
            "text": "MEK",
            "probability": 2.0384788513183594e-05
        },
        {
            "start_logit": -8.6171875,
            "end_logit": 0.36376953125,
            "text": "Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.0132789611816406e-05
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 0.36376953125,
            "text": "/MEK",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -10.390625,
            "end_logit": 0.36376953125,
            "text": "existing BRAF/MEK",
            "probability": 1.7285346984863281e-06
        },
        {
            "start_logit": -10.421875,
            "end_logit": 0.36376953125,
            "text": "bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.6689300537109375e-06
        },
        {
            "start_logit": -10.484375,
            "end_logit": 0.36376953125,
            "text": "Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": -10.515625,
            "end_logit": 0.36376953125,
            "text": ": Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 0.36376953125,
            "text": "over existing BRAF/MEK",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": -10.734375,
            "end_logit": 0.36376953125,
            "text": "fenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 0.36376953125,
            "text": "approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -8.6171875,
            "end_logit": -1.76953125,
            "text": "Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -10.859375,
            "end_logit": 0.36376953125,
            "text": "with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 0.36376953125,
            "text": "etinib offers a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 0.36376953125,
            "text": "a new approach that may offer benefits over existing BRAF/MEK",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -10.390625,
            "end_logit": -1.76953125,
            "text": "existing BRAF",
            "probability": 2.384185791015625e-07
        }
    ],
    "5e319789fbd6abf43b00004a_29": [
        {
            "start_logit": 10.4296875,
            "end_logit": 10.0703125,
            "text": "BRAFV600E-mutated melanoma who developed pyogenic granulomas 16, 10, and 12 weeks after treatment initiation with the selective BRAF",
            "probability": 0.65869140625
        },
        {
            "start_logit": 9.7734375,
            "end_logit": 10.0703125,
            "text": "BRAF",
            "probability": 0.341552734375
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -4.50390625,
            "text": "BRAFV600E",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -6.6015625,
            "text": "BRAF",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.4765625,
            "end_logit": 10.0703125,
            "text": "00E-mutated melanoma who developed pyogenic granulomas 16, 10, and 12 weeks after treatment initiation with the selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -8.9921875,
            "end_logit": 10.0703125,
            "text": "V600E-mutated melanoma who developed pyogenic granulomas 16, 10, and 12 weeks after treatment initiation with the selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -9.671875,
            "text": "BRAFV6",
            "probability": 0.0
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -9.9296875,
            "text": "BRAFV600E-mutated melanoma",
            "probability": 0.0
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -10.1171875,
            "text": "BRAFV600E-mutated melanoma who",
            "probability": 0.0
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -10.234375,
            "text": "BRAFV600E-",
            "probability": 0.0
        },
        {
            "start_logit": 10.4296875,
            "end_logit": -10.265625,
            "text": "BRAFV600",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -10.1015625,
            "text": "BRAF inhibitors vemurafenib",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -10.1328125,
            "text": "BRAF inhibitors vemurafenib or encorafenib (LGX818",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -10.171875,
            "text": "BRAF inhibitors vemurafenib or encorafenib (LGX818).",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 10.0703125,
            "text": "pyogenic granulomas 16, 10, and 12 weeks after treatment initiation with the selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -10.2734375,
            "text": "BRAF inhibitors vemurafenib or encorafenib (LGX81",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -10.328125,
            "text": "BRAF inhibitors vemurafenib or enc",
            "probability": 0.0
        },
        {
            "start_logit": 9.7734375,
            "end_logit": -10.34375,
            "text": "BRAF inhibitors vemurafenib or encorafenib (LG",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 10.0703125,
            "text": "male patients with metastatic BRAFV600E-mutated melanoma who developed pyogenic granulomas 16, 10, and 12 weeks after treatment initiation with the selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 10.0703125,
            "text": "granulomas 16, 10, and 12 weeks after treatment initiation with the selective BRAF",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_30": [
        {
            "start_logit": 10.9453125,
            "end_logit": 9.0546875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -2.59765625,
            "text": "BRAF and MEK",
            "probability": 8.64267349243164e-06
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -7.50390625,
            "text": "BRAF and MEK inhibitors, respectively.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -8.6015625,
            "text": "BRAF and MEK inhibitors, respectively",
            "probability": 0.0
        },
        {
            "start_logit": 10.9453125,
            "end_logit": -10.3125,
            "text": "BRAF and MEK inhibitors",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": 9.0546875,
            "text": "new BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 9.0546875,
            "text": "November 2015, with Encorafenib and Binimetinib, new BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": 9.0546875,
            "text": ", with Encorafenib and Binimetinib, new BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": 9.0546875,
            "text": "fenib and Binimetinib, new BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": 9.0546875,
            "text": "and Binimetinib, new BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.15625,
            "end_logit": 9.0546875,
            "text": "Encorafenib and Binimetinib, new BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.1640625,
            "end_logit": 9.0546875,
            "text": "Binimetinib, new BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.1953125,
            "end_logit": 9.0546875,
            "text": ", new BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -8.3671875,
            "end_logit": -2.59765625,
            "text": "MEK",
            "probability": 0.0
        },
        {
            "start_logit": -9.0625,
            "end_logit": -2.59765625,
            "text": "new BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -2.59765625,
            "text": "and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": -2.59765625,
            "text": "November 2015, with Encorafenib and Binimetinib, new BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": -2.59765625,
            "text": ", with Encorafenib and Binimetinib, new BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": -2.59765625,
            "text": "fenib and Binimetinib, new BRAF and MEK",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": -2.59765625,
            "text": "and Binimetinib, new BRAF and MEK",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_31": [
        {
            "start_logit": 11.203125,
            "end_logit": 11.3046875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -9.203125,
            "text": "BRAF (encorafenib)/MEK (binimetinib) inhibitor combination or the ERK",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -9.359375,
            "text": "BRAF (encorafenib)/MEK",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -9.6796875,
            "text": "BRAF (encorafenib)/MEK (binimetinib) inhibitor combination",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -9.6796875,
            "text": "BRAF (encorafenib)/MEK (binimetinib) inhibitor combination or the ERK inhibitor VX-11e was confirmed",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -9.8984375,
            "text": "BRAF (encorafenib)/MEK (binimetinib) inhibitor combination or the ERK inhibitor VX-11e",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -10.046875,
            "text": "BRAF (encorafenib)/MEK (binimetinib",
            "probability": 0.0
        },
        {
            "start_logit": 11.203125,
            "end_logit": -10.0859375,
            "text": "BRAF (encorafenib)/MEK (binimetinib) inhibitor combination or the ERK inhibitor VX-11e was confirmed in vivo Amplification",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 11.3046875,
            "text": "-PI3K inhibitor BKM120 with either BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -8.2109375,
            "text": "MET",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -9.9453125,
            "text": "MET was observed in 3 PDX models, a higher frequency than expected and a possible novel mechanism of resistance.",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -10.015625,
            "text": "MET was observed in 3 PDX models, a higher frequency than expected and a possible novel mechanism of resistance",
            "probability": 0.0
        },
        {
            "start_logit": -7.6875,
            "end_logit": -10.0859375,
            "text": "MET was observed in 3 PDX",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -8.2109375,
            "text": "of MET",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": -8.2109375,
            "text": "/MEK (binimetinib) inhibitor combination or the ERK inhibitor VX-11e was confirmed in vivo Amplification of MET",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": -8.2109375,
            "text": "in vivo Amplification of MET",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": -8.2109375,
            "text": "-11e was confirmed in vivo Amplification of MET",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": -9.203125,
            "text": "/MEK (binimetinib) inhibitor combination or the ERK",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": -9.203125,
            "text": "-PI3K inhibitor BKM120 with either BRAF (encorafenib)/MEK (binimetinib) inhibitor combination or the ERK",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": -9.359375,
            "text": "/MEK",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_32": [
        {
            "start_logit": 3.162109375,
            "end_logit": 7.71484375,
            "text": "BRAF",
            "probability": 0.998046875
        },
        {
            "start_logit": -3.181640625,
            "end_logit": 7.71484375,
            "text": "C-KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK inhibitor, encorafenib a BRAF",
            "probability": 0.0017538070678710938
        },
        {
            "start_logit": -7.76953125,
            "end_logit": 7.71484375,
            "text": "KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK inhibitor, encorafenib a BRAF",
            "probability": 1.7881393432617188e-05
        },
        {
            "start_logit": 0.16357421875,
            "end_logit": -0.379150390625,
            "text": "BRAF, NRAS, and C-KIT",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": 0.16357421875,
            "end_logit": -1.650390625,
            "text": "BRAF",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": -9.875,
            "end_logit": 7.71484375,
            "text": "a BRAF",
            "probability": 2.205371856689453e-06
        },
        {
            "start_logit": -10.5,
            "end_logit": 7.71484375,
            "text": "-KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK inhibitor, encorafenib a BRAF",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 7.71484375,
            "text": "background for a thorough review of newly developed agents namely binimetinib, a MEK inhibitor, encorafenib a BRAF",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 7.71484375,
            "text": "and C-KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK inhibitor, encorafenib a BRAF",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -10.78125,
            "end_logit": 7.71484375,
            "text": ", encorafenib a BRAF",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -3.181640625,
            "end_logit": -0.379150390625,
            "text": "C-KIT",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 3.162109375,
            "end_logit": -8.890625,
            "text": "BRAF inhibitor, and masitinib which inhibits C-KIT.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 3.162109375,
            "end_logit": -10.296875,
            "text": "BRAF inhibitor, and masitinib",
            "probability": 0.0
        },
        {
            "start_logit": 3.162109375,
            "end_logit": -10.3125,
            "text": "BRAF inhibitor, and masitinib which inhibits C-KIT",
            "probability": 0.0
        },
        {
            "start_logit": -7.76953125,
            "end_logit": -0.379150390625,
            "text": "KIT",
            "probability": 0.0
        },
        {
            "start_logit": 0.16357421875,
            "end_logit": -9.2578125,
            "text": "BRAF, NRAS, and C-KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK",
            "probability": 0.0
        },
        {
            "start_logit": 0.16357421875,
            "end_logit": -9.6640625,
            "text": "BRAF, NRAS, and C",
            "probability": 0.0
        },
        {
            "start_logit": 0.16357421875,
            "end_logit": -9.9765625,
            "text": "BRAF, NRAS",
            "probability": 0.0
        },
        {
            "start_logit": 0.16357421875,
            "end_logit": -10.046875,
            "text": "BRAF, NRAS, and C-KIT inhibitors provides background for a thorough",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": -0.379150390625,
            "text": "Areas covered: A brief review of current BRAF, NRAS, and C-KIT",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_33": [
        {
            "start_logit": 13.2109375,
            "end_logit": 1.0556640625,
            "text": "BRAF",
            "probability": 0.95263671875
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -1.958984375,
            "text": "BRAF V600E",
            "probability": 0.04669189453125
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -7.44140625,
            "text": "BRAF V600E kinase",
            "probability": 0.0001938343048095703
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -7.94921875,
            "text": "BRAF V",
            "probability": 0.00011754035949707031
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -9.5390625,
            "text": "BRAF V600E kinase activity with a prolonged off-rate and suppressed proliferation and tumor growth of BRAF V600E-mutant melanoma models.",
            "probability": 2.390146255493164e-05
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -9.625,
            "text": "BRAF V600E kinase activity with a prolonged off-rate and suppressed proliferation and tumor growth of BRAF V600E-mutant melanoma",
            "probability": 2.193450927734375e-05
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -9.78125,
            "text": "BRAF V600",
            "probability": 1.8715858459472656e-05
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -9.9140625,
            "text": "BRAF V600E kinase activity with a prolonged off-rate and suppressed proliferation and tumor growth of BRAF V600E-mutant melanoma models",
            "probability": 1.6391277313232422e-05
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -9.9375,
            "text": "BRAF V600E kinase activity",
            "probability": 1.6033649444580078e-05
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -9.9765625,
            "text": "BRAF V600E kinase activity with a prolonged off-rate and",
            "probability": 1.5437602996826172e-05
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -10.21875,
            "text": "BRAF V600E kinase activity with a prolonged off-rate and suppressed proliferation",
            "probability": 1.2099742889404297e-05
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -10.234375,
            "text": "BRAF V600E kinase activity with a prolonged off-rate and suppressed proliferation and tumor growth of BRAF V600E",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": 13.2109375,
            "end_logit": -10.2421875,
            "text": "BRAF V600E kinase activity with",
            "probability": 1.1801719665527344e-05
        },
        {
            "start_logit": -6.15625,
            "end_logit": -1.958984375,
            "text": "V600E",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 1.0556640625,
            "text": "encorafenib inhibited BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 1.0556640625,
            "text": ": Preclinical data demonstrated that encorafenib inhibited BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 1.0556640625,
            "text": "Preclinical data demonstrated that encorafenib inhibited BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 1.0556640625,
            "text": "Results: Preclinical data demonstrated that encorafenib inhibited BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 1.0556640625,
            "text": "inhibited BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": -1.958984375,
            "text": "600E",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_34": [
        {
            "start_logit": 11.625,
            "end_logit": 11.328125,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.34375,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same class.",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.4765625,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same class",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 11.328125,
            "text": "greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -9.953125,
            "text": "BRAF inhibition and increased potency",
            "probability": 0.0
        },
        {
            "start_logit": 11.625,
            "end_logit": -10.21875,
            "text": "BRAF inhibition and increased potency compared with other drugs in the same",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 11.328125,
            "text": "target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.328125,
            "text": "encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 11.328125,
            "text": "the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 11.328125,
            "text": "binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.328125,
            "text": "providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 11.328125,
            "text": "prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 11.328125,
            "text": "to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 11.328125,
            "text": "the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 11.328125,
            "text": "fenib, with prolonged binding to the target molecule providing greater BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -9.34375,
            "text": "greater BRAF inhibition and increased potency compared with other drugs in the same class.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -9.4765625,
            "text": "greater BRAF inhibition and increased potency compared with other drugs in the same class",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -9.34375,
            "text": "target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5703125,
            "end_logit": -9.953125,
            "text": "greater BRAF inhibition and increased potency",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -9.4765625,
            "text": "target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_35": [
        {
            "start_logit": 11.5625,
            "end_logit": 11.6171875,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -7.5,
            "text": "BRAF Inhibitor Encorafenib (LGX818) in Metastatic",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -10.125,
            "text": "BRAF Inhibitor Encorafenib",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -10.1640625,
            "text": "BRAF Inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -10.21875,
            "text": "BRAF Inhibitor Encorafenib (LGX818",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -10.3046875,
            "text": "BRAF Inhibitor Encorafenib (LGX81",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -10.3125,
            "text": "BRAF Inhibitor Enc",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -10.328125,
            "text": "BRAF Inhibitor Encorafenib (LGX818) in",
            "probability": 0.0
        },
        {
            "start_logit": 11.5625,
            "end_logit": -10.3828125,
            "text": "BRAF Inhibitor Encorafenib (LGX818)",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 11.6171875,
            "text": "-Expansion Study of the BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 11.6171875,
            "text": "the BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.6171875,
            "text": "-Escalation and -Expansion Study of the BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 11.6171875,
            "text": "Phase I Dose-Escalation and -Expansion Study of the BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 11.6171875,
            "text": "Dose-Escalation and -Expansion Study of the BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 11.6171875,
            "text": "of the BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": -7.5,
            "text": "(LGX818) in Metastatic",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -7.5,
            "text": "in Metastatic",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": -7.5,
            "text": "-Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": -7.5,
            "text": "the BRAF Inhibitor Encorafenib (LGX818) in Metastatic",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": -7.5,
            "text": "-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic",
            "probability": 0.0
        }
    ],
    "5e319789fbd6abf43b00004a_36": [
        {
            "start_logit": 11.546875,
            "end_logit": 11.453125,
            "text": "BRAF",
            "probability": 1.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -9.46875,
            "text": "BRAF inhibitor (BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -9.8828125,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis.",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.0078125,
            "text": "BRAF inhibitor (BRAFi",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.171875,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.2265625,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.2421875,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAF",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.2421875,
            "text": "BRAF inhibitor",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.3515625,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.4375,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active",
            "probability": 0.0
        },
        {
            "start_logit": 11.546875,
            "end_logit": -10.4453125,
            "text": "BRAF inhibitor (BRAFi), has a pharmacologic profile that",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 11.453125,
            "text": ": Encorafenib, a selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 11.453125,
            "text": "selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 11.453125,
            "text": "Encorafenib, a selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 11.453125,
            "text": "a selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 11.453125,
            "text": "fenib, a selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 11.453125,
            "text": "Purpose: Encorafenib, a selective BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -9.46875,
            "text": "BRAF",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -9.8828125,
            "text": "BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis.",
            "probability": 0.0
        },
        {
            "start_logit": -8.171875,
            "end_logit": -10.0078125,
            "text": "BRAFi",
            "probability": 0.0
        }
    ],
    "5a89800efcd1d6a10c00000c_1": [
        {
            "start_logit": 8.3515625,
            "end_logit": 11.734375,
            "text": "UCP1+ adipocytes",
            "probability": 1.0
        },
        {
            "start_logit": -1.2236328125,
            "end_logit": 11.734375,
            "text": "adipocytes",
            "probability": 6.866455078125e-05
        },
        {
            "start_logit": 8.3515625,
            "end_logit": 1.3583984375,
            "text": "UCP1",
            "probability": 3.0934810638427734e-05
        },
        {
            "start_logit": -2.134765625,
            "end_logit": 11.734375,
            "text": "in UCP1+ adipocytes",
            "probability": 2.777576446533203e-05
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -0.4560546875,
            "text": "UCP1+ adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids.",
            "probability": 5.0067901611328125e-06
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -3.51171875,
            "text": "UCP1+ adipocytes,",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -6.97265625,
            "end_logit": 11.734375,
            "text": "+ adipocytes",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -4.2421875,
            "text": "UCP1+",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.84375,
            "end_logit": 11.734375,
            "text": "P1+ adipocytes",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -5.078125,
            "text": "UC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 11.734375,
            "text": "A secreted enzyme, PM20D1, enriched in UCP1+ adipocytes",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 11.734375,
            "text": "enriched in UCP1+ adipocytes",
            "probability": 0.0
        },
        {
            "start_logit": -2.134765625,
            "end_logit": 1.3583984375,
            "text": "in UCP1",
            "probability": 0.0
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -9.8125,
            "text": "UCP1+ adipocytes, exhibits catalytic and hydrolytic",
            "probability": 0.0
        },
        {
            "start_logit": -1.2236328125,
            "end_logit": -0.4560546875,
            "text": "adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids.",
            "probability": 0.0
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -10.1484375,
            "text": "UCP1+ adipocytes, exhibits",
            "probability": 0.0
        },
        {
            "start_logit": 8.3515625,
            "end_logit": -10.1796875,
            "text": "UCP1+ adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids",
            "probability": 0.0
        },
        {
            "start_logit": -2.134765625,
            "end_logit": -0.4560546875,
            "text": "in UCP1+ adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids.",
            "probability": 0.0
        },
        {
            "start_logit": -1.2236328125,
            "end_logit": -3.51171875,
            "text": "adipocytes,",
            "probability": 0.0
        },
        {
            "start_logit": -2.134765625,
            "end_logit": -3.51171875,
            "text": "in UCP1+ adipocytes,",
            "probability": 0.0
        }
    ],
    "5319ac36b166e2b806000031_1": [
        {
            "start_logit": 14.546875,
            "end_logit": 14.953125,
            "text": "GIT1",
            "probability": 1.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -1.423828125,
            "text": "GI",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.46875,
            "end_logit": 14.953125,
            "text": "T1",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 14.953125,
            "text": "of GIT1",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -8.8984375,
            "text": "GIT1 is required for GIT1-cortactin complex localization to the leading edge.",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -8.921875,
            "text": "GIT1 is",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -9.5390625,
            "text": "GIT1 is required for GIT1-cortactin complex localization to the leading edge. The",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -9.5546875,
            "text": "GIT1 is required for GIT1-cortactin complex localization to the leading edge. The mechanisms involved extracellular signal-regulated kinases 1 and 2",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -9.5859375,
            "text": "GIT1 is required for GIT1-cortactin complex localization to the leading edge. The mechanisms involved extracellular signal-regulated kinases",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 14.953125,
            "text": "the Spa homology domain (aa 250-420) of GIT1",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -9.671875,
            "text": "GIT1 is required for GIT1-cortactin",
            "probability": 0.0
        },
        {
            "start_logit": 14.546875,
            "end_logit": -9.671875,
            "text": "GIT1 is required for GIT1-cortactin complex localization to the leading edge. The mechanisms involved extracellular signal-regulated kinases 1 and",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 14.953125,
            "text": "Spa homology domain (aa 250-420) of GIT1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 14.953125,
            "text": "We specifically identified that the Spa homology domain (aa 250-420) of GIT1",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 14.953125,
            "text": "aa 250-420) of GIT1",
            "probability": 0.0
        },
        {
            "start_logit": -7.83203125,
            "end_logit": -1.423828125,
            "text": "of GI",
            "probability": 0.0
        },
        {
            "start_logit": -2.46875,
            "end_logit": -8.8984375,
            "text": "T1 is required for GIT1-cortactin complex localization to the leading edge.",
            "probability": 0.0
        },
        {
            "start_logit": -2.46875,
            "end_logit": -8.921875,
            "text": "T1 is",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -1.423828125,
            "text": "the Spa homology domain (aa 250-420) of GI",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": -1.423828125,
            "text": "Spa homology domain (aa 250-420) of GI",
            "probability": 0.0
        }
    ],
    "5319ac36b166e2b806000031_2": [
        {
            "start_logit": 11.90625,
            "end_logit": 11.5,
            "text": "Rac1",
            "probability": 1.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": 11.5,
            "text": "protein Rac1",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -9.2109375,
            "text": "Rac1 to the plasma membrane and induce the local formation of lamellipodia in response to focal illumination.",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": 11.5,
            "text": "LAD constructs that can recruit the small G-protein Rac1",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 11.5,
            "text": "G-protein Rac1",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -9.65625,
            "text": "Rac1 to the plasma membrane",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -9.9609375,
            "text": "Rac1 to the plasma membrane and",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 11.5,
            "text": "small G-protein Rac1",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -10.0,
            "text": "Rac1 to the plasma membrane and induce the local formation of lamellipodia in response to focal illumination",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -10.1015625,
            "text": "Rac1 to the plasma membrane and induce the local formation of lamellipodia",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -10.2421875,
            "text": "Rac1 to the plasma membrane and induce the local formation of lamellipodia in response to",
            "probability": 0.0
        },
        {
            "start_logit": 11.90625,
            "end_logit": -10.2578125,
            "text": "Rac1 to the plasma membrane and induce",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 11.5,
            "text": "the utility of this system with LAD constructs that can recruit the small G-protein Rac1",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 11.5,
            "text": "the small G-protein Rac1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 11.5,
            "text": "this system with LAD constructs that can recruit the small G-protein Rac1",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 11.5,
            "text": "recruit the small G-protein Rac1",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 11.5,
            "text": "We demonstrated the utility of this system with LAD constructs that can recruit the small G-protein Rac1",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 11.5,
            "text": "demonstrated the utility of this system with LAD constructs that can recruit the small G-protein Rac1",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -9.1875,
            "text": "protein",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -9.2109375,
            "text": "protein Rac1 to the plasma membrane and induce the local formation of lamellipodia in response to focal illumination.",
            "probability": 0.0
        }
    ],
    "6217db1b3a8413c653000027_1": [
        {
            "start_logit": 2.16796875,
            "end_logit": 12.1953125,
            "text": "haemophagocytic lymphohistiocytosis",
            "probability": 0.9990234375
        },
        {
            "start_logit": -5.37109375,
            "end_logit": 12.1953125,
            "text": "ocytosis",
            "probability": 0.0005335807800292969
        },
        {
            "start_logit": -6.48046875,
            "end_logit": 12.1953125,
            "text": "ocytic lymphohistiocytosis",
            "probability": 0.0001766681671142578
        },
        {
            "start_logit": -7.0625,
            "end_logit": 12.1953125,
            "text": "ophagocytic lymphohistiocytosis",
            "probability": 9.828805923461914e-05
        },
        {
            "start_logit": -9.171875,
            "end_logit": 12.1953125,
            "text": "of haemophagocytic lymphohistiocytosis",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 12.1953125,
            "text": "lymphohistiocytosis",
            "probability": 1.1861324310302734e-05
        },
        {
            "start_logit": -9.2578125,
            "end_logit": 12.1953125,
            "text": "tiocytosis",
            "probability": 1.0967254638671875e-05
        },
        {
            "start_logit": -9.59375,
            "end_logit": 12.1953125,
            "text": "histiocytosis",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 12.1953125,
            "text": "immune deregulation. Most such cases lead to clinical manifestations of haemophagocytic lymphohistiocytosis",
            "probability": 4.291534423828125e-06
        },
        {
            "start_logit": -10.2578125,
            "end_logit": 12.1953125,
            "text": "clinical manifestations of haemophagocytic lymphohistiocytosis",
            "probability": 4.0531158447265625e-06
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 12.1953125,
            "text": "to clinical manifestations of haemophagocytic lymphohistiocytosis",
            "probability": 2.6226043701171875e-06
        },
        {
            "start_logit": -10.71875,
            "end_logit": 12.1953125,
            "text": "Most such cases lead to clinical manifestations of haemophagocytic lymphohistiocytosis",
            "probability": 2.562999725341797e-06
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 12.1953125,
            "text": "manifestations of haemophagocytic lymphohistiocytosis",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": 2.16796875,
            "end_logit": -8.921875,
            "text": "haemophagocytic lymphohistiocytosis (HLH",
            "probability": 0.0
        },
        {
            "start_logit": 2.16796875,
            "end_logit": -9.28125,
            "text": "haemophagocytic lymphohisti",
            "probability": 0.0
        },
        {
            "start_logit": 2.16796875,
            "end_logit": -9.328125,
            "text": "haemophagocytic lympho",
            "probability": 0.0
        },
        {
            "start_logit": 2.16796875,
            "end_logit": -9.625,
            "text": "haemophagocytic lymphohistiocytosis (HLH).",
            "probability": 0.0
        },
        {
            "start_logit": -5.37109375,
            "end_logit": -8.921875,
            "text": "ocytosis (HLH",
            "probability": 0.0
        },
        {
            "start_logit": -5.37109375,
            "end_logit": -9.625,
            "text": "ocytosis (HLH).",
            "probability": 0.0
        },
        {
            "start_logit": -6.48046875,
            "end_logit": -8.921875,
            "text": "ocytic lymphohistiocytosis (HLH",
            "probability": 0.0
        }
    ],
    "5a9d8a651d1251d03b00001f_1": [
        {
            "start_logit": 2.390625,
            "end_logit": 11.1875,
            "text": "Mini-BioArchive system",
            "probability": 0.9970703125
        },
        {
            "start_logit": -4.03515625,
            "end_logit": 11.1875,
            "text": "cryopreservation and storage system (Mini-BioArchive system",
            "probability": 0.0016145706176757812
        },
        {
            "start_logit": -4.75,
            "end_logit": 11.1875,
            "text": "system (Mini-BioArchive system",
            "probability": 0.000789642333984375
        },
        {
            "start_logit": -6.1875,
            "end_logit": 11.1875,
            "text": "system",
            "probability": 0.0001876354217529297
        },
        {
            "start_logit": -6.484375,
            "end_logit": 11.1875,
            "text": "automated cryopreservation and storage system (Mini-BioArchive system",
            "probability": 0.00013947486877441406
        },
        {
            "start_logit": -4.03515625,
            "end_logit": 8.421875,
            "text": "cryopreservation and storage system",
            "probability": 0.00010198354721069336
        },
        {
            "start_logit": -4.75,
            "end_logit": 8.421875,
            "text": "system",
            "probability": 4.976987838745117e-05
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 11.1875,
            "text": "-BioArchive system",
            "probability": 3.808736801147461e-05
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 11.1875,
            "text": "(Mini-BioArchive system",
            "probability": 2.3305416107177734e-05
        },
        {
            "start_logit": -8.53125,
            "end_logit": 11.1875,
            "text": "storage system (Mini-BioArchive system",
            "probability": 1.800060272216797e-05
        },
        {
            "start_logit": -8.6171875,
            "end_logit": 11.1875,
            "text": "BioArchive system",
            "probability": 1.6510486602783203e-05
        },
        {
            "start_logit": -6.484375,
            "end_logit": 8.421875,
            "text": "automated cryopreservation and storage system",
            "probability": 8.821487426757812e-06
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 11.1875,
            "text": "and storage system (Mini-BioArchive system",
            "probability": 6.020069122314453e-06
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 11.1875,
            "text": "scale automated cryopreservation and storage system (Mini-BioArchive system",
            "probability": 4.76837158203125e-06
        },
        {
            "start_logit": -8.53125,
            "end_logit": 8.421875,
            "text": "storage system",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -9.6328125,
            "end_logit": 8.421875,
            "text": "and storage system",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 8.421875,
            "text": "scale automated cryopreservation and storage system",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 2.390625,
            "end_logit": -7.46875,
            "text": "Mini-BioArchive",
            "probability": 0.0
        },
        {
            "start_logit": 2.390625,
            "end_logit": -8.4921875,
            "text": "Mini-BioArchive system) used in the banking of umbilical cord blood (UCB) units was evaluated.",
            "probability": 0.0
        },
        {
            "start_logit": 2.390625,
            "end_logit": -9.046875,
            "text": "Mini-BioArch",
            "probability": 0.0
        }
    ],
    "56f961b3cf1c325851000003_1": [
        {
            "start_logit": 12.1875,
            "end_logit": 10.9140625,
            "text": "blue",
            "probability": 1.0
        },
        {
            "start_logit": 12.1875,
            "end_logit": -6.8515625,
            "text": "blue protein from a different species of frog, displays a novel structure with a unique chromophoric crosslink.",
            "probability": 0.0
        },
        {
            "start_logit": 12.1875,
            "end_logit": -9.953125,
            "text": "blue protein from a different species of frog, displays",
            "probability": 0.0
        },
        {
            "start_logit": 12.1875,
            "end_logit": -9.96875,
            "text": "blue protein from a different species of frog, displays a novel structure with a unique chromophoric crosslink",
            "probability": 0.0
        },
        {
            "start_logit": 12.1875,
            "end_logit": -9.984375,
            "text": "blue protein from a different species of frog,",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": 10.9140625,
            "text": "Ranasmurfin, a blue",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 10.9140625,
            "text": "asmurfin, a blue",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 10.9140625,
            "text": "urfin, a blue",
            "probability": 0.0
        },
        {
            "start_logit": -8.984375,
            "end_logit": -6.8515625,
            "text": "Ranasmurfin, a blue protein from a different species of frog, displays a novel structure with a unique chromophoric crosslink.",
            "probability": 0.0
        },
        {
            "start_logit": -9.5078125,
            "end_logit": -6.8515625,
            "text": "frog, displays a novel structure with a unique chromophoric crosslink.",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -6.8515625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": -6.8515625,
            "text": "of frog, displays a novel structure with a unique chromophoric crosslink.",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -6.8515625,
            "text": "species of frog, displays a novel structure with a unique chromophoric crosslink.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -6.8515625,
            "text": "different species of frog, displays a novel structure with a unique chromophoric crosslink.",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": -6.8515625,
            "text": "asmurfin, a blue protein from a different species of frog, displays a novel structure with a unique chromophoric crosslink.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": -6.8515625,
            "text": "from a different species of frog, displays a novel structure with a unique chromophoric crosslink.",
            "probability": 0.0
        },
        {
            "start_logit": -10.53125,
            "end_logit": -6.8515625,
            "text": "crosslink.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": -6.8515625,
            "text": "protein from a different species of frog, displays a novel structure with a unique chromophoric crosslink.",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": -6.8515625,
            "text": "a different species of frog, displays a novel structure with a unique chromophoric crosslink.",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": -6.8515625,
            "text": "chromophoric crosslink.",
            "probability": 0.0
        }
    ],
    "56f961b3cf1c325851000003_2": [
        {
            "start_logit": 11.609375,
            "end_logit": 10.484375,
            "text": "blue",
            "probability": 1.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": 1.267578125,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax, has been purified and crystallized. The crystals are an intense blue",
            "probability": 9.918212890625e-05
        },
        {
            "start_logit": 11.609375,
            "end_logit": -4.44921875,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax, has been purified and crystallized. The crystals are an intense blue colour",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 2.5546875,
            "end_logit": 1.267578125,
            "text": "blue",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -9.40625,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax, has been purified and crystallized.",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -9.78125,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax, has been purified and crystallized. The crystals are an intense",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -9.9140625,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax, has been purified",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -9.9375,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax,",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -9.9765625,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax, has been purified and crystallized. The crystals",
            "probability": 0.0
        },
        {
            "start_logit": 11.609375,
            "end_logit": -10.0078125,
            "text": "blue protein found in the nests of the frog Polypedates leucomystax",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 10.484375,
            "text": "approximately 13 kDa blue",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 10.484375,
            "text": "uncharacterized approximately 13 kDa blue",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 10.484375,
            "text": "Ranasmurfin, a previously uncharacterized approximately 13 kDa blue",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 10.484375,
            "text": "kDa blue",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 10.484375,
            "text": "previously uncharacterized approximately 13 kDa blue",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 10.484375,
            "text": "asmurfin, a previously uncharacterized approximately 13 kDa blue",
            "probability": 0.0
        },
        {
            "start_logit": 2.5546875,
            "end_logit": -4.44921875,
            "text": "blue colour",
            "probability": 0.0
        },
        {
            "start_logit": -8.53125,
            "end_logit": 1.267578125,
            "text": "intense blue",
            "probability": 0.0
        },
        {
            "start_logit": -9.8671875,
            "end_logit": 1.267578125,
            "text": "frog Polypedates leucomystax, has been purified and crystallized. The crystals are an intense blue",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 1.267578125,
            "text": "Polypedates leucomystax, has been purified and crystallized. The crystals are an intense blue",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_1": [
        {
            "start_logit": 14.4296875,
            "end_logit": 15.1328125,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": -1.7529296875,
            "end_logit": 15.1328125,
            "text": "encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -2.10546875,
            "text": "experimental",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -2.361328125,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -7.03125,
            "end_logit": 15.1328125,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -7.01171875,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -7.52734375,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -7.6953125,
            "text": "experimental autoimmune encephalomyelitis (EAE) animal model of multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -7.91015625,
            "text": "experimental autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.7265625,
            "text": "experimental autoimmune encephalomyelitis (EAE) animal",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -9.78125,
            "text": "experimental autoimmune encephalomyelitis (EAE) animal model",
            "probability": 0.0
        },
        {
            "start_logit": 14.4296875,
            "end_logit": -10.0546875,
            "text": "experimental autoimmune encephalomyelitis (EAE) animal model of multiple",
            "probability": 0.0
        },
        {
            "start_logit": -1.7529296875,
            "end_logit": -2.361328125,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -1.7529296875,
            "end_logit": -7.01171875,
            "text": "encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -1.7529296875,
            "end_logit": -7.52734375,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -7.03125,
            "end_logit": -2.361328125,
            "text": "autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -1.7529296875,
            "end_logit": -7.6953125,
            "text": "encephalomyelitis (EAE) animal model of multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": -7.140625,
            "end_logit": -2.361328125,
            "text": "(",
            "probability": 0.0
        },
        {
            "start_logit": -1.7529296875,
            "end_logit": -9.7265625,
            "text": "encephalomyelitis (EAE) animal",
            "probability": 0.0
        },
        {
            "start_logit": -1.7529296875,
            "end_logit": -9.78125,
            "text": "encephalomyelitis (EAE) animal model",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_2": [
        {
            "start_logit": 13.953125,
            "end_logit": 14.7578125,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": 13.953125,
            "end_logit": 6.19921875,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 0.00019109249114990234
        },
        {
            "start_logit": 13.953125,
            "end_logit": -0.6953125,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.8984375,
            "end_logit": 14.7578125,
            "text": "encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.953125,
            "end_logit": -2.96484375,
            "text": "experimental",
            "probability": 0.0
        },
        {
            "start_logit": 13.953125,
            "end_logit": -5.62109375,
            "text": "experimental autoimmune encephalomyelitis (EAE) mouse",
            "probability": 0.0
        },
        {
            "start_logit": 13.953125,
            "end_logit": -7.28125,
            "text": "experimental autoimmune encephalomyelitis (EAE) mouse model of MS",
            "probability": 0.0
        },
        {
            "start_logit": 13.953125,
            "end_logit": -7.37890625,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -8.609375,
            "end_logit": 14.7578125,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 13.953125,
            "end_logit": -9.078125,
            "text": "experimental autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": 13.953125,
            "end_logit": -9.21875,
            "text": "experimental autoimmune encephalomyelitis (EAE) mouse model",
            "probability": 0.0
        },
        {
            "start_logit": -1.8984375,
            "end_logit": 6.19921875,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 14.7578125,
            "text": "the chronic experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -5.3046875,
            "end_logit": 6.19921875,
            "text": "(",
            "probability": 0.0
        },
        {
            "start_logit": -8.609375,
            "end_logit": 6.19921875,
            "text": "autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -1.8984375,
            "end_logit": -0.6953125,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 6.19921875,
            "text": "the chronic experimental autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -5.3046875,
            "end_logit": -0.6953125,
            "text": "(EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -1.8984375,
            "end_logit": -5.62109375,
            "text": "encephalomyelitis (EAE) mouse",
            "probability": 0.0
        },
        {
            "start_logit": -1.8984375,
            "end_logit": -7.28125,
            "text": "encephalomyelitis (EAE) mouse model of MS",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_3": [
        {
            "start_logit": 14.4765625,
            "end_logit": 15.21875,
            "text": "Experimental Autoimmune Encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": -1.521484375,
            "end_logit": 15.21875,
            "text": "Encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -0.9833984375,
            "text": "Experimental Autoimmune Encephalomyelitis (",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -1.6826171875,
            "text": "Experimental",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -4.86328125,
            "text": "Experimental Autoimmune Encephalomyelitis (EAE) in the rat",
            "probability": 0.0
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 15.21875,
            "text": "Autoimmune Encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -7.3828125,
            "text": "Experimental Autoimmune Encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -8.1328125,
            "text": "Experimental Autoimmune Encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -8.703125,
            "text": "Experimental Autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -8.7421875,
            "text": "Experimental Autoimmune Encephalomyelitis (EAE) in",
            "probability": 0.0
        },
        {
            "start_logit": 14.4765625,
            "end_logit": -9.21875,
            "text": "Experimental Autoimmune Encephalomyelitis (EAE) in the",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 15.21875,
            "text": "of Experimental Autoimmune Encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 15.21875,
            "text": "the clinical signs linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 15.21875,
            "text": "linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 15.21875,
            "text": "clinical signs linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 15.21875,
            "text": "persistent pain in two models of Experimental Autoimmune Encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": 15.21875,
            "text": "pain in two models of Experimental Autoimmune Encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.1328125,
            "end_logit": 15.21875,
            "text": "The aim of our study was to characterize the sensory abnormalities and in particular the clinical signs linked to persistent pain in two models of Experimental Autoimmune Encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -1.521484375,
            "end_logit": -0.9833984375,
            "text": "Encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -1.521484375,
            "end_logit": -4.86328125,
            "text": "Encephalomyelitis (EAE) in the rat",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_4": [
        {
            "start_logit": 14.5234375,
            "end_logit": 15.203125,
            "text": "Experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -0.383544921875,
            "text": "Experimental autoimmune encephalomyelitis (EAE)",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -1.6240234375,
            "end_logit": 15.203125,
            "text": "encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -1.748046875,
            "text": "Experimental",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -4.0546875,
            "text": "Experimental autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -6.3515625,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": 15.203125,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -7.58203125,
            "text": "Experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -8.6171875,
            "text": "Experimental autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.578125,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.6875,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model for studying multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.6953125,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.8203125,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model for studying multiple sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.8359375,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model for studying multiple sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.9765625,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is an animal model for",
            "probability": 0.0
        },
        {
            "start_logit": -1.6240234375,
            "end_logit": -0.383544921875,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -1.6240234375,
            "end_logit": -4.0546875,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -6.046875,
            "end_logit": -0.383544921875,
            "text": "(EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -7.16796875,
            "end_logit": -0.383544921875,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -1.6240234375,
            "end_logit": -6.3515625,
            "text": "encephalomyelitis (EAE) is",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_5": [
        {
            "start_logit": 14.140625,
            "end_logit": 14.8828125,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": 0.96533203125,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -2.05859375,
            "end_logit": 14.8828125,
            "text": "encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.140625,
            "end_logit": -2.875,
            "text": "experimental",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -3.939453125,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -7.46875,
            "end_logit": 14.8828125,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -7.3671875,
            "text": "experimental autoimmune encephalomyelitis (EAE),",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -7.85546875,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -8.7734375,
            "text": "experimental autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.6484375,
            "text": "experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.6484375,
            "text": "experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.7578125,
            "text": "experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.796875,
            "text": "experimental autoimmune encephalomyelitis (EAE), an",
            "probability": 0.0
        },
        {
            "start_logit": 14.140625,
            "end_logit": -9.9453125,
            "text": "experimental autoimmune encephalomyelitis (EAE), an animal model",
            "probability": 0.0
        },
        {
            "start_logit": -2.05859375,
            "end_logit": 0.96533203125,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -2.05859375,
            "end_logit": -3.939453125,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -6.984375,
            "end_logit": 0.96533203125,
            "text": "(EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -7.46875,
            "end_logit": 0.96533203125,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -8.015625,
            "end_logit": 0.96533203125,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 0.96533203125,
            "text": "EAE)",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_6": [
        {
            "start_logit": 14.4921875,
            "end_logit": 15.21875,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": -1.4892578125,
            "end_logit": 15.21875,
            "text": "encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -1.69140625,
            "text": "experimental",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -3.44140625,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -6.34375,
            "end_logit": 15.21875,
            "text": "in experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -6.96484375,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -7.0625,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -7.89453125,
            "end_logit": 15.21875,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -7.5859375,
            "text": "experimental autoimmune encephalomyelitis (EAE), similar changes occur",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -8.515625,
            "text": "experimental autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.6640625,
            "text": "experimental autoimmune encephalomyelitis (EAE), similar changes",
            "probability": 0.0
        },
        {
            "start_logit": 14.4921875,
            "end_logit": -9.7734375,
            "text": "experimental autoimmune encephalomyelitis (EAE), similar",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 15.21875,
            "text": "animal model for MS, namely in experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 15.21875,
            "text": "for MS, namely in experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 15.21875,
            "text": "In this study we investigated whether in an animal model for MS, namely in experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": 15.21875,
            "text": "MS, namely in experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.2265625,
            "end_logit": 15.21875,
            "text": "namely in experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -1.4892578125,
            "end_logit": -3.44140625,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -6.34375,
            "end_logit": -1.69140625,
            "text": "in experimental",
            "probability": 0.0
        },
        {
            "start_logit": -1.4892578125,
            "end_logit": -6.96484375,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_7": [
        {
            "start_logit": 14.0234375,
            "end_logit": 14.875,
            "text": "Experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": 2.95703125,
            "text": "Experimental autoimmune encephalomyelitis (EAE)",
            "probability": 6.616115570068359e-06
        },
        {
            "start_logit": -1.982421875,
            "end_logit": 14.875,
            "text": "encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -3.171875,
            "text": "Experimental",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -5.18359375,
            "text": "Experimental autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -6.2734375,
            "text": "Experimental autoimmune encephalomyelitis (EAE),",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 14.875,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -8.1640625,
            "text": "Experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -8.7890625,
            "text": "Experimental autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.859375,
            "text": "Experimental autoimmune encephalomyelitis (EAE), a widely recognized animal model of multiple sclerosis",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.9296875,
            "text": "Experimental autoimmune encephalomyelitis (EAE), a widely recognized animal model of multiple sclerosis (MS)",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.9765625,
            "text": "Experimental autoimmune encephalomyelitis (EAE), a widely recognized animal model of multiple sclerosis (MS",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.9765625,
            "text": "Experimental autoimmune encephalomyelitis (EAE), a",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -10.0078125,
            "text": "Experimental autoimmune encephalomyelitis (EAE), a widely",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -10.0078125,
            "text": "Experimental autoimmune encephalomyelitis (EAE), a widely recognized animal model",
            "probability": 0.0
        },
        {
            "start_logit": -1.982421875,
            "end_logit": 2.95703125,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -7.4609375,
            "end_logit": 2.95703125,
            "text": ")",
            "probability": 0.0
        },
        {
            "start_logit": -7.48828125,
            "end_logit": 2.95703125,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -7.90234375,
            "end_logit": 2.95703125,
            "text": "(EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -1.982421875,
            "end_logit": -5.18359375,
            "text": "encephalomyelitis (",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_8": [
        {
            "start_logit": 13.6953125,
            "end_logit": 14.4765625,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": 1.2314453125,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -1.978515625,
            "end_logit": 14.4765625,
            "text": "encephalomyelitis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -3.259765625,
            "text": "experimental",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -7.0703125,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 14.4765625,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -7.72265625,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -7.87890625,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin D (CyPD)",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -8.71875,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -8.8515625,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin D (CyPD",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -9.3828125,
            "text": "experimental autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -9.6640625,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin D",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -9.6953125,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin D (CyP",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -9.8828125,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice lacking cyclophilin",
            "probability": 0.0
        },
        {
            "start_logit": 13.6953125,
            "end_logit": -9.9609375,
            "text": "experimental autoimmune encephalomyelitis (EAE) mice lacking",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 14.4765625,
            "text": "murine disease model, experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.1328125,
            "end_logit": 14.4765625,
            "text": ", experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": 14.4765625,
            "text": "disease model, experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -1.978515625,
            "end_logit": 1.2314453125,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -6.05078125,
            "end_logit": 1.2314453125,
            "text": "(",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_9": [
        {
            "start_logit": 14.0390625,
            "end_logit": 14.9921875,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": -1.9013671875,
            "end_logit": 14.9921875,
            "text": "encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -2.859375,
            "text": "experimental",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -6.31640625,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -6.49609375,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 14.9921875,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -8.1328125,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 14.9921875,
            "text": "model experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 14.0390625,
            "end_logit": -9.3125,
            "text": "experimental autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 14.9921875,
            "text": "the classical MS model experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 14.9921875,
            "text": "the strong impact of the classical MS model experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -1.9013671875,
            "end_logit": -6.31640625,
            "text": "encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -1.9013671875,
            "end_logit": -6.49609375,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -1.9013671875,
            "end_logit": -8.1328125,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -2.859375,
            "text": "model experimental",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": -2.859375,
            "text": "the classical MS model experimental",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": -2.859375,
            "text": "the strong impact of the classical MS model experimental",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": -6.31640625,
            "text": "autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": -6.49609375,
            "text": "autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -8.25,
            "end_logit": -6.31640625,
            "text": "(EAE",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_10": [
        {
            "start_logit": 13.0390625,
            "end_logit": 14.4765625,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": -2.546875,
            "end_logit": 14.4765625,
            "text": "encephalomyelitis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.0390625,
            "end_logit": -1.9892578125,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.0390625,
            "end_logit": -4.58203125,
            "text": "experimental",
            "probability": 0.0
        },
        {
            "start_logit": 13.0390625,
            "end_logit": -6.15625,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": 13.0390625,
            "end_logit": -6.2734375,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": 14.4765625,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 14.4765625,
            "text": ", experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": 14.4765625,
            "text": "animal model of MS, experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -2.546875,
            "end_logit": -1.9892578125,
            "text": "encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -2.546875,
            "end_logit": -6.15625,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -2.546875,
            "end_logit": -6.2734375,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -1.9892578125,
            "text": "autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": -1.9892578125,
            "text": "(EAE",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": -1.9892578125,
            "text": ", experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": -1.9892578125,
            "text": "animal model of MS, experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": -1.9892578125,
            "text": "EAE",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -6.15625,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -8.03125,
            "end_logit": -6.2734375,
            "text": "autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": -6.15625,
            "text": "(EAE)",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_11": [
        {
            "start_logit": 14.4375,
            "end_logit": 15.234375,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": 15.234375,
            "text": "encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.4375,
            "end_logit": -1.900390625,
            "text": "experimental",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.4375,
            "end_logit": -4.34765625,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -4.84765625,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -7.234375,
            "end_logit": 15.234375,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -7.046875,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": 14.4375,
            "end_logit": -8.3671875,
            "text": "experimental autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": -9.265625,
            "end_logit": 15.234375,
            "text": "of experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 15.234375,
            "text": "a targeted model of experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 15.234375,
            "text": "targeted model of experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 15.234375,
            "text": "model of experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 15.234375,
            "text": "animal model of multiple sclerosis (MS), we have used a targeted model of experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.046875,
            "end_logit": 15.234375,
            "text": "used a targeted model of experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 15.234375,
            "text": "of multiple sclerosis (MS), we have used a targeted model of experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": -4.34765625,
            "text": "encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": -4.84765625,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -1.58984375,
            "end_logit": -7.046875,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -6.8046875,
            "end_logit": -4.34765625,
            "text": "(EAE",
            "probability": 0.0
        },
        {
            "start_logit": -9.265625,
            "end_logit": -1.900390625,
            "text": "of experimental",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_12": [
        {
            "start_logit": 14.03125,
            "end_logit": 14.796875,
            "text": "Experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.7119140625
        },
        {
            "start_logit": 14.03125,
            "end_logit": 13.890625,
            "text": "Experimental autoimmune encephalomyelitis",
            "probability": 0.287841796875
        },
        {
            "start_logit": 14.03125,
            "end_logit": 2.5859375,
            "text": "Experimental autoimmune encephalomyelitis (",
            "probability": 3.5762786865234375e-06
        },
        {
            "start_logit": -1.732421875,
            "end_logit": 14.796875,
            "text": ")",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.169921875,
            "end_logit": 14.796875,
            "text": "encephalomyelitis (EAE)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.03125,
            "end_logit": -2.93359375,
            "text": "Experimental",
            "probability": 0.0
        },
        {
            "start_logit": -3.169921875,
            "end_logit": 13.890625,
            "text": "encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -6.46875,
            "end_logit": 14.796875,
            "text": "(EAE)",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -6.4140625,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 14.796875,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -7.6640625,
            "end_logit": 13.890625,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -8.5625,
            "text": "Experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.4765625,
            "text": "Experimental autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.7421875,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is a well-studied disease in rodents that",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.7734375,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is a well-studied disease in rodents that mimics many clinical and pathological features of MS",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.8984375,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is a well-studied disease in rodents that mimics many clinical and pathological features of MS,",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.9609375,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is a well",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -10.109375,
            "text": "Experimental autoimmune encephalomyelitis (EAE) is a well-studied disease in rodents that mimics many",
            "probability": 0.0
        },
        {
            "start_logit": -3.169921875,
            "end_logit": 2.5859375,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -6.46875,
            "end_logit": 2.5859375,
            "text": "(",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_13": [
        {
            "start_logit": 14.1015625,
            "end_logit": 14.59375,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": -2.501953125,
            "end_logit": 14.59375,
            "text": "encephalomyelitis",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -2.552734375,
            "text": "experimental",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -3.81640625,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -5.484375,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -7.921875,
            "end_logit": 14.59375,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.1171875,
            "text": "experimental autoimmune encephalomyelitis (EAE), its animal model, involve inflammatory attack on central nervous system (CNS) white matter",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -8.6875,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.0234375,
            "text": "experimental autoimmune encephalomyelitis (EAE), its",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.6484375,
            "text": "experimental autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.859375,
            "text": "experimental autoimmune encephalomyelitis (EAE), its animal model, involve",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -9.90625,
            "text": "experimental autoimmune encephalomyelitis (EAE),",
            "probability": 0.0
        },
        {
            "start_logit": 14.1015625,
            "end_logit": -10.03125,
            "text": "experimental autoimmune encephalomyelitis (EAE), its animal model",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.59375,
            "text": "and experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": 14.59375,
            "text": "multiple sclerosis (MS) and experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -2.501953125,
            "end_logit": -3.81640625,
            "text": "encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -2.501953125,
            "end_logit": -5.484375,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -2.501953125,
            "end_logit": -8.1171875,
            "text": "encephalomyelitis (EAE), its animal model, involve inflammatory attack on central nervous system (CNS) white matter",
            "probability": 0.0
        },
        {
            "start_logit": -7.3046875,
            "end_logit": -3.81640625,
            "text": "(EAE",
            "probability": 0.0
        },
        {
            "start_logit": -2.501953125,
            "end_logit": -8.6875,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_14": [
        {
            "start_logit": 13.359375,
            "end_logit": 14.4609375,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": 0.28466796875,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -2.365234375,
            "end_logit": 14.4609375,
            "text": "encephalomyelitis",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.359375,
            "end_logit": -3.962890625,
            "text": "experimental",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -5.69140625,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": 14.4609375,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -7.80078125,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 14.4609375,
            "text": ", experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 14.4609375,
            "text": "animal model, experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 13.359375,
            "end_logit": -10.234375,
            "text": "experimental autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": -2.365234375,
            "end_logit": 0.28466796875,
            "text": "encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -2.365234375,
            "end_logit": -5.69140625,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": 0.28466796875,
            "text": "autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -8.875,
            "end_logit": 0.28466796875,
            "text": "(EAE",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 0.28466796875,
            "text": ", experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 0.28466796875,
            "text": "EAE",
            "probability": 0.0
        },
        {
            "start_logit": -2.365234375,
            "end_logit": -7.80078125,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 0.28466796875,
            "text": "animal model, experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": -3.962890625,
            "text": ", experimental",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": -5.69140625,
            "text": "autoimmune encephalomyelitis (",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_15": [
        {
            "start_logit": 13.9375,
            "end_logit": 14.890625,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": -1.8525390625,
            "end_logit": 14.890625,
            "text": "encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.9375,
            "end_logit": -2.908203125,
            "text": "experimental",
            "probability": 0.0
        },
        {
            "start_logit": 13.9375,
            "end_logit": -3.875,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": 13.9375,
            "end_logit": -4.69921875,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": 13.9375,
            "end_logit": -5.55078125,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": 14.890625,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 14.890625,
            "text": "model experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 14.890625,
            "text": "In the MS animal model experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 13.9375,
            "end_logit": -9.8046875,
            "text": "experimental autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 14.890625,
            "text": "animal model experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -1.8525390625,
            "end_logit": -3.875,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -1.8525390625,
            "end_logit": -4.69921875,
            "text": "encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -1.8525390625,
            "end_logit": -5.55078125,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -6.65234375,
            "end_logit": -3.875,
            "text": "(",
            "probability": 0.0
        },
        {
            "start_logit": -6.65234375,
            "end_logit": -4.69921875,
            "text": "(EAE",
            "probability": 0.0
        },
        {
            "start_logit": -6.65234375,
            "end_logit": -5.55078125,
            "text": "(EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": -3.875,
            "text": "autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": -2.908203125,
            "text": "model experimental",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": -4.69921875,
            "text": "autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        }
    ],
    "5139b31dbee46bd34c000004_16": [
        {
            "start_logit": 13.953125,
            "end_logit": 14.7578125,
            "text": "experimental autoimmune encephalomyelitis",
            "probability": 1.0
        },
        {
            "start_logit": -2.103515625,
            "end_logit": 14.7578125,
            "text": "encephalomyelitis",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.953125,
            "end_logit": -2.939453125,
            "text": "experimental",
            "probability": 0.0
        },
        {
            "start_logit": 13.953125,
            "end_logit": -5.40625,
            "text": "experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": 14.7578125,
            "text": "autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 13.953125,
            "end_logit": -8.4921875,
            "text": "experimental autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": 13.953125,
            "end_logit": -8.5703125,
            "text": "experimental autoimmune encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 14.7578125,
            "text": "and experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": 13.953125,
            "end_logit": -9.765625,
            "text": "experimental autoimmune",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 14.7578125,
            "text": "inflammatory demyelination in multiple sclerosis (MS) lesions and experimental autoimmune encephalomyelitis",
            "probability": 0.0
        },
        {
            "start_logit": -2.103515625,
            "end_logit": -5.40625,
            "text": "encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -2.103515625,
            "end_logit": -8.4921875,
            "text": "encephalomyelitis (EAE)",
            "probability": 0.0
        },
        {
            "start_logit": -2.103515625,
            "end_logit": -8.5703125,
            "text": "encephalomyelitis (",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": -2.939453125,
            "text": "and experimental",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": -5.40625,
            "text": "autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": -2.939453125,
            "text": "inflammatory demyelination in multiple sclerosis (MS) lesions and experimental",
            "probability": 0.0
        },
        {
            "start_logit": -9.375,
            "end_logit": -5.40625,
            "text": "(EAE",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": -5.40625,
            "text": "and experimental autoimmune encephalomyelitis (EAE",
            "probability": 0.0
        },
        {
            "start_logit": -9.6640625,
            "end_logit": -5.40625,
            "text": "EAE",
            "probability": 0.0
        },
        {
            "start_logit": -7.91015625,
            "end_logit": -8.4921875,
            "text": "autoimmune encephalomyelitis (EAE)",
            "probability": 0.0
        }
    ],
    "553ca8d8f32186855800000d_1": [
        {
            "start_logit": 10.796875,
            "end_logit": -0.26171875,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA)",
            "probability": 0.73974609375
        },
        {
            "start_logit": 10.796875,
            "end_logit": -1.8681640625,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RFB)",
            "probability": 0.149169921875
        },
        {
            "start_logit": 10.796875,
            "end_logit": -2.814453125,
            "text": "replication",
            "probability": 0.057952880859375
        },
        {
            "start_logit": 10.796875,
            "end_logit": -2.951171875,
            "text": "replication defects",
            "probability": 0.05035400390625
        },
        {
            "start_logit": 10.796875,
            "end_logit": -6.55859375,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RFB",
            "probability": 0.0013685226440429688
        },
        {
            "start_logit": 10.796875,
            "end_logit": -7.1640625,
            "text": "replication defects at multiple sites within ribosomal DNA",
            "probability": 0.0007467269897460938
        },
        {
            "start_logit": 10.796875,
            "end_logit": -7.5078125,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA),",
            "probability": 0.0005297660827636719
        },
        {
            "start_logit": 10.796875,
            "end_logit": -8.96875,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA",
            "probability": 0.00012290477752685547
        },
        {
            "start_logit": 10.796875,
            "end_logit": -8.9765625,
            "text": "replication defects at multiple",
            "probability": 0.00012189149856567383
        },
        {
            "start_logit": 10.796875,
            "end_logit": -9.4453125,
            "text": "replication defects at multiple sites within ribosomal DNA (",
            "probability": 7.62939453125e-05
        },
        {
            "start_logit": 10.796875,
            "end_logit": -9.8125,
            "text": "replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RF",
            "probability": 5.2809715270996094e-05
        },
        {
            "start_logit": -9.0859375,
            "end_logit": -0.26171875,
            "text": "Lack of the yeast Rrm3p DNA helicase causes replication defects at multiple sites within ribosomal DNA (rDNA)",
            "probability": 0.0
        },
        {
            "start_logit": -9.171875,
            "end_logit": -0.26171875,
            "text": "DNA helicase causes replication defects at multiple sites within ribosomal DNA (rDNA)",
            "probability": 0.0
        },
        {
            "start_logit": -7.8359375,
            "end_logit": -1.8681640625,
            "text": "replication fork barrier (RFB)",
            "probability": 0.0
        },
        {
            "start_logit": -9.4609375,
            "end_logit": -0.26171875,
            "text": "at multiple sites within ribosomal DNA (rDNA)",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": -0.26171875,
            "text": "within ribosomal DNA (rDNA)",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": -0.26171875,
            "text": "defects at multiple sites within ribosomal DNA (rDNA)",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": -0.26171875,
            "text": "ribosomal DNA (rDNA)",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": -0.26171875,
            "text": "causes replication defects at multiple sites within ribosomal DNA (rDNA)",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -0.26171875,
            "text": "helicase causes replication defects at multiple sites within ribosomal DNA (rDNA)",
            "probability": 0.0
        }
    ],
    "58e9f0ba3e8b6dc87c00000e_1": [
        {
            "start_logit": 5.0078125,
            "end_logit": 2.14453125,
            "text": "Macrosteles quadrilineatus",
            "probability": 0.583984375
        },
        {
            "start_logit": 1.16796875,
            "end_logit": 5.61328125,
            "text": "Sulcia muelleri",
            "probability": 0.40283203125
        },
        {
            "start_logit": 1.16796875,
            "end_logit": 2.14453125,
            "text": "Sulcia muelleri and Nasuia deltocephalinicola, of the phloem-feeding pest insect, Macrosteles quadrilineatus",
            "probability": 0.01255035400390625
        },
        {
            "start_logit": 5.0078125,
            "end_logit": -5.16015625,
            "text": "Macrosteles",
            "probability": 0.0003924369812011719
        },
        {
            "start_logit": 1.16796875,
            "end_logit": -1.9384765625,
            "text": "Sulcia muelleri and Nasuia deltocephalinicola",
            "probability": 0.0002117156982421875
        },
        {
            "start_logit": 5.0078125,
            "end_logit": -6.88671875,
            "text": "Macrosteles quadrilineatus (Auchenorrhyncha: Cicadellidae).",
            "probability": 6.985664367675781e-05
        },
        {
            "start_logit": -7.78515625,
            "end_logit": 5.61328125,
            "text": "i",
            "probability": 5.1856040954589844e-05
        },
        {
            "start_logit": -8.4375,
            "end_logit": 5.61328125,
            "text": "a muelleri",
            "probability": 2.7120113372802734e-05
        },
        {
            "start_logit": -4.98828125,
            "end_logit": 2.14453125,
            "text": "Nasuia deltocephalinicola, of the phloem-feeding pest insect, Macrosteles quadrilineatus",
            "probability": 2.6524066925048828e-05
        },
        {
            "start_logit": -8.875,
            "end_logit": 5.61328125,
            "text": "cia muelleri",
            "probability": 1.7523765563964844e-05
        },
        {
            "start_logit": 5.0078125,
            "end_logit": -8.3125,
            "text": "Macrosteles quadrilineatus (Auchenorrhyncha: Cicadellidae",
            "probability": 1.6868114471435547e-05
        },
        {
            "start_logit": 5.0078125,
            "end_logit": -8.5,
            "text": "Macroste",
            "probability": 1.3947486877441406e-05
        },
        {
            "start_logit": -9.375,
            "end_logit": 5.61328125,
            "text": "muelleri",
            "probability": 1.0609626770019531e-05
        },
        {
            "start_logit": 1.16796875,
            "end_logit": -5.16015625,
            "text": "Sulcia muelleri and Nasuia deltocephalinicola, of the phloem-feeding pest insect, Macrosteles",
            "probability": 8.463859558105469e-06
        },
        {
            "start_logit": -9.640625,
            "end_logit": 5.61328125,
            "text": "symbionts, Sulcia muelleri",
            "probability": 8.165836334228516e-06
        },
        {
            "start_logit": 5.0078125,
            "end_logit": -9.1875,
            "text": "Macrosteles quadriline",
            "probability": 7.033348083496094e-06
        },
        {
            "start_logit": 5.0078125,
            "end_logit": -9.3203125,
            "text": "Macrosteles quadrilineatus (Auchenorrhynch",
            "probability": 6.079673767089844e-06
        },
        {
            "start_logit": 5.0078125,
            "end_logit": -9.3203125,
            "text": "Macrosteles quadr",
            "probability": 6.079673767089844e-06
        },
        {
            "start_logit": -6.4921875,
            "end_logit": 2.14453125,
            "text": "teles quadrilineatus",
            "probability": 5.900859832763672e-06
        },
        {
            "start_logit": 1.16796875,
            "end_logit": -6.5859375,
            "text": "Sulcia",
            "probability": 2.0265579223632812e-06
        }
    ],
    "5a6e2578b750ff445500003d_1": [
        {
            "start_logit": 14.046875,
            "end_logit": 15.3046875,
            "text": "diffloop",
            "probability": 1.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": 15.3046875,
            "text": "op",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.046875,
            "end_logit": -2.8359375,
            "text": "difflo",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -3.0078125,
            "text": "diff",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -7.1171875,
            "text": "diffloop:",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 15.3046875,
            "text": "loop",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -9.3828125,
            "text": "diffloop: a computational framework for identifying and analyzing differential DNA loops from sequencing data.",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -10.0546875,
            "text": "diffloop: a computational framework",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -10.1640625,
            "text": "diffloop: a computational framework for identifying and analyzing differential DNA loops from sequencing data",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -10.171875,
            "text": "diffloop: a",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -10.2734375,
            "text": "diffloop: a computational framework for identifying and analyzing differential DNA loops",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -10.2734375,
            "text": "diffloop: a computational framework for identifying and analyzing differential DNA loops from sequencing",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -7.1171875,
            "text": "op:",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -9.3828125,
            "text": "op: a computational framework for identifying and analyzing differential DNA loops from sequencing data.",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -10.0546875,
            "text": "op: a computational framework",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -10.1640625,
            "text": "op: a computational framework for identifying and analyzing differential DNA loops from sequencing data",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -10.171875,
            "text": "op: a",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -10.2734375,
            "text": "op: a computational framework for identifying and analyzing differential DNA loops",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -10.2734375,
            "text": "op: a computational framework for identifying and analyzing differential DNA loops from sequencing",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": -2.8359375,
            "text": "lo",
            "probability": 0.0
        }
    ],
    "5a6e2578b750ff445500003d_2": [
        {
            "start_logit": 13.984375,
            "end_logit": 15.3125,
            "text": "diffloop",
            "probability": 1.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": 15.3125,
            "text": "op",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.984375,
            "end_logit": -2.689453125,
            "text": "difflo",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -3.064453125,
            "text": "diff",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -4.5625,
            "text": "diffloop,",
            "probability": 0.0
        },
        {
            "start_logit": -8.6640625,
            "end_logit": 15.3125,
            "text": "introduce diffloop",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 15.3125,
            "text": "loop",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -8.90625,
            "text": "diffloop, an",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 15.3125,
            "text": "changes in DNA looping architecture between samples, we introduce diffloop",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 15.3125,
            "text": "looping architecture between samples, we introduce diffloop",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.890625,
            "text": "diffloop, an R/Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.8984375,
            "text": "diffloop, an R",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.984375,
            "text": "diffloop, an R/Bioconductor package that provides a suite",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -10.0859375,
            "text": "diffloop, an R/Bioconductor package that provides a suite of functions for the quality control",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -4.5625,
            "text": "op,",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -8.90625,
            "text": "op, an",
            "probability": 0.0
        },
        {
            "start_logit": -8.6640625,
            "end_logit": -2.689453125,
            "text": "introduce difflo",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -9.890625,
            "text": "op, an R/Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -9.8984375,
            "text": "op, an R",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -9.984375,
            "text": "op, an R/Bioconductor package that provides a suite",
            "probability": 0.0
        }
    ],
    "5a6e2578b750ff445500003d_3": [
        {
            "start_logit": 13.984375,
            "end_logit": 15.3125,
            "text": "diffloop",
            "probability": 1.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": 15.3125,
            "text": "op",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.984375,
            "end_logit": -2.689453125,
            "text": "difflo",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -3.064453125,
            "text": "diff",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -4.5625,
            "text": "diffloop,",
            "probability": 0.0
        },
        {
            "start_logit": -8.6640625,
            "end_logit": 15.3125,
            "text": "introduce diffloop",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 15.3125,
            "text": "loop",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -8.90625,
            "text": "diffloop, an",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 15.3125,
            "text": "changes in DNA looping architecture between samples, we introduce diffloop",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 15.3125,
            "text": "looping architecture between samples, we introduce diffloop",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.890625,
            "text": "diffloop, an R/Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.8984375,
            "text": "diffloop, an R",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.984375,
            "text": "diffloop, an R/Bioconductor package that provides a suite",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -10.0859375,
            "text": "diffloop, an R/Bioconductor package that provides a suite of functions for the quality control",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -4.5625,
            "text": "op,",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -8.90625,
            "text": "op, an",
            "probability": 0.0
        },
        {
            "start_logit": -8.6640625,
            "end_logit": -2.689453125,
            "text": "introduce difflo",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -9.890625,
            "text": "op, an R/Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -9.8984375,
            "text": "op, an R",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -9.984375,
            "text": "op, an R/Bioconductor package that provides a suite",
            "probability": 0.0
        }
    ],
    "5a6e2578b750ff445500003d_4": [
        {
            "start_logit": 14.046875,
            "end_logit": 15.3046875,
            "text": "diffloop",
            "probability": 1.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": 15.3046875,
            "text": "op",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.046875,
            "end_logit": -2.8359375,
            "text": "difflo",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -3.0078125,
            "text": "diff",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -7.1171875,
            "text": "diffloop:",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 15.3046875,
            "text": "loop",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -9.3828125,
            "text": "diffloop: a computational framework for identifying and analyzing differential DNA loops from sequencing data.",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -10.0546875,
            "text": "diffloop: a computational framework",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -10.1640625,
            "text": "diffloop: a computational framework for identifying and analyzing differential DNA loops from sequencing data",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -10.171875,
            "text": "diffloop: a",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -10.2734375,
            "text": "diffloop: a computational framework for identifying and analyzing differential DNA loops",
            "probability": 0.0
        },
        {
            "start_logit": 14.046875,
            "end_logit": -10.2734375,
            "text": "diffloop: a computational framework for identifying and analyzing differential DNA loops from sequencing",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -7.1171875,
            "text": "op:",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -9.3828125,
            "text": "op: a computational framework for identifying and analyzing differential DNA loops from sequencing data.",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -10.0546875,
            "text": "op: a computational framework",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -10.1640625,
            "text": "op: a computational framework for identifying and analyzing differential DNA loops from sequencing data",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -10.171875,
            "text": "op: a",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -10.2734375,
            "text": "op: a computational framework for identifying and analyzing differential DNA loops",
            "probability": 0.0
        },
        {
            "start_logit": -1.6064453125,
            "end_logit": -10.2734375,
            "text": "op: a computational framework for identifying and analyzing differential DNA loops from sequencing",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": -2.8359375,
            "text": "lo",
            "probability": 0.0
        }
    ],
    "5a6e2578b750ff445500003d_5": [
        {
            "start_logit": 13.984375,
            "end_logit": 15.3125,
            "text": "diffloop",
            "probability": 1.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": 15.3125,
            "text": "op",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 13.984375,
            "end_logit": -2.689453125,
            "text": "difflo",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -3.064453125,
            "text": "diff",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -4.5625,
            "text": "diffloop,",
            "probability": 0.0
        },
        {
            "start_logit": -8.6640625,
            "end_logit": 15.3125,
            "text": "introduce diffloop",
            "probability": 0.0
        },
        {
            "start_logit": -9.953125,
            "end_logit": 15.3125,
            "text": "loop",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -8.90625,
            "text": "diffloop, an",
            "probability": 0.0
        },
        {
            "start_logit": -10.9375,
            "end_logit": 15.3125,
            "text": "changes in DNA looping architecture between samples, we introduce diffloop",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 15.3125,
            "text": "looping architecture between samples, we introduce diffloop",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.890625,
            "text": "diffloop, an R/Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.8984375,
            "text": "diffloop, an R",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.984375,
            "text": "diffloop, an R/Bioconductor package that provides a suite",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -10.0859375,
            "text": "diffloop, an R/Bioconductor package that provides a suite of functions for the quality control",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -4.5625,
            "text": "op,",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -8.90625,
            "text": "op, an",
            "probability": 0.0
        },
        {
            "start_logit": -8.6640625,
            "end_logit": -2.689453125,
            "text": "introduce difflo",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -9.890625,
            "text": "op, an R/Bioconductor package",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -9.8984375,
            "text": "op, an R",
            "probability": 0.0
        },
        {
            "start_logit": -1.6357421875,
            "end_logit": -9.984375,
            "text": "op, an R/Bioconductor package that provides a suite",
            "probability": 0.0
        }
    ],
    "5e29fb27aa19d74431000005_1": [
        {
            "start_logit": -5.8515625,
            "end_logit": -0.385498046875,
            "text": "JNK activation, and modulated the expression of 14-3-3 binding sites.",
            "probability": 0.73193359375
        },
        {
            "start_logit": -5.8515625,
            "end_logit": -2.185546875,
            "text": "JNK",
            "probability": 0.12091064453125
        },
        {
            "start_logit": -6.79296875,
            "end_logit": -2.185546875,
            "text": "hyperphosphorylation of DDR proteins (BRCA1, Chk2, and \u03b3H2AX), altered the chronology and persistence of JNK",
            "probability": 0.04736328125
        },
        {
            "start_logit": -8.65625,
            "end_logit": -0.385498046875,
            "text": ".",
            "probability": 0.044464111328125
        },
        {
            "start_logit": -3.73828125,
            "end_logit": -6.75,
            "text": "LB100 also induced constitutive hyperphosphorylation",
            "probability": 0.0104827880859375
        },
        {
            "start_logit": -8.3125,
            "end_logit": -2.185546875,
            "text": "constitutive hyperphosphorylation of DDR proteins (BRCA1, Chk2, and \u03b3H2AX), altered the chronology and persistence of JNK",
            "probability": 0.01032257080078125
        },
        {
            "start_logit": -10.703125,
            "end_logit": -0.385498046875,
            "text": "\u03b3H2AX), altered the chronology and persistence of JNK activation, and modulated the expression of 14-3-3 binding sites.",
            "probability": 0.005741119384765625
        },
        {
            "start_logit": -10.78125,
            "end_logit": -0.385498046875,
            "text": ", and \u03b3H2AX), altered the chronology and persistence of JNK activation, and modulated the expression of 14-3-3 binding sites.",
            "probability": 0.00531005859375
        },
        {
            "start_logit": -10.9296875,
            "end_logit": -0.385498046875,
            "text": "and \u03b3H2AX), altered the chronology and persistence of JNK activation, and modulated the expression of 14-3-3 binding sites.",
            "probability": 0.00457763671875
        },
        {
            "start_logit": -11.0234375,
            "end_logit": -0.385498046875,
            "text": "altered the chronology and persistence of JNK activation, and modulated the expression of 14-3-3 binding sites.",
            "probability": 0.004169464111328125
        },
        {
            "start_logit": -3.73828125,
            "end_logit": -7.77734375,
            "text": "LB100 also",
            "probability": 0.0037384033203125
        },
        {
            "start_logit": -3.73828125,
            "end_logit": -8.0078125,
            "text": "LB100 also induced constitutive hyperphosphorylation of",
            "probability": 0.002956390380859375
        },
        {
            "start_logit": -9.8828125,
            "end_logit": -2.185546875,
            "text": "induced constitutive hyperphosphorylation of DDR proteins (BRCA1, Chk2, and \u03b3H2AX), altered the chronology and persistence of JNK",
            "probability": 0.0021457672119140625
        },
        {
            "start_logit": -3.73828125,
            "end_logit": -8.984375,
            "text": "LB100 also induced",
            "probability": 0.0011224746704101562
        },
        {
            "start_logit": -10.703125,
            "end_logit": -2.185546875,
            "text": "\u03b3H2AX), altered the chronology and persistence of JNK",
            "probability": 0.0009450912475585938
        },
        {
            "start_logit": -10.78125,
            "end_logit": -2.185546875,
            "text": ", and \u03b3H2AX), altered the chronology and persistence of JNK",
            "probability": 0.0008740425109863281
        },
        {
            "start_logit": -3.73828125,
            "end_logit": -9.25,
            "text": "LB100",
            "probability": 0.0008606910705566406
        },
        {
            "start_logit": -10.8515625,
            "end_logit": -2.185546875,
            "text": ", Chk2, and \u03b3H2AX), altered the chronology and persistence of JNK",
            "probability": 0.0008144378662109375
        },
        {
            "start_logit": -3.73828125,
            "end_logit": -9.3515625,
            "text": "LB100 also induced constitutive hyperphosphorylation of DDR proteins (BRCA1, Chk2, and \u03b3H2AX)",
            "probability": 0.0007715225219726562
        },
        {
            "start_logit": -10.9296875,
            "end_logit": -2.185546875,
            "text": "and \u03b3H2AX), altered the chronology and persistence of JNK",
            "probability": 0.0007534027099609375
        }
    ],
    "5c6e0f537c78d6947100004a_1": [
        {
            "start_logit": 12.4140625,
            "end_logit": 12.6875,
            "text": "tropomyosin receptor kinases",
            "probability": 1.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -4.96484375,
            "text": "tropomyosin",
            "probability": 0.0
        },
        {
            "start_logit": -5.47265625,
            "end_logit": 12.6875,
            "text": "kinases",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -8.09375,
            "text": "tropomyosin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": 12.6875,
            "text": "receptor kinases",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -8.4921875,
            "text": "tropomyosin receptor kinases (TRK",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -9.421875,
            "text": "tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (NTR",
            "probability": 0.0
        },
        {
            "start_logit": -9.7734375,
            "end_logit": 12.6875,
            "text": "of tropomyosin receptor kinases",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -9.6171875,
            "text": "tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (NTRK",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -9.875,
            "text": "tropomyosin receptor kinases (TR",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -10.1171875,
            "text": "tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 12.6875,
            "text": ", potent, and selective inhibitor of tropomyosin receptor kinases",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 12.6875,
            "text": "Loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 12.6875,
            "text": "s oral, potent, and selective inhibitor of tropomyosin receptor kinases",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 12.6875,
            "text": "-101), Loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 12.6875,
            "text": "and selective inhibitor of tropomyosin receptor kinases",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 12.6875,
            "text": ", and selective inhibitor of tropomyosin receptor kinases",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 12.6875,
            "text": "LOXO-101), Loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -10.4140625,
            "text": "tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (NTRK)-fusion",
            "probability": 0.0
        },
        {
            "start_logit": 12.4140625,
            "end_logit": -10.4453125,
            "text": "tropomyosin receptor kinases (TRK), demonstrated unprecedented efficacy on unresectable or metastatic solid tumors with neurotrophic tropomyosin receptor kinase (NTRK)",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_1": [
        {
            "start_logit": 13.5,
            "end_logit": 15.15625,
            "text": "Sudden Unexpected Death in Epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": 15.15625,
            "text": "Epilepsy",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 13.5,
            "end_logit": -3.87890625,
            "text": "Sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 15.15625,
            "text": "Death in Epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 15.15625,
            "text": "Unexpected Death in Epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 15.15625,
            "text": "in Epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.3046875,
            "text": "Sudden Unexpected Death in",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.4453125,
            "text": "Sudden Unexpected Death in Epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.5390625,
            "text": "Sudden Unexpected Death in Epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.7890625,
            "text": "Sudden Unexpected Death in Epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.9453125,
            "text": "Sudden Unexpected Death in Epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.4453125,
            "text": "Epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.5390625,
            "text": "Epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.7890625,
            "text": "Epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.9453125,
            "text": "Epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.3046875,
            "text": "Death in",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.4453125,
            "text": "Death in Epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.5390625,
            "text": "Death in Epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.7890625,
            "text": "Death in Epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.9453125,
            "text": "Death in Epilepsy (SUDEP)",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_2": [
        {
            "start_logit": 13.3515625,
            "end_logit": 15.0703125,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -1.3056640625,
            "end_logit": 15.0703125,
            "text": "epilepsy",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -4.07421875,
            "text": "sudden",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": 15.0703125,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": 15.0703125,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.25,
            "end_logit": 15.0703125,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -9.234375,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -9.796875,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -9.8515625,
            "text": "sudden unexpected death in",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -9.8515625,
            "text": "sudden unexpected death in epilepsy (SUDEP),",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -9.890625,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 13.3515625,
            "end_logit": -10.03125,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -1.3056640625,
            "end_logit": -9.234375,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.3056640625,
            "end_logit": -9.796875,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -1.3056640625,
            "end_logit": -9.8515625,
            "text": "epilepsy (SUDEP),",
            "probability": 0.0
        },
        {
            "start_logit": -1.3056640625,
            "end_logit": -9.890625,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -1.3056640625,
            "end_logit": -10.03125,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -9.234375,
            "text": "death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -7.59375,
            "end_logit": -9.234375,
            "text": "unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -7.1171875,
            "end_logit": -9.796875,
            "text": "death in epilepsy (SUDEP",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_3": [
        {
            "start_logit": 13.7578125,
            "end_logit": 15.2109375,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.264404296875,
            "end_logit": 15.2109375,
            "text": "epilepsy",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -3.505859375,
            "text": "Sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.80859375,
            "end_logit": 15.2109375,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.8125,
            "end_logit": 15.2109375,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.3125,
            "end_logit": 15.2109375,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -9.4609375,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -9.7265625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -9.9375,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -9.9609375,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -10.015625,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -10.0234375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is the most important direct seizure-related cause of death, and",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -10.0703125,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is the most",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -10.15625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is the most important",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -10.1796875,
            "text": "Sudden unexpected death in",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -10.21875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is the most important direct seizure-related cause",
            "probability": 0.0
        },
        {
            "start_logit": 13.7578125,
            "end_logit": -10.265625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is the most important direct seizure-related cause of death, and most cases usually occur in patients with intractable",
            "probability": 0.0
        },
        {
            "start_logit": -0.264404296875,
            "end_logit": -9.4609375,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -0.264404296875,
            "end_logit": -9.7265625,
            "text": "epilepsy (SUDEP) is",
            "probability": 0.0
        },
        {
            "start_logit": -0.264404296875,
            "end_logit": -9.9375,
            "text": "epilepsy (SUD",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_4": [
        {
            "start_logit": 14.21875,
            "end_logit": 15.3984375,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -1.0947265625,
            "end_logit": 15.3984375,
            "text": "epilepsy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 14.21875,
            "end_logit": -2.6953125,
            "text": "Sudden",
            "probability": 0.0
        },
        {
            "start_logit": -5.640625,
            "end_logit": 15.3984375,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -6.92578125,
            "end_logit": 15.3984375,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": 15.3984375,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -8.9296875,
            "text": "Sudden unexpected death in",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.5234375,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.8046875,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.84375,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.9140625,
            "text": "Sudden unexpected death in epilepsy (SUDEP): what do patients think",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.9453125,
            "text": "Sudden unexpected death in epilepsy (SUDEP): what",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -10.03125,
            "text": "Sudden unexpected",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -10.1015625,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -10.25,
            "text": "Sudden unexpected death in epilepsy (SUDEP):",
            "probability": 0.0
        },
        {
            "start_logit": -1.0947265625,
            "end_logit": -9.5234375,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.0947265625,
            "end_logit": -9.8046875,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -1.0947265625,
            "end_logit": -9.84375,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -1.0947265625,
            "end_logit": -9.9140625,
            "text": "epilepsy (SUDEP): what do patients think",
            "probability": 0.0
        },
        {
            "start_logit": -1.0947265625,
            "end_logit": -9.9453125,
            "text": "epilepsy (SUDEP): what",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_5": [
        {
            "start_logit": 13.65625,
            "end_logit": 15.2578125,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.67431640625,
            "end_logit": 15.2578125,
            "text": "epilepsy",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 13.65625,
            "end_logit": -3.724609375,
            "text": "Sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.421875,
            "end_logit": 15.2578125,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -8.21875,
            "end_logit": 15.2578125,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 15.2578125,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -8.171875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a major cause of mortality in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 15.2578125,
            "text": ": Sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -8.8125,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.4296875,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 15.2578125,
            "text": "OBJECTIVES: Sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.53125,
            "text": "Sudden unexpected death in",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.7109375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a major",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.7890625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a major cause of mortality in epilepsy.",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.796875,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.859375,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a major cause of mortality",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -9.8828125,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.65625,
            "end_logit": -10.109375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a major cause",
            "probability": 0.0
        },
        {
            "start_logit": -0.67431640625,
            "end_logit": -8.171875,
            "text": "epilepsy (SUDEP) is a major cause of mortality in epilepsy",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_6": [
        {
            "start_logit": 13.4921875,
            "end_logit": 15.3515625,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.0252532958984375,
            "end_logit": 15.3515625,
            "text": "epilepsy",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -3.974609375,
            "text": "sudden",
            "probability": 0.0
        },
        {
            "start_logit": -7.2578125,
            "end_logit": 15.3515625,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 15.3515625,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 15.3515625,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.875,
            "end_logit": 15.3515625,
            "text": "death was sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 15.3515625,
            "text": "cause of death was sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 15.3515625,
            "text": "patients cause of death was sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.296875,
            "end_logit": 15.3515625,
            "text": "In 11 patients cause of death was sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 15.3515625,
            "text": "of death was sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.3515625,
            "text": "11 patients cause of death was sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.828125,
            "end_logit": 15.3515625,
            "text": "was sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.859375,
            "text": "sudden unexpected death in epilepsy (SUDEP).",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.984375,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -9.984375,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.4921875,
            "end_logit": -10.1484375,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -0.0252532958984375,
            "end_logit": -9.859375,
            "text": "epilepsy (SUDEP).",
            "probability": 0.0
        },
        {
            "start_logit": -0.0252532958984375,
            "end_logit": -9.984375,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -0.0252532958984375,
            "end_logit": -9.984375,
            "text": "epilepsy (",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_7": [
        {
            "start_logit": 13.7421875,
            "end_logit": 15.1953125,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -1.052734375,
            "end_logit": 15.1953125,
            "text": "epilepsy",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -3.685546875,
            "text": "sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.05859375,
            "end_logit": 15.1953125,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 15.1953125,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.79296875,
            "end_logit": 15.1953125,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.1796875,
            "end_logit": 15.1953125,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 15.1953125,
            "text": "death, particularly sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -8.75,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.265625,
            "text": "sudden unexpected death in epilepsy (SUDEP), is still underestimated",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 15.1953125,
            "text": "related death, particularly sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.6015625,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.6171875,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.6328125,
            "text": "sudden unexpected death in epilepsy (SUDEP), is still underestimated by healthcare professionals and this may reflect the mistaken belief that epilepsy is a benign condition",
            "probability": 0.0
        },
        {
            "start_logit": -11.0859375,
            "end_logit": 15.1953125,
            "text": "-related death, particularly sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.640625,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.6640625,
            "text": "sudden unexpected death in epilepsy (SUDEP), is",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.6796875,
            "text": "sudden unexpected death in epilepsy (SUDEP), is still underestimated by healthcare professionals and this may",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.6875,
            "text": "sudden unexpected death in epilepsy (SUDEP), is still underestimated by healthcare professionals and this may reflect the mistaken belief that epilepsy is a benign",
            "probability": 0.0
        },
        {
            "start_logit": -11.1484375,
            "end_logit": 15.1953125,
            "text": "particularly sudden unexpected death in epilepsy",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_8": [
        {
            "start_logit": 14.03125,
            "end_logit": 15.2734375,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.39697265625,
            "end_logit": 15.2734375,
            "text": "epilepsy",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 14.03125,
            "end_logit": -3.0546875,
            "text": "Sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.44921875,
            "end_logit": 15.2734375,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.6484375,
            "end_logit": 15.2734375,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -8.9921875,
            "end_logit": 15.2734375,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.59375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a - probably heterogeneous - condition where patients with epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.671875,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.7109375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -9.765625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a - probably heterogeneous - condition",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -10.0078125,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -10.0625,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -10.1484375,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -10.2578125,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a - probably heterogeneous - condition where",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -10.2734375,
            "text": "Sudden unexpected",
            "probability": 0.0
        },
        {
            "start_logit": 14.03125,
            "end_logit": -10.2734375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is a - probably heterogeneous - condition where patients with epilepsy die suddenly, almost certainly during a seizure",
            "probability": 0.0
        },
        {
            "start_logit": -0.39697265625,
            "end_logit": -9.59375,
            "text": "epilepsy (SUDEP) is a - probably heterogeneous - condition where patients with epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -0.39697265625,
            "end_logit": -9.671875,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -0.39697265625,
            "end_logit": -9.7109375,
            "text": "epilepsy (SUDEP) is",
            "probability": 0.0
        },
        {
            "start_logit": -0.39697265625,
            "end_logit": -9.765625,
            "text": "epilepsy (SUDEP) is a - probably heterogeneous - condition",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_9": [
        {
            "start_logit": 11.328125,
            "end_logit": 11.25,
            "text": "Epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -7.8671875,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -9.484375,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is the most important direct epilepsy-related cause of death.",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -9.921875,
            "text": "Epilepsy is the most common serious neurological condition",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.1953125,
            "text": "Epilepsy is the most common serious neurological condition and",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.2265625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is the most important direct epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.390625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.40625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.4140625,
            "text": "Epilepsy is the most",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.4296875,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.4375,
            "text": "Epilepsy is the most common",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.4453125,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is",
            "probability": 0.0
        },
        {
            "start_logit": -0.1636962890625,
            "end_logit": -7.8671875,
            "text": "sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -0.1636962890625,
            "end_logit": -9.484375,
            "text": "sudden unexpected death in epilepsy (SUDEP) is the most important direct epilepsy-related cause of death.",
            "probability": 0.0
        },
        {
            "start_logit": -0.1636962890625,
            "end_logit": -10.2265625,
            "text": "sudden unexpected death in epilepsy (SUDEP) is the most important direct epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -0.1636962890625,
            "end_logit": -10.390625,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -0.1636962890625,
            "end_logit": -10.40625,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -0.1636962890625,
            "end_logit": -10.4296875,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -0.1636962890625,
            "end_logit": -10.4453125,
            "text": "sudden unexpected death in epilepsy (SUDEP) is",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -7.8671875,
            "text": "death in epilepsy",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_10": [
        {
            "start_logit": 11.328125,
            "end_logit": 11.25,
            "text": "Epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -7.8671875,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -9.484375,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is the most important direct epilepsy-related cause of death.",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -9.921875,
            "text": "Epilepsy is the most common serious neurological condition",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.1953125,
            "text": "Epilepsy is the most common serious neurological condition and",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.2265625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is the most important direct epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.390625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.40625,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.4140625,
            "text": "Epilepsy is the most",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.4296875,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.4375,
            "text": "Epilepsy is the most common",
            "probability": 0.0
        },
        {
            "start_logit": 11.328125,
            "end_logit": -10.4453125,
            "text": "Epilepsy is the most common serious neurological condition and sudden unexpected death in epilepsy (SUDEP) is",
            "probability": 0.0
        },
        {
            "start_logit": -0.1636962890625,
            "end_logit": -7.8671875,
            "text": "sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -0.1636962890625,
            "end_logit": -9.484375,
            "text": "sudden unexpected death in epilepsy (SUDEP) is the most important direct epilepsy-related cause of death.",
            "probability": 0.0
        },
        {
            "start_logit": -0.1636962890625,
            "end_logit": -10.2265625,
            "text": "sudden unexpected death in epilepsy (SUDEP) is the most important direct epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -0.1636962890625,
            "end_logit": -10.390625,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -0.1636962890625,
            "end_logit": -10.40625,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -0.1636962890625,
            "end_logit": -10.4296875,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -0.1636962890625,
            "end_logit": -10.4453125,
            "text": "sudden unexpected death in epilepsy (SUDEP) is",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": -7.8671875,
            "text": "death in epilepsy",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_11": [
        {
            "start_logit": 13.984375,
            "end_logit": 15.375,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.52880859375,
            "end_logit": 15.375,
            "text": "epilepsy",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 13.984375,
            "end_logit": -3.099609375,
            "text": "Sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.70703125,
            "end_logit": 15.375,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.55078125,
            "end_logit": 15.375,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.1328125,
            "end_logit": 15.375,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.609375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.734375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is an exceptionally difficult condition to study in humans.",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.7734375,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.8828125,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is an exceptionally",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.9296875,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -9.953125,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is an exceptionally difficult",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -10.0,
            "text": "Sudden unexpected death in",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -10.078125,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -10.125,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -10.1875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is an exceptionally difficult condition to study",
            "probability": 0.0
        },
        {
            "start_logit": 13.984375,
            "end_logit": -10.25,
            "text": "Sudden unexpected death in epilepsy (SUDEP) is an exceptionally difficult condition",
            "probability": 0.0
        },
        {
            "start_logit": -0.52880859375,
            "end_logit": -9.609375,
            "text": "epilepsy (SUDEP) is",
            "probability": 0.0
        },
        {
            "start_logit": -0.52880859375,
            "end_logit": -9.734375,
            "text": "epilepsy (SUDEP) is an exceptionally difficult condition to study in humans.",
            "probability": 0.0
        },
        {
            "start_logit": -0.52880859375,
            "end_logit": -9.7734375,
            "text": "epilepsy (",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_12": [
        {
            "start_logit": 14.1484375,
            "end_logit": 15.328125,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -1.115234375,
            "end_logit": 15.328125,
            "text": "epilepsy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -2.82421875,
            "text": "Sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.1484375,
            "end_logit": 15.328125,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.3046875,
            "end_logit": 15.328125,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": 15.328125,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -8.953125,
            "text": "Sudden unexpected death in",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.40625,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.828125,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.8515625,
            "text": "Sudden unexpected death in epilepsy (SUDEP): don't ask, don't tell",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.921875,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.9453125,
            "text": "Sudden unexpected death in epilepsy (SUDEP): don't ask",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -9.9609375,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 14.1484375,
            "end_logit": -10.140625,
            "text": "Sudden unexpected",
            "probability": 0.0
        },
        {
            "start_logit": -1.115234375,
            "end_logit": -9.40625,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.115234375,
            "end_logit": -9.828125,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -1.115234375,
            "end_logit": -9.8515625,
            "text": "epilepsy (SUDEP): don't ask, don't tell",
            "probability": 0.0
        },
        {
            "start_logit": -1.115234375,
            "end_logit": -9.921875,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -1.115234375,
            "end_logit": -9.9453125,
            "text": "epilepsy (SUDEP): don't ask",
            "probability": 0.0
        },
        {
            "start_logit": -1.115234375,
            "end_logit": -9.9609375,
            "text": "epilepsy (SUD",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_13": [
        {
            "start_logit": 13.21875,
            "end_logit": 15.0859375,
            "text": "sudden unexpected death in epilepsy",
            "probability": 0.9990234375
        },
        {
            "start_logit": 5.72265625,
            "end_logit": 15.0859375,
            "text": "epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected death in epilepsy",
            "probability": 0.0005526542663574219
        },
        {
            "start_logit": -1.1708984375,
            "end_logit": 15.0859375,
            "text": "epilepsy",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": 5.72265625,
            "end_logit": 4.875,
            "text": "epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -5.98046875,
            "end_logit": 15.0859375,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -4.4296875,
            "text": "sudden",
            "probability": 0.0
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 15.0859375,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.125,
            "end_logit": 15.0859375,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 15.0859375,
            "text": "with epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 15.0859375,
            "text": "Many individuals with epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 15.0859375,
            "text": "individuals with epilepsy, as well as their partners, relatives, and friends, are unaware of the risk for sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 15.0859375,
            "text": "for sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -8.859375,
            "text": "sudden unexpected death in epilepsy (SUDEP).",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 15.0859375,
            "text": "risk for sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 15.0859375,
            "text": ", relatives, and friends, are unaware of the risk for sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 15.0859375,
            "text": ", and friends, are unaware of the risk for sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -11.1171875,
            "end_logit": 15.0859375,
            "text": "partners, relatives, and friends, are unaware of the risk for sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -11.1328125,
            "end_logit": 15.0859375,
            "text": "friends, are unaware of the risk for sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -9.765625,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.21875,
            "end_logit": -9.8046875,
            "text": "sudden unexpected death in",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_14": [
        {
            "start_logit": 10.9921875,
            "end_logit": 12.5078125,
            "text": "sudden unexpected death in epilepsy",
            "probability": 0.7060546875
        },
        {
            "start_logit": 10.0859375,
            "end_logit": 12.5078125,
            "text": "epilepsy and sudden unexpected death in epilepsy",
            "probability": 0.285400390625
        },
        {
            "start_logit": 10.0859375,
            "end_logit": 9.0234375,
            "text": "epilepsy",
            "probability": 0.00875091552734375
        },
        {
            "start_logit": -4.05859375,
            "end_logit": 12.5078125,
            "text": "epilepsy",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.1875,
            "end_logit": 12.5078125,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 12.5078125,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -6.8515625,
            "text": "sudden",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -6.8515625,
            "text": "epilepsy and sudden",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": 12.5078125,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -8.1875,
            "text": "sudden unexpected death in epilepsy (SUDEP).",
            "probability": 0.0
        },
        {
            "start_logit": -9.78125,
            "end_logit": 12.5078125,
            "text": "The baboon represents a natural model for genetic generalized epilepsy and sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.171875,
            "end_logit": 12.5078125,
            "text": "baboon represents a natural model for genetic generalized epilepsy and sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 10.0859375,
            "end_logit": -8.1875,
            "text": "epilepsy and sudden unexpected death in epilepsy (SUDEP).",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 12.5078125,
            "text": "genetic generalized epilepsy and sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 12.5078125,
            "text": "generalized epilepsy and sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -9.4375,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 12.5078125,
            "text": "for genetic generalized epilepsy and sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -11.03125,
            "end_logit": 12.5078125,
            "text": "and sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -9.9453125,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 10.9921875,
            "end_logit": -10.03125,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_15": [
        {
            "start_logit": 13.609375,
            "end_logit": 15.046875,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": 0.16748046875,
            "end_logit": 15.046875,
            "text": "epilepsy",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": 13.609375,
            "end_logit": -3.82421875,
            "text": "Sudden",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": 15.046875,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": 15.046875,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.484375,
            "end_logit": 15.046875,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -9.5859375,
            "text": "Sudden unexpected death in epilepsy (SUDEP) refers",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -9.8671875,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -9.9140625,
            "text": "Sudden unexpected death in epilepsy (SUDEP) refers to the sudden death of a seemingly healthy individual with epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -10.0859375,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -10.15625,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.609375,
            "end_logit": -10.4921875,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": 0.16748046875,
            "end_logit": -9.5859375,
            "text": "epilepsy (SUDEP) refers",
            "probability": 0.0
        },
        {
            "start_logit": 0.16748046875,
            "end_logit": -9.8671875,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 0.16748046875,
            "end_logit": -9.9140625,
            "text": "epilepsy (SUDEP) refers to the sudden death of a seemingly healthy individual with epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 0.16748046875,
            "end_logit": -10.0859375,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 0.16748046875,
            "end_logit": -10.15625,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 0.16748046875,
            "end_logit": -10.4921875,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -7.4375,
            "end_logit": -9.5859375,
            "text": "death in epilepsy (SUDEP) refers",
            "probability": 0.0
        },
        {
            "start_logit": -7.578125,
            "end_logit": -9.5859375,
            "text": "unexpected death in epilepsy (SUDEP) refers",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_16": [
        {
            "start_logit": 13.7421875,
            "end_logit": 15.1875,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.7841796875,
            "end_logit": 15.1875,
            "text": "epilepsy",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -3.57421875,
            "text": "sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": 15.1875,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -8.0625,
            "end_logit": 15.1875,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -8.7734375,
            "end_logit": 15.1875,
            "text": "called sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.1484375,
            "end_logit": 15.1875,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 15.1875,
            "text": "This condition is called sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 15.1875,
            "text": "condition is called sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.6171875,
            "text": "sudden unexpected death in epilepsy (SUDEP), and it accounts for a large proportion of deaths among people with epilepsy.",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.640625,
            "text": "sudden unexpected death in epilepsy (SUDEP), and it accounts for a large proportion of deaths among people with epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.7890625,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.875,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.9296875,
            "text": "sudden unexpected",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.9375,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -9.9921875,
            "text": "sudden unexpected death in epilepsy (SUDEP), and",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -10.0,
            "text": "sudden unexpected death in",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -10.1328125,
            "text": "sudden unexpected death in epilepsy (SUDEP),",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -10.1953125,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": 13.7421875,
            "end_logit": -10.203125,
            "text": "sudden unexpected death in epilepsy (SUDEP), and it accounts for a large proportion",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_17": [
        {
            "start_logit": 13.765625,
            "end_logit": 15.1953125,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -0.9306640625,
            "end_logit": 15.1953125,
            "text": "epilepsy",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -4.6484375,
            "end_logit": 15.1953125,
            "text": "Epilepsy-related death, particularly sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -3.638671875,
            "text": "sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.98046875,
            "end_logit": 15.1953125,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": 15.1953125,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 15.1953125,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 15.1953125,
            "text": "death, particularly sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -8.9453125,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.3515625,
            "text": "sudden unexpected death in epilepsy (SUDEP), is still underestimated",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 15.1953125,
            "text": "related death, particularly sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 15.1953125,
            "text": "-related death, particularly sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 15.1953125,
            "text": "particularly sudden unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.6796875,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.7109375,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.75,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.75,
            "text": "sudden unexpected death in epilepsy (SUDEP), is",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.78125,
            "text": "sudden unexpected death in epilepsy (SUDEP), is still underestimated by healthcare professionals and this may",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.78125,
            "text": "sudden unexpected death in epilepsy (SUDEP), is still underestimated by healthcare professionals and this may reflect the mistaken belief that epilepsy is a benign",
            "probability": 0.0
        },
        {
            "start_logit": 13.765625,
            "end_logit": -9.8828125,
            "text": "sudden unexpected death in epilepsy (SUDEP), is still underestimated by healthcare professionals and this may reflect the mistaken belief",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_18": [
        {
            "start_logit": 13.671875,
            "end_logit": 15.15625,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -1.3662109375,
            "end_logit": 15.15625,
            "text": "epilepsy",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 13.671875,
            "end_logit": -3.548828125,
            "text": "Sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": 15.15625,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": 15.15625,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.671875,
            "end_logit": -6.296875,
            "text": "Sudden unexpected death in epilepsy (SUDEP) i",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 15.15625,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.671875,
            "end_logit": -9.3515625,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.671875,
            "end_logit": -9.375,
            "text": "Sudden unexpected death in",
            "probability": 0.0
        },
        {
            "start_logit": 13.671875,
            "end_logit": -9.6875,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.671875,
            "end_logit": -9.8984375,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -1.3662109375,
            "end_logit": -6.296875,
            "text": "epilepsy (SUDEP) i",
            "probability": 0.0
        },
        {
            "start_logit": -1.3662109375,
            "end_logit": -9.3515625,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.3662109375,
            "end_logit": -9.6875,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -1.3662109375,
            "end_logit": -9.8984375,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -6.296875,
            "text": "death in epilepsy (SUDEP) i",
            "probability": 0.0
        },
        {
            "start_logit": -7.5859375,
            "end_logit": -6.296875,
            "text": "unexpected death in epilepsy (SUDEP) i",
            "probability": 0.0
        },
        {
            "start_logit": -8.703125,
            "end_logit": -6.296875,
            "text": "i",
            "probability": 0.0
        },
        {
            "start_logit": -9.0390625,
            "end_logit": -6.296875,
            "text": "in epilepsy (SUDEP) i",
            "probability": 0.0
        },
        {
            "start_logit": -6.671875,
            "end_logit": -9.3515625,
            "text": "death in epilepsy (",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_19": [
        {
            "start_logit": 13.5,
            "end_logit": 15.15625,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": 15.15625,
            "text": "epilepsy",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 13.5,
            "end_logit": -3.87890625,
            "text": "sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 15.15625,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 15.15625,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 15.15625,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.3046875,
            "text": "sudden unexpected death in",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.4453125,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.5390625,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.7890625,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.9453125,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.4453125,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.5390625,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.7890625,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.9453125,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.3046875,
            "text": "death in",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.4453125,
            "text": "death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.5390625,
            "text": "death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.7890625,
            "text": "death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.9453125,
            "text": "death in epilepsy (SUDEP)",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_20": [
        {
            "start_logit": 13.5859375,
            "end_logit": 15.171875,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -1.322265625,
            "end_logit": 15.171875,
            "text": "epilepsy",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -3.728515625,
            "text": "sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.65234375,
            "end_logit": 15.171875,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.90625,
            "end_logit": 15.171875,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": 15.171875,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.2421875,
            "text": "sudden unexpected death in epilepsy (SUDEP) f",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.34375,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.484375,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.5078125,
            "text": "sudden unexpected death in",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.8046875,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.9765625,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -1.322265625,
            "end_logit": -9.2421875,
            "text": "epilepsy (SUDEP) f",
            "probability": 0.0
        },
        {
            "start_logit": -1.322265625,
            "end_logit": -9.34375,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.322265625,
            "end_logit": -9.484375,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -1.322265625,
            "end_logit": -9.8046875,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -1.322265625,
            "end_logit": -9.9765625,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -6.65234375,
            "end_logit": -9.2421875,
            "text": "death in epilepsy (SUDEP) f",
            "probability": 0.0
        },
        {
            "start_logit": -6.65234375,
            "end_logit": -9.34375,
            "text": "death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.65234375,
            "end_logit": -9.484375,
            "text": "death in epilepsy (SUDEP",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_21": [
        {
            "start_logit": 13.5,
            "end_logit": 15.15625,
            "text": "Sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": 15.15625,
            "text": "epilepsy",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 13.5,
            "end_logit": -3.87890625,
            "text": "Sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 15.15625,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 15.15625,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 15.15625,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.3046875,
            "text": "Sudden unexpected death in",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.4453125,
            "text": "Sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.5390625,
            "text": "Sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.7890625,
            "text": "Sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.9453125,
            "text": "Sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.4453125,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.5390625,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.7890625,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.9453125,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.3046875,
            "text": "death in",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.4453125,
            "text": "death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.5390625,
            "text": "death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.7890625,
            "text": "death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.9453125,
            "text": "death in epilepsy (SUDEP)",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_22": [
        {
            "start_logit": 13.5,
            "end_logit": 15.15625,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": 15.15625,
            "text": "epilepsy",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 13.5,
            "end_logit": -3.87890625,
            "text": "sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 15.15625,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 15.15625,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 15.15625,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.3046875,
            "text": "sudden unexpected death in",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.4453125,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.5390625,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.7890625,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.9453125,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.4453125,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.5390625,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.7890625,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.9453125,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.3046875,
            "text": "death in",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.4453125,
            "text": "death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.5390625,
            "text": "death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.7890625,
            "text": "death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.9453125,
            "text": "death in epilepsy (SUDEP)",
            "probability": 0.0
        }
    ],
    "58dbb8968acda3452900001b_23": [
        {
            "start_logit": 13.5,
            "end_logit": 15.15625,
            "text": "sudden unexpected death in epilepsy",
            "probability": 1.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": 15.15625,
            "text": "epilepsy",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 13.5,
            "end_logit": -3.87890625,
            "text": "sudden",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": 15.15625,
            "text": "death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 15.15625,
            "text": "unexpected death in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 15.15625,
            "text": "in epilepsy",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.3046875,
            "text": "sudden unexpected death in",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.4453125,
            "text": "sudden unexpected death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.5390625,
            "text": "sudden unexpected death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.7890625,
            "text": "sudden unexpected death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": 13.5,
            "end_logit": -9.9453125,
            "text": "sudden unexpected death in epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.4453125,
            "text": "epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.5390625,
            "text": "epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.7890625,
            "text": "epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -1.4140625,
            "end_logit": -9.9453125,
            "text": "epilepsy (SUDEP)",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.3046875,
            "text": "death in",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.4453125,
            "text": "death in epilepsy (",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.5390625,
            "text": "death in epilepsy (SUDEP",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.7890625,
            "text": "death in epilepsy (SUD",
            "probability": 0.0
        },
        {
            "start_logit": -6.2890625,
            "end_logit": -9.9453125,
            "text": "death in epilepsy (SUDEP)",
            "probability": 0.0
        }
    ],
    "5a87f44061bb38fb2400000f_1": [
        {
            "start_logit": 9.609375,
            "end_logit": 7.66796875,
            "text": "cancer",
            "probability": 0.9990234375
        },
        {
            "start_logit": 9.609375,
            "end_logit": 0.70263671875,
            "text": "cancer. Crizotinib is an ALK inhibitor, which was approved in 2011",
            "probability": 0.0009398460388183594
        },
        {
            "start_logit": 9.609375,
            "end_logit": -8.9453125,
            "text": "cancer. Crizotinib is an ALK inhibitor, which was approved in 2011 for the treatment of ALK-positive lung cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -0.6240234375,
            "end_logit": 0.70263671875,
            "text": "2011",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.83203125,
            "end_logit": 7.66796875,
            "text": "Anaplastic lymphoma kinase (ALK) rearrangement is detected in 3-7% of patients with non-small-cell lung cancer",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -9.9375,
            "text": "cancer. Crizotinib is an ALK inhibitor, which was approved in 2011 for the treatment of ALK-positive lung cancer.",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -10.25,
            "text": "cancer. Crizotinib is an ALK inhibitor, which",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -10.2578125,
            "text": "cancer. Crizotinib",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -10.3046875,
            "text": "cancer. Crizotinib is an ALK inhibitor, which was approved in 2011 for the treatment of ALK-positive lung",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -10.375,
            "text": "cancer. Crizotinib is",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -10.3984375,
            "text": "cancer. Crizotinib is an ALK",
            "probability": 0.0
        },
        {
            "start_logit": 9.609375,
            "end_logit": -10.5625,
            "text": "cancer. Crizotinib is an ALK inhibitor,",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 7.66796875,
            "text": "small-cell lung cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.09375,
            "end_logit": 7.66796875,
            "text": "non-small-cell lung cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 7.66796875,
            "text": "-small-cell lung cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 7.66796875,
            "text": "with non-small-cell lung cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": 7.66796875,
            "text": "cell lung cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.3671875,
            "end_logit": 0.70263671875,
            "text": "Crizotinib is an ALK inhibitor, which was approved in 2011",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 0.70263671875,
            "text": "approved in 2011",
            "probability": 0.0
        },
        {
            "start_logit": -9.90625,
            "end_logit": 0.70263671875,
            "text": "in 2011",
            "probability": 0.0
        }
    ],
    "6057bf0694d57fd879000031_1": [
        {
            "start_logit": 11.7578125,
            "end_logit": 11.015625,
            "text": "apoE4-165",
            "probability": 1.0
        },
        {
            "start_logit": 11.7578125,
            "end_logit": -4.98046875,
            "text": "apoE",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.7578125,
            "end_logit": -5.59375,
            "text": "apoE4-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.7421875,
            "end_logit": 11.015625,
            "text": "apoE4 fragment, apoE4-165",
            "probability": 0.0
        },
        {
            "start_logit": -5.8125,
            "end_logit": 11.015625,
            "text": "165",
            "probability": 0.0
        },
        {
            "start_logit": 11.7578125,
            "end_logit": -6.96484375,
            "text": "apoE4",
            "probability": 0.0
        },
        {
            "start_logit": -0.92822265625,
            "end_logit": 4.9921875,
            "text": "The apolipoprotein (apo) E4",
            "probability": 0.0
        },
        {
            "start_logit": -7.0,
            "end_logit": 11.015625,
            "text": ", apoE4-165",
            "probability": 0.0
        },
        {
            "start_logit": -8.4765625,
            "end_logit": 11.015625,
            "text": "4-165",
            "probability": 0.0
        },
        {
            "start_logit": -2.4765625,
            "end_logit": 4.9921875,
            "text": "apolipoprotein (apo) E4",
            "probability": 0.0
        },
        {
            "start_logit": 11.7578125,
            "end_logit": -9.9296875,
            "text": "apoE4-165,",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 11.015625,
            "text": "-165",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 11.015625,
            "text": "terminal truncated apoE4 forms have been found in AD patients' brain. We have previously shown that a specific apoE4 fragment, apoE4-165",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 4.9921875,
            "text": "E4",
            "probability": 0.0
        },
        {
            "start_logit": -8.4765625,
            "end_logit": 4.9921875,
            "text": ") E4",
            "probability": 0.0
        },
        {
            "start_logit": -0.92822265625,
            "end_logit": -5.66796875,
            "text": "The apolipoprotein (apo) E4 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -2.4765625,
            "end_logit": -5.66796875,
            "text": "apolipoprotein (apo) E4 isoform",
            "probability": 0.0
        },
        {
            "start_logit": -0.92822265625,
            "end_logit": -8.3046875,
            "text": "The apolipoprotein (apo) E4 isoform is the strongest risk factor for late-onset Alzheimer's disease (AD). ApoE4",
            "probability": 0.0
        },
        {
            "start_logit": -0.92822265625,
            "end_logit": -9.1796875,
            "text": "The apolipoprotein (apo)",
            "probability": 0.0
        },
        {
            "start_logit": -2.3046875,
            "end_logit": -8.3046875,
            "text": "ApoE4",
            "probability": 0.0
        }
    ],
    "6057bf0694d57fd879000031_2": [
        {
            "start_logit": 8.828125,
            "end_logit": 9.3046875,
            "text": "apoE4-165",
            "probability": 0.9990234375
        },
        {
            "start_logit": 8.828125,
            "end_logit": 2.462890625,
            "text": "apoE4-165,",
            "probability": 0.0010738372802734375
        },
        {
            "start_logit": -1.607421875,
            "end_logit": 9.3046875,
            "text": "apoE4 fragment, apoE4-165",
            "probability": 2.956390380859375e-05
        },
        {
            "start_logit": -3.453125,
            "end_logit": 9.3046875,
            "text": "a specific apoE4 fragment, apoE4-165",
            "probability": 4.649162292480469e-06
        },
        {
            "start_logit": -6.84375,
            "end_logit": 9.3046875,
            "text": "165",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.31640625,
            "text": "apoE",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.828125,
            "end_logit": -7.90234375,
            "text": "apoE4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -1.607421875,
            "end_logit": 2.462890625,
            "text": "apoE4 fragment, apoE4-165,",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.8046875,
            "end_logit": 9.3046875,
            "text": "4-165",
            "probability": 0.0
        },
        {
            "start_logit": -9.046875,
            "end_logit": 9.3046875,
            "text": ", apoE4-165",
            "probability": 0.0
        },
        {
            "start_logit": 8.828125,
            "end_logit": -8.6328125,
            "text": "apoE4-",
            "probability": 0.0
        },
        {
            "start_logit": -9.2578125,
            "end_logit": 9.3046875,
            "text": "fragment, apoE4-165",
            "probability": 0.0
        },
        {
            "start_logit": -9.3359375,
            "end_logit": 9.3046875,
            "text": "-165",
            "probability": 0.0
        },
        {
            "start_logit": -1.607421875,
            "end_logit": 1.2841796875,
            "text": "apoE4 fragment",
            "probability": 0.0
        },
        {
            "start_logit": 8.828125,
            "end_logit": -9.28125,
            "text": "apoE4-165, promotes",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 9.3046875,
            "text": "specific apoE4 fragment, apoE4-165",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 9.3046875,
            "text": "4 fragment, apoE4-165",
            "probability": 0.0
        },
        {
            "start_logit": -3.453125,
            "end_logit": 2.462890625,
            "text": "a specific apoE4 fragment, apoE4-165,",
            "probability": 0.0
        },
        {
            "start_logit": 8.828125,
            "end_logit": -10.0703125,
            "text": "apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH",
            "probability": 0.0
        },
        {
            "start_logit": 8.828125,
            "end_logit": -10.078125,
            "text": "apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242)",
            "probability": 0.0
        }
    ],
    "6057bf0694d57fd879000031_3": [
        {
            "start_logit": 8.9296875,
            "end_logit": 8.515625,
            "text": "apoE4-165",
            "probability": 1.0
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -0.1358642578125,
            "text": "apoE4-165,",
            "probability": 0.0001767873764038086
        },
        {
            "start_logit": -1.662109375,
            "end_logit": 8.515625,
            "text": "apoE4 fragment, apoE4-165",
            "probability": 2.5272369384765625e-05
        },
        {
            "start_logit": -4.43359375,
            "end_logit": 8.515625,
            "text": "a specific apoE4 fragment, apoE4-165",
            "probability": 1.5497207641601562e-06
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.35546875,
            "text": "apoE",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.35546875,
            "end_logit": 8.515625,
            "text": "165",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -7.93359375,
            "text": "apoE4",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -8.546875,
            "text": "apoE4-",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -9.15625,
            "text": "apoE4-165, promotes",
            "probability": 0.0
        },
        {
            "start_logit": -8.953125,
            "end_logit": 8.515625,
            "text": "4-165",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": 8.515625,
            "text": ", apoE4-165",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 8.515625,
            "text": "-165",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 8.515625,
            "text": "fragment, apoE4-165",
            "probability": 0.0
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -10.0625,
            "text": "apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242)",
            "probability": 0.0
        },
        {
            "start_logit": -1.662109375,
            "end_logit": 0.3271484375,
            "text": "apoE4 fragment",
            "probability": 0.0
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -10.265625,
            "text": "apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in human neuroblastoma SK-N-SH",
            "probability": 0.0
        },
        {
            "start_logit": 8.9296875,
            "end_logit": -10.2734375,
            "text": "apoE4-165, promotes amyloid-peptide beta 42 (A\u03b242) accumulation in",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 8.515625,
            "text": "e previously shown that a specific apoE4 fragment, apoE4-165",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 8.515625,
            "text": "specific apoE4 fragment, apoE4-165",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 8.515625,
            "text": "4 fragment, apoE4-165",
            "probability": 0.0
        }
    ],
    "6057bf0694d57fd879000031_4": [
        {
            "start_logit": 9.515625,
            "end_logit": -0.86962890625,
            "text": "apoE4-165",
            "probability": 0.857421875
        },
        {
            "start_logit": 9.515625,
            "end_logit": -2.716796875,
            "text": "apoE4",
            "probability": 0.1346435546875
        },
        {
            "start_logit": 9.515625,
            "end_logit": -6.05859375,
            "text": "apoE",
            "probability": 0.004772186279296875
        },
        {
            "start_logit": 9.515625,
            "end_logit": -6.80078125,
            "text": "apoE4-",
            "probability": 0.0022716522216796875
        },
        {
            "start_logit": 9.515625,
            "end_logit": -8.5390625,
            "text": "apoE4-165 is",
            "probability": 0.0003993511199951172
        },
        {
            "start_logit": 9.515625,
            "end_logit": -9.0234375,
            "text": "apoE4-165 is structurally distinct and less thermodynamically stable suggesting",
            "probability": 0.0002460479736328125
        },
        {
            "start_logit": 9.515625,
            "end_logit": -9.7578125,
            "text": "apoE4-165 is structurally distinct and",
            "probability": 0.00011807680130004883
        },
        {
            "start_logit": 9.515625,
            "end_logit": -9.84375,
            "text": "apoE4-165 is structurally distinct and less thermodynamically stable suggesting that the combination",
            "probability": 0.00010836124420166016
        },
        {
            "start_logit": -9.4140625,
            "end_logit": -0.86962890625,
            "text": "4-165",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -0.86962890625,
            "text": ", apoE4-165",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -0.86962890625,
            "text": "allelic backgrounds, apoE4-165",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": -0.86962890625,
            "text": "-165",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": -2.716796875,
            "text": "4",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -2.716796875,
            "text": ", apoE4",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -2.716796875,
            "text": "allelic backgrounds, apoE4",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": -6.80078125,
            "text": "4-",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -6.05859375,
            "text": ", apoE",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -6.05859375,
            "text": "allelic backgrounds, apoE",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -6.80078125,
            "text": ", apoE4-",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -6.80078125,
            "text": "allelic backgrounds, apoE4-",
            "probability": 0.0
        }
    ],
    "606b75c194d57fd87900006c_1": [
        {
            "start_logit": 11.015625,
            "end_logit": 11.4609375,
            "text": "2017",
            "probability": 1.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 11.4609375,
            "text": "Federal Drug Administration (FDA) in 2017",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 11.4609375,
            "text": "in 2017",
            "probability": 0.0
        },
        {
            "start_logit": 11.015625,
            "end_logit": -9.9375,
            "text": "2017.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 11.4609375,
            "text": "prior to the registration of dupilumab by both the European Medicines Agency (EMA) and Federal Drug Administration (FDA) in 2017",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 11.4609375,
            "text": "Drug Administration (FDA) in 2017",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 11.4609375,
            "text": "binding prior to the registration of dupilumab by both the European Medicines Agency (EMA) and Federal Drug Administration (FDA) in 2017",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 11.4609375,
            "text": "dupilumab by both the European Medicines Agency (EMA) and Federal Drug Administration (FDA) in 2017",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 11.4609375,
            "text": "and Federal Drug Administration (FDA) in 2017",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 11.4609375,
            "text": "European Medicines Agency (EMA) and Federal Drug Administration (FDA) in 2017",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 11.4609375,
            "text": "the European Medicines Agency (EMA) and Federal Drug Administration (FDA) in 2017",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": -9.9375,
            "text": "Federal Drug Administration (FDA) in 2017.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -9.59375,
            "text": "dermatologic treatment standards of selected countries",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": -9.59375,
            "text": "the disease and summarizes dermatologic treatment standards of selected countries",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": -10.4765625,
            "text": "Federal Drug Administration (FDA)",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": -9.9375,
            "text": "in 2017.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -10.140625,
            "text": "dermatologic treatment standards of selected countries binding prior to the registration",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -10.1953125,
            "text": "dermatologic treatment standards of selected countries binding prior to the registration of dupilumab",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -9.9375,
            "text": "prior to the registration of dupilumab by both the European Medicines Agency (EMA) and Federal Drug Administration (FDA) in 2017.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -9.59375,
            "text": "covers etiology of the disease and summarizes dermatologic treatment standards of selected countries",
            "probability": 0.0
        }
    ],
    "571cdd227de986d80d00000f_1": [
        {
            "start_logit": 14.7578125,
            "end_logit": 15.203125,
            "text": "Yersinia pestis",
            "probability": 1.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -0.96923828125,
            "text": "Yersinia",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.6298828125,
            "end_logit": 15.203125,
            "text": "is",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -2.7109375,
            "text": "Yersinia pest",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": 15.203125,
            "text": "pestis",
            "probability": 0.0
        },
        {
            "start_logit": -8.4453125,
            "end_logit": 15.203125,
            "text": "bacteria Yersinia pestis",
            "probability": 0.0
        },
        {
            "start_logit": -9.1875,
            "end_logit": 15.203125,
            "text": "the causative bacteria Yersinia pestis",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -9.2578125,
            "text": "Yersinia pestis as an agent of biological warfare have highlighted the need for a safe, efficacious, and rapidly producible vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 15.203125,
            "text": "causative bacteria Yersinia pestis",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -9.7265625,
            "text": "Yersinia pestis as an agent of biological warfare",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -9.7890625,
            "text": "Yersinia pestis as an agent of biological warfare have highlighted the need for a safe, efficacious, and rapidly producible vaccine",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -9.984375,
            "text": "Yersinia pestis as",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -10.3203125,
            "text": "Yersinia pestis as an agent of biological warf",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -10.3984375,
            "text": "Yersinia pestis as an agent of biological warfare have highlighted the need",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -10.421875,
            "text": "Yersinia pestis as an agent of biological warfare have highlighted the need for a safe, efficacious, and rapidly producible",
            "probability": 0.0
        },
        {
            "start_logit": 14.7578125,
            "end_logit": -10.4921875,
            "text": "Yersinia pestis as an agent of biological warfare have highlighted the need for a safe, efficacious",
            "probability": 0.0
        },
        {
            "start_logit": -8.4453125,
            "end_logit": -0.96923828125,
            "text": "bacteria Yersinia",
            "probability": 0.0
        },
        {
            "start_logit": -9.1875,
            "end_logit": -0.96923828125,
            "text": "the causative bacteria Yersinia",
            "probability": 0.0
        },
        {
            "start_logit": -1.6298828125,
            "end_logit": -9.2578125,
            "text": "is as an agent of biological warfare have highlighted the need for a safe, efficacious, and rapidly producible vaccine.",
            "probability": 0.0
        },
        {
            "start_logit": -8.2578125,
            "end_logit": -2.7109375,
            "text": "pest",
            "probability": 0.0
        }
    ],
    "621d02f33a8413c653000047_1": [
        {
            "start_logit": 0.1099853515625,
            "end_logit": 6.69140625,
            "text": "mechanotransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
            "probability": 0.6728515625
        },
        {
            "start_logit": 5.56640625,
            "end_logit": 0.47802734375,
            "text": "Piezo1 is a key element of the mechanotransduction",
            "probability": 0.3154296875
        },
        {
            "start_logit": -4.27734375,
            "end_logit": 6.69140625,
            "text": ".",
            "probability": 0.00836944580078125
        },
        {
            "start_logit": 0.1099853515625,
            "end_logit": 0.47802734375,
            "text": "mechanotransduction",
            "probability": 0.00135040283203125
        },
        {
            "start_logit": -7.10546875,
            "end_logit": 6.69140625,
            "text": "transduce mechanical signals into biological signals by mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
            "probability": 0.0004949569702148438
        },
        {
            "start_logit": 5.56640625,
            "end_logit": -6.06640625,
            "text": "Piezo1 is a key element of the mechanotransduction process and",
            "probability": 0.00045418739318847656
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 6.69140625,
            "text": "e mechanical signals into biological signals by mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
            "probability": 0.00018858909606933594
        },
        {
            "start_logit": 5.56640625,
            "end_logit": -7.56640625,
            "text": "Piezo1 is a key element of the mechanotransduction process",
            "probability": 0.0001016855239868164
        },
        {
            "start_logit": 5.56640625,
            "end_logit": -7.609375,
            "text": "Piezo",
            "probability": 9.703636169433594e-05
        },
        {
            "start_logit": -9.0,
            "end_logit": 6.69140625,
            "text": "mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
            "probability": 7.444620132446289e-05
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 6.69140625,
            "text": "ansduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
            "probability": 7.045269012451172e-05
        },
        {
            "start_logit": -9.40625,
            "end_logit": 6.69140625,
            "text": "mechanical signals into biological signals by mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
            "probability": 4.9591064453125e-05
        },
        {
            "start_logit": -9.4609375,
            "end_logit": 6.69140625,
            "text": "cytoskeletal remodeling and stress alterations.",
            "probability": 4.696846008300781e-05
        },
        {
            "start_logit": -9.546875,
            "end_logit": 6.69140625,
            "text": "into biological signals by mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
            "probability": 4.309415817260742e-05
        },
        {
            "start_logit": 5.56640625,
            "end_logit": -8.6328125,
            "text": "Piezo1 is a key element of the mechanotransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx,",
            "probability": 3.4868717193603516e-05
        },
        {
            "start_logit": -9.8828125,
            "end_logit": 6.69140625,
            "text": "otransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
            "probability": 3.081560134887695e-05
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 6.69140625,
            "text": "Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
            "probability": 3.0338764190673828e-05
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 6.69140625,
            "text": "regulates cytoskeletal remodeling and stress alterations.",
            "probability": 2.7120113372802734e-05
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 6.69140625,
            "text": "stress alterations.",
            "probability": 2.676248550415039e-05
        },
        {
            "start_logit": 5.56640625,
            "end_logit": -9.109375,
            "text": "Piezo1",
            "probability": 2.1636486053466797e-05
        }
    ],
    "6032899c1cb411341a000144_1": [
        {
            "start_logit": 2.845703125,
            "end_logit": 8.9296875,
            "text": "Integrins are transmembrane glycoproteins that are broadly distributed in living organisms.",
            "probability": 1.0
        },
        {
            "start_logit": -5.61328125,
            "end_logit": 8.9296875,
            "text": ".",
            "probability": 0.00021326541900634766
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 8.9296875,
            "text": "transmembrane glycoproteins that are broadly distributed in living organisms.",
            "probability": 4.172325134277344e-06
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 8.9296875,
            "text": "living organisms.",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 8.9296875,
            "text": "distributed in living organisms.",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 8.9296875,
            "text": "glycoproteins that are broadly distributed in living organisms.",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -10.859375,
            "end_logit": 8.9296875,
            "text": "in living organisms.",
            "probability": 1.1324882507324219e-06
        },
        {
            "start_logit": -11.0703125,
            "end_logit": 8.9296875,
            "text": "organisms.",
            "probability": 8.940696716308594e-07
        },
        {
            "start_logit": -11.2265625,
            "end_logit": 8.9296875,
            "text": "are broadly distributed in living organisms.",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -11.390625,
            "end_logit": 8.9296875,
            "text": "broadly distributed in living organisms.",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -11.5234375,
            "end_logit": 8.9296875,
            "text": "are transmembrane glycoproteins that are broadly distributed in living organisms.",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 2.845703125,
            "end_logit": -9.2578125,
            "text": "Integrins are",
            "probability": 0.0
        },
        {
            "start_logit": 2.845703125,
            "end_logit": -9.421875,
            "text": "Integrins are transmembrane glycoproteins that",
            "probability": 0.0
        },
        {
            "start_logit": 2.845703125,
            "end_logit": -9.671875,
            "text": "Integrins are transmembrane glycoproteins that are broadly",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": -9.421875,
            "text": "transmembrane glycoproteins that",
            "probability": 0.0
        },
        {
            "start_logit": -9.5390625,
            "end_logit": -9.671875,
            "text": "transmembrane glycoproteins that are broadly",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -9.421875,
            "text": "glycoproteins that",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": -9.671875,
            "text": "glycoproteins that are broadly",
            "probability": 0.0
        },
        {
            "start_logit": -11.5234375,
            "end_logit": -9.2578125,
            "text": "are",
            "probability": 0.0
        },
        {
            "start_logit": -11.2265625,
            "end_logit": -9.671875,
            "text": "are broadly",
            "probability": 0.0
        }
    ],
    "6057c2f894d57fd879000033_1": [
        {
            "start_logit": 14.578125,
            "end_logit": 15.1484375,
            "text": "EpiMethylTag",
            "probability": 1.0
        },
        {
            "start_logit": -2.056640625,
            "end_logit": 15.1484375,
            "text": "g",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.578125,
            "end_logit": -1.740234375,
            "text": "Epi",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.578125,
            "end_logit": -6.00390625,
            "text": "EpiMethyl",
            "probability": 0.0
        },
        {
            "start_logit": -7.0234375,
            "end_logit": 15.1484375,
            "text": "MethylTag",
            "probability": 0.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -6.86328125,
            "text": "EpiMethylTa",
            "probability": 0.0
        },
        {
            "start_logit": -7.6796875,
            "end_logit": 15.1484375,
            "text": "Tag",
            "probability": 0.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -8.625,
            "text": "EpiMethylTag:",
            "probability": 0.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -8.9375,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq or ChIP-seq signals with DNA methylation.",
            "probability": 0.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -9.453125,
            "text": "EpiMethylTag: simultaneous",
            "probability": 0.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -9.7265625,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq or ChIP-seq signals with DNA methylation",
            "probability": 0.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -9.75,
            "text": "EpiMethylTag: simultaneous detection",
            "probability": 0.0
        },
        {
            "start_logit": 14.578125,
            "end_logit": -9.9140625,
            "text": "EpiMethylTag: simultaneous detection of ATAC",
            "probability": 0.0
        },
        {
            "start_logit": -2.056640625,
            "end_logit": -8.625,
            "text": "g:",
            "probability": 0.0
        },
        {
            "start_logit": -2.056640625,
            "end_logit": -8.9375,
            "text": "g: simultaneous detection of ATAC-seq or ChIP-seq signals with DNA methylation.",
            "probability": 0.0
        },
        {
            "start_logit": -2.056640625,
            "end_logit": -9.453125,
            "text": "g: simultaneous",
            "probability": 0.0
        },
        {
            "start_logit": -2.056640625,
            "end_logit": -9.7265625,
            "text": "g: simultaneous detection of ATAC-seq or ChIP-seq signals with DNA methylation",
            "probability": 0.0
        },
        {
            "start_logit": -2.056640625,
            "end_logit": -9.75,
            "text": "g: simultaneous detection",
            "probability": 0.0
        },
        {
            "start_logit": -2.056640625,
            "end_logit": -9.9140625,
            "text": "g: simultaneous detection of ATAC",
            "probability": 0.0
        },
        {
            "start_logit": -7.0234375,
            "end_logit": -6.00390625,
            "text": "Methyl",
            "probability": 0.0
        }
    ],
    "6057c2f894d57fd879000033_2": [
        {
            "start_logit": 14.0625,
            "end_logit": 15.0390625,
            "text": "EpiMethylTag",
            "probability": 1.0
        },
        {
            "start_logit": -2.41015625,
            "end_logit": 15.0390625,
            "text": "g",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.0625,
            "end_logit": -2.84375,
            "text": "Epi",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -5.27734375,
            "text": "EpiMethylTa",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -5.58203125,
            "text": "EpiMethyl",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": 15.0390625,
            "text": "Tag",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": 15.0390625,
            "text": ", EpiMethylTag",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": 15.0390625,
            "text": "MethylTag",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -9.8359375,
            "text": "EpiMethylTag, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP) with bisulfite conversion",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -9.9375,
            "text": "EpiMethylTag, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP",
            "probability": 0.0
        },
        {
            "start_logit": 14.0625,
            "end_logit": -9.9453125,
            "text": "EpiMethylTag, that combines ATAC-seq or ChIP-seq (M-ATAC",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -2.84375,
            "text": ", Epi",
            "probability": 0.0
        },
        {
            "start_logit": -2.41015625,
            "end_logit": -9.8359375,
            "text": "g, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP) with bisulfite conversion",
            "probability": 0.0
        },
        {
            "start_logit": -2.41015625,
            "end_logit": -9.9375,
            "text": "g, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP",
            "probability": 0.0
        },
        {
            "start_logit": -2.41015625,
            "end_logit": -9.9453125,
            "text": "g, that combines ATAC-seq or ChIP-seq (M-ATAC",
            "probability": 0.0
        },
        {
            "start_logit": -7.51171875,
            "end_logit": -5.27734375,
            "text": "Ta",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -5.27734375,
            "text": ", EpiMethylTa",
            "probability": 0.0
        },
        {
            "start_logit": -8.109375,
            "end_logit": -5.58203125,
            "text": ", EpiMethyl",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": -5.27734375,
            "text": "MethylTa",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": -5.58203125,
            "text": "Methyl",
            "probability": 0.0
        }
    ],
    "6057c2f894d57fd879000033_3": [
        {
            "start_logit": 14.328125,
            "end_logit": 15.0,
            "text": "EpiMethylTag",
            "probability": 1.0
        },
        {
            "start_logit": -2.4375,
            "end_logit": 15.0,
            "text": "g",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.328125,
            "end_logit": -2.375,
            "text": "Epi",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -6.26171875,
            "text": "EpiMethyl",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -6.96875,
            "text": "EpiMethylTa",
            "probability": 0.0
        },
        {
            "start_logit": -7.7265625,
            "end_logit": 15.0,
            "text": "Tag",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -7.29296875,
            "text": "EpiMethylTag, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP) with bisulfite conversion",
            "probability": 0.0
        },
        {
            "start_logit": -8.1953125,
            "end_logit": 15.0,
            "text": "MethylTag",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -8.8125,
            "text": "EpiMethylTag, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -9.0234375,
            "text": "EpiMethylTag,",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 15.0,
            "text": ", EpiMethylTag",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -9.546875,
            "text": "EpiMethylTag, that",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -9.734375,
            "text": "EpiMethylTag, that combines",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -9.78125,
            "text": "EpiMethylTag, that combines ATAC-seq or ChIP-seq (M-ATAC",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 15.0,
            "text": ", low-input, low sequencing depth method, EpiMethylTag",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 15.0,
            "text": ", low sequencing depth method, EpiMethylTag",
            "probability": 0.0
        },
        {
            "start_logit": -2.4375,
            "end_logit": -7.29296875,
            "text": "g, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP) with bisulfite conversion",
            "probability": 0.0
        },
        {
            "start_logit": -2.4375,
            "end_logit": -8.8125,
            "text": "g, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP",
            "probability": 0.0
        },
        {
            "start_logit": -2.4375,
            "end_logit": -9.0234375,
            "text": "g,",
            "probability": 0.0
        },
        {
            "start_logit": -2.4375,
            "end_logit": -9.484375,
            "text": "g, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP) with bisulfite conversion,",
            "probability": 0.0
        }
    ],
    "6057c2f894d57fd879000033_4": [
        {
            "start_logit": 14.296875,
            "end_logit": 14.96875,
            "text": "EpiMethylTag",
            "probability": 1.0
        },
        {
            "start_logit": -2.50390625,
            "end_logit": 14.96875,
            "text": "g",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.296875,
            "end_logit": -2.453125,
            "text": "Epi",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -6.41015625,
            "text": "EpiMethyl",
            "probability": 0.0
        },
        {
            "start_logit": -7.73046875,
            "end_logit": 14.96875,
            "text": "Tag",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -7.1796875,
            "text": "EpiMethylTa",
            "probability": 0.0
        },
        {
            "start_logit": -8.34375,
            "end_logit": 14.96875,
            "text": "MethylTag",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": 14.96875,
            "text": "veloped a fast, low-input, low sequencing depth method, EpiMethylTag",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -8.75,
            "text": "EpiMethylTag, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -8.8359375,
            "text": "EpiMethylTag, that combines ATAC-seq or ChIP-seq (M-ATAC or M-ChIP) with bisulfite conversion",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -8.9140625,
            "text": "EpiMethylTag,",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -9.640625,
            "text": "EpiMethylTag, that",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": 14.96875,
            "text": "oped a fast, low-input, low sequencing depth method, EpiMethylTag",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -9.7578125,
            "text": "EpiMethylTag, that combines",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -9.796875,
            "text": "EpiMethylTag, that combines ATAC-seq or ChIP-seq (M-ATAC",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 14.96875,
            "text": ", EpiMethylTag",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 14.96875,
            "text": ", low-input, low sequencing depth method, EpiMethylTag",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 14.96875,
            "text": ", low sequencing depth method, EpiMethylTag",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 14.96875,
            "text": "input, low sequencing depth method, EpiMethylTag",
            "probability": 0.0
        },
        {
            "start_logit": -8.71875,
            "end_logit": -2.453125,
            "text": "veloped a fast, low-input, low sequencing depth method, Epi",
            "probability": 0.0
        }
    ],
    "6057c2f894d57fd879000033_5": [
        {
            "start_logit": 14.1953125,
            "end_logit": 14.7578125,
            "text": "EpiMethylTag",
            "probability": 1.0
        },
        {
            "start_logit": -2.798828125,
            "end_logit": 14.7578125,
            "text": "g",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -2.498046875,
            "text": "Epi",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.04296875,
            "end_logit": 14.7578125,
            "text": "MethylTag",
            "probability": 0.0
        },
        {
            "start_logit": -7.08984375,
            "end_logit": 14.7578125,
            "text": "Tag",
            "probability": 0.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -6.87109375,
            "text": "EpiMethyl",
            "probability": 0.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -8.1171875,
            "text": "EpiMethylTa",
            "probability": 0.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -8.46875,
            "text": "EpiMethylTag:",
            "probability": 0.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -9.2734375,
            "text": "EpiMethylTag: simultaneous detection of ATAC-seq or ChIP-seq signals with DNA methylation",
            "probability": 0.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -9.5,
            "text": "EpiMethylTag: simultaneous",
            "probability": 0.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -9.6875,
            "text": "EpiMethylTag: simultaneous detection",
            "probability": 0.0
        },
        {
            "start_logit": 14.1953125,
            "end_logit": -9.984375,
            "text": "EpiMethylTag: simultaneous detection of",
            "probability": 0.0
        },
        {
            "start_logit": -2.798828125,
            "end_logit": -8.46875,
            "text": "g:",
            "probability": 0.0
        },
        {
            "start_logit": -2.798828125,
            "end_logit": -9.2734375,
            "text": "g: simultaneous detection of ATAC-seq or ChIP-seq signals with DNA methylation",
            "probability": 0.0
        },
        {
            "start_logit": -2.798828125,
            "end_logit": -9.5,
            "text": "g: simultaneous",
            "probability": 0.0
        },
        {
            "start_logit": -2.798828125,
            "end_logit": -9.6875,
            "text": "g: simultaneous detection",
            "probability": 0.0
        },
        {
            "start_logit": -2.798828125,
            "end_logit": -9.984375,
            "text": "g: simultaneous detection of",
            "probability": 0.0
        },
        {
            "start_logit": -7.04296875,
            "end_logit": -6.87109375,
            "text": "Methyl",
            "probability": 0.0
        },
        {
            "start_logit": -7.04296875,
            "end_logit": -8.1171875,
            "text": "MethylTa",
            "probability": 0.0
        },
        {
            "start_logit": -7.08984375,
            "end_logit": -8.1171875,
            "text": "Ta",
            "probability": 0.0
        }
    ],
    "5ebac76b0d431b5f7300000d_1": [
        {
            "start_logit": 14.5234375,
            "end_logit": 15.4453125,
            "text": "H3K9me",
            "probability": 1.0
        },
        {
            "start_logit": -1.142578125,
            "end_logit": 15.4453125,
            "text": "me",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -1.875,
            "text": "H3K9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -1.9140625,
            "text": "H3K",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -5.265625,
            "text": "H3K9me,",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -5.4609375,
            "text": "H3K9me, an epigenetic mark generated by the histone methyltransferases SU(VAR)3-9 and orthologues.",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": 15.4453125,
            "text": "9me",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": 15.4453125,
            "text": "recognize H3K9me",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.5,
            "text": "H3K9me, an epigenetic mark generated by the histone methyltransferases SU(VAR)3-9 and orthologues",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 15.4453125,
            "text": "proteins that recognize H3K9me",
            "probability": 0.0
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 15.4453125,
            "text": "functions of the Heterochromatin Protein 1 (HP1) family of proteins that recognize H3K9me",
            "probability": 0.0
        },
        {
            "start_logit": -11.0625,
            "end_logit": 15.4453125,
            "text": "the Heterochromatin Protein 1 (HP1) family of proteins that recognize H3K9me",
            "probability": 0.0
        },
        {
            "start_logit": -1.142578125,
            "end_logit": -5.265625,
            "text": "me,",
            "probability": 0.0
        },
        {
            "start_logit": -1.142578125,
            "end_logit": -5.4609375,
            "text": "me, an epigenetic mark generated by the histone methyltransferases SU(VAR)3-9 and orthologues.",
            "probability": 0.0
        },
        {
            "start_logit": -1.142578125,
            "end_logit": -9.5,
            "text": "me, an epigenetic mark generated by the histone methyltransferases SU(VAR)3-9 and orthologues",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": -1.875,
            "text": "9",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": -1.875,
            "text": "recognize H3K9",
            "probability": 0.0
        },
        {
            "start_logit": -9.46875,
            "end_logit": -1.9140625,
            "text": "recognize H3K",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -1.875,
            "text": "proteins that recognize H3K9",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": -1.9140625,
            "text": "proteins that recognize H3K",
            "probability": 0.0
        }
    ],
    "5ebac76b0d431b5f7300000d_2": [
        {
            "start_logit": 14.3984375,
            "end_logit": 15.28125,
            "text": "H3K9me",
            "probability": 1.0
        },
        {
            "start_logit": -1.4521484375,
            "end_logit": 15.28125,
            "text": "me",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -1.8720703125,
            "text": "H3K9",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -2.107421875,
            "text": "H3K",
            "probability": 0.0
        },
        {
            "start_logit": -4.1640625,
            "end_logit": 15.28125,
            "text": "(H3K9me",
            "probability": 0.0
        },
        {
            "start_logit": -6.8984375,
            "end_logit": 15.28125,
            "text": "methylation of histone H3 lysine 9 (H3K9me",
            "probability": 0.0
        },
        {
            "start_logit": -8.90625,
            "end_logit": 15.28125,
            "text": "histone H3 lysine 9 (H3K9me",
            "probability": 0.0
        },
        {
            "start_logit": -9.15625,
            "end_logit": 15.28125,
            "text": "lysine 9 (H3K9me",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 15.28125,
            "text": "9me",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -8.6796875,
            "text": "H3K9me),",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -8.6875,
            "text": "H3K9me)",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -8.7265625,
            "text": "H3K9me), are important regulators of heterochromatin-mediated gene silencing and chromosome structure.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 15.28125,
            "text": "9 (H3K9me",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 15.28125,
            "text": "H3 lysine 9 (H3K9me",
            "probability": 0.0
        },
        {
            "start_logit": -10.2421875,
            "end_logit": 15.28125,
            "text": "recognized readers of the heterochromatin mark methylation of histone H3 lysine 9 (H3K9me",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 15.28125,
            "text": "of histone H3 lysine 9 (H3K9me",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.4140625,
            "text": "H3K9me), are important regulators of heterochromatin",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 15.28125,
            "text": "Heterochromatin protein 1 (HP1) proteins, recognized readers of the heterochromatin mark methylation of histone H3 lysine 9 (H3K9me",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.8046875,
            "text": "H3K9me), are important regulators of heterochromatin-mediated gene silencing",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.28125,
            "text": "mark methylation of histone H3 lysine 9 (H3K9me",
            "probability": 0.0
        }
    ],
    "5c632cc1e842deac6700000f_1": [
        {
            "start_logit": 9.859375,
            "end_logit": 12.0625,
            "text": "primary ovarian insufficiency",
            "probability": 0.9990234375
        },
        {
            "start_logit": 9.859375,
            "end_logit": 5.453125,
            "text": "primary ovarian insufficiency.",
            "probability": 0.001346588134765625
        },
        {
            "start_logit": -2.7265625,
            "end_logit": 12.0625,
            "text": "STAG3 truncating variant as the cause of primary ovarian insufficiency",
            "probability": 3.3974647521972656e-06
        },
        {
            "start_logit": -5.4765625,
            "end_logit": 12.0625,
            "text": "insufficiency",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.9765625,
            "end_logit": 12.0625,
            "text": "ovarian insufficiency",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": 12.0625,
            "text": "of primary ovarian insufficiency",
            "probability": 0.0
        },
        {
            "start_logit": -2.7265625,
            "end_logit": 5.453125,
            "text": "STAG3 truncating variant as the cause of primary ovarian insufficiency.",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 12.0625,
            "text": "cause of primary ovarian insufficiency",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -7.62890625,
            "text": "primary",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 12.0625,
            "text": "as the cause of primary ovarian insufficiency",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 12.0625,
            "text": "the cause of primary ovarian insufficiency",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 12.0625,
            "text": "truncating variant as the cause of primary ovarian insufficiency",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 12.0625,
            "text": "variant as the cause of primary ovarian insufficiency",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 12.0625,
            "text": "3 truncating variant as the cause of primary ovarian insufficiency",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 12.0625,
            "text": "G3 truncating variant as the cause of primary ovarian insufficiency",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 12.0625,
            "text": "ating variant as the cause of primary ovarian insufficiency",
            "probability": 0.0
        },
        {
            "start_logit": 9.859375,
            "end_logit": -9.0859375,
            "text": "primary ovarian",
            "probability": 0.0
        },
        {
            "start_logit": -5.4765625,
            "end_logit": 5.453125,
            "text": "insufficiency.",
            "probability": 0.0
        },
        {
            "start_logit": -6.98828125,
            "end_logit": 5.453125,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -8.9765625,
            "end_logit": 5.453125,
            "text": "ovarian insufficiency.",
            "probability": 0.0
        }
    ],
    "5c632cc1e842deac6700000f_2": [
        {
            "start_logit": 9.7109375,
            "end_logit": 10.5859375,
            "text": "a homozygous two base pair duplication (c.1947_48dupCT",
            "probability": 0.984375
        },
        {
            "start_logit": 9.7109375,
            "end_logit": 5.8203125,
            "text": "a homozygous two base pair duplication",
            "probability": 0.00838470458984375
        },
        {
            "start_logit": 9.7109375,
            "end_logit": 5.21875,
            "text": "a homozygous two base pair duplication (c.1947_48dupC",
            "probability": 0.0045928955078125
        },
        {
            "start_logit": 3.556640625,
            "end_logit": 10.5859375,
            "text": "(c.1947_48dupCT",
            "probability": 0.0020885467529296875
        },
        {
            "start_logit": 9.7109375,
            "end_logit": 0.10748291015625,
            "text": "a homozygous two base pair duplication (c.1947_48dupCT)",
            "probability": 2.777576446533203e-05
        },
        {
            "start_logit": 3.556640625,
            "end_logit": 5.21875,
            "text": "(c.1947_48dupC",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -2.376953125,
            "text": "a homozygous two base pair duplication (c.1947_48du",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -4.66796875,
            "end_logit": 10.5859375,
            "text": "c.1947_48dupCT",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -4.90234375,
            "end_logit": 10.5859375,
            "text": "T",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 3.556640625,
            "end_logit": 0.10748291015625,
            "text": "(c.1947_48dupCT)",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.46875,
            "end_logit": 10.5859375,
            "text": "duplication (c.1947_48dupCT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.57421875,
            "end_logit": 10.5859375,
            "text": ".1947_48dupCT",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.91796875,
            "end_logit": 10.5859375,
            "text": "pCT",
            "probability": 0.0
        },
        {
            "start_logit": -8.1171875,
            "end_logit": 10.5859375,
            "text": "1947_48dupCT",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 10.5859375,
            "text": "base pair duplication (c.1947_48dupCT",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -7.546875,
            "text": "a",
            "probability": 0.0
        },
        {
            "start_logit": -8.5,
            "end_logit": 10.5859375,
            "text": "dupCT",
            "probability": 0.0
        },
        {
            "start_logit": -9.0,
            "end_logit": 10.5859375,
            "text": "homozygous two base pair duplication (c.1947_48dupCT",
            "probability": 0.0
        },
        {
            "start_logit": 9.7109375,
            "end_logit": -8.140625,
            "text": "a homozygous",
            "probability": 0.0
        },
        {
            "start_logit": -9.046875,
            "end_logit": 10.5859375,
            "text": "pair duplication (c.1947_48dupCT",
            "probability": 0.0
        }
    ],
    "5c632cc1e842deac6700000f_3": [
        {
            "start_logit": 1.63671875,
            "end_logit": 6.2734375,
            "text": "primary ovarian insufficiency",
            "probability": 0.65869140625
        },
        {
            "start_logit": 0.9794921875,
            "end_logit": 6.2734375,
            "text": "STAG3 truncating variant as the cause of primary ovarian insufficiency",
            "probability": 0.341552734375
        },
        {
            "start_logit": -8.3984375,
            "end_logit": 6.2734375,
            "text": "of primary ovarian insufficiency",
            "probability": 2.8967857360839844e-05
        },
        {
            "start_logit": -8.8671875,
            "end_logit": 6.2734375,
            "text": "ovarian insufficiency",
            "probability": 1.811981201171875e-05
        },
        {
            "start_logit": -9.140625,
            "end_logit": 6.2734375,
            "text": "insufficiency",
            "probability": 1.3709068298339844e-05
        },
        {
            "start_logit": -9.25,
            "end_logit": 6.2734375,
            "text": "cause of primary ovarian insufficiency",
            "probability": 1.2278556823730469e-05
        },
        {
            "start_logit": -9.28125,
            "end_logit": 6.2734375,
            "text": "as the cause of primary ovarian insufficiency",
            "probability": 1.1920928955078125e-05
        },
        {
            "start_logit": -9.671875,
            "end_logit": 6.2734375,
            "text": "G3 truncating variant as the cause of primary ovarian insufficiency",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": -9.7578125,
            "end_logit": 6.2734375,
            "text": "truncating variant as the cause of primary ovarian insufficiency",
            "probability": 7.450580596923828e-06
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 6.2734375,
            "text": "3 truncating variant as the cause of primary ovarian insufficiency",
            "probability": 4.947185516357422e-06
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 6.2734375,
            "text": "variant as the cause of primary ovarian insufficiency",
            "probability": 4.231929779052734e-06
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 6.2734375,
            "text": "ating variant as the cause of primary ovarian insufficiency",
            "probability": 3.7550926208496094e-06
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 6.2734375,
            "text": "the cause of primary ovarian insufficiency",
            "probability": 3.6954879760742188e-06
        },
        {
            "start_logit": 0.9794921875,
            "end_logit": -8.453125,
            "text": "STAG3 truncating variant",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 1.63671875,
            "end_logit": -9.1796875,
            "text": "primary ovarian insufficiency.Primary ovarian insufficiency (POI) is a distressing cause of infertility in young women.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 0.9794921875,
            "end_logit": -9.546875,
            "text": "STAG3 truncating variant as",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.63671875,
            "end_logit": -10.2890625,
            "text": "primary ovarian insufficiency.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 0.9794921875,
            "end_logit": -9.6328125,
            "text": "STAG3 truncating variant as the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.63671875,
            "end_logit": -10.4296875,
            "text": "primary ovarian insufficiency.Primary ovarian insufficiency (PO",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.63671875,
            "end_logit": -10.4375,
            "text": "primary ovarian insufficiency.Primary ovarian insufficiency",
            "probability": 5.960464477539063e-08
        }
    ],
    "5c632cc1e842deac6700000f_4": [
        {
            "start_logit": -4.08984375,
            "end_logit": 3.083984375,
            "text": "primary ovarian insufficiency.",
            "probability": 0.84716796875
        },
        {
            "start_logit": -6.35546875,
            "end_logit": 3.083984375,
            "text": "loss-of-function variants in the STAG3 gene leading to primary ovarian insufficiency.",
            "probability": 0.087890625
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 3.083984375,
            "text": ".",
            "probability": 0.04248046875
        },
        {
            "start_logit": -8.6015625,
            "end_logit": 3.083984375,
            "text": "variants in the STAG3 gene leading to primary ovarian insufficiency.",
            "probability": 0.00933837890625
        },
        {
            "start_logit": -9.4375,
            "end_logit": 3.083984375,
            "text": "ovarian insufficiency.",
            "probability": 0.004047393798828125
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 3.083984375,
            "text": "to primary ovarian insufficiency.",
            "probability": 0.00208282470703125
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 3.083984375,
            "text": "rare loss-of-function variants in the STAG3 gene leading to primary ovarian insufficiency.",
            "probability": 0.0015239715576171875
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 3.083984375,
            "text": "-of-function variants in the STAG3 gene leading to primary ovarian insufficiency.",
            "probability": 0.0014314651489257812
        },
        {
            "start_logit": -10.515625,
            "end_logit": 3.083984375,
            "text": "function variants in the STAG3 gene leading to primary ovarian insufficiency.",
            "probability": 0.001377105712890625
        },
        {
            "start_logit": -10.5390625,
            "end_logit": 3.083984375,
            "text": "STAG3 gene leading to primary ovarian insufficiency.",
            "probability": 0.0013446807861328125
        },
        {
            "start_logit": -10.5625,
            "end_logit": 3.083984375,
            "text": "of-function variants in the STAG3 gene leading to primary ovarian insufficiency.",
            "probability": 0.0013141632080078125
        },
        {
            "start_logit": -4.08984375,
            "end_logit": -4.9765625,
            "text": "primary ovarian insufficiency",
            "probability": 0.0002689361572265625
        },
        {
            "start_logit": -6.35546875,
            "end_logit": -4.9765625,
            "text": "loss-of-function variants in the STAG3 gene leading to primary ovarian insufficiency",
            "probability": 2.7894973754882812e-05
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -4.9765625,
            "text": "variants in the STAG3 gene leading to primary ovarian insufficiency",
            "probability": 2.9206275939941406e-06
        },
        {
            "start_logit": -9.4375,
            "end_logit": -4.9765625,
            "text": "ovarian insufficiency",
            "probability": 1.2516975402832031e-06
        },
        {
            "start_logit": -6.35546875,
            "end_logit": -8.2578125,
            "text": "loss-of-function variants in the STAG3 gene",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": -6.35546875,
            "end_logit": -8.640625,
            "text": "loss-of-function variants in the",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": -10.1015625,
            "end_logit": -4.9765625,
            "text": "to primary ovarian insufficiency",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -6.35546875,
            "end_logit": -8.7734375,
            "text": "loss-of-function variants in the STAG3 gene leading",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.4140625,
            "end_logit": -4.9765625,
            "text": "rare loss-of-function variants in the STAG3 gene leading to primary ovarian insufficiency",
            "probability": 4.76837158203125e-07
        }
    ],
    "5c632cc1e842deac6700000f_5": [
        {
            "start_logit": 1.8427734375,
            "end_logit": 8.15625,
            "text": "A homozygous NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency.",
            "probability": 0.99609375
        },
        {
            "start_logit": -4.28515625,
            "end_logit": 8.15625,
            "text": "primary ovarian insufficiency.",
            "probability": 0.002170562744140625
        },
        {
            "start_logit": -5.046875,
            "end_logit": 8.15625,
            "text": ".",
            "probability": 0.0010137557983398438
        },
        {
            "start_logit": -5.96875,
            "end_logit": 8.15625,
            "text": "NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency.",
            "probability": 0.0004029273986816406
        },
        {
            "start_logit": -8.2890625,
            "end_logit": 8.15625,
            "text": "homozygous NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency.",
            "probability": 3.9577484130859375e-05
        },
        {
            "start_logit": -8.75,
            "end_logit": 8.15625,
            "text": "to primary ovarian insufficiency.",
            "probability": 2.4974346160888672e-05
        },
        {
            "start_logit": -8.7890625,
            "end_logit": 8.15625,
            "text": "defective transcriptional activation and leads to primary ovarian insufficiency.",
            "probability": 2.4020671844482422e-05
        },
        {
            "start_logit": -8.859375,
            "end_logit": 8.15625,
            "text": "truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency.",
            "probability": 2.2411346435546875e-05
        },
        {
            "start_logit": -8.984375,
            "end_logit": 8.15625,
            "text": "ovarian insufficiency.",
            "probability": 1.9788742065429688e-05
        },
        {
            "start_logit": -9.3359375,
            "end_logit": 8.15625,
            "text": "variant causes defective transcriptional activation and leads to primary ovarian insufficiency.",
            "probability": 1.3887882232666016e-05
        },
        {
            "start_logit": -9.90625,
            "end_logit": 8.15625,
            "text": "transcriptional activation and leads to primary ovarian insufficiency.",
            "probability": 7.808208465576172e-06
        },
        {
            "start_logit": -9.9375,
            "end_logit": 8.15625,
            "text": "leads to primary ovarian insufficiency.",
            "probability": 7.62939453125e-06
        },
        {
            "start_logit": -9.96875,
            "end_logit": 8.15625,
            "text": "BOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency.",
            "probability": 7.3909759521484375e-06
        },
        {
            "start_logit": -10.15625,
            "end_logit": 8.15625,
            "text": "causes defective transcriptional activation and leads to primary ovarian insufficiency.",
            "probability": 6.139278411865234e-06
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 8.15625,
            "text": "activation and leads to primary ovarian insufficiency.",
            "probability": 3.993511199951172e-06
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 8.15625,
            "text": "ating variant causes defective transcriptional activation and leads to primary ovarian insufficiency.",
            "probability": 3.814697265625e-06
        },
        {
            "start_logit": 1.8427734375,
            "end_logit": -5.4609375,
            "text": "A homozygous NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency",
            "probability": 1.1920928955078125e-06
        },
        {
            "start_logit": 1.8427734375,
            "end_logit": -8.203125,
            "text": "A homozygous NOBOX truncating variant causes defective transcriptional activation and",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.8427734375,
            "end_logit": -8.8359375,
            "text": "A",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 1.8427734375,
            "end_logit": -9.75,
            "text": "A homozygous NOBOX truncating variant",
            "probability": 0.0
        }
    ],
    "5c632cc1e842deac6700000f_6": [
        {
            "start_logit": 6.6484375,
            "end_logit": -5.04296875,
            "text": "compound heterozygous variants in the STAG3 gene",
            "probability": 0.50732421875
        },
        {
            "start_logit": 6.6484375,
            "end_logit": -5.1953125,
            "text": "compound heterozygous",
            "probability": 0.435791015625
        },
        {
            "start_logit": 6.6484375,
            "end_logit": -8.640625,
            "text": "compound",
            "probability": 0.0139007568359375
        },
        {
            "start_logit": 6.6484375,
            "end_logit": -8.9609375,
            "text": "compound heterozygous variants in the",
            "probability": 0.0100860595703125
        },
        {
            "start_logit": 6.6484375,
            "end_logit": -9.2578125,
            "text": "compound heterozygous variants in",
            "probability": 0.00749969482421875
        },
        {
            "start_logit": 6.6484375,
            "end_logit": -9.8046875,
            "text": "compound heterozygous variants in the STAG3 gene, supporting the key role of the STAG3 gene in the etiology of primary ovarian insufficiency",
            "probability": 0.00434112548828125
        },
        {
            "start_logit": 6.6484375,
            "end_logit": -10.1171875,
            "text": "compound heterozygous variants in the STAG3 gene, supporting the key role of the STAG3 gene in the etiology of primary ovarian insufficiency.",
            "probability": 0.003173828125
        },
        {
            "start_logit": 6.6484375,
            "end_logit": -10.140625,
            "text": "compound heterozygous variants in the STA",
            "probability": 0.003101348876953125
        },
        {
            "start_logit": 6.6484375,
            "end_logit": -10.171875,
            "text": "compound heterozygous variants",
            "probability": 0.0030059814453125
        },
        {
            "start_logit": 6.6484375,
            "end_logit": -10.1953125,
            "text": "compound heterozygous variants in the STAG3 gene, supporting the key role of the STAG3 gene",
            "probability": 0.00293731689453125
        },
        {
            "start_logit": 6.6484375,
            "end_logit": -10.2109375,
            "text": "compound heterozygous variants in the STAG3 gene, supporting the key role of the STAG3 gene in the etiology of primary ovarian insufficiency.<br",
            "probability": 0.0028896331787109375
        },
        {
            "start_logit": 6.6484375,
            "end_logit": -10.234375,
            "text": "compound heterozygous variants in the STAG3 gene,",
            "probability": 0.0028247833251953125
        },
        {
            "start_logit": 6.6484375,
            "end_logit": -10.25,
            "text": "compound heterozygous variants in the STAG3",
            "probability": 0.0027790069580078125
        },
        {
            "start_logit": -5.43359375,
            "end_logit": -5.04296875,
            "text": "variants in the STAG3 gene",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -7.87109375,
            "end_logit": -5.04296875,
            "text": "heterozygous variants in the STAG3 gene",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -7.87109375,
            "end_logit": -5.1953125,
            "text": "heterozygous",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -8.765625,
            "end_logit": -5.04296875,
            "text": "pathogenic compound heterozygous variants in the STAG3 gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -8.765625,
            "end_logit": -5.1953125,
            "text": "pathogenic compound heterozygous",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.43359375,
            "end_logit": -8.9609375,
            "text": "variants in the",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -5.04296875,
            "text": "by pathogenic compound heterozygous variants in the STAG3 gene",
            "probability": 5.960464477539063e-08
        }
    ],
    "5c632cc1e842deac6700000f_7": [
        {
            "start_logit": 9.59375,
            "end_logit": 1.2509765625,
            "text": "compound heterozygous variants in the STAG3 gene",
            "probability": 0.9970703125
        },
        {
            "start_logit": 9.59375,
            "end_logit": -5.12890625,
            "text": "compound heterozygous",
            "probability": 0.0016918182373046875
        },
        {
            "start_logit": 9.59375,
            "end_logit": -6.453125,
            "text": "compound heterozygous variants in the",
            "probability": 0.00044989585876464844
        },
        {
            "start_logit": 9.59375,
            "end_logit": -7.4921875,
            "text": "compound",
            "probability": 0.00015926361083984375
        },
        {
            "start_logit": 9.59375,
            "end_logit": -8.8828125,
            "text": "compound heterozygous variants in",
            "probability": 3.9637088775634766e-05
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.015625,
            "text": "compound heterozygous variants in the STAG3 gene, supporting the key role of the STAG3 gene in the etiology of primary ovarian insufficiency.",
            "probability": 3.4689903259277344e-05
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.1171875,
            "text": "compound heterozygous variants in the STAG3 gene,",
            "probability": 3.135204315185547e-05
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.609375,
            "text": "compound heterozygous variants in the STAG3 gene, supporting the key role of the STAG3 gene in the etiology of primary ovarian insufficiency",
            "probability": 1.919269561767578e-05
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.9453125,
            "text": "compound heterozygous variants in the STAG3",
            "probability": 1.3649463653564453e-05
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.984375,
            "text": "compound heterozygous variants in the STAG3 gene, supporting the key role of the STAG3 gene",
            "probability": 1.3172626495361328e-05
        },
        {
            "start_logit": 9.59375,
            "end_logit": -10.1015625,
            "text": "compound heterozygous variants in the STAG3 gene, supporting the key role of the STAG3 gene in the",
            "probability": 1.1682510375976562e-05
        },
        {
            "start_logit": 9.59375,
            "end_logit": -10.2890625,
            "text": "compound heterozygous variants in the STAG3 gene, supporting the key role of the STAG3 gene in the etiology",
            "probability": 9.715557098388672e-06
        },
        {
            "start_logit": -4.234375,
            "end_logit": 1.2509765625,
            "text": "variants in the STAG3 gene",
            "probability": 1.0132789611816406e-06
        },
        {
            "start_logit": -6.3125,
            "end_logit": 1.2509765625,
            "text": "pathogenic compound heterozygous variants in the STAG3 gene",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.0546875,
            "end_logit": 1.2509765625,
            "text": "heterozygous variants in the STAG3 gene",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.046875,
            "end_logit": 1.2509765625,
            "text": "POI is caused by pathogenic compound heterozygous variants in the STAG3 gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 1.2509765625,
            "text": "STAG3 gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 1.2509765625,
            "text": "in the STAG3 gene",
            "probability": 0.0
        },
        {
            "start_logit": -9.6171875,
            "end_logit": 1.2509765625,
            "text": "by pathogenic compound heterozygous variants in the STAG3 gene",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 1.2509765625,
            "text": "that POI is caused by pathogenic compound heterozygous variants in the STAG3 gene",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_1": [
        {
            "start_logit": 14.0703125,
            "end_logit": 14.234375,
            "text": "orexin receptor",
            "probability": 1.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -1.275390625,
            "text": "orexin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.560546875,
            "end_logit": 14.234375,
            "text": "receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -9.1328125,
            "text": "orexin receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -9.5078125,
            "text": "orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -9.6171875,
            "text": "orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 14.234375,
            "text": "dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.0703125,
            "end_logit": -10.0390625,
            "text": "orexin receptor antagonist for the treatment of sleep onset and sleep maintenance",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 14.234375,
            "text": "Suvorexant: a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 14.234375,
            "text": "a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -11.1953125,
            "end_logit": 14.234375,
            "text": "orexant: a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": 14.234375,
            "text": ": a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.9296875,
            "end_logit": -1.275390625,
            "text": "dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": -1.275390625,
            "text": "Suvorexant: a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": -1.275390625,
            "text": "a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -11.1953125,
            "end_logit": -1.275390625,
            "text": "orexant: a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -11.203125,
            "end_logit": -1.275390625,
            "text": ": a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -3.560546875,
            "end_logit": -9.1328125,
            "text": "receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -3.560546875,
            "end_logit": -9.5078125,
            "text": "receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.",
            "probability": 0.0
        },
        {
            "start_logit": -3.560546875,
            "end_logit": -9.6171875,
            "text": "receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_2": [
        {
            "start_logit": 12.984375,
            "end_logit": 13.2578125,
            "text": "orexin receptor",
            "probability": 1.0
        },
        {
            "start_logit": 12.984375,
            "end_logit": -2.072265625,
            "text": "orexin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -4.37109375,
            "end_logit": 13.2578125,
            "text": "receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 13.2578125,
            "text": "dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 12.984375,
            "end_logit": -9.7421875,
            "text": "orexin receptor antagonist approved for the treatment of insomnia",
            "probability": 0.0
        },
        {
            "start_logit": 12.984375,
            "end_logit": -9.7890625,
            "text": "orexin receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 12.984375,
            "end_logit": -10.0703125,
            "text": "orexin receptor antagonist approved for the treatment of insomnia.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 13.2578125,
            "text": "first dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 13.2578125,
            "text": ": Suvorexant is the first dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 12.984375,
            "end_logit": -10.2265625,
            "text": "orexin receptor antagonist approved",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 13.2578125,
            "text": "Suvorexant is the first dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 13.2578125,
            "text": "CONCLUSION: Suvorexant is the first dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 13.2578125,
            "text": "the first dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -11.078125,
            "end_logit": 13.2578125,
            "text": "is the first dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": -2.072265625,
            "text": "dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -2.072265625,
            "text": "first dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": -2.072265625,
            "text": ": Suvorexant is the first dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": -2.072265625,
            "text": "Suvorexant is the first dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": -2.072265625,
            "text": "CONCLUSION: Suvorexant is the first dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": -2.072265625,
            "text": "the first dual orexin",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_3": [
        {
            "start_logit": 14.21875,
            "end_logit": 14.3671875,
            "text": "orexin receptor",
            "probability": 1.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -1.3828125,
            "text": "orexin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.541015625,
            "end_logit": 14.3671875,
            "text": "OX2 orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -3.56640625,
            "end_logit": 14.3671875,
            "text": "receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": 14.3671875,
            "text": "2 orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.6328125,
            "end_logit": 14.3671875,
            "text": "human OX2 orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.25,
            "text": "orexin receptor bound to the insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 14.3671875,
            "text": "Crystal structure of the human OX2 orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.328125,
            "text": "orexin receptor bound to the insomnia drug suvorexant.",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 14.3671875,
            "text": "the human OX2 orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -9.4765625,
            "text": "orexin receptor bound",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -10.0234375,
            "text": "orexin receptor bound to the insomnia drug suvorexant",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -10.1015625,
            "text": "orexin receptor bound to the insomnia drug suvorex",
            "probability": 0.0
        },
        {
            "start_logit": 14.21875,
            "end_logit": -10.1953125,
            "text": "orexin receptor bound to the insomnia drug",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 14.3671875,
            "text": "structure of the human OX2 orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -3.541015625,
            "end_logit": -1.3828125,
            "text": "OX2 orexin",
            "probability": 0.0
        },
        {
            "start_logit": -8.328125,
            "end_logit": -1.3828125,
            "text": "2 orexin",
            "probability": 0.0
        },
        {
            "start_logit": -3.541015625,
            "end_logit": -6.46484375,
            "text": "OX",
            "probability": 0.0
        },
        {
            "start_logit": -8.6328125,
            "end_logit": -1.3828125,
            "text": "human OX2 orexin",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": -1.3828125,
            "text": "Crystal structure of the human OX2 orexin",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_4": [
        {
            "start_logit": 13.6796875,
            "end_logit": 14.484375,
            "text": "Orexin receptor",
            "probability": 1.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -1.9443359375,
            "text": "Orexin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -3.3125,
            "end_logit": 14.484375,
            "text": "receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.40625,
            "text": "Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.4765625,
            "text": "Orexin receptor antagonism for treatment of insomnia",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.640625,
            "text": "Orexin receptor antagonism",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.828125,
            "text": "Orexin receptor antagonism for treatment of insomnia: a",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.8671875,
            "text": "Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.9296875,
            "text": "Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorex",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -9.953125,
            "text": "Orexin receptor antagonism for",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -10.1015625,
            "text": "Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial",
            "probability": 0.0
        },
        {
            "start_logit": 13.6796875,
            "end_logit": -10.265625,
            "text": "Orexin receptor antagonism for treatment of",
            "probability": 0.0
        },
        {
            "start_logit": -3.3125,
            "end_logit": -9.40625,
            "text": "receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.",
            "probability": 0.0
        },
        {
            "start_logit": -3.3125,
            "end_logit": -9.4765625,
            "text": "receptor antagonism for treatment of insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -3.3125,
            "end_logit": -9.640625,
            "text": "receptor antagonism",
            "probability": 0.0
        },
        {
            "start_logit": -3.3125,
            "end_logit": -9.828125,
            "text": "receptor antagonism for treatment of insomnia: a",
            "probability": 0.0
        },
        {
            "start_logit": -3.3125,
            "end_logit": -9.8671875,
            "text": "receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant",
            "probability": 0.0
        },
        {
            "start_logit": -3.3125,
            "end_logit": -9.9296875,
            "text": "receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorex",
            "probability": 0.0
        },
        {
            "start_logit": -3.3125,
            "end_logit": -9.953125,
            "text": "receptor antagonism for",
            "probability": 0.0
        },
        {
            "start_logit": -3.3125,
            "end_logit": -10.1015625,
            "text": "receptor antagonism for treatment of insomnia: a randomized clinical trial",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_5": [
        {
            "start_logit": 12.765625,
            "end_logit": 13.2109375,
            "text": "orexin receptor",
            "probability": 1.0
        },
        {
            "start_logit": 12.765625,
            "end_logit": -2.015625,
            "text": "orexin",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -4.2890625,
            "end_logit": 13.2109375,
            "text": "receptor",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -8.8515625,
            "end_logit": 13.2109375,
            "text": "dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 12.765625,
            "end_logit": -8.6875,
            "text": "orexin receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": 13.2109375,
            "text": "novel dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 12.765625,
            "end_logit": -9.046875,
            "text": "orexin receptor antagonist.",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 13.2109375,
            "text": "a novel dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 13.2109375,
            "text": "sleep by suvorexant-a novel dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -11.1328125,
            "end_logit": 13.2109375,
            "text": "Promotion of sleep by suvorexant-a novel dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -11.2265625,
            "end_logit": 13.2109375,
            "text": "-a novel dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -11.2421875,
            "end_logit": 13.2109375,
            "text": "suvorexant-a novel dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -11.4375,
            "end_logit": 13.2109375,
            "text": "of sleep by suvorexant-a novel dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.8515625,
            "end_logit": -2.015625,
            "text": "dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -9.3203125,
            "end_logit": -2.015625,
            "text": "novel dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -2.015625,
            "text": "a novel dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -4.2890625,
            "end_logit": -8.6875,
            "text": "receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": -2.015625,
            "text": "sleep by suvorexant-a novel dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -11.1328125,
            "end_logit": -2.015625,
            "text": "Promotion of sleep by suvorexant-a novel dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -11.2265625,
            "end_logit": -2.015625,
            "text": "-a novel dual orexin",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_6": [
        {
            "start_logit": 6.0546875,
            "end_logit": 7.9609375,
            "text": "orexin",
            "probability": 1.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 7.9609375,
            "text": "and orexin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -10.1328125,
            "end_logit": 7.9609375,
            "text": "substance P (or neurokinin) for aprepitant, melatonin for ramelteon, and orexin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -10.203125,
            "end_logit": 7.9609375,
            "text": "or neurokinin) for aprepitant, melatonin for ramelteon, and orexin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 7.9609375,
            "text": ", substance P (or neurokinin) for aprepitant, melatonin for ramelteon, and orexin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 7.9609375,
            "text": ", and orexin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.515625,
            "end_logit": 7.9609375,
            "text": "neurokinin) for aprepitant, melatonin for ramelteon, and orexin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 7.9609375,
            "text": "dopamine for varenicline, substance P (or neurokinin) for aprepitant, melatonin for ramelteon, and orexin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 7.9609375,
            "text": ", melatonin for ramelteon, and orexin",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.0546875,
            "end_logit": -9.90625,
            "text": "orexin for suvorexant. The indications",
            "probability": 0.0
        },
        {
            "start_logit": 6.0546875,
            "end_logit": -10.0703125,
            "text": "orexin for suvorexant.",
            "probability": 0.0
        },
        {
            "start_logit": 6.0546875,
            "end_logit": -10.109375,
            "text": "orexin for",
            "probability": 0.0
        },
        {
            "start_logit": 6.0546875,
            "end_logit": -10.15625,
            "text": "orexin for suvorexant. The indications were chemotherapy-induced nausea and vomiting for ondansetron",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": -9.90625,
            "text": "and orexin for suvorexant. The indications",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": -10.0703125,
            "text": "and orexin for suvorexant.",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": -10.109375,
            "text": "and orexin for",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": -10.15625,
            "text": "and orexin for suvorexant. The indications were chemotherapy-induced nausea and vomiting for ondansetron",
            "probability": 0.0
        },
        {
            "start_logit": -10.1328125,
            "end_logit": -9.90625,
            "text": "substance P (or neurokinin) for aprepitant, melatonin for ramelteon, and orexin for suvorexant. The indications",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": -9.4453125,
            "text": "neurotransmitter systems",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -9.90625,
            "text": "or neurokinin) for aprepitant, melatonin for ramelteon, and orexin for suvorexant. The indications",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_7": [
        {
            "start_logit": 14.0234375,
            "end_logit": 14.4375,
            "text": "orexin receptor",
            "probability": 1.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -1.4189453125,
            "text": "orexin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.443359375,
            "end_logit": 14.4375,
            "text": "receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.5859375,
            "end_logit": 14.4375,
            "text": "dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.3046875,
            "text": "orexin receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.40625,
            "text": "orexin receptor antagonist for the management of insomnia.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 14.4375,
            "text": "Suvorexant, a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.8359375,
            "text": "orexin receptor antagonist for the management of insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 14.4375,
            "text": "a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.4375,
            "text": ", a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 14.4375,
            "text": "orexant, a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -11.25,
            "end_logit": 14.4375,
            "text": "ant, a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.5859375,
            "end_logit": -1.4189453125,
            "text": "dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -1.4189453125,
            "text": "Suvorexant, a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -1.4189453125,
            "text": "a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": -1.4189453125,
            "text": ", a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": -1.4189453125,
            "text": "orexant, a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -11.25,
            "end_logit": -1.4189453125,
            "text": "ant, a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -3.443359375,
            "end_logit": -9.3046875,
            "text": "receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -3.443359375,
            "end_logit": -9.40625,
            "text": "receptor antagonist for the management of insomnia.",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_8": [
        {
            "start_logit": 14.0234375,
            "end_logit": 14.4375,
            "text": "orexin receptor",
            "probability": 1.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -1.4189453125,
            "text": "orexin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -3.443359375,
            "end_logit": 14.4375,
            "text": "receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.5859375,
            "end_logit": 14.4375,
            "text": "dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.3046875,
            "text": "orexin receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.40625,
            "text": "orexin receptor antagonist for the management of insomnia.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": 14.4375,
            "text": "Suvorexant, a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 14.0234375,
            "end_logit": -9.8359375,
            "text": "orexin receptor antagonist for the management of insomnia",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 14.4375,
            "text": "a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 14.4375,
            "text": ", a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": 14.4375,
            "text": "orexant, a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -11.25,
            "end_logit": 14.4375,
            "text": "ant, a dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -8.5859375,
            "end_logit": -1.4189453125,
            "text": "dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -1.4189453125,
            "text": "Suvorexant, a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -1.4189453125,
            "text": "a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": -1.4189453125,
            "text": ", a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -10.9765625,
            "end_logit": -1.4189453125,
            "text": "orexant, a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -11.25,
            "end_logit": -1.4189453125,
            "text": "ant, a dual orexin",
            "probability": 0.0
        },
        {
            "start_logit": -3.443359375,
            "end_logit": -9.3046875,
            "text": "receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -3.443359375,
            "end_logit": -9.40625,
            "text": "receptor antagonist for the management of insomnia.",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_9": [
        {
            "start_logit": 4.765625,
            "end_logit": 5.5625,
            "text": "orexin",
            "probability": 1.0
        },
        {
            "start_logit": 4.765625,
            "end_logit": -7.40625,
            "text": "orexin activity.",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -9.5390625,
            "end_logit": 5.5625,
            "text": "Suvorexant helps in decreasing wakefulness by counteracting orexin",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 5.5625,
            "text": "ing orexin",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": -10.3125,
            "end_logit": 5.5625,
            "text": "decreasing wakefulness by counteracting orexin",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 4.765625,
            "end_logit": -9.5234375,
            "text": "orexin activity",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -11.0546875,
            "end_logit": 5.5625,
            "text": "ant helps in decreasing wakefulness by counteracting orexin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.1015625,
            "end_logit": 5.5625,
            "text": "orexant helps in decreasing wakefulness by counteracting orexin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.109375,
            "end_logit": 5.5625,
            "text": "in decreasing wakefulness by counteracting orexin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.1875,
            "end_logit": 5.5625,
            "text": "helps in decreasing wakefulness by counteracting orexin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -11.34375,
            "end_logit": 5.5625,
            "text": "wakefulness by counteracting orexin",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.5390625,
            "end_logit": -7.40625,
            "text": "Suvorexant helps in decreasing wakefulness by counteracting orexin activity.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": -7.40625,
            "text": "ing orexin activity.",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -7.40625,
            "text": "decreasing wakefulness by counteracting orexin activity.",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": -7.40625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -11.0546875,
            "end_logit": -7.40625,
            "text": "ant helps in decreasing wakefulness by counteracting orexin activity.",
            "probability": 0.0
        },
        {
            "start_logit": -11.1015625,
            "end_logit": -7.40625,
            "text": "orexant helps in decreasing wakefulness by counteracting orexin activity.",
            "probability": 0.0
        },
        {
            "start_logit": -11.109375,
            "end_logit": -7.40625,
            "text": "in decreasing wakefulness by counteracting orexin activity.",
            "probability": 0.0
        },
        {
            "start_logit": -11.1640625,
            "end_logit": -7.40625,
            "text": "activity.",
            "probability": 0.0
        },
        {
            "start_logit": -11.1875,
            "end_logit": -7.40625,
            "text": "helps in decreasing wakefulness by counteracting orexin activity.",
            "probability": 0.0
        }
    ],
    "56c1f003ef6e394741000039_10": [
        {
            "start_logit": 10.5859375,
            "end_logit": 11.5078125,
            "text": "orexin receptor",
            "probability": 1.0
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -4.09765625,
            "text": "orexin",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -5.2265625,
            "end_logit": 11.5078125,
            "text": "receptor",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.3671875,
            "end_logit": 11.5078125,
            "text": "called dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 11.5078125,
            "text": "dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -9.390625,
            "text": "orexin receptor antagonist",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 11.5078125,
            "text": ";s suvorexant (MK-4305) is the first compound of the so-called dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 11.5078125,
            "text": "&apos;s suvorexant (MK-4305) is the first compound of the so-called dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 11.5078125,
            "text": "s suvorexant (MK-4305) is the first compound of the so-called dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": -10.484375,
            "end_logit": 11.5078125,
            "text": "(MK-4305) is the first compound of the so-called dual orexin receptor",
            "probability": 0.0
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -9.734375,
            "text": "orexin receptor antagonist (DORA) class",
            "probability": 0.0
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -9.75,
            "text": "orexin receptor antagonist (DORA) class expected",
            "probability": 0.0
        },
        {
            "start_logit": 10.5859375,
            "end_logit": -10.125,
            "text": "orexin receptor antagonist (DOR",
            "probability": 0.0
        },
        {
            "start_logit": -5.43359375,
            "end_logit": -2.5390625,
            "text": "orexin (hypocretin) system",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": -2.5390625,
            "text": "the orexin (hypocretin) system",
            "probability": 0.0
        },
        {
            "start_logit": -5.43359375,
            "end_logit": -5.58203125,
            "text": "orexin",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": -2.5390625,
            "text": "hypocretin) system",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -2.5390625,
            "text": "recent years, particularly upon the highly anticipated novel target, the orexin (hypocretin) system",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": -2.5390625,
            "text": "upon the highly anticipated novel target, the orexin (hypocretin) system",
            "probability": 0.0
        },
        {
            "start_logit": -10.2578125,
            "end_logit": -2.5390625,
            "text": "more focused in recent years, particularly upon the highly anticipated novel target, the orexin (hypocretin) system",
            "probability": 0.0
        }
    ],
    "5a70d42899e2c3af26000002_1": [
        {
            "start_logit": 14.40625,
            "end_logit": 14.9921875,
            "text": "SLC2A10",
            "probability": 1.0
        },
        {
            "start_logit": -2.357421875,
            "end_logit": 14.9921875,
            "text": "10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.40625,
            "end_logit": -2.345703125,
            "text": "SLC",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -3.505859375,
            "text": "SLC2A",
            "probability": 0.0
        },
        {
            "start_logit": -6.09765625,
            "end_logit": 14.9921875,
            "text": "Mutations in SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -5.77734375,
            "text": "SLC2A10,",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -6.9765625,
            "text": "SLC2A10, a gene that encodes the facilitative glucose transporter GLUT1",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -7.34375,
            "text": "SLC2A10, a",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -7.671875,
            "text": "SLC2A10, a gene that encodes the facilitative glucose transporter GLUT10, cause ATS.",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -7.83203125,
            "text": "SLC2A10, a gene that encodes the facilitative glucose transporter GLUT10",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": 14.9921875,
            "text": "in SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -8.7578125,
            "text": "SLC2A10, a gene that encodes the facilitative glucose transporter GLUT10, cause ATS",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -8.828125,
            "text": "SLC2A10, a gene that encodes the facilitative glucose transporter GLUT10,",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.234375,
            "text": "SLC2A10, a gene",
            "probability": 0.0
        },
        {
            "start_logit": 14.40625,
            "end_logit": -9.2421875,
            "text": "SLC2A10, a gene that encodes the facilitative glucose transporter GLUT10, cause",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 14.9921875,
            "text": "2A10",
            "probability": 0.0
        },
        {
            "start_logit": -2.357421875,
            "end_logit": -5.77734375,
            "text": "10,",
            "probability": 0.0
        },
        {
            "start_logit": -6.09765625,
            "end_logit": -2.345703125,
            "text": "Mutations in SLC",
            "probability": 0.0
        },
        {
            "start_logit": -2.357421875,
            "end_logit": -6.9765625,
            "text": "10, a gene that encodes the facilitative glucose transporter GLUT1",
            "probability": 0.0
        },
        {
            "start_logit": -6.09765625,
            "end_logit": -3.505859375,
            "text": "Mutations in SLC2A",
            "probability": 0.0
        }
    ],
    "5a70d42899e2c3af26000002_2": [
        {
            "start_logit": 14.3046875,
            "end_logit": 14.90625,
            "text": "SLC2A10",
            "probability": 1.0
        },
        {
            "start_logit": -2.486328125,
            "end_logit": 14.90625,
            "text": "10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -2.578125,
            "text": "SLC",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -3.3828125,
            "text": "SLC2A",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -4.1796875,
            "text": "SLC2A10,",
            "probability": 0.0
        },
        {
            "start_logit": -5.84765625,
            "end_logit": 14.90625,
            "text": "Arterial tortuosity syndrome (ATS) is an autosomal recessive connective tissue disorder caused by loss-of-function mutations in SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -5.71875,
            "text": "SLC2A10, which encodes facilitative glucose transporter 10 (GLUT10).",
            "probability": 0.0
        },
        {
            "start_logit": -7.4921875,
            "end_logit": 14.90625,
            "text": "in SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -7.0625,
            "text": "SLC2A10, which encodes facilitative glucose transporter 10 (GLUT10",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": 14.90625,
            "text": "connective tissue disorder caused by loss-of-function mutations in SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -8.828125,
            "text": "SLC2A10, which encodes facilitative glucose transporter 10 (GLUT1",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 14.90625,
            "text": "mutations in SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.046875,
            "text": "SLC2A10, which encodes facilitative glucose transporter 10 (GLUT10)",
            "probability": 0.0
        },
        {
            "start_logit": -9.9765625,
            "end_logit": 14.90625,
            "text": "2A10",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 14.90625,
            "text": "loss-of-function mutations in SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 14.90625,
            "text": "tortuosity syndrome (ATS) is an autosomal recessive connective tissue disorder caused by loss-of-function mutations in SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -9.984375,
            "text": "SLC2A10, which",
            "probability": 0.0
        },
        {
            "start_logit": 14.3046875,
            "end_logit": -10.03125,
            "text": "SLC2A10, which encodes facilitative glucose transporter 10",
            "probability": 0.0
        },
        {
            "start_logit": -2.486328125,
            "end_logit": -4.1796875,
            "text": "10,",
            "probability": 0.0
        },
        {
            "start_logit": -2.486328125,
            "end_logit": -5.71875,
            "text": "10, which encodes facilitative glucose transporter 10 (GLUT10).",
            "probability": 0.0
        }
    ],
    "5a70d42899e2c3af26000002_3": [
        {
            "start_logit": 14.671875,
            "end_logit": 15.171875,
            "text": "SLC2A10",
            "probability": 1.0
        },
        {
            "start_logit": -1.9150390625,
            "end_logit": 15.171875,
            "text": "10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.671875,
            "end_logit": -1.4970703125,
            "text": "SLC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.671875,
            "end_logit": -2.51171875,
            "text": "SLC2A",
            "probability": 0.0
        },
        {
            "start_logit": 14.671875,
            "end_logit": -8.609375,
            "text": "SLC2A10 missense",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 15.171875,
            "text": "2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.671875,
            "end_logit": -9.4453125,
            "text": "SLC2A10 missense mutations in",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": 15.171875,
            "text": "recurrent SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.671875,
            "end_logit": -9.8828125,
            "text": "SLC2A10 missense mutations",
            "probability": 0.0
        },
        {
            "start_logit": 14.671875,
            "end_logit": -9.9765625,
            "text": "SLC2A10 missense mutations in three families with severe cardiopulmonary complications in infancy and a literature review.",
            "probability": 0.0
        },
        {
            "start_logit": 14.671875,
            "end_logit": -10.265625,
            "text": "SLC2A10 missense mutations in three families with severe cardiopulmonary complications in infancy and a literature",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 15.171875,
            "text": "homozygosity for two novel and one recurrent SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 15.171875,
            "text": "one recurrent SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": -1.9150390625,
            "end_logit": -8.609375,
            "text": "10 missense",
            "probability": 0.0
        },
        {
            "start_logit": -1.9150390625,
            "end_logit": -9.4453125,
            "text": "10 missense mutations in",
            "probability": 0.0
        },
        {
            "start_logit": -10.265625,
            "end_logit": -1.4970703125,
            "text": "recurrent SLC",
            "probability": 0.0
        },
        {
            "start_logit": -1.9150390625,
            "end_logit": -9.8828125,
            "text": "10 missense mutations",
            "probability": 0.0
        },
        {
            "start_logit": -1.9150390625,
            "end_logit": -9.9765625,
            "text": "10 missense mutations in three families with severe cardiopulmonary complications in infancy and a literature review.",
            "probability": 0.0
        },
        {
            "start_logit": -1.9150390625,
            "end_logit": -10.265625,
            "text": "10 missense mutations in three families with severe cardiopulmonary complications in infancy and a literature",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": -1.4970703125,
            "text": "homozygosity for two novel and one recurrent SLC",
            "probability": 0.0
        }
    ],
    "5a70d42899e2c3af26000002_4": [
        {
            "start_logit": 14.5078125,
            "end_logit": 15.171875,
            "text": "SLC2A10",
            "probability": 1.0
        },
        {
            "start_logit": -1.8583984375,
            "end_logit": 15.171875,
            "text": "10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -2.11328125,
            "text": "SLC",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -2.291015625,
            "text": "SLC2A10 gene",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -2.44921875,
            "text": "SLC2A",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -7.265625,
            "text": "SLC2A10 gene,",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -7.81640625,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter 10 (GLUT10",
            "probability": 0.0
        },
        {
            "start_logit": -9.1171875,
            "end_logit": 15.171875,
            "text": "ATS is caused by mutations in the SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": -9.203125,
            "end_logit": 15.171875,
            "text": "the SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": -9.265625,
            "end_logit": 15.171875,
            "text": "mutations in the SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -8.6171875,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter 10 (GLUT1",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 15.171875,
            "text": "2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.2734375,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter 10 (GLUT10)",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.4765625,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter 10",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.5546875,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter 10 (GLUT10).",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 15.171875,
            "text": "in the SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.78125,
            "text": "SLC2A10 gene, which encodes the facilitative glucose transporter 10 (GLUT10). Approximately 100 ATS patients have been described, and 21",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -9.796875,
            "text": "SLC2A10 gene, which",
            "probability": 0.0
        },
        {
            "start_logit": -1.8583984375,
            "end_logit": -2.291015625,
            "text": "10 gene",
            "probability": 0.0
        },
        {
            "start_logit": -1.8583984375,
            "end_logit": -7.265625,
            "text": "10 gene,",
            "probability": 0.0
        }
    ],
    "5a70d42899e2c3af26000002_5": [
        {
            "start_logit": 14.234375,
            "end_logit": 14.8359375,
            "text": "SLC2A10",
            "probability": 1.0
        },
        {
            "start_logit": -2.431640625,
            "end_logit": 14.8359375,
            "text": "10",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.234375,
            "end_logit": -2.69921875,
            "text": "SLC",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -4.72265625,
            "text": "SLC2A",
            "probability": 0.0
        },
        {
            "start_logit": -7.14453125,
            "end_logit": 14.8359375,
            "text": "Mutations in SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -6.546875,
            "text": "SLC2A10/GLUT10",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -8.0,
            "text": "SLC2A10/GLUT1",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -8.5390625,
            "text": "SLC2A10/GLUT10, a member of the facilitative glucose transporter family, are",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 14.8359375,
            "text": "2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.0234375,
            "text": "SLC2A10/GLUT10,",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 14.8359375,
            "text": "in SLC2A10",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.3671875,
            "text": "SLC2A10/GLUT10, a",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.421875,
            "text": "SLC2A10/GLUT10, a member of the facilitative glucose transporter family,",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.6640625,
            "text": "SLC2A10/GLUT10, a member of the facilitative glucose transporter family, are associated with altered transforming growth factor-\u03b2 (TGF\u03b2)",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.7421875,
            "text": "SLC2A10/GLUT10, a member of the facilitative glucose transporter family, are associated with",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.7421875,
            "text": "SLC2A10/GLUT10, a member of the facilitative glucose transporter family, are associated with altered transforming growth factor-\u03b2 (TGF\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.9296875,
            "text": "SLC2A10/GLUT10, a member of the facilitative glucose transporter family, are associated with altered transforming growth factor-\u03b2",
            "probability": 0.0
        },
        {
            "start_logit": 14.234375,
            "end_logit": -9.96875,
            "text": "SLC2A10/GLUT10, a member of the facilitative glucose transporter family, are associated with altered transforming growth factor-\u03b2 (",
            "probability": 0.0
        },
        {
            "start_logit": -2.431640625,
            "end_logit": -6.546875,
            "text": "10/GLUT10",
            "probability": 0.0
        },
        {
            "start_logit": -7.14453125,
            "end_logit": -2.69921875,
            "text": "Mutations in SLC",
            "probability": 0.0
        }
    ],
    "58da1aa08acda34529000012_1": [
        {
            "start_logit": -3.83203125,
            "end_logit": 7.26171875,
            "text": "hCG",
            "probability": 0.97265625
        },
        {
            "start_logit": -7.9140625,
            "end_logit": 7.26171875,
            "text": "total hCG",
            "probability": 0.01641845703125
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 7.26171875,
            "text": "placental weight and hyperemesis gravidarum symptoms were associated with total hCG",
            "probability": 0.004486083984375
        },
        {
            "start_logit": -9.890625,
            "end_logit": 7.26171875,
            "text": "hyperemesis gravidarum symptoms were associated with total hCG",
            "probability": 0.0022735595703125
        },
        {
            "start_logit": -10.5078125,
            "end_logit": 7.26171875,
            "text": "Maternal smoking, BMI, parity, ethnicity, fetal gender, placental weight and hyperemesis gravidarum symptoms were associated with total hCG",
            "probability": 0.0012264251708984375
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 7.26171875,
            "text": "fetal gender, placental weight and hyperemesis gravidarum symptoms were associated with total hCG",
            "probability": 0.0010824203491210938
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 7.26171875,
            "text": "gender, placental weight and hyperemesis gravidarum symptoms were associated with total hCG",
            "probability": 0.0008296966552734375
        },
        {
            "start_logit": -11.171875,
            "end_logit": 7.26171875,
            "text": ", ethnicity, fetal gender, placental weight and hyperemesis gravidarum symptoms were associated with total hCG",
            "probability": 0.0006313323974609375
        },
        {
            "start_logit": -11.171875,
            "end_logit": 7.26171875,
            "text": "mesis gravidarum symptoms were associated with total hCG",
            "probability": 0.0006313323974609375
        },
        {
            "start_logit": -3.83203125,
            "end_logit": -8.75,
            "text": "hCG.",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.9140625,
            "end_logit": -8.75,
            "text": "total hCG.",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": -8.75,
            "text": "placental weight and hyperemesis gravidarum symptoms were associated with total hCG.",
            "probability": 0.0
        },
        {
            "start_logit": -9.890625,
            "end_logit": -8.75,
            "text": "hyperemesis gravidarum symptoms were associated with total hCG.",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": -9.4921875,
            "text": "placental weight and hyperemesis gravidarum symptoms were",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": -9.7109375,
            "text": "placental weight and hyperemesis gravidarum symptoms were associated",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": -9.7578125,
            "text": "placental weight and hyperemesis gravidarum",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": -9.765625,
            "text": "placental weight and hyperemesis gravidarum symptoms were associated with",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": -9.921875,
            "text": "placental weight and",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": -9.9921875,
            "text": "placental weight",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": -10.0234375,
            "text": "placental weight and hyperemesis grav",
            "probability": 0.0
        }
    ],
    "58da1aa08acda34529000012_2": [
        {
            "start_logit": 8.09375,
            "end_logit": 10.28125,
            "text": "hCG",
            "probability": 1.0
        },
        {
            "start_logit": 8.09375,
            "end_logit": -8.6796875,
            "text": "hCG promotes progesterone production by corpus luteal cells; promotes angiogenesis in uterine vasculature; promoted the fusion of cytotrophoblast cell and differentiation",
            "probability": 0.0
        },
        {
            "start_logit": -2.689453125,
            "end_logit": 1.6396484375,
            "text": "syncytiotrophoblast",
            "probability": 0.0
        },
        {
            "start_logit": 8.09375,
            "end_logit": -9.5390625,
            "text": "hCG promotes progesterone production by corpus luteal cells; promotes angiogenesis in uterine vasculature; promoted the fusion of cytotrophoblast",
            "probability": 0.0
        },
        {
            "start_logit": 8.09375,
            "end_logit": -9.96875,
            "text": "hCG promotes progesterone",
            "probability": 0.0
        },
        {
            "start_logit": -3.96484375,
            "end_logit": 1.6396484375,
            "text": "make syncytiotrophoblast",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": 1.6396484375,
            "text": "tiotrophoblast",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": 1.6396484375,
            "text": "otrophoblast",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": 1.6396484375,
            "text": "oblast",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": 1.6396484375,
            "text": "the fusion of cytotrophoblast cell and differentiation to make syncytiotrophoblast",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 1.6396484375,
            "text": "of cytotrophoblast cell and differentiation to make syncytiotrophoblast",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 1.6396484375,
            "text": "promoted the fusion of cytotrophoblast cell and differentiation to make syncytiotrophoblast",
            "probability": 0.0
        },
        {
            "start_logit": -2.689453125,
            "end_logit": -6.234375,
            "text": "syncytiotrophoblast cells",
            "probability": 0.0
        },
        {
            "start_logit": -3.96484375,
            "end_logit": -6.234375,
            "text": "make syncytiotrophoblast cells",
            "probability": 0.0
        },
        {
            "start_logit": -2.689453125,
            "end_logit": -7.68359375,
            "text": "syncytiotroph",
            "probability": 0.0
        },
        {
            "start_logit": -3.96484375,
            "end_logit": -7.68359375,
            "text": "make syncytiotroph",
            "probability": 0.0
        },
        {
            "start_logit": -9.3046875,
            "end_logit": -6.234375,
            "text": "tiotrophoblast cells",
            "probability": 0.0
        },
        {
            "start_logit": -9.65625,
            "end_logit": -6.234375,
            "text": "otrophoblast cells",
            "probability": 0.0
        },
        {
            "start_logit": -10.0234375,
            "end_logit": -6.234375,
            "text": "oblast cells",
            "probability": 0.0
        },
        {
            "start_logit": -10.0546875,
            "end_logit": -6.234375,
            "text": "the fusion of cytotrophoblast cell and differentiation to make syncytiotrophoblast cells",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_1": [
        {
            "start_logit": 4.33203125,
            "end_logit": 9.53125,
            "text": "prostate cancer",
            "probability": 0.9970703125
        },
        {
            "start_logit": -1.408203125,
            "end_logit": 9.53125,
            "text": "cancer",
            "probability": 0.003223419189453125
        },
        {
            "start_logit": 4.33203125,
            "end_logit": -2.779296875,
            "text": "prostate",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 9.53125,
            "text": "in prostate cancer",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -10.0078125,
            "end_logit": 9.53125,
            "text": "The Gleason score is an important parameter for clinical outcome in prostate cancer",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.625,
            "end_logit": 9.53125,
            "text": "an important parameter for clinical outcome in prostate cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 9.53125,
            "text": "clinical outcome in prostate cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.84375,
            "end_logit": 9.53125,
            "text": "for clinical outcome in prostate cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 9.53125,
            "text": "score is an important parameter for clinical outcome in prostate cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -11.0390625,
            "end_logit": 9.53125,
            "text": "outcome in prostate cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -11.1640625,
            "end_logit": 9.53125,
            "text": "parameter for clinical outcome in prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -11.265625,
            "end_logit": 9.53125,
            "text": "is an important parameter for clinical outcome in prostate cancer",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 4.33203125,
            "end_logit": -9.859375,
            "text": "prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -1.408203125,
            "end_logit": -9.859375,
            "text": "cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": -2.779296875,
            "text": "in prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -2.779296875,
            "text": "The Gleason score is an important parameter for clinical outcome in prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": -2.779296875,
            "text": "an important parameter for clinical outcome in prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": -2.779296875,
            "text": "clinical outcome in prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.84375,
            "end_logit": -2.779296875,
            "text": "for clinical outcome in prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": -2.779296875,
            "text": "score is an important parameter for clinical outcome in prostate",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_2": [
        {
            "start_logit": 11.8125,
            "end_logit": 12.46875,
            "text": "prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": 11.8125,
            "end_logit": 1.025390625,
            "text": "prostate",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": -1.6005859375,
            "end_logit": 12.46875,
            "text": "cancer",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 11.8125,
            "end_logit": -7.9375,
            "text": "prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": 11.8125,
            "end_logit": -8.8828125,
            "text": "prostate cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 12.46875,
            "text": "Gleason score 8 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 12.46875,
            "text": "score 8 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 12.46875,
            "text": "8 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 1.025390625,
            "text": "Gleason score 8 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 1.025390625,
            "text": "score 8 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -1.6005859375,
            "end_logit": -7.9375,
            "text": "cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 1.025390625,
            "text": "8 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -1.6005859375,
            "end_logit": -8.8828125,
            "text": "cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -7.9375,
            "text": "Gleason score 8 prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": -7.9375,
            "text": "score 8 prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -7.9375,
            "text": "patients",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -8.8828125,
            "text": "Gleason score 8 prostate cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -7.9375,
            "text": "8 prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": -8.8828125,
            "text": "score 8 prostate cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -8.8828125,
            "text": "patients.",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_3": [
        {
            "start_logit": 11.8125,
            "end_logit": 12.46875,
            "text": "prostate cancer",
            "probability": 1.0
        },
        {
            "start_logit": 11.8125,
            "end_logit": 1.025390625,
            "text": "prostate",
            "probability": 1.0728836059570312e-05
        },
        {
            "start_logit": -1.6005859375,
            "end_logit": 12.46875,
            "text": "cancer",
            "probability": 1.4901161193847656e-06
        },
        {
            "start_logit": 11.8125,
            "end_logit": -7.9375,
            "text": "prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": 11.8125,
            "end_logit": -8.8828125,
            "text": "prostate cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 12.46875,
            "text": "Gleason score 8 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 12.46875,
            "text": "score 8 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 12.46875,
            "text": "8 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": 1.025390625,
            "text": "Gleason score 8 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 1.025390625,
            "text": "score 8 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -1.6005859375,
            "end_logit": -7.9375,
            "text": "cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 1.025390625,
            "text": "8 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -1.6005859375,
            "end_logit": -8.8828125,
            "text": "cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -7.9375,
            "text": "Gleason score 8 prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": -7.9375,
            "text": "score 8 prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -7.9375,
            "text": "patients",
            "probability": 0.0
        },
        {
            "start_logit": -9.6484375,
            "end_logit": -8.8828125,
            "text": "Gleason score 8 prostate cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -7.9375,
            "text": "8 prostate cancer patients",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": -8.8828125,
            "text": "score 8 prostate cancer patients.",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -8.8828125,
            "text": "patients.",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_4": [
        {
            "start_logit": 10.0078125,
            "end_logit": 9.1171875,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -4.734375,
            "text": "prostate cancer",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -9.3203125,
            "text": "prostate cancer have worse outcomes compared to those with Gleason 8 disease.",
            "probability": 0.0
        },
        {
            "start_logit": 10.0078125,
            "end_logit": -10.2578125,
            "text": "prostate cancer have worse",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": 9.1171875,
            "text": "Men with Gleason score 9-10 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 9.1171875,
            "text": "score 9-10 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 9.1171875,
            "text": "9-10 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": 9.1171875,
            "text": "with Gleason score 9-10 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 9.1171875,
            "text": "10 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 9.1171875,
            "text": "Gleason score 9-10 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 9.1171875,
            "text": "-10 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -4.734375,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4296875,
            "end_logit": -4.734375,
            "text": "Men with Gleason score 9-10 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -4.734375,
            "text": "score 9-10 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -4.734375,
            "text": "9-10 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": -4.734375,
            "text": "with Gleason score 9-10 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": -4.734375,
            "text": "10 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": -4.734375,
            "text": "Gleason score 9-10 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": -4.734375,
            "text": "-10 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.9453125,
            "end_logit": -9.3203125,
            "text": "cancer have worse outcomes compared to those with Gleason 8 disease.",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_5": [
        {
            "start_logit": 8.71875,
            "end_logit": 10.5625,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 10.5625,
            "text": "Most adenocarcinomas of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 10.5625,
            "text": "the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": 10.5625,
            "text": "of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": 10.5625,
            "text": ": Most adenocarcinomas of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 10.5625,
            "text": "OBJECTIVES: Most adenocarcinomas of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.453125,
            "end_logit": 10.5625,
            "text": "adenocarcinomas of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": 8.71875,
            "end_logit": -9.703125,
            "text": "prostate with",
            "probability": 0.0
        },
        {
            "start_logit": 8.71875,
            "end_logit": -9.9921875,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy",
            "probability": 0.0
        },
        {
            "start_logit": 8.71875,
            "end_logit": -10.2109375,
            "text": "prostate with a Gleason score greater than 8",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": -9.703125,
            "text": "Most adenocarcinomas of the prostate with",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": -9.703125,
            "text": "the prostate with",
            "probability": 0.0
        },
        {
            "start_logit": -10.0,
            "end_logit": -9.703125,
            "text": "of the prostate with",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": -9.9921875,
            "text": "Most adenocarcinomas of the prostate with a Gleason score greater than 8 at radical prostatectomy",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": -9.9921875,
            "text": "greater than 8 at radical prostatectomy",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": -9.703125,
            "text": ": Most adenocarcinomas of the prostate with",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": -9.9921875,
            "text": "the prostate with a Gleason score greater than 8 at radical prostatectomy",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": -10.2109375,
            "text": "Most adenocarcinomas of the prostate with a Gleason score greater than 8",
            "probability": 0.0
        },
        {
            "start_logit": -9.9609375,
            "end_logit": -9.9921875,
            "text": "at radical prostatectomy",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": -10.2109375,
            "text": "greater than 8",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_6": [
        {
            "start_logit": 10.328125,
            "end_logit": 11.2578125,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -7.03515625,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": 11.2578125,
            "text": "high-grade prostate",
            "probability": 0.0
        },
        {
            "start_logit": -9.2890625,
            "end_logit": 11.2578125,
            "text": "grade prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -8.8359375,
            "text": "prostate cancer and an increased Gleason score upgrading.",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 11.2578125,
            "text": "-grade prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 11.2578125,
            "text": "Preoperative low serum testosterone is associated with high-grade prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 11.2578125,
            "text": "with high-grade prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 11.2578125,
            "text": "serum testosterone is associated with high-grade prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 11.2578125,
            "text": "low serum testosterone is associated with high-grade prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.9140625,
            "end_logit": 11.2578125,
            "text": "testosterone is associated with high-grade prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -10.1015625,
            "text": "prostate cancer and an increased Gleason",
            "probability": 0.0
        },
        {
            "start_logit": 10.328125,
            "end_logit": -10.28125,
            "text": "prostate cancer and an increased Gleason score upgrading",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -7.03515625,
            "text": "high-grade prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.46875,
            "end_logit": -7.03515625,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.2890625,
            "end_logit": -7.03515625,
            "text": "grade prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.3203125,
            "end_logit": -8.8359375,
            "text": "high-grade prostate cancer and an increased Gleason score upgrading.",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": -7.03515625,
            "text": "-grade prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": -7.03515625,
            "text": "Preoperative low serum testosterone is associated with high-grade prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -8.46875,
            "end_logit": -8.8359375,
            "text": "cancer and an increased Gleason score upgrading.",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_7": [
        {
            "start_logit": 11.234375,
            "end_logit": 11.7265625,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -9.4296875,
            "text": "prostate biopsies and in prostate tissue",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -10.015625,
            "text": "prostate biopsies and in prostate tissue specimens, crosschecked by two uro-pathologists.",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 11.7265625,
            "text": "eason score (GS) and predominant Gleason pattern were determined in prostate",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -10.203125,
            "text": "prostate biopsies and in prostate tissue specimens",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -10.2109375,
            "text": "prostate biopsies and in prostate tissue specimens, crosschecked by two",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -10.2265625,
            "text": "prostate biopsies and",
            "probability": 0.0
        },
        {
            "start_logit": 11.234375,
            "end_logit": -10.234375,
            "text": "prostate biopsies",
            "probability": 0.0
        },
        {
            "start_logit": -10.7265625,
            "end_logit": 11.7265625,
            "text": "in prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 11.7265625,
            "text": "predominant Gleason pattern were determined in prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 11.7265625,
            "text": "score (GS) and predominant Gleason pattern were determined in prostate",
            "probability": 0.0
        },
        {
            "start_logit": -8.6875,
            "end_logit": -9.4296875,
            "text": "prostate tissue",
            "probability": 0.0
        },
        {
            "start_logit": -8.6875,
            "end_logit": -10.015625,
            "text": "prostate tissue specimens, crosschecked by two uro-pathologists.",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": -9.4296875,
            "text": "tissue",
            "probability": 0.0
        },
        {
            "start_logit": -8.6875,
            "end_logit": -10.203125,
            "text": "prostate tissue specimens",
            "probability": 0.0
        },
        {
            "start_logit": -8.6875,
            "end_logit": -10.2109375,
            "text": "prostate tissue specimens, crosschecked by two",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": -10.015625,
            "text": "tissue specimens, crosschecked by two uro-pathologists.",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": -10.203125,
            "text": "tissue specimens",
            "probability": 0.0
        },
        {
            "start_logit": -9.40625,
            "end_logit": -10.2109375,
            "text": "tissue specimens, crosschecked by two",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": -9.4296875,
            "text": "eason score (GS) and predominant Gleason pattern were determined in prostate biopsies and in prostate tissue",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_8": [
        {
            "start_logit": 6.3125,
            "end_logit": 7.234375,
            "text": "prostate cancer",
            "probability": 0.9990234375
        },
        {
            "start_logit": 6.3125,
            "end_logit": -0.7490234375,
            "text": "prostate",
            "probability": 0.00034046173095703125
        },
        {
            "start_logit": -2.412109375,
            "end_logit": 7.234375,
            "text": "cancer",
            "probability": 0.0001621246337890625
        },
        {
            "start_logit": -5.79296875,
            "end_logit": 7.234375,
            "text": "cribriform growth in Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate cancer",
            "probability": 5.4836273193359375e-06
        },
        {
            "start_logit": -8.09375,
            "end_logit": 7.234375,
            "text": "grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate cancer",
            "probability": 5.364418029785156e-07
        },
        {
            "start_logit": -8.796875,
            "end_logit": 7.234375,
            "text": "in Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate cancer",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -9.0234375,
            "end_logit": 7.234375,
            "text": "Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate cancer",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -9.671875,
            "end_logit": 7.234375,
            "text": "iform growth in Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate cancer",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 7.234375,
            "text": "briform growth in Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.9921875,
            "end_logit": 7.234375,
            "text": ", cribriform growth in Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.296875,
            "end_logit": 7.234375,
            "text": "growth in Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 7.234375,
            "text": "distant metastasis and disease-specific death in patients with Gleason score 7 prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.484375,
            "end_logit": 7.234375,
            "text": "score 7 prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 7.234375,
            "text": "with Gleason score 7 prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.3125,
            "end_logit": -9.640625,
            "text": "prostate cancer at radical prostatectomy.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.3125,
            "end_logit": -10.0859375,
            "text": "prostate cancer at radical prostatectomy",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -5.79296875,
            "end_logit": -0.7490234375,
            "text": "cribriform growth in Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -8.09375,
            "end_logit": -0.7490234375,
            "text": "grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -8.796875,
            "end_logit": -0.7490234375,
            "text": "in Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate",
            "probability": 0.0
        },
        {
            "start_logit": -9.0234375,
            "end_logit": -0.7490234375,
            "text": "Gleason grade 4 is a strong prognostic marker for distant metastasis and disease-specific death in patients with Gleason score 7 prostate",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_9": [
        {
            "start_logit": 10.65625,
            "end_logit": 11.15625,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -7.48046875,
            "text": "prostate adenocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.015625,
            "end_logit": 11.15625,
            "text": "Gleason pattern 5 (GP5) prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -9.4609375,
            "text": "prostate adenocarcinoma (PCa",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": 11.15625,
            "text": ") prostate",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": 11.15625,
            "text": "pattern 5 (GP5) prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -9.796875,
            "text": "prostate adenocarcinoma (PCa)",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 11.15625,
            "text": "(GP5) prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 11.15625,
            "text": "Accurate recognition of Gleason pattern 5 (GP5) prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -10.09375,
            "text": "prostate adenocarcinoma (PCa) on core biopsy (NBX) is critical because it is associated with disease progression and the worst clinical outcome.",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -10.1640625,
            "text": "prostate adenocarcinoma (",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -10.21875,
            "text": "prostate adenocarcinoma (PCa) on core biopsy (NBX)",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 11.15625,
            "text": "recognition of Gleason pattern 5 (GP5) prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -10.25,
            "text": "prostate adenocarcinoma (PCa) on core biopsy (NBX) is critical because it is associated with disease progression and the worst",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -10.3046875,
            "text": "prostate adenocarcinoma (PCa) on core biopsy (NBX",
            "probability": 0.0
        },
        {
            "start_logit": 10.65625,
            "end_logit": -10.3359375,
            "text": "prostate adenocarcinoma (PCa) on core biopsy (NB",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 11.15625,
            "text": "of Gleason pattern 5 (GP5) prostate",
            "probability": 0.0
        },
        {
            "start_logit": -9.015625,
            "end_logit": -7.48046875,
            "text": "Gleason pattern 5 (GP5) prostate adenocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": -7.48046875,
            "text": ") prostate adenocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.984375,
            "end_logit": -7.48046875,
            "text": "pattern 5 (GP5) prostate adenocarcinoma",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_10": [
        {
            "start_logit": 10.8203125,
            "end_logit": 11.4140625,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 10.8203125,
            "end_logit": -7.3359375,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": 10.8203125,
            "end_logit": -8.859375,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher",
            "probability": 0.0
        },
        {
            "start_logit": -10.2109375,
            "end_logit": 11.4140625,
            "text": "the first time that reelin is expressed in prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.8203125,
            "end_logit": -9.7109375,
            "text": "prostate cancer and not in benign prostate tissue",
            "probability": 0.0
        },
        {
            "start_logit": 10.8203125,
            "end_logit": -9.7890625,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly with increasing of single Gleason patterns.",
            "probability": 0.0
        },
        {
            "start_logit": 10.8203125,
            "end_logit": -9.8828125,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason",
            "probability": 0.0
        },
        {
            "start_logit": 10.8203125,
            "end_logit": -9.90625,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly with increasing of single Gleason patterns. This suggests reelin",
            "probability": 0.0
        },
        {
            "start_logit": 10.8203125,
            "end_logit": -9.96875,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly with increasing",
            "probability": 0.0
        },
        {
            "start_logit": 10.8203125,
            "end_logit": -10.0,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly with",
            "probability": 0.0
        },
        {
            "start_logit": 10.8203125,
            "end_logit": -10.0,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 11.4140625,
            "text": "in prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.8203125,
            "end_logit": -10.046875,
            "text": "prostate cancer and not in benign prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.8203125,
            "end_logit": -10.078125,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly",
            "probability": 0.0
        },
        {
            "start_logit": 10.8203125,
            "end_logit": -10.1015625,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score and correlates significantly with increasing of single Gleason",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 11.4140625,
            "text": "first time that reelin is expressed in prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.8203125,
            "end_logit": -10.125,
            "text": "prostate cancer and not in benign prostate tissue and its expression occurs in higher Gleason score",
            "probability": 0.0
        },
        {
            "start_logit": 10.8203125,
            "end_logit": -10.2265625,
            "text": "prostate cancer and not in benign prostate tissue and",
            "probability": 0.0
        },
        {
            "start_logit": -7.1328125,
            "end_logit": -8.859375,
            "text": "higher",
            "probability": 0.0
        },
        {
            "start_logit": -8.859375,
            "end_logit": -7.3359375,
            "text": "cancer",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_11": [
        {
            "start_logit": 10.609375,
            "end_logit": 11.5,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 10.609375,
            "end_logit": -7.6328125,
            "text": "prostate needle biopsy and radical prostatectomy cases with Gleason score 7 prostatic adenocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 11.5,
            "text": "of Gleason pattern 4 in the pathology reports of prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 11.5,
            "text": "of prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 11.5,
            "text": "grading system recommended from the International Society of Urological Pathology consensus conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 11.5,
            "text": "International Society of Urological Pathology consensus conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.609375,
            "end_logit": -9.8046875,
            "text": "prostate needle biopsy and radical prostatectomy cases with Gleason score 7",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 11.5,
            "text": "the percentage of Gleason pattern 4 in the pathology reports of prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 11.5,
            "text": "pattern 4 in the pathology reports of prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 11.5,
            "text": "the International Society of Urological Pathology consensus conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.609375,
            "end_logit": -9.8984375,
            "text": "prostate needle biopsy and radical prostatectomy cases with Gleason score 7 prostatic adenocarcinoma.",
            "probability": 0.0
        },
        {
            "start_logit": -10.796875,
            "end_logit": 11.5,
            "text": "the Gleason grading system recommended from the International Society of Urological Pathology consensus conference is recording the percentage of Gleason pattern 4 in the pathology reports of prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.609375,
            "end_logit": -10.078125,
            "text": "prostate needle biopsy and radical prostatectomy",
            "probability": 0.0
        },
        {
            "start_logit": 10.609375,
            "end_logit": -10.3359375,
            "text": "prostate needle biopsy and radical prostatectomy cases with Gleason",
            "probability": 0.0
        },
        {
            "start_logit": 10.609375,
            "end_logit": -10.359375,
            "text": "prostate needle biopsy",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": -7.6328125,
            "text": "prostatic adenocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.375,
            "end_logit": -7.6328125,
            "text": "with Gleason score 7 prostatic adenocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": -7.6328125,
            "text": "of Gleason pattern 4 in the pathology reports of prostate needle biopsy and radical prostatectomy cases with Gleason score 7 prostatic adenocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": -7.6328125,
            "text": "score 7 prostatic adenocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": -7.6328125,
            "text": "of prostate needle biopsy and radical prostatectomy cases with Gleason score 7 prostatic adenocarcinoma",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_12": [
        {
            "start_logit": 3.10546875,
            "end_logit": 11.03125,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": 11.03125,
            "text": "the prostate",
            "probability": 3.635883331298828e-06
        },
        {
            "start_logit": -9.7890625,
            "end_logit": 11.03125,
            "text": "adenocarcinoma of the prostate",
            "probability": 2.5033950805664062e-06
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 11.03125,
            "text": "of the prostate",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -10.328125,
            "end_logit": 11.03125,
            "text": "high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 11.03125,
            "text": "histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -10.875,
            "end_logit": 11.03125,
            "text": "of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -10.921875,
            "end_logit": 11.03125,
            "text": "score 8 to 10 adenocarcinoma of the prostate",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -10.984375,
            "end_logit": 11.03125,
            "text": "and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -11.0,
            "end_logit": 11.03125,
            "text": "patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -11.0078125,
            "end_logit": 11.03125,
            "text": "10 adenocarcinoma of the prostate",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 3.10546875,
            "end_logit": -9.171875,
            "text": "prostate in needle biopsy tissue",
            "probability": 0.0
        },
        {
            "start_logit": 3.10546875,
            "end_logit": -9.9296875,
            "text": "prostate in",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": -9.171875,
            "text": "the prostate in needle biopsy tissue",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": -9.171875,
            "text": "adenocarcinoma of the prostate in needle biopsy tissue",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": -9.171875,
            "text": "of the prostate in needle biopsy tissue",
            "probability": 0.0
        },
        {
            "start_logit": -9.7890625,
            "end_logit": -9.5,
            "text": "adenocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": -9.9296875,
            "text": "the prostate in",
            "probability": 0.0
        },
        {
            "start_logit": -10.328125,
            "end_logit": -9.171875,
            "text": "high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -9.171875,
            "text": "tissue",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_13": [
        {
            "start_logit": 10.828125,
            "end_logit": 11.6484375,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": 11.6484375,
            "text": "The Gleason score of prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.828125,
            "end_logit": -8.484375,
            "text": "prostate adenocarcinomas",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 11.6484375,
            "text": "of prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.828125,
            "end_logit": -9.40625,
            "text": "prostate adenocarcinomas is an important preoperative predictor of cancer behavior, and is used to help guide treatment.",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 11.6484375,
            "text": "score of prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 11.6484375,
            "text": "Gleason score of prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.828125,
            "end_logit": -10.140625,
            "text": "prostate adenocarcinomas is an important preoperative predictor of cancer behavior,",
            "probability": 0.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": -8.484375,
            "text": "The Gleason score of prostate adenocarcinomas",
            "probability": 0.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": -9.40625,
            "text": "The Gleason score of prostate adenocarcinomas is an important preoperative predictor of cancer behavior, and is used to help guide treatment.",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -8.484375,
            "text": "of prostate adenocarcinomas",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": -9.40625,
            "text": "cancer behavior, and is used to help guide treatment.",
            "probability": 0.0
        },
        {
            "start_logit": -9.09375,
            "end_logit": -10.140625,
            "text": "The Gleason score of prostate adenocarcinomas is an important preoperative predictor of cancer behavior,",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": -8.484375,
            "text": "score of prostate adenocarcinomas",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": -8.484375,
            "text": "Gleason score of prostate adenocarcinomas",
            "probability": 0.0
        },
        {
            "start_logit": -10.1484375,
            "end_logit": -9.40625,
            "text": "of prostate adenocarcinomas is an important preoperative predictor of cancer behavior, and is used to help guide treatment.",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -9.40625,
            "text": "used to help guide treatment.",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": -10.140625,
            "text": "cancer behavior,",
            "probability": 0.0
        },
        {
            "start_logit": -10.578125,
            "end_logit": -9.40625,
            "text": "treatment.",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": -9.40625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_14": [
        {
            "start_logit": 10.7421875,
            "end_logit": 11.78125,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": 11.78125,
            "text": "high Gleason score prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.7421875,
            "end_logit": -9.03125,
            "text": "prostate cancers",
            "probability": 0.0
        },
        {
            "start_logit": 10.7421875,
            "end_logit": -9.2421875,
            "text": "prostate cancers, we explored whether reelin expression is influenced by single Gleason patterns. While Gleason 3 patt",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.78125,
            "text": "in high Gleason score prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.7421875,
            "end_logit": -9.5703125,
            "text": "prostate cancers, we explored whether reelin expression is influenced by single Gleason patterns. While Gleason 3",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 11.78125,
            "text": "score prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 11.78125,
            "text": "found in high Gleason score prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.7421875,
            "end_logit": -9.9140625,
            "text": "prostate cancers, we explored",
            "probability": 0.0
        },
        {
            "start_logit": -10.953125,
            "end_logit": 11.78125,
            "text": "Gleason score prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.7421875,
            "end_logit": -10.046875,
            "text": "prostate cancers, we explored whether reelin expression is influenced by single Gleason patterns.",
            "probability": 0.0
        },
        {
            "start_logit": 10.7421875,
            "end_logit": -10.0546875,
            "text": "prostate cancers, we explored whether reelin expression is influenced",
            "probability": 0.0
        },
        {
            "start_logit": 10.7421875,
            "end_logit": -10.09375,
            "text": "prostate cancers, we explored whether reelin",
            "probability": 0.0
        },
        {
            "start_logit": 10.7421875,
            "end_logit": -10.171875,
            "text": "prostate cancers,",
            "probability": 0.0
        },
        {
            "start_logit": 10.7421875,
            "end_logit": -10.28125,
            "text": "prostate cancers, we explored whether reelin expression is",
            "probability": 0.0
        },
        {
            "start_logit": 10.7421875,
            "end_logit": -10.296875,
            "text": "prostate cancers, we",
            "probability": 0.0
        },
        {
            "start_logit": 10.7421875,
            "end_logit": -10.34375,
            "text": "prostate cancers, we explored whether reelin expression is influenced by single Gleason",
            "probability": 0.0
        },
        {
            "start_logit": 10.7421875,
            "end_logit": -10.34375,
            "text": "prostate cancers, we explored whether",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": -9.03125,
            "text": "high Gleason score prostate cancers",
            "probability": 0.0
        },
        {
            "start_logit": -9.03125,
            "end_logit": -9.2421875,
            "text": "high Gleason score prostate cancers, we explored whether reelin expression is influenced by single Gleason patterns. While Gleason 3 patt",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_15": [
        {
            "start_logit": 11.25,
            "end_logit": 11.4921875,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -8.8125,
            "text": "prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": 11.4921875,
            "text": "of prostate",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -9.7265625,
            "text": "prostate cancer would",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -9.8984375,
            "text": "prostate cancer would occur within Gleason scores 3 to 10",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -10.1796875,
            "text": "prostate cancer would occur",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -10.21875,
            "text": "prostate cancer would occur within",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -10.21875,
            "text": "prostate cancer would occur within Gleason scores 3 to 10 even though higher scores are usually considered more aggressive forms of prostate cancers.",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -10.2265625,
            "text": "prostate cancer would occur within Gleason scores 3 to 10 even though higher scores are usually considered more aggressive forms of prostate cancers. Since our study",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -10.2421875,
            "text": "prostate cancer would occur within Gleason scores 3 to 10 even though higher scores are usually considered more aggressive forms of prostate cancers. Since our",
            "probability": 0.0
        },
        {
            "start_logit": 11.25,
            "end_logit": -10.3359375,
            "text": "prostate cancer would occur within Gleason scores 3 to 10 even",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": -8.8125,
            "text": "of prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.3125,
            "end_logit": -9.7265625,
            "text": "li",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": -9.7265625,
            "text": "of prostate cancer would",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -8.8125,
            "text": "cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": -9.8984375,
            "text": "of prostate cancer would occur within Gleason scores 3 to 10",
            "probability": 0.0
        },
        {
            "start_logit": -9.96875,
            "end_logit": -9.7265625,
            "text": "more aggressive forms of prostate cancers. Since our study is based upon a very li",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": -10.1796875,
            "text": "of prostate cancer would occur",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": -10.21875,
            "text": "of prostate cancer would occur within",
            "probability": 0.0
        },
        {
            "start_logit": -9.53125,
            "end_logit": -10.21875,
            "text": "of prostate cancer would occur within Gleason scores 3 to 10 even though higher scores are usually considered more aggressive forms of prostate cancers.",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_16": [
        {
            "start_logit": 9.59375,
            "end_logit": 11.3125,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 11.3125,
            "text": "Most adenocarcinomas of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": 11.3125,
            "text": "the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": 11.3125,
            "text": "of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": 11.3125,
            "text": ": Most adenocarcinomas of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.4765625,
            "end_logit": 11.3125,
            "text": "OBJECTIVES: Most adenocarcinomas of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.671875,
            "end_logit": 11.3125,
            "text": "adenocarcinomas of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.703125,
            "text": "prostate with",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -9.859375,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -10.25,
            "text": "prostate with a Gleason score greater than 8",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -10.296875,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic extension",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -10.3125,
            "text": "prostate with a Gleason",
            "probability": 0.0
        },
        {
            "start_logit": 9.59375,
            "end_logit": -10.3359375,
            "text": "prostate with a Gleason score greater than 8 at radical prostatectomy have extraprostatic",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": -9.703125,
            "text": "Most adenocarcinomas of the prostate with",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": -9.703125,
            "text": "the prostate with",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": -9.859375,
            "text": "Most adenocarcinomas of the prostate with a Gleason score greater than 8 at radical prostatectomy",
            "probability": 0.0
        },
        {
            "start_logit": -9.9453125,
            "end_logit": -9.859375,
            "text": "the prostate with a Gleason score greater than 8 at radical prostatectomy",
            "probability": 0.0
        },
        {
            "start_logit": -10.1171875,
            "end_logit": -9.703125,
            "text": "of the prostate with",
            "probability": 0.0
        },
        {
            "start_logit": -10.203125,
            "end_logit": -9.703125,
            "text": ": Most adenocarcinomas of the prostate with",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": -9.859375,
            "text": "greater than 8 at radical prostatectomy",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_17": [
        {
            "start_logit": 10.2734375,
            "end_logit": 12.296875,
            "text": "prostate",
            "probability": 1.0
        },
        {
            "start_logit": -8.7578125,
            "end_logit": 12.296875,
            "text": "high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": 12.296875,
            "text": "adenocarcinoma of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -9.609375,
            "end_logit": 12.296875,
            "text": "the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 12.296875,
            "text": "of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 12.296875,
            "text": "score 8 to 10 adenocarcinoma of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 12.296875,
            "text": "histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 12.296875,
            "text": "of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.8828125,
            "end_logit": 12.296875,
            "text": "to 10 adenocarcinoma of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 12.296875,
            "text": "and unusual histologic patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 12.296875,
            "text": "10 adenocarcinoma of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 12.296875,
            "text": "patterns of high Gleason score 8 to 10 adenocarcinoma of the prostate",
            "probability": 0.0
        },
        {
            "start_logit": 10.2734375,
            "end_logit": -9.6953125,
            "text": "prostate in needle biopsy tissue",
            "probability": 0.0
        },
        {
            "start_logit": 10.2734375,
            "end_logit": -9.7265625,
            "text": "prostate in needle biopsy tissue.",
            "probability": 0.0
        },
        {
            "start_logit": 10.2734375,
            "end_logit": -10.2265625,
            "text": "prostate in",
            "probability": 0.0
        },
        {
            "start_logit": -8.7578125,
            "end_logit": -8.6796875,
            "text": "high Gleason score 8 to 10 adenocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": -8.6796875,
            "text": "adenocarcinoma",
            "probability": 0.0
        },
        {
            "start_logit": -8.7578125,
            "end_logit": -9.6953125,
            "text": "high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue",
            "probability": 0.0
        },
        {
            "start_logit": -8.7578125,
            "end_logit": -9.7265625,
            "text": "high Gleason score 8 to 10 adenocarcinoma of the prostate in needle biopsy tissue.",
            "probability": 0.0
        },
        {
            "start_logit": -8.7578125,
            "end_logit": -10.1171875,
            "text": "high Gleason",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_18": [
        {
            "start_logit": 8.453125,
            "end_logit": 7.18359375,
            "text": "prostate cancer",
            "probability": 0.998046875
        },
        {
            "start_logit": 8.453125,
            "end_logit": 1.095703125,
            "text": "prostate",
            "probability": 0.0022525787353515625
        },
        {
            "start_logit": -2.63671875,
            "end_logit": 7.18359375,
            "text": "cancer",
            "probability": 1.519918441772461e-05
        },
        {
            "start_logit": -7.953125,
            "end_logit": 7.18359375,
            "text": "in Gleason score 7 prostate cancer",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 8.453125,
            "end_logit": -9.234375,
            "text": "prostate cancer.",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.109375,
            "end_logit": 7.18359375,
            "text": "Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.765625,
            "end_logit": 7.18359375,
            "text": "Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -9.8984375,
            "end_logit": 7.18359375,
            "text": "score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 7.18359375,
            "text": "postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.4921875,
            "end_logit": 7.18359375,
            "text": "metastasis and disease-specific death in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.59375,
            "end_logit": 7.18359375,
            "text": "highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 7.18359375,
            "text": "iform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 7.18359375,
            "text": "for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.640625,
            "end_logit": 7.18359375,
            "text": "predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 7.18359375,
            "text": "and disease-specific death in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 7.18359375,
            "text": "disease-specific death in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.71875,
            "end_logit": 7.18359375,
            "text": "growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 7.18359375,
            "text": "briform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 7.18359375,
            "text": "7 prostate cancer",
            "probability": 0.0
        },
        {
            "start_logit": -7.953125,
            "end_logit": 1.095703125,
            "text": "in Gleason score 7 prostate",
            "probability": 0.0
        }
    ],
    "622b9d593a8413c653000095_19": [
        {
            "start_logit": 4.2890625,
            "end_logit": 4.45703125,
            "text": "prostate",
            "probability": 0.9990234375
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -3.548828125,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores for prostate",
            "probability": 0.0003325939178466797
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -4.078125,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores for prostate cancer",
            "probability": 0.00019538402557373047
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -8.7265625,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores for prostate cancer. These variations showed",
            "probability": 1.8477439880371094e-06
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -8.765625,
            "text": "prostate and benign prostatic hyperplasia",
            "probability": 1.7881393432617188e-06
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -9.046875,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -1.2646484375,
            "end_logit": -3.548828125,
            "text": "prostate",
            "probability": 1.3113021850585938e-06
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -9.2890625,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores for prostate cancer. These variations",
            "probability": 1.0728836059570312e-06
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -9.53125,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -9.6171875,
            "text": "prostate and benign prostatic hyperplasia (BPH",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -1.2646484375,
            "end_logit": -4.078125,
            "text": "prostate cancer",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -9.6953125,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas",
            "probability": 7.152557373046875e-07
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -9.734375,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores for prostate cancer. These",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -9.7734375,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores for prostate cancer.",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -9.78125,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -9.7890625,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -9.875,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 4.2890625,
            "end_logit": -9.9140625,
            "text": "prostate and benign prostatic hyperplasia (BPH) whereas they varied consistently within and between Gleason histologic scores for",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 4.45703125,
            "text": "normal prostate",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 4.45703125,
            "text": "in normal prostate",
            "probability": 2.384185791015625e-07
        }
    ],
    "516e7fda298dcd4e51000081_1": [
        {
            "start_logit": 14.2265625,
            "end_logit": 15.234375,
            "text": "adenosylmethionine",
            "probability": 1.0
        },
        {
            "start_logit": -1.9130859375,
            "end_logit": 15.234375,
            "text": "ionine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -2.306640625,
            "text": "adenosyl",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -4.97265625,
            "text": "adenosylmeth",
            "probability": 0.0
        },
        {
            "start_logit": -6.1796875,
            "end_logit": 15.234375,
            "text": "the adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -8.640625,
            "end_logit": 15.234375,
            "text": "methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.21875,
            "text": "adenosylmethionine methyl",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.265625,
            "text": "adenosylmethionine methyl donor, or a critical tyrosine predicted to interact with the substrate lysine epsilon-amino group",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 15.234375,
            "text": "the lysine-substrate binding pocket, the binding site for the adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 15.234375,
            "text": "binding site for the adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 15.234375,
            "text": "SET domain structures, the mutations likely affect either the lysine-substrate binding pocket, the binding site for the adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.5859375,
            "end_logit": 15.234375,
            "text": "the binding site for the adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 15.234375,
            "text": "for the adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.703125,
            "end_logit": 15.234375,
            "text": "binding pocket, the binding site for the adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 15.234375,
            "text": "-substrate binding pocket, the binding site for the adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 15.234375,
            "text": "domain structures, the mutations likely affect either the lysine-substrate binding pocket, the binding site for the adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.8125,
            "end_logit": 15.234375,
            "text": "lysine-substrate binding pocket, the binding site for the adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -9.9453125,
            "text": "adenosylmethionine methyl donor,",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -10.03125,
            "text": "adenosylmethionine methyl donor, or a critical tyrosine predicted to interact with the substrate lysine epsilon",
            "probability": 0.0
        },
        {
            "start_logit": 14.2265625,
            "end_logit": -10.109375,
            "text": "adenosylmethionine methyl donor",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_2": [
        {
            "start_logit": 6.52734375,
            "end_logit": -0.6865234375,
            "text": "methionine",
            "probability": 0.9921875
        },
        {
            "start_logit": 6.52734375,
            "end_logit": -6.25390625,
            "text": "methionine (Met) and S-adenosylmethionine (AdoMet) in a unique reaction catalyzed by Met S-methyltransferase (MMT",
            "probability": 0.0037937164306640625
        },
        {
            "start_logit": 6.52734375,
            "end_logit": -6.375,
            "text": "methionine (Met) and S-adenosylmethionine (AdoMet",
            "probability": 0.003360748291015625
        },
        {
            "start_logit": 6.52734375,
            "end_logit": -9.15625,
            "text": "methionine (Met)",
            "probability": 0.00020825862884521484
        },
        {
            "start_logit": 6.52734375,
            "end_logit": -9.765625,
            "text": "methionine (Met) and S-adenosylmethionine (AdoMet)",
            "probability": 0.00011324882507324219
        },
        {
            "start_logit": 6.52734375,
            "end_logit": -9.8359375,
            "text": "methionine (Met) and S-adenosylmethionine",
            "probability": 0.0001055598258972168
        },
        {
            "start_logit": 6.52734375,
            "end_logit": -9.953125,
            "text": "methionine (Met) and S-adenosylmethionine (AdoMet) in a unique",
            "probability": 9.387731552124023e-05
        },
        {
            "start_logit": -7.08203125,
            "end_logit": 1.9326171875,
            "text": "homocysteine",
            "probability": 1.6868114471435547e-05
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -0.6865234375,
            "text": "S-methylmethionine (SMM) from methionine",
            "probability": 3.159046173095703e-06
        },
        {
            "start_logit": -9.078125,
            "end_logit": 1.9326171875,
            "text": "from homocysteine",
            "probability": 2.3245811462402344e-06
        },
        {
            "start_logit": -9.53125,
            "end_logit": 1.9326171875,
            "text": "AdoMet) in a unique reaction catalyzed by Met S-methyltransferase (MMT). SMM serves as methyl donor for Met synthesis from homocysteine",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -9.5703125,
            "end_logit": 1.9326171875,
            "text": "(AdoMet) in a unique reaction catalyzed by Met S-methyltransferase (MMT). SMM serves as methyl donor for Met synthesis from homocysteine",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -7.453125,
            "end_logit": -0.6865234375,
            "text": "methylmethionine (SMM) from methionine",
            "probability": 8.344650268554688e-07
        },
        {
            "start_logit": -7.5859375,
            "end_logit": -0.6865234375,
            "text": "Angiosperms synthesize S-methylmethionine (SMM) from methionine",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -10.203125,
            "end_logit": 1.9326171875,
            "text": "as methyl donor for Met synthesis from homocysteine",
            "probability": 7.748603820800781e-07
        },
        {
            "start_logit": -9.75,
            "end_logit": -0.6865234375,
            "text": "methionine (SMM) from methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -7.08203125,
            "end_logit": -4.72265625,
            "text": "homocysteine, catalyzed by homocysteine S-methyltransferase (HMT).",
            "probability": 0.0
        },
        {
            "start_logit": -6.1328125,
            "end_logit": -6.375,
            "text": "S-methylmethionine (SMM) from methionine (Met) and S-adenosylmethionine (AdoMet",
            "probability": 0.0
        },
        {
            "start_logit": -7.5078125,
            "end_logit": -6.25390625,
            "text": "S-adenosylmethionine (AdoMet) in a unique reaction catalyzed by Met S-methyltransferase (MMT",
            "probability": 0.0
        },
        {
            "start_logit": -9.078125,
            "end_logit": -4.72265625,
            "text": "from homocysteine, catalyzed by homocysteine S-methyltransferase (HMT).",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_3": [
        {
            "start_logit": 13.03125,
            "end_logit": 13.765625,
            "text": "S-methylmethionine",
            "probability": 1.0
        },
        {
            "start_logit": -4.12890625,
            "end_logit": 13.765625,
            "text": "ionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.03125,
            "end_logit": -4.49609375,
            "text": "S",
            "probability": 0.0
        },
        {
            "start_logit": -5.3046875,
            "end_logit": 13.765625,
            "text": "methylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -5.53515625,
            "end_logit": 13.765625,
            "text": "Plants synthesize S-methylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -7.20703125,
            "text": "S-methylmethionine (",
            "probability": 0.0
        },
        {
            "start_logit": -8.359375,
            "end_logit": 13.765625,
            "text": "methionine",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -8.28125,
            "text": "S-methylmethionine (SMM) from S-adenosylmethionine (AdoMet",
            "probability": 0.0
        },
        {
            "start_logit": -9.515625,
            "end_logit": 13.765625,
            "text": "synthesize S-methylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -8.828125,
            "text": "S-methylmethionine (SMM) from S-adenosylmethionine (AdoMet), and methionine (Met) by a unique reaction and",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -9.234375,
            "text": "S-methylmethionine (SMM)",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -9.234375,
            "text": "S-methylmethionine (SMM) from S-adenosylmethionine (AdoMet)",
            "probability": 0.0
        },
        {
            "start_logit": -10.1015625,
            "end_logit": 13.765625,
            "text": "-methylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -9.453125,
            "text": "S-methylmeth",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -9.71875,
            "text": "S-methylmethionine (SMM) from S-adenosylmethionine (AdoMet), and methionine (Met) by a unique",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -9.78125,
            "text": "S-methylmethionine (SMM) from S-adenosylmethionine (AdoMet), and methionine",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -9.9140625,
            "text": "S-methylmethionine (SMM",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -9.9296875,
            "text": "S-methylmethionine (SMM) from S-adenosylmethionine (AdoMet), and methionine (Met)",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -9.96875,
            "text": "S-methylmethionine (SMM) from S-adenosylmethionine (AdoMet), and methionine (",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -10.0546875,
            "text": "S-methylmethionine (SMM) from S-adenosylmethionine (AdoMet), and methionine (Met) by a",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_4": [
        {
            "start_logit": 14.515625,
            "end_logit": 15.5,
            "text": "adenosylmethionine",
            "probability": 1.0
        },
        {
            "start_logit": -1.1142578125,
            "end_logit": 15.5,
            "text": "ionine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.515625,
            "end_logit": -1.7353515625,
            "text": "adenosyl",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.515625,
            "end_logit": -4.10546875,
            "text": "adenosylmeth",
            "probability": 0.0
        },
        {
            "start_logit": -6.45703125,
            "end_logit": 15.5,
            "text": "CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -7.63671875,
            "text": "adenosylmethionine and diminished histone methylation activity.",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": 15.5,
            "text": "the phosphorylated serine residue, the mutant CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -9.421875,
            "end_logit": 15.5,
            "text": "serine residue is mutated to glutamic acid, which mimics the phosphorylated serine residue, the mutant CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 15.5,
            "text": "donor adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 15.5,
            "text": "methionine",
            "probability": 0.0
        },
        {
            "start_logit": -9.734375,
            "end_logit": 15.5,
            "text": "mutant CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -9.796875,
            "end_logit": 15.5,
            "text": "the mutant CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 15.5,
            "text": "phosphorylated serine residue, the mutant CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.046875,
            "end_logit": 15.5,
            "text": "glutamic acid, which mimics the phosphorylated serine residue, the mutant CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 15.5,
            "text": "to glutamic acid, which mimics the phosphorylated serine residue, the mutant CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.28125,
            "text": "adenosylmethionine and",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": 15.5,
            "text": "M1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 15.5,
            "text": "mimics the phosphorylated serine residue, the mutant CARM1 exhibits diminished ability to bind the methyl donor adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.46875,
            "end_logit": 15.5,
            "text": "the methyl donor adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.515625,
            "end_logit": -9.96875,
            "text": "adenosylmethionine and diminished histone methylation",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_5": [
        {
            "start_logit": 14.5234375,
            "end_logit": 15.359375,
            "text": "S-adenosylmethionine",
            "probability": 1.0
        },
        {
            "start_logit": -1.4912109375,
            "end_logit": 15.359375,
            "text": "ionine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.5546875,
            "end_logit": 15.359375,
            "text": "adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -1.8798828125,
            "text": "S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -6.9296875,
            "end_logit": 15.359375,
            "text": "methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -6.19921875,
            "text": "S-adenosylmeth",
            "probability": 0.0
        },
        {
            "start_logit": -7.7890625,
            "end_logit": 15.359375,
            "text": "-adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -7.15625,
            "text": "S-adenosylmethionine (",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -7.18359375,
            "text": "S-adenosylmethionine (SAMe",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -7.35546875,
            "text": "S-",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -8.3984375,
            "text": "S-adenosylmethionine (SAMe),",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -8.4140625,
            "text": "S-adenosyl",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -8.5078125,
            "text": "S-adenosylmethionine (SAMe)",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.015625,
            "text": "S-adenosylmethionine (SAMe), the major methyl donor for DNA",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.078125,
            "text": "S-adenosylmethionine (SAMe), the major",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.3359375,
            "text": "S-adenosylmethionine (SAMe), the major methyl donor for DNA and histone methylation",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.4765625,
            "text": "S-adenosylmethionine (SAMe), the major methyl donor for DNA and histone methylation was fed with ethanol for 1mon",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.53125,
            "text": "S-adenosylmethionine (SAMe), the major methyl donor for DNA and histone methylation was fed with ethanol",
            "probability": 0.0
        },
        {
            "start_logit": -1.4912109375,
            "end_logit": -7.15625,
            "text": "ionine (",
            "probability": 0.0
        },
        {
            "start_logit": -1.4912109375,
            "end_logit": -7.18359375,
            "text": "ionine (SAMe",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_6": [
        {
            "start_logit": 14.3984375,
            "end_logit": 15.4453125,
            "text": "S-Adenosyl methionine",
            "probability": 1.0
        },
        {
            "start_logit": -1.220703125,
            "end_logit": 15.4453125,
            "text": "methionine",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -2.013671875,
            "text": "S",
            "probability": 0.0
        },
        {
            "start_logit": -6.6796875,
            "end_logit": 15.4453125,
            "text": "-Adenosyl methionine",
            "probability": 0.0
        },
        {
            "start_logit": -7.23046875,
            "end_logit": 15.4453125,
            "text": "Adenosyl methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -6.73046875,
            "text": "S-Adenosyl",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -7.70703125,
            "text": "S-Adenosyl methionine.",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": 15.4453125,
            "text": "the methyl group donor S-Adenosyl methionine",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": 15.4453125,
            "text": "donor S-Adenosyl methionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": 15.4453125,
            "text": "Ezh2 through direct binding to the enzyme and competing with the methyl group donor S-Adenosyl methionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": 15.4453125,
            "text": "methyl group donor S-Adenosyl methionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 15.4453125,
            "text": "the enzymatic activity of Ezh2 through direct binding to the enzyme and competing with the methyl group donor S-Adenosyl methionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 15.4453125,
            "text": "EI1, which inhibits the enzymatic activity of Ezh2 through direct binding to the enzyme and competing with the methyl group donor S-Adenosyl methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.3984375,
            "end_logit": -9.78125,
            "text": "S-",
            "probability": 0.0
        },
        {
            "start_logit": -1.220703125,
            "end_logit": -7.70703125,
            "text": "methionine.",
            "probability": 0.0
        },
        {
            "start_logit": -9.546875,
            "end_logit": -2.013671875,
            "text": "the methyl group donor S",
            "probability": 0.0
        },
        {
            "start_logit": -9.921875,
            "end_logit": -2.013671875,
            "text": "donor S",
            "probability": 0.0
        },
        {
            "start_logit": -10.2734375,
            "end_logit": -2.013671875,
            "text": "Ezh2 through direct binding to the enzyme and competing with the methyl group donor S",
            "probability": 0.0
        },
        {
            "start_logit": -10.515625,
            "end_logit": -2.013671875,
            "text": "methyl group donor S",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": -2.013671875,
            "text": "the enzymatic activity of Ezh2 through direct binding to the enzyme and competing with the methyl group donor S",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_7": [
        {
            "start_logit": 14.59375,
            "end_logit": 15.6328125,
            "text": "S-adenosyl-l-methionine",
            "probability": 1.0
        },
        {
            "start_logit": -0.33154296875,
            "end_logit": 15.6328125,
            "text": "methionine",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 14.59375,
            "end_logit": -1.638671875,
            "text": "S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -2.767578125,
            "end_logit": 15.6328125,
            "text": "adenosyl-l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -3.931640625,
            "text": "S-adenosyl-l-methionine (SAM",
            "probability": 0.0
        },
        {
            "start_logit": -7.1015625,
            "end_logit": 15.6328125,
            "text": "-adenosyl-l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": -7.6328125,
            "end_logit": 15.6328125,
            "text": "-l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -6.76953125,
            "text": "S-adenosyl-l-methionine (SAM) as the methyl donor.",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -6.90625,
            "text": "S-adenosyl-l-methionine (",
            "probability": 0.0
        },
        {
            "start_logit": -8.5078125,
            "end_logit": 15.6328125,
            "text": "-methionine",
            "probability": 0.0
        },
        {
            "start_logit": -8.7734375,
            "end_logit": 15.6328125,
            "text": "The enzyme was capable of transferring methyl groups to selected lysine residues in a substrate protein using S-adenosyl-l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": -8.8515625,
            "end_logit": 15.6328125,
            "text": "using S-adenosyl-l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 15.6328125,
            "text": "transferring methyl groups to selected lysine residues in a substrate protein using S-adenosyl-l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -8.3359375,
            "text": "S-adenosyl-l",
            "probability": 0.0
        },
        {
            "start_logit": -9.6796875,
            "end_logit": 15.6328125,
            "text": "l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -8.9140625,
            "text": "S-adenosyl",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -9.0390625,
            "text": "S-adenosyl-l-methionine (SAM)",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 15.6328125,
            "text": "methyl groups to selected lysine residues in a substrate protein using S-adenosyl-l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 15.6328125,
            "text": "enzyme was capable of transferring methyl groups to selected lysine residues in a substrate protein using S-adenosyl-l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.59375,
            "end_logit": -9.34375,
            "text": "S-adenosyl-l-methionine (SAM) as the methyl",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_8": [
        {
            "start_logit": 11.09375,
            "end_logit": 11.90625,
            "text": "SAM",
            "probability": 1.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -3.72265625,
            "text": "SAM is the main methyl group donor for methyltransferases to modify DNA, RNA, protein, metabolites, or phospholipid target substrates.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.09375,
            "end_logit": -9.046875,
            "text": "SAM is the main",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -9.3515625,
            "text": "SAM is the main methyl group donor for methyltransferases to modify DNA, RNA, protein, metabolites, or phospholipid target substrates",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -9.578125,
            "text": "SAM is the main methyl group donor for methyltransferases to modify DNA, RNA, protein, metabolites, or phospholipid",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -9.8515625,
            "text": "SAM is",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -9.9296875,
            "text": "SAM is the main methyl group donor for methyltransferases to modify DNA, RNA",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -9.9453125,
            "text": "SAM is the main methyl group donor for",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -9.984375,
            "text": "SAM is the main methyl group donor for methyltransferases to modify",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -9.9921875,
            "text": "SAM is the main methyl group donor for methyltransferases to modify DNA",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -9.9921875,
            "text": "SAM is the main methyl group donor for methyltransferases",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.1015625,
            "text": "SAM is the main methyl group donor for methyltransferases to modify DNA, RNA, protein, metabolites",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.1171875,
            "text": "SAM is the main methyl group donor for methyltransferase",
            "probability": 0.0
        },
        {
            "start_logit": 11.09375,
            "end_logit": -10.1171875,
            "text": "SAM is the main methyl group donor for methyltransferases to modify DNA, RNA, protein, metabolites, or phospholipid target",
            "probability": 0.0
        },
        {
            "start_logit": -8.5390625,
            "end_logit": -3.72265625,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": -3.72265625,
            "text": "methyl group donor for methyltransferases to modify DNA, RNA, protein, metabolites, or phospholipid target substrates.",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": -3.72265625,
            "text": "phospholipid target substrates.",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": -3.72265625,
            "text": "the main methyl group donor for methyltransferases to modify DNA, RNA, protein, metabolites, or phospholipid target substrates.",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": -3.72265625,
            "text": "target substrates.",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": -3.72265625,
            "text": "is the main methyl group donor for methyltransferases to modify DNA, RNA, protein, metabolites, or phospholipid target substrates.",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_9": [
        {
            "start_logit": 14.640625,
            "end_logit": 15.609375,
            "text": "S-adenosyl-l-methionine",
            "probability": 1.0
        },
        {
            "start_logit": -0.38330078125,
            "end_logit": 15.609375,
            "text": "methionine",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": -2.3046875,
            "end_logit": 15.609375,
            "text": "adenosyl-l-methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.640625,
            "end_logit": -1.498046875,
            "text": "S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.640625,
            "end_logit": -4.24609375,
            "text": "S-adenosyl-l-methionine (",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -4.50390625,
            "text": "S-adenosyl-l-methionine (SAM",
            "probability": 0.0
        },
        {
            "start_logit": -7.1640625,
            "end_logit": 15.609375,
            "text": "-adenosyl-l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 15.609375,
            "text": "-l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": -8.484375,
            "end_logit": 15.609375,
            "text": "-methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -7.859375,
            "text": "S-",
            "probability": 0.0
        },
        {
            "start_logit": -9.4375,
            "end_logit": 15.609375,
            "text": "l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -8.4765625,
            "text": "S-adenosyl-l-methionine (SAM) analogue",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -8.515625,
            "text": "S-adenosyl-l-methionine (SAM)",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -8.859375,
            "text": "S-adenosyl-l",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -9.0625,
            "text": "S-adenosyl",
            "probability": 0.0
        },
        {
            "start_logit": -10.1953125,
            "end_logit": 15.609375,
            "text": "vSET in vivo with an engineered S-adenosyl-l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -9.34375,
            "text": "S-adenosyl-",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 15.609375,
            "text": "an engineered S-adenosyl-l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 15.609375,
            "text": "engineered S-adenosyl-l-methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.640625,
            "end_logit": -9.578125,
            "text": "S-adenosyl-l-",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_10": [
        {
            "start_logit": 10.6640625,
            "end_logit": 11.90625,
            "text": "SAM",
            "probability": 1.0
        },
        {
            "start_logit": 10.6640625,
            "end_logit": -5.96875,
            "text": "SAM as the methyl donor.",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": 11.90625,
            "text": "protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": 11.90625,
            "text": "with SAM",
            "probability": 0.0
        },
        {
            "start_logit": -8.65625,
            "end_logit": 11.90625,
            "text": "arginine methylation, is catalyzed by protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 0.0
        },
        {
            "start_logit": -10.125,
            "end_logit": 11.90625,
            "text": "One of the well-studied PTMs, arginine methylation, is catalyzed by protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 11.90625,
            "text": "methylation, is catalyzed by protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": 11.90625,
            "text": "PTMs, arginine methylation, is catalyzed by protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 11.90625,
            "text": ", arginine methylation, is catalyzed by protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 11.90625,
            "text": "by protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 11.90625,
            "text": "studied PTMs, arginine methylation, is catalyzed by protein arginine methyltransferases (PRMTs) with SAM",
            "probability": 0.0
        },
        {
            "start_logit": 10.6640625,
            "end_logit": -10.0234375,
            "text": "SAM as the methyl",
            "probability": 0.0
        },
        {
            "start_logit": 10.6640625,
            "end_logit": -10.1171875,
            "text": "SAM as the methyl donor",
            "probability": 0.0
        },
        {
            "start_logit": -8.3828125,
            "end_logit": -5.96875,
            "text": "protein arginine methyltransferases (PRMTs) with SAM as the methyl donor.",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": -5.96875,
            "text": "with SAM as the methyl donor.",
            "probability": 0.0
        },
        {
            "start_logit": -8.65625,
            "end_logit": -5.96875,
            "text": "arginine methylation, is catalyzed by protein arginine methyltransferases (PRMTs) with SAM as the methyl donor.",
            "probability": 0.0
        },
        {
            "start_logit": -8.8984375,
            "end_logit": -5.96875,
            "text": ".",
            "probability": 0.0
        },
        {
            "start_logit": -9.8125,
            "end_logit": -5.96875,
            "text": "methyl donor.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -5.96875,
            "text": "the methyl donor.",
            "probability": 0.0
        },
        {
            "start_logit": -10.0625,
            "end_logit": -5.96875,
            "text": "as the methyl donor.",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_11": [
        {
            "start_logit": 14.5078125,
            "end_logit": 15.40625,
            "text": "S-adenosylmethionine",
            "probability": 1.0
        },
        {
            "start_logit": -1.501953125,
            "end_logit": 15.40625,
            "text": "ionine",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -2.46875,
            "end_logit": 15.40625,
            "text": "adenosylmethionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -1.8828125,
            "text": "S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -4.5625,
            "text": "S-adenosylmeth",
            "probability": 0.0
        },
        {
            "start_logit": -5.75390625,
            "end_logit": 15.40625,
            "text": "cytochrome can act as a methyl acceptor for a methyltransferase activity in the cell extract that uses S-adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -6.2421875,
            "end_logit": 15.40625,
            "text": "uses S-adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -5.40234375,
            "text": "S-adenosylmethionine as methyl donor.",
            "probability": 0.0
        },
        {
            "start_logit": -7.09375,
            "end_logit": 15.40625,
            "text": "methionine",
            "probability": 0.0
        },
        {
            "start_logit": -7.60546875,
            "end_logit": 15.40625,
            "text": "The purified cytochrome can act as a methyl acceptor for a methyltransferase activity in the cell extract that uses S-adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -7.96875,
            "end_logit": 15.40625,
            "text": "-adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -7.2421875,
            "text": "S-",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -7.72265625,
            "text": "S-adenosyl",
            "probability": 0.0
        },
        {
            "start_logit": 14.5078125,
            "end_logit": -8.6171875,
            "text": "S-adenosylmethionine as",
            "probability": 0.0
        },
        {
            "start_logit": -9.6015625,
            "end_logit": 15.40625,
            "text": "methyl acceptor for a methyltransferase activity in the cell extract that uses S-adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -9.671875,
            "end_logit": 15.40625,
            "text": "cell extract that uses S-adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.40625,
            "end_logit": 15.40625,
            "text": "the cell extract that uses S-adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.625,
            "end_logit": 15.40625,
            "text": "purified cytochrome can act as a methyl acceptor for a methyltransferase activity in the cell extract that uses S-adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 15.40625,
            "text": "in the cell extract that uses S-adenosylmethionine",
            "probability": 0.0
        },
        {
            "start_logit": -10.7578125,
            "end_logit": 15.40625,
            "text": "a methyltransferase activity in the cell extract that uses S-adenosylmethionine",
            "probability": 0.0
        }
    ],
    "516e7fda298dcd4e51000081_12": [
        {
            "start_logit": 14.5703125,
            "end_logit": 15.5546875,
            "text": "S-adenosyl-L-methionine",
            "probability": 1.0
        },
        {
            "start_logit": -0.78466796875,
            "end_logit": 15.5546875,
            "text": "methionine",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -2.109375,
            "end_logit": 15.5546875,
            "text": "adenosyl-L-methionine",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -1.7021484375,
            "text": "S",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -5.578125,
            "text": "S-adenosyl-L-methionine as the methyl donor.",
            "probability": 0.0
        },
        {
            "start_logit": -7.3671875,
            "end_logit": 15.5546875,
            "text": "-L-methionine",
            "probability": 0.0
        },
        {
            "start_logit": -7.70703125,
            "end_logit": 15.5546875,
            "text": "-adenosyl-L-methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -6.765625,
            "text": "S-adenosyl-L",
            "probability": 0.0
        },
        {
            "start_logit": -8.2734375,
            "end_logit": 15.5546875,
            "text": "-methionine",
            "probability": 0.0
        },
        {
            "start_logit": -8.7109375,
            "end_logit": 15.5546875,
            "text": "L-methionine",
            "probability": 0.0
        },
        {
            "start_logit": -9.2578125,
            "end_logit": 15.5546875,
            "text": "This enzyme utilizes S-adenosyl-L-methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -8.2890625,
            "text": "S-adenosyl-L-methionine as the methyl",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -8.4296875,
            "text": "S-adenosyl-L-methionine as",
            "probability": 0.0
        },
        {
            "start_logit": -9.5859375,
            "end_logit": 15.5546875,
            "text": "utilizes S-adenosyl-L-methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -8.796875,
            "text": "S-adenosyl-L-",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -8.8359375,
            "text": "S-adenosyl-L-methionine as the",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -8.8984375,
            "text": "S-adenosyl-",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -8.96875,
            "text": "S-adenosyl",
            "probability": 0.0
        },
        {
            "start_logit": -10.21875,
            "end_logit": 15.5546875,
            "text": "enzyme utilizes S-adenosyl-L-methionine",
            "probability": 0.0
        },
        {
            "start_logit": 14.5703125,
            "end_logit": -9.40625,
            "text": "S-adenosyl-L-methionine as the methyl donor",
            "probability": 0.0
        }
    ],
    "602598101cb411341a0000ae_1": [
        {
            "start_logit": 14.171875,
            "end_logit": 15.328125,
            "text": "disease-modifying antirheumatic drugs",
            "probability": 1.0
        },
        {
            "start_logit": -1.46875,
            "end_logit": 15.328125,
            "text": "drugs",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 14.171875,
            "end_logit": -2.78125,
            "text": "disease",
            "probability": 0.0
        },
        {
            "start_logit": -7.1484375,
            "end_logit": 15.328125,
            "text": "modifying antirheumatic drugs",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -6.1484375,
            "text": "disease-modifying antirheumatic",
            "probability": 0.0
        },
        {
            "start_logit": -7.609375,
            "end_logit": 15.328125,
            "text": "antirheumatic drugs",
            "probability": 0.0
        },
        {
            "start_logit": -7.72265625,
            "end_logit": 15.328125,
            "text": "targeted synthetic disease-modifying antirheumatic drugs",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": 15.328125,
            "text": "-modifying antirheumatic drugs",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -7.52734375,
            "text": "disease-modifying antirheumatic drugs (",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -7.5390625,
            "text": "disease-modifying",
            "probability": 0.0
        },
        {
            "start_logit": -9.015625,
            "end_logit": 15.328125,
            "text": "synthetic disease-modifying antirheumatic drugs",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": 15.328125,
            "text": "biological and targeted synthetic disease-modifying antirheumatic drugs",
            "probability": 0.0
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 15.328125,
            "text": "that biological and targeted synthetic disease-modifying antirheumatic drugs",
            "probability": 0.0
        },
        {
            "start_logit": -10.3359375,
            "end_logit": 15.328125,
            "text": "matic drugs",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 15.328125,
            "text": "eumatic drugs",
            "probability": 0.0
        },
        {
            "start_logit": -10.4140625,
            "end_logit": 15.328125,
            "text": "and targeted synthetic disease-modifying antirheumatic drugs",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -9.2734375,
            "text": "disease-modifying anti",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -9.75,
            "text": "disease-modifying antirheumatic drugs (b/tsDMARDs) should",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -9.8828125,
            "text": "disease-modifying antirheu",
            "probability": 0.0
        },
        {
            "start_logit": 14.171875,
            "end_logit": -9.90625,
            "text": "disease-modifying antirheumatic drugs (b/tsDMARDs) should be used in combination with methotrexate in the treatment of rheumatoid arthritis",
            "probability": 0.0
        }
    ],
    "626aeab6e764a5320400003e_1": [
        {
            "start_logit": 14.1875,
            "end_logit": 15.015625,
            "text": "In May 2019",
            "probability": 1.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": 15.015625,
            "text": "2019",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": 14.1875,
            "end_logit": -2.607421875,
            "text": "In",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -6.6328125,
            "text": "In May",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": 15.015625,
            "text": "May 2019",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -8.4140625,
            "text": "In May 2019, volanesorsen was approved in the EU for the treatment of adult patients with FCS",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -9.1484375,
            "text": "In May 2019,",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -10.046875,
            "text": "In May 2019, volanesorsen was",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -10.0546875,
            "text": "In May 2019, volanesorsen was approved in the EU for the treatment of adult patients with",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -10.1171875,
            "text": "In May 2019, volanesorsen was approved in the EU",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -10.265625,
            "text": "In May 2019, volanesorsen was approved in the EU for the treatment of adult patients with FCS based",
            "probability": 0.0
        },
        {
            "start_logit": 14.1875,
            "end_logit": -10.3828125,
            "text": "In May 2019, volanesorsen was approved in the EU for",
            "probability": 0.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": -8.4140625,
            "text": "2019, volanesorsen was approved in the EU for the treatment of adult patients with FCS",
            "probability": 0.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": -9.1484375,
            "text": "2019,",
            "probability": 0.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": -10.046875,
            "text": "2019, volanesorsen was",
            "probability": 0.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": -10.0546875,
            "text": "2019, volanesorsen was approved in the EU for the treatment of adult patients with",
            "probability": 0.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": -10.1171875,
            "text": "2019, volanesorsen was approved in the EU",
            "probability": 0.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": -10.265625,
            "text": "2019, volanesorsen was approved in the EU for the treatment of adult patients with FCS based",
            "probability": 0.0
        },
        {
            "start_logit": -1.17578125,
            "end_logit": -10.3828125,
            "text": "2019, volanesorsen was approved in the EU for",
            "probability": 0.0
        },
        {
            "start_logit": -8.1875,
            "end_logit": -6.6328125,
            "text": "May",
            "probability": 0.0
        }
    ],
    "601db60e1cb411341a000049_1": [
        {
            "start_logit": 8.5,
            "end_logit": 12.921875,
            "text": "chromosome D2",
            "probability": 1.0
        },
        {
            "start_logit": -1.9912109375,
            "end_logit": 12.921875,
            "text": "on chromosome D2",
            "probability": 2.777576446533203e-05
        },
        {
            "start_logit": -5.85546875,
            "end_logit": 12.921875,
            "text": "D2",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": -10.5625,
            "end_logit": 12.921875,
            "text": "3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 12.921875,
            "text": "for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": 12.921875,
            "text": "-99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -10.7109375,
            "end_logit": 12.921875,
            "text": "SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -10.765625,
            "end_logit": 12.921875,
            "text": "99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -10.8203125,
            "end_logit": 12.921875,
            "text": "21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 12.921875,
            "text": "(95.87-99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 12.921875,
            "text": "a genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 12.921875,
            "text": ".87-99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 12.921875,
            "text": "genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -11.0,
            "end_logit": 12.921875,
            "text": "Linkage mapping defined a genomic region for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -11.0234375,
            "end_logit": 12.921875,
            "text": "-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": 8.5,
            "end_logit": -7.484375,
            "text": "chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -1.9912109375,
            "end_logit": -7.484375,
            "text": "on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -10.5625,
            "end_logit": -7.484375,
            "text": "3-Mb region, (95.87-99.21 Mb) on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": -7.484375,
            "text": "for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -10.6484375,
            "end_logit": -7.484375,
            "text": "-99.21 Mb) on chromosome",
            "probability": 0.0
        }
    ],
    "601db60e1cb411341a000049_2": [
        {
            "start_logit": 11.640625,
            "end_logit": 14.171875,
            "text": "chromosome D2",
            "probability": 1.0
        },
        {
            "start_logit": -3.990234375,
            "end_logit": 14.171875,
            "text": "D2",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 11.640625,
            "end_logit": -4.74609375,
            "text": "chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -7.3125,
            "end_logit": 14.171875,
            "text": "on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": 14.171875,
            "text": "-99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -9.0,
            "text": "chromosome D2, (peak logarithm of the odds = 10.5,",
            "probability": 0.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -9.6953125,
            "text": "chromosome D2,",
            "probability": 0.0
        },
        {
            "start_logit": 11.640625,
            "end_logit": -9.78125,
            "text": "chromosome D2, (peak logarithm of the odds = 10",
            "probability": 0.0
        },
        {
            "start_logit": -7.3125,
            "end_logit": -4.74609375,
            "text": "on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -3.990234375,
            "end_logit": -9.0,
            "text": "D2, (peak logarithm of the odds = 10.5,",
            "probability": 0.0
        },
        {
            "start_logit": -3.990234375,
            "end_logit": -9.6953125,
            "text": "D2,",
            "probability": 0.0
        },
        {
            "start_logit": -3.990234375,
            "end_logit": -9.78125,
            "text": "D2, (peak logarithm of the odds = 10",
            "probability": 0.0
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -4.74609375,
            "text": "-99.21 Mb) on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -7.3125,
            "end_logit": -9.0,
            "text": "on chromosome D2, (peak logarithm of the odds = 10.5,",
            "probability": 0.0
        },
        {
            "start_logit": -9.84375,
            "end_logit": -6.515625,
            "text": "chromosome 10 in the human genome. In the dom",
            "probability": 0.0
        },
        {
            "start_logit": -10.078125,
            "end_logit": -6.515625,
            "text": "dom",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": -6.515625,
            "text": "In the dom",
            "probability": 0.0
        },
        {
            "start_logit": -7.3125,
            "end_logit": -9.6953125,
            "text": "on chromosome D2,",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -6.515625,
            "text": "on chromosome 10 in the human genome. In the dom",
            "probability": 0.0
        },
        {
            "start_logit": -7.3125,
            "end_logit": -9.78125,
            "text": "on chromosome D2, (peak logarithm of the odds = 10",
            "probability": 0.0
        }
    ],
    "601db60e1cb411341a000049_3": [
        {
            "start_logit": 10.5078125,
            "end_logit": 14.015625,
            "text": "chromosome D2",
            "probability": 1.0
        },
        {
            "start_logit": -4.1640625,
            "end_logit": 14.015625,
            "text": "D2",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -6.62109375,
            "end_logit": 14.015625,
            "text": "on chromosome D2",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -5.62890625,
            "text": "chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 14.015625,
            "text": "-99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.015625,
            "text": "(95.87-99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -10.78125,
            "end_logit": 14.015625,
            "text": "for SILVER as a 3.3-Mb region, (95.87-99.21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": -10.8046875,
            "end_logit": 14.015625,
            "text": "21 Mb) on chromosome D2",
            "probability": 0.0
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -9.375,
            "text": "chromosome D2, (peak logarithm of the odds = 10.5,",
            "probability": 0.0
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -9.703125,
            "text": "chromosome D2, (peak logarithm of the odds = 10",
            "probability": 0.0
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -9.78125,
            "text": "chromosome D2,",
            "probability": 0.0
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -10.0703125,
            "text": "chromosome D2, (peak logarithm of the odds = 10.",
            "probability": 0.0
        },
        {
            "start_logit": 10.5078125,
            "end_logit": -10.078125,
            "text": "chromosome D2, (peak logarithm of the odds = 10.5, = 0), which displays conserved synteny",
            "probability": 0.0
        },
        {
            "start_logit": -6.62109375,
            "end_logit": -5.62890625,
            "text": "on chromosome",
            "probability": 0.0
        },
        {
            "start_logit": -4.1640625,
            "end_logit": -9.375,
            "text": "D2, (peak logarithm of the odds = 10.5,",
            "probability": 0.0
        },
        {
            "start_logit": -4.1640625,
            "end_logit": -9.703125,
            "text": "D2, (peak logarithm of the odds = 10",
            "probability": 0.0
        },
        {
            "start_logit": -4.1640625,
            "end_logit": -9.78125,
            "text": "D2,",
            "probability": 0.0
        },
        {
            "start_logit": -4.1640625,
            "end_logit": -10.0703125,
            "text": "D2, (peak logarithm of the odds = 10.",
            "probability": 0.0
        },
        {
            "start_logit": -4.1640625,
            "end_logit": -10.078125,
            "text": "D2, (peak logarithm of the odds = 10.5, = 0), which displays conserved synteny",
            "probability": 0.0
        },
        {
            "start_logit": -6.62109375,
            "end_logit": -9.375,
            "text": "on chromosome D2, (peak logarithm of the odds = 10.5,",
            "probability": 0.0
        }
    ],
    "5c61f767e842deac67000007_1": [
        {
            "start_logit": 14.2734375,
            "end_logit": 15.3046875,
            "text": "Telomerecat",
            "probability": 1.0
        },
        {
            "start_logit": -1.587890625,
            "end_logit": 15.3046875,
            "text": "t",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -2.7109375,
            "text": "Telomere",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -3.529296875,
            "text": "Telomereca",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -6.25390625,
            "text": "Telomerecat:",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": 15.3046875,
            "text": "cat",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.4765625,
            "text": "Telomerecat: A ploidy",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.4921875,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.875,
            "text": "Telomerecat: A ploidy-agnostic method",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -9.9921875,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -10.0546875,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length",
            "probability": 0.0
        },
        {
            "start_logit": 14.2734375,
            "end_logit": -10.1015625,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data",
            "probability": 0.0
        },
        {
            "start_logit": -1.587890625,
            "end_logit": -6.25390625,
            "text": "t:",
            "probability": 0.0
        },
        {
            "start_logit": -1.587890625,
            "end_logit": -9.4765625,
            "text": "t: A ploidy",
            "probability": 0.0
        },
        {
            "start_logit": -1.587890625,
            "end_logit": -9.4921875,
            "text": "t: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.",
            "probability": 0.0
        },
        {
            "start_logit": -1.587890625,
            "end_logit": -9.875,
            "text": "t: A ploidy-agnostic method",
            "probability": 0.0
        },
        {
            "start_logit": -1.587890625,
            "end_logit": -9.9921875,
            "text": "t: A ploidy-agnostic method for estimating telomere length from whole genome sequencing",
            "probability": 0.0
        },
        {
            "start_logit": -1.587890625,
            "end_logit": -10.0546875,
            "text": "t: A ploidy-agnostic method for estimating telomere length",
            "probability": 0.0
        },
        {
            "start_logit": -1.587890625,
            "end_logit": -10.1015625,
            "text": "t: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data",
            "probability": 0.0
        },
        {
            "start_logit": -8.28125,
            "end_logit": -3.529296875,
            "text": "ca",
            "probability": 0.0
        }
    ],
    "5c61f767e842deac67000007_2": [
        {
            "start_logit": 14.5234375,
            "end_logit": 15.390625,
            "text": "Telomerecat",
            "probability": 1.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -0.4326171875,
            "text": "Telomereca",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -1.3076171875,
            "end_logit": 15.390625,
            "text": "t",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -2.0234375,
            "text": "Telomere",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -8.4921875,
            "text": "Telomerecat,",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": 15.390625,
            "text": "cat",
            "probability": 0.0
        },
        {
            "start_logit": 14.5234375,
            "end_logit": -9.4453125,
            "text": "Telomerecat, a novel",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": 15.390625,
            "text": "present Telomerecat",
            "probability": 0.0
        },
        {
            "start_logit": -1.3076171875,
            "end_logit": -8.4921875,
            "text": "t,",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": -0.4326171875,
            "text": "ca",
            "probability": 0.0
        },
        {
            "start_logit": -1.3076171875,
            "end_logit": -9.4453125,
            "text": "t, a novel",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": -0.4326171875,
            "text": "present Telomereca",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": -2.0234375,
            "text": "present Telomere",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": -8.4921875,
            "text": "cat,",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": -8.4921875,
            "text": "present Telomerecat,",
            "probability": 0.0
        },
        {
            "start_logit": -9.625,
            "end_logit": -9.4453125,
            "text": "cat, a novel",
            "probability": 0.0
        },
        {
            "start_logit": -10.390625,
            "end_logit": -9.4453125,
            "text": "present Telomerecat, a novel",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -9.984375,
            "text": "Telomerecat performs well at telomere length estimation when compared to leading experimental and computational methods. Furthermore, we show that it detects expected patterns in",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -9.984375,
            "text": "Telomerecat performs well at telomere length estimation",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": -10.0234375,
            "text": "Telomerecat performs well at telomere length estimation when compared to leading experimental and computational methods. Furthermore, we show that it detects expected patterns in longitudinal",
            "probability": 0.0
        }
    ],
    "5c61f767e842deac67000007_3": [
        {
            "start_logit": 14.328125,
            "end_logit": 15.3125,
            "text": "Telomerecat",
            "probability": 1.0
        },
        {
            "start_logit": -1.5341796875,
            "end_logit": 15.3125,
            "text": "t",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 14.328125,
            "end_logit": -2.615234375,
            "text": "Telomere",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -3.4921875,
            "text": "Telomereca",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -6.45703125,
            "text": "Telomerecat:",
            "probability": 0.0
        },
        {
            "start_logit": -8.6328125,
            "end_logit": 15.3125,
            "text": "cat",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -9.671875,
            "text": "Telomerecat: A ploidy",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -10.0625,
            "text": "Telomerecat: A ploidy-agnostic method",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -10.2109375,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.Telomere length is a risk",
            "probability": 0.0
        },
        {
            "start_logit": 14.328125,
            "end_logit": -10.2265625,
            "text": "Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing",
            "probability": 0.0
        },
        {
            "start_logit": -1.5341796875,
            "end_logit": -6.45703125,
            "text": "t:",
            "probability": 0.0
        },
        {
            "start_logit": -1.5341796875,
            "end_logit": -9.671875,
            "text": "t: A ploidy",
            "probability": 0.0
        },
        {
            "start_logit": -1.5341796875,
            "end_logit": -10.0625,
            "text": "t: A ploidy-agnostic method",
            "probability": 0.0
        },
        {
            "start_logit": -1.5341796875,
            "end_logit": -10.2109375,
            "text": "t: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.Telomere length is a risk",
            "probability": 0.0
        },
        {
            "start_logit": -1.5341796875,
            "end_logit": -10.2265625,
            "text": "t: A ploidy-agnostic method for estimating telomere length from whole genome sequencing",
            "probability": 0.0
        },
        {
            "start_logit": -8.6328125,
            "end_logit": -3.4921875,
            "text": "ca",
            "probability": 0.0
        },
        {
            "start_logit": -8.6328125,
            "end_logit": -6.45703125,
            "text": "cat:",
            "probability": 0.0
        },
        {
            "start_logit": -10.0078125,
            "end_logit": -6.45703125,
            "text": ":",
            "probability": 0.0
        },
        {
            "start_logit": -8.6328125,
            "end_logit": -9.671875,
            "text": "cat: A ploidy",
            "probability": 0.0
        },
        {
            "start_logit": -8.6328125,
            "end_logit": -10.0625,
            "text": "cat: A ploidy-agnostic method",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_1": [
        {
            "start_logit": 13.0859375,
            "end_logit": 15.0,
            "text": "Alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -1.7119140625,
            "end_logit": 15.0,
            "text": "synuclein",
            "probability": 3.5762786865234375e-07
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -4.4296875,
            "text": "Alpha",
            "probability": 0.0
        },
        {
            "start_logit": -9.0546875,
            "end_logit": 15.0,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -7.234375,
            "text": "Alpha-",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -8.2890625,
            "text": "Alpha-synuclein, the main component of Lewy bodies, plays a central role in the PD pathogenesis",
            "probability": 0.0
        },
        {
            "start_logit": -10.3125,
            "end_logit": 15.0,
            "text": "PD) is one of the most common neurodegenerative diseases. Majority of PD are sporadic, for which genetic causes remain largely unknown. Alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.3203125,
            "end_logit": 15.0,
            "text": ") is one of the most common neurodegenerative diseases. Majority of PD are sporadic, for which genetic causes remain largely unknown. Alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.5546875,
            "end_logit": 15.0,
            "text": "Majority of PD are sporadic, for which genetic causes remain largely unknown. Alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 15.0,
            "text": "PD are sporadic, for which genetic causes remain largely unknown. Alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -8.734375,
            "text": "Alpha-synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 15.0,
            "text": "which genetic causes remain largely unknown. Alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.6796875,
            "end_logit": 15.0,
            "text": ". Alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.6875,
            "end_logit": 15.0,
            "text": "of PD are sporadic, for which genetic causes remain largely unknown. Alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -9.6796875,
            "text": "Alpha-synuclein, the main component of Lewy bodies, plays a central role in the PD",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -9.84375,
            "text": "Alpha-synuclein, the main",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -10.1328125,
            "text": "Alpha-synuclein, the main component of Lewy bodies, plays a central",
            "probability": 0.0
        },
        {
            "start_logit": 13.0859375,
            "end_logit": -10.2109375,
            "text": "Alpha-synuclein, the main component of Lewy bodies, plays a central role in the",
            "probability": 0.0
        },
        {
            "start_logit": -1.7119140625,
            "end_logit": -8.2890625,
            "text": "synuclein, the main component of Lewy bodies, plays a central role in the PD pathogenesis",
            "probability": 0.0
        },
        {
            "start_logit": -5.8046875,
            "end_logit": -4.515625,
            "text": "Parkinson's disease (PD)",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_2": [
        {
            "start_logit": 11.109375,
            "end_logit": 13.4921875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -4.83203125,
            "end_logit": 13.4921875,
            "text": "synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -7.5703125,
            "end_logit": 13.4921875,
            "text": "is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": 13.4921875,
            "text": "Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 11.109375,
            "end_logit": -5.87109375,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": -8.5390625,
            "end_logit": 13.4921875,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": 13.4921875,
            "text": "The main component of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 11.109375,
            "end_logit": -8.046875,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 13.4921875,
            "text": "bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": 13.4921875,
            "text": "of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": 13.4921875,
            "text": "component of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": -5.87109375,
            "text": "is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": -5.87109375,
            "text": "Lewy bodies is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -9.4453125,
            "end_logit": -5.87109375,
            "text": "The main component of Lewy bodies is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.5703125,
            "end_logit": -8.046875,
            "text": "is alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -7.8671875,
            "end_logit": -8.046875,
            "text": "Lewy bodies is alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -8.5390625,
            "end_logit": -8.046875,
            "text": "-",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": -5.87109375,
            "text": "bodies is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -10.96875,
            "end_logit": -5.87109375,
            "text": "of Lewy bodies is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -10.9921875,
            "end_logit": -5.87109375,
            "text": "component of Lewy bodies is alpha",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_3": [
        {
            "start_logit": 13.5859375,
            "end_logit": 15.234375,
            "text": "Alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": 1.7265625,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration",
            "probability": 1.3709068298339844e-06
        },
        {
            "start_logit": -1.01953125,
            "end_logit": 15.234375,
            "text": "synuclein",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -3.6015625,
            "text": "Alpha",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -6.4375,
            "text": "Alpha-",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -7.1484375,
            "text": "Alpha-synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": -9.3984375,
            "end_logit": 15.234375,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -8.4765625,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.0703125,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.1171875,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.4921875,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.53125,
            "text": "Alpha-synuclein, a main",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.640625,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.6640625,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.7734375,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.78125,
            "text": "Alpha-synuclein, a",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.7890625,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally",
            "probability": 0.0
        },
        {
            "start_logit": 13.5859375,
            "end_logit": -9.90625,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques",
            "probability": 0.0
        },
        {
            "start_logit": -1.01953125,
            "end_logit": 1.7265625,
            "text": "synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration",
            "probability": 0.0
        },
        {
            "start_logit": -8.796875,
            "end_logit": 1.7265625,
            "text": "Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_4": [
        {
            "start_logit": 13.59375,
            "end_logit": 15.21875,
            "text": "alpha-Synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.93115234375,
            "end_logit": 15.21875,
            "text": "Synuclein",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 13.59375,
            "end_logit": -3.693359375,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -6.02734375,
            "text": "alpha-Synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -7.265625,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 15.21875,
            "text": "-Synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -8.8203125,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.265625,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.3203125,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.3828125,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.4296875,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140), but",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.453125,
            "text": "alpha-Synuclein, the main component of LBs, is",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.4921875,
            "text": "alpha-Synuclein, the main component of LBs,",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.6640625,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140)",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.7578125,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140), but little is known about their differential",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.796875,
            "text": "alpha-Synuclein, the main",
            "probability": 0.0
        },
        {
            "start_logit": -0.93115234375,
            "end_logit": -6.02734375,
            "text": "Synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": -0.93115234375,
            "end_logit": -8.8203125,
            "text": "Synuclein, the main component of LBs, is expressed as two",
            "probability": 0.0
        },
        {
            "start_logit": -0.93115234375,
            "end_logit": -9.265625,
            "text": "Synuclein, the main component of LBs, is expressed as two main",
            "probability": 0.0
        },
        {
            "start_logit": -0.93115234375,
            "end_logit": -9.3203125,
            "text": "Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_5": [
        {
            "start_logit": 12.53125,
            "end_logit": 13.6875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -3.064453125,
            "end_logit": 13.6875,
            "text": "synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.53125,
            "end_logit": -4.65234375,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -5.58984375,
            "text": "alpha-synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -7.65234375,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -9.125,
            "end_logit": 13.6875,
            "text": "Amyloid precursor protein (APP) is involved in the accumulation of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.4140625,
            "end_logit": 13.6875,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.15625,
            "end_logit": 13.6875,
            "text": "the accumulation of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.234375,
            "end_logit": 13.6875,
            "text": "accumulation of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": 13.6875,
            "text": "of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 13.6875,
            "text": "precursor protein (APP) is involved in the accumulation of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.890625,
            "end_logit": 13.6875,
            "text": "protein (APP) is involved in the accumulation of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -9.7890625,
            "text": "alpha-synuclein, the main",
            "probability": 0.0
        },
        {
            "start_logit": -10.984375,
            "end_logit": 13.6875,
            "text": "in the accumulation of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 12.53125,
            "end_logit": -10.046875,
            "text": "alpha-synuclein, the",
            "probability": 0.0
        },
        {
            "start_logit": -3.064453125,
            "end_logit": -5.58984375,
            "text": "synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": -3.064453125,
            "end_logit": -9.7890625,
            "text": "synuclein, the main",
            "probability": 0.0
        },
        {
            "start_logit": -3.064453125,
            "end_logit": -10.046875,
            "text": "synuclein, the",
            "probability": 0.0
        },
        {
            "start_logit": -9.125,
            "end_logit": -4.65234375,
            "text": "Amyloid precursor protein (APP) is involved in the accumulation of alpha",
            "probability": 0.0
        },
        {
            "start_logit": -9.125,
            "end_logit": -5.58984375,
            "text": "Amyloid precursor protein (APP) is involved in the accumulation of alpha-synuclein,",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_6": [
        {
            "start_logit": 6.98046875,
            "end_logit": 10.9296875,
            "text": "The pre-synaptic protein alpha-synuclein",
            "probability": 0.9990234375
        },
        {
            "start_logit": -0.69287109375,
            "end_logit": 10.9296875,
            "text": "protein alpha-synuclein",
            "probability": 0.00046515464782714844
        },
        {
            "start_logit": -3.59765625,
            "end_logit": 10.9296875,
            "text": "alpha-synuclein",
            "probability": 2.5451183319091797e-05
        },
        {
            "start_logit": -5.7265625,
            "end_logit": 10.9296875,
            "text": "synuclein",
            "probability": 3.039836883544922e-06
        },
        {
            "start_logit": -7.28125,
            "end_logit": 10.9296875,
            "text": "synaptic protein alpha-synuclein",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -9.0078125,
            "end_logit": 10.9296875,
            "text": "-synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.5546875,
            "end_logit": 10.9296875,
            "text": "pre-synaptic protein alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -10.234375,
            "end_logit": 10.9296875,
            "text": "-synaptic protein alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -6.3828125,
            "text": "The pre-synaptic protein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -6.55859375,
            "text": "The pre-synaptic protein alpha-synuclein is",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -6.92578125,
            "text": "The pre-synaptic protein alpha-synuclein is the main component of Lewy bodies and Lewy neurites,",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -8.015625,
            "text": "The pre-synaptic protein alpha",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -8.7265625,
            "text": "The",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -8.875,
            "text": "The pre-synaptic protein alpha-synuclein is the main component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -9.1640625,
            "text": "The pre-synaptic protein alpha-",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -9.3046875,
            "text": "The pre-synaptic protein alpha-synuclein is the main component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -9.3203125,
            "text": "The pre-synaptic protein alpha-synuclein is the main",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -9.5234375,
            "text": "The pre-synaptic protein alpha-synuclein is the main component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -9.765625,
            "text": "The pre-synaptic protein alpha-synuclein is the main component of Lewy bodies and Lewy neurites",
            "probability": 0.0
        },
        {
            "start_logit": 6.98046875,
            "end_logit": -9.8515625,
            "text": "The pre-synaptic protein alpha-synuclein is the main component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_7": [
        {
            "start_logit": -3.0390625,
            "end_logit": 6.578125,
            "text": "alpha-synuclein.",
            "probability": 0.88037109375
        },
        {
            "start_logit": -5.94921875,
            "end_logit": 6.578125,
            "text": ".",
            "probability": 0.0479736328125
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 6.578125,
            "text": "alpha-synucleinopathy because the main component of Lewy body is alpha-synuclein.",
            "probability": 0.032073974609375
        },
        {
            "start_logit": -3.0390625,
            "end_logit": 2.033203125,
            "text": "alpha-synuclein",
            "probability": 0.00933074951171875
        },
        {
            "start_logit": -7.59375,
            "end_logit": 6.578125,
            "text": "synuclein.",
            "probability": 0.0092620849609375
        },
        {
            "start_logit": -7.84375,
            "end_logit": 6.578125,
            "text": "is alpha-synuclein.",
            "probability": 0.007213592529296875
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 6.578125,
            "text": "the main component of Lewy body is alpha-synuclein.",
            "probability": 0.005401611328125
        },
        {
            "start_logit": -8.5625,
            "end_logit": 6.578125,
            "text": "-synuclein.",
            "probability": 0.00351715087890625
        },
        {
            "start_logit": -9.328125,
            "end_logit": 6.578125,
            "text": "Lewy body is alpha-synuclein.",
            "probability": 0.0016345977783203125
        },
        {
            "start_logit": -9.4609375,
            "end_logit": 6.578125,
            "text": "synucleinopathy because the main component of Lewy body is alpha-synuclein.",
            "probability": 0.0014314651489257812
        },
        {
            "start_logit": -10.1484375,
            "end_logit": 6.578125,
            "text": "component of Lewy body is alpha-synuclein.",
            "probability": 0.0007195472717285156
        },
        {
            "start_logit": -10.21875,
            "end_logit": 6.578125,
            "text": "of Lewy body is alpha-synuclein.",
            "probability": 0.0006709098815917969
        },
        {
            "start_logit": -6.3515625,
            "end_logit": 2.033203125,
            "text": "alpha-synucleinopathy because the main component of Lewy body is alpha-synuclein",
            "probability": 0.00033974647521972656
        },
        {
            "start_logit": -7.59375,
            "end_logit": 2.033203125,
            "text": "synuclein",
            "probability": 9.816884994506836e-05
        },
        {
            "start_logit": -7.84375,
            "end_logit": 2.033203125,
            "text": "is alpha-synuclein",
            "probability": 7.647275924682617e-05
        },
        {
            "start_logit": -8.1328125,
            "end_logit": 2.033203125,
            "text": "the main component of Lewy body is alpha-synuclein",
            "probability": 5.728006362915039e-05
        },
        {
            "start_logit": -8.5625,
            "end_logit": 2.033203125,
            "text": "-synuclein",
            "probability": 3.725290298461914e-05
        },
        {
            "start_logit": -2.369140625,
            "end_logit": -4.87109375,
            "text": "Lewy bodies are present in the central and sympathetic nervous systems,",
            "probability": 1.8298625946044922e-05
        },
        {
            "start_logit": -9.328125,
            "end_logit": 2.033203125,
            "text": "Lewy body is alpha-synuclein",
            "probability": 1.7344951629638672e-05
        },
        {
            "start_logit": -9.4609375,
            "end_logit": 2.033203125,
            "text": "synucleinopathy because the main component of Lewy body is alpha-synuclein",
            "probability": 1.5139579772949219e-05
        }
    ],
    "550c3d45a103b78016000008_8": [
        {
            "start_logit": 12.7578125,
            "end_logit": 14.4609375,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -2.2890625,
            "end_logit": 14.4609375,
            "text": "synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -1.2275390625,
            "text": "alpha-synuclein.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.67578125,
            "end_logit": 14.4609375,
            "text": "In Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.9765625,
            "end_logit": 14.4609375,
            "text": "Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -5.6875,
            "end_logit": 14.4609375,
            "text": "inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -4.3125,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": -6.1015625,
            "end_logit": 14.4609375,
            "text": "Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -7.515625,
            "end_logit": 14.4609375,
            "text": "as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -8.5234375,
            "end_logit": 14.4609375,
            "text": "is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -7.12890625,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -8.9375,
            "end_logit": 14.4609375,
            "text": "the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 14.4609375,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 14.4609375,
            "text": "their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 14.4609375,
            "text": "component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 14.4609375,
            "text": "bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 14.4609375,
            "text": "referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 14.4609375,
            "text": "'s disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -2.2890625,
            "end_logit": -1.2275390625,
            "text": "synuclein.",
            "probability": 0.0
        },
        {
            "start_logit": -3.67578125,
            "end_logit": -1.2275390625,
            "text": "In Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_9": [
        {
            "start_logit": 13.03125,
            "end_logit": 14.640625,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": 14.640625,
            "text": "synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.078125,
            "end_logit": 14.640625,
            "text": "Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -4.25,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -4.72265625,
            "text": "alpha-synuclein.",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 14.640625,
            "text": "is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -6.9921875,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": 14.640625,
            "text": "The main component of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -8.9765625,
            "end_logit": 14.640625,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.640625,
            "text": "of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.640625,
            "text": "bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 14.640625,
            "text": "component of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": -4.72265625,
            "text": "synuclein.",
            "probability": 0.0
        },
        {
            "start_logit": -5.078125,
            "end_logit": -4.25,
            "text": "Lewy bodies is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -5.078125,
            "end_logit": -4.72265625,
            "text": "Lewy bodies is alpha-synuclein.",
            "probability": 0.0
        },
        {
            "start_logit": -5.078125,
            "end_logit": -6.9921875,
            "text": "Lewy bodies is alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -4.25,
            "text": "is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": -4.25,
            "text": "The main component of Lewy bodies is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -4.72265625,
            "text": "is alpha-synuclein.",
            "probability": 0.0
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -4.72265625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_10": [
        {
            "start_logit": 11.6875,
            "end_logit": 12.625,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -3.048828125,
            "end_logit": 12.625,
            "text": "Lewy bodies is alpha-synuclein",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -4.26171875,
            "end_logit": 12.625,
            "text": "synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 11.6875,
            "end_logit": -4.06640625,
            "text": "alpha-synuclein (AS).",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 11.6875,
            "end_logit": -5.41796875,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -5.73828125,
            "text": "alpha-synuclein (AS)",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -7.25390625,
            "text": "alpha-synuclein (AS",
            "probability": 0.0
        },
        {
            "start_logit": -8.296875,
            "end_logit": 12.625,
            "text": "The main component of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -8.4765625,
            "end_logit": 12.625,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -7.55859375,
            "text": "alpha-synuclein (",
            "probability": 0.0
        },
        {
            "start_logit": 11.6875,
            "end_logit": -7.765625,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -8.8203125,
            "end_logit": 12.625,
            "text": "is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.734375,
            "end_logit": 12.625,
            "text": "component of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.8515625,
            "end_logit": 12.625,
            "text": "bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.8984375,
            "end_logit": 12.625,
            "text": "of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -3.048828125,
            "end_logit": -4.06640625,
            "text": "Lewy bodies is alpha-synuclein (AS).",
            "probability": 0.0
        },
        {
            "start_logit": -4.26171875,
            "end_logit": -4.06640625,
            "text": "synuclein (AS).",
            "probability": 0.0
        },
        {
            "start_logit": -3.048828125,
            "end_logit": -5.41796875,
            "text": "Lewy bodies is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -3.048828125,
            "end_logit": -5.73828125,
            "text": "Lewy bodies is alpha-synuclein (AS)",
            "probability": 0.0
        },
        {
            "start_logit": -4.26171875,
            "end_logit": -5.73828125,
            "text": "synuclein (AS)",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_11": [
        {
            "start_logit": 12.015625,
            "end_logit": 12.8046875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": 0.9462890625,
            "text": "alpha-synuclein, the main component of Lewy bodies.",
            "probability": 7.152557373046875e-06
        },
        {
            "start_logit": -3.96484375,
            "end_logit": 12.8046875,
            "text": "synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -5.0625,
            "end_logit": 12.8046875,
            "text": "Amyloid precursor protein (APP) is involved in the accumulation of alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 12.015625,
            "end_logit": -4.71875,
            "text": "alpha-synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -5.25,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": -8.609375,
            "end_logit": 12.8046875,
            "text": "accumulation of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -8.2265625,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -9.28125,
            "end_logit": 12.8046875,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.6875,
            "end_logit": 12.8046875,
            "text": "precursor protein (APP) is involved in the accumulation of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.7109375,
            "end_logit": 12.8046875,
            "text": "the accumulation of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.7421875,
            "end_logit": 12.8046875,
            "text": "of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.0703125,
            "end_logit": 12.8046875,
            "text": "protein (APP) is involved in the accumulation of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -9.4765625,
            "text": "alpha-synuclein, the main",
            "probability": 0.0
        },
        {
            "start_logit": -10.34375,
            "end_logit": 12.8046875,
            "text": "(APP) is involved in the accumulation of alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 12.015625,
            "end_logit": -9.96875,
            "text": "alpha-synuclein, the",
            "probability": 0.0
        },
        {
            "start_logit": -1.861328125,
            "end_logit": 0.9462890625,
            "text": "Lewy bodies.",
            "probability": 0.0
        },
        {
            "start_logit": -3.96484375,
            "end_logit": 0.9462890625,
            "text": "synuclein, the main component of Lewy bodies.",
            "probability": 0.0
        },
        {
            "start_logit": -5.0625,
            "end_logit": 0.9462890625,
            "text": "Amyloid precursor protein (APP) is involved in the accumulation of alpha-synuclein, the main component of Lewy bodies.",
            "probability": 0.0
        },
        {
            "start_logit": -7.3359375,
            "end_logit": 0.9462890625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_12": [
        {
            "start_logit": 13.4609375,
            "end_logit": 15.203125,
            "text": "Alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.90185546875,
            "end_logit": 15.203125,
            "text": "synuclein",
            "probability": 5.960464477539062e-07
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -2.71875,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration.",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -3.802734375,
            "text": "Alpha",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -5.875,
            "text": "Alpha-synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -6.75,
            "text": "Alpha-",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -7.140625,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration",
            "probability": 0.0
        },
        {
            "start_logit": -9.0859375,
            "end_logit": 15.203125,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -7.69921875,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease,",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -8.5390625,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -8.8828125,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -9.390625,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -9.390625,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -9.421875,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -9.484375,
            "text": "Alpha-synuclein, a main",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -9.5,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -9.6640625,
            "text": "Alpha-synuclein, a",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -9.890625,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally",
            "probability": 0.0
        },
        {
            "start_logit": 13.4609375,
            "end_logit": -9.890625,
            "text": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques",
            "probability": 0.0
        },
        {
            "start_logit": -0.90185546875,
            "end_logit": -2.71875,
            "text": "synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration.",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_13": [
        {
            "start_logit": 13.03125,
            "end_logit": 14.640625,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": 14.640625,
            "text": "synuclein",
            "probability": 2.384185791015625e-07
        },
        {
            "start_logit": -5.078125,
            "end_logit": 14.640625,
            "text": "Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -4.25,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -4.72265625,
            "text": "alpha-synuclein.",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": 14.640625,
            "text": "is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 13.03125,
            "end_logit": -6.9921875,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": 14.640625,
            "text": "The main component of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -8.9765625,
            "end_logit": 14.640625,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.65625,
            "end_logit": 14.640625,
            "text": "of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.6953125,
            "end_logit": 14.640625,
            "text": "bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.75,
            "end_logit": 14.640625,
            "text": "component of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -2.33203125,
            "end_logit": -4.72265625,
            "text": "synuclein.",
            "probability": 0.0
        },
        {
            "start_logit": -5.078125,
            "end_logit": -4.25,
            "text": "Lewy bodies is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -5.078125,
            "end_logit": -4.72265625,
            "text": "Lewy bodies is alpha-synuclein.",
            "probability": 0.0
        },
        {
            "start_logit": -5.078125,
            "end_logit": -6.9921875,
            "text": "Lewy bodies is alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -4.25,
            "text": "is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": -4.25,
            "text": "The main component of Lewy bodies is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -8.390625,
            "end_logit": -4.72265625,
            "text": "is alpha-synuclein.",
            "probability": 0.0
        },
        {
            "start_logit": -8.6015625,
            "end_logit": -4.72265625,
            "text": ".",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_14": [
        {
            "start_logit": 12.7578125,
            "end_logit": 14.4609375,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -2.2890625,
            "end_logit": 14.4609375,
            "text": "synuclein",
            "probability": 2.980232238769531e-07
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -1.2275390625,
            "text": "alpha-synuclein.",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": -3.67578125,
            "end_logit": 14.4609375,
            "text": "In Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -4.9765625,
            "end_logit": 14.4609375,
            "text": "Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -5.6875,
            "end_logit": 14.4609375,
            "text": "inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -4.3125,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": -6.1015625,
            "end_logit": 14.4609375,
            "text": "Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -7.515625,
            "end_logit": 14.4609375,
            "text": "as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -8.5234375,
            "end_logit": 14.4609375,
            "text": "is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 12.7578125,
            "end_logit": -7.12890625,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -8.9375,
            "end_logit": 14.4609375,
            "text": "the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 14.4609375,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.1796875,
            "end_logit": 14.4609375,
            "text": "their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.2890625,
            "end_logit": 14.4609375,
            "text": "component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": 14.4609375,
            "text": "bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.4375,
            "end_logit": 14.4609375,
            "text": "referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 14.4609375,
            "text": "'s disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -2.2890625,
            "end_logit": -1.2275390625,
            "text": "synuclein.",
            "probability": 0.0
        },
        {
            "start_logit": -3.67578125,
            "end_logit": -1.2275390625,
            "text": "In Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein.",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_15": [
        {
            "start_logit": 13.59375,
            "end_logit": 15.21875,
            "text": "alpha-Synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -0.93115234375,
            "end_logit": 15.21875,
            "text": "Synuclein",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 13.59375,
            "end_logit": -3.693359375,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -6.02734375,
            "text": "alpha-Synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -7.265625,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -9.8046875,
            "end_logit": 15.21875,
            "text": "-Synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -8.8203125,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.265625,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.3203125,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.3828125,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.4296875,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140), but",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.453125,
            "text": "alpha-Synuclein, the main component of LBs, is",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.4921875,
            "text": "alpha-Synuclein, the main component of LBs,",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.6640625,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140)",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.7578125,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140), but little is known about their differential",
            "probability": 0.0
        },
        {
            "start_logit": 13.59375,
            "end_logit": -9.796875,
            "text": "alpha-Synuclein, the main",
            "probability": 0.0
        },
        {
            "start_logit": -0.93115234375,
            "end_logit": -6.02734375,
            "text": "Synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": -0.93115234375,
            "end_logit": -8.8203125,
            "text": "Synuclein, the main component of LBs, is expressed as two",
            "probability": 0.0
        },
        {
            "start_logit": -0.93115234375,
            "end_logit": -9.265625,
            "text": "Synuclein, the main component of LBs, is expressed as two main",
            "probability": 0.0
        },
        {
            "start_logit": -0.93115234375,
            "end_logit": -9.3203125,
            "text": "Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_16": [
        {
            "start_logit": 12.859375,
            "end_logit": 13.8203125,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -2.951171875,
            "end_logit": 13.8203125,
            "text": "synuclein",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 12.859375,
            "end_logit": -4.74609375,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 12.859375,
            "end_logit": -5.59375,
            "text": "alpha-synuclein is",
            "probability": 0.0
        },
        {
            "start_logit": -6.84375,
            "end_logit": 13.8203125,
            "text": "Lewy body dementia, alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 12.859375,
            "end_logit": -6.76171875,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -8.5703125,
            "end_logit": 13.8203125,
            "text": "Parkinson's disease and Lewy body dementia, alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.265625,
            "end_logit": 13.8203125,
            "text": ", alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.453125,
            "end_logit": 13.8203125,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 12.859375,
            "end_logit": -8.9609375,
            "text": "alpha-synuclein is the main",
            "probability": 0.0
        },
        {
            "start_logit": -10.03125,
            "end_logit": 13.8203125,
            "text": "In Parkinson's disease and Lewy body dementia, alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.5703125,
            "end_logit": 13.8203125,
            "text": "body dementia, alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 12.859375,
            "end_logit": -9.9921875,
            "text": "alpha-synuclein is the main component of Lewy bodies and dystrophic neurites; alpha-synuclein also",
            "probability": 0.0
        },
        {
            "start_logit": 12.859375,
            "end_logit": -9.9921875,
            "text": "alpha-synuclein is the main component of Lewy bodies and dystrophic neurites; alpha-synuclein also accumulates in the cytoplasm of glial cells",
            "probability": 0.0
        },
        {
            "start_logit": 12.859375,
            "end_logit": -10.125,
            "text": "alpha-synuclein is the main component of Lewy bodies and dystrophic neurites; alpha-synuclein also accumulates",
            "probability": 0.0
        },
        {
            "start_logit": 12.859375,
            "end_logit": -10.328125,
            "text": "alpha-synuclein is the main component of Lewy bodies and dystrophic neurites",
            "probability": 0.0
        },
        {
            "start_logit": 12.859375,
            "end_logit": -10.3671875,
            "text": "alpha-synuclein is the main component of Lewy bodies and dystrophic neurites; alpha-synuclein also accumulates in the",
            "probability": 0.0
        },
        {
            "start_logit": -2.951171875,
            "end_logit": -5.59375,
            "text": "synuclein is",
            "probability": 0.0
        },
        {
            "start_logit": -6.84375,
            "end_logit": -4.74609375,
            "text": "Lewy body dementia, alpha",
            "probability": 0.0
        },
        {
            "start_logit": -2.951171875,
            "end_logit": -8.9609375,
            "text": "synuclein is the main",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_17": [
        {
            "start_logit": 12.2578125,
            "end_logit": 14.3515625,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -3.3671875,
            "end_logit": 14.3515625,
            "text": "synuclein",
            "probability": 1.7881393432617188e-07
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -4.62109375,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": 14.3515625,
            "text": "inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": 14.3515625,
            "text": "Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": 14.3515625,
            "text": "In Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -8.734375,
            "end_logit": 14.3515625,
            "text": "is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -8.8984375,
            "end_logit": 14.3515625,
            "text": "Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.2109375,
            "end_logit": 14.3515625,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 12.2578125,
            "end_logit": -7.73046875,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -9.9140625,
            "end_logit": 14.3515625,
            "text": "as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.0859375,
            "end_logit": 14.3515625,
            "text": "the inclusion bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": 14.3515625,
            "text": "their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.6171875,
            "end_logit": 14.3515625,
            "text": "component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.7890625,
            "end_logit": 14.3515625,
            "text": "referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.8359375,
            "end_logit": 14.3515625,
            "text": "bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.9453125,
            "end_logit": 14.3515625,
            "text": "bodies are referred to as Lewy bodies and their main component is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -7.76171875,
            "end_logit": -4.62109375,
            "text": "inclusion bodies are referred to as Lewy bodies and their main component is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.95703125,
            "end_logit": -4.62109375,
            "text": "Lewy bodies and their main component is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -8.453125,
            "end_logit": -4.62109375,
            "text": "In Parkinson's disease, the inclusion bodies are referred to as Lewy bodies and their main component is alpha",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_18": [
        {
            "start_logit": 10.5390625,
            "end_logit": 12.46875,
            "text": "alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -4.0859375,
            "end_logit": 12.46875,
            "text": "synuclein",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": -7.0,
            "end_logit": 12.46875,
            "text": "Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 10.5390625,
            "end_logit": -5.93359375,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 10.5390625,
            "end_logit": -6.4296875,
            "text": "alpha-synuclein (",
            "probability": 0.0
        },
        {
            "start_logit": -8.578125,
            "end_logit": 12.46875,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 10.5390625,
            "end_logit": -6.71484375,
            "text": "alpha-synuclein (AS)",
            "probability": 0.0
        },
        {
            "start_logit": 10.5390625,
            "end_logit": -6.97265625,
            "text": "alpha-synuclein (AS",
            "probability": 0.0
        },
        {
            "start_logit": -9.3828125,
            "end_logit": 12.46875,
            "text": "is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -9.4296875,
            "end_logit": 12.46875,
            "text": "The main component of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 10.5390625,
            "end_logit": -7.85546875,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -10.859375,
            "end_logit": 12.46875,
            "text": "bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.9296875,
            "end_logit": 12.46875,
            "text": "of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -10.9609375,
            "end_logit": 12.46875,
            "text": "component of Lewy bodies is alpha-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": -4.0859375,
            "end_logit": -6.4296875,
            "text": "synuclein (",
            "probability": 0.0
        },
        {
            "start_logit": -4.0859375,
            "end_logit": -6.71484375,
            "text": "synuclein (AS)",
            "probability": 0.0
        },
        {
            "start_logit": -4.0859375,
            "end_logit": -6.97265625,
            "text": "synuclein (AS",
            "probability": 0.0
        },
        {
            "start_logit": -7.0,
            "end_logit": -5.93359375,
            "text": "Lewy bodies is alpha",
            "probability": 0.0
        },
        {
            "start_logit": -7.0,
            "end_logit": -6.4296875,
            "text": "Lewy bodies is alpha-synuclein (",
            "probability": 0.0
        },
        {
            "start_logit": -7.0,
            "end_logit": -6.71484375,
            "text": "Lewy bodies is alpha-synuclein (AS)",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_19": [
        {
            "start_logit": 13.5078125,
            "end_logit": 15.1640625,
            "text": "alpha-Synuclein",
            "probability": 1.0
        },
        {
            "start_logit": -1.1962890625,
            "end_logit": 15.1640625,
            "text": "Synuclein",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -3.828125,
            "text": "alpha",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -5.6796875,
            "text": "alpha-Synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -7.37890625,
            "text": "alpha-",
            "probability": 0.0
        },
        {
            "start_logit": -9.8359375,
            "end_logit": 15.1640625,
            "text": "-Synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -8.8046875,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -9.25,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -9.25,
            "text": "alpha-Synuclein, the main component of LBs, is",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -9.2578125,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -9.34375,
            "text": "alpha-Synuclein, the main component of LBs,",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -9.3515625,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140)",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -9.3671875,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -9.515625,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140), but",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -9.6796875,
            "text": "alpha-Synuclein, the main",
            "probability": 0.0
        },
        {
            "start_logit": 13.5078125,
            "end_logit": -9.6953125,
            "text": "alpha-Synuclein, the main component of LBs, is expressed as two main isoforms (112 and 140), but little is known about their differential",
            "probability": 0.0
        },
        {
            "start_logit": -1.1962890625,
            "end_logit": -5.6796875,
            "text": "Synuclein,",
            "probability": 0.0
        },
        {
            "start_logit": -1.1962890625,
            "end_logit": -8.8046875,
            "text": "Synuclein, the main component of LBs, is expressed as two",
            "probability": 0.0
        },
        {
            "start_logit": -1.1962890625,
            "end_logit": -9.25,
            "text": "Synuclein, the main component of LBs, is expressed as",
            "probability": 0.0
        },
        {
            "start_logit": -1.1962890625,
            "end_logit": -9.25,
            "text": "Synuclein, the main component of LBs, is",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_20": [
        {
            "start_logit": -4.28515625,
            "end_logit": -6.58984375,
            "text": "Lewy bodies",
            "probability": 0.77099609375
        },
        {
            "start_logit": -4.28515625,
            "end_logit": -9.171875,
            "text": "Lewy",
            "probability": 0.05853271484375
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -6.34375,
            "text": "Lewy body protein components that may play antagonistic roles in the",
            "probability": 0.0328369140625
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -6.40234375,
            "text": "Lewy body protein components that may play antagonistic roles in the pathogenesis of",
            "probability": 0.0310821533203125
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -6.58984375,
            "text": "Lewy body protein components that may play antagonistic roles in the pathogenesis of Lewy bodies",
            "probability": 0.0257720947265625
        },
        {
            "start_logit": -10.109375,
            "end_logit": -4.765625,
            "text": "alpha-Synuclein and ubiquitin are",
            "probability": 0.01412200927734375
        },
        {
            "start_logit": -8.5390625,
            "end_logit": -6.40234375,
            "text": "of",
            "probability": 0.013275146484375
        },
        {
            "start_logit": -8.5390625,
            "end_logit": -6.58984375,
            "text": "of Lewy bodies",
            "probability": 0.0110015869140625
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -4.765625,
            "text": "Synuclein and ubiquitin are",
            "probability": 0.0077362060546875
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -8.1953125,
            "text": "Lewy body protein components that may",
            "probability": 0.00519561767578125
        },
        {
            "start_logit": -11.109375,
            "end_logit": -4.765625,
            "text": "ubiquitin are",
            "probability": 0.00519561767578125
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -8.3125,
            "text": "Lewy body protein components that may play antagonistic roles in the pathogenesis",
            "probability": 0.00458526611328125
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -8.5,
            "text": "Lewy body protein components that may play antagonistic",
            "probability": 0.0037994384765625
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -8.75,
            "text": "Lewy body protein components that",
            "probability": 0.002960205078125
        },
        {
            "start_logit": -10.109375,
            "end_logit": -6.34375,
            "text": "alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles in the",
            "probability": 0.0029144287109375
        },
        {
            "start_logit": -10.109375,
            "end_logit": -6.40234375,
            "text": "alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles in the pathogenesis of",
            "probability": 0.00273895263671875
        },
        {
            "start_logit": -10.109375,
            "end_logit": -6.58984375,
            "text": "alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles in the pathogenesis of Lewy bodies",
            "probability": 0.002269744873046875
        },
        {
            "start_logit": -7.68359375,
            "end_logit": -9.171875,
            "text": "Lewy body protein components that may play antagonistic roles in the pathogenesis of Lewy",
            "probability": 0.001941680908203125
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -6.34375,
            "text": "Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles in the",
            "probability": 0.0015840530395507812
        },
        {
            "start_logit": -10.7109375,
            "end_logit": -6.40234375,
            "text": "Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles in the pathogenesis of",
            "probability": 0.0015115737915039062
        }
    ],
    "550c3d45a103b78016000008_21": [
        {
            "start_logit": 0.402587890625,
            "end_logit": -6.4609375,
            "text": "Lewy bodies and Lewy neurites",
            "probability": 0.96435546875
        },
        {
            "start_logit": 0.402587890625,
            "end_logit": -9.84375,
            "text": "Lewy bodies and",
            "probability": 0.032867431640625
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -6.4609375,
            "text": "protein alpha-synuclein was shown to be a major component of Lewy bodies and Lewy neurites",
            "probability": 0.0017690658569335938
        },
        {
            "start_logit": -7.7265625,
            "end_logit": -6.4609375,
            "text": "Lewy neurites",
            "probability": 0.0002856254577636719
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -9.046875,
            "text": "protein alpha-synuclein was shown to be a major",
            "probability": 0.0001327991485595703
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -9.3828125,
            "text": "protein alpha-synuclein",
            "probability": 9.560585021972656e-05
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -9.4609375,
            "text": "protein alpha-synuclein was shown to be",
            "probability": 8.845329284667969e-05
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -9.515625,
            "text": "protein alpha-synuclein was shown to be a",
            "probability": 8.302927017211914e-05
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -9.5390625,
            "text": "protein alpha-synuclein was shown to",
            "probability": 8.177757263183594e-05
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -9.84375,
            "text": "protein alpha-synuclein was",
            "probability": 5.984306335449219e-05
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -9.84375,
            "text": "protein alpha-synuclein was shown to be a major component of Lewy bodies and",
            "probability": 5.984306335449219e-05
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -9.921875,
            "text": "protein alpha-synuclein was shown to be a major component of",
            "probability": 5.537271499633789e-05
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -10.046875,
            "text": "protein alpha",
            "probability": 4.887580871582031e-05
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -10.2109375,
            "text": "protein alpha-synuclein was shown to be a major component",
            "probability": 4.178285598754883e-05
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -10.2421875,
            "text": "protein alpha-",
            "probability": 4.0471553802490234e-05
        },
        {
            "start_logit": -5.90234375,
            "end_logit": -10.390625,
            "text": "protein alpha-synuclein was shown",
            "probability": 3.463029861450195e-05
        },
        {
            "start_logit": -9.84375,
            "end_logit": -6.4609375,
            "text": "Recently, the presynaptic protein alpha-synuclein was shown to be a major component of Lewy bodies and Lewy neurites",
            "probability": 3.409385681152344e-05
        },
        {
            "start_logit": -10.0234375,
            "end_logit": -6.4609375,
            "text": "alpha-synuclein was shown to be a major component of Lewy bodies and Lewy neurites",
            "probability": 2.872943878173828e-05
        },
        {
            "start_logit": -10.484375,
            "end_logit": -6.4609375,
            "text": "and Lewy neurites",
            "probability": 1.8298625946044922e-05
        },
        {
            "start_logit": -10.5703125,
            "end_logit": -6.4609375,
            "text": "shown to be a major component of Lewy bodies and Lewy neurites",
            "probability": 1.6629695892333984e-05
        }
    ],
    "550c3d45a103b78016000008_22": [
        {
            "start_logit": 12.109375,
            "end_logit": 14.390625,
            "text": "Alpha-synuclein",
            "probability": 1.0
        },
        {
            "start_logit": 12.109375,
            "end_logit": 0.1436767578125,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation is a key event in the pathogenesis of PD",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -2.400390625,
            "end_logit": 14.390625,
            "text": "synuclein",
            "probability": 4.76837158203125e-07
        },
        {
            "start_logit": 12.109375,
            "end_logit": -5.16015625,
            "text": "Alpha",
            "probability": 0.0
        },
        {
            "start_logit": 12.109375,
            "end_logit": -6.67578125,
            "text": "Alpha-",
            "probability": 0.0
        },
        {
            "start_logit": 12.109375,
            "end_logit": -6.81640625,
            "text": "Alpha-synuclein (AS) is",
            "probability": 0.0
        },
        {
            "start_logit": -9.359375,
            "end_logit": 14.390625,
            "text": "-synuclein",
            "probability": 0.0
        },
        {
            "start_logit": 12.109375,
            "end_logit": -8.8203125,
            "text": "Alpha-synuclein (AS)",
            "probability": 0.0
        },
        {
            "start_logit": 12.109375,
            "end_logit": -9.125,
            "text": "Alpha-synuclein (",
            "probability": 0.0
        },
        {
            "start_logit": 12.109375,
            "end_logit": -9.390625,
            "text": "Alpha-synuclein (AS) is the main",
            "probability": 0.0
        },
        {
            "start_logit": 12.109375,
            "end_logit": -9.5625,
            "text": "Alpha-synuclein (AS",
            "probability": 0.0
        },
        {
            "start_logit": 12.109375,
            "end_logit": -9.8046875,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and",
            "probability": 0.0
        },
        {
            "start_logit": 12.109375,
            "end_logit": -10.0,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation is a key event in the",
            "probability": 0.0
        },
        {
            "start_logit": 12.109375,
            "end_logit": -10.2109375,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation is a key event in the pathogenesis",
            "probability": 0.0
        },
        {
            "start_logit": 12.109375,
            "end_logit": -10.3046875,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation",
            "probability": 0.0
        },
        {
            "start_logit": 12.109375,
            "end_logit": -10.34375,
            "text": "Alpha-synuclein (AS) is the",
            "probability": 0.0
        },
        {
            "start_logit": 12.109375,
            "end_logit": -10.359375,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation is",
            "probability": 0.0
        },
        {
            "start_logit": 12.109375,
            "end_logit": -10.4609375,
            "text": "Alpha-synuclein (AS) is the main component of Lewy bodies and its aggregation is a key",
            "probability": 0.0
        },
        {
            "start_logit": -2.400390625,
            "end_logit": 0.1436767578125,
            "text": "synuclein (AS) is the main component of Lewy bodies and its aggregation is a key event in the pathogenesis of PD",
            "probability": 0.0
        },
        {
            "start_logit": -6.38671875,
            "end_logit": 0.1436767578125,
            "text": "Lewy bodies and its aggregation is a key event in the pathogenesis of PD",
            "probability": 0.0
        }
    ],
    "550c3d45a103b78016000008_23": [
        {
            "start_logit": -4.875,
            "end_logit": -2.904296875,
            "text": "with Lewy bodies.",
            "probability": 0.57275390625
        },
        {
            "start_logit": -6.40234375,
            "end_logit": -2.658203125,
            "text": "dementia",
            "probability": 0.158935546875
        },
        {
            "start_logit": -6.3359375,
            "end_logit": -2.904296875,
            "text": "Lewy bodies.",
            "probability": 0.1329345703125
        },
        {
            "start_logit": -6.40234375,
            "end_logit": -2.904296875,
            "text": "dementia with Lewy bodies.",
            "probability": 0.1248779296875
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -2.658203125,
            "text": "for dementia",
            "probability": 0.002716064453125
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -2.904296875,
            "text": "for dementia with Lewy bodies.",
            "probability": 0.0021152496337890625
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -2.658203125,
            "text": "The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia",
            "probability": 0.00208282470703125
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -2.904296875,
            "text": "The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies.",
            "probability": 0.001621246337890625
        },
        {
            "start_logit": -4.875,
            "end_logit": -9.0546875,
            "text": "with Lewy bodies",
            "probability": 0.0012235641479492188
        },
        {
            "start_logit": -6.3359375,
            "end_logit": -9.0546875,
            "text": "Lewy bodies",
            "probability": 0.00028395652770996094
        },
        {
            "start_logit": -6.40234375,
            "end_logit": -9.0546875,
            "text": "dementia with Lewy bodies",
            "probability": 0.0002665519714355469
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -8.4765625,
            "text": "for",
            "probability": 8.046627044677734e-06
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -8.4765625,
            "text": "The therapeutical potential of alpha-synuclein antiaggregatory agents for",
            "probability": 6.198883056640625e-06
        },
        {
            "start_logit": -10.4765625,
            "end_logit": -9.0546875,
            "text": "for dementia with Lewy bodies",
            "probability": 4.5299530029296875e-06
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -9.0546875,
            "text": "The therapeutical potential of alpha-synuclein antiaggregatory agents for dementia with Lewy bodies",
            "probability": 3.4570693969726562e-06
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -9.1953125,
            "text": "The therapeutical potential of alpha-synuclein antiaggregatory",
            "probability": 2.9802322387695312e-06
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -9.265625,
            "text": "The",
            "probability": 2.86102294921875e-06
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -9.4921875,
            "text": "The therapeutical potential of",
            "probability": 2.2649765014648438e-06
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -9.625,
            "text": "The therapeutical",
            "probability": 1.9669532775878906e-06
        },
        {
            "start_logit": -10.7421875,
            "end_logit": -9.765625,
            "text": "The therapeutical potential",
            "probability": 1.7285346984863281e-06
        }
    ],
    "5c7aae9dd774d0424000000a_1": [
        {
            "start_logit": 7.25,
            "end_logit": -0.01354217529296875,
            "text": "Stimulator of interferon genes (STING) is an adaptor protein that plays an important role in the activation of type I interferons",
            "probability": 0.580078125
        },
        {
            "start_logit": 7.25,
            "end_logit": -0.473388671875,
            "text": "Stimulator of interferon genes",
            "probability": 0.365966796875
        },
        {
            "start_logit": 7.25,
            "end_logit": -3.01171875,
            "text": "Stimulator of interferon genes (",
            "probability": 0.0288848876953125
        },
        {
            "start_logit": -4.16796875,
            "end_logit": 7.171875,
            "text": "interferons in response to cytosolic nucleic acid ligands. Recent evidence indicates involvement of the STING pathway in the induction of antitumor immune response.",
            "probability": 0.0084075927734375
        },
        {
            "start_logit": 7.25,
            "end_logit": -4.48828125,
            "text": "Stimulator of interferon genes (STING) is",
            "probability": 0.00659942626953125
        },
        {
            "start_logit": -4.9140625,
            "end_logit": 7.171875,
            "text": ".",
            "probability": 0.003986358642578125
        },
        {
            "start_logit": -5.44921875,
            "end_logit": 7.171875,
            "text": "Recent evidence indicates involvement of the STING pathway in the induction of antitumor immune response.",
            "probability": 0.0023345947265625
        },
        {
            "start_logit": -6.078125,
            "end_logit": 7.171875,
            "text": "activation of type I interferons in response to cytosolic nucleic acid ligands. Recent evidence indicates involvement of the STING pathway in the induction of antitumor immune response.",
            "probability": 0.0012445449829101562
        },
        {
            "start_logit": 7.25,
            "end_logit": -6.23828125,
            "text": "Stimulator of interferon genes (STING)",
            "probability": 0.0011463165283203125
        },
        {
            "start_logit": -7.75390625,
            "end_logit": 7.171875,
            "text": "nucleic acid ligands. Recent evidence indicates involvement of the STING pathway in the induction of antitumor immune response.",
            "probability": 0.00023293495178222656
        },
        {
            "start_logit": -8.453125,
            "end_logit": 7.171875,
            "text": "immune response.",
            "probability": 0.00011616945266723633
        },
        {
            "start_logit": 7.25,
            "end_logit": -8.609375,
            "text": "Stimulator of interferon genes (STING) is an adaptor protein that plays an important role in the activation of type I interferons in response to cytosolic nucleic acid",
            "probability": 0.0001074671745300293
        },
        {
            "start_logit": -8.5546875,
            "end_logit": 7.171875,
            "text": "in response to cytosolic nucleic acid ligands. Recent evidence indicates involvement of the STING pathway in the induction of antitumor immune response.",
            "probability": 0.00010412931442260742
        },
        {
            "start_logit": 7.25,
            "end_logit": -8.6875,
            "text": "Stimulator of interferon genes (STING) is an adaptor protein that plays an important role in the activation",
            "probability": 9.936094284057617e-05
        },
        {
            "start_logit": -8.765625,
            "end_logit": 7.171875,
            "text": "antitumor immune response.",
            "probability": 8.499622344970703e-05
        },
        {
            "start_logit": 7.25,
            "end_logit": -8.8671875,
            "text": "Stimulator of interferon genes (STING) is an adaptor protein that plays an important role in the activation of type I interferons in response to",
            "probability": 8.243322372436523e-05
        },
        {
            "start_logit": 7.25,
            "end_logit": -9.0078125,
            "text": "Stimulator",
            "probability": 7.158517837524414e-05
        },
        {
            "start_logit": -9.0390625,
            "end_logit": 7.171875,
            "text": "induction of antitumor immune response.",
            "probability": 6.41942024230957e-05
        },
        {
            "start_logit": -9.1328125,
            "end_logit": 7.171875,
            "text": "of type I interferons in response to cytosolic nucleic acid ligands. Recent evidence indicates involvement of the STING pathway in the induction of antitumor immune response.",
            "probability": 5.841255187988281e-05
        },
        {
            "start_logit": 7.25,
            "end_logit": -9.265625,
            "text": "Stimulator of interferon",
            "probability": 5.5730342864990234e-05
        }
    ],
    "62005e02c9dfcb9c09000018_1": [
        {
            "start_logit": 14.296875,
            "end_logit": 15.1171875,
            "text": "MBPpred",
            "probability": 1.0
        },
        {
            "start_logit": -2.169921875,
            "end_logit": 15.1171875,
            "text": "d",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.296875,
            "end_logit": -2.509765625,
            "text": "MBP",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -2.55078125,
            "text": "MBPpre",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": 15.1171875,
            "text": "pred",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -8.0546875,
            "text": "MBPpred: Proteome-wide detection of membrane lipid-binding proteins using profile Hidden Markov Models",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -8.5703125,
            "text": "MBPpred: Proteome-wide detection of membrane lipid-binding proteins using profile Hidden Markov Models.",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -9.5,
            "text": "MBPpred:",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -9.890625,
            "text": "MBPpred: Proteome-wide detection of membrane lipid-binding proteins",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -9.953125,
            "text": "MBPpred: Proteome-wide detection",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -9.9609375,
            "text": "MBPpred: Proteome",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -10.1015625,
            "text": "MBPpred: Proteome-wide detection of membrane",
            "probability": 0.0
        },
        {
            "start_logit": 14.296875,
            "end_logit": -10.109375,
            "text": "MBPpred: Proteome-wide",
            "probability": 0.0
        },
        {
            "start_logit": -2.169921875,
            "end_logit": -8.0546875,
            "text": "d: Proteome-wide detection of membrane lipid-binding proteins using profile Hidden Markov Models",
            "probability": 0.0
        },
        {
            "start_logit": -8.1640625,
            "end_logit": -2.55078125,
            "text": "pre",
            "probability": 0.0
        },
        {
            "start_logit": -2.169921875,
            "end_logit": -8.5703125,
            "text": "d: Proteome-wide detection of membrane lipid-binding proteins using profile Hidden Markov Models.",
            "probability": 0.0
        },
        {
            "start_logit": -2.169921875,
            "end_logit": -9.5,
            "text": "d:",
            "probability": 0.0
        },
        {
            "start_logit": -2.169921875,
            "end_logit": -9.890625,
            "text": "d: Proteome-wide detection of membrane lipid-binding proteins",
            "probability": 0.0
        },
        {
            "start_logit": -2.169921875,
            "end_logit": -9.953125,
            "text": "d: Proteome-wide detection",
            "probability": 0.0
        },
        {
            "start_logit": -2.169921875,
            "end_logit": -9.9609375,
            "text": "d: Proteome",
            "probability": 0.0
        }
    ],
    "62005e02c9dfcb9c09000018_2": [
        {
            "start_logit": 14.515625,
            "end_logit": 15.2265625,
            "text": "MBPpred",
            "probability": 1.0
        },
        {
            "start_logit": -1.84765625,
            "end_logit": 15.2265625,
            "text": "d",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.515625,
            "end_logit": -1.9130859375,
            "text": "MBP",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 14.515625,
            "end_logit": -1.9267578125,
            "text": "MBPpre",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": -9.0703125,
            "end_logit": 15.2265625,
            "text": "pred",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 15.2265625,
            "text": "called MBPpred",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": 15.2265625,
            "text": "Membrane Binding Proteins (MBPs) from information encoded in their amino acid sequence, called MBPpred",
            "probability": 0.0
        },
        {
            "start_logit": -9.0703125,
            "end_logit": -1.9267578125,
            "text": "pre",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -1.9130859375,
            "text": "called MBP",
            "probability": 0.0
        },
        {
            "start_logit": -9.4921875,
            "end_logit": -1.9267578125,
            "text": "called MBPpre",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": -1.9130859375,
            "text": "Membrane Binding Proteins (MBPs) from information encoded in their amino acid sequence, called MBP",
            "probability": 0.0
        },
        {
            "start_logit": -10.421875,
            "end_logit": -1.9267578125,
            "text": "Membrane Binding Proteins (MBPs) from information encoded in their amino acid sequence, called MBPpre",
            "probability": 0.0
        },
        {
            "start_logit": -10.3046875,
            "end_logit": -5.53125,
            "text": "peripheral or transmembrane. MBPpred is available online at http://bioinformatics.biol.uoa.gr",
            "probability": 0.0
        },
        {
            "start_logit": -10.3515625,
            "end_logit": -5.53125,
            "text": "available online at http://bioinformatics.biol.uoa.gr",
            "probability": 0.0
        },
        {
            "start_logit": -10.3828125,
            "end_logit": -5.53125,
            "text": "as peripheral or transmembrane. MBPpred is available online at http://bioinformatics.biol.uoa.gr",
            "probability": 0.0
        },
        {
            "start_logit": -10.4453125,
            "end_logit": -5.53125,
            "text": "or transmembrane. MBPpred is available online at http://bioinformatics.biol.uoa.gr",
            "probability": 0.0
        },
        {
            "start_logit": -10.5,
            "end_logit": -5.53125,
            "text": ".biol.uoa.gr",
            "probability": 0.0
        },
        {
            "start_logit": -10.5078125,
            "end_logit": -5.53125,
            "text": "/bioinformatics.biol.uoa.gr",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -5.53125,
            "text": ".uoa.gr",
            "probability": 0.0
        },
        {
            "start_logit": -10.5390625,
            "end_logit": -5.53125,
            "text": "uoa.gr",
            "probability": 0.0
        }
    ],
    "603219c21cb411341a000133_1": [
        {
            "start_logit": -4.73046875,
            "end_logit": -0.5400390625,
            "text": "the term 'Vesiduction' as a fourth mode of intercellular DNA transfer.",
            "probability": 0.67333984375
        },
        {
            "start_logit": -4.73046875,
            "end_logit": -2.2421875,
            "text": "the term 'Vesiduction' as a fourth",
            "probability": 0.12261962890625
        },
        {
            "start_logit": -6.82421875,
            "end_logit": -0.5400390625,
            "text": "fourth mode of intercellular DNA transfer.",
            "probability": 0.08294677734375
        },
        {
            "start_logit": -7.8046875,
            "end_logit": -0.5400390625,
            "text": "term 'Vesiduction' as a fourth mode of intercellular DNA transfer.",
            "probability": 0.0311279296875
        },
        {
            "start_logit": -6.82421875,
            "end_logit": -2.2421875,
            "text": "fourth",
            "probability": 0.01515960693359375
        },
        {
            "start_logit": -8.9140625,
            "end_logit": -0.5400390625,
            "text": ".",
            "probability": 0.01026153564453125
        },
        {
            "start_logit": -9.0234375,
            "end_logit": -0.5400390625,
            "text": "Vesiduction' as a fourth mode of intercellular DNA transfer.",
            "probability": 0.0092010498046875
        },
        {
            "start_logit": -9.0546875,
            "end_logit": -0.5400390625,
            "text": "intercellular DNA transfer.",
            "probability": 0.00891876220703125
        },
        {
            "start_logit": -9.0625,
            "end_logit": -0.5400390625,
            "text": "propose the term 'Vesiduction' as a fourth mode of intercellular DNA transfer.",
            "probability": 0.00884246826171875
        },
        {
            "start_logit": -9.15625,
            "end_logit": -0.5400390625,
            "text": "'Vesiduction' as a fourth mode of intercellular DNA transfer.",
            "probability": 0.008056640625
        },
        {
            "start_logit": -9.2265625,
            "end_logit": -0.5400390625,
            "text": "a fourth mode of intercellular DNA transfer.",
            "probability": 0.007511138916015625
        },
        {
            "start_logit": -7.8046875,
            "end_logit": -2.2421875,
            "text": "term 'Vesiduction' as a fourth",
            "probability": 0.005664825439453125
        },
        {
            "start_logit": -6.5,
            "end_logit": -4.19140625,
            "text": "DNA transfer involving extracellular vesicles is still under appreciated.",
            "probability": 0.002986907958984375
        },
        {
            "start_logit": -10.2890625,
            "end_logit": -0.5400390625,
            "text": "domains of life. Here, we propose the term 'Vesiduction' as a fourth mode of intercellular DNA transfer.",
            "probability": 0.0025959014892578125
        },
        {
            "start_logit": -6.5,
            "end_logit": -4.3671875,
            "text": "DNA transfer involving extracellular vesicles is still under appreciated. However, this widespread phenomenon has been observed in the three domains of life.",
            "probability": 0.00249481201171875
        },
        {
            "start_logit": -10.3671875,
            "end_logit": -0.5400390625,
            "text": "DNA transfer.",
            "probability": 0.002399444580078125
        },
        {
            "start_logit": -9.0234375,
            "end_logit": -2.2421875,
            "text": "Vesiduction' as a fourth",
            "probability": 0.0016756057739257812
        },
        {
            "start_logit": -9.0625,
            "end_logit": -2.2421875,
            "text": "propose the term 'Vesiduction' as a fourth",
            "probability": 0.0016117095947265625
        },
        {
            "start_logit": -9.15625,
            "end_logit": -2.2421875,
            "text": "'Vesiduction' as a fourth",
            "probability": 0.0014667510986328125
        },
        {
            "start_logit": -9.2265625,
            "end_logit": -2.2421875,
            "text": "a fourth",
            "probability": 0.0013675689697265625
        }
    ],
    "601bde6e1cb411341a000006_1": [
        {
            "start_logit": 0.494384765625,
            "end_logit": 5.5703125,
            "text": "Multisystem Disease with Abnormal Neurodevelopment.",
            "probability": 0.9853515625
        },
        {
            "start_logit": 0.494384765625,
            "end_logit": 1.2861328125,
            "text": "Multisystem Disease with Abnormal Neurodevelopment",
            "probability": 0.01357269287109375
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 5.5703125,
            "text": "De Novo VPS4A Mutations Cause Multisystem Disease with Abnormal Neurodevelopment.",
            "probability": 0.0005669593811035156
        },
        {
            "start_logit": -8.59375,
            "end_logit": 5.5703125,
            "text": ".",
            "probability": 0.00011074542999267578
        },
        {
            "start_logit": -8.671875,
            "end_logit": 5.5703125,
            "text": "Abnormal Neurodevelopment.",
            "probability": 0.00010246038436889648
        },
        {
            "start_logit": -9.09375,
            "end_logit": 5.5703125,
            "text": "Disease with Abnormal Neurodevelopment.",
            "probability": 6.711483001708984e-05
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 5.5703125,
            "text": "ystem Disease with Abnormal Neurodevelopment.",
            "probability": 4.547834396362305e-05
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 5.5703125,
            "text": "Neurodevelopment.",
            "probability": 2.9385089874267578e-05
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 5.5703125,
            "text": "Cause Multisystem Disease with Abnormal Neurodevelopment.",
            "probability": 2.3186206817626953e-05
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 5.5703125,
            "text": "VPS4A Mutations Cause Multisystem Disease with Abnormal Neurodevelopment.",
            "probability": 1.728534698486328e-05
        },
        {
            "start_logit": -10.6015625,
            "end_logit": 5.5703125,
            "text": "with Abnormal Neurodevelopment.",
            "probability": 1.4960765838623047e-05
        },
        {
            "start_logit": -10.625,
            "end_logit": 5.5703125,
            "text": "ment.",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": -10.6328125,
            "end_logit": 5.5703125,
            "text": "Novo VPS4A Mutations Cause Multisystem Disease with Abnormal Neurodevelopment.",
            "probability": 1.4483928680419922e-05
        },
        {
            "start_logit": -10.734375,
            "end_logit": 5.5703125,
            "text": "Mutations Cause Multisystem Disease with Abnormal Neurodevelopment.",
            "probability": 1.3053417205810547e-05
        },
        {
            "start_logit": -6.96484375,
            "end_logit": 1.2861328125,
            "text": "De Novo VPS4A Mutations Cause Multisystem Disease with Abnormal Neurodevelopment",
            "probability": 7.748603820800781e-06
        },
        {
            "start_logit": -8.671875,
            "end_logit": 1.2861328125,
            "text": "Abnormal Neurodevelopment",
            "probability": 1.430511474609375e-06
        },
        {
            "start_logit": -9.09375,
            "end_logit": 1.2861328125,
            "text": "Disease with Abnormal Neurodevelopment",
            "probability": 9.5367431640625e-07
        },
        {
            "start_logit": -9.4921875,
            "end_logit": 1.2861328125,
            "text": "ystem Disease with Abnormal Neurodevelopment",
            "probability": 6.556510925292969e-07
        },
        {
            "start_logit": -9.9296875,
            "end_logit": 1.2861328125,
            "text": "Neurodevelopment",
            "probability": 4.172325134277344e-07
        },
        {
            "start_logit": -10.1640625,
            "end_logit": 1.2861328125,
            "text": "Cause Multisystem Disease with Abnormal Neurodevelopment",
            "probability": 2.980232238769531e-07
        }
    ],
    "5aacd487fcf4565872000007_1": [
        {
            "start_logit": 13.453125,
            "end_logit": 13.125,
            "text": "POLQ",
            "probability": 1.0
        },
        {
            "start_logit": 13.453125,
            "end_logit": 4.41796875,
            "text": "POLQ gene",
            "probability": 0.00016605854034423828
        },
        {
            "start_logit": 13.453125,
            "end_logit": -3.341796875,
            "text": "POL",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.453125,
            "end_logit": -4.39453125,
            "text": "POLQ gene in mammalian genomes.",
            "probability": 0.0
        },
        {
            "start_logit": -5.32421875,
            "end_logit": 13.125,
            "text": "Q",
            "probability": 0.0
        },
        {
            "start_logit": -6.10546875,
            "end_logit": 13.125,
            "text": "the POLQ",
            "probability": 0.0
        },
        {
            "start_logit": 13.453125,
            "end_logit": -7.65234375,
            "text": "POLQ gene in",
            "probability": 0.0
        },
        {
            "start_logit": -8.546875,
            "end_logit": 13.125,
            "text": "by the POLQ",
            "probability": 0.0
        },
        {
            "start_logit": -8.671875,
            "end_logit": 13.125,
            "text": "DNA polymerase theta (pol \u03b8) is an evolutionarily conserved protein encoded by the POLQ",
            "probability": 0.0
        },
        {
            "start_logit": 13.453125,
            "end_logit": -9.15625,
            "text": "POLQ gene in mammalian genomes",
            "probability": 0.0
        },
        {
            "start_logit": -10.7734375,
            "end_logit": 13.125,
            "text": "encoded by the POLQ",
            "probability": 0.0
        },
        {
            "start_logit": -10.8671875,
            "end_logit": 13.125,
            "text": "polymerase theta (pol \u03b8) is an evolutionarily conserved protein encoded by the POLQ",
            "probability": 0.0
        },
        {
            "start_logit": -11.015625,
            "end_logit": 13.125,
            "text": "evolutionarily conserved protein encoded by the POLQ",
            "probability": 0.0
        },
        {
            "start_logit": -11.15625,
            "end_logit": 13.125,
            "text": "protein encoded by the POLQ",
            "probability": 0.0
        },
        {
            "start_logit": -11.28125,
            "end_logit": 13.125,
            "text": "pol \u03b8) is an evolutionarily conserved protein encoded by the POLQ",
            "probability": 0.0
        },
        {
            "start_logit": -5.32421875,
            "end_logit": 4.41796875,
            "text": "Q gene",
            "probability": 0.0
        },
        {
            "start_logit": -6.10546875,
            "end_logit": 4.41796875,
            "text": "the POLQ gene",
            "probability": 0.0
        },
        {
            "start_logit": -8.0703125,
            "end_logit": 4.41796875,
            "text": "gene",
            "probability": 0.0
        },
        {
            "start_logit": -8.546875,
            "end_logit": 4.41796875,
            "text": "by the POLQ gene",
            "probability": 0.0
        },
        {
            "start_logit": -8.671875,
            "end_logit": 4.41796875,
            "text": "DNA polymerase theta (pol \u03b8) is an evolutionarily conserved protein encoded by the POLQ gene",
            "probability": 0.0
        }
    ],
    "58a2df9c60087bc10a000006_1": [
        {
            "start_logit": 13.8125,
            "end_logit": 14.7890625,
            "text": "8%",
            "probability": 1.0
        },
        {
            "start_logit": -2.07421875,
            "end_logit": 14.7890625,
            "text": "%",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": 13.8125,
            "end_logit": -1.26171875,
            "text": "8",
            "probability": 1.1920928955078125e-07
        },
        {
            "start_logit": -9.6640625,
            "end_logit": 14.7890625,
            "text": "very common in Greece, the incidence of beta-thalassemia trait being 8%",
            "probability": 0.0
        },
        {
            "start_logit": -9.6953125,
            "end_logit": 14.7890625,
            "text": "Hemoglobinopathies are very common in Greece, the incidence of beta-thalassemia trait being 8%",
            "probability": 0.0
        },
        {
            "start_logit": -9.8203125,
            "end_logit": 14.7890625,
            "text": "being 8%",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -9.0,
            "text": "8% and that of sickle cell trait ranging from 1 to 32% in various districts.",
            "probability": 0.0
        },
        {
            "start_logit": -10.25,
            "end_logit": 14.7890625,
            "text": "thalassemia trait being 8%",
            "probability": 0.0
        },
        {
            "start_logit": -10.28125,
            "end_logit": 14.7890625,
            "text": "beta-thalassemia trait being 8%",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -9.5078125,
            "text": "8% and that of sickle cell trait ranging from 1 to 32% in various districts",
            "probability": 0.0
        },
        {
            "start_logit": -10.5234375,
            "end_logit": 14.7890625,
            "text": "the incidence of beta-thalassemia trait being 8%",
            "probability": 0.0
        },
        {
            "start_logit": -10.609375,
            "end_logit": 14.7890625,
            "text": "common in Greece, the incidence of beta-thalassemia trait being 8%",
            "probability": 0.0
        },
        {
            "start_logit": -10.6640625,
            "end_logit": 14.7890625,
            "text": "trait being 8%",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -9.7734375,
            "text": "8% and that of sickle cell trait ranging from 1 to 32%",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -9.84375,
            "text": "8% and that of sickle cell trait ranging from 1 to 32% in",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -9.859375,
            "text": "8% and that of sickle cell trait ranging from 1 to 32",
            "probability": 0.0
        },
        {
            "start_logit": 13.8125,
            "end_logit": -9.8984375,
            "text": "8% and",
            "probability": 0.0
        },
        {
            "start_logit": -10.875,
            "end_logit": 14.7890625,
            "text": "of beta-thalassemia trait being 8%",
            "probability": 0.0
        },
        {
            "start_logit": -10.90625,
            "end_logit": 14.7890625,
            "text": "-thalassemia trait being 8%",
            "probability": 0.0
        },
        {
            "start_logit": -10.921875,
            "end_logit": 14.7890625,
            "text": "opathies are very common in Greece, the incidence of beta-thalassemia trait being 8%",
            "probability": 0.0
        }
    ],
    "5c910ae0ecadf2e73f000007_1": [
        {
            "start_logit": 13.484375,
            "end_logit": 13.9296875,
            "text": "Bristol-Myers Squibb",
            "probability": 1.0
        },
        {
            "start_logit": -3.16015625,
            "end_logit": 13.9296875,
            "text": "b",
            "probability": 5.960464477539063e-08
        },
        {
            "start_logit": 13.484375,
            "end_logit": -4.15234375,
            "text": "Br",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -6.21484375,
            "text": "Bristol-Myers Squibb) of nivolumab",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -7.125,
            "text": "Bristol-Myers Squ",
            "probability": 0.0
        },
        {
            "start_logit": -7.7734375,
            "end_logit": 13.9296875,
            "text": "istol-Myers Squibb",
            "probability": 0.0
        },
        {
            "start_logit": -7.984375,
            "end_logit": 13.9296875,
            "text": "Squibb",
            "probability": 0.0
        },
        {
            "start_logit": -8.625,
            "end_logit": 13.9296875,
            "text": "ibb",
            "probability": 0.0
        },
        {
            "start_logit": -9.265625,
            "end_logit": 13.9296875,
            "text": "Myers Squibb",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -8.828125,
            "text": "Brist",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -8.90625,
            "text": "Bristol-Myers Squib",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -9.1875,
            "text": "Bristol-Myers Squibb) of niv",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -9.296875,
            "text": "Bristol-Myers Squibb)",
            "probability": 0.0
        },
        {
            "start_logit": -9.8515625,
            "end_logit": 13.9296875,
            "text": "-Myers Squibb",
            "probability": 0.0
        },
        {
            "start_logit": -9.859375,
            "end_logit": 13.9296875,
            "text": "(Bristol-Myers Squibb",
            "probability": 0.0
        },
        {
            "start_logit": -9.9375,
            "end_logit": 13.9296875,
            "text": "ers Squibb",
            "probability": 0.0
        },
        {
            "start_logit": -10.109375,
            "end_logit": 13.9296875,
            "text": "ol-Myers Squibb",
            "probability": 0.0
        },
        {
            "start_logit": -10.3984375,
            "end_logit": 13.9296875,
            "text": "the manufacturer (Bristol-Myers Squibb",
            "probability": 0.0
        },
        {
            "start_logit": -10.4609375,
            "end_logit": 13.9296875,
            "text": "manufacturer (Bristol-Myers Squibb",
            "probability": 0.0
        },
        {
            "start_logit": 13.484375,
            "end_logit": -10.1015625,
            "text": "Bristol-Myers Squibb) of nivolumab (Opdivo",
            "probability": 0.0
        }
    ]
}
